PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	RIDKER, PM; HENNEKENS, CH; LINDPAINTER, K; STAMPFER, MJ; EISENBERG, PR; MILETICH, JP				RIDKER, PM; HENNEKENS, CH; LINDPAINTER, K; STAMPFER, MJ; EISENBERG, PR; MILETICH, JP			MUTATION IN THE GENE CODING FOR COAGULATION-FACTOR-V AND THE RISK OF MYOCARDIAL-INFARCTION, STROKE, AND VENOUS THROMBOSIS IN APPARENTLY HEALTHY-MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POOR ANTICOAGULANT RESPONSE; DEEP-VEIN THROMBOSIS; ACTIVATED PROTEIN-C; PLASMINOGEN-ACTIVATOR; HEART-DISEASE; THROMBOPHILIA; FIBRINOGEN; INHIBITOR; PLASMA	Background. A specific point mutation in the gene coding for coagulation factor V is associated with resistance to degradation by activated protein C, a recently described abnormality of coagulation that may be associated with an increased risk of venous thrombosis. Whether this mutation also predisposes patients to arterial thrombosis is unknown, as is the value of screening for the mutation in order to define the risk of venous thrombosis among unselected healthy people. Methods. Among 14,916 apparently healthy men in the Physicians' Health Study who provided base-line blood samples, 374 had myocardial infarctions, 209 had strokes, and 121 had deep venous thrombosis, pulmonary embolism, or both, during a mean follow-up of 8.6 years. We determined whether a mutation at nucleotide position 1691 of the factor V gene was present or absent in these 704 men and in an equal number of matched participants who remained free of vascular disease. Results. The prevalence of heterozygosity for the mutation among men who had myocardial infarctions (6.1 percent, P=0.9) or strokes (4.3 percent, P=0.4) was similar to that among men who remained free of vascular disease (6.0 percent). However, the prevalence of the mutation was significantly higher among men who had venous thrombosis, pulmonary embolism, or both (11.6 percent, P=0.02). In adjusted analyses, the relative risk of venous thrombosis among men with the mutation was 2.7 (95 percent confidence interval, 1.3 to 5.6; P=0.008). This increased risk was seen with primary venous thrombosis (relative risk, 3.5; 95 percent confidence interval, 1.5 to 8.4; P=0.004) but not with secondary venous thrombosis (relative risk, 1.7; 95 percent confidence interval, 0.6 to 5.3; P=0.3), and it was most apparent among older men. Specifically, the prevalence of the mutation among men over the age of 60 in whom primary venous thrombosis developed was 25.8 percent (relative risk, 7.0; 95 percent confidence interval, 2.6 to 19.1; P<0.001). Conclusions. In a large cohort of apparently healthy men, the presence of a specific point mutation in the factor V gene was associated with an increased risk of venous thrombosis, particularly primary venous thrombosis. The presence of the mutation was not associated with an increased risk of myocardial infarction or stroke. This mutation appears to be the most common inherited factor thus far recognized that predisposes patients to venous thrombosis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC DIS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115; CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV LAB MED,ST LOUIS,MO 63110	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-34595, HL-14147, HL-26490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P257; FOWKES FGR, 1993, LANCET, V342, P84, DOI 10.1016/0140-6736(93)91288-W; GOLDHABER SZ, 1985, PULMONARY EMBOLISM D; GRIFFIN JH, 1993, BLOOD, V82, P1989; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HIRSH J, 1981, VENOUS THROMBOEMBOLI; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; PRANDONI P, 1992, NEW ENGL J MED, V327, P11228; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, CIRCULATION, V90, P2236, DOI 10.1161/01.CIR.90.5.2236; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8; 1971, ISCHEMIC HEART DISEA	29	986	1009	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					912	917		10.1056/NEJM199504063321403	http://dx.doi.org/10.1056/NEJM199504063321403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877648				2022-12-24	WOS:A1995QP89300003
J	MATZUK, MM; KUMAR, TR; VASSALLI, A; BICKENBACH, JR; ROOP, DR; JAENISCH, R; BRADLEY, A				MATZUK, MM; KUMAR, TR; VASSALLI, A; BICKENBACH, JR; ROOP, DR; JAENISCH, R; BRADLEY, A			FUNCTIONAL-ANALYSIS OF ACTIVINS DURING MAMMALIAN DEVELOPMENT	NATURE			English	Article							PREIMPLANTATION MOUSE EMBRYOS; XENOPUS EMBRYOGENESIS; AXIAL STRUCTURES; EXPRESSION; MESODERM; INHIBIN; CLONING; INDUCE; GENES	ACTIVINS are dimeric (beta A beta A; beta B beta B; beta A beta B) members of the transforming growth factor-beta superfamily(1). They are widely expressed during murine development(1-6), are highly conserved during vertebrate evolution(1,7-11), and may be involved in mesoderm induction and neurulation in Xenopus laevis and Oryzias latipes(10-17). To investigate the function of mammalian activins in vivo, we generated mice with mutations either in activin-beta A or in both activin-beta A and activin-beta B. Activin-beta A-deficient mice develop to term but die within 24 h of birth. They lack whiskers and lower incisors and have defects in their secondary palates, including cleft palate, demonstrating that activin-beta A must have a role during craniofacial development. Mice lacking both activin subunits show the defects of both individual mutants but no additional defects, indicating that there is no functional redundancy between these proteins during embryogenesis. In contrast to observations in lower vertebrates(10-17), zygotic expression of activins is not essential for mesoderm formation in mice.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	MATZUK, MM (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.		Vassalli, Anne/M-7866-2016	Vassalli, Anne/0000-0002-5314-5620; Bradley, Allan/0000-0002-2349-8839				ALBANO RM, 1994, DEVELOPMENT, V120, P803; ALBANO RM, 1993, DEVELOPMENT, V117, P711; BRADLEY A, 1987, TERATOCARCINOMAS EMB; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CONLON FL, 1994, DEVELOPMENT, V120, P1919; ESCH FS, 1987, MOL ENDOCRINOL, V1, P388, DOI 10.1210/mend-1-5-388; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; GE W, 1993, BIOCHEM BIOPH RES CO, V193, P711, DOI 10.1006/bbrc.1993.1683; GLUECKSOHN, 1961, MNI, V25, P12; GORLIN RJ, 1990, OXFORD MONOGRAPHS ME, V19, P693; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LU RZ, 1993, BIOL REPROD, V49, P1163, DOI 10.1095/biolreprod49.6.1163; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; MANOVA K, 1992, MECH DEVELOP, V36, P141, DOI 10.1016/0925-4773(92)90065-R; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE WW, 1990, PEPTIDE GROWTH FACTO, V2; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WITTBRODT J, 1994, GENE DEV, V8, P1448, DOI 10.1101/gad.8.12.1448; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	31	497	508	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					354	356		10.1038/374354a0	http://dx.doi.org/10.1038/374354a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885473				2022-12-24	WOS:A1995QN63000058
J	CABELLI, RJ; HOHN, A; SHATZ, CJ				CABELLI, RJ; HOHN, A; SHATZ, CJ			INHIBITION OF OCULAR DOMINANCE COLUMN FORMATION BY INFUSION OF NT-4/5 OR BDNF	SCIENCE			English	Article							NERVE GROWTH-FACTOR; CATS VISUAL-CORTEX; NEUROTROPHIC FACTOR; MESSENGER-RNA; FACTOR FAMILY; MONOCULAR DEPRIVATION; MOLECULAR-CLONING; LIMBIC SEIZURES; STRIATE CORTEX; NGF	During the development of the visual system of higher mammals, axons from the lateral geniculate nucleus (LGN) become segregated into eye-specific patches (the ocular dominance columns) within their target, layer 4 of the primary visual cortex. This occurs as a consequence of activity-dependent synaptic competition between axons representing the two eyes, The possibility that this competition could be mediated through neurotrophin-receptor interactions was tested. Infusion of neurotrophin-4/5 (NT-4/5) or brain-derived neurotrophic factor (BDNF) into cat primary visual cortex inhibited column formation within the immediate vicinity of the infusion site but not elsewhere in the visual cortex. Infusion of nerve growth factor, neurotrophin 3 (NT-3), or vehicle solution did not affect column formation. These observations implicate TrkB, the common receptor for BDNF and NT-4/5, in the segregation of LGN axons into ocular dominance columns in layer 4. Moreover, they suggest that in addition to their better known roles in the prevention of cell death, neurotrophins may also mediate the activity-dependent control of axonal branching during development of the central nervous system.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	CABELLI, RJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.				NATIONAL EYE INSTITUTE [R01EY002858, R37EY002858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NEI NIH HHS [EY06327, EY02858] Funding Source: Medline; NIMH NIH HHS [MH 48108] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLENDOERFER KL, 1994, J NEUROSCI, V14, P1795; ANTONINI A, 1993, J NEUROSCI, V13, P3549; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CABELLI RJ, 1993, 23RD ANN M SOC NEUR; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHUN JJM, 1989, J COMP NEUROL, V282, P555, DOI 10.1002/cne.902820407; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COHENCORY S, 1991, J NEUROSCI, V11, P462; DIAMOND J, 1992, J NEUROSCI, V12, P1454; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; ERNFORS P, 1991, NEURON, V7, P164; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GHOSH A, 1994, J NEUROSCI, V14, P3862; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GU Q, 1994, P NATL ACAD SCI USA, V91, P8408, DOI 10.1073/pnas.91.18.8408; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HAYASHI M, 1990, NEUROSCIENCE, V36, P683, DOI 10.1016/0306-4522(90)90011-R; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOHN A, 1994, 24TH ANN M SOC NEUR; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; ISAACSON LG, 1992, J COMP NEUROL, V326, P327, DOI 10.1002/cne.903260302; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVAY S, 1975, J COMP NEUROL, V159, P559, DOI 10.1002/cne.901590408; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LOHOF AM, 1993, NATURE, V363; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PURVES D, 1988, NATURE, V336, P123, DOI 10.1038/336123a0; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; VAZQUEZ ME, 1991, NEUROREPORT, V2, P593, DOI 10.1097/00001756-199110000-00010; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	44	525	532	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1662	1666		10.1126/science.7886458	http://dx.doi.org/10.1126/science.7886458			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886458				2022-12-24	WOS:A1995QM39700042
J	BRENNAN, JA; BOYLE, JO; KOCH, WM; GOODMAN, SN; HRUBAN, RH; EBY, YJ; COUCH, MJ; FORASTIERE, AA; SIDRANSKY, D				BRENNAN, JA; BOYLE, JO; KOCH, WM; GOODMAN, SN; HRUBAN, RH; EBY, YJ; COUCH, MJ; FORASTIERE, AA; SIDRANSKY, D			ASSOCIATION BETWEEN CIGARETTE-SMOKING AND MUTATION OF THE P53 GENE IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL CAVITY; COLORECTAL TUMORIGENESIS; ALCOHOL-DRINKING; TOBACCO SMOKING; POINT MUTATIONS; HUMAN CANCERS; LUNG-CANCER; EXPRESSION; PROTEIN; LARYNX	Background. Although epidemiologic studies have long associated tobacco and alcohol use with the development of squamous-cell carcinoma of the head and neck, the molecular targets of these carcinogens have yet to be identified. We performed a molecular analysis to determine the pattern of mutations in the p53 gene in neoplasms from patients with squamous-cell carcinoma of the head and neck and a history of tobacco or alcohol use. Methods. Sequence analysis of the conserved regions of the p53 gene was performed in tumor samples from 129 patients with primary squamous-cell carcinoma of the head and neck. We then used statistical analysis to identify any patient characteristics associated with mutation of the p53 gene. Results. We found p53 mutations in 42 percent of the patients (54 of 129). Fifty-eight percent of the patients who smoked cigarettes and used alcohol (37 of 64; 95 percent confidence interval, 45 to 70 percent), 33 percent of the patients who smoked but abstained from alcohol (13 of 39; 95 percent confidence interval, 19 to 50 percent), and 17 percent of the patients who neither smoked nor drank alcohol (4 of 24, 95 percent confidence interval, 5 to 37 percent) had p53 mutations (P = 0.001). (Two patients used alcohol but did not smoke, and neither had a p53 mutation.) Furthermore, 100 percent of the mutations in the patients who neither drank nor smoked occurred at sites containing cytidine phosphate guanosine dinucleotides (potentially representing endogenous mutations) within the p53 gene (5 of 5 mutations; 95 percent confidence interval, 48 to 100 percent), whereas only 23 percent of those in cigarette smokers consisted of such changes (12 of 53 mutations; 95 percent confidence interval, 12 to 36 percent; P = 0.001). Conclusions. In our study, a history of tobacco and alcohol use was associated with a high frequency of p53 mutations in patients with squamous-cell carcinoma of the head and neck. Preliminary evidence linked cigarette smoking to p53 mutations at nonendogenous mutation sites. Our findings suggest a role for tobacco in the molecular progression of squamous-cell carcinoma of the head and neck and support the epidemiologic evidence that abstinence from smoking is important to prevent head and neck cancer.	JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, DIV HEAD & NECK CANC RES, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV BIOSTAT, BALTIMORE, MD USA; JOHNS HOPKINS UNIV HOSP, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine				Goodman, Steven/0000-0002-3872-5723	NCI NIH HHS [CA-58184-01, CA-54672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054672, P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; BAKER SJ, 1990, CANCER RES, V50, P7717; Beahrs OH, 1988, MANUAL STAGING CANCE, P27; BOFFETTA P, 1992, INT J CANCER, V52, P530, DOI 10.1002/ijc.2910520405; BONGIORNO PF, 1994, J THORAC CARDIOV SUR, V107, P590, DOI 10.1016/S0022-5223(94)70107-5; BOREK C, 1993, ENVIRON HEALTH PERSP, V101, P237, DOI 10.2307/3431732; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1991, CANCER RES, V51, P6393; BREIMER LH, 1988, BRIT J CANCER, V57, P6, DOI 10.1038/bjc.1988.2; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BUCHMAN GW, 1992, FOCUS, V14, P41; CARBONE D, 1992, AM J MED, V93, pS13, DOI 10.1016/0002-9343(92)90621-H; CHOI SY, 1991, INT J EPIDEMIOL, V20, P878, DOI 10.1093/ije/20.4.878; CHRISTEN AG, 1992, AM J MED, V93, pS25, DOI 10.1016/0002-9343(92)90624-K; CULLEN J, 1986, HDB PREVENTION, P308; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DUFFY MJ, 1993, CLIN BIOCHEM, V26, P439, DOI 10.1016/0009-9120(93)80007-H; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4; GOSNEY JR, 1993, INT J ONCOL, V2, P1071; HABUCHI T, 1993, CANCER RES, V53, P3795; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HONG WK, 1993, CANCER RES, V53, P5113; LESMES GR, 1992, AM J MED, V93, pS55, DOI 10.1016/0002-9343(92)90629-P; MAESTRO R, 1992, ONCOGENE, V7, P1159; MASHBERG A, 1993, CANCER-AM CANCER SOC, V72, P1369, DOI 10.1002/1097-0142(19930815)72:4<1369::AID-CNCR2820720436>3.0.CO;2-L; PUISIEUX A, 1991, CANCER RES, V51, P6185; RENAN MJ, 1992, RADIAT RES, V131, P227, DOI 10.2307/3578445; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SPRUCK CH, 1993, CANCER RES, V53, P2427; SPRUCK CH, 1993, CANCER RES, V53, P1162; STRAUSS BS, 1992, CANCER RES, V52, P249; SUZUKI H, 1992, CANCER RES, V52, P734; THOMAS S, 1994, CANCER RES, V54, P3588; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; VOGELSTEIN B, 1992, NATURE, V355, P209, DOI 10.1038/355209a0; WAGATA T, 1993, CANCER RES, V53, P846; WOGAN GN, 1992, ENVIRON HEALTH PERSP, V98, P167, DOI 10.2307/3431264; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; ZHANG ZF, 1994, CANCER EPIDEM BIOMAR, V3, P19; 1989, DHHS CDC898411 PUBL	47	505	512	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					712	717		10.1056/NEJM199503163321104	http://dx.doi.org/10.1056/NEJM199503163321104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854378				2022-12-24	WOS:A1995QL78800004
J	MILLAR, AJ; CARRE, IA; STRAYER, CA; CHUA, NH; KAY, SA				MILLAR, AJ; CARRE, IA; STRAYER, CA; CHUA, NH; KAY, SA			CIRCADIAN CLOCK MUTANTS IN ARABIDOPSIS IDENTIFIED BY LUCIFERASE IMAGING	SCIENCE			English	Article							THALIANA	The cycling bioluminescence of Arabidopsis plants carrying a firefly luciferase fusion construct was used to identify mutant individuals with aberrant cycling patterns. Both long- and short-period mutants were recovered. A semidominant short-period mutation, timing of CAB expression (toc1), was mapped to chromosome 5. The toc1 mutation shortens the period of two distinct circadian rhythms, the expression of chlorophyll a/b-binding protein (CAB) genes and the movements of primary leaves, although toc1 mutants do not show extensive pleiotropy for other phenotypes.	UNIV VIRGINIA, DEPT BIOL, NSF, CTR BIOL TIMING, CHARLOTTESVILLE, VA 22903 USA; ROCKEFELLER UNIV, PLANT MOLEC BIOL LAB, NEW YORK, NY 10021 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; Rockefeller University			Kay, Steve A/F-6025-2011; Millar, Andrew J/G-2423-2012; CARRE, Isabelle A/D-8802-2011	Kay, Steve A/0000-0002-0402-2878; Millar, Andrew J/0000-0003-1756-3654; CARRE, Isabelle A/0000-0002-0548-7378	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044640, R56GM044640] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44640] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DEITZER GF, 1984, LIGHT FLOWERING PROC, P51; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DUNLAP JC, 1983, ANNU REV PHYSIOL, V55, P683; ENGELMANN W, 1992, Z NATURFORSCH C, V47, P925; HALL JC, 1990, ANNU REV GENET, V24, P659; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KOOMEEF M, 1992, METHODS ARABIDOPSIS, P83; MCCLUNG CR, 1994, ARABIDOPSIS THALIANA, P615; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MILLAR AJ, UNPUB; MILLAR AJ, 1994, THESIS ROCKEFFELLER; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; REITER RS, 1992, P NATL ACAD SCI USA, V89, P1477, DOI 10.1073/pnas.89.4.1477; TEAKLE GR, UNPUB	19	446	467	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	1995	267	5201					1161	1163		10.1126/science.7855595	http://dx.doi.org/10.1126/science.7855595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855595				2022-12-24	WOS:A1995QJ23700035
J	STITT, TN; CONN, G; GORE, M; LAI, C; BRUNO, J; RADZIEJEWSKI, C; MATTSSON, K; FISHER, J; GIES, DR; JONES, PF; MASIAKOWSKI, P; RYAN, TE; TOBKES, NJ; CHEN, DH; DISTEFANO, PS; LONG, GL; BASILICO, C; GOLDFARB, MP; LEMKE, G; GLASS, DJ; YANCOPOULOS, GD				STITT, TN; CONN, G; GORE, M; LAI, C; BRUNO, J; RADZIEJEWSKI, C; MATTSSON, K; FISHER, J; GIES, DR; JONES, PF; MASIAKOWSKI, P; RYAN, TE; TOBKES, NJ; CHEN, DH; DISTEFANO, PS; LONG, GL; BASILICO, C; GOLDFARB, MP; LEMKE, G; GLASS, DJ; YANCOPOULOS, GD			THE ANTICOAGULATION FACTOR PROTEIN-S AND ITS RELATIVE, GAS6, ARE LIGANDS FOR THE TYRO 3/AXL FAMILY OF RECEPTOR TYROSINE KINASES	CELL			English	Article							HEPATOCYTE GROWTH-FACTOR; K-DEPENDENT PROTEIN; C4B-BINDING PROTEIN; BLOOD-COAGULATION; NERVOUS-SYSTEM; MESSENGER-RNA; CELLS; COMPONENT; DEFICIENCY; CNTF	We report the identification of ligands for Tyro 3 (alternatively called Sky, rse, brt, or tif) and Axl (alternatively, Ark or UFO), members of a previously orphan family of receptor-like tyrosine kinases. These ligands correspond to protein S, a protease regulator that is a potent anticoagulant, and Gas6, a protein related to protein S but lacking any known function. Our results are reminiscent of recent findings that the procoagulant thrombin, a protease that drives clot formation by cleaving fibrinogen to form fibrin, also binds and activates intracellular signaling via a G protein-coupled cell surface receptor. Proteases and protease regulators that also activate specific cell surface receptors may serve to integrate coagulation with associated cellular responses required for tissue repair and growth, as well as to coordinate protease cascades and associated cellular responses in other systems, such as those involved in growth and remodeling of the nervous system.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA; NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	Salk Institute; University of California System; University of California San Diego; Scripps Research Institute; University of Vermont; New York University; New York University	STITT, TN (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAI W, 1994, ONCOGENE, V9, P975; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HESSING M, 1991, BIOCHEM J, V277, P581, DOI 10.1042/bj2770581; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MAHASANDANA C, 1990, J PEDIATR-US, V117, P750, DOI 10.1016/S0022-3476(05)83335-9; MAILLARD C, 1992, ENDOCRINOLOGY, V130, P1599, DOI 10.1210/en.130.3.1599; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1994, J BIOL CHEM, V269, P10720; Monard D, 1993, Perspect Dev Neurobiol, V1, P165; NELSON RM, 1992, J BIOL CHEM, V267, P8140; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; OREILLY DR, 1992, BACULOVIRUS EXPRESSI; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PEGELOW CH, 1992, PEDIATRICS, V89, P674; PHILLIPS DJ, 1993, J NEUROCHEM, V61, P344, DOI 10.1111/j.1471-4159.1993.tb03574.x; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZHAN X, 1987, ONCOGENE, V1, P369	43	595	638	1	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					661	670		10.1016/0092-8674(95)90520-0	http://dx.doi.org/10.1016/0092-8674(95)90520-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867073	hybrid			2022-12-24	WOS:A1995QJ60200018
J	BURKLY, L; HESSION, C; OGATA, L; REILLY, C; MARCONI, LA; OLSON, D; TIZARD, R; CATE, R; LO, D				BURKLY, L; HESSION, C; OGATA, L; REILLY, C; MARCONI, LA; OLSON, D; TIZARD, R; CATE, R; LO, D			EXPRESSION OF RELB IS REQUIRED FOR THE DEVELOPMENT OF THYMIC MEDULLA AND DENDRITIC CELLS	NATURE			English	Article							ANTIGEN-PRESENTING CELLS; EPITHELIAL-CELLS; T-CELLS; GENE; MOUSE	DENDRITIC cells (DC) derived from bone marrow are critical in the function of the immune system, for they are the primary antigen-presenting cells in the activation of T-lymphocyte response. Their differentiation from precursor cells has not been defined at a molecular level, but recent studies have shown an association between expression of the relB subunit of the NF-kappa B complex(1-5) and the presence of DC in specific regions of normal unstimulated lymphoid tissues(4-6). Here we show that relB expression also correlates with differentiation of DC in autoimmune infiltrates in situ, and that a mutation disrupting the relB gene results in mice with impaired antigen-presenting cell function, and a syndrome of excess production of granulocytes and macrophages. Thymic UEA-1(+) medullary epithelial cells from normal mice show striking similarities to DC and, interestingly, these cells are also absent in relB mutant mice. Taken together, these results suggest that relB is critical in the coordinated activation of genes necessary for the differentiation of two unrelated but phenotypically similar cells (DC and thymic UEA-1(+) medullary epithelial cells) and is therefore a candidate for a gene determining lineage commitment in the immune system.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; BIOGEN INC, CAMBRIDGE, MA 02142 USA	Scripps Research Institute; Biogen								ARNOLD B, 1984, NUCLEIC ACIDS RES, V12, P9473, DOI 10.1093/nar/12.24.9473; BURKLY LC, 1993, J IMMUNOL, V151, P3954; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; COUTELIER JP, 1987, J EXP MED, V165, P64, DOI 10.1084/jem.165.1.64; DEGERMANN S, 1994, J IMMUNOL, V152, P3254; FARR AG, 1985, J IMMUNOL, V134, P2971; GRILLI M, 1993, INT REV CYTOL, V143, P1; HOCART MJ, 1989, J GEN VIROL, V70, P809, DOI 10.1099/0022-1317-70-4-809; HOFFMAN MW, 1992, P NATL ACAD SCI USA, V89, P2536; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEVIN D, 1993, J IMMUNOL, V151, P6742; LO D, 1992, AM J PATHOL, V141, P1237; LO D, 1993, EUR J IMMUNOL, V23, P1693, DOI 10.1002/eji.1830230744; METLAY JP, 1989, J EXP MED, V169, P239, DOI 10.1084/jem.169.1.239; MIZUOCHI T, 1992, J EXP MED, V175, P1601, DOI 10.1084/jem.175.6.1601; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NELSON AJ, 1993, J IMMUNOL, V151, P2453; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; POIRIER B, 1994, J IMMUNITY, V1, P385; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; Sprent J, 1989, Int Immunol, V1, P517, DOI 10.1093/intimm/1.5.517; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495	29	648	670	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					531	536		10.1038/373531a0	http://dx.doi.org/10.1038/373531a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845467				2022-12-24	WOS:A1995QF72400062
J	JEEVAN, A; KRIPKE, ML				JEEVAN, A; KRIPKE, ML			OZONE DEPLETION AND THE IMMUNE-SYSTEM	LANCET			English	Article							HUMANS; RADIATION; INDUCTION; SKIN		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; JEEVAN A, 1992, BIOL EFFECTS LIGHT, P83; KRIPKE ML, 1990, J NATL CANCER I, V82, P1392, DOI 10.1093/jnci/82.17.1392; VERMEER M, 1991, J INVEST DERMATOL, V97, P729, DOI 10.1111/1523-1747.ep12484259; YOSHIKAWA T, 1990, J INVEST DERMATOL, V95, P530, DOI 10.1111/1523-1747.ep12504877	5	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1159	1160		10.1016/0140-6736(93)92131-C	http://dx.doi.org/10.1016/0140-6736(93)92131-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901483				2022-12-24	WOS:A1993MF19800017
J	WRIGHT, SW; EDWARDS, KM; DECKER, MD; ZELDIN, MH				WRIGHT, SW; EDWARDS, KM; DECKER, MD; ZELDIN, MH			PERTUSSIS INFECTION IN ADULTS WITH PERSISTENT COUGH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							OUTBREAK; DIAGNOSIS; FACILITY	Objective.-To determine the prevalence of Bordetella pertussis infection in adult patients with persistent cough. Design.-Prospective case series. Setting.-Urban university hospital emergency department. Patients.-Convenience sample of 75 patients aged 18 years or older with a cough lasting 2 weeks or longer. Serum specimens from 67 patients without respiratory complaints were used to develop reference values. Interventions.-In patients with cough, nasopharyngeal culture and direct fluorescent antibody testing for B pertussis were performed and serum samples were obtained at the first visit and 1 month later. Serum specimens were assayed for antibody to pertussis toxin (PT) and filamentous hemagglutinin (FHA). Main Outcome Measures.-A subject with one or more of the following was defined as having a pertussis infection: a positive B pertussis culture result, a fourfold change in PT or FHA titer, and/or a single PT or FHA titer at least 2 SDs greater than the geometric mean of the control group. Results.-No subject tested culture positive for B pertussis. Sixteen (21%) (95% confidence interval [CI], 13% to 32%) of 75 subjects met the serologic criteria for pertussis infection; for 13 (81%; 95% CI, 54% to 96%) of the 16, the criteria were met by the initial serum specimen. In contrast, the geometric mean levels of antibody to PT and FHA for the remaining 59 subjects with cough did not differ from those of the control group. Clinical symptoms and the lymphocyte count did not differentiate patients with pertussis from those without the disease. Conclusion.-Pertussis is a common cause of persistent cough in adults and should be considered in the differential diagnosis. Clinical symptoms, pertussis culture, direct fluorescent antibody testing, and lymphocytosis are of limited value in making the diagnosis.	VANDERBILT UNIV,MED CTR,DEPT PEDIAT,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT PREVENT MED,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT MED,DIV INFECT DIS,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University	WRIGHT, SW (corresponding author), VANDERBILT UNIV,MED CTR,DEPT EMERGENCY MED,703 OXFORD HOUSE,NASHVILLE,TN 37232, USA.			Decker, Michael/0000-0003-1008-7472	PHS HHS [N0I-M-02645] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADDISS DG, 1991, J INFECT DIS, V164, P704, DOI 10.1093/infdis/164.4.704; BRAMAN SS, 1985, PRIMARY CARE, V12, P217; CHERRY JD, 1989, WESTERN J MED, V150, P319; CHRISTIE CDC, 1994, NEW ENGL J MED, V331, P16, DOI 10.1056/NEJM199407073310104; CROMER BA, 1993, AM J DIS CHILD, V147, P575, DOI 10.1001/archpedi.1993.02160290081031; EDWARDS KM, 1993, JAMA-J AM MED ASSOC, V269, P53, DOI 10.1001/jama.269.1.53; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; HE QS, 1994, J PEDIATR-US, V124, P421, DOI 10.1016/S0022-3476(94)70365-5; HERWALDT LA, 1993, JAMA-J AM MED ASSOC, V269, P93, DOI 10.1001/jama.269.1.93; HERWALDT LA, 1991, ARCH INTERN MED, V109, P1510; LINNEMANN CC, 1977, ANNU REV MED, V28, P179, DOI 10.1146/annurev.me.28.020177.001143; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; MERTSOLA J, 1983, J PEDIATR-US, V103, P359, DOI 10.1016/S0022-3476(83)80403-X; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; PATRIARCA PA, 1988, AM J PUBLIC HEALTH, V78, P833, DOI 10.2105/AJPH.78.7.833; ROBERTSON PW, 1987, MED J AUSTRALIA, V147, P522; STEKETEE RW, 1988, J INFECT DIS, V157, P441, DOI 10.1093/infdis/157.3.441; STEKETEE RW, 1988, J INFECT DIS, V157, P434, DOI 10.1093/infdis/157.3.434; 1994, MMWR-MORBID MORTAL W, V42, P959; 1994, MMWR-MORBID MORTAL W, V42, P952	23	194	207	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1044	1046		10.1001/jama.273.13.1044	http://dx.doi.org/10.1001/jama.273.13.1044			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897789				2022-12-24	WOS:A1995QP89000036
J	HAMMEL, HB; BEEBE, RF; INGERSOLL, AP; ORTON, GS; MILLS, JR; SIMON, AA; CHODAS, P; CLARKE, JT; DEJONG, E; DOWLING, TE; HARRINGTON, J; HUBER, LF; KARKOSCHKA, E; SANTORI, CM; TOIGO, A; YEOMANS, D; WEST, RA				HAMMEL, HB; BEEBE, RF; INGERSOLL, AP; ORTON, GS; MILLS, JR; SIMON, AA; CHODAS, P; CLARKE, JT; DEJONG, E; DOWLING, TE; HARRINGTON, J; HUBER, LF; KARKOSCHKA, E; SANTORI, CM; TOIGO, A; YEOMANS, D; WEST, RA			HST IMAGING OF ATMOSPHERIC PHENOMENA CREATED BY THE IMPACT OF COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article							GREAT RED SPOT; JUPITERS	Hubble Space Telescope (HST) images reveal major atmospheric changes created by the collision of comet Shoemaker-Levy 9 with Jupiter. Plumes rose to 3000 kilometers with ejection velocities on the order of 10 kilometers second(-1); some plumes were visible in the shadow of Jupiter before rising into sunlight. During some impacts, the incoming bolide may have been detected. Impact times were on average about 8 minutes later than predicted. Atmospheric waves were seen with a wave front speed of 454 +/- 20 meters second(-1). The HST images reveal impact site evolution and record the overall change in Jupiter's appearance as a result of the bombardment.	MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA; CALTECH, DIV GEOL & PLANETARY SCI, PASADENA, CA 91125 USA; CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; UNIV MICHIGAN, DEPT ATMOSPHER & OCEAN SCI, ANN ARBOR, MI 48109 USA; UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; NEW MEXICO STATE UNIV, DEPT ASTRON, LAS CRUCES, NM 88003 USA	Massachusetts Institute of Technology (MIT); California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Michigan System; University of Michigan; University of Arizona; New Mexico State University	HAMMEL, HB (corresponding author), MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA.		Clarke, John/C-8644-2013; Dowling, Timothy E/J-4537-2013; Simon, Amy/C-8020-2012; Harrington, Joseph/E-6250-2011; Santori, Charles/A-7314-2009; Orton, Glenn/AAD-9862-2020	Dowling, Timothy E/0000-0002-7400-2274; Simon, Amy/0000-0003-4641-6186; Harrington, Joseph/0000-0002-8955-8531				AHRENS TJ, 1994, GEOPHYS RES LETT, V21, P1087, DOI 10.1029/94GL01325; [Anonymous], COMMUNICATION; Atreya S. K., 1986, ATMOSPHERES IONOSPHE; BELTON MJS, 1992, SPACE SCI REV, V60, P413, DOI 10.1007/BF00216864; BOSLOUGH MB, 1994, GEOPHYS RES LETT, V21, P1555, DOI 10.1029/94GL01582; BRONSHTEN VA, 1983, PHYSICS METEORIC PHE; BURROWS CJ, 1994, WIDE FIELD PLANETARY; CHODAS PW, COMMUNICATION; CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; DOWLING T, 1980, CLASSICAL MECHANICS, P40; DOWLING TE, 1989, J ATMOS SCI, V46, P3256, DOI 10.1175/1520-0469(1989)046<3256:JGRSAA>2.0.CO;2; GIERASCH PJ, 1986, ICARUS, V67, P456, DOI 10.1016/0019-1035(86)90125-9; HARRINGTON J, 1994, NATURE, V368, P525, DOI 10.1038/368525a0; HERBST T, UNPUB; HOLTZMAN JA, IN PRESS PUBL ASTRON; INGERSOLL AP, 1994, GEOPHYS RES LETT, V21, P1083, DOI 10.1029/94GL01057; INGERSOLL AP, 1981, J GEOPHYS RES-SPACE, V86, P8733, DOI 10.1029/JA086iA10p08733; INGERSOLL AP, UNPUB; LOW MMM, 1986, ICARUS, V65, P353, DOI 10.1016/0019-1035(86)90143-0; MACLOW MM, 1994, B AM ASTRON SOC, V26, P926; MARCUS PS, 1988, NATURE, V331, P693, DOI 10.1038/331693a0; Martin T, COMMUNICATION; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; SCOTTI J, 1994, 26TH ANN DIV PLAN SC; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEISSMAN P, 1994, NATURE, V370, P94, DOI 10.1038/370094a0; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; WILLIAMS GP, 1988, J ATMOS SCI, V45, P207, DOI 10.1175/1520-0469(1988)045<0207:TSAGOR>2.0.CO;2; ZAHNLE K, 1994, ICARUS, V108, P1, DOI 10.1006/icar.1994.1038; [No title captured]	31	177	181	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	1995	267	5202					1288	1296		10.1126/science.7871425	http://dx.doi.org/10.1126/science.7871425			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871425				2022-12-24	WOS:A1995QK06800030
J	HEIM, MH; KERR, IM; STARK, GR; DARNELL, JE				HEIM, MH; KERR, IM; STARK, GR; DARNELL, JE			CONTRIBUTION OF STAT SH2 GROUPS TO SPECIFIC INTERFERON SIGNALING BY THE JAK-STAT PATHWAY	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; MUTANT-CELL LINE; TRANSCRIPTION FACTOR; TRANSDUCTION; GAMMA; ALPHA; COMPLEMENTATION; PHOSPHORYLATION; POLYPEPTIDE; ACTIVATION	In response to specific ligands, various STAT proteins (signal transducers and activators of transcription) are phosphorylated on tyrosine by Jak protein kinases and translocated to the nucleus to direct gene transcription. Selection of a STAT at the interferon gamma receptor as well as specific STAT dimer formation depended on the presence of particular SH2 groups (phosphotyrosine-binding domains), whereas the amino acid sequence Surrounding the phosphorylated tyrosine on the STAT could vary. Thus, SH2 groups in STAT proteins may play crucial roles in specificity at the receptor kinase complex and in subsequent dimerization, whereas the kinases are relatively nonspecific.	ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; CLEVELAND CLIN FDN,RES INST,CLEVELAND,OH 44195	Rockefeller University; Cancer Research UK; Cleveland Clinic Foundation			Heim, Markus/A-7526-2008	Heim, Markus/0000-0002-7523-4894	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034420, R01AI032489, R01AI034420] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32489, AI34420] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTGETSINGER LS, 1993, CELL, V74, P237; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HEIM MH, UNPUB; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; LEUNG S, IN PRESS MOL CELL BI; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, UNPUB; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1994, NATURE, V366, P580; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG ZP, UNPUB	25	312	318	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1347	1349		10.1126/science.7871432	http://dx.doi.org/10.1126/science.7871432			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871432				2022-12-24	WOS:A1995QK06800045
J	KEEFE, AD; NEWTON, GL; MILLER, SL				KEEFE, AD; NEWTON, GL; MILLER, SL			A POSSIBLE PREBIOTIC SYNTHESIS OF PANTETHEINE, A PRECURSOR TO COENZYME-A	NATURE			English	Article							PURINE NUCLEOSIDES; ACIDS	THE involvement of coenzyme A in many enzyme reactions suggests that it acted in this capacity very early in the development of life on Earth. Particularly relevant in this regard is its role in the activation of amino acids and hydroxy acids in the biosynthesis of some peptide antibiotics(1,2)-a mechanism of peptide synthesis that forms the basis for the proposal that a thioester world(3) could have preceded the RNA world(4), The components of coenzyme A have been shown to be probable prebiotic compounds: beta-alanine, pantoyl lactone and cysteamine(5,6) and possibly adenosine(7,8). We show here that the pantetheine moiety of coenzyme A (which also occurs in a number of enzymes) can be synthesized in yields of several per cent by heating pantoyl lactone, beta-alanine and cysteamine at temperatures as low as 40 degrees C. These components are extremely soluble and so would have been preferentially concentrated in evaporating bodies of water, for example on beaches and at lagoon margins. Our results show that amide bonds can be formed at temperatures as low as 40 degrees C, and provide circumstantial support for the suggestion that pantetheine and coenzyme A were important in the earliest metabolic systems.			KEEFE, AD (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.							BISHOP MJ, 1972, NATURE, V237, P162, DOI 10.1038/237162a0; de Duve C, 1991, BLUEPRINT CELL NATUR; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; Fox SW, 1972, MOL EVOLUTION ORIGIN; FULLER WD, 1972, J MOL EVOL, V1, P249, DOI 10.1007/BF01660244; FULLER WD, 1972, J MOL BIOL, V67, P25, DOI 10.1016/0022-2836(72)90383-X; GESTELAND RF, 1993, RNA WORLD; GUNNING HE, 1966, ADV PHOTOCHEM, V4, P143; KVENVOLDEN KA, 1971, P NATL ACAD SCI USA, V68, P486, DOI 10.1073/pnas.68.2.486; LAKINTHOMAS PL, 1985, EUR J BIOCHEM, V146, P141, DOI 10.1111/j.1432-1033.1985.tb08630.x; LOHRMANN R, 1977, J MOL EVOL, V10, P137, DOI 10.1007/BF01751807; Miller S. L., 1974, ORIGINS LIFE EARTH; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; Peltzer E T, 1984, Adv Space Res, V4, P69, DOI 10.1016/0273-1177(84)90546-5; ROHLFING DL, 1976, SCIENCE, V193, P68, DOI 10.1126/science.935858; SCHLESINGER G, 1993, J MOL EVOL, V36, P308; SCHLESINGER G, 1993, J MOL EVOL, V36, P302; Smith ERB, 1940, J BIOL CHEM, V132, P47; Torchinsky Y, 1981, SULFUR PROTEINS	19	59	59	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					683	685		10.1038/373683a0	http://dx.doi.org/10.1038/373683a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854449				2022-12-24	WOS:A1995QH92800049
J	DAVIS, JG; OBERHOLTZER, JC; BURNS, FR; GREENE, MI				DAVIS, JG; OBERHOLTZER, JC; BURNS, FR; GREENE, MI			MOLECULAR-CLONING AND CHARACTERIZATION OF AN INNER EAR-SPECIFIC STRUCTURAL PROTEIN	SCIENCE			English	Article							TRIPLE-HELICAL DOMAINS; X COLLAGEN GENE; TECTORIAL MEMBRANE; HAIR-CELLS; MONOCLONAL-ANTIBODIES; OTOLITHIC MEMBRANE; V COLLAGEN; LOCALIZATION; ORGANIZATION; COCHLEA	Molecular biological studies of the mammalian inner ear have been limited by the relatively small size of the sensory endorgans contained within. The saccular otolithic organ in teleostian fish is structurally similar to its mammalian counterpart but can contain an order of magnitude more sensory cells. The prospect of the evolutionary conservation of proteins utilized in the vertebrate inner ear and the relative abundance of teleostian saccular sensory tissue made this an attractive system for molecular biological studies. A complementary DNA obtained by differential screening of a saccular complementary DNA library was identified that encodes an inner ear-specific collagen molecule.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DIV NEUROPATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Burns, Frank/0000-0001-9528-4808	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000069] Funding Source: NIH RePORTER; NIDCD NIH HHS [K08-DC00069] Funding Source: Medline; NINDS NIH HHS [5 T32 NS07064-13] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIGES M, 1983, ACTA OTO-LARYNGOL, V95, P522, DOI 10.3109/00016488309139436; CORWIN JT, 1981, J COMP NEUROL, V201, P541, DOI 10.1002/cne.902010406; CORWIN JT, 1991, ANNU REV NEUROSCI, V14, P301, DOI 10.1146/annurev.neuro.14.1.301; DAVIS JG, 1994, THESIS U PENNSYLVANI; DOHLMAN GF, 1960, NEURAL MECHANISMS AU, P258; DRESCHER DG, 1989, BRAIN RES, V485, P225, DOI 10.1016/0006-8993(89)90565-9; GILLESPIE PG, 1991, J CELL BIOL, V112, P625, DOI 10.1083/jcb.112.4.625; GOODYEAR R, 1994, HEARING RES, V80, P93, DOI 10.1016/0378-5955(94)90013-2; HASKO JA, 1988, HEARING RES, V35, P21, DOI 10.1016/0378-5955(88)90037-8; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; KACHAR B, 1990, HEARING RES, V45, P179, DOI 10.1016/0378-5955(90)90119-A; KAWAMATA S, 1993, ACTA OTOLARYNGOL S S, V504, P30; KHAN KM, 1990, HEARING RES, V43, P149, DOI 10.1016/0378-5955(90)90224-D; KILLICK R, 1992, HEARING RES, V64, P21, DOI 10.1016/0378-5955(92)90165-J; KILLICK R, 1994, MAY MECH SENS REG C; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Lewis E. R., 1985, VERTEBRATE INNER EAR; Lim D J, 1973, Adv Otorhinolaryngol, V19, P35; Lim D J, 1973, Ann Otol Rhinol Laryngol, V82, P23; LIM DJ, 1990, ACTA OTO-LARYNGOL, V110, P224, DOI 10.3109/00016489009122541; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; OBERHOLTZER JC, 1986, HEARING RES, V23, P161, DOI 10.1016/0378-5955(86)90013-4; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; Platt C., 1981, HEARING SOUND COMMUN; POPPER AN, 1984, HEARING RES, V15, P133, DOI 10.1016/0378-5955(84)90044-3; POPPER AN, 1993, BRAIN BEHAV EVOLUT, V41, P14, DOI 10.1159/000113821; PRIETO JJ, 1991, HEARING RES, V54, P59, DOI 10.1016/0378-5955(91)90136-W; PRIETO JJ, 1990, HEARING RES, V45, P51, DOI 10.1016/0378-5955(90)90182-O; REID KBM, 1990, IMMUNOL TODAY, V11, P387, DOI 10.1016/0167-5699(90)90150-8; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; RICHARDSON GP, 1987, HEARING RES, V25, P45, DOI 10.1016/0378-5955(87)90078-5; SAWADA H, 1984, EUR J CELL BIOL, V35, P226; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SCHMID TM, 1984, J ULTRA MOL STRUCT R, V86, P186, DOI 10.1016/S0022-5320(84)80057-X; SHEPHERD GMG, 1989, P NATL ACAD SCI USA, V86, P4973, DOI 10.1073/pnas.86.13.4973; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SLEPECKY NB, 1992, ACTA OTO-LARYNGOL, V112, P611, DOI 10.3109/00016489209137449; SLEPECKY NB, 1992, CELL TISSUE RES, V267, P413, DOI 10.1007/BF00319363; SOKOLOWSKI BHA, 1986, SCANNING ELECTRON MI, V4, P1635; SPRINGER J, 1991, J HISTOCHEM CYTOCHEM, V39, P23; STEEL K, 1980, ACTA OTO-LARYNGOL, V89, P27, DOI 10.3109/00016488009127104; STEEL KP, 1983, HEARING RES, V9, P327, DOI 10.1016/0378-5955(83)90035-7; SUMMERS TA, 1988, J BIOL CHEM, V263, P581; TAKUMIDA M, 1992, ACTA OTO-LARYNGOL, V112, P643, DOI 10.3109/00016489209137454; THALMANN I, 1987, LARYNGOSCOPE, V97, P357; THALMANN I, 1980, ARCH OTO-RHINO-LARYN, V226, P123, DOI 10.1007/BF00455126; TILNEY MS, 1989, J CELL BIOL, V109, P1711, DOI 10.1083/jcb.109.4.1711; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P1602; ZAJIC G, 1991, HEARING RES, V52, P59, DOI 10.1016/0378-5955(91)90187-E	57	67	69	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1031	1034		10.1126/science.7863331	http://dx.doi.org/10.1126/science.7863331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863331				2022-12-24	WOS:A1995QG99000041
J	TONG, P; THOMAS, T; BERRISH, T; HUMPHRISS, D; BARRIOCANAL, L; STEWART, M; WALKER, M; WILKINSON, R; ALBERTI, KGMM				TONG, P; THOMAS, T; BERRISH, T; HUMPHRISS, D; BARRIOCANAL, L; STEWART, M; WALKER, M; WILKINSON, R; ALBERTI, KGMM			CELL-MEMBRANE DYNAMICS AND INSULIN-RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							FLUIDITY; PROTEINS	Insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) could be ralated to changes in cell membrane properties. We measured insulin sensitivity and mononuclear leucocyte membrane fluidity by fluorescence polarisation in fifteen NIDDM patients and twenty-one normal subjects. Core-region anisotropy was significantly lower in leucocytes from diabetic subjects (mean 0.164 vs 0.174, p<0.001). Insulin sensitivity was positively correlated with such anisotropy before and after acute invitro insulin treatment. There was no difference in superficial membrane anisotropy. This study suggests that altered membrane dynamics in NIDDM may contribute to insulin resistance.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,SUBDEPT NEPHROL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	TONG, P (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.							AKINMOKUN A, 1992, DIABETIC MED, V9, P432, DOI 10.1111/j.1464-5491.1992.tb01813.x; BECKNIELSEN H, 1977, DIABETOLOGIA, V13, P563, DOI 10.1007/BF01236308; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DANEMAN D, 1992, DIABETES, V41, P227, DOI 10.2337/diabetes.41.2.227; KINNUNEN PKJ, 1991, CHEM PHYS LIPIDS, V57, P375, DOI 10.1016/0009-3084(91)90087-R; LONNROTH P, 1991, J INTERN MED, V229, P23; TONG P, 1994, BIOCHEM MED METAB B, V52, P132, DOI 10.1006/bmmb.1994.1044; WATALA C, 1992, EUR J CLIN CHEM CLIN, V30, P513; WATALA C, 1993, DIABETIC MED, V10, P13, DOI 10.1111/j.1464-5491.1993.tb01990.x; WINOCOUR PD, 1992, J LAB CLIN MED, V120, P921	10	56	59	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					357	358		10.1016/S0140-6736(95)90343-7	http://dx.doi.org/10.1016/S0140-6736(95)90343-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845118				2022-12-24	WOS:A1995QF72200011
J	HEAGERTY, AM				HEAGERTY, AM			WINNING RHYTHM	LANCET			English	Editorial Material											HEAGERTY, AM (corresponding author), UNIV HOSP S MANCHESTER,DEPT MED,MANCHESTER M20 8LR,LANCS,ENGLAND.			Heagerty, Anthony/0000-0002-9043-2119				BENNET WC, 1935, TARAHUMARA INDIAN TR, P113; EDWARDS RG, 1972, J APPL PHYSIOL, V32, P386, DOI 10.1152/jappl.1972.32.3.386; NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P270; OROURKE M, 1993, AUST NZ J MED, V23, P703; PALATINI P, 1989, J APPL PHYSIOL, V67, P52, DOI 10.1152/jappl.1989.67.1.52; ROST R, 1983, MUNCHEN MED WOCHEN, V125, P1025; ROWE WJ, 1992, LANCET, V340, P712, DOI 10.1016/0140-6736(92)92243-9; ROWELL LB, 1968, CIRCULATION, V37, P954, DOI 10.1161/01.CIR.37.6.954; VANCITTERS RL, 1969, CIRC RES, V24, P33, DOI 10.1161/01.RES.24.1.33	9	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					310	310		10.1016/S0140-6736(94)91160-6	http://dx.doi.org/10.1016/S0140-6736(94)91160-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905142				2022-12-24	WOS:A1994MU98500006
J	LISSAU, I; SORENSEN, TIA				LISSAU, I; SORENSEN, TIA			PARENTAL NEGLECT DURING CHILDHOOD AND INCREASED RISK OF OBESITY IN YOUNG ADULTHOOD	LANCET			English	Article							BODY-MASS INDEX; ADOPTION	The association of various features of family life with obesity in childhood is well established, but less is known about the effect of these influences on the risk of later obesity. In this prospective, population-based study, we examined the influence of parental care in childhood on the risk of obesity in the offspring in young adulthood. In 1974, 1258 pupils aged 9-10 years were randomly selected from the third grade of Copenhagen schools. Information on 987 pupils was obtained from the form teachers on family structure and the perceived support from the parents; school medical services reported on the child's general hygiene. 756 (86%) of the 881 eligible participants were followed up 10 years later. The influence of family factors in childhood on the risk of obesity (body-mass index > 95th centile) in young adulthood was estimated by odds ratios with control for age and body-mass index in 1974, sex, and social background. Family structure (biological or other parents and number of siblings) did not significantly affect the risk of adult obesity. Parental neglect greatly increased the risk in comparison with harmonious support (odds ratio 7.1 [95% CI 2.6-19.3]). Dirty and neglected children had a much greater risk of adult obesity than averagely groomed children (9.8 [3.5-28.2]). However, being an only child, receiving overprotective parental support, or being well-groomed had no effect. Parental neglect during childhood predicts a great risk of obesity in young adulthood, independent of age and body-mass index in childhood, sex, and social background.	UNIV COPENHAGEN, RIGSHOSP, DEPT PAEDIAT, DK-2100 COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen	LISSAU, I (corresponding author), KOMMUNE HOSP COPENHAGEN, INST PREVENT MED, COPENHAGEN HLTH SERV, DK-1399 COPENHAGEN, DENMARK.		Lissau, Inge/AAJ-3971-2020	Lissau, Inge/0000-0002-2225-9975				BRUCH H, 1957, IMPORTANCE OVERWEIGH; DIETZ WH, 1984, AM J CLIN NUTR, V39, P619, DOI 10.1093/ajcn/39.4.619; DIETZ WH, 1986, PEDIATR CLIN N AM, V33, P823; FRIISASCHE E, 1981, THESIS COPENHAGEN; GARROW JS, 1992, INT J OBESITY, V16, pS59; GARROW JS, 1988, MANAGEMENT PREVENTIO; HERTZEL BS, 1987, CARDIOVASCULAR RISK; JOHNSTON FE, 1985, ANN INTERN MED, V103, P1068, DOI 10.7326/0003-4819-103-6-1068; KINSTON W, 1988, J PSYCHOSOM RES, V32, P513, DOI 10.1016/0022-3999(88)90036-0; LISSAU I, 1993, INT J OBESITY, V17, P125; LISSAU I, 1993, INT J OBESITY, V17, P169; LISSAU I, 1993, THESIS U COPENHAGEN; LISSAULUNDSORENSEN I, 1992, INT J OBESITY, V16, P169; LOADER PJ, 1985, INT J EAT DISORDER, V4, P211, DOI 10.1002/1098-108X(198505)4:2<211::AID-EAT2260040208>3.0.CO;2-P; POWER C, 1988, INT J OBESITY, V12, P445; QUAADE F, 1955, OBESE CHILDREN ANTHR; SILVERMAN WK, 1987, BEHAV THERAPIST, V10, P197; SORENSEN TIA, 1992, INT J OBESITY, V16, P705; SORENSEN TIA, 1992, INT J OBESITY, V16, P227; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; 1985, SAS USERS GUIDE STAT	21	316	320	1	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	1994	343	8893					324	327		10.1016/S0140-6736(94)91163-0	http://dx.doi.org/10.1016/S0140-6736(94)91163-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905145				2022-12-24	WOS:A1994MU98500009
J	CATASSI, C; RATSCH, IM; FABIANI, E; ROSSINI, M; BORDICCHIA, F; CANDELA, F; COPPA, GV; GIORGI, PL				CATASSI, C; RATSCH, IM; FABIANI, E; ROSSINI, M; BORDICCHIA, F; CANDELA, F; COPPA, GV; GIORGI, PL			CELIAC-DISEASE IN THE YEAR 2000 - EXPLORING THE ICEBERG	LANCET			English	Article							SELECTIVE IGA DEFICIENCY; CELIAC-DISEASE; ANTIGLIADIN ANTIBODIES; CHILDREN; MALIGNANCY	lt is now generally believed that subclinical coeliac disease is common in the general population. We have undertaken screening for this disorder in a school district in central Italy. Screening was divided into three levels: first, IgG and IgA antigliadin antibody (AGA) assay on capillary blood obtained by finger prick; second. AGA plus IgA anti-endomysium antibody (AEA) test and measurement of serum immunoglobulins in venous blood: and third, intestinal biopsy. 3351 students (66% of the eligible population) aged 11-15 years attended first level screening. 71 (2%) were recalled because of AGA positivity; 18 of these satisfied second-level criteria and underwent intestinal biopsy. Coeliac disease was diagnosed in 11 subjects, most of whom had no serious symptoms. Selective IgA deficiency was found in 4 subjects, 1 of whom also had coeliac disease. The prevalence of subclinical coeliac disease in the study group was 3.28 per 1000. Coeliac disease screening is feasible and involves only slight discomfort to the general population. Such screening can detect large numbers of cases of coeliac disease, which can be treated with a gluten-free diet. Many subclinical cases of coeliac disease would not be detected by screening only a selected group of at-risk patients.	G SALESI CHILDRENS HOSP, DEPT CLIN CHEM, ANCONA, ITALY		CATASSI, C (corresponding author), UNIV ANCONA, DEPT PEDIAT, VIA CORRIDONI 11, I-60123 ANCONA, ITALY.							BARERA G, 1991, ARCH DIS CHILD, V66, P491, DOI 10.1136/adc.66.4.491; BURGINWOLFF A, 1989, EUR J PEDIATR, V148, P496, DOI 10.1007/BF00441541; BURGINWOLFF A, 1991, ARCH DIS CHILD, V66, P941, DOI 10.1136/adc.66.8.941; CACCIARI E, 1985, LANCET, V1, P1469; COLLIN P, 1992, SCAND J GASTROENTERO, V27, P367, DOI 10.3109/00365529209000089; CORAZZA G, 1992, GASTROENTEROLOGY, V103, P1517, DOI 10.1016/0016-5085(92)91172-Z; CUNNINGHAMRUNDLES C, 1981, CLIN EXP IMMUNOL, V45, P299; FERGUSON MM, 1980, GUT, V21, P223, DOI 10.1136/gut.21.3.223; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Greco L., 1992, COMMON FOOD INTOLERA, P25; GRODZINSKY E, 1992, ANN ALLERGY, V69, P66; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; HOLMES GKT, 1992, COMMON FOOD INTOLERA, V1, P105; KOISTINEN J, 1975, VOX SANG, V29, P192, DOI 10.1111/j.1423-0410.1975.tb00494.x; Logan R. F. A., 1992, COMMON FOOD INTOLERA, P14; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; MAKI M, 1992, COMMON FOOD INTOLERA, V1, P93; MAZZETTI DP, 1992, ITAL J GASTROENTEROL, V24, P352; SAVILAHTI E, 1983, LANCET, V1, P320; SWINSON CM, 1983, LANCET, V1, P111; TRONCONE R, 1991, J PEDIATR GASTR NUTR, V12, P150, DOI 10.1097/00005176-199102000-00002; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909	22	618	641	0	45	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	1994	343	8891					200	203		10.1016/S0140-6736(94)90989-X	http://dx.doi.org/10.1016/S0140-6736(94)90989-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904667				2022-12-24	WOS:A1994MT33200008
J	EASTWOOD, R; SCHNEIDERMAN, G				EASTWOOD, R; SCHNEIDERMAN, G			COUCH FELLOWS	LANCET			English	Editorial Material											EASTWOOD, R (corresponding author), CLARKE INST PSYCHIAT, TORONTO M5T 1R8, ONTARIO, CANADA.							ANDREWS G, 1989, AM J PSYCHIAT, V146, P881; CAILLARD VF, 1992, INT PSYCHIATRY TODAY, V2, P1; KUPFER DJ, 1993, J CLIN PSYCHIAT, V54, P29; PAYKEL ES, 1993, INT ACAD B, V5, P62; REYNOLDS CF, 1992, AM J PSYCHIAT, V149, P1687; RODENHAUSER P, 1993, INT J GROUP PSYCHOTH, V43, P11, DOI 10.1080/00207284.1994.11491203	6	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	1994	343	8890					131	132		10.1016/S0140-6736(94)90929-6	http://dx.doi.org/10.1016/S0140-6736(94)90929-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903999				2022-12-24	WOS:A1994MQ86900005
J	GREWE, M; GYUFKO, K; SCHOPF, E; KRUTMANN, J				GREWE, M; GYUFKO, K; SCHOPF, E; KRUTMANN, J			LESIONAL EXPRESSION OF INTERFERON-GAMMA IN ATOPIC ECZEMA	LANCET			English	Note							DERMATITIS	Atopic eczema is thought to be caused by skin-infiltrating CD4 T cells of the Th1-like and/or Th2-like subtype. We assessed expression of the Th1-like cytokine, interferon-gamma, and the Th2-like cytokine, interleukin-4, in lesional atopic skin. Compared with that in normal skin, interferon-gamma and interleukin-4 mRNA expression were increased in eczematous skin lesions in 13 and 4 of 15 patients, respectively. After successful therapy of atopic dermatitis, the increased interferon-gamma mRNA expression but not the increased interleukin-4 mRNA expression was significantly down-regulated. These data indicate that in-situ expression of interferon-gamma is linked to the clinical course of atopic dermatitis.			KRUTMANN, J (corresponding author), UNIV FREIBURG,DEPT DERMATOL,PHOTODERMATOL SECT,D-79104 FREIBURG,GERMANY.							BOS JD, 1992, ARCH DERMATOL, V128, P1509, DOI 10.1001/archderm.128.11.1509; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HENNINGER HP, 1991, BIOCH BIOPHYS HOPPE, V374, P625; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KRUTMANN J, 1992, J AM ACAD DERMATOL, V26, P225, DOI 10.1016/0190-9622(92)70031-A; KRUTMANN J, 1994, EPIDERMAL CYTOKINES, P4415; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SZER N, 1992, J ALLERGY CLIN IMMUN, V89, P801	9	345	354	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					25	26		10.1016/S0140-6736(94)90879-6	http://dx.doi.org/10.1016/S0140-6736(94)90879-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905045				2022-12-24	WOS:A1994MN93700015
J	BONITA, R; BROAD, JB; BEAGLEHOLE, R				BONITA, R; BROAD, JB; BEAGLEHOLE, R			CHANGES IN STROKE INCIDENCE AND CASE-FATALITY IN AUCKLAND, NEW-ZEALAND, 1981-91	LANCET			English	Article							CEREBROVASCULAR-DISEASE; COMMUNITY; DECLINE; PROJECT; TRENDS; RATES	The explanation for the substantial decline in stroke death rates can be investigated only by measuring trends in stroke incidence and case-fatality. Two community-based studies carried out in Auckland, New Zealand, in 1981 and 1991 used comparable methods and definitions, met criteria for well-designed studies, and had the power to detect small changes in incidence and case-fatality rates. 703 events (representing 50% of all strokes) were registered in 1981 and 1735 events in 1991. 521 (74.1%) and 1255 (72.3%) events in 1981 and 1991, respectively, were first-ever (in a lifetime) strokes. Although there was no change in overall stroke incidence between 1981 and 1991, there were changes in age and sex groups. The incidence rate among women younger than 75 years rose by a fifth (rate ratio 1.23 [95% CI 1.04-1.47]), whereas that in men of 75 years and older fell by a third (rate ratio 0.67 [0.54-0.82]). The 28-day case-fatality declined from 27.1 (21.7-32.6)% to 21.9 (18.1-25.7)% in men and from 37.6 (31.8-43.5)%to 25.8 (22.3-29.4)% in women from 1981 to 1991, but the decline was not statistically significant in any age or sex group. These findings suggest that we need to reappraise strategies for the prevention of stroke and assess the implications of improved survival in elderly stroke patients.	UNIV AUCKLAND,SCH MED,DEPT MED,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland; University of Auckland			Broad, Joanna B/D-1194-2010	Broad, Joanna B/0000-0003-0157-7031				ANDERSON CS, 1993, MED J AUSTRALIA, V158, P80, DOI 10.5694/j.1326-5377.1993.tb137528.x; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BONITA R, 1983, COMMUNITY HEALTH ST, V7, P111; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; BONITA R, 1984, AM J EPIDEMIOL, V120, P236, DOI 10.1093/oxfordjournals.aje.a113885; BONITA R, 1993, LANCET, V341, P1510, DOI 10.1016/0140-6736(93)90640-3; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; FRASER GE, 1978, INT J EPIDEMIOL, V7, P277, DOI 10.1093/ije/7.3.277; GARRAWAY WM, 1983, MAYO CLIN PROC, V58, P520; HARMSEN P, 1992, STROKE, V23, P1410, DOI 10.1161/01.STR.23.10.1410; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; MALMGREN R, 1987, LANCET, V2, P1196; MALMGREN R, 1989, BRIT MED J, V298, P656, DOI 10.1136/bmj.298.6674.656; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; TERENT A, 1988, STROKE, V19, P598, DOI 10.1161/01.STR.19.5.598; Waterhouse J., 1976, CANCER INCIDENCE 5 C, V3, P456; 1988, J CLIN EPIDEMIOL, V41, P105	18	148	149	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1470	1473		10.1016/0140-6736(93)92938-P	http://dx.doi.org/10.1016/0140-6736(93)92938-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902487				2022-12-24	WOS:A1993ML21700014
J	NICHOLLS, N				NICHOLLS, N			EL-NINO-SOUTHERN OSCILLATION AND VECTOR-BORNE DISEASE	LANCET			English	Article											NICHOLLS, N (corresponding author), BUR METEOROL RES CTR,POB 1289K,MELBOURNE 3001,AUSTRALIA.		Nicholls, Neville/A-1240-2008	Nicholls, Neville/0000-0002-1298-4356				LIEHNE PFS, 1988, GREENHOUSE PLANNING, P752; MEEHL GA, 1993, SCIENCE, V260, P1101, DOI 10.1126/science.260.5111.1101; NICHOLLS N, 1986, AUST J EXP BIOL MED, V64, P587, DOI 10.1038/icb.1986.62; Nicholls N., 1991, TELECONNECTIONS LINK, P493; 1990, CLIMATE CHANGE IPCC	5	105	110	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1284	1285		10.1016/0140-6736(93)92368-4	http://dx.doi.org/10.1016/0140-6736(93)92368-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901589				2022-12-24	WOS:A1993MH56600018
J	FIORETTO, P; MAUER, SM; BILOUS, RW; GOETZ, FC; SUTHERLAND, DER; STEFFES, MW				FIORETTO, P; MAUER, SM; BILOUS, RW; GOETZ, FC; SUTHERLAND, DER; STEFFES, MW			EFFECTS OF PANCREAS TRANSPLANTATION ON GLOMERULAR STRUCTURE IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH THEIR OWN KIDNEYS	LANCET			English	Article							ISLET TRANSPLANTATION; NEPHROPATHY; MELLITUS; SURFACE; VOLUME; RATS	Pancreas transplantation prevents or retards development of earlY diabetic glomerular lesions in renal allografts transplanted to patients with insulin-dependent diabetes mellitus (IDDM), but its effect on established renal lesions in native kidneys of such patients is unknown. Renal biopsy samples were taken before and 5 years after pancreas transplantation from 13 non-uraemic IDDM patients and compared with baseline and 5-year biopsy samples from 10 persistently hyperglycaemic IDDM patients who did not undergo transplantation. The two groups were similar in age, duration of diabetes, metabolic control, renal function, and blood pressure. Glomerular structures were measured by standard morphometric techniques. Haemoglobin A1 concentrations fell to within the normal range after pancreas transplantation but did not change in the comparison group. Glomerular basement membrane width did not significantly change in either group. Glomerular volume decreased and mesangial fractional volume increased in the pancreas transplant recipients but there was no significant change in total mesangial volume over 5 years. By contrast, both glomerular volume and mesangial fractional volume increased in the comparison patients, resulting in increased total mesangial volume. Diabetic glomerular lesions in patients with their own kidneys were not ameliorated by pancreas transplantation, despite 5 years of normoglycaemia. Pancreas transplantation can correct severe metabolic instability and thus improve quality of life, but it cannot yet be recommended for the treatment of established lesions of diabetic nephropathy.	UNIV MINNESOTA,SCH MED,DEPT PEDIAT,DULUTH,MN 55812; UNIV MINNESOTA,SCH MED,DEPT MED,DULUTH,MN 55812; UNIV MINNESOTA,SCH MED,DEPT SURG,DULUTH,MN 55812; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,DULUTH,MN 55812; MIDDLESBROUGH GEN HOSP,DEPT MED,MIDDLESBROUGH,ENGLAND	University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth			fioretto, paola/AHD-4415-2022	FIORETTO, PAOLA/0000-0003-3445-0387	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017697, P01DK013083, R01DK043605] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-17697, DK-43605, DK-13083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBOSA J, 1992, DIABETES S1, V41; BERTANI T, 1991, KIDNEY INT, V40, P243, DOI 10.1038/ki.1991.206; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; BILOUS RW, 1989, DIABETES, V38, P1142, DOI 10.2337/diabetes.38.9.1142; BOHMAN SO, 1985, DIABETES, V34, P306, DOI 10.2337/diabetes.34.3.306; De Francisco A M, 1987, J Diabet Complications, V1, P128, DOI 10.1016/S0891-6632(87)80070-3; ELLIS EN, 1986, KIDNEY INT, V29, P889, DOI 10.1038/ki.1986.82; ELLIS EN, 1986, METHODS DIABETES RES, V2, P633; FUETREN G, 1992, NEW ENGL J MED, V326, P1654; JENSEN EB, 1979, J MICROSC-OXFORD, V115, P19, DOI 10.1111/j.1365-2818.1979.tb00149.x; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; ORLOFF MJ, 1986, DIABETES, V35, P347, DOI 10.2337/diabetes.35.3.347; OSTERBY R, 1980, DIABETOLOGIA, V18, P493; PEREJDA AJ, 1982, COLLAGEN REL RES, V2, P83; RAMSAY RC, 1988, NEW ENGL J MED, V318, P208, DOI 10.1056/NEJM198801283180403; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; STEFFES MW, 1980, DIABETES, V29, P509, DOI 10.2337/diab.29.7.509; STEFFES MW, 1979, LAB INVEST, V41, P116; STEFFES MW, 1992, DIABETES, V41, P679, DOI 10.2337/diabetes.41.6.679; SUTHERLAND DER, 1989, ANN SURG, V210, P274, DOI 10.1097/00000658-198909000-00003; SUTHERLAND DER, 1988, SURGERY, V104, P453; ZEHRER CL, 1991, DIABETOLOGIA S1, V34, P145	25	131	132	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1193	1196		10.1016/0140-6736(93)92183-T	http://dx.doi.org/10.1016/0140-6736(93)92183-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901527				2022-12-24	WOS:A1993MG27400007
J	ERNST, JA; CLUBB, RT; ZHOU, HX; GRONENBORN, AM; CLORE, GM				ERNST, JA; CLUBB, RT; ZHOU, HX; GRONENBORN, AM; CLORE, GM			DEMONSTRATION OF POSITIONALLY DISORDERED WATER WITHIN A PROTEIN HYDROPHOBIC CAVITY BY NMR	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; FOLDING THERMODYNAMICS; TRYPSIN-INHIBITOR; CRYSTAL-STRUCTURE; AQUEOUS-SOLUTION; INTERLEUKIN-1-BETA; HYDRATION; SPECTROSCOPY; RESOLUTION; MOLECULES	The presence and location of water of hydration (thai is, bound water) in the solution structure of human interleukin-1 beta (hIL-1 beta) was investigated with water-selective two-dimensional heteronuclear magnetic resonance spectroscopy. It is shown here that in addition to water al the surface of the protein and ordered internal water molecules involved in bridging hydrogen bonds, positionally disordered water is present within a large, naturally occurring hydrophobic cavity located at the center oi the molecule. These water molecules of hydration have residency times in the range of 1 to 2 nanoseconds to 100 to 200 microseconds and can be readily detected by nuclear magnetic resonance (NMR). Thus, large hydrophobic cavities in proteins may not be truly empty, as analysis oi crystal structures appears to show, but may contain mobile water molecules that are crystallographically invisible but detectable by NMR.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			zhou, huan/GYJ-4398-2022; Zhou, Huan-Xiang/M-5170-2016; Zhou, Huan-Xiang/AAH-9836-2020; Clore, G. Marius/A-3511-2008	Zhou, Huan-Xiang/0000-0001-9020-0302; Zhou, Huan-Xiang/0000-0001-9020-0302; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				Ben-Naim A., 1987, SOLVATION THERMODYNA; BENNAIM A, 1984, J CHEM PHYS, V81, P2016, DOI 10.1063/1.447824; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1994, STRUCTURE, V2, P89, DOI 10.1016/S0969-2126(00)00011-3; DELAGLIO F, 1994, 35TH P EXP NUCL MAGN, P262; EDSALL JT, 1983, ADV BIOPHYS, V16, P53; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FINNEY JL, 1977, PHILOS T ROY SOC B, V278, P3, DOI 10.1098/rstb.1977.0029; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRZESIEK S, 1994, J AM CHEM SOC, V116, P1581, DOI 10.1021/ja00083a058; GRZESIEK S, 1993, J BIOMOL NMR, V3, P627; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; JEFFERY GA, 1994, HYDROGEN BONDING BIO, V14, P770; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; KARPLUS PA, 1994, CURR OPIN STRUC BIOL, V4, P770, DOI 10.1016/S0959-440X(94)90178-3; KOSSIAKOFF AA, 1992, PROTEINS, V12, P223, DOI 10.1002/prot.340120303; LEE TW, 1970, J CHEM PHYS, V52, P6353; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; Lovas F. J., 1978, Journal of Physical and Chemical Reference Data, V7, P1445, DOI 10.1063/1.555588; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MCLACHLAN AD, 1979, J MOL BIOL, V133, P557, DOI 10.1016/0022-2836(79)90408-X; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ONESTI S, 1991, J MOL BIOL, V217, P153, DOI 10.1016/0022-2836(91)90618-G; OTTING G, 1989, J AM CHEM SOC, V111, P1871, DOI 10.1021/ja00187a050; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PRATT LR, 1980, J CHEM PHYS, V73, P3430, DOI 10.1063/1.440540; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; RAVISHANKER G, 1982, FARADAY S CHEM SER, V17, P70; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WALSHAW J, 1993, J MOL BIOL, V231, P392, DOI 10.1006/jmbi.1993.1290; Westhof E., 1993, WATER BIOL MACROMOLE; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; WOLFENDEN R, 1994, SCIENCE, V265, P936, DOI 10.1126/science.8052849; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHOU HX, 1993, BIOPHYS J, V65, P955, DOI 10.1016/S0006-3495(93)81094-4; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	49	238	243	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1813	1817		10.1126/science.7892604	http://dx.doi.org/10.1126/science.7892604			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892604				2022-12-24	WOS:A1995QN70200037
J	WILCOCKSON, RW; CREAN, CS; DAY, TH				WILCOCKSON, RW; CREAN, CS; DAY, TH			HERITABILITY OF A SEXUALLY SELECTED CHARACTER EXPRESSED IN BOTH SEXES	NATURE			English	Article							TAIL ORNAMENT SIZE; COELOPA-FRIGIDA; SEAWEED FLY; MATING PREFERENCE; MATE CHOICE; EVOLUTION; DIMORPHISM; PARASITES; TRAITS	SEXUAL selection is thought to be responsible for the evolution of exaggerated male characters and of female mate preferences(1-7). Evolutionary mechanisms driven by an advantage to the progeny are only effective if the preferred character has a large genetic component of variance; in most systems in which sexual selection operates, little is known of the relevant genetics(8), We have measured parent-offspring correlations, and report here that the preferred character (adult size) in seaweed flies has large additive genetic variance in males, but not in females, Virtually all the variance in male size is attributable to a chromosomal inversion system and, consequently, because this system is also a major determinant of larval viability(9,10), male size could be used by females as a reliable indicator of offspring survival.	UNIV NOTTINGHAM, QUEENS MED CTR, DEPT GENET, NOTTINGHAM NG7 2UH, ENGLAND	University of Nottingham								ALATALO RV, 1988, BIOL J LINN SOC, V34, P363, DOI 10.1111/j.1095-8312.1988.tb01969.x; ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; Andersson Malte, 1994; AZIZ JB, 1975, THESIS U NEWCASTLE T; BORGIA G, 1990, AM ZOOL, V30, P279; BUTLIN RK, 1985, HEREDITY, V54, P107, DOI 10.1038/hdy.1985.14; BUTLIN RK, 1984, HEREDITY, V52, P415, DOI 10.1038/hdy.1984.49; BUTLIN RK, 1982, HEREDITY, V48, P45, DOI 10.1038/hdy.1982.5; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; DAY TH, 1982, HEREDITY, V48, P35, DOI 10.1038/hdy.1982.4; Falconer D. S., 1989, Introduction to quantitative genetics.; GILBURN AS, 1994, GENET RES, V64, P19, DOI 10.1017/S001667230003250X; GILBURN AS, 1992, HEREDITY, V69, P209, DOI 10.1038/hdy.1992.118; HOULE D, 1992, GENETICS, V130, P195; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LANDE R, 1980, EVOLUTION, V34, P292, DOI 10.1111/j.1558-5646.1980.tb04817.x; LANDE R, 1985, J THEOR BIOL, V117, P651, DOI 10.1016/S0022-5193(85)80245-9; MILINSKI M, 1990, NATURE, V344, P330, DOI 10.1038/344330a0; MOLLER AP, 1991, EVOLUTION, V45, P1823, DOI 10.1111/j.1558-5646.1991.tb02690.x; POMIANKOWSKI A, 1991, EVOLUTION, V45, P1422, DOI 10.1111/j.1558-5646.1991.tb02645.x; POMIANKOWSKI A, IN PRESS P R SOC B; RITCHIE MG, 1992, TRENDS ECOL EVOL, V7, P328, DOI 10.1016/0169-5347(92)90123-S; SIMMONS LW, 1991, J EVOLUTION BIOL, V4, P593, DOI 10.1046/j.1420-9101.1991.4040593.x; SMITH JM, 1991, TRENDS ECOL EVOL, V6, P146, DOI 10.1016/0169-5347(91)90055-3; ZUK M, 1990, AM ZOOL, V30, P235; [No title captured]	26	43	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	1995	374	6518					158	159		10.1038/374158a0	http://dx.doi.org/10.1038/374158a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877687				2022-12-24	WOS:A1995QL39700057
J	DICKERSON, JEC; BROWN, MJ				DICKERSON, JEC; BROWN, MJ			INFLUENCE OF AGE ON GENERAL-PRACTITIONERS DEFINITION AND TREATMENT OF HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT		UNIV CAMBRIDGE,ADDENBROOKES HOSP,CLIN PHARMACOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge								BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; HART JT, 1993, BRIT MED J, V306, P437, DOI 10.1136/bmj.306.6875.437; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; 1985, BRIT MED J, V291, P97; 1992, BRIT MED J, V304, P405	5	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					574	574		10.1136/bmj.310.6979.574	http://dx.doi.org/10.1136/bmj.310.6979.574			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888934	Green Published, Green Submitted			2022-12-24	WOS:A1995QK70000022
J	ORTON, G; AHEARN, M; BAINES, K; DEMING, D; DOWLING, T; GOGUEN, J; GRIFFITH, C; HAMMEL, H; HOFFMANN, W; HUNTEN, D; JEWITT, D; KOSTIUK, T; MILLER, S; NOLL, K; ZAHNLE, K; ACHILLEOS, N; DAYAL, A; DEUTSCH, L; ESPENAK, F; ESTERLE, P; FRIEDSON, J; FAST, K; HARRINGTON, J; HORA, J; JOSEPH, R; KELLY, D; KNACKE, R; LACY, J; LISSE, C; RAYNER, J; SPRAGUE, A; SHURE, M; WELLS, K; YANAMANDRAFISHER, P; ZIPOY, D; BJORAKER, G; BUHL, D; GOLISCH, W; GRIEP, D; KAMINSKI, C; ARDEN, C; CHAIKIN, A; GOLDSTEIN, J; GILMORE, D; FAZIO, G; KANAMORI, T; LAM, H; LIVENGOOD, T; MACLOW, MM; MARLEY, M; MOMARY, T; ROBERTSON, D; ROMANI, P; SPITALE, J; SYKES, M; TENNYSON, J; WELLNITZ, D; YING, SW				ORTON, G; AHEARN, M; BAINES, K; DEMING, D; DOWLING, T; GOGUEN, J; GRIFFITH, C; HAMMEL, H; HOFFMANN, W; HUNTEN, D; JEWITT, D; KOSTIUK, T; MILLER, S; NOLL, K; ZAHNLE, K; ACHILLEOS, N; DAYAL, A; DEUTSCH, L; ESPENAK, F; ESTERLE, P; FRIEDSON, J; FAST, K; HARRINGTON, J; HORA, J; JOSEPH, R; KELLY, D; KNACKE, R; LACY, J; LISSE, C; RAYNER, J; SPRAGUE, A; SHURE, M; WELLS, K; YANAMANDRAFISHER, P; ZIPOY, D; BJORAKER, G; BUHL, D; GOLISCH, W; GRIEP, D; KAMINSKI, C; ARDEN, C; CHAIKIN, A; GOLDSTEIN, J; GILMORE, D; FAZIO, G; KANAMORI, T; LAM, H; LIVENGOOD, T; MACLOW, MM; MARLEY, M; MOMARY, T; ROBERTSON, D; ROMANI, P; SPITALE, J; SYKES, M; TENNYSON, J; WELLNITZ, D; YING, SW			COLLISION OF COMET SHOEMAKER-LEVY-9 WITH JUPITER OBSERVED BY THE NASA INFRARED TELESCOPE FACILITY	SCIENCE			English	Article							ETHANE	The National Aeronautics and Space Administration (NASA) Infrared Telescope Facility was used to investigate the collision of comet Shoemaker-Levy 9 with Jupiter from 12 July to 7 August 1994. Strong thermal infrared emission lasting several minutes was observed after the impacts of fragments C, G, and R. All impacts warmed the stratosphere and some the troposphere up to several degrees. The abundance of stratospheric ammonia increased by more than 50 times. Impact-related particles extended up to a level where the atmospheric pressure measured several millibars. The north polar near-infrared aurora brightened by nearly a factor of 5 a week after the impacts.	UNIV MARYLAND, DEPT ASTRON, COLLEGE PK, MD 20742 USA; NASA, GODDARD SPACE FLIGHT CTR, GREENBELT, MD 20771 USA; MIT, CAMBRIDGE, MA 02139 USA; NO ARIZONA UNIV, DEPT PHYS & ASTRON, FLAGSTAFF, AZ 86011 USA; UNIV ARIZONA, STEWARD OBSERV, TUCSON, AZ 85721 USA; UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; UCL, DEPT PHYS & ASTRON, LONDON WC1E 6BT, ENGLAND; SPACE TELESCOPE SCI INST, BALTIMORE, MD 21218 USA; NASA, AMES RES CTR, MOFFETT FIELD, CA 94053 USA; UNIV MASSACHUSETTS, FIVE COLL ASTRON DEPT, AMHERST, MA 01003 USA; UNIV TEXAS, DEPT ASTRON, AUSTIN, TX 78712 USA; PENN STATE UNIV, ERIE, PA 16563 USA; UNIV ST ANDREWS, DEPT PHYS, ST ANDREWS, FIFE, SCOTLAND; SMITHSONIAN INST, NATL AIR & SPACE MUSEUM, WASHINGTON, DC 20560 USA; SMITHSONIAN ASTROPHYS OBSERV, CAMBRIDGE, MA 02138 USA; STANFORD UNIV, DEPT MECH ENGN & DESIGN, STANFORD, CA 94305 USA; UNIV CHICAGO, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA; NEW MEXICO STATE UNIV, DEPT ASTRON, LAS CRUCES, NM 88003 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA; UNIV LEICESTER, DEPT PHYS & ASTRON, LEICESTER LE1 7RH, LEICS, ENGLAND; CALTECH, PASADENA, CA 91126 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2BZ, ENGLAND	University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Northern Arizona University; University of Arizona; University of Arizona; University of Hawaii System; University of London; University College London; Space Telescope Science Institute; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Massachusetts System; University of Massachusetts Amherst; University of Texas System; University of Texas Austin; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of St Andrews; Smithsonian Institution; Harvard University; Smithsonian Institution; Stanford University; University of Chicago; New Mexico State University; University of California System; University of California Los Angeles; University of Leicester; California Institute of Technology; Imperial College London	ORTON, G (corresponding author), CALTECH, JET PROP LAB, 4800 OAK GROVE DR, PASADENA, CA 91109 USA.		Romani, Paul N/D-2729-2012; Harrington, Joseph/E-6250-2011; Bjoraker, Gordon L/D-5032-2012; Achilleos, Nicholas/C-1647-2008; Kostiuk, Theodor/A-3077-2014; Goguen, Jay/E-5389-2018; Orton, Glenn/AAD-9862-2020; Livengood, Timothy A/C-8512-2012; Wellnitz, Dennis/B-4080-2012; Marley, Mark S/I-4704-2013; Tennyson, Jonathan/I-2222-2012; Dowling, Timothy E/J-4537-2013; Lisse, Carey M/B-7772-2016; Low, Mordecai-Mark Mac/AAN-1967-2021; Noll, Keith/C-8447-2012	Tennyson, Jonathan/0000-0002-4994-5238; Dowling, Timothy E/0000-0002-7400-2274; Lisse, Carey M/0000-0002-9548-1526; Low, Mordecai-Mark Mac/0000-0003-0064-4060; Miller, Steven/0000-0002-7159-6871; Rayner, John/0000-0002-3165-159X; Achilleos, Nicholas/0000-0002-5886-3509; Hora, Joseph/0000-0002-5599-4650; Harrington, Joseph/0000-0002-8955-8531				ATREYA SK, 1981, ASTROPHYS J, V147, pL43; CALDWELL J, 1983, ICARUS, V53, P133, DOI 10.1016/0019-1035(83)90026-X; DROSSART P, 1989, NATURE, V340, P539, DOI 10.1038/340539a0; FESTOU MC, 1981, J GEOPHYS RES-SPACE, V86, P5715, DOI 10.1029/JA086iA07p05715; FLASAR M, 1986, NASA SPEC PUBL, V494, P324; GIERASCH PJ, 1986, ICARUS, V67, P456, DOI 10.1016/0019-1035(86)90125-9; GRAHAM JR, 1995, SCIENCE, V167, P1320; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P313, DOI 10.1117/12.158684; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; HARRINGTON J, 1994, NATURE, V368, P525, DOI 10.1038/368525a0; HOFFMANN WF, 1993, P SOC PHOTO-OPT INS, V1946, P449, DOI 10.1117/12.158697; HOFFMANN WF, 1994, INFRARED PHYS TECHN, V35, P175, DOI 10.1016/1350-4495(94)90079-5; HUNTEN DH, 1994, GEOPHYS RES LETT, V1, P1094; JEWITT D, 1994, COMMUNICATION   0719; KIM SJ, 1988, ICARUS, V75, P399, DOI 10.1016/0019-1035(88)90153-4; KOSTIUK T, 1987, ICARUS, V72, P394, DOI 10.1016/0019-1035(87)90182-5; KOSTIUK T, 1983, APPL OPTICS, V22, P2644, DOI 10.1364/AO.22.002644; KOSTIUK T, 1994, INFRARED PHYS TECHN, V35, P243, DOI 10.1016/1350-4495(94)90084-1; LACY JH, 1989, PUBL ASTRON SOC PAC, V101, P1166, DOI 10.1086/132593; LIVENGOOD TA, 1993, J GEOPHYS RES-PLANET, V98, P18813, DOI 10.1029/93JE01043; MARLEY MS, 1994, ASTROPHYS J, V427, pL63, DOI 10.1086/187365; MILLER S, 1995, GEOPHYS RES LETT, V22, P1629, DOI 10.1029/95GL00700; NICHOLSON PD, IN PRESS GEOPHYS RES; ORTON G, 1992, B AM ASTRON SOC, V24, P1041; ORTON GS, 1991, SCIENCE, V252, P537, DOI 10.1126/science.252.5005.537; ORTON GS, 1994, SCIENCE, V265, P625, DOI 10.1126/science.265.5172.625; RAYNER J, 1993, P SOC PHOTO-OPT INS, V1946, P490, DOI 10.1117/12.158701; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426	28	64	64	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1277	1282		10.1126/science.7871423	http://dx.doi.org/10.1126/science.7871423			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871423				2022-12-24	WOS:A1995QK06800028
J	SZANKASI, P; SMITH, GR				SZANKASI, P; SMITH, GR			A ROLE FOR EXONUCLEASE-I FROM S-POMBE IN MUTATION AVOIDANCE AND MISMATCH CORRECTION	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; DNA; REPAIR; ENDONUCLEASE; EXCISION	Exonuclease I (Exo I) from Schizosaccharomyces pombe, a 5' --> 3' double-stranded DNA exonuclease, is induced during meiotic prophase I. The exo1 gene is a member of a family of related DNA repair genes, including RAD2/rad13/xpgc and YKL510/rad2, conserved from yeast to humans. An exo1 mutant displays a mutator phenotype and alters activity of the ade6-M387 marker effect. These results suggest that Exo I acts in a pathway that corrects mismatched base pairs.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center				Smith, Gerald/0000-0002-8747-1352	NCI NIH HHS [P30 CA15704-20] Funding Source: Medline; NIGMS NIH HHS [GM32194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P145; CLAVERYS JP, 1983, P NATL ACAD SCI-BIOL, V80, P5956, DOI 10.1073/pnas.80.19.5956; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DETLOFF P, 1992, GENETICS, V132, P113; DEVEAUX LC, 1992, GENETICS, V130, P251; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLECK O, IN PRESS NUCLEIC ACI; GRIMM C, 1994, GENETICS, V136, P41; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIEB M, 1986, GENETICS, V114, P1041; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MARYON E, 1989, MOL CELL BIOL, V9, P4862, DOI 10.1128/MCB.9.11.4862; MCGREADY SJ, 1989, CURR GENET, V15, P27; MOORE CW, 1988, GENETICS, V119, P21; MUNZ P, 1975, MUTAT RES, V29, P155, DOI 10.1016/0027-5107(75)90030-5; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; Phipps J, 1985, Adv Genet, V23, P1, DOI 10.1016/S0065-2660(08)60511-8; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P963; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAR P, 1993, GENETICS, V133, P825; SCHAR P, 1993, GENETICS, V133, P815; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SMITH GR, 1988, MICROBIOL REV, V52, P1; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; SZANKASI P, UNPUB; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WHITE JH, 1985, NATURE, V315, P350, DOI 10.1038/315350a0; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; WILLIAMSON MS, 1985, GENETICS, V110, P609	49	179	183	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1166	1169		10.1126/science.7855597	http://dx.doi.org/10.1126/science.7855597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855597				2022-12-24	WOS:A1995QJ23700037
J	HEBERLEIN, U; SINGH, CM; LUK, AY; DONOHOE, TJ				HEBERLEIN, U; SINGH, CM; LUK, AY; DONOHOE, TJ			GROWTH AND DIFFERENTIATION IN THE DROSOPHILA EYE COORDINATED BY HEDGEHOG	NATURE			English	Article							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; BETA FAMILY; HAIRY GENE; EXPRESSION; PROTEIN; HOMOLOG; DIRECTS; RETINA	DIFFERENTIATION Of the Drosophila retina is asynchronous: it starts at the posterior margin of the eye imaginal disc and progresses anteriorly over two days. During this time the disc continues to grow, increasing in size by approximately eightfold, An indentation in the epithelium, the morphogenetic furrow(1), marks the front edge of the differentiation wave. Anterior progression of the furrow is thought to be driven by signals emanating from differentiating photoreceptor cells in the posterior eye disc(2,3). A good candidate for such a signal is the product of the hedgehog (hh) gene(4-7); it is expressed, and presumably secreted, by differentiating photoreceptors and its function is required for continued furrow movement(2,3). Here we show that ectopic expression of hedgehog sets in motion ectopic furrows in the anterior eye disc, In addition to changes in cell shape, these ectopic furrows are associated with a tightly orchestrated series of events, including proliferation, cell cycle synchronization and pattern formation, that parallel normal furrow progression. We propose that the morphogenetic furrow coincides with a transient boundary that coordinates growth and differentiation of the eye disc, and that hedgehog is necessary and sufficient to propagate this boundary across the epithelium.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	HEBERLEIN, U (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT NEUROL,GALLO CTR BLDG 1,RM 101,SAN FRANCISCO,CA 94110, USA.							ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BROWN NL, 1991, DEVELOPMENT, V113, P1245; BROWN NL, IN PRESS CELL; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thomas Barbara J., 1994, Trends in Cell Biology, V4, P389, DOI 10.1016/0962-8924(94)90051-5; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5	30	176	182	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					709	711		10.1038/373709a0	http://dx.doi.org/10.1038/373709a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854455				2022-12-24	WOS:A1995QH92800057
J	STRACHAN, DP; LEON, DA; DODGEON, B				STRACHAN, DP; LEON, DA; DODGEON, B			MORTALITY FROM CARDIOVASCULAR-DISEASE AMONG INTERREGIONAL MIGRANTS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; GEOGRAPHIC VARIATIONS; DEATH RATES; ADULT LIFE; MIGRATION; INFANCY; BRITAIN; STROKE	Objective-To investigate the extent to which geographical variations in mortality from ischaemic heart disease and stroke in Britain are influenced by factors in early life or in adulthood. Design-Longitudinal study of migrants. Subjects-1% sample of residents in England and Wales born before October 1939 and enumerated at the 1971 census (the Office of Population Censuses and Surveys' longitudinal study). Main outcome measure-18221 deaths from ischaemic heart disease and 9899 deaths from stroke during 1971-88 were analysed by areas of residence in 1939 and 1971. These included 2928 deaths from ischaemic heart disease and 1608 deaths from stroke among individuals moving between 14 areas defined by the major conurbations and nine standard administrative regions of England and Wales. Results-The southeast to northwest gradient in mortality from ischaemic heart disease was related significantly to both the 1939 area (chi(2)=6.09, df=1) and area in 1971 (chi(2)=5.05, df=1). Geographical variations in mortality from stroke were related significantly to the 1939 area (chi(2)=4.09, df=1) but the effect of area in 1971 was greater (chi(2)=8.07, df=1). The effect of 1971 area on mortality from stroke was largely due to a lower risk of death from stroke among individuals moving into Greater London compared with migrants to the rest of the South East region (chi(2)=4.54, df=1). Conclusions-Geographical variations in mortality from cardiovascular disease in Britain may be partly determined by genetic factors, environmental exposures, or lifestyle acquired early in life, but the risk of fatal ischaemic heart disease and stroke changes on migration between areas with differing mortality. The low risk of death from stroke associated with residence in Greater London is acquired by individuals who move there.	LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON EC1V 0HB,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; City University London	STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762				BAKER RJ, 1978, GLIM SYSTEM; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARKER DJP, 1987, BMJ-BRIT MED J, V295, P83, DOI 10.1136/bmj.295.6590.83; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1992, BRIT MED J, V305, P1551, DOI 10.1136/bmj.305.6868.1551; Barker DJP, 1992, FETAL INFANT ORIGINS; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BRITTON M, 1990, SERIES DS, V9, P80; ELFORD J, 1989, LANCET, V1, P343; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; FOX AJ, 1982, SERIES LS, V1; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEON DA, 1993, ENVIRON PLANN A, V25, P1441, DOI 10.1068/a251441; MARMOT MG, 1984, LANCET, V1, P1003; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; OSMOND C, 1990, SERIES DS, V9, P96; WILLIAMS DRR, 1979, J EPIDEMIOL COMMUNIT, V39, P199; 1944, NATIONAL REGISTER UK; 1932, REGISTRAR GENERALS 1; 1937, REGISTRAR GENERALS 1; 1935, REGISTRAR GENERALS 1; 1933, REGISTRAR GENERALS 1; 1936, REGISTRAR GENERALS 1; 1934, REGISTRAR GENERALS 1; 1931, REGISTRAR GENERALS 1; 1938, REGISTRAR GENERALS 1; 1975, REORGANISATION LOCAL	29	54	56	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					423	427		10.1136/bmj.310.6977.423	http://dx.doi.org/10.1136/bmj.310.6977.423			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873946	Green Published			2022-12-24	WOS:A1995QJ24200015
J	MALNATI, MS; PERUZZI, M; PARKER, KC; BIDDISON, WE; CICCONE, E; MORETTA, A; LONG, EO				MALNATI, MS; PERUZZI, M; PARKER, KC; BIDDISON, WE; CICCONE, E; MORETTA, A; LONG, EO			PEPTIDE SPECIFICITY IN THE RECOGNITION OF MHC CLASS-I BY NATURAL-KILLER-CELL CLONES	SCIENCE			English	Article							VIRUS-INFECTED CELLS; COMPLEX CLASS-I; NK CLONES; HLA-C; MOLECULES; BINDING; HLA-B27; LYSIS; SELF; BETA-2-MICROGLOBULIN	Recognition by natural killer (NK) cells of major histocompatibility complex (MHC) class I molecules on target cells inhibits NK-mediated lysis. Here, inhibition of NK clones by HLA-B*2705 molecules mutated at single amino acids in the peptide binding site varied among HLA-B*2705-specific NK clones. In addition, a subset of such NK clones was inhibited by only one of several self peptides loaded onto HLA-B*2705 molecules expressed in peptide transporter-deficient cells, showing that recognition was peptide-specific. These data demonstrate that specific self peptides, complexed with MHC class I, provide protection from NK-mediated lysis.	NIAID,IMMUNOGENET LAB,ROCKVILLE,MD 20852; NIAID,MOLEC STRUCT LAB,ROCKVILLE,MD 20852; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV GENOA,IST ISTOL & EMBRIOL GEN,I-16132 GENOA,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Genoa; IRCCS AOU San Martino IST; University of Genoa			Malnati, Mauro/AAN-4207-2020; Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728; Malnati, mauro/0000-0001-5355-1680; Parker, Kenneth/0000-0002-6282-2478				ANDERSON KS, 1993, J IMMUNOL, V151, P3407; BELLONE G, 1993, J EXP MED, V177, P1117, DOI 10.1084/jem.177.4.1117; CARBONE E, 1993, EUR J IMMUNOL, V23, P1752, DOI 10.1002/eji.1830230803; CARRENO BM, 1992, MOL IMMUNOL, V29, P1131, DOI 10.1016/0161-5890(92)90046-Z; CARRENO BM, 1993, INT IMMUNOL, V5, P353, DOI 10.1093/intimm/5.4.353; CHADWICK BS, 1992, J IMMUNOL, V149, P3150; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; CICCONE E, 1994, EUR J IMMUNOL, V24, P1003, DOI 10.1002/eji.1830240434; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; DIBRINO M, 1994, J IMMUNOL, V152, P620; DIBRINO M, 1994, J BIOL CHEM, V269, P32426; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KAUFMAN DS, 1992, P NATL ACAD SCI USA, V89, P8337, DOI 10.1073/pnas.89.17.8337; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; LJUNGGREN HG, 1994, P NATL ACAD SCI USA, V91, P6520, DOI 10.1073/pnas.91.14.6520; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MALNATI MS, 1993, J EXP MED, V178, P961, DOI 10.1084/jem.178.3.961; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; PARKER KC, 1994, BIOCHEMISTRY-US, V33, P7736, DOI 10.1021/bi00190a029; PARKER KC, 1992, J IMMUNOL, V149, P1896; STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; STORKUS WJ, 1992, J IMMUNOL, V149, P1185; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	31	282	288	1	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1016	1018		10.1126/science.7863326	http://dx.doi.org/10.1126/science.7863326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863326				2022-12-24	WOS:A1995QG99000036
J	AFONSO, LCC; SCHARTON, TM; VIEIRA, LQ; WYSOCKA, M; TRINCHIERI, G; SCOTT, P				AFONSO, LCC; SCHARTON, TM; VIEIRA, LQ; WYSOCKA, M; TRINCHIERI, G; SCOTT, P			THE ADJUVANT EFFECT OF INTERLEUKIN-12 IN A VACCINE AGAINST LEISHMANIA-MAJOR	SCIENCE			English	Article							CELL STIMULATORY FACTOR; CUTANEOUS LEISHMANIASIS; PROTECTIVE IMMUNITY; INTERFERON-GAMMA; MURINE MODEL; INDUCTION; SUBSETS	Protection induced by vaccination depends on the capacity of the vaccine to elicit an appropriate immune response. In leishmaniasis, protection requires leishmanial-specific CD4+ T helper (T(H)) cells. Vaccination of BAL-B/c mice with leishmanial antigens and interleukin-12 (IL-12) promoted the development of leishmanial-specific CD4+ T(H)1 cells These mice were resistant to subsequent infection with Leishmania major. Thus, IL-12 is an effective adjuvant for the initiation of protective cell-mediated immunity against leishmaniasis and may be an important component in other vaccines that need tc induce cell-mediated immunity.	UNIV PENN,SCH VET MED,DEPT PATHOBIOL,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute			Trinchieri, Giorgio/F-9369-2015; Vieira, Leda Q/G-7487-2014; Vieira, Leda Quercia/AAD-3424-2019; Afonso, Luis C C/C-2224-2013; Afonso, Luis C C/G-5436-2012	Trinchieri, Giorgio/0000-0001-5892-7464; Vieira, Leda Quercia/0000-0001-5481-9618; Afonso, Luis C C/0000-0003-2498-4086; Afonso, Luis C C/0000-0003-2498-4086	NATIONAL CANCER INSTITUTE [R01CA020833, R37CA020833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030073] Funding Source: NIH RePORTER; NCI NIH HHS [CA-20833] Funding Source: Medline; NIAID NIH HHS [AI-30073] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFONSO LCC, UNPUB; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; MACATONIA SE, 1993, INT IMMUNOL, V5, P1119, DOI 10.1093/intimm/5.9.1119; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; SCOTT P, 1987, J IMMUNOL, V139, P221; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; WARREN HS, 1986, ANNU REV IMMUNOL, V4, P369, DOI 10.1146/annurev.iy.04.040186.002101	18	661	707	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					235	237		10.1126/science.7904381	http://dx.doi.org/10.1126/science.7904381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	7904381				2022-12-24	WOS:A1994MQ87900038
J	DURRINGTON, PN				DURRINGTON, PN			HOW HDL PROTECTS AGAINST ATHEROMA	LANCET			English	Editorial Material							CHOLESTERYL-ESTER TRANSFER; DENSITY-LIPOPROTEIN; MUTATION				DURRINGTON, PN (corresponding author), UNIV MANCHESTER, DEPT MED, MANCHESTER M13 9PL, LANCS, ENGLAND.							[Anonymous], 1991, LANCET, V338, P666; ASSMANN G, 1989, INT CONGR SER, V826, P51; BAGDADE JD, 1991, EUR J CLIN INVEST, V21, P161, DOI 10.1111/j.1365-2362.1991.tb01805.x; BHATNAGAR D, 1992, ATHEROSCLEROSIS, V92, P49, DOI 10.1016/0021-9150(92)90009-6; BREWER HB, 1984, CLIN METABOLIC ASPEC, P273; DEEB SS, 1990, AM J HUM GENET, V46, P822; FAGER G, 1981, ARTERIOSCLEROSIS, V1, P273, DOI 10.1161/01.ATV.1.4.273; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; NEARY R, 1991, ATHEROSCLEROSIS, V89, P35, DOI 10.1016/0021-9150(91)90005-N; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; SIMONS LA, 1986, AM J CARDIOL, V57, pG5, DOI 10.1016/0002-9149(86)90659-4; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912	14	26	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1993	342	8883					1315	1316		10.1016/0140-6736(93)92243-M	http://dx.doi.org/10.1016/0140-6736(93)92243-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901633				2022-12-24	WOS:A1993MJ03900006
J	WILLIAMS, RS				WILLIAMS, RS			BOOSTING CARDIAC CONTRACTILITY WITH GENES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											WILLIAMS, RS (corresponding author), UNIV TEXAS,SW MED CTR,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017	1	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					817	818		10.1056/NEJM199503233321212	http://dx.doi.org/10.1056/NEJM199503233321212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862189				2022-12-24	WOS:A1995QN44200012
J	ALMROTH, S; LATHAM, MC				ALMROTH, S; LATHAM, MC			RATIONAL HOME MANAGEMENT OF DIARRHEA	LANCET			English	Editorial Material							CHILDHOOD DIARRHEA; HEALTH-EDUCATION; MOTHERS; DISEASE		CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Cornell University								[Anonymous], 1978, LANCET, V2, P300; BARROS FC, 1991, B WORLD HEALTH ORGAN, V69, P59; Benakappa D G, 1990, Indian J Pediatr, V57, P21, DOI 10.1007/BF02722124; BENTLEY ME, 1988, SOC SCI MED, V27, P75, DOI 10.1016/0277-9536(88)90165-7; BENTLEY ME, 1988, SOC SCI MED, V27, P107, DOI 10.1016/0277-9536(88)90168-2; CHUNG AW, 1948, J PEDIATR-US, V33, P1, DOI 10.1016/S0022-3476(48)80147-2; CHUNG AW, 1948, J PEDIATR-US, V33, P14, DOI 10.1016/S0022-3476(48)80148-4; FIELD M, 1977, NEW ENGL J MED, V297, P1121, DOI 10.1056/NEJM197711172972011; GREEN EC, 1985, SOC SCI MED, V20, P277, DOI 10.1016/0277-9536(85)90242-4; GREENOUGH WB, 1987, CEREAL BASED ORAL RE, P52; HOYLE B, 1980, AM J CLIN NUTR, V33, P2365, DOI 10.1093/ajcn/33.11.2365; HUFFMAN SL, 1991, J DIARRHOEAL DIS RES, V9, P295; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; Mahalanabis D, 1983, J Diarrhoeal Dis Res, V1, P76; MARTINEZ H, 1991, J DIARRHOEAL DIS RES, V9, P235; MULL JD, 1984, J FAM PRACTICE, V18, P485; OYOO A, 1991, HEALTH POLICY PLANN, V6, P380, DOI 10.1093/heapol/6.4.380; RASHEED P, 1993, SOC SCI MED, V36, P373, DOI 10.1016/0277-9536(93)90022-V; SCHULTZ SG, 1977, AM J PHYSIOL, V233, pE249, DOI 10.1152/ajpendo.1977.233.4.E249; Tulloch J, 1987, World Health Stat Q, V40, P110; WILSON R, 1989, CEREAL BASED ORAL RE, P13; 1993, SELECTION FLUIDS FOO; 1983, LANCET, V2, P259; 1990, WHO1988 1989 PROGR C; 1987, DECISION PROCESS EST; 1978, WHO CHRON, V32, P369; 1993, WHO1992 PROGR CONTR	27	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	1995	345	8951					709	711		10.1016/S0140-6736(95)90873-0	http://dx.doi.org/10.1016/S0140-6736(95)90873-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM732	7885128				2022-12-24	WOS:A1995QM73200014
J	ACKAH, AN; COULIBALY, D; DIGBEU, H; DIALLO, K; VETTER, KM; COULIBALY, IM; GREENBERG, AE; DECOCK, KM				ACKAH, AN; COULIBALY, D; DIGBEU, H; DIALLO, K; VETTER, KM; COULIBALY, IM; GREENBERG, AE; DECOCK, KM			RESPONSE TO TREATMENT, MORTALITY, AND CD4 LYMPHOCYTE COUNTS IN HIV-INFECTED PERSONS WITH TUBERCULOSIS IN ABIDJAN, COTE-DIVOIRE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; HIV-1-INFECTED PATIENTS; PULMONARY TUBERCULOSIS; ZAIRE; KENYA; MORBIDITY; KINSHASA; NAIROBI; CITY	We examined the severity of immune deficiency in patients with HIV-associated tuberculosis in Cote d'Ivoire and assessed its effect on mortality and response to treatment. Consecutive patients attending a tuberculosis treatment in Abidjan with smear-positive pulmonary or diagnosed extrapulmonary tuberculosis were tested for HIV-1 and HIV-2 infections and had CD4 lymphocyte counts measured. Patients received standard short-course chemotherapy. Analysis of outcome (restricted to smear-positive tuberculosis patients) was done at 6 months. The 247 HIV-positive patients were significantly more likely than the 312 HIV-negative patients to have CD4 lymphocyte counts of less than 200/mu L (43% vs 1%; odds ratio 56.9; [95% CI 19.7-185.3]) and 200-499/mu L (39% vs 14%, odds ratio 3.8; [2.5-5.9]). HIV-positive patients, median CD4 lymphocyte in those with extrapulmonary tuberculosis (198/mu L; n=67) was lower, but not significantly so, than among those with pulmonary tuberculosis (257/mu L; n=180). Among 460 patients with pulmonary tuberculosis, the overall mortality rate was significantly higher in HIV-positive than HIV-negative persons (6% vs 0.4%; relative risk 17.1 [2.2-131.4]), and increased with the severity of immune deficiency; mortality rates in HIV-positive patients with CD4 counts of <200/mu L and 200-499/mu L were 10% and 4%, relative risk 27.6 (3.5-220.8); and 11.5 (1.2-109), respectively, compared to HIV-negatives. Among patients completing treatment, cure rates were similar in HIV-positive patients (93%) and HIV-negative patients (92%), and were not related to CD4 counts. Severity of immune deficiency was the major determinant of mortality in HIV-associated tuberculosis. Among people completing treatment, microbiological response was satisfactory irrespective of serological or immune status.	PROJET RETRO CI,ABIDJAN,COTE IVOIRE; CTR ANTITUBERCULEUX,ABIDJAN,COTE IVOIRE; EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	Emory University; Centers for Disease Control & Prevention - USA								BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1993, LANCET, V342, P437, DOI 10.1016/0140-6736(93)92853-L; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DJOMAND G, 1994, AIDS, V8, P843, DOI 10.1097/00002030-199406000-00019; DJOMAND G, 1993, 8TH INT C AIDS AFR 8; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; KASSIM S, 1993, 8TH INT C AIDS AFR 8; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LOUIE E, 1986, CHEST, V256, P362; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; POZNIAK A, 1992, 8 INT C AIDS 3 STD W; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; 1986, WHO WKLY EPIDEMIOL R, V61, P72	20	190	194	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					607	610		10.1016/S0140-6736(95)90519-7	http://dx.doi.org/10.1016/S0140-6736(95)90519-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898177				2022-12-24	WOS:A1995QM07500007
J	PEYRAT, JP; BONNETERRE, J; LUBIN, R; VANLEMMENS, L; FOURNIER, J; SOUSSI, T				PEYRAT, JP; BONNETERRE, J; LUBIN, R; VANLEMMENS, L; FOURNIER, J; SOUSSI, T			PROGNOSTIC-SIGNIFICANCE OF CIRCULATING P53 ANTIBODIES IN PATIENTS UNDERGOING SURGERY FOR LOCOREGIONAL BREAST-CANCER	LANCET			English	Note							PROTEIN; EPITOPES	P53 mutations can lead to the production of P53 antibodies in serum of cancer patients. Here we studied the prognostic value of P53 antibodies in 353 primary breast cancer patients. P53 antibodies were detected in 42 cases (12%) and were negatively related to oestradiol and progesterone receptors. The median duration of follow-up for live patients was 5.3 years. In actuarial analyses, overall survival was worse in patients with P53 antibody (p<0.0005); in Cox's multivariate analysis, P53 antibody was an independent prognostic variable. Thus plasma assay of P53 antibody would be useful to select rapidly and easily a population of patients with poor prognosis.	CTR OSCAR LAMBRET,DEPT MED ONCOL,F-59020 LILLE,FRANCE; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE	UNICANCER; Centre Oscar Lambret; Institut National de la Sante et de la Recherche Medicale (Inserm)	PEYRAT, JP (corresponding author), CTR OSCAR LAMBRET,ONCOL MOLEC HUMAINE LAB,BP 307,F-59020 LILLE,FRANCE.			VANLEMMENS, LAURENCE/0000-0001-7799-1648; soussi, thierry/0000-0001-8184-3293				BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BONNETERRE J, 1990, CANCER RES, V50, P6931; CALLAHAN R, 1992, J NATL CANCER I, V84, P826, DOI 10.1093/jnci/84.11.826; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; LUBIN R, 1993, CANCER RES, V53, P5872; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845	9	141	142	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					621	622		10.1016/S0140-6736(95)90523-5	http://dx.doi.org/10.1016/S0140-6736(95)90523-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898180				2022-12-24	WOS:A1995QM07500011
J	TONG, G; SHEPHERD, D; JAHR, CE				TONG, G; SHEPHERD, D; JAHR, CE			SYNAPTIC DESENSITIZATION OF NMDA RECEPTORS BY CALCINEURIN	SCIENCE			English	Article							ISOLATED HIPPOCAMPAL-NEURONS; PROTEIN PHOSPHATASE-ACTIVITY; D-ASPARTATE RECEPTOR; CONDUCTANCES; PROBABILITY; RESPONSES; CULTURE; RELEASE; ACTIN; RAT	Desensitization is a phenomenon that is common to many ligand-gated ion channels but has been demonstrated only rarely with physiological stimulation. Numerous studies describe desensitization of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor by exogenous agonists, but whether synaptic stimulation causes desensitization has been unknown. Synaptic stimulation of NMDA receptors on rat hippocampal neurons resulted in desensitization that was prevented by intracellular 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), adenosine-5'-O-(3-thiotriphosphate) (ATP-gamma-S), or inhibitors of phosphatase 2B (calcineurin), but not by inhibitors of phosphatases 1 and 2A or of tyrosine phosphatases. Synaptic NMDA receptors may fluctuate between phosphorylated and dephosphorylated forms, depending on the rate of synaptic stimulation and the magnitude of the associated influx of calcium through NMDA receptors.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			Tong, Gary/AAC-9426-2022		NINDS NIH HHS [NS21419] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021419] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; CHIZHMAKOV IV, 1992, J PHYSIOL-LONDON, V448, P453, DOI 10.1113/jphysiol.1992.sp019051; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAHR CE, 1990, J NEUROSCI, V10, P3178; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; MAYER ML, 1987, J NEUROSCI, V7, P3230; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; PETHIG R, 1989, CELL CALCIUM, V10, P491, DOI 10.1016/0143-4160(89)90026-2; ROSENMUND C, 1995, J NEUROPHYSIOL, V73, P427, DOI 10.1152/jn.1995.73.1.427; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0	26	339	345	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1510	1512		10.1126/science.7878472	http://dx.doi.org/10.1126/science.7878472			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878472				2022-12-24	WOS:A1995QL49700041
J	NOLL, KS; MCGRATH, MA; TRAFTON, LM; ATREYA, SK; CALDWELL, JJ; WEAVER, HA; YELLE, RV; BARNET, C; EDGINGTON, S				NOLL, KS; MCGRATH, MA; TRAFTON, LM; ATREYA, SK; CALDWELL, JJ; WEAVER, HA; YELLE, RV; BARNET, C; EDGINGTON, S			HST SPECTROSCOPIC OBSERVATIONS OF JUPITER AFTER THE COLLISION OF COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article							CROSS-SECTION MEASUREMENTS; CARBON-MONOXIDE; NM; REGION; SO2; S2	Ultraviolet spectra obtained with the Hubble Space Telescope identified at least 10 molecules and atoms in the perturbed stratosphere near the G impact site, most never before observed in Jupiter. The large mass of sulfur-containing material, more than 10(14) grams in S-2 alone, indicates that many of the sulfur-containing molecules S-2, CS2, CS, H2S, and S+ may be derived from a sulfur-bearing parent molecule native to Jupiter. If so, the fragment must have penetrated at least as deep as the predicted NH4SH cloud at a pressure of approximately 1 to 2 bars, Stratospheric NH3 was also observed, which is consistent with fragment penetration below the cloud tops. Approximately 10(7) grams of neutral and ionized metals were observed in emission, including Mg II, Mg I, Si I, Fe I, and Fe II. Oxygen-containing molecules were conspicuous by their absence; upper limits for SO2, SO, CO, SiO, and H2O are derived,	UNIV TEXAS,DEPT ASTRON,AUSTIN,TX 78712; UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; INST SPACE & TERR SCI,SPACE ASTROPHYS LAB,N YORK,ON M3J 3K1,CANADA; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	University of Texas System; University of Texas Austin; University of Michigan System; University of Michigan; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	NOLL, KS (corresponding author), SPACE TELESCOPE SCI INST,3700 SAN MARTIN DR,BALTIMORE,MD 21218, USA.		Barnet, Christopher/F-5573-2010; Weaver, Harold A/D-9188-2016; Noll, Keith/C-8447-2012	Weaver, Harold A/0000-0003-0951-7762; 				AHEARN MF, 1983, ASTROPHYS J, V274, pL99, DOI 10.1086/184158; AHEARN MF, 1983, TR AP83044 U MAR TEC; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ANDERSON WR, 1979, J CHEM PHYS, V71, P821, DOI 10.1063/1.438372; Atreya S. K., 1987, ATMOSPHERES IONOSPHE; ATREYA SK, 1977, ICARUS, V31, P348, DOI 10.1016/0019-1035(77)90027-6; ATREYA SK, 1985, PLANETARY METEOROLOG, P17; BARROW RF, 1965, ELEMENTAL SULFUR; BEEBE R, COMMUNICATION; Chen F., UNPUB; CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; FELDMAN PD, 1993, ASTROPHYS J, V406, P279, DOI 10.1086/172439; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; JESSBURGER EK, 1989, COMPOSITION CORNETS; LANGHOFF S, COMMUNICATION; LARSON HP, 1984, ICARUS, V60, P621, DOI 10.1016/0019-1035(84)90169-6; LELLOUCH E, B AM ASTRON SOC; LEWIS JS, 1970, SCIENCE, V169, P472, DOI 10.1126/science.169.3944.472; MARTINEZ RD, 1992, GEOPHYS RES LETT, V19, P277, DOI 10.1029/91GL03165; MCGRATH MA, 1995, SCIENCE, V267, P1313, DOI 10.1126/science.7871429; MEYER KA, 1973, J CHEM PHYS, V59, P1933, DOI 10.1063/1.1680279; MOSES JI, UNPUB; NOLL KS, 1988, ASTROPHYS J, V324, P1210, DOI 10.1086/165975; ORTON G, 1995, SCIENCE, V267, P1277, DOI 10.1126/science.7871423; PRATHER MJ, 1978, ASTROPHYS J, V223, P1072, DOI 10.1086/156340; QUICK CR, 1981, J CHEM PHYS, V74, P4951, DOI 10.1063/1.441748; SMITH WH, 1969, J QUANT SPECTROSC RA, V9, P1191, DOI 10.1016/0022-4073(69)90106-X; TOZZI GP, UNPUB; TRAFTON LM, 1994, ASTROPHYS J, V421, P816, DOI 10.1086/173694; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; WIESE WL, 1969, NSRDSNBS22, V2; WU CYR, 1981, GEOPHYS RES LETT, V8, P769, DOI 10.1029/GL008i007p00769; XU H, 1993, GEOPHYS RES LETT, V20, P1035, DOI 10.1029/93GL00809; YEOMANS DK, COMMUNICATION; ZAHNLE K, 1994, ICARUS, V108, P1, DOI 10.1006/icar.1994.1038	36	109	109	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1307	1313		10.1126/science.7871428	http://dx.doi.org/10.1126/science.7871428			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871428				2022-12-24	WOS:A1995QK06800033
J	SWAFFIELD, JC; MELCHER, K; JOHNSTON, SA				SWAFFIELD, JC; MELCHER, K; JOHNSTON, SA			A HIGHLY CONSERVED ATPASE PROTEIN AS A MEDIATOR BETWEEN ACIDIC ACTIVATION DOMAINS AND THE TATA-BINDING PROTEIN	NATURE			English	Article							MOLECULAR-WEIGHT PROTEASES; SACCHAROMYCES-CEREVISIAE; MULTICATALYTIC PROTEINASE; 26-S PROTEASE; YEAST; GENE; GAL4; MEMBER; FAMILY; PURIFICATION	BIOCHEMICAL and genetic studies suggest the existence of mediators that work between the activation domains (ADs) of regulatory proteins and the basic transcriptional machinery. We have previously shown genetically that Sug1 interacts with the AD of the yeast activator Ga14(1). Here we provide evidence that the Sug1 protein of yeast binds directly to the ADs of Ga14 and the viral activator, VP16. Sug1 protein is associated with the TATA-binding protein in vivo and binds to it in vitro, consistent with a mediator function. We also demonstrate that Sug1 is not a component of the 26S proteasome, contrary to previous reports(2-5). Sug1 is a member of a large, highly conserved family of ATPases, implying a role for ATP hydrolysis in the activation of transcription.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75325; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75325	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Melcher, Karsten/AAZ-3861-2020	Melcher, Karsten/0000-0002-9125-4027				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA CP, 1992, J BIOL CHEM, V267, P10515; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TOMAYAZU T, 1993, J BACTERIOL, V176, P1344; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WAXMAN L, 1987, J BIOL CHEM, V262, P2451	30	133	136	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					88	91		10.1038/374088a0	http://dx.doi.org/10.1038/374088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870180				2022-12-24	WOS:A1995QK07900060
J	STRUTT, DI; WIERSDORFF, V; MLODZIK, M				STRUTT, DI; WIERSDORFF, V; MLODZIK, M			REGULATION OF FURROW PROGRESSION IN THE DROSOPHILA EYE BY CAMP-DEPENDENT PROTEIN-KINASE-A	NATURE			English	Article							POLARITY GENE HEDGEHOG; DECAPENTAPLEGIC GENE; PATCHED GENE; BETA FAMILY; MELANOGASTER; EXPRESSION; RETINA	THE earliest physical sign of differentiation in the Drosophila retina is the passage of the morphogenetic furrow across the epithelium of the eye disc(1,2). Secreted factors encoded by hedgehog (hh)(3-7) and decapentaplegic (dpp)(8-10) have been implicated in propagation of the furrow(11,12) and the subsequent initiation of photoreceptor differentiation. The morphogenetic furrow initiates at the posterior edge of the third larval instar eye imaginal disc, Its continued progression towards the anterior is believed to depend upon secretion of Hh protein by the differentiating clusters of photoreceptors that emerge posterior to the moving furrow(11,12). This progression is marked by the initiation of expression of the transforming growth factor-beta homologue Dpp in cells entering the furrow anteriorly, and loss of dpp expression in cells emerging posteriorly(16,17). Although the transmembrane protein encoded by the patched gene has been genetically implicated as the Hh receptor(12,18-20), the intercellular signalling pathways involved in these inductive processes remain uncharacterized. Here we show that the catalytic subunit of cyclic AMP-dependent protein kinase A (Pka-C1)(13-15) is required for the correct spatial regulation of dpp expression during eye development. Loss of Pka-C1 function is sufficient to produce an ectopic morphogenetic wave marked by premature ectopic photoreceptor differentiation and non-autonomous propagation of dpp expression. Our results indicate that Pka-C1 lies in a signalling pathway that controls the orderly temporal progression of differentiation across the eye imaginal disc.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Strutt, David/E-6196-2010	Strutt, David/0000-0001-8185-4515; Wiersdorff, Volker/0000-0003-1460-334X				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; FOSTER JL, 1988, J BIOL CHEM, V263, P1676; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; LANE ME, 1993, GENESDEV, V7, P129; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOROK T, 1993, GENETICS, V135, P71; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; XU T, 1993, DEVELOPMENT, V117, P1223	28	116	118	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					705	709		10.1038/373705a0	http://dx.doi.org/10.1038/373705a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854454				2022-12-24	WOS:A1995QH92800056
J	XUE, QF; YEUNG, ES				XUE, QF; YEUNG, ES			DIFFERENCES IN THE CHEMICAL-REACTIVITY OF INDIVIDUAL MOLECULES OF AN ENZYME	NATURE			English	Article							CONFORMATIONAL CHANGES; DENATURED PROTEINS; KINETIC ASPECTS	MUCH attention has been focused recently on the detection and physical characterization of individual molecules(1-11). Using such methods to study the chemical properties, such as reactivity, of single molecules offers the potential to investigate how these might vary from molecule to molecule, and for individual molecules as a function of time, The complex structures of biomolecules such as enzymes make them particularly attractive targets for studying how subtle changes or differences at the molecular level might influence chemical reactivity. We have shown previously(12,13) that very small (zeptomole) amounts of enzymes can be studied using a fluorescence microassay; single enzyme molecules have also been detected in oil-dispersed droplets by fluorescence microscopy(14,15). Here we report the observation of reactions of individual molecules of lactate dehydrogenase (LDH-1), which produces NADH from lactate and nicotinamide adenine dinucleotide (NAD(+)), When they are present at very low concentrations in a narrow capillary, each enzyme molecule produces a discrete zone of NADH; these can be manipulated electrophoretically and monitored by fluorescence spectroscopy, We find that the activity of individual electrophoretically pure enzyme molecules can vary by up to a factor of four, and that these activities remain unchanged over a two-hour period. We suggest that the origin of the activity differences may lie in the presence of several stable forms of the enzyme.	IOWA STATE UNIV SCI & TECHNOL,US DOE,AMES LAB,AMES,IA 50011; IOWA STATE UNIV SCI & TECHNOL,DEPT CHEM,AMES,IA 50011	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University								AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; BARNES MD, 1993, ANAL CHEM, V65, P2360, DOI 10.1021/ac00065a032; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; EVERSE J, 1973, ADV ENZYMOL RAMB, V37, P61; HOLBROOK JJ, 1975, ENZYMES, P280; ISHIKAWA M, 1994, JPN J APPL PHYS 1, V33, P1571, DOI 10.1143/JJAP.33.1571; LEVI AS, 1971, J BIOL CHEM, V246, P6409; MILLER KJ, 1993, ANAL CHEM, V65, P3267, DOI 10.1021/ac00070a017; MOERNER WE, 1994, SCIENCE, V285, P46; ORITT M, 1993, J PHYS CHEM-US, V97, P10256; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; Rotman B., 1973, FLUORESCENCE TECHNIQ, P333; SMITH RD, 1994, NATURE, V369, P137, DOI 10.1038/369137a0; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; STRANFORD PE, 1962, JAMA-J AM MED ASSOC, V182, P123; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P798, DOI 10.1021/bi00781a012; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; XUE QF, 1994, ANAL CHEM, V66, P1175, DOI 10.1021/ac00079a036; ZUBAY G, 1993, BIOCHEMISTRY-US, P859	23	293	318	1	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					681	683		10.1038/373681a0	http://dx.doi.org/10.1038/373681a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854448				2022-12-24	WOS:A1995QH92800048
J	PAVORD, ID; TATTERSFIELD, AE				PAVORD, ID; TATTERSFIELD, AE			BRONCHOPROTECTIVE ROLE FOR ENDOGENOUS PROSTAGLANDIN E(2)	LANCET			English	Note							INHALED PROSTAGLANDIN-E2; BRONCHIAL REACTIVITY; ASTHMATIC-PATIENTS; INDOMETHACIN; EXERCISE; ASPIRIN; TRANSMISSION; METHACHOLINE; INHIBITION; CHALLENGE	The possibility that impaired production of bronchoprotective factors contributes to the pathogenesis of asthma cannot be excluded. Prostaglandin E(2) (PGE(2)) could be such a factor. It is a dominant cyclo-oxygenase product of airway epithelium and smooth muscle; it has inhibitory effects on inflammatory cells and pathways involved in bronchoconstriction at concentrations known to occur in the airway; inhalation of PGE(2) has considerable bronchoprotective effects in patients with asthma; and manoeuvres that increase or decrease endogenous production of PGE(2) have beneficial and deleterious effects on airway function.			PAVORD, ID (corresponding author), UNIV NOTTINGHAM,CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND.			Pavord, Ian/0000-0002-4288-5973				ALAM R, 1993, AM REV RESPIR DIS, V148, P1066, DOI 10.1164/ajrccm/148.4_Pt_1.1066; BECKETT WS, 1992, CHEST, V102, P775, DOI 10.1378/chest.102.3.775; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822, DOI 10.1164/arrd.1987.135.4.822; CHOUAIB S, 1987, J CLIN INVEST, V80, P333, DOI 10.1172/JCI113077; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; CRAVEN PA, 1982, J PHARMACOL EXP THER, V222, P306; DELAMERE F, 1994, BRIT J PHARMACOL, V111, P983, DOI 10.1111/j.1476-5381.1994.tb14840.x; GARDINER PJ, 1980, PROSTAGLANDINS, V19, P819, DOI 10.1016/0090-6980(80)90116-1; HOLGATE S, 1993, THORAX, V48, P103, DOI 10.1136/thx.48.2.103; ITO I, 1990, PROSTAGLANDINS, V39, P639, DOI 10.1016/0090-6980(90)90024-P; ITO Y, 1981, J PHYSIOL-LONDON, V319, P379, DOI 10.1113/jphysiol.1981.sp013915; LEE TH, 1991, J ALLERGY CLIN IMMUN, V88, P827, DOI 10.1016/0091-6749(91)90237-I; MATHE AA, 1975, AM REV RESPIR DIS, V111, P313; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P678, DOI 10.1016/S0091-6749(87)80165-3; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; OCONNOR BJ, 1994, THORAX, V49, P307, DOI 10.1136/thx.49.4.307; OZAKI T, 1987, J APPL PHYSIOL, V62, P219, DOI 10.1152/jappl.1987.62.1.219; PASARGIKLIAN M, 1977, RESPIRATION, V34, P79, DOI 10.1159/000193780; PASARGIKLIAN M, 1976, ADV PROSTAG THROMB R, V1, P461; PAVORD I, 1994, THORAX, V49, P245, DOI 10.1136/thx.49.3.245; PAVORD I, 1992, THORAX, V47, P895; PAVORD ID, 1994, EUR RESPIR J, V7, P50, DOI 10.1183/09031936.94.07010050; PAVORD ID, 1991, THORAX, V46, P633, DOI 10.1136/thx.46.9.633; PAVORD ID, 1992, THORAX, V47, P797, DOI 10.1136/thx.47.10.797; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; POLOSA R, 1992, THORAX, V47, P853; SWEATMAN WJ, 1968, NATURE, V217, P69, DOI 10.1038/217069a0; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; VERLEDEN GM, 1994, THORAX, V49, P657, DOI 10.1136/thx.49.7.657; 1990, LANCET, V335, P944	33	188	192	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					436	438		10.1016/S0140-6736(95)90409-3	http://dx.doi.org/10.1016/S0140-6736(95)90409-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853958				2022-12-24	WOS:A1995QG90400017
J	LI, XT; NICKLAS, RB				LI, XT; NICKLAS, RB			MITOTIC FORCES CONTROL A CELL-CYCLE CHECKPOINT	NATURE			English	Article							ANAPHASE	EVERY time a cell divides, the chromosomes must be distributed accurately to the daughter cells. Errors in distribution arise if chromosomes are improperly attached to the mitotic spindle. Improper attachment is detected by a cell-cycle checkpoint in many cells(1,2) and the completion of cell division is delayed, allowing time for error correction. How is an improperly attached chromosome detected? An absence of tension from mitotic forces is one possibility(3). Here we test this possibility directly by applying tension to an improperly attached chromosome with a micromanipulation needle, In the absence of tension, the entry into anaphase and the completion of mitosis was delayed by 5-6 hours. When the misattached chromosome was placed under tension, however, the cell entered anaphase in 56 minutes, on average. Tension from mitotic forces or from a micromanipulator's needle evidently signals to the checkpoint that all is in order and that cell division can proceed.			LI, XT (corresponding author), DUKE UNIV,DEPT ZOOL,BOX 91000,DURHAM,NC 27708, USA.							CALLAN H. G., 1957, JOUR GENETICS, V55, P200, DOI 10.1007/BF02981625; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Hughes-Schrader S, 1943, BIOL BULL-US, V85, P265, DOI 10.2307/1538227; LUCA FC, 1993, CURR BIOL, V3, P716, DOI 10.1016/0960-9822(93)90078-3; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; VANDRE DD, 1989, J CELL SCI, V94, P245; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	11	460	466	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					630	632		10.1038/373630a0	http://dx.doi.org/10.1038/373630a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854422				2022-12-24	WOS:A1995QG99700059
J	HEAGERTY, AHM; FITZGERALD, D; SMITH, A; BOWERS, B; JONES, P; FRYER, AA; ZHAO, L; ALLDERSEA, J; STRANGE, RC				HEAGERTY, AHM; FITZGERALD, D; SMITH, A; BOWERS, B; JONES, P; FRYER, AA; ZHAO, L; ALLDERSEA, J; STRANGE, RC			GLUTATHIONE-S-TRANSFERASE GSTM1 PHENOTYPES AND PROTECTION AGAINST CUTANEOUS TUMORS	LANCET			English	Note							SQUAMOUS-CELL CARCINOMA; CANCER SUSCEPTIBILITY; RISK; SKIN	Multiple allelism at loci encoding detoxicating enzymes is associated with cancer risk. We have studied genetic variation at the glutathione S-transferase GSTM1 locus to see whether phenotypes confer altered susceptibility to basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma (MM), or multiple skin tumours of different histological types. The frequency of GSTM1 null in cases and controls (52%) was similar, except for patients with two or more tumours of different types (71%, p = 0.033). GSTM1 A/B was reduced in frequency (p < 0.05) in patients with single or multiple BCC. Thus GSTM1 A/B may be protective, and effectiveness of detoxication may be a factor determining susceptibility to skin cancer.	ROYAL CORNWALL HOSP,DEPT DERMATOL,TRURO,CORNWALL,ENGLAND; UNIV KEELE,DEPT MATH,KEELE ST5 5BG,STAFFS,ENGLAND; KEELE UNIV,N STAFFORDSHIRE HOSP,SCH POSTGRAD MED,CTR PATHOL & MOLEC MED,STOKE ON TRENT,STAFFS,ENGLAND	Royal Cornwall Hospital; Keele University; Keele University; University Hospital of North Staffordshire NHS Trust	HEAGERTY, AHM (corresponding author), N STAFFORDSHIRE HOSP,DEPT DERMATOL,STOKE ON TRENT ST4 7BQ,STAFFS,ENGLAND.			Fryer, Anthony/0000-0001-8678-0404				AUBRY F, 1985, CANCER-AM CANCER SOC, V55, P907, DOI 10.1002/1097-0142(19850215)55:4<907::AID-CNCR2820550433>3.0.CO;2-5; FRYER AA, 1993, BIOCHEM J, V295, P313, DOI 10.1042/bj2950313; KARAGAS MR, 1992, JAMA-J AM MED ASSOC, V267, P3305, DOI 10.1001/jama.267.24.3305; KETTERER B, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P97; MUKHTAR H, 1993, CANCER RES, V53, P3439; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; STRANGE RC, 1991, CARCINOGENESIS, V12, P25, DOI 10.1093/carcin/12.1.25; STRANGE RC, 1993, STRUCTURE FUNCTION G, P160; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035; ZHONG S, 1991, CARCINOGENESIS, V12, P1533, DOI 10.1093/carcin/12.9.1533	10	161	163	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					266	268		10.1016/S0140-6736(94)91115-0	http://dx.doi.org/10.1016/S0140-6736(94)91115-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905099				2022-12-24	WOS:A1994MT44000013
J	WEST, LJ; MORRIS, PJ; WOOD, KJ				WEST, LJ; MORRIS, PJ; WOOD, KJ			FETAL LIVER HEMATOPOIETIC-CELLS AND TOLERANCE TO ORGAN ALLOGRAFTS	LANCET			English	Note							TRANSPLANTATION	Fetal liver haematopoietic cells were used to induce neonatal tolerance to cardiac allografts. Newborn mice were injected with fetal or newborn haematopoietic liver cells in two fully allogeneic strain combinations. There was no clinical evidence of graft-versus-host disease. Long-term survival of subsequent cardiac allografts occurred in both strains without immunosuppressants. Unresponsiveness was found not to be donor-specific with prolongation of third-party allografts as well as donor-type grafts. These findings have important implications for inducing tolerance in paediatric organ transplantation.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND	University of Oxford				West, Lori/0000-0002-1990-3651				BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; FLAKE AW, 1986, SCIENCE, V233, P76; HARRISON MR, 1989, LANCET, V2, P1425; ROYO C, 1987, THYMUS, V10, P57; SANHADJI K, 1992, BONE MARROW TRANSPL, V9, P77; STREILEIN JW, 1991, TRANSPLANTATION, V252, P1; SUPERINA RA, 1986, TRANSPLANTATION, V42, P227; TOURAINE JL, 1992, BONE MARROW TRANSPL, V9, P121; TOURAINE JL, 1989, TRANSPLANT P, V21, P3112	9	30	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					148	149		10.1016/S0140-6736(94)90936-9	http://dx.doi.org/10.1016/S0140-6736(94)90936-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904006				2022-12-24	WOS:A1994MQ86900012
J	LUCARELLI, G; ANGELUCCI, E; GIARDINI, C; BARONCIANI, D; GALIMBERTI, M; POLCHI, P; BARTOLUCCI, M; MURETTO, P; ALBERTINI, F				LUCARELLI, G; ANGELUCCI, E; GIARDINI, C; BARONCIANI, D; GALIMBERTI, M; POLCHI, P; BARTOLUCCI, M; MURETTO, P; ALBERTINI, F			FATE OF IRON STORES IN THALASSEMIA AFTER BONE-MARROW TRANSPLANTATION	LANCET			English	Article							THALASSEMIA; CHELATION	After successful bone-marrow transplantation (BMT) in thalassaemia, the individual acquires the pattern of globin synthesis of the donor. We call such an individual ''exthalassaemic after BMT'', a term that underscores the cure of the genetic defect but maintenance of residual signs of organ damage due to iron overload and dysfunction acquired during the pretransplant years. We have analysed the extent and fate of tissue iron overload in 151 ex-thalassaemic patients after BMT, according to the risk factors of hepatomegaly, hepatic portal fibrosis, and inadequate chelation therapy. Serum ferritin concentrations decreased and unbound iron binding capacity (UIBC) increased slowly during the years after the transplant. When analysed according to risk group (assigned at the time of the transplant), ferritin and UIBC returned within the normal ranges in only the low-risk group (without hepatomegaly or portal fibrosis, and with adequate chelation pre-BMT). Ferritin and UIBC were still abnormal 7 years after the transplant in the moderate-risk group (those with one or two risk factors) and highly abnormal in the high-risk group (all three risk factors) indicating persistence of, respectively, moderate and severe iron overload at the time of transplant. In ex-thalassaemic patients who were studied before and yearly after the transplant the extent of haemosiderosis, as judged by staining of liver biopsy samples, decreased during the years after transplant. The degree of iron deposition and rate of post-BMT linear growth seem to influence rate of post-BMT decrease in tissue iron overload in different risk groups at the time of BMT.	OSPED PESARO,CTR TRAPIANTO MIDOLLO OSSEO MURAGLIA,I-61100 PESARO,ITALY; OSPED PESARO,SERV LAB ANAL,I-61100 PESARO,ITALY; OSPED PESARO,SERV ANAT PATOL,I-61100 PESARO,ITALY		LUCARELLI, G (corresponding author), OSPED PESARO,DIV EMATOL,I-61100 PESARO,ITALY.		Angelucci, Emanuele/AAC-1855-2021	Angelucci, Emanuele/0000-0002-6512-6080; Baronciani, Donatella/0000-0001-6087-2431				[Anonymous], 1978, Br J Haematol, V38, P281, DOI 10.1111/j.1365-2141.1978.tb01044.x; BORGNAPIGNATTI C, 1991, HAEMATOLOGICA, V76, P409; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRONSPIEGELWEINTROB N, 1990, NEW ENGL J MED, V323, P713, DOI 10.1056/NEJM199009133231104; DEVIRGILIIS S, 1980, ARCH DIS CHILD, V55, P43, DOI 10.1136/adc.55.1.43; FORSBURG MT, 1990, BLOOD, V76, P435; LEY TS, 1982, CCLIN HAEMATOL, V11, P439; LUCARELLI G, 1985, LANCET, V1, P1355; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MURETTO P, IN PRESS LIVER; OVERMOYER BA, 1987, ARCH PATHOL LAB MED, V111, P549; THOMAS ED, 1982, LANCET, V2, P227; 1993, BONE MARROW TRANS S1, V12, pS56	13	62	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1388	1391		10.1016/0140-6736(93)92753-G	http://dx.doi.org/10.1016/0140-6736(93)92753-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901682				2022-12-24	WOS:A1993MK09500010
J	WILDEN, JN				WILDEN, JN			RAPID RESUSCITATION IN SEVERE HEAD-INJURY	LANCET			English	Editorial Material											WILDEN, JN (corresponding author), ROYAL LONDON HOSP,DEPT NEUROSURG,LONDON,ENGLAND.							ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; KONG DL, 1991, CRIT CARE MED, V19, P532, DOI 10.1097/00003246-199104000-00013; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1378	1378		10.1016/0140-6736(93)92750-N	http://dx.doi.org/10.1016/0140-6736(93)92750-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901679				2022-12-24	WOS:A1993MK09500007
J	SHERMAN, DIN; WARD, RJ; WARRENPERRY, M; WILLIAMS, R; PETERS, TJ				SHERMAN, DIN; WARD, RJ; WARRENPERRY, M; WILLIAMS, R; PETERS, TJ			ASSOCIATION OF RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM IN ALCOHOL DEHYDROGENASE-2 GENE WITH ALCOHOL-INDUCED LIVER-DAMAGE	BRITISH MEDICAL JOURNAL			English	Article							ALDEHYDE DEHYDROGENASE; DISEASE; PREDISPOSITION; SENSITIVITY; CIRRHOSIS; GENOTYPES; WOMEN	Objective-To investigate the role of genetically determined differences in the enzymes of alcohol metabolism in susceptibility to liver damage from misusing alcohol. Design-Use of pADH36 probe to study PVU II restriction length fragment polymorphism in alcohol dehydrogenase 2 gene in white alcohol misusers and controls. Setting-Teaching hospital referral centres for fiver disease and alcohol misuse. Subjects-45 white alcohol misusers (38 with alcoholic liver disease) and 23 healthy controls. Main outcome measures-Alcohol misuse, the presence and severity of alcoholic liver disease, alcohol dependency, and family history of alcohol misuse. Results-A two allele polymorphism (A and B) was identified. In control subjects the allele frequencies were 85% for A and 15% for B compared with 37% and 63% respectively in alcohol misusers (p < 0.001). B allele was significantly associated with severe liver damage (p < 0.05) as well as alcohol dependency and family history of alcohol misuse compared with controls. Conclusion-Inherited variation in enzymes of ethanol metabolism may contribute to the pathogenesis of alcohol induced liver damage. This supports the presence of a genetic component in alcohol misuse.	KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	SHERMAN, DIN (corresponding author), KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 9PJ,ENGLAND.			Ward, Roberta J/0000-0002-5671-784X; opoku, anita/0000-0001-7243-8157				AGARWAL D, PHARMACOL THERAPEUT, V45, P69; BOHMAN M, 1981, ARCH GEN PSYCHIAT, V38, P965; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; CLONINGER CR, 1990, BANB REPORT, V33, P105; COLLINS MA, 1979, SCIENCE, V206, P1184, DOI 10.1126/science.505002; COUZIGOU P, 1990, ALCOHOL ALCOHOLISM, V25, P623, DOI 10.1093/oxfordjournals.alcalc.a045058; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; DAY CP, 1991, HEPATOLOGY, V14, P798, DOI 10.1002/hep.1840140509; DUESTER G, 1986, J BIOL CHEM, V261, P2027; ENOMOTO N, 1991, HEPATOLOGY, V13, P1071, DOI 10.1002/hep.1840130611; GOEDDE HW, 1987, ENZYME, V37, P29, DOI 10.1159/000469239; HITTLE JB, 1988, J LAB CLIN MED, V112, P7; HRUBEC Z, 1981, ALCOHOL CLIN EXP RES, V5, P207, DOI 10.1111/j.1530-0277.1981.tb04890.x; Lelbach W K, 1976, Prog Liver Dis, V5, P494; MARTIN NG, 1985, BEHAV GENET, V15, P93, DOI 10.1007/BF01065891; Peters T J, 1987, Prog Clin Biol Res, V241, P215; SAUNDERS JB, 1981, BMJ-BRIT MED J, V282, P1140, DOI 10.1136/bmj.282.6270.1140; SHIBUYA A, 1988, AM J HUM GENET, V43, P744; SMITH M, 1986, ADV HUM GENET, V15, P249; SORRELL MF, 1985, ALCOHOL CLIN EXP RES, V9, P306, DOI 10.1111/j.1530-0277.1985.tb05549.x; 1987, GREAT GROWING EVIL M	22	31	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1388	1390		10.1136/bmj.307.6916.1388	http://dx.doi.org/10.1136/bmj.307.6916.1388			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	7903883	Green Published, Bronze			2022-12-24	WOS:A1993MK42000019
J	MCKENNA, MT; MCCRAY, E; ONORATO, I				MCKENNA, MT; MCCRAY, E; ONORATO, I			THE EPIDEMIOLOGY OF TUBERCULOSIS AMONG FOREIGN-BORN PERSONS IN THE UNITED-STATES, 1986 TO 1993	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDOCHINESE REFUGEES; BRITISH-COLUMBIA; IMMIGRANTS; CONVERSIONS; COUNTRIES; INFECTION; CHILDREN; HEALTH	Background. One third of the world's population is infected with Mycobacterium tuberculosis, and in the developed countries immigration is a major force that sustains the incidence of tuberculosis. We studied the effects of immigration on the epidemiology of tuberculosis and its recent resurgence in the United States. Methods. We analyzed data from the national tuberculosis reporting system of the Centers for Disease Control and Prevention. Since 1986 reports of tuberculosis have included the patient's country of origin. Population estimates for foreign-born persons were derived from special samples from the 1980 and 1990 censuses. Results. The proportion of persons reported to have tuberculosis who were foreign-born increased from 21.6 percent (4925 cases) in 1986 to 29.6 percent (7346 cases) in 1993. For the entire eight-year period, most foreign-born patients with tuberculosis were from Latin America (43.9 percent; 21,115 cases) and Southeast Asia (34.6 percent; 16,643 cases). Among foreign-born persons the incidence rate was almost quadruple the rate for native residents of the United States (30.6 vs. 8.1 per 100,000 person-years), and 55 percent of immigrants with tuberculosis had the condition diagnosed in their first five years in the United States. Conclusions. Immigration has had an increasingly important effect on the epidemiology of tuberculosis in the United States. It will be difficult to eliminate tuberculosis without better efforts to prevent and control it among immigrants and greater efforts to control it in the countries from which they come.			MCKENNA, MT (corresponding author), CTR DIS CONTROL & PREVENT,DIV TUBERCULOSIS ELIMINAT,1600 CLIFTON RD E-10,ATLANTA,GA 30333, USA.							AICKIN M, 1991, AM J PUBLIC HEALTH, V81, P918, DOI 10.2105/AJPH.81.7.918; ASCH S, 1994, WESTERN J MED, V161, P373; BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670; BROEKMANS JF, 1993, TUBERCULOSIS COMPREH, P641; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; CLAYTON D, 1993, STATISTICAL MODELS E; ENARSON DA, 1989, AM J EPIDEMIOL, V129, P1268, DOI 10.1093/oxfordjournals.aje.a115246; FEIN DJ, 1990, DEMOGRAPHY, V27, P285, DOI 10.2307/2061454; JACOBSON ML, 1987, AM J PUBLIC HEALTH, V77, P29, DOI 10.2105/AJPH.77.1.29; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MORSE DL, 1985, AM REV RESPIR DIS, V132, P516; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NOLAN CM, 1988, AM REV RESPIR DIS, V137, P805, DOI 10.1164/ajrccm/137.4.805; NOLAN CM, 1989, AM REV RESPIR DIS, V140, P996, DOI 10.1164/ajrccm/140.4.996; ONORATO IM, 1992, J INFECT DIS, V165, P87, DOI 10.1093/infdis/165.1.87; ORMEROD LP, 1990, RESP MED, V84, P269, DOI 10.1016/S0954-6111(08)80051-0; ORR P, 1993, TUBERCULOSIS COMPREH, P531; ORR PH, 1990, CAN MED ASSOC J, V142, P453; PEREZSTABLE EJ, 1985, PEDIATR INFECT DIS J, V4, P476, DOI 10.1097/00006454-198509000-00007; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; POWELL KE, 1983, JAMA-J AM MED ASSOC, V249, P1455, DOI 10.1001/jama.249.11.1455; POWELL KE, 1981, AM J PUBLIC HEALTH, V71, P1223, DOI 10.2105/AJPH.71.11.1223; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STEHRGREEN JK, 1992, NEW ZEAL MED J, V105, P301; STYBLO K, 1989, REV INFECT DIS, V11, pS339; SUTTER RW, 1990, AM REV RESPIR DIS, V141, P1483, DOI 10.1164/ajrccm/141.6.1483; WANG JS, 1991, TUBERCLE, V72, P277, DOI 10.1016/0041-3879(91)90054-V; WANG JS, 1989, TUBERCLE, V70, P179, DOI 10.1016/0041-3879(89)90048-2; 1990, MMWR-MORBID MORTAL W, V39, P1; 1992, AM REV RESPIR DIS, V146, P1623; 1991, DHHS PHS911101; 1977, PROCEDURAL GUIDE REC; 1993, 1993 WORLD BANK WORL; 1992, 1990 CENSUS POPULATI; 1993, 1990 CENSUS POPULATI; 1994, STATISTICAL YB IMMIG; 1994, MMWR-MORBID MORTAL W, V43, P361; 1994, LANCET, V344, P277; 1991, TECHNICAL INSTRUCTIO; 1992, THORAX, V47, P770; 1989, MMWR MORB MORTAL SS3, V38, P1; 1993, MMWR-MORBID MORTAL W, V42, P1	49	320	324	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1071	1076		10.1056/NEJM199504203321606	http://dx.doi.org/10.1056/NEJM199504203321606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT187	7898526	Bronze			2022-12-24	WOS:A1995QT18700006
J	KUMAR, L				KUMAR, L			SECONDARY LEUKEMIA AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION	LANCET			English	Editorial Material							HODGKINS-DISEASE; LEUKEMIA; THERAPY; DRUG				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI,INDIA.							ARMITAGE J, 1993, P AN M AM SOC CLIN, V12, P363; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; CANNELL PK, 1992, BONE MARROW TRANSPL, V9, P301; CHAN T, 1994, BONE MARROW TRANSPL, V13, P145; CHOPRA R, 1993, BLOOD, V81, P1137; International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993, NEW ENGL J MED, V329, P987; LEVINE EG, 1992, SEMIN ONCOL, V19, P47; MAROLLEAU JP, 1993, J CLIN ONCOL, V11, P590, DOI 10.1200/JCO.1993.11.3.590; MILLER JS, 1994, BLOOD, V83, P3780; SOUTAR RL, 1991, BRIT MED J, V303, P123, DOI 10.1136/bmj.303.6794.123-c; STONE RM, 1994, BLOOD, V83, P3437; TRAWEEK ST, 1993, BLOOD S, V82, P455	12	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					810	810		10.1016/S0140-6736(95)92960-6	http://dx.doi.org/10.1016/S0140-6736(95)92960-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898226				2022-12-24	WOS:A1995QQ19500005
J	SIMONDS, RJ; LINDEGREN, ML; THOMAS, P; HANSON, D; CALDWELL, B; SCOTT, G; ROGERS, M				SIMONDS, RJ; LINDEGREN, ML; THOMAS, P; HANSON, D; CALDWELL, B; SCOTT, G; ROGERS, M			PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA AMONG CHILDREN WITH PERINATALLY ACQUIRED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV-INFECTION; CHEMOPROPHYLAXIS; POPULATION; AIDS	Background. Pneumocystis carinii pneumonia (PCP) remains a common and often fatal opportunistic infection among children infected with the human immunodeficiency virus (HIV). HIV-infected infants between three and six months of age are particularly vulnerable. Current guidelines recommend prophylaxis in children from birth to 11 months old who have CD4+ counts below 1500 cells per cubic millimeter. Methods. We used national surveillance data to estimate the annual incidence of PCP among children less than one year old. We reviewed the medical records of 300 children given a diagnosis of PCP between January 1991 and June 1993 to determine why treatment according to the 1991 guidelines for prophylaxis against PCP either was not given or failed to prevent the disease. Results. In our study the incidence of PCP in the first year of life among infants born to HIV-infected mothers changed little between 1989 and 1992. Among 7080 children born to HIV-infected mothers in 1992, PCP developed in 2.4 percent. Of 300 children with PCP diagnosed from January 1991 through June 1993, 199 (66 percent) had never received prophylaxis, and for 118 of those children (59 percent) exposure to HIV was first identified 30 days or less before the diagnosis of PCP, Among 129 children less than one year old, the CD4+ count declined by an estimated 967 cells per cubic millimeter (95 percent confidence interval, 724 to 1210 cells per cubic millimeter) during the three months before the diagnosis of PCP, Among infants in whom CD4+ counts were determined within one month of the diagnosis of PCP, 18 percent (20 of 113) had at least 1500 cells per cubic millimeter, a level higher than the currently recommended threshold for prophylaxis. Conclusions. In the United States the incidence of PCP among HIV-infected infants has not declined. If this infection is to be prevented, infants exposed to HIV must be identified earlier, and prophylaxis must be offered to more children than the guidelines currently recommend.	NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA; UNIV MIAMI, SCH MED, DEPT PEDIAT, MIAMI, FL USA	New York City Department of Health & Mental Hygiene; University of Miami	SIMONDS, RJ (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV HIV AIDS, 1600 CLIFTON RD, MAILSTOP E-45, ATLANTA, GA 30333 USA.							[Anonymous], 1991, MMWR Recomm Rep, V40, P1; CALDWELL B, 1994, 34TH INT C ANT AG CH; CALDWELL B, 1994, 34TH INT C ANT AG CH, P36; CALDWELL MB, 1992, PEDIATRICS, V90, P603; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P1484, DOI 10.1001/jama.267.11.1484; DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P3154; Efron Bradley., 1994, INTRO BOOTSTRAP; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HSU HW, 1992, PEDIATR INFECT DIS J, V11, P941, DOI 10.1097/00006454-199211110-00007; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; ISRAELE V, 1992, pB233; Karon J M, 1992, MMWR Recomm Rep, V41, P1; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; MCKINNEY RE, 1992, PEDIATR INFECT DIS J, V11, P639; MOFENSON LM, 1993, J ACQ IMMUN DEF SYND, V6, P1103; NEWELL ML, 1994, BRIT MED J, V308, P437; OLESKE J, 1994, CLIN INFECT DIS, V19, P611; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; RUEBUSH TK, 1978, AM J DIS CHILD, V132, P143, DOI 10.1001/archpedi.1978.02120270041009; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018, DOI 10.1097/00006454-199211120-00006	26	67	67	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					786	790		10.1056/NEJM199503233321206	http://dx.doi.org/10.1056/NEJM199503233321206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862183				2022-12-24	WOS:A1995QN44200006
J	KANG, HJ; SCHUMAN, EM				KANG, HJ; SCHUMAN, EM			LONG-LASTING NEUROTROPHIN-INDUCED ENHANCEMENT OF SYNAPTIC TRANSMISSION IN THE ADULT HIPPOCAMPUS	SCIENCE			English	Article							TERM POTENTIATION; KINASE-ACTIVITY; MESSENGER-RNAS; TRK FAMILY; CA1 REGION; BDNF; INHIBITOR; EXPRESSION; RECEPTORS; NT-3	The neurotrophins are signaling factors important for the differentiation and survival of distinct neuronal populations during development, To test whether the neurotrophins also function in the mature nervous system, the effects of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophic factor 3 (NT-3) on the strength of synaptic transmission in hippocampal slices were determined. Application of BDNF or NT-3 produced a dramatic and sustained (2 to 3 hours) enhancement of synaptic strength at the Schaffer collateral-CA1 synapses; NGF was without significant effect. The enhancement was blocked by K252a, an inhibitor of receptor tyrosine kinases, BDNF and NT-3 decreased paired-pulse facilitation, which is consistent with a possible presynaptic modification. Long-term potentiation could still be elicited in slices previously potentiated by exposure to the neurotrophic factors, which implies that these two forms of plasticity may use at least partially independent cellular mechanisms.	CALTECH,DIV BIOL 21676,PASADENA,CA 91125	California Institute of Technology			Schuman, Erin M/D-6204-2011					BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BERG MM, 1992, J BIOL CHEM, V267, P13; ENFORS P, 1992, EUR J NEUROSCI, V4, P1140; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KANG H, UNPUB; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KNUSEL B, 1991, J NEUROCHEM, V57, P955, DOI 10.1111/j.1471-4159.1991.tb08243.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LU B, 1991, P NATL ACAD SCI USA, V88, P937; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; TAPLEY P, 1992, ONCOGENE, V7, P371; VASQUEZ ME, 1991, NEUROREPORT, V2, P593; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	19	1162	1173	2	45	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1658	1662		10.1126/science.7886457	http://dx.doi.org/10.1126/science.7886457			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886457				2022-12-24	WOS:A1995QM39700041
J	KIKUYAMA, S; TOYODA, F; OHMIYA, Y; MATSUDA, K; TANAKA, S; HAYASHI, H				KIKUYAMA, S; TOYODA, F; OHMIYA, Y; MATSUDA, K; TANAKA, S; HAYASHI, H			SODEFRIN - A FEMALE-ATTRACTING PEPTIDE PHEROMONE IN NEWT CLOACAL GLANDS	SCIENCE			English	Article							CRESTED NEWT; GOLDFISH	A decapeptide called sodefrin was isolated from the abdominal gland of the cloaca of the male red-bellied newt, Cynops pyrrhogaster. The native peptide, as well as the synthetic one, had a female-attracting activity. Sodefrin was found in the apical portion of the epithelial cells of the abdominal gland. Sodefrin is apparently species specific because it did not attract females of Cynops ensicauda. This is the first amphibian pheromone to be identified and the first peptide pheromone identified in a vertebrate.	NARA MED UNIV,DEPT PHYSIOL,KASHIHARA,NARA 634,JAPAN; RIKEN,RES DEV CORP,WAKO,SAITAMA 35101,JAPAN; NIPPON MED COLL,DEPT PHARMACOL,TOKYO 113,JAPAN; GUNMA UNIV,INST ENDOCRINOL,MAEBASHI,GUMMA 371,JAPAN; GUNMA PREFECTURAL COLL HLTH SCI,MAEBASHI,GUMMA 371,JAPAN	Nara Medical University; RIKEN; Nippon Medical School; Gunma University	KIKUYAMA, S (corresponding author), WASEDA UNIV,SCH EDUC,DEPT BIOL,NISHIWASEDA,TOKYO 16950,JAPAN.		Ohmiya, Yoshihiro/J-7143-2013	Ohmiya, Yoshihiro/0000-0002-4944-509X				CEDRINI L, 1971, Monitore Zoologico Italiano, V5, P223; COLOMBO L, 1980, Bollettino di Zoologia, V47, P355; Houck L.D., 1986, CHEM SIGNALS VERTEBR, P173; Lebedeva N.Y., 1975, J ICHTHYOL, V15, P472; MALACARNE G, 1984, MONIT ZOOL ITAL, V18, P33; MALACARNE G, 1982, BEHAV PROCESS, V7, P307, DOI 10.1016/0376-6357(82)90003-1; MASON RT, 1989, SCIENCE, V245, P290, DOI 10.1126/science.2749261; NOVOTNY M, 1990, CHEM SIGNAL, V5, P1; OKADA H, 1979, SCI REP HOKKAIDO FIS, V33, P89; PFEIFFER W, 1978, J CHEM ECOL, V4, P665, DOI 10.1007/BF00990277; PFUDERER P, 1974, J EXP ZOOL, V187, P375, DOI 10.1002/jez.1401870306; RODRIGUEZ H, 1989, TECHNIQUES PROTEIN C, P186; Salthe S.N., 1974, P309; SORENSEN PW, 1988, BIOL REPROD, V39, P1039, DOI 10.1095/biolreprod39.5.1039; STACEY NE, 1986, CAN J ZOOL, V64, P2412, DOI 10.1139/z86-360; TAKATA K, 1991, J HISTOCHEM CYTOCHEM, V39, P287, DOI 10.1177/39.3.1993828; TOYODA F, 1994, PHYSIOL BEHAV, V55, P569, DOI 10.1016/0031-9384(94)90118-X; Tucker D., 1972, OLFACTION TASTE, VIV, P121	18	190	193	1	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1643	1645		10.1126/science.7886452	http://dx.doi.org/10.1126/science.7886452			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886452				2022-12-24	WOS:A1995QM39700036
J	SCHONWETTER, BS; STOLZENBERG, ED; ZASLOFF, MA				SCHONWETTER, BS; STOLZENBERG, ED; ZASLOFF, MA			EPITHELIAL ANTIBIOTICS INDUCED AT SITES OF INFLAMMATION	SCIENCE			English	Article							ANTIMICROBIAL PEPTIDES; INSECT IMMUNITY; MESSENGER-RNA; DEFENSINS; CELLS; PURIFICATION; PRECURSOR; CDNA	The role of antimicrobial peptides in epithelial defense is not fully understood. An epithelial beta-defensin, lingual antimicrobial peptide (LAP), was isolated from bovine tongue and the corresponding complementary DNA cloned. LAP showed a broad spectrum of antibacterial and antifungal activities. LAP messenger RNA abundance was markedly increased in the epithelium surrounding naturally occurring tongue lesions. This increase coincided with the cellular hallmarks of acute and chronic inflammation in the underlying lamina propria, supporting a role for epithelial antimicrobial peptides as integral components of the inflammatory response.			SCHONWETTER, BS (corresponding author), MAGAININ PHARMACEUT INC,MAGAININ RES INST,5110 CAMPUS DR,PLYMOUTH MEETING,PA 19462, USA.							BEVINS CL, COMMUNICATION; BLAND PW, 1991, GASTROENTEROL CLIN N, V20, P577; BREY PT, 1993, P NATL ACAD SCI USA, V90, P6275, DOI 10.1073/pnas.90.13.6275; CHIRGWIN JJ, 1979, BIOCHEMISTRY-US, V13, P5294; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; DIAMOND G, 1994, CHEST, V105, pS51, DOI 10.1378/chest.105.3_Supplement.51S; GALLIN JI, 1988, INFLAMMATION; GANZ T, 1990, EUR J HAEMATOL, V44, P1; JACOB L, 1994, CIBA F SYMP, V186, P197; JONES DE, 1992, J BIOL CHEM, V267, P23216; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; MOORE KS, 1991, J BIOL CHEM, V266, P19851; NAKASHIMA H, 1993, AIDS, V7, P1129, DOI 10.1097/00002030-199308000-00019; NALLY F, 1991, PRACTITIONER, V235, P65; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SUN SC, 1992, COMP BIOCHEM PHYS B, V103, P225, DOI 10.1016/0305-0491(92)90436-U; WERSHIL BK, 1992, GASTROENTEROL CLIN N, V21, P387; YOUNG WS, 1986, NEUROSCI LETT, V70, P198; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZEGARELLI DJ, 1993, OTOLARYNG CLIN N AM, V26, P1069	24	359	399	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1645	1648		10.1126/science.7886453	http://dx.doi.org/10.1126/science.7886453			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886453				2022-12-24	WOS:A1995QM39700037
J	BOND, RA; LEFF, P; JOHNSON, TD; MILANO, CA; ROCKMAN, HA; MCMINN, TR; APPARSUNDARAM, S; HYEK, MF; KENAKIN, TP; ALLEN, LF; LEFKOWITZ, RJ				BOND, RA; LEFF, P; JOHNSON, TD; MILANO, CA; ROCKMAN, HA; MCMINN, TR; APPARSUNDARAM, S; HYEK, MF; KENAKIN, TP; ALLEN, LF; LEFKOWITZ, RJ			PHYSIOLOGICAL-EFFECTS OF INVERSE AGONISTS IN TRANSGENIC MICE WITH MYOCARDIAL OVEREXPRESSION OF THE BETA(2)-ADRENOCEPTOR	NATURE			English	Article							NUCLEOTIDE BINDING-PROTEIN; TERNARY COMPLEX MODEL; REGULATORY PROTEINS; INTRINSIC ACTIVITY; BETA-ADRENOCEPTOR; OPIOID RECEPTORS; ANTAGONISTS; MUTATION	G-PROTEIN-COUPLED receptors are thought to have an inactive conformation (R), requiring an agonist-induced conformational change for receptor/G-protein coupling(1-3). But new evidence suggests a two-state model(4-19) in which receptors are in equilibrium between the inactive conformation (R), and a spontaneously active conformation (R*) that can couple to G protein in the absence of ligand (Fig, 1). Classic agonists have a high affinity for R* and increase the concentration of R*, whereas inverse agonists have a high affinity for R and decrease the concentration of R*. Neutral competitive antagonists have equal affinity for R and R* and do not displace the equilibrium, but can competitively antagonize the effects both of agonists and of inverse agonists. The lack of suitable in vivo model systems has restricted the evidence for the existence of inverse agonists to computer simulations(7,8) and in vitro systems(5,9-12,20-23). We have used a transgenic mouse model in which there is such marked myocardial overexpression of beta(2)-adrenoceptors that a significant population of spontaneously activated receptor (R*) is present, inducing a maximal response without agonist(24). We show that the beta(2)-adrenoceptor ligand ICI-118,551 functions as an inverse agonist, providing evidence supporting the existence of inverse agonists and validating the two-state model of G-protein-coupled receptor activation.	FISONS PLC,DEPT PHARMACOL,LOUGHBOROUGH LE11 0RH,LEICS,ENGLAND; BAYLOR COLL MED,DEPT ANESTHESIOL,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CARDIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093; GLAXO INC,RES,RES TRIANGLE PK,NC 27709	Baylor College of Medicine; Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute; University of California System; University of California San Diego; GlaxoSmithKline	BOND, RA (corresponding author), UNIV HOUSTON,DEPT PHARMACOL & PHARMACEUT SCI,HOUSTON,TX 77204, USA.		Lefkowitz, Robert/AAW-2649-2021					AHRIENS EJ, 1954, ARCH INT PHARMACOD T, V99, P32; ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; BARKER EL, 1994, J BIOL CHEM, V269, P11687; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Clark Alfred Joseph., 1933, MODE ACTION DRUGS CE; Colquhoun D., 1973, DRUG RECEPTORS, P149, DOI [10.1007/978-1-349-00910-7_11, DOI 10.1007/978-1-349-00910-7_11]; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1992, MOL PHARMACOL, V41, P549; COSTA T, 1990, MOL PHARMACOL, V37, P383; DELEAN A, 1980, J BIOL CHEM, V255, P7108; EHLERT FJ, 1986, TRENDS PHARMACOL SCI, V7, P28, DOI 10.1016/0165-6147(86)90237-3; GOTZE K, 1964, EUR J PHARMACOL, V268, P151; LEFF P, IN PRESS TRENDS PHAR; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MEWES T, 1993, CIRCULATION, V88, P2916, DOI 10.1161/01.CIR.88.6.2916; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; ONARAN HO, 1992, MOL PHARMACOL, V43, P245; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; SCHWARTZ DD, 1988, J PHARMACOL EXP THER, V244, P11; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SENOGLES SE, 1987, J BIOL CHEM, V262, P4860; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; TIAN WN, 1994, MOL PHARMACOL, V45, P524	29	410	436	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					272	276		10.1038/374272a0	http://dx.doi.org/10.1038/374272a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885448	Green Submitted			2022-12-24	WOS:A1995QM38700053
J	SERIZAWA, H; MAKELA, TP; CONAWAY, JW; CONAWAY, RC; WEINBERG, RA; YOUNG, RA				SERIZAWA, H; MAKELA, TP; CONAWAY, JW; CONAWAY, RC; WEINBERG, RA; YOUNG, RA			ASSOCIATION OF CDK-ACTIVATING KINASE SUBUNITS WITH TRANSCRIPTION FACTOR TFIIH	NATURE			English	Article							RNA POLYMERASE-II; C-TERMINAL DOMAIN; FACTOR-DELTA; RAT-LIVER; INITIATION; PHOSPHORYLATION; PROMOTERS; HELICASE; ATPASE; YEAST	THE RNA polymerase II large subunit contains an essential carboxy-terminal domain (CTD) believed to be involved in the response to regulators during transcription initiation(1-10). The CTD is phosphorylated on a portion of RNA polymerase II molecules in vivo(11,12) and it can be phosphorylated by the general transcription factor TFIIH in vitro(13-15). A highly purified TFIIH from rat liver has been described(16); this, like human and yeast TFIIH, contains associated CTD kinase and helicase activities(13-18). We report here that two polypeptides of the purified mammalian TFIIH are the MO15/Cdk7 kinase and cyclin H subunits of the Cdk-activating kinase Cak(19-21), previously identified as a positive regulator of Cdc2 and Cdk2. TFIIH and Cak preparations are each capable of phosphorylating recombinant CTD and recombinant Cdk2 proteins. The presence of Cak in TFIIH indicates that Cak may have roles in transcriptional regulation and in cell-cycle control.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	Massachusetts Institute of Technology (MIT); Oklahoma Medical Research Foundation	SERIZAWA, H (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		makela, tomi/B-3734-2009; Young, Richard A/F-6495-2012	makela, tomi/0000-0002-4869-8044; Young, Richard A/0000-0001-8855-8647; Conaway, Joan/0000-0002-2786-0663				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARLOW E, 1989, ANTIBODIES LABORATOR; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	32	327	342	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					280	282		10.1038/374280a0	http://dx.doi.org/10.1038/374280a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885450				2022-12-24	WOS:A1995QM38700055
J	PEREZTRALLERO, E; MONTES, M; ALCORTA, M; ZUBILLAGA, P; TELLERIA, E				PEREZTRALLERO, E; MONTES, M; ALCORTA, M; ZUBILLAGA, P; TELLERIA, E			NON-ENDOSCOPIC METHOD TO OBTAIN HELICOBACTER-PYLORI FOR CULTURE	LANCET			English	Note								A sampling method to collect samples for Helicobacter pylori culture that is easier than endoscopy would be useful. We used a capsule attached to a highly absorbent nylon string, which is swallowed to obtain gastric secretions. Antral biopsy and string specimens, sequentially obtained from 36 adults with clinically suspected ulcer or gastric disease were cultured. 9 (25%) patients were negative in both tests; 18 (50%) were positive by both methods; 6 (17%) were biopsy positive and string-test negative; and 3 (8%) were biopsy negative and string-test positive. The new test is useful, simple, and causes little discomfort.	HOSP NS ARANZAZU,FAC MED,UNIDAD EPIDEMIOL INFECCIOSA,E-20080 SAN SEBASTIAN,SPAIN		PEREZTRALLERO, E (corresponding author), HOSP NS ARANZAZU,FAC MED,MICROBIOL SERV,E-20080 SAN SEBASTIAN,SPAIN.								0	43	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					622	623		10.1016/S0140-6736(95)90524-3	http://dx.doi.org/10.1016/S0140-6736(95)90524-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898181				2022-12-24	WOS:A1995QM07500012
J	JEFFREY, PD; GORINA, S; PAVLETICH, NP				JEFFREY, PD; GORINA, S; PAVLETICH, NP			CRYSTAL-STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE P53 TUMOR-SUPPRESSOR AT 1.7 ANGSTROMS	SCIENCE			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; DNA-BINDING; MUTANT P53; GENE AMPLIFICATION; PROTEIN; TRANSCRIPTION; SEQUENCE; IDENTIFICATION; REFINEMENT	The p53 protein is a tetrameric transcription factor that plays a central role in the prevention of neoplastic transformation. Oligomerization appears to be essential for the tumor suppressing activity of p53 because oligomerization-deficient p53 mutants cannot suppress the growth of carcinoma cell lines. The crystal structure of the tetramerization domain of p53 (residues 325 to 356) was determined at 1.7 angstrom resolution and refined to a crystallographic R factor of 19.2 percent. The monomer, which consists of a beta strand and an alpha helix, associates with a second monomer across an antiparallel beta sheet and an antiparallel helix-helix interface to form a dimer. Two of these dimers associate across a second and distinct parallel helix-helix interface to form the tetramer.			JEFFREY, PD (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021, USA.			Jeffrey, Philip/0000-0002-4351-5341	NCI NIH HHS [CA08748-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR V3 1 MANUAL; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P273; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREENBLATT MS, 1994, DATABASE P53 MUTATIO; HALVEY O, 1990, SCIENCE, V250, P113; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	51	433	454	0	24	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1498	1502		10.1126/science.7878469	http://dx.doi.org/10.1126/science.7878469			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878469				2022-12-24	WOS:A1995QL49700038
J	BRACKBILL, RM; SIEGEL, PZ; ACKERMANN, SP				BRACKBILL, RM; SIEGEL, PZ; ACKERMANN, SP			SELF-REPORTED HYPERTENSION AMONG UNEMPLOYED PEOPLE IN THE UNITED-STATES	BRITISH MEDICAL JOURNAL			English	Article											BRACKBILL, RM (corresponding author), CTR DIS CONTROL & PREVENT,MAILSTOP E-44,ATLANTA,GA 30333, USA.							FRANCO LJ, 1985, AM J EPIDEMIOL, V21, P684; LEEFLANG RLI, 1992, SOC SCI MED, V34, P351, DOI 10.1016/0277-9536(92)90295-2; SMITH R, 1991, BRIT MED J, V305, P972; THEORELL T, 1975, INT J EPIDEMIOL, V4, P281, DOI 10.1093/ije/4.4.281; 1989, SURVEY DATA ANAL SUD	5	9	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					568	568		10.1136/bmj.310.6979.568	http://dx.doi.org/10.1136/bmj.310.6979.568			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QK700	7888932	Green Published			2022-12-24	WOS:A1995QK70000020
J	TRUSWELL, AS				TRUSWELL, AS			CHOLESTEROL-LOWERING IN INFANCY	LANCET			English	Editorial Material											TRUSWELL, AS (corresponding author), UNIV SYDNEY,HUMAN NUTR UNIT,SYDNEY,NSW,AUSTRALIA.							FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; HANSEN D, 1992, ACTA PAEDIATR, V81, P1023, DOI 10.1111/j.1651-2227.1992.tb12167.x; JAMES WPT, 1988, EUROEPAN SERIES, V24; RASANEN L, 1992, ACTA PAEDIATR, V81, P7, DOI 10.1111/j.1651-2227.1992.tb12069.x; TRUSWELL AS, 1976, EARLY NUTRITION LATE, P229; WIDDOWSON EM, 1975, BRIT MED J, V1, P653, DOI 10.1136/bmj.1.5959.653; 1989, DIET HLTH; 1992, REPORT AGE LIMIT ADO; 1991, REPORT HLTH SOCIAL S, V41; 1992, PEDIATRICS, V90, P469; 1994, NUTRITIONAL ASPECTS, V46; 1991, NIH N4LB1 US DHEW NA	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					468	469		10.1016/S0140-6736(95)90577-4	http://dx.doi.org/10.1016/S0140-6736(95)90577-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861871				2022-12-24	WOS:A1995QH92900004
J	HECHT, A; LAROCHE, T; STRAHLBOLSINGER, S; GASSER, SM; GRUNSTEIN, M				HECHT, A; LAROCHE, T; STRAHLBOLSINGER, S; GASSER, SM; GRUNSTEIN, M			HISTONE H3 AND H4 N-TERMINI INTERACT WITH SIR3 AND SIR4 PROTEINS - A MOLECULAR-MODEL FOR THE FORMATION OF HETEROCHROMATIN IN YEAST	CELL			English	Article							SILENT MATING LOCI; POSITION EFFECT VARIEGATION; SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; DNA; TELOMERES; TRANSCRIPTION; REPRESSION; DROSOPHILA; SEQUENCE	The silent mating loci and chromosomal regions adjacent to telomeres of S. cerevisiae have features similar to heterochromatin of more complex eukaryotes. Transcriptional repression at these sites depends on the silent information regulators SIR3 and SIR4 as well as histones H3 and H4. We show here that the SIR3 and SIR4 proteins interact with specific silencing domains of the H3 and H4 N-termini in vitro. Certain mutations in these factors, which affect their silencing functions in vivo, also disrupt their interactions in vitro. Immunofluorescence studies with antibodies against RAP1 and SIR3 demonstrate that the H3 and H4 N-termini are required for the association of SIR3 with telomeric chromatin and the perinuclear positioning of yeast telomeres. Based on these interactions, we propose a model for heterochromatin-mediated transcriptional silencing in yeast, which may serve as a paradigm for other eukaryotic organisms as well.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Swiss Institute Experimental Cancer Research				Gasser, Susan/0000-0003-3610-9123; Hecht, Andreas/0000-0003-2262-2575	NIGMS NIH HHS [GM42421] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042421] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHICOINE LG, 1987, J CELL BIOL, V105, P127, DOI 10.1083/jcb.105.1.127; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MOORE GD, 1983, GENETICS, V105, P327; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RIVIER DH, 1994, CELL, V76, P963, DOI 10.1016/0092-8674(94)90373-5; SCHUSTER T, 1986, CELL, V45, P445, DOI 10.1016/0092-8674(86)90330-2; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TARTOF KD, 1990, DEVELOPMENT S, V120, P35; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	43	690	707	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					583	592		10.1016/0092-8674(95)90512-X	http://dx.doi.org/10.1016/0092-8674(95)90512-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867066	Bronze			2022-12-24	WOS:A1995QJ60200010
J	HUANG, ZJ; CURTIN, KD; ROSBASH, M				HUANG, ZJ; CURTIN, KD; ROSBASH, M			PER PROTEIN INTERACTIONS AND TEMPERATURE COMPENSATION OF A CIRCADIAN CLOCK IN DROSOPHILA	SCIENCE			English	Article							MESSENGER-RNA LEVELS; PERIOD GENE-PRODUCT; B P50 PRECURSOR; NEUROSPORA-CRASSA; VISUAL-SYSTEM; DNA-BINDING; MELANOGASTER; RHYTHMS; MUTANTS; DIMERIZATION	The periods of circadian clocks are relatively temperature-insensitive. Indeed, the per(L) mutation in the Drosophila melanogaster period gene, a central component of the clock, affects temperature compensation as well as period length. The per protein (PER) contains a dimerization domain (PAS) within which the per(L) mutation is located. Amino acid substitutions at the per(L) position rendered PER dimerization temperature-sensitive. In addition, another region of PER interacted with PAS, and the per(L) mutation enhanced this putative intramolecular interaction, which may compete with PAS-PAS intermolecular interactions. Therefore, temperature compensation of circadian period in Drosophila may be due in part to temperature-independent PER activity, which is based on competition between inter- and intramolecular interactions with similar temperature coefficients.			HUANG, ZJ (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.			Huang, Z. Josh/0000-0003-0592-028X	NIGMS NIH HHS [GM-33205] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COTE GG, 1986, J THEOR BIOL, V121, P487, DOI 10.1016/S0022-5193(86)80104-7; CURTIN K, 1994, NEURON, V13, P1167; DELABROUSSE FC, 1993, TRENDS GENET, V9, P151, DOI 10.1016/0168-9525(93)90149-C; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; EWER J, 1990, J NEUROGENET, V7, P31, DOI 10.3109/01677069009084151; Feldman J.F., 1986, J BIOL RHYTHM, V1, P18767; GARDNER GF, 1981, PLANT PHYSIOL, V68, P1244, DOI 10.1104/pp.68.6.1244; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HASTINGS JW, 1957, P NATL ACAD SCI USA, V43, P804, DOI 10.1073/pnas.43.9.804; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG Z, UNPUB; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1989, J NEUROGENET, V6, P1, DOI 10.3109/01677068909107096; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAKINTHOMAS PL, 1990, CRIT REV MICROBIOL, V17, P365, DOI 10.3109/10408419009114762; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MATTERN DL, 1982, P NATL ACAD SCI-BIOL, V79, P825, DOI 10.1073/pnas.79.3.825; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PITTENDRIGH CS, 1954, P NATL ACAD SCI USA, V40, P1018, DOI 10.1073/pnas.40.10.1018; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SMITH RF, 1982, MOL GEN GENET, V189, P30; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Worden, 1974, NEUROSCIENCES 3RD ST, P437; YU Q, 1987, P NATL ACAD SCI USA, V84, P784, DOI 10.1073/pnas.84.3.784; ZERR DM, 1990, J NEUROSCI, V10, P2749	38	127	127	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1169	1172		10.1126/science.7855598	http://dx.doi.org/10.1126/science.7855598			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855598	Green Submitted			2022-12-24	WOS:A1995QJ23700038
J	LEESMILLER, SP; GODBOUT, R; CHAN, DW; WEINFELD, M; DAY, RS; BARRON, GM; ALLALUNISTURNER, J				LEESMILLER, SP; GODBOUT, R; CHAN, DW; WEINFELD, M; DAY, RS; BARRON, GM; ALLALUNISTURNER, J			ABSENCE OF P350 SUBUNIT OF DNA-ACTIVATED PROTEIN-KINASE FROM A RADIOSENSITIVE HUMAN CELL-LINE	SCIENCE			English	Article							TERMINAL TRANSACTIVATION DOMAIN; RNA POLYMERASE-II; KU-PROTEIN; HUMAN CHROMOSOME-8; BINDING PROTEIN; SCID MUTATION; BREAK REPAIR; MICE; PHOSPHORYLATES; RADIATION	The radiosensitive rodent mutant cell line xrs-5 is defective in DNA double-strand break repair and lacks the Ku component of the DNA-activated protein kinase, DNA-PK. Here radiosensitive human cell lines were analyzed for DNA-PK activity and for the presence of related proteins. The radiosensitive human malignant glioma M059J cell line was found to be defective in DNA double-strand break repair, but fails to express the p350 subunit of DNA-PK. These results suggest that DNA-PK kinase activity is involved in DNA double-strand break repair.	CROSS CANC INST,RADIOBIOL PROGRAM,EDMONTON,AB T6G 1Z2,CANADA; UNIV CALGARY,DEPT BIOL SCI,CALGARY,AB T2N 1N4,CANADA; CROSS CANC INST,MOLEC ONCOL PROGRAM,EDMONTON,AB T6G 1Z2,CANADA	University of Alberta; University of Calgary; University of Alberta			Godbout, Roseline/I-4639-2016; Chan, Doris/O-1227-2014	Godbout, Roseline/0000-0002-4779-9265; Chan, Doris/0000-0002-4990-986X; Lees-Miller, Susan/0000-0001-5809-2516				ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; ALLALUNISTURNER MJ, UNPUB; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CC, COMMUNICATION; ANDERSON CW, IN PRESS METHODS PRO; ANDERSON CW, 1994, TRENDS BIOCHEM SCI, V18, P433; BANGA SS, 1994, MUTAT RES-DNA REPAIR, V315, P239, DOI 10.1016/0921-8777(94)90035-3; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHAN D, UNPUB; CHEN YR, 1991, J VIROL, V10, P5131; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; ILIAKIS G, 1991, INT J RADIAT BIOL, V59, P927, DOI 10.1080/09553009114550821; ITOH M, 1993, RADIAT RES, V134, P364, DOI 10.2307/3578198; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KOMATSU K, 1993, HUM MOL GENET, V2, P1031, DOI 10.1093/hmg/2.7.1031; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KURIMASA A, 1994, HUM GENET, V93, P21; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, UNPUB; LIU SH, 1993, J BIOL CHEM, V268, P21147; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MITSIS PG, 1989, J BIOL CHEM, V264, P5195; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1422; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WANATABE F, 1994, BIOCHIM BIOPHYS ACTA, V1223, P255; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	52	497	504	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1183	1185		10.1126/science.7855602	http://dx.doi.org/10.1126/science.7855602			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855602				2022-12-24	WOS:A1995QJ23700042
J	DEBERKER, D; IBBOTSON, S; SIMPSON, NB; MATTHEWS, JNS; IDLE, JR; REES, JL				DEBERKER, D; IBBOTSON, S; SIMPSON, NB; MATTHEWS, JNS; IDLE, JR; REES, JL			REDUCED EXPERIMENTAL CONTACT SENSITIVITY IN SQUAMOUS-CELL BUT NOT BASAL-CELL CARCINOMAS OF SKIN	LANCET			English	Note							EXPOSURE; BIOLOGY	Basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) show clinical and epidemiological differences not accounted for by different ultraviolet radiation exposure. We have studied experimentally induced contact sensitivity to dinitrochlorobenzene by measuring increases in skin-fold thickness. Patients (n=37) with squamous tumours had impaired responses compared with controls (33) and patients with BCCs (31) (mean increase 4.5 vs 7.8 and 8.6 mm, respectively; p=0.002). This diminished immunological response may be causally related to the development of SCC. Because glutathione S-transferase (GST) metabolises dinitrochlorobenzene and polymorphisms of GST are associated with multiple skin tumours, variations in GST may underlie these differences.	UNIV NEWCASTLE UPON TYNE,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED STAT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Ibbotson, Sally H/H-7061-2019; Matthews, John N S/H-7502-2013	Ibbotson, Sally H/0000-0001-5685-752X; Matthews, John N S/0000-0003-2559-037X				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; FRIEDMANN PS, 1990, CLIN EXP IMMUNOL, V81, P507; GRANSTEIN RD, 1990, SEMIN DERMATOL, V9, P16; HEAGERTY AHM, 1994, LANCET, V343, P266, DOI 10.1016/S0140-6736(94)91115-0; JONES SM, 1988, CARCINOGENESIS, V9, P395, DOI 10.1093/carcin/9.3.395; KWA RE, 1992, J AM ACAD DERMATOL, V26, P1, DOI 10.1016/0190-9622(92)70001-V; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; REES JL, 1989, BRIT J DERMATOL, V120, P371, DOI 10.1111/j.1365-2133.1989.tb04162.x	9	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					425	426		10.1016/S0140-6736(95)90406-9	http://dx.doi.org/10.1016/S0140-6736(95)90406-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853955				2022-12-24	WOS:A1995QG90400014
J	VOLBEDA, A; CHARON, MH; PIRAS, C; HATCHIKIAN, EC; FREY, M; FONTECILLACAMPS, JC				VOLBEDA, A; CHARON, MH; PIRAS, C; HATCHIKIAN, EC; FREY, M; FONTECILLACAMPS, JC			CRYSTAL-STRUCTURE OF THE NICKEL-IRON HYDROGENASE FROM DESULFOVIBRIO-GIGAS	NATURE			English	Article							SULFATE-REDUCING BACTERIA; ESR-DETECTABLE NICKEL; ACTIVE-SITE NICKEL; ELECTRON-TRANSFER; NIFE HYDROGENASE; METHANOCOCCUS-VOLTAE; CHROMATIUM-VINOSUM; REDOX PROPERTIES; SULFUR CENTERS; BACULATUS	The X-ray structure of the heterodimeric Ni-Fe hydrogenase from Desulfovibrio gigas, the enzyme responsible for the metabolism of molecular hydrogen, has been solved at 2.84 Angstrom resolution. The active site, which appears to contain, besides nickel, a second metal ion, is buried in the 60K subunit. The 28K subunit, which coordinates one [3Fe-4S] and two [4Fe-4S] clusters, contains an amino-terminal domain with similarities to the redox protein flavodoxin. The structure suggests plausible electron and proton transfer pathways.	INST BIOL STRUCT,CRISTALLOG & CRISTALLOGENESE PROT LAB,F-38027 GRENOBLE 1,FRANCE; CNRS,UNITE BIOENERGET & INGN PROT,F-13402 MARSEILLE 20,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite				Volbeda, Anne/0000-0002-6038-0979				ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ADAMS MWW, 1981, BIOCHIM BIOPHYS ACTA, V594, P105; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAGYINKA C, 1993, J AM CHEM SOC, V115, P3576, DOI 10.1021/ja00062a022; BARONDEAU DP, 1994, J AM CHEM SOC, V116, P3442, DOI 10.1021/ja00087a033; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOXER SG, 1994, STRUCT BIOL, V11, P749; BRICOGNE G, 1991, ISOMORPHOUS REPLACEM, P60; BRUNGER A, 1988, CRYSTALLOGRAPHIC COM, V4, P127; CAMMACK R, 1982, FEBS LETT, V142, P289, DOI 10.1016/0014-5793(82)80154-3; CAMMACK R, 1987, BIOCHIM BIOPHYS ACTA, V912, P98, DOI 10.1016/0167-4838(87)90252-4; CERIOTTI A, 1984, INORG CHEM, V23, P1363, DOI 10.1021/ic00178a013; CHAPMAN A, 1988, FEBS LETT, V242, P134, DOI 10.1016/0014-5793(88)81001-9; EIDSNESS MK, 1989, P NATL ACAD SCI USA, V86, P147, DOI 10.1073/pnas.86.1.147; FAN CL, 1991, J AM CHEM SOC, V113, P20, DOI 10.1021/ja00001a003; FAUQUE G, 1988, FEMS MICROBIOL LETT, V54, P299, DOI 10.1111/j.1574-6968.1988.tb02748.x; FERNANDEZ VM, 1986, BIOCHIM BIOPHYS ACTA, V883, P145, DOI 10.1016/0304-4165(86)90145-5; HATCHIKIAN EC, 1978, BIOCHEM BIOPH RES CO, V82, P451, DOI 10.1016/0006-291X(78)90896-3; HE SH, 1989, J BIOL CHEM, V264, P2678; Hendrickson W. A., 1980, COMPUTING CRYSTALLOG; HIGUCHI Y, 1994, ACTA CRYSTALLOGR D, V50, P781, DOI 10.1107/S0907444994002416; HUYNH BH, 1987, J BIOL CHEM, V262, P795; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1990, ACTA CRYSTALLOGR A, V47, P110; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOLODZIEJ AF, 1994, PROG INORG CHEM, V41, P493, DOI 10.1002/9780470166420.ch7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, ESFCCP4 NEWSL, V27, P30; MENON NK, 1993, FEBS LETT, V331, P91, DOI 10.1016/0014-5793(93)80303-C; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NIVIERE V, 1988, BIOCHIM BIOPHYS ACTA, V935, P34, DOI 10.1016/0005-2728(88)90105-3; ODOM JM, 1984, ANNU REV MICROBIOL, V38, P551, DOI 10.1146/annurev.mi.38.100184.003003; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; Otwinowski Z, 1991, ISOMORPHOUS REPLACEM, P60; PRZYBYLA AE, 1992, FEMS MICROBIOL LETT, V88, P109, DOI 10.1016/0378-1097(92)90687-J; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SMITH WW, 1977, J MOL BIOL, V117, P195, DOI 10.1016/0022-2836(77)90031-6; SORGENFREI O, 1993, FEBS LETT, V332, P291, DOI 10.1016/0014-5793(93)80652-B; SORGENFREI O, 1993, EUR J BIOCHEM, V213, P1355, DOI 10.1111/j.1432-1033.1993.tb17888.x; TEIXEIRA M, 1989, J BIOL CHEM, V264, P16435; VANDERZWAAN JW, 1985, FEBS LETT, V179, P271, DOI 10.1016/0014-5793(85)80533-0; VANDERZWAAN JW, 1986, BIOCHIM BIOPHYS ACTA, V872, P208, DOI 10.1016/0167-4838(86)90273-6; VELLIEUX FMD, IN PRESS J APPL CRYS; VOLBEDA A, 1993, ESF CCP4 NEWSLETTER, V28, P30; VOORDOUW G, 1992, ADV INORG CHEM, V38, P397, DOI 10.1016/S0898-8838(08)60069-0; VOORDOUW G, 1989, J BACTERIOL, V171, P2894, DOI 10.1128/jb.171.5.2894-2899.1989; WHITEHEAD JP, 1993, J AM CHEM SOC, V115, P5629, DOI 10.1021/ja00066a032; WU LF, 1993, FEMS MICROBIOL LETT, V104, P243	50	1343	1365	5	217	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					580	587		10.1038/373580a0	http://dx.doi.org/10.1038/373580a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854413				2022-12-24	WOS:A1995QG99700044
J	GERASIMENKO, OV; GERASIMENKO, JV; TEPIKIN, AV; PETERSEN, OH				GERASIMENKO, OV; GERASIMENKO, JV; TEPIKIN, AV; PETERSEN, OH			ATP-DEPENDENT ACCUMULATION AND INOSITOL TRISPHOSPHATE-MEDIATED OR CYCLIC ADP-RIBOSE-MEDIATED RELEASE OF CA2+ FROM THE NUCLEAR-ENVELOPE	CELL			English	Article							RAT-LIVER NUCLEI; IP(3) RECEPTOR; CALCIUM; CELLS; OSCILLATIONS; CHANNELS; MEMBRANE; WAVES; EGGS	Uptake and release of Ca2+ from isolated liver nuclei were studied with fluorescent probes. We show with the help of digital imaging and confocal microscopy that the Ca2+-sensitive fluorescent probe Fura 2 is concentrated in or around the nuclear envelope and that the distribution of Fura 2 fluorescence is similar to that of an endoplasmic reticulum marker. The previously demonstrated ATP-dependent uptake of Ca2+ into isolated nuclei and release of the accumulated Ca2+ by inositol 1,4,5-trisphosphate (IP3) are therefore due to transport of Ca2+ into and out of the nuclear envelope and not the nucleoplasm. Dextrans labeled with fluorescent Ca2+ indicators (calcium-Green 1 and Fura 2) are distributed uniformly in the nucleoplasm and can be used to show that changes in the external Ca2+ concentration produce rapid changes in the nucleoplasmic Ca2+ concentration. Nevertheless, IP3 and cyclic ADP-ribose evoke transient intranuclear Ca2+ elevations. The release from the Ca2+ stores in or around the nuclear envelope appears to be directed into the nucleoplasm from where it can diffuse out through the permeable nuclear pore complexes.			GERASIMENKO, OV (corresponding author), UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.		Gerasimenko, Oleg/A-6622-2010; Gerasimenko, Julia/A-7688-2010; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Petersen, Ole/0000-0002-6998-0380; Gerasimenko, Julia/0000-0002-2262-2543; Tepikin, Alexei/0000-0002-8172-7513				ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; GILLOT I, 1993, J EXP BIOL, V184, P213; HECHTENBERG S, 1993, BIOCHEM J, V289, P757, DOI 10.1042/bj2890757; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LANINI L, 1992, J BIOL CHEM, V267, P11548; LEE HC, 1989, J BIOL CHEM, V264, P1608; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P8858; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799	27	332	343	3	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					439	444		10.1016/0092-8674(95)90494-8	http://dx.doi.org/10.1016/0092-8674(95)90494-8			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859285	Bronze			2022-12-24	WOS:A1995QG47000010
J	KENNEDY, BK; AUSTRIACO, NR; ZHANG, JS; GUARENTE, L				KENNEDY, BK; AUSTRIACO, NR; ZHANG, JS; GUARENTE, L			MUTATION IN THE SILENCING GENE SIR4 CAN DELAY AGING IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL STATES; INDEFINITE DIVISION; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; YEAST TELOMERES; DNA-SEQUENCES	Aging in S. cerevisiae is exemplified by the fixed number of cell divisions that mother cells undergo (termed their life span). We have exploited a correlation between life span and stress resistance to identify mutations in four genes that extend life span. One of these, SIR4, encodes a component of the silencing apparatus at HM loci and telomeres. The sir4-42 mutation extends life span by more than 30% and is semidominant. Our findings suggest that sir4-42 extends life span by preventing recruitment of the SIR proteins to HM loci and telomeres, thereby increasing their concentration at other chromosomal regions. Maintaining silencing at these other regions may be critical in preventing aging. Consistent with this view, expression of only the carboxyl terminus of SIR4 interferes with silencing at HM loci and telomeres, which also extends life span. Possible links among silencing, telomere maintenance, and aging in other organisms are discussed.			KENNEDY, BK (corresponding author), MIT, DEPT BIOL, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.			Austriaco, Nicanor/0000-0003-1854-8181; Kennedy, Brian/0000-0002-5754-1874	NIA NIH HHS [AG11119] Funding Source: Medline; NIGMS NIH HHS [GM3054] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011119, R37AG011119] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARKING R, 1991, DEV GENET, V12, P362, DOI 10.1002/dvg.1020120505; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; COMPANY M, 1988, MOL CELL BIOL, V8, P2545, DOI 10.1128/MCB.8.6.2545; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; EGILMEZ NK, 1989, J BACTERIOL, V171, P37, DOI 10.1128/jb.171.1.37-42.1989; EGILMEZ NK, 1990, J GERONTOL, V45, pB9, DOI 10.1093/geronj/45.1.B9; Finch CE, 1990, LONGEVITY SENESCENCE; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Gompertz B, 1825, PHILOS T ROY SOC LON, V31, P513, DOI [10.1098/rstl.1825.0026, DOI 10.1098/RSTL.1825.0026]; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; GROVE GL, 1977, J CELL PHYSIOL, V90, P415, DOI 10.1002/jcp.1040900305; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; HERSKOWITZ I, 1991, P132; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JAZWINSKI SM, 1989, EXP GERONTOL, V24, P423; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; JOHNSTON JR, 1966, ANTON VAN LEE J M S, V32, P94, DOI 10.1007/BF02097448; KENNEDY BK, 1994, IN PRESS J CELL BIOL; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1980, MECH AGEING DEV, V12, P47, DOI 10.1016/0047-6374(80)90028-7; MULLER I, 1971, ARCH MIKROBIOL, V77, P20, DOI 10.1007/BF00407985; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; PLESSET J, 1982, BIOCHEM BIOPH RES CO, V108, P1340, DOI 10.1016/0006-291X(82)92147-7; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RILES L, 1993, GENETICS, V134, P81; RINE J, 1987, GENETICS, V116, P9; ROSE MR, 1981, GENETICS, V97, P172; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; Sherman F, 1979, METHODS YEAST GENETI; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SIKORSKI RS, 1989, GENETICS, V122, P19; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VOWELS JJ, 1992, GENETICS, V130, P105; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILSON VL, 1983, SCIENCE, V220, P1054	65	382	392	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					485	496		10.1016/0092-8674(95)90499-9	http://dx.doi.org/10.1016/0092-8674(95)90499-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859289	Bronze			2022-12-24	WOS:A1995QG47000015
J	NAITO, T; KUSANO, K; KOBAYASHI, I				NAITO, T; KUSANO, K; KOBAYASHI, I			SELFISH BEHAVIOR OF RESTRICTION-MODIFICATION SYSTEMS	SCIENCE			English	Article							GENES; ENDONUCLEASE	Plasmids carrying gene pairs encoding type II DNA restriction endonucleases and their cognate modification enzymes were shown to have increased stability in Escherichia coli. The descendants of cells that had lost these genes appeared unable to modify a sufficient number of recognition sites in their chromosomes to protect them from lethal attack by the remaining restriction enzyme molecules. The capacity of these genes to act as a selfish symbiont is likely to have contributed to the evolution of restriction-modification gene pairs.	UNIV TOKYO,INST MED SCI,DEPT MOLEC BIOL,TOKYO 108,JAPAN	University of Tokyo			Kobayashi, Ichizo/GVT-8377-2022	Kobayashi, Ichizo/0000-0002-3854-1879				BETLACH M, 1976, FED PROC, V35, P2037; GILLEN JR, 1981, J BACTERIOL, V157, P521; GINGERAS TR, 1983, P NATL ACAD SCI-BIOL, V80, P402, DOI 10.1073/pnas.80.2.402; HASHIMOTOGOTOH T, 1981, GENE, V16, P227, DOI 10.1016/0378-1119(81)90079-2; HEITMAN J, 1989, P NATL ACAD SCI USA, V86, P2281, DOI 10.1073/pnas.86.7.2281; Kobayashi I, 1992, Adv Biophys, V28, P81, DOI 10.1016/0065-227X(92)90023-K; KUSANO K, 1989, J MOL BIOL, V209, P623, DOI 10.1016/0022-2836(89)90000-4; KUSANO K, 1994, GENE, V138, P17; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Nordstrom K., 1993, PLASMIDS PRACTICAL A, P1; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; ROBBINS LG, 1994, GENETICS, V138, P401; Roberts R, 1993, NUCLEASES, P35; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P355, DOI 10.1093/nar/16.1.355	15	277	284	0	31	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					897	899		10.1126/science.7846533	http://dx.doi.org/10.1126/science.7846533			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846533				2022-12-24	WOS:A1995QG20700062
J	PUSCH, M; LUDEWIG, U; REHFELDT, A; JENTSCH, TJ				PUSCH, M; LUDEWIG, U; REHFELDT, A; JENTSCH, TJ			GATING OF THE VOLTAGE-DEPENDENT CHLORIDE CHANNEL CIC-O BY THE PERMEANT ANION	NATURE			English	Article							POTASSIUM CHANNEL; SODIUM-CHANNEL; AMINO-ACIDS; K+ CHANNELS; INACTIVATION; ACTIVATION; EXPRESSION; MUTATIONS; CLONING	CHLORIDE channels of the ClC family are important for the control of membrane excitability(1-3), cell volume regulation(4,5), and possibly transepithelial transport lacking the typical voltage-sensor found in cation gating of ClC channels is clearly voltage-dependent. For the prototype Torpedo channel ClC-0 (refs 11-15) we now show that channel opening is strongly facilitated by external chloride. Other less permeable anions can substitute for chloride with less efficiency. ClC-0 conductance shows an anomalous mole fraction behaviour with Cl-/NO3- mixtures, suggesting a multi-ion pore. Gating shows a similar anomalous behaviour, tightly linking permeation to gating. Eliminating a positive charge at the cytoplasmic end of domain D12 changes kinetics, concentration dependence and halide selectivity of gating, and alters pore properties such as ion selectivity, single-channel conductance and rectification. Taken together, our results strongly suggest that in these channels voltage-dependent gating is conferred by the permeating ion itself, acting as the gating charge.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20246 HAMBURG,GERMANY	University of Hamburg				Pusch, Michael/0000-0002-8644-8847; Jentsch, Thomas/0000-0002-3509-2553				BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAGIWARA S, 1979, J GEN PHYSIOL, V67, P621; HANKE W, 1983, J GEN PHYSIOL, V82, P25, DOI 10.1085/jgp.82.1.25; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PUSCH M, 1994, BIOPHYS J, V86, P149; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; WHITE MM, 1979, J BIOL CHEM, V254, P161; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	29	301	305	2	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					527	531		10.1038/373527a0	http://dx.doi.org/10.1038/373527a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845466				2022-12-24	WOS:A1995QF72400061
J	SAVVA, R; MCAULEYHECHT, K; BROWN, T; PEARL, L				SAVVA, R; MCAULEYHECHT, K; BROWN, T; PEARL, L			THE STRUCTURAL BASIS OF SPECIFIC BASE-EXCISION REPAIR BY URACIL-DNA GLYCOSYLASE	NATURE			English	Article							SIMPLEX VIRUS TYPE-1; ESCHERICHIA-COLI; N-GLYCOSIDASE; SEQUENCE; PURIFICATION; NUCLEAR; ENZYME; ERRORS; CELLS; GENE	The 1.75-Angstrom crystal structure of the uracil-DNA glycosylase from herpes simplex virus type-L reveals a new fold, distantly related to dinucleotide-binding proteins. Complexes with a trideoxynucleotide, and with uracil, define the DNA-binding site and allow a detailed understanding of the exquisitely specific recognition of uracil in DNA. The overall structure suggests binding models for elongated single- and double-stranded DNA substrates. Conserved residues close to the uracil-binding site suggest a catalytic mechanism for hydrolytic base excision.	UCL, DEPT BIOCHEM & MOLEC BIOL, STRUCT BIOCHEM SECT, LONDON WC1E 6BT, ENGLAND; UNIV EDINBURGH, DEPT CHEM, EDINBURGH EH9 3JJ, MIDLOTHIAN, SCOTLAND	University of London; University College London; University of Edinburgh			Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Brown, Tom/0000-0003-4683-1873; Pearl, Laurence/0000-0002-6910-1809; McAuley, Katherine/0000-0002-9545-072X; Brown, Tom/0000-0002-6538-3036; Savva, Renos/0000-0001-7375-2340	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARADONNA S, 1987, J VIROL, V61, P3040, DOI 10.1128/JVI.61.10.3040-3047.1987; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; CROSBY B, 1981, NUCLEIC ACIDS RES, V9, P5797, DOI 10.1093/nar/9.21.5797; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABOEV OK, 1985, J BACTERIOL, V164, P421, DOI 10.1128/JB.164.1.421-424.1985; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; KROKAN HE, 1993, JUL P NY AC SCI ABST; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1994, MOSFLM USERS GUIDE; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; MOSBAUGH DW, 1988, REV BIOCHEM TOXICOL, V9, P69; MULLANEY J, 1989, J GEN VIROL, V70, P449, DOI 10.1099/0022-1317-70-2-449; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; OTWINOWSKI Z, 1991, ISOMORPHOUS REPLACEM, P23; PFLUGRATH JW, 1992, MUNICH AREA DETECTOR; PYLES RB, 1994, J VIROL, V68, P4963, DOI 10.1128/JVI.68.8.4963-4972.1994; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SAVVA R, 1993, J MOL BIOL, V234, P910, DOI 10.1006/jmbi.1993.1642; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775	38	355	398	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					487	493		10.1038/373487a0	http://dx.doi.org/10.1038/373487a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845459				2022-12-24	WOS:A1995QF72400048
J	OFFERHAUS, GJA				OFFERHAUS, GJA			GASTRIC STUMP CANCER - LESSONS FROM OLD SPECIMENS	LANCET			English	Editorial Material											OFFERHAUS, GJA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,1105 AZ AMSTERDAM,NETHERLANDS.							ALEXANDERWILLIAMS J, 1991, BRIT MED J, V302, P547, DOI 10.1136/bmj.302.6776.547; CORREA P, 1992, CANCER RES, V52, P6735; DUBROW R, 1993, J NATL CANCER I, V85, P1268, DOI 10.1093/jnci/85.16.1268; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHER SG, 1993, JNCI-J NATL CANCER I, V85, P1303, DOI 10.1093/jnci/85.16.1303; LEE S, 1990, SCAND J GASTROENTERO, V25, P1223, DOI 10.3109/00365529008998557; OFFERHAUS GJA, 1985, EUR J CANCER CLIN ON, V21, P73, DOI 10.1016/0277-5379(85)90203-2; OFFERHAUS GJA, 1992, LANCET, V340, P33, DOI 10.1016/0140-6736(92)92433-G; VONHOLSTEIN CS, 1993, CANCER, V72, P1532; WRIGHT PA, 1993, GUT, V34, P145, DOI 10.1136/gut.34.2.145	10	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					66	67		10.1016/S0140-6736(94)90807-9	http://dx.doi.org/10.1016/S0140-6736(94)90807-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903770				2022-12-24	WOS:A1994MQ09200002
J	GENDRONMAGUIRE, M; MALLO, M; ZHANG, M; GRIDLEY, T				GENDRONMAGUIRE, M; MALLO, M; ZHANG, M; GRIDLEY, T			HOXA-2 MUTANT MICE EXHIBIT HOMEOTIC TRANSFORMATION OF SKELETAL ELEMENTS DERIVED FROM CRANIAL NEURAL CREST	CELL			English	Article							HOMEOBOX GENE; RETINOIC ACID; TARGETED DISRUPTION; DEVELOPMENTAL DEFECTS; DROSOPHILA EMBRYO; EXPRESSION; CELLS; HINDBRAIN; PATTERN; HOX-1.6	Mice homozygous for a targeted mutation of the Hoxa-2 (Hox 1.11) gene are born with cleft palates and die within 24 hr of birth. Analysis of stained skeletons revealed that homozygous mutant animals contained multiple cranial skeletal defects, including a duplication of the ossification centers of the bones of the middle ear. Histological analysis suggested that this duplication resulted from the transformation of skeletal elements derived from the second branchial arch into more anterior structures, resulting in a duplication of Meckel's cartilage adjacent to the otic capsule. Skeletal elements normally derived from the second arch were absent in the mutants. These data provide direct experimental evidence for the existence of a branchial Hox code.	HOFFMANN LA ROCHE INC, DEPT TOXICOL & PATHOL, NUTLEY, NJ 07110 USA	Roche Holding	GENDRONMAGUIRE, M (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA.		Mallo, Moises/D-5907-2016	Mallo, Moises/0000-0002-9744-0912				AKAM M, 1987, DEVELOPMENT, V101, P1; ALTMAN J, 1982, ADV ANAT EMBRYOL CEL, V74, P1; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; COULY GF, 1993, DEVELOPMENT, V117, P409; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; HOGAN B, 1992, NATURE, V355, P494, DOI 10.1038/355494a0; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; Kaufman M.H., 1992, ATLAS MOUSE DEV; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOORE KL, 1993, DEV HUMAN CLIN ORIEN, P186; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1993, J NEUROBIOL, V24, P248, DOI 10.1002/neu.480240210; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; Paxinos G., 1991, ATLAS DEV RAT BRAIN; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; Sambrook J., 1989, MOL CLONING LAB MANU; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SMITH DE, 1992, DEVELOPMENT, V116, P555; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STJOHNSTON D, 1992, CELL, V68, P201; STONER CM, 1989, CANCER RES, V49, P1497; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; Van de Water T R, 1980, Birth Defects Orig Artic Ser, V16, P147	51	460	465	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1317	1331		10.1016/0092-8674(93)90619-2	http://dx.doi.org/10.1016/0092-8674(93)90619-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7903600				2022-12-24	WOS:A1993MP86900011
J	SAATCIOGLU, F; DENG, TL; KARIN, M				SAATCIOGLU, F; DENG, TL; KARIN, M			A NOVEL CIS-ELEMENT MEDIATING LIGAND-INDEPENDENT ACTIVATION BY C-ERBA - IMPLICATIONS FOR HORMONAL-REGULATION	CELL			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; DNA-BINDING; PROGESTERONE-RECEPTOR; NEGATIVE REGULATION; RESPONSE ELEMENTS; AP-1-RESPONSIVE GENES; TRANSCRIPTION FACTOR; TRANS-ACTIVATION	A novel type of hormone-responsive element (HRE) is described. Unlike classical HREs, this element, RSV-T3RE (found in Rous sarcoma virus-long terminal repeat), mediates strong activation by the c-ErbAalpha thyroid hormone (T3) receptor in the absence of T3, and addition of T3 reverses this response. Whereas both c-ErbAalpha and v-ErbA are potent ligand-independent activators through the RSV-T3RE, c-ErbAbeta is not. The RSV-T3RE is recognized and activated by either c-ErbAalpha homodimers or c-ErbAalpha/retinoid X receptor (RXR) heterodimers. Ligand-independent activation by c-ErbAalpha depends on a unique N-terminal activation domain, while the C-terminal activation domain is not absolutely required. Ligand-dependent activation, on the other hand, requires the C-terminal but not the N-terminal activation domain. Upon binding to the RSV-T3RE, c-ErbAalpha assumes a different conformation than when bound to a classical T3RE. c-ErbAalpha is therefore capable of selective deployment of activation domains, dictated both by the HRE with which it interacts and by T3 binding.	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	SAATCIOGLU, F (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.				NCI NIH HHS [CA50528] Funding Source: Medline; NHLBI NIH HHS [HL35018] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBOIS C, 1991, CELL, V67, P731; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P597; GLASS CK, 1991, MOL ASPECTS CELLULAR, V6, P229; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1989, BIOCHEM PHARMACOL, V38, P3135, DOI 10.1016/0006-2952(89)90605-9; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Ivarie R D, 1980, Recent Prog Horm Res, V36, P195; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAKAI DD, 1988, GENE DEV, V2, P114; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	121	121	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1095	1105		10.1016/0092-8674(93)90319-L	http://dx.doi.org/10.1016/0092-8674(93)90319-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7903219				2022-12-24	WOS:A1993MM89300008
J	POWELL, JT; GREENHALGH, RM; RUCKLEY, CV; FOWKES, FGR				POWELL, JT; GREENHALGH, RM; RUCKLEY, CV; FOWKES, FGR			PROLOGUE TO A SURGICAL TRIAL	LANCET			English	Editorial Material							ABDOMINAL AORTIC-ANEURYSMS		UNIV EDINBURGH,WOLFSON UNIT PREVENT PERIPHERAL VASC DIS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	POWELL, JT (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; HARRIS PL, 1992, BMJ-BRIT MED J, V305, P697, DOI 10.1136/bmj.305.6855.697; HORTON R, 1993, LANCET, V342, P192, DOI 10.1016/0140-6736(93)92295-5; Naylor A R, 1988, Eur J Vasc Surg, V2, P217, DOI 10.1016/S0950-821X(88)80029-X; 1991, LANCET, V337, P1235	6	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1473	1474		10.1016/0140-6736(93)92939-Q	http://dx.doi.org/10.1016/0140-6736(93)92939-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902488				2022-12-24	WOS:A1993ML21700015
J	RITTER, K; KUHLENCORD, A; THOMSSEN, R; BOMMER, W				RITTER, K; KUHLENCORD, A; THOMSSEN, R; BOMMER, W			PROLONGED HEMOLYTIC-ANEMIA IN MALARIA AND AUTOANTIBODIES AGAINST TRIOSEPHOSPHATE ISOMERASE	LANCET			English	Note							PLASMODIUM-FALCIPARUM MALARIA; IGM ANTIBODIES; ANEMIA	Prolonged haemolysis may accompany infection with Plasmodium falciparum. We observed prolonged haemolysis in 4 of 10 patients with this type of malaria after parasitological cure. IgM antibodies specific for the glycolytic enzyme triosephosphate isomerase were detected in these patients' sera. Clinical recovery and a decrease in haemolysis coincided with a fall in these autoantibodies. In vitro, affinity purified autoantibodies isolated from the sera directed against triosephosphate isomerase induced lysis of erythrocytes and activation of complement as shown by the Cr-51 release assay. We assume that autoantibodies against triosephosphate isomerase contribute to the development of prolonged haemolysis and anaemia in P. falciparum malaria.	UNIV GOTTINGEN,DEPT TROP MED,D-37075 GOTTINGEN,GERMANY	University of Gottingen	RITTER, K (corresponding author), UNIV GOTTINGEN,ZENTRUM HYG & HUMANGENET,MED MIKROBIOL ABT,D-37075 GOTTINGEN,GERMANY.							Brown I. N., 1969, Adv. Immunol., V11, P267, DOI 10.1016/S0065-2776(08)60481-2; GEURS F, 1992, ACTA HAEMATOL-BASEL, V88, P142; RITTER K, 1991, J IMMUNOL METHODS, V137, P209, DOI 10.1016/0022-1759(91)90026-C; RITTER K, 1990, J EXP MED, V171, P565, DOI 10.1084/jem.171.2.565; ROSENBERG EB, 1973, AM J TROP MED HYG, V22, P146, DOI 10.4269/ajtmh.1973.22.146; ROSENBERG YJ, 1978, NATURE, V274, P170, DOI 10.1038/274170a0; ROSSI F, 1990, EUR J IMMUNOL, V20, P2089, DOI 10.1002/eji.1830200930; WEATHERALL DJ, 1982, BRIT MED BULL, V38, P147, DOI 10.1093/oxfordjournals.bmb.a071751; WEATHERALL DJ, 1983, CIBA F SYMP, V94, P74; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6	10	40	40	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1333	1334		10.1016/0140-6736(93)92248-R	http://dx.doi.org/10.1016/0140-6736(93)92248-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901638				2022-12-24	WOS:A1993MJ03900011
J	JENSEN, GB; PAKKENBERG, B				JENSEN, GB; PAKKENBERG, B			DO ALCOHOLICS DRINK THEIR NEURONS AWAY	LANCET			English	Article							BRAIN; ATROPHY; DENDRITES; ETHANOL; NUMBER	Although it is commonly believed that chronic alcohol abuse results in loss of neocortical neurons, this assumption has not been properly tested. We used new stereological techniques to make a precise and unbiased estimate of the total number of neurons in the neocortex of brains obtained at necropsy from 11 chronic alcoholic men and 11 control men. The groups were matched with respect to age and height. Total mean neocortical neuron numbers in the two groups did not differ (alcoholics 23.4 x 10(9), controls 23.2 x 10(9)). Estimation of macroscopic brain volumes showed significant reductions in alcoholics compared with controls of the volume/weight ratios of white matter (11%, p = 0.013) and of archicortex (30%, p = 0.028). The volume of the ventricles in the alcoholic group was enlarged by 26%, but this was not statistically significant. There was no difference in the volumes of the neocortices. Our study confirms that chronic alcoholics lose white matter, and this could provide the basis for their functional impairment. However, the results also suggest that the observed brain damage in the alcoholic group is potentially reversible since preserved nerve-cell bodies might allow lost or malfunctioning axons to be re-established and restored to function after prolonged abstinence and/or treatment. By contrast, lost neocortical neurons cannot be replaced.	KOMMUNE HOSP COPENHAGEN, BARTHOLIN INST, NEUROL RES LAB, DK-1399 COPENHAGEN K, DENMARK; AARHUS UNIV, BARTHOLIN BYGNINGEN, STEREOL RES LAB, DK-8000 AARHUS, DENMARK	Aarhus University				pakkenberg, bente/0000-0003-3851-6494				BRAENDGAARD H, 1990, J MICROSC-OXFORD, V157, P285, DOI 10.1111/j.1365-2818.1990.tb02967.x; CARLEN PL, 1987, ACTA MED SCAND, P19; CARLEN PL, 1981, NEUROLOGY, V31, P377; CHARNESS ME, 1989, NEW ENGL J MED, V321, P442, DOI 10.1056/NEJM198908173210706; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; DELAMONTE SM, 1988, ARCH NEUROL-CHICAGO, V45, P990, DOI 10.1001/archneur.1988.00520330076013; FERRER I, 1986, NEUROSCI LETT, V69, P115, DOI 10.1016/0304-3940(86)90425-8; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HANSEN LA, 1991, ARCH NEUROL-CHICAGO, V48, P939, DOI 10.1001/archneur.1991.00530210065025; HARPER C, 1987, BRIT MED J, V294, P534, DOI 10.1136/bmj.294.6571.534; HARPER C, 1985, J NEUROL NEUROSUR PS, V48, P211, DOI 10.1136/jnnp.48.3.211; HARPER C, 1990, J NEUROL NEUROSUR PS, V53, P856, DOI 10.1136/jnnp.53.10.856; HARPER CG, 1982, J NEUROL NEUROSUR PS, V45, P838, DOI 10.1136/jnnp.45.9.838; HARPER CG, 1990, ALCOHOL ALCOHOLISM, V25, P445; HARPER CG, 1990, ALCOHOL ALCOHOLISM, V25, P207, DOI 10.1093/oxfordjournals.alcalc.a044994; HARPER CG, 1985, BRIT MED J, V290, P501, DOI 10.1136/bmj.290.6467.501; HILL SY, 1979, SCIENCE, V204, P1237, DOI 10.1126/science.451571; ISHII T, 1983, ACTA PSYCHIAT SCAND, V309, P7; KJELLSTROM C, 1993, ACTA NEUROPATHOL, V85, P117; LEE K, 1979, LANCET, V2, P759; LISHMAN WA, 1987, ACTA MED SCAND, P5; MCMULLEN PA, 1984, J COMP NEUROL, V225, P111, DOI 10.1002/cne.902250112; Pakkenberg B, 1989, ACTA STEREOL, V8, P251; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; TAVARES MA, 1983, J NEUROCYTOL, V12, P939, DOI 10.1007/BF01153343; THOMSON AD, 1982, BRIT MED BULL, V38, P87, DOI 10.1093/oxfordjournals.bmb.a071740; TORVIK A, 1987, ACTA MED SCAND, P47; 1987, DIAGNOSTIC STATISTIC	29	80	83	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1201	1204						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901529				2022-12-24	WOS:A1993MG27400009
J	CLARKE, IMC				CLARKE, IMC			PEPPERING PAIN	LANCET			English	Editorial Material							CAPSAICIN				CLARKE, IMC (corresponding author), UNIV CALGARY,CALGARY T2N 1N4,ALBERTA,CANADA.							CARPENTER SE, 1983, ADV PAIN RES THER, V5, P83; DRAY A, 1992, LIFE SCI, V51, P1759, DOI 10.1016/0024-3205(92)90045-Q; GEPPETTI P, 1992, REGUL PEPTIDES, V41, P83, DOI 10.1016/0167-0115(92)90516-W; LAMOTTE RH, 1992, J PHYSIOL-LONDON, V448, P749, DOI 10.1113/jphysiol.1992.sp019068; LEVINE JD, 1988, 5TH P WORLD C PAIN, P33	5	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1130	1130		10.1016/0140-6736(93)92120-I	http://dx.doi.org/10.1016/0140-6736(93)92120-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901472				2022-12-24	WOS:A1993MF19800006
J	NAKAMURA, T; EBIHARA, I; SHIRATO, I; FUKUI, M; TOMINO, Y; KOIDE, H				NAKAMURA, T; EBIHARA, I; SHIRATO, I; FUKUI, M; TOMINO, Y; KOIDE, H			ENDOTHELIN-1 MESSENGER-RNA EXPRESSION BY PERIPHERAL-BLOOD MONOCYTES IN IGA NEPHROPATHY	LANCET			English	Note							CELLS	We investigated endothelin-1 mRNA expression in peripheral blood monocytes from 40 patients with IgA nephropathy, 40 with other glomerulonephritides and 10 with essential hypertension without renal diseases, and from 30 healthy age-matched controls. 95% of patients with IgA nephropathy had increased endothelin-1 mRNA expression in monocytes but little was detected from the other groups. Endothelin-1 mRNA was positively correlated with urinary protein excretion (95% CI 0.835-0.952) and histopathological findings (0.796-0.939). In. 15 patients with IgA nephropathy endothelin-1 mRNA values and proteinuria decreased gradually after treatment Endathelin-1 mRNA-expressing activated monocytes may be associated with the progression of IgA nephropathy.	JUNTENDO UNIV,SCH MED,DEPT MED,DIV NEPHROL,TOKYO 113,JAPAN	Juntendo University								BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; ISHIMURA E, 1989, AM J PATHOL, V134, P843; LEE SMK, 1982, HUM PATHOL, V13, P314, DOI 10.1016/S0046-8177(82)80221-9; NAKAMURA T, 1992, AM J NEPHROL, V12, P292, DOI 10.1159/000168463; NAKAMURA T, 1992, J LAB CLIN MED, V120, P212	6	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1147	1148		10.1016/0140-6736(93)92126-E	http://dx.doi.org/10.1016/0140-6736(93)92126-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901478				2022-12-24	WOS:A1993MF19800012
J	SNYDER, EY; TAYLOR, RM; WOLFE, JH				SNYDER, EY; TAYLOR, RM; WOLFE, JH			NEURAL PROGENITOR-CELL ENGRAFTMENT CORRECTS LYSOSOMAL STORAGE THROUGHOUT THE MPS-VII MOUSE-BRAIN	NATURE			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; BETA-GLUCURONIDASE DEFICIENCY; BONE-MARROW TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; GENE-TRANSFER; MICE; IMPLANTATION; SPLEEN; LINES; MODEL	MANY metabolic diseases affecting the central nervous system are refractory to treatment because the blood-brain barrier restricts entry of therapeutic molecules. It may be possible to deliver therapeutic gene products directly to the brain by transplantation of neural progenitor cells, which can integrate into the murine central nervous system in a cytoarchitecturally appropriate manner(1-7). We tested this approach in mucopolysaccharidosis VII (Sly disease), a lysosomal storage disorder of humans, dogs and mice caused by an inherited deficiency of beta-glucuronidase(8-10). Lysosomal accumulation of glycosaminoglycans occurs in the brain and other tissues, causing a fatal progressive degenerative disorder, including mental retardation(11). Treatments are designed to provide a source of normal enzyme for uptake by diseased cells(12-20). We report here that by transplanting beta-glucuronidase-expressing neural progenitors into the cerebral ventricles of newborn mice, donor cells engrafted throughout the neuraxis. At maturity, donor-derived cells were present as normal constituents of diverse brain regions. beta-Glucuronidase activity was expressed along the entire neuraxis, resulting in widespread correction of lysosomal storage in neurons and glia in affected mice.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; UNIV PENN,SCH VET MED,PATHOL LAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH VET MED,MED GENET SECT,PHILADELPHIA,PA 19104	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Pennsylvania; University of Pennsylvania								ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANTON R, 1994, EXP NEUROL, V127, P207, DOI 10.1006/exnr.1994.1097; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; BIRKENMEIER EH, 1991, BLOOD, V78, P3081; BREAKEFIELD XO, 1993, NAT GENET, V3, P187, DOI 10.1038/ng0393-187; CHRISTIE D, 1994, ARCH DIS CHILD, V70, P275, DOI 10.1136/adc.70.4.275; FISHER LJ, 1994, FASEB J, V8, P489, DOI 10.1096/fasebj.8.8.8181667; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; HASKINS M, 1991, TREATMENT GENETIC DI, P183; HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450-198418100-00014; KITCHENS DL, 1994, J NEUROBIOL, V25, P797, DOI 10.1002/neu.480250705; KYLE JW, 1990, P NATL ACAD SCI USA, V87, P3914, DOI 10.1073/pnas.87.10.3914; MACKLIS JD, 1994, EXP NEUROL, V129, P9; MARECHAL V, 1993, BLOOD, V82, P1358; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; ONNIFER SM, 1993, EXP NEUROL, V122, P130; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; SANDS MS, 1993, P NATL ACAD SCI USA, V90, P6567, DOI 10.1073/pnas.90.14.6567; SANDS MS, 1993, LAB INVEST, V68, P676; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; Snyder E. Y., 1993, Society for Neuroscience Abstracts, V19, P613; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SNYDER EY, 1992, SEMIN PERINATOL, V16, P106; SUHR ST, 1993, ARCH NEUROL-CHICAGO, V50, P1252, DOI 10.1001/archneur.1993.00540110122012; TAYLOR RM, 1994, EXP CELL RES, V214, P606, DOI 10.1006/excr.1994.1298; VOGLER C, 1990, AM J PATHOL, V136, P207; VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450-199312000-00028; WOLFE JH, 1995, GENE THER, V2, P70; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFE JH, 1992, NATURE, V360, P749, DOI 10.1038/360749a0; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	34	397	412	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					367	370		10.1038/374367a0	http://dx.doi.org/10.1038/374367a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885477				2022-12-24	WOS:A1995QN63000062
J	RUMBYRT, JS; BORISH, LC				RUMBYRT, JS; BORISH, LC			HOME ADMINISTRATION OF ALLERGEN EXTRACTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											RUMBYRT, JS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206, USA.							REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; TURKELTAUB PC, 1994, FDA MED B, V24, P7; 1990, J ALLERGY CLIN IMMUN, V85, P526	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					897	897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869565				2022-12-24	WOS:A1995QL40200033
J	HANSEN, P				HANSEN, P			CRISTINA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					686	686						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853608				2022-12-24	WOS:A1995QH81400002
J	LIU, B; ALBERTS, BM				LIU, B; ALBERTS, BM			HEAD-ON COLLISION BETWEEN A DNA-REPLICATION APPARATUS AND RNA-POLYMERASE TRANSCRIPTION COMPLEX	SCIENCE			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; FORK; TERMINATION; ELONGATION; SEQUENCE; HELICASE; PROTEIN; GENES; CHROMOSOME	An in vitro system reconstituted from purified proteins has been used to examine what happens when the DNA replication apparatus of bacteriophage T4 collides with an Escherichia coli RNA polymerase ternary transcription complex that is poised to move in the direction opposite to that of the moving replication fork. In the absence of a DNA helicase, the replication fork stalls for many minutes after its encounter with the RNA polymerase. However, when the T4 gene 41 DNA helicase is present, the replication fork passes the RNA polymerase after a pause of a few seconds. This brief pause is longer than the pause observed for a codirectional collision between the same two polymerases, suggesting that there is an inherent disadvantage to having replication and transcription directions oriented head to head. As for a codirectional collision, the RNA polymerase remains competent to resume faithful RNA chain elongation after the DNA replication fork passes; most strikingly, the RNA polymerase has switched from its original template strand to use the newly synthesized daughter DNA strand as the template.			LIU, B (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM-24020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T R SOC B, V317, P385; BARRY J, 1994, J BIOL CHEM, V269, P33049; BAUTZ EKF, 1976, RNA POLYMERASE, P273; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CAMPBELL AM, 1993, CURR OPIN GENET DEV, V3, P837, DOI 10.1016/0959-437X(93)90002-7; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1991, NATURE, V340, P730; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; LEE EH, 1992, J BIOL CHEM, V267, P8778; LINSKENS MH, 1988, MOL CELL BIOL, V8, P492; LIU B, 1994, P NATL ACAD SCI USA, V91, P10660, DOI 10.1073/pnas.91.22.10660; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MEDIGUE C, 1990, MOL MICROBIOL, V4, P1443, DOI 10.1111/j.1365-2958.1990.tb02055.x; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SANDERSON KE, 1988, MICROBIOL REV, V52, P485, DOI 10.1128/MMBR.52.4.485-532.1988; SELICK HE, 1987, DNA REPLICATION RECO, P183; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZEIGLER DR, 1990, GENETICS, V125, P703	38	161	163	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1131	1137		10.1126/science.7855590	http://dx.doi.org/10.1126/science.7855590			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855590				2022-12-24	WOS:A1995QJ23700027
J	DICKSON, BJ; DOMINGUEZ, M; VANDERSTRATEN, A; HAFEN, E				DICKSON, BJ; DOMINGUEZ, M; VANDERSTRATEN, A; HAFEN, E			CONTROL OF DROSOPHILA PHOTORECEPTOR CELL FATES BY PHYLLOPOD, A NOVEL NUCLEAR-PROTEIN ACTING DOWNSTREAM OF THE RAF KINASE	CELL			English	Article							RECEPTOR TYROSINE KINASE; SEVENLESS PROTEIN; POSITIONAL INFORMATION; COMPOUND EYE; R7 CELL; EXPRESSION; GENE; ACTIVATION; DISK; RAS1	The phyllopod (phyl) gene regulates the fates of a subset of cells in the developing Drosophila eye; in the absence of phyl function, the R1, R6, and R7 photoreceptors are transformed into additional cone cells, whereas ectopic phyl expression in the cone cell precursors transforms these cells into additional R7 cells. Within this group of cells, phyl expression thus mimics activation of the Raf pathway in its ability to induce photoreceptor rather than cone cell development. Furthermore, the transformation of cone cells into R7 cells in response to Raf activation is both accompanied by and dependent upon ectopic phyl expression. phyl thus represents a possible target gene of the Raf pathway during eye development, controlling the fates of a novel subset of photoreceptors.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich			Dickson, Barry/AAE-7632-2019; Dominguez, Maria/G-2171-2014	Dickson, Barry/0000-0003-0715-892X; Dominguez, Maria/0000-0002-3329-7862				BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Cagan Ross Leigh, 1992, P189; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEILER R, 1992, J NEUROSCI, V12, P3862; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MEINICK MB, 1993, DEVELOPMENT, V118, P127; MLODZIK M, 1992, MECH DEVELOP, V37, P37, DOI 10.1016/0925-4773(92)90013-A; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NILSSON DE, 1983, CELL TISSUE RES, V230, P401; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PIROTTA V, 1988, VECTORS SURVEY MOL C, P438; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	41	93	94	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					453	462		10.1016/0092-8674(95)90496-4	http://dx.doi.org/10.1016/0092-8674(95)90496-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859287	Bronze, Green Accepted			2022-12-24	WOS:A1995QG47000012
J	ALTMAN, DG; BLAND, JM				ALTMAN, DG; BLAND, JM			THE NORMAL-DISTRIBUTION	BRITISH MEDICAL JOURNAL			English	Note											ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND,MED STAT LAB,POB 123,LONDON WC2A 3PX,ENGLAND.							Altman DG., 1991, PRACTICAL STAT MED R, P132; GARDNER MJ, 1989, STATISTICS CONFIDENC, P17; Gardner MJ, 1989, STAT CONFIDENCE, P28	3	179	182	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					298	298		10.1136/bmj.310.6975.298	http://dx.doi.org/10.1136/bmj.310.6975.298			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866172	Bronze, Green Published			2022-12-24	WOS:A1995QF71700027
J	CHAZOUILLERES, O; MAMISH, D; KIM, M; CAREY, K; FERRELL, L; ROBERTS, JP; ASCHER, NL; WRIGHT, TL				CHAZOUILLERES, O; MAMISH, D; KIM, M; CAREY, K; FERRELL, L; ROBERTS, JP; ASCHER, NL; WRIGHT, TL			OCCULT HEPATITIS-B VIRUS AS SOURCE OF INFECTION IN LIVER-TRANSPLANT RECIPIENTS	LANCET			English	Article							CLINICAL IMPLICATIONS; VIRAL-INFECTION; NON-A; DNA; SEQUENCES; DISEASE; SERUM	Hepatitis B virus (HBV) infection almost always recurs after liver transplantation in patients who were surface antigen (HBsAg) positive before surgery but apparent de novo acquisition of infection in a transplant setting has not previously been reported. We have used sensitive techniques to elucidate the origin of such infections in patients in a Californian transplantation programme. We tested post-transplant serum from 207 patients who had been HBsAg negative and found 20 to be HBsAg positive. The origin of infection was identified in 7 patients, being occult pre-transplant infection in 5 and occult infection in the donor in 2. No pre-transplant patient nor donor with demonstrable HBV DNA had serological markers of hepatitis B. Post-transplant HBV DNA was present in serum from 19 patients. Analysis of the variable pre-S region of HBV demonstrated 100% sequence homology between recipient liver and post-transplant serum (2 patients) and between donor serum and recipient post-transplant serum (2). There was only 84% homology between the 2 different patients infected with subtype adw. 19 patients are alive, 9 without histological evidence of hepatitis (mean follow-up 33 months), and survival was significantly greater than that of a group with recurrent HBV infection. Apparent acquisition of HBV infection with liver transplantation is not rare, and may be due to occult pre-transplant infection or occult infection in the donor. The post-transplant outcome of this infection tends to be benign but our findings do underscore the clinical relevance of HBV infection in the absence of serological markers.	DEPT VET AFFAIRS MED CTR,DEPT MED,4150 CLEMENT ST,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [R29AI32242-01] Funding Source: Medline; NIDDK NIH HHS [P30DK26743] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUM HE, 1991, HEPATOLOGY, V14, P56, DOI 10.1002/hep.1840140110; BRECHOT C, 1991, J HEPATOL, V13, pS49, DOI 10.1016/0168-8278(91)90023-5; BROWN J L, 1992, Hepatology, V15, P144, DOI 10.1002/hep.1840150124; CADRANEL JF, 1991, TRANSPLANTATION, V52, P645, DOI 10.1097/00007890-199110000-00013; DEGOS F, 1988, GASTROENTEROLOGY, V94, P151, DOI 10.1016/0016-5085(88)90623-3; DEMETRIS AJ, 1990, AM J PATHOL, V137, P667; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; HOOFNAGLE JH, 1978, NEW ENGL J MED, V298, P1379, DOI 10.1056/NEJM197806222982502; LAVINE JE, 1991, GASTROENTEROLOGY, V100, P263, DOI 10.1016/0016-5085(91)90611-N; LIANG TJ, 1991, HEPATOLOGY, V13, P1044, DOI 10.1002/hep.1840130607; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MALTER JM, 1991, HEPATOLOGY, V13, P188, DOI 10.1002/hep.1840130127; OGRADY JG, 1992, J HEPATOL, V14, P104, DOI 10.1016/0168-8278(92)90138-F; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; PETERS M, 1991, HEPATOLOGY, V13, P977, DOI 10.1016/0270-9139(91)90273-X; Sambrook J., 1989, MOL CLONING LAB MANU; THIERS V, 1988, LANCET, V2, P1273; WRIGHT TL, 1992, LANCET, V339, P952, DOI 10.1016/0140-6736(92)91530-L; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R; YOFFE B, 1990, HEPATOLOGY, V12, P187, DOI 10.1002/hep.1840120202; ZELDIS JB, 1989, J CLIN INVEST, V84, P1503, DOI 10.1172/JCI114326	21	266	275	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					142	146		10.1016/S0140-6736(94)90934-2	http://dx.doi.org/10.1016/S0140-6736(94)90934-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904004				2022-12-24	WOS:A1994MQ86900010
J	SIMOONS, ML; MAGGIONI, AP; KNATTERUD, G; LEIMBERGER, JD; DEJAEGERE, P; VANDOMBURG, R; BOERSMA, E; FRANZOSI, MG; CALIFF, R; SCHRODER, R; BRAUNWALD, E				SIMOONS, ML; MAGGIONI, AP; KNATTERUD, G; LEIMBERGER, JD; DEJAEGERE, P; VANDOMBURG, R; BOERSMA, E; FRANZOSI, MG; CALIFF, R; SCHRODER, R; BRAUNWALD, E			INDIVIDUAL RISK ASSESSMENT FOR INTRACRANIAL HEMORRHAGE DURING THROMBOLYTIC THERAPY	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE PLASMINOGEN-ACTIVATOR; INTRAVENOUS STREPTOKINASE; INTRACEREBRAL HEMORRHAGE; RANDOMIZED TRIAL; PHASE-II; STROKE; EPIDEMIOLOGY; NETHERLANDS; ANGIOPLASTY	Thrombolytic therapy improves outcome in patients with myocardial infarction but is associated with an increased risk of intracranial haemorrhage. For some patients, this risk may outweigh the potential benefits of thrombolytic treatment. Using data from other studies, we developed a model for the assessment of an individual's risk of intracranial haemorrhage during thrombolysis. Data were available from 150 patients with documented intracranial haemorrhage and 294 matched controls. 49 patients with intracranial haemorrhage and 122 controls had been treated with streptokinase, whereas 88 cases and 148 controls had received alteplase. By multivariate analysis, four factors were identified as independent predictors of intracranial haemorrhage; age over 65 years (odds ratio 2.2 [95% CI 1.4-3.5]), bodyweight below 70 kg (2.1 [1.3-3.2]), hypertension on hospital admission (2.0 [1.2-3.2]), and administration of alteplase (1.6 [1.0-2.5]). If the overall incidence of intracranial haemorrhage is assumed to be 0.75%, patients without risk factors who receive streptokinase have a 0.26% probability of intracranial haemorrhage. The risk is 0.96%, 1.32%, and 2.17% in patients with one, two, or three risk factors, respectively. We present a model for individual risk assessment that can be used easily in clinical practice.	ERASMUS UNIV ROTTERDAM, THORAXCTR, 3000 DR ROTTERDAM, NETHERLANDS; MARIO NEGRI INST PHARMACOL RES, I-20157 MILAN, ITALY; DUKE UNIV, DEPT CARDIOL, DURHAM, NC 27706 USA; FREE UNIV BERLIN, W-1000 BERLIN 33, GERMANY; MARYLAND MED RES INST, BALTIMORE, MD USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Erasmus University Rotterdam; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Duke University; Free University of Berlin; Harvard University; Brigham & Women's Hospital	SIMOONS, ML (corresponding author), UNIV HOSP ROTTERDAM, THORAXCTR, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Maggioni, Aldo Pietro/AAL-5334-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BOSSUYT PMM, 1990, KLINISCHE BESLISKUND, P127; BRAUNWALD E, 1987, J AM COLL CARDIOL, V10, P970, DOI 10.1016/S0735-1097(87)80296-6; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; CAPLAN LR, 1992, LANCET, V339, P656, DOI 10.1016/0140-6736(92)90804-C; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; KASE CS, 1992, AM J MED, V92, P384, DOI 10.1016/0002-9343(92)90268-G; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MUELLER HS, 1987, J AM COLL CARDIOL, V10, P479, DOI 10.1016/S0735-1097(87)80188-2; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; PASSAMANI E, 1987, J AM COLL CARDIOL, V10, pB51, DOI 10.1016/S0735-1097(87)80429-1; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1988, LANCET, V1, P199; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; VERMEER F, 1986, CIRCULATION, V74, P1379, DOI 10.1161/01.CIR.74.6.1379; VERMEER F, 1988, BRIT HEART J, V59, P527; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; WALL TC, 1992, J AM COLL CARDIOL, V19, P482, DOI 10.1016/S0735-1097(10)80259-1; WILCOX RG, 1988, LANCET, V2, P525	33	231	236	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1523	1528		10.1016/S0140-6736(05)80089-3	http://dx.doi.org/10.1016/S0140-6736(05)80089-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902905	Green Submitted			2022-12-24	WOS:A1993MM40200016
J	MARTIN, GB; BROMMONSCHENKEL, SH; CHUNWONGSE, J; FRARY, A; GANAL, MW; SPIVEY, R; WU, TY; EARLE, ED; TANKSLEY, SD				MARTIN, GB; BROMMONSCHENKEL, SH; CHUNWONGSE, J; FRARY, A; GANAL, MW; SPIVEY, R; WU, TY; EARLE, ED; TANKSLEY, SD			MAP-BASED CLONING OF A PROTEIN-KINASE GENE CONFERRING DISEASE RESISTANCE IN TOMATO	SCIENCE			English	Article							CLONED AVIRULENCE GENES; SYRINGAE PV GLYCINEA; VIRULENCE DETERMINANT; CONSERVED FEATURES; BRASSICA-OLERACEA; RAF ONCOGENE; IDENTIFICATION; LOCUS; SEQUENCE; INCOMPATIBILITY	The Pto gene in tomato confers resistance to races of Pseudomonas syringae pv. tomato that carry the avirulence gene avrPto. A yeast artificial chromosome clone that spans the Pto region was identified and used to probe a leaf complementary DNA (cDNA) library. A cDNA clone was isolated that represents a gene family, at least six members of which genetically cosegregate with Pto. When susceptible tomato plants were transformed with a cDNA from this family, they were resistant to the pathogen. Analysis of the amino acid sequence revealed similarity to serine-threonine protein kinases, suggesting a role for Pto in a signal transduction pathway.	CORNELL UNIV, DEPT PLANT BREEDING & BIOMETRY, ITHACA, NY 14853 USA	Cornell University			Frary, Anne/A-5417-2015; Martin, Gregory B/F-6262-2011; Brommonschenkel, Sergio/C-5748-2013	Frary, Anne/0000-0002-8973-0100; Martin, Gregory B/0000-0003-0044-6830; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arumuganathan K., 1991, PLANT MOL BIOL REP, V9, P229, DOI [10.1007/BF02672073, DOI 10.1007/BF02672073]; BENNETZEN JL, 1992, PLANT MOL BIOL, V20, P575, DOI 10.1007/BF00046442; BERNATZKY R, 1986, GENETICS, V112, P887; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CHUNWONGSE J, UNPUB; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DICKINSON MJ, 1993, MOL PLANT MICROBE IN, V6, P341, DOI 10.1094/MPMI-6-341; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; FARMER EE, 1991, J BIOL CHEM, V266, P3140; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; FRARY A, UNPUB; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GABRIEL DW, 1986, P NATL ACAD SCI USA, V83, P6415, DOI 10.1073/pnas.83.17.6415; GOUGH CL, 1992, MOL PLANT MICROBE IN, V5, P384, DOI 10.1094/MPMI-5-384; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; HULBERT SH, 1985, THEOR APPL GENET, V70, P520, DOI 10.1007/BF00305985; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; KING EO, 1954, J LAB CLIN MED, V44, P301; KOBAYASHI DY, 1989, P NATL ACAD SCI USA, V86, P157, DOI 10.1073/pnas.86.1.157; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MARTIN G, UNPUB; MARTIN GB, 1991, P NATL ACAD SCI USA, V88, P2336, DOI 10.1073/pnas.88.6.2336; MARTIN GB, 1992, MOL GEN GENET, V233, P25, DOI 10.1007/BF00587557; MARTIN GB, 1993, MOL PLANT MICROBE IN, V6, P26, DOI 10.1094/MPMI-6-026; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MESHI T, 1989, PLANT CELL, V1, P515, DOI 10.1105/tpc.1.5.515; MESSEGUER R, 1991, THEOR APPL GENET, V82, P529, DOI 10.1007/BF00226787; OCHMAN H, 1988, GENETICS, V120, P621; RAZ V, 1993, PLANT CELL, V5, P523, DOI 10.1105/tpc.5.5.523; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; SARFATTI M, 1989, THEOR APPL GENET, V78, P755, DOI 10.1007/BF00262574; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; TANKSLEY SD, 1992, GENETICS, V132, P1141; TOBIAS CM, 1992, PLANT PHYSIOL, V99, P284, DOI 10.1104/pp.99.1.284; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; Watterson J.C., 1986, TOMATO CROP SCI BASI, P443; ZAMIR D, 1988, MOL GEN GENET, V213, P254, DOI 10.1007/BF00339589	55	1081	1262	5	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1993	262	5138					1432	1436		10.1126/science.7902614	http://dx.doi.org/10.1126/science.7902614			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	7902614				2022-12-24	WOS:A1993MJ04600037
J	LLOYD, SA				LLOYD, SA			STRATOSPHERIC OZONE DEPLETION	LANCET			English	Article							ANTARCTIC VORTEX; SUNLIGHT; EXPOSURE; RISK		HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University								ANDERSON DE, 1990, J GEOPHYS RES-ATMOS, V95, P7429, DOI 10.1029/JD095iD06p07429; ANDERSON JG, 1989, J GEOPHYS RES-ATMOS, V94, P11480, DOI 10.1029/JD094iD09p11480; ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; EMMETT EA, 1986, EFFECTS CHANGES STRA, V1, P129; GLEASON JF, 1993, SCIENCE, V260, P523, DOI 10.1126/science.260.5107.523; KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366; ROWLAND FS, 1974, NATURE, V249, P810; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1481, DOI 10.1001/archopht.1989.01070020555039; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; TUCKER MA, 1985, NEW ENGL J MED, V313, P789, DOI 10.1056/NEJM198509263131305; WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038; 1986, NASA16 WORLD MET ORG, V1; 1991, REPORT INT OZONE TRE; [No title captured]	16	42	44	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1156	1158		10.1016/0140-6736(93)92130-L	http://dx.doi.org/10.1016/0140-6736(93)92130-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901482				2022-12-24	WOS:A1993MF19800016
J	COLDITZ, GA; WILLETT, WC; ROTNITZKY, A; MANSON, JE				COLDITZ, GA; WILLETT, WC; ROTNITZKY, A; MANSON, JE			WEIGHT-GAIN AS A RISK FACTOR FOR CLINICAL DIABETES-MELLITUS IN WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						WEIGHT GAIN; DIABETES MELLITUS; BODY MASS INDEX; AGE FACTORS; RISK FACTORS	GUIDELINES; AMERICANS; MASS	Objective: To examine the relation between adult weight change and the risk for clinical diabetes mellitus among middle-aged women. Design: Prospective cohort study with follow-up from 1976 to 1990. Setting: if U.S. states. Participants: 114 281 female registered nurses aged 30 to 55 years who did not have diagnosed diabetes mellitus, coronary heart disease, stroke, or cancer in 1976. Outcome Measures: Non-insulin-dependent diabetes mellitus. Results: 2204 cases of diabetes were diagnosed during 1.49 million person-years of follow-up. After adjustment for age, body mass index was the dominant predictor of risk for diabetes mellitus. Risk increased with greater body mass index, and even women with average weight (body mass index, 24.0 kg/m(2)) had an elevated risk. Compared with women with stable weight (those who gained or lost less than 5 kg between age 18 years and 1976) and after adjustment for age and body mass index at age 18 years, the relative risk for diabetes mellitus among women who had a weight gain of 5.0 to 7.9 kg was 1.9 (95% CI, 1.5 to 2.3). The corresponding relative risk for women who gained 8.0 to 10.9 kg was 2.7 (CI, 2.1 to 3.3). In contrast, women who lost more than 5.0 kg reduced their risk for diabetes mellitus by 50% or more. These results were independent of family history of diabetes. Conclusion: The excess risk for diabetes with even modest and typical adult weight gain is substantial. These findings support the importance of maintaining a constant body weight throughout adult life and suggest that the 1990 U.S. Department of Agriculture guidelines that allow a substantial weight gain after 35 years of age are misleading.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR & EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	COLDITZ, GA (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798, P30DK046200] Funding Source: NIH RePORTER; NCI NIH HHS [CA40935] Funding Source: Medline; NIDDK NIH HHS [DK36798, P30-DK-46200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BERGER M, 1975, RECENT ADV OBESITY R, P128; BRAY GA, 1992, AM J CLIN NUTR, V55, P481, DOI 10.1093/ajcn/55.2.481a; BRAY GA, 1992, INT J OBESITY, V16, pS13; CALLAWAY CW, 1991, AM J CLIN NUTR, V54, P171, DOI 10.1093/ajcn/54.1.171a; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; HARLAN WR, 1988, AM J EPIDEMIOL, V128, P1065; HARRIS M, 1979, DIABETES, V28, P1039; HOLBROOK TL, 1989, INT J OBESITY, V13, P723; MANSON JE, 1994, AM J EPIDEMIOL, V139, pS46; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROTH A, 1977, PHS HRP0900603, P182; SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033, DOI 10.1093/ajcn/55.6.1033; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT W, 1994, AM J EPIDEMIOL, V139, pS25; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102; 1990, REPORT CRUDELINES AD; 1987, DHHS PHS871688 US DE	20	1303	1358	3	64	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					481	486		10.7326/0003-4819-122-7-199504010-00001	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872581				2022-12-24	WOS:A1995QP00800001
J	BLUNT, T; FINNIE, NJ; TACCIOLI, GE; SMITH, GCM; DEMENGEOT, J; GOTTLIEB, TM; MIZUTA, R; VARGHESE, AJ; ALT, FW; JEGGO, PA; JACKSON, SP				BLUNT, T; FINNIE, NJ; TACCIOLI, GE; SMITH, GCM; DEMENGEOT, J; GOTTLIEB, TM; MIZUTA, R; VARGHESE, AJ; ALT, FW; JEGGO, PA; JACKSON, SP			DEFECTIVE DNA-DEPENDENT PROTEIN-KINASE ACTIVITY IS LINKED TO V(D)J RECOMBINATION AND DNA-REPAIR DEFECTS ASSOCIATED WITH THE MURINE SCID MUTATION	CELL			English	Article							STRAND BREAK REPAIR; COMBINED IMMUNE-DEFICIENCY; RAY SENSITIVE MUTANTS; HAMSTER OVARY CELLS; RNA POLYMERASE-II; TRANSCRIPTION FACTORS; JUNCTIONAL SEQUENCES; IONIZING-RADIATION; HUMAN CHROMOSOME-8; RECEPTOR GAMMA	Murine cells homozygous for the severe combined immune deficiency mutation (scid) and V3 mutant hamster cells fall into the same complementation group and show similar defects in V(D)J recombination and DNA double-stranded break repair. Here we show that both cell types lack DNA-dependent protein kinase (DNA-PK) activity owing to defects in DNA-PKcs, the catalytic subunit of this enzyme. Furthermore, we demonstrate that yeast artificial chromosomes containing the DNA-PKcs, gene complement both the DNA repair and recombination deficiencies of V3 cells, and we conclude that DNA-PKcs, is encoded by the XRCC7 gene. As DNA-PK binds to DNA ends and is activated by these structures, our findings provide novel insights into V(D)J recombination and DNA repair processes.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND; HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT GENET,BOSTON,MA 02115; ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	University of Cambridge; University of Sussex; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto	BLUNT, T (corresponding author), UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Dry, Kate/I-2328-2014; demengeot, jocelyne/K-8072-2014; Jackson, Stephen Philip/R-4548-2019	demengeot, jocelyne/0000-0002-4761-614X; Jackson, Stephen Philip/0000-0001-9317-7937	NIAID NIH HHS [AI-20047, AI-35714-01] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, R37AI020047, P01AI035714] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ANAND R, 1990, NUCLEIC ACIDS RES, V8, P1951; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BANGA SS, 1994, MUTAT RES-DNA REPAIR, V315, P239, DOI 10.1016/0921-8777(94)90035-3; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL KT, 1988, ANNU REV GENET, V23, P630; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GOTLIEB TM, 1994, TRENDS BIOCHEM SCI, V19, P500; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; ITOH M, 1993, RADIAT RES, V134, P364, DOI 10.2307/3578198; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1985, MUTAT RES, V145, P171, DOI 10.1016/0167-8817(85)90024-0; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KOMATSU K, 1993, HUM MOL GENET, V7, P1031; KUHN A, 1995, GENE DEV, V9, P198; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; MOMBAERT P, 1992, CELL, V68, P867; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TACCIOLI GE, 1994, J BIOL CHEM, V269, P4739; WEIBEZAHN KF, 1985, MUTAT RES, V145, P177, DOI 10.1016/0167-8817(85)90025-2; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881	54	759	771	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					813	823		10.1016/0092-8674(95)90360-7	http://dx.doi.org/10.1016/0092-8674(95)90360-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889575	Bronze			2022-12-24	WOS:A1995QM39900018
J	LUNDBLAD, JR; KWOK, RPS; LAURANCE, ME; HARTER, ML; GOODMAN, RH				LUNDBLAD, JR; KWOK, RPS; LAURANCE, ME; HARTER, ML; GOODMAN, RH			ADENOVIRAL E1A-ASSOCIATED PROTEIN P300 AS A FUNCTIONAL HOMOLOG OF THE TRANSCRIPTIONAL COACTIVATOR CBP	NATURE			English	Article							REGION 1A PROTEINS; ESCHERICHIA-COLI; PROMOTER; IDENTIFICATION; ASSOCIATION; BINDS; GENE	THE 265K nuclear protein CBP was initially identified as a coactivator for the protein kinase A (PKA)-phosphorylated form of the transcription factor CREB(1). The domains in CBP that are involved in CREB binding and transcriptional activation are highly related to the adenoviral E1A-associated cellular protein p300 (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, R10E11.1 and K03H1.10 (refs 4 and 5, respectively), whose functions are unknown. Here, we show that CBP and p300 have similar binding affinity for the PKA-phosphorylated form of CREB, and that p300 can substitute for CBP in potentiating CREB-activated gene expression. We find that E1A binds to CBP through a domain conserved with p300 acid represses the CREB-dependent co-activator functions of both CBP and p300. Our results indicate that the gene repression and cell immortalization functions associated with E1A involve the inactivation of a family of related proteins that normally participate in second-messenger-regulated gene expression.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; CLEVELAND CLIN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Oregon Health & Science University; Cleveland Clinic Foundation								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARANY Z, 1994, CELL, V77, P7799; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANERJEE AC, 1994, ONCOGENE, V5, P1733; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KWOK RPS, 1994, NATURE, V378, P223; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH M, 1994, Z29560 GENB ACC; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	21	530	541	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					85	88		10.1038/374085a0	http://dx.doi.org/10.1038/374085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870179				2022-12-24	WOS:A1995QK07900059
J	PICCIOTTO, MR; ZOLL, M; LENA, C; BESSIS, A; LALLEMAND, Y; LENOVERE, N; VINCENT, P; PICH, EM; BRULET, P; CHANGEUX, JP				PICCIOTTO, MR; ZOLL, M; LENA, C; BESSIS, A; LALLEMAND, Y; LENOVERE, N; VINCENT, P; PICH, EM; BRULET, P; CHANGEUX, JP			ABNORMAL AVOIDANCE-LEARNING IN MICE LACKING FUNCTIONAL HIGH-AFFINITY NICOTINE RECEPTOR IN THE BRAIN	NATURE			English	Article							RAT-BRAIN; ACETYLCHOLINE-RECEPTORS; ALPHA-BUNGAROTOXIN; GENE; BETA-2-SUBUNIT; LOCALIZATION; BEHAVIOR; BINDING; SYSTEM	NICOTINE affects many aspects of behaviour including learning and memory(1,2) through its interaction with neuronal nicotinic acetylcholine receptors (nAChR). Functional nAChRs are pentameric proteins containing at least one type of alpha-subunit and one type of beta-subunit(3-5). The involvement of a particular neuronal nicotinic subunit in pharmacology and behaviour was examined using gene targeting to mutate beta 2, the most widely expressed nAChR subunit in the central nervous system(6-8). We report here that high-affinity binding sites for nicotine are absent from the brains of mice homozygous for the beta 2-subunit mutation. Further, electrophysiological recording from brain slices reveals that thalamic neurons from these mice do not respond to nicotine application. Finally, bebavioural tests demonstrate that nicotine no longer augments the performance of beta 2(-/-) mice on passive avoidance, a test of associative memory. Paradoxically, mutant mice are able to perform better than their non-mutant siblings on this task.	INST PASTEUR,UNITE EMBRYOL MOLEC,ERS 67,PARIS,FRANCE; GLAXO INST MOLEC BIOL SA,DEPT NEUROBIOL,CH-1211 GENEVA,SWITZERLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GlaxoSmithKline	PICCIOTTO, MR (corresponding author), INST PASTEUR,CNRS,UNITE NEUROBIOL MOLEC D1284,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Léna, Clément/P-6929-2019; Beldar, Sagar V/C-8542-2011; Zoli, Michele/C-8899-2016; Léna, Clément/ABE-4862-2021; Le Novère, Nicolas/F-9973-2010; Vincent, Pierre/A-1055-2012; , clement/ADN-8076-2022; Léna, Clément/T-8458-2018; Picciotto, Marina R./F-8747-2012	Léna, Clément/0000-0002-1431-7717; Zoli, Michele/0000-0002-8034-2849; Léna, Clément/0000-0002-1431-7717; Le Novère, Nicolas/0000-0002-6309-7327; Vincent, Pierre/0000-0002-8479-1908; Léna, Clément/0000-0002-1431-7717; Picciotto, Marina R./0000-0002-4404-1280; Bessis, Alain/0000-0001-8362-6874				ANAND R, 1991, J BIOL CHEM, V266, P11192; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; CRAWLEY JN, 1985, NEUROSCI BIOBEHAV R, V9, P37, DOI 10.1016/0149-7634(85)90030-2; DECKER MW, 1994, J PHARMACOL EXP THER, V2270, P319; FAIMAN CP, 1991, BEHAV NEURAL BIOL, V56, P1183; FLICKER C, 1983, PHARMACOL BIOCHEM BE, V18, P973, DOI 10.1016/S0091-3057(83)80023-9; FLORES CM, 1992, MOL PHARMACOL, V41, P31; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; HILL JA, 1993, J NEUROSCI, V13, P1551; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVIN ED, 1992, PSYCHOPHARMACOLOGY, V108, P417, DOI 10.1007/BF02247415; LUETJE CW, 1991, J NEUROSCI, V11, P837; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MARKS MJ, 1982, MOL PHARMACOL, V22, P554; MMARKS MJ, 1982, J NEUROSCI, V12, P2765; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; NORDBERG A, 1985, ACTA PHARMACOL TOX, V56, P337; OLIVERIO A, 1966, J PHARMACOL EXP THER, V154, P350; PICH EM, 1989, PHARMACOL RES, V21, P595; ROMANO C, 1980, SCIENCE, V210, P647, DOI 10.1126/science.7433991; Sambrook J., 1989, MOL CLONING LAB MANU; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SWANSON LW, 1983, P NATL ACAD SCI-BIOL, V80, P4532, DOI 10.1073/pnas.80.14.4532; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; ZOLI M, IN PRESS J NEUROSCI	28	540	556	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					65	67		10.1038/374065a0	http://dx.doi.org/10.1038/374065a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870173				2022-12-24	WOS:A1995QK07900053
J	FIROUZI, A; KUMAR, D; BULL, LM; BESIER, T; SIEGER, P; HUO, Q; WALKER, SA; ZASADZINSKI, JA; GLINKA, C; NICOL, J; MARGOLESE, D; STUCKY, GD; CHMELKA, BF				FIROUZI, A; KUMAR, D; BULL, LM; BESIER, T; SIEGER, P; HUO, Q; WALKER, SA; ZASADZINSKI, JA; GLINKA, C; NICOL, J; MARGOLESE, D; STUCKY, GD; CHMELKA, BF			COOPERATIVE ORGANIZATION OF INORGANIC-SURFACTANT AND BIOMIMETIC ASSEMBLIES	SCIENCE			English	Article							SILICATE SOLUTIONS; CETYLTRIMETHYLAMMONIUM BROMIDE; TETRAMETHYLAMMONIUM SILICATE; ORGANIC INTERFACES; MAGNETIC-RESONANCE; COUNTERION BINDING; AQUEOUS-SOLUTIONS; X-RAY; MICELLES; CHLORIDE	A model that makes use of the cooperative organization of inorganic and organic molecular species into three dimensionally structured arrays is generalized for the synthesis of nanocomposite materials. In this model, the properties and structure of a system are determined by dynamic interplay among ion-pair inorganic and organic species, so that different phases can be readily obtained through small variations of controllable synthesis parameters, including mixture composition and temperature. Nucleation, growth, and phase transitions may be directed by the charge density, coordination, and steric requirements of the inorganic and organic species at the interface and not necessarily by a preformed structure. A specific example is presented in which organic molecules in the presence of multiply charged silicate oligomers self-assemble into silicatropic liquid crystals. The organization of these silicate-surfactant mesophases is investigated with and without interfacial silicate condensation to separate the effects of self-assembly from the kinetics of silicate polymerization.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,MAT RES LAB,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106; NIST,GAITHERSBURG,MD 20899	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; National Institute of Standards & Technology (NIST) - USA			Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067	NIGMS NIH HHS [GM 47334] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFREDSSON V, 1994, J CHEM SOC CHEM COMM, P921, DOI 10.1039/c39940000921; ARCHIBALD DD, 1993, NATURE, V364, P430, DOI 10.1038/364430a0; AUVRAY X, 1989, J PHYS CHEM-US, V93, P7458, DOI 10.1021/j100358a040; BACKLUND S, 1982, ACTA CHEM SCAND A, V36, P698, DOI 10.3891/acta.chem.scand.36a-0698; BARAL S, 1993, CHEM MATER, V5, P145, DOI 10.1021/cm00026a001; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; BLACKMORE ES, 1990, LIQ CRYST, V8, P131, DOI 10.1080/02678299008047336; BUNKER BC, 1994, SCIENCE, V264, P48, DOI 10.1126/science.264.5155.48; CHEN CY, 1993, MICROPOROUS MATER, V2, P17, DOI 10.1016/0927-6513(93)80058-3; CHEN CY, 1993, MICROPOROUS MATER, V2, P27, DOI 10.1016/0927-6513(93)80059-4; DAVIS ME, IN PRESS MATER RES S; EKWALL P, 1971, J COLLOID INTERF SCI, V35, P519, DOI 10.1016/0021-9797(71)90210-4; ENGELHARDT G, 1984, J MOL LIQ, V27, P125; Engelhardt G, 1987, HIGH RESOLUTION SOLI; EVANS DF, 1989, WATER SCI REV, V4, P1; FEHR FJ, 1989, J AM CHEM SOC, V111, P1288; FIROUZI A, UNPUB; GAMBOA C, 1989, J PHYS CHEM-US, V93, P5540, DOI 10.1021/j100351a043; GROENEN EJJ, 1986, ZEOLITES, V6, P403, DOI 10.1016/0144-2449(86)90070-9; HARRIS RK, 1982, J MOL STRUCT, V78, P273, DOI 10.1016/0022-2860(82)80013-6; HENDRICKS WM, 1991, J PHYS CHEM-US, V95, P9519, DOI 10.1021/j100176a088; HERRINGTON KL, 1993, J PHYS CHEM-US, V97, P13792, DOI 10.1021/j100153a058; HEYWOOD BR, 1994, ADV MATER, V6, P9, DOI 10.1002/adma.19940060103; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016; IKEDA S, 1991, COLLOID POLYM SCI, V269, P49, DOI 10.1007/BF00654659; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; JACOBSON K, 1975, BIOCHEMISTRY-US, V14, P152, DOI 10.1021/bi00672a026; KALER EW, 1992, J PHYS CHEM-US, V96, P6698, DOI 10.1021/j100195a033; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; KNIGHT CTG, 1989, ZEOLITES, V9, P448, DOI 10.1016/0144-2449(89)90103-6; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kumar D., UNPUB; LANGEVIN D, 1992, ANNU REV PHYS CHEM, V43, P341, DOI 10.1146/annurev.pc.43.100192.002013; LINDEMUTH PM, 1993, J PHYS CHEM-US, V97, P7769, DOI 10.1021/j100131a055; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MANN S, 1993, SCIENCE, V261, P1286, DOI 10.1126/science.261.5126.1286; Mann S., 1989, BIOMINERALIZATION CH; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; MURTHY AK, 1991, J COLLOID INTERF SCI, V145, P598, DOI 10.1016/0021-9797(91)90391-K; OGAWA M, 1994, J AM CHEM SOC, V116, P7941, DOI 10.1021/ja00096a079; OZEKI S, 1981, B CHEM SOC JPN, V54, P552, DOI 10.1246/bcsj.54.552; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; QUIRION F, 1986, J PHYS CHEM-US, V90, P5435, DOI 10.1021/j100412a108; REISSHUSSON F, 1964, J PHYS CHEM-US, V68, P3504, DOI 10.1021/j100794a011; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; STEEL A, 1994, J CHEM SOC CHEM COMM, P1571, DOI 10.1039/c39940001571; STEIN A, UNPUB; STUCKY GD, 1994, MOL CRYST LIQ CRYS A, V240, P187, DOI 10.1080/10587259408029730; SZLEIFER I, 1990, J CHEM PHYS, V92, P6800, DOI 10.1063/1.458267; VERKLEIJ AJ, 1974, BIOCHIM BIOPHYS ACTA, V339, P432, DOI 10.1016/0005-2736(74)90171-0; VONHOEBBEL D, 1982, Z ANORG ALLG CHEM, V494, P31; WARNHEIM T, 1988, J COLLOID INTERF SCI, V125, P627, DOI 10.1016/0021-9797(88)90030-6; WEINER S, 1986, CRC CR REV BIOCH MOL, V20, P365, DOI 10.3109/10409238609081998; WEINER S, 1984, PHILOS T ROY SOC B, V304, P425, DOI 10.1098/rstb.1984.0036; WIEBCKE M, 1992, J CHEM SOC DA, V16, P2451; ZASADZINSKI JAN, 1989, J ELECTRON MICR TECH, V13, P309, DOI 10.1002/jemt.1060130406	57	707	739	6	310	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1138	1143		10.1126/science.7855591	http://dx.doi.org/10.1126/science.7855591			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855591				2022-12-24	WOS:A1995QJ23700028
J	BERLINER, E; YOUNG, EC; ANDERSON, K; MAHTANI, HK; GELLES, J				BERLINER, E; YOUNG, EC; ANDERSON, K; MAHTANI, HK; GELLES, J			FAILURE OF A SINGLE-HEADED KINESIN TO TRACK PARALLEL TO MICROTUBULE PROTOFILAMENTS	NATURE			English	Article							LIGHT-MICROSCOPY; MOVEMENT; MOLECULES; DENSITIES; DOMAINS	KINESIS, a two-headed motor enzyme molecule, hydrolyses ATP to direct organelle transport along microtubules. As it moves along a microtubule, kinesin remains associated with, or (tracks', microtubule protofilaments(1,2). We have prepared truncated kinesin derivatives that contain either two mechanochemical head domains(3) or only a single head. Unlike intact kinesin and the two-headed derivatives, the one-headed enzyme frequently fails to track protofilaments, suggesting that it detaches from microtubules during movement. In this way, the one-headed kinesin derivative is similar to the motor enzyme myosin, which frequently detaches from the actin filament during movement(4). For myosin (which has two heads), the consequence of this detachment is that single molecules do not appear to drive continuous movement along the filament(5). Our observations suggest that the ability of single two-headed kinesin molecules to drive continuous movement(6,7) results from a 'hand-over-hand' mechanism(6-8) in which one head remains bound to the microtubule while the other detaches and moves forwards.	BRANDEIS UNIV, GRAD DEPT BIOCHEM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, BIOPHYS PROGRAM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA	Brandeis University; Brandeis University; Brandeis University				Young, Edgar C./0000-0002-8453-088X; Gelles, Jeff/0000-0001-7910-3421				BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, 1994, J BIOL CHEM, V269, P23382; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GELLES J, 1989, Journal of Cell Biology, V109, p157A; GELLES J, IN PRESS BIOPHYS J; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Summers MD, 1987, MANUAL METHODS BACUL; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; YOUNG EC, IN PRESS J BIOL CHEM	28	164	165	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	1995	373	6516					718	721		10.1038/373718a0	http://dx.doi.org/10.1038/373718a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854458				2022-12-24	WOS:A1995QH92800060
J	BRADLEY, DC; QIAN, N; ANDERSEN, RA				BRADLEY, DC; QIAN, N; ANDERSEN, RA			INTEGRATION OF MOTION AND STEREOPSIS IN MIDDLE TEMPORAL CORTICAL AREA OF MACAQUES	NATURE			English	Article							VISUAL AREA; FUNCTIONAL-PROPERTIES; NEURONS; MONKEY; DIRECTION; SELECTIVITY; ORIENTATION; SENSITIVITY; PERCEPTION; DISPARITY	THE primate visual system incorporates a highly specialized subsystem for the analysis of motion in the visual field(1-6). A key element of this subsystem is the middle temporal (MT) cortical area, which contains a majority of direction-selective neurons(1-3). MT neurons are also selective for binocular disparity (depth), which is perplexing given that they are not sensitive to motion through depth(7). What is the role of disparity in MT? Our data suggest an important link between disparity and transparent motion detection. Motion signals in different directions tend to inhibit each other within a given MT receptive field(8). This inhibition has an averaging effect which minimizes MT responses to random motion signals created by light intensity changes and other non-motion stimuli (motion noise)9. But, in the absence of disparity cues, inhibition may also occur between surfaces moving in different directions through the same part of the visual field (transparent motion), thus impairing the detection of either surface. Here we show that inhibition in MT occurs mainly between motion signals with similar disparities. Transparent surface movements at different depths are thus represented independently in MT (that is, without inhibiting each other) whereas spurious motion signals from a given surface tend to cancel out. To our knowledge, these results provide the first evidence for a functional integration of motion and disparity in MT.			BRADLEY, DC (corresponding author), CALTECH,DIV BIOL 21676,PASADENA,CA 91125, USA.							ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ALLMAN JM, 1971, BRAIN RES, V31, P84; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; LINIDSEY DT, 1994, INVEST OPHTH VIS SCI, V35, P1389; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MATHER G, 1983, Q J EXP PSYCHOL-A, V35, P513, DOI 10.1080/14640748308402485; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1148, DOI 10.1152/jn.1983.49.5.1148; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; QIAN N, 1994, J NEUROSCI, V14, P7367; QIAN N, 1994, J NEUROSCI, V14, P7357; ROY JP, 1992, J NEUROSCI, V12, P2478; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; SNOWDEN RJ, 1989, J OPT SOC AM A, V6, P1096, DOI 10.1364/JOSAA.6.001096; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679	19	181	182	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					609	611		10.1038/373609a0	http://dx.doi.org/10.1038/373609a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854417				2022-12-24	WOS:A1995QG99700053
J	HERRINTON, LJ; FRIEDMAN, GD				HERRINTON, LJ; FRIEDMAN, GD			SERUM-CHOLESTEROL CONCENTRATION AND RISK OF BRAIN CANCER	BRITISH MEDICAL JOURNAL			English	Article							TUMORS				HERRINTON, LJ (corresponding author), KAISER PERMANENTE MED CTR,DIV RES,3505 BROADWAY AVE,OAKLAND,CA 96411, USA.				NCI NIH HHS [R35 CA49761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; KNEKT P, 1991, BRIT MED J, V302, P90, DOI 10.1136/bmj.302.6768.90; NEUGUT AI, 1989, INT J EPIDEMIOL, V18, P798, DOI 10.1093/ije/18.4.798; SMITH GD, 1989, BMJ-BRIT MED J, V299, P26, DOI 10.1136/bmj.299.6690.26; SMITH GD, 1992, AM J EPIDEMIOL, V135, P259, DOI 10.1093/oxfordjournals.aje.a116279	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					367	368		10.1136/bmj.310.6976.367	http://dx.doi.org/10.1136/bmj.310.6976.367			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866214	Green Published			2022-12-24	WOS:A1995QG72100019
J	PENTTINEN, J				PENTTINEN, J			BACK PAIN AND RISK OF FATAL ISCHEMIC-HEART-DISEASE - 13 YEAR FOLLOW-UP OF FINNISH FARMERS	BRITISH MEDICAL JOURNAL			English	Article											PENTTINEN, J (corresponding author), KUOPIO REG INST OCCUPAT HLTH,POB 93,SF-70701 KUOPIO,FINLAND.							BIERINGSORENSEN F, 1983, SCAND J REHABIL MED, V15, P71; BOSHUIZEN HC, 1993, SPINE, V18, P35, DOI 10.1097/00007632-199301000-00007; KAUPPILA LI, 1993, J SPINAL DISORD, V6, P124; NUWAYHID IA, 1993, AM J EPIDEMIOL, V137, P539, DOI 10.1093/oxfordjournals.aje.a116707; SVENSSON HO, 1983, SPINE, V8, P277, DOI 10.1097/00007632-198304000-00008	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1267	1268		10.1136/bmj.309.6964.1267	http://dx.doi.org/10.1136/bmj.309.6964.1267			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888848	Green Published			2022-12-24	WOS:A1994PT03300021
J	SILVA, JM; SILVA, PS				SILVA, JM; SILVA, PS			SEXLESS HDL	LANCET			English	Editorial Material											SILVA, JM (corresponding author), UNIV HOSP COIMBRA,DEPT MED 2,COIMBRA,PORTUGAL.							AILHAUD G, 1993, ANN BIOL CLIN-PARIS, V51, P267; ASSMANN G, 1993, CIRCULATION, V87, P28; DEMIROVIC J, 1992, AM J EPIDEMIOL, V136, P155, DOI 10.1093/oxfordjournals.aje.a116482; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; KUSHWAHA RS, 1992, CURR OPIN LIPIDOL, V3, P167; WALLDIUS G, 1992, CURR OPIN LIPIDOL, V3, P34; WILSON PWF, 1990, AM J CARDIOL, V66, pA7, DOI 10.1016/0002-9149(90)90562-F; 1992, NUTR META CARDIOVASC, V2, P113; 1988, EUROPEAN HEART J, V9, P571	9	1	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					129	130		10.1016/S0140-6736(94)90927-X	http://dx.doi.org/10.1016/S0140-6736(94)90927-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903997				2022-12-24	WOS:A1994MQ86900003
J	CUI, KH; WARNES, GM; JEFFREY, R; MATTHEWS, CD				CUI, KH; WARNES, GM; JEFFREY, R; MATTHEWS, CD			SEX DETERMINATION OF PREIMPLANTATION EMBRYOS BY HUMAN TESTIS-DETERMINING-GENE AMPLIFICATION	LANCET			English	Article							DNA AMPLIFICATION; SPERM RECEPTOR; INVITRO; FERTILIZATION; PROTEIN; BIOPSY; ZP3	When there is a risk of inherited disease, preimplantation diagnosis gives couples an opportunity to avoid having a child with the disease. Sex determination can be used to exclude the likelihood of a sex-linked disorder. Accuracy of the diagnosis is important. We have tested the reliability of sex determination based on the recognition of a testis-determining gene (SRY) sequence. DNA from the blood of 120 men and women and from 38 single lymphocytes was amplified by polymerase chain reaction (PCR) with the SRY and control (ZP3) gene primers. All results confirmed the correct sex of origin (100%). The test was then used to determine the sex of 21 single embryo cells biopsied from 21 (4-8 cell) human polyspermic embryos. 2 embryo cells recognised at biopsy to have degenerated produced negative results. The other 19 single embryo cells showed 100% PCR amplification. 11 (58%) of the embryos were judged to be ''male'' and 8 (42%) ''female''. The SRY and ZP3 gene primers selected are highly specific and give accurate results in sex determination and their use provides a new reliable method for routine preimplantation and general prenatal sex determination in man.			CUI, KH (corresponding author), UNIV ADELAIDE,QUEEN ELIZABETH HOSP,DEPT OBSTET & GYNAECOL,WOODVILLE,SA 5011,AUSTRALIA.							BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; BRADBURY MW, 1990, P NATL ACAD SCI USA, V87, P4053, DOI 10.1073/pnas.87.11.4053; CHAMBERLIN ME, 1990, P NATL ACAD SCI USA, V87, P6014, DOI 10.1073/pnas.87.16.6014; CUI KH, 1993, HUM REPROD, V8, P621, DOI 10.1093/oxfordjournals.humrep.a138107; CUI KH, 1993, NATURE, V366, P117, DOI 10.1038/366117b0; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; Kawasaki E. S., 1990, PCR PROTOCOLS GUIDE, P146; LO YMD, 1989, LANCET, V2, P1363; NAKAGOME Y, 1990, LANCET, V335, P291, DOI 10.1016/0140-6736(90)90109-I; NAKAHORI Y, 1986, NUCLEIC ACIDS RES, V14, P7569, DOI 10.1093/nar/14.19.7569; PAYNE D, 1991, HUM REPROD, V6, P423, DOI 10.1093/oxfordjournals.humrep.a137352; QUINN P, 1985, ANN NY ACAD SCI, V442, P195, DOI 10.1111/j.1749-6632.1985.tb37520.x; RINGUETTE MJ, 1988, DEV BIOL, V127, P287, DOI 10.1016/0012-1606(88)90315-6; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STROM CM, 1991, J IN VITRO FERTIL EM, V8, P225, DOI 10.1007/BF01130810; TROUNSON AL, 1992, HUM REPROD, V7, P583; VANDUIN M, 1991, CYTOGENET CELL GENET, V58, P1927; WINSTON RML, 1991, HUM REPROD, V6, P281	20	54	53	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					79	82		10.1016/S0140-6736(94)90815-X	http://dx.doi.org/10.1016/S0140-6736(94)90815-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903778				2022-12-24	WOS:A1994MQ09200010
J	KALKSTEIN, LS				KALKSTEIN, LS			DIRECT IMPACTS IN CITIES	LANCET			English	Article							HUMAN MORTALITY; UNITED-STATES; WEATHER				KALKSTEIN, LS (corresponding author), UNIV DELAWARE,DEPT GEOG,CTR CLIMAT RES,NEWARK,DE 19716, USA.							KAKSTEIN LS, IN PRESS DIFFERENTIA; KALKSTEIN LS, 1989, ANN ASSOC AM GEOGR, V79, P44, DOI 10.1111/j.1467-8306.1989.tb00249.x; KALKSTEIN LS, 1991, ENVIRON HEALTH PERSP, V96, P145, DOI 10.2307/3431223; KALKSTEIN LS, 1993, EXPERIENTIA, V49, P1; KALKSTEIN LS, IN PRESS POTENTIAL I; MCMICHAEL AJ, 1993, INT J EPIDEMIOL, V22, P1, DOI 10.1093/ije/22.1.1; RANGO N, 1984, AM J PUBLIC HEALTH, V74, P1159, DOI 10.2105/AJPH.74.10.1159; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106, DOI 10.1093/oxfordjournals.aje.a116413; SCHERAGA JS, IN PRESS PRELIMINARY; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600, DOI 10.1164/ajrccm/145.3.600; SMITH J, 1989, POTENTIAL EFFECTS GL, P172; 1990, POTENTIAL HLTH EFFEC	12	120	123	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1397	1399		10.1016/0140-6736(93)92757-K	http://dx.doi.org/10.1016/0140-6736(93)92757-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901686				2022-12-24	WOS:A1993MK09500014
J	SPORN, MB				SPORN, MB			CHEMOPREVENTION OF CANCER	LANCET			English	Editorial Material							RECEPTOR SUPERFAMILY; PREVENTION; CARCINOGENESIS; TAMOXIFEN; DISEASE; EFFICACY; TRIALS; TUMORS				SPORN, MB (corresponding author), NCI, CHEMOPREVENT LAB, BLDG 41, ROOM C629, BETHESDA, MD 20892 USA.							ABE O, 1992, LANCET, V339, P71; [Anonymous], 1992, Lancet, V339, P1; BOONE CW, 1992, CANCER RES, V52, P1651; CHIESA F, 1992, ORAL ONCOL, V28B, P97; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; CONNEY AH, 1977, FED PROC, V36, P1647; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUGHBERMAN A, 1992, LANCET, V340, P1143, DOI 10.1016/0140-6736(92)93161-F; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KOHN EC, 1992, CANCER RES, V52, P3208; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G; RATKO TA, 1989, CANCER RES, V49, P4472; ROBERTS AB, 1992, CANCER SURV, V14, P205; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SPORN MB, 1976, FED PROC, V35, P1332; SPORN MB, 1991, CANCER RES, V51, P6215; SPORN MB, 1980, NATURE, V287, P107, DOI 10.1038/287107a0; WATTENBERG LW, 1983, CANCER RES, V43, P2448; WATTENBERG LW, 1985, CANCER RES, V45, P1; Yoshizawa S., 1987, PHYTOTHER RES, V1, P44, DOI [10.1002/ptr.2650010110, DOI 10.1002/PTR.2650010110]; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; 1976, CANCER RES, V36, P2475	29	69	70	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1211	1213						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901533				2022-12-24	WOS:A1993MG27400013
J	MCGAVOCK, H; WEBB, CH; JOHNSTON, GD; MILLIGAN, E				MCGAVOCK, H; WEBB, CH; JOHNSTON, GD; MILLIGAN, E			MARKET PENETRATION OF NEW DRUGS IN ONE UNITED-KINGDOM REGION - IMPLICATIONS FOR GENERAL-PRACTITIONERS AND ADMINISTRATORS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the use of new drugs in one United Kingdom region. Design-Examination of data on prescribing of angiotensin converting enzyme inhibitors, new broad spectrum antibiotics, and H-2 receptor antagonists. Calculation of number of defined daily doses prescribed each month. Setting-All general practices in Northern Ireland. Main outcome measures-Drug use index and market share of each drug. Results-During 1988-91 prescribing of angiotensin converting enzyme inhibitors increased by 126%, of H-2 receptor antagonists by 46%, and of new antibiotics by 207%. The first drug on the market usually retained the largest market share. Use of oral antibiotics increased threefold irrespective of the reporting policy of the general practitioners' local laboratory. Conclusions-The increase in prescribing of these drugs seems to be greater than can be accounted for by an increase in patients with specific indications for these drugs. This suggests that the profession has not instituted effective checks to ensure that the legitimate promotion of new products does not lead to inappropriate and wasteful use.	ROYAL VICTORIA HOSP,DEPT BACTERIOL,BELFAST BT12 6BA,NORTH IRELAND		MCGAVOCK, H (corresponding author), QUEENS UNIV BELFAST,DEPT THERAPEUT & PHARMACOL,DRUG UTILIZAT RES UNIT,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.							Elmes P C, 1978, Ulster Med J, V47, P79; GRIFFITHS K, 1985, EUR J CLIN PHARMACOL, V29, P1; HAWKEY PM, 1989, J ANTIMICROB CHEMOTH, V24, P477, DOI 10.1093/jac/24.4.477; HOOD H, 1968, LANCET, V2, P96; MARSHALL BJ, 1988, LANCET, V2, P1437; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; WADE OL, 1972, BRIT J PREV SOC MED, V26, P121; 1992, BMJ, V304, P405; 1985, BMJ, V291, P97; 1993, ANATOMICAL THERAPEUT, P1; 1993, BRIT NATIONAL FORMUL, V25, P203; 1987, DRUG THERAPEUTICS B, V25, P69	12	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1118	1120		10.1136/bmj.307.6912.1118	http://dx.doi.org/10.1136/bmj.307.6912.1118			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	7902744	Green Published, Bronze			2022-12-24	WOS:A1993ME91800021
J	ROSENMUND, C; CLEMENTS, JD; WESTBROOK, GL				ROSENMUND, C; CLEMENTS, JD; WESTBROOK, GL			NONUNIFORM PROBABILITY OF GLUTAMATE RELEASE AT A HIPPOCAMPAL SYNAPSE	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; QUANTAL ANALYSIS; CELL-CULTURE; TIME COURSE; CURRENTS; NEURONS; SLICES; TRANSMISSION; CHANNELS	A change in the probability of neurotransmitter release (P(r)) is an important mechanism underlying synaptic plasticity. Although P(r) is often assumed to be the same for all terminals at a single synapse, this assumption is difficult to reconcile with the nonuniform size and structure of synaptic terminals in the central nervous system. Release probability was measured at excitatory synapses on cultured hippocampal neurons by analysis of the progressive block of N-methyl-D-aspartate receptor-mediated synaptic currents by the irreversible open channel blocker MK-801. Release probability was nonuniform (range of 0.09 to 0.54) for terminals arising from a single axon, the majority of which had a low P(r). However, terminals with high P(r) are more likely to be affected by the activity-dependent modulation that occurs in long-term potentiation.	OREGON HLTH SCI UNIV,VOLLUM 1ST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046613, R37MH046613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026494, R29NS026494] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46613] Funding Source: Medline; NINDS NIH HHS [NS26494] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BROWN TH, 1976, P NATL ACAD SCI USA, V73, P2913, DOI 10.1073/pnas.73.8.2913; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; CLEMENTS JD, 1993, PRESYNAPTIC RECEPTOR, P180; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1986, NEUROSCIENCE, V19, P857, DOI 10.1016/0306-4522(86)90304-0; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JAHR CE, 1992, SCIENCE, V255, P470, DOI 10.1126/science.1346477; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; LANTHORN TH, 1981, BRAIN RES, V225, P171, DOI 10.1016/0006-8993(81)90326-7; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; McLachlan E M, 1978, Int Rev Physiol, V17, P49; POTIER B, 1993, EUR J PHARMACOL, V231, P427, DOI 10.1016/0014-2999(93)90120-7; PUN RYK, 1986, J NEUROPHYSIOL, V56, P1242, DOI 10.1152/jn.1986.56.5.1242; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; REDMAN S, 1983, J PHYSIOL-LONDON, V343, P135, DOI 10.1113/jphysiol.1983.sp014885; SEGAL MM, 1991, J NEUROPHYSIOL, V65, P761, DOI 10.1152/jn.1991.65.4.761; TONG G, 1993, SOC NEUR ABSTR, V19; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; WALMSLEY B, 1988, J NEUROPHYSIOL, V60, P889, DOI 10.1152/jn.1988.60.3.889	30	498	501	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					754	757		10.1126/science.7901909	http://dx.doi.org/10.1126/science.7901909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	7901909				2022-12-24	WOS:A1993MD95200046
J	MATZUK, MM; LU, NF; VOGEL, H; SELLHEYER, K; ROOP, DR; BRADLEY, A				MATZUK, MM; LU, NF; VOGEL, H; SELLHEYER, K; ROOP, DR; BRADLEY, A			MULTIPLE DEFECTS AND PERINATAL DEATH IN MICE DEFICIENT IN FOLLISTATIN	NATURE			English	Article							ACTIVIN-BINDING PROTEIN; EMBRYONIC-DEVELOPMENT; RAT FOLLISTATIN; MESSENGER-RNA; EXPRESSION; RECEPTOR; INHIBIN	FOLLISTATIN, an activin-binding protein and activin antagonist in vitro(1,2), can bind to heparan sulphate proteoglycans(3) and may function in vivo to present activins to their receptors. In the mouse, follistatin messenger RNA is first detected in the deciduum (on embryonic day 5.5), and later in the developing hindbrain, somites, vibrissae, teeth, epidermis and muscle(4-11). In Xenopus laevis, overexpression of follistatin leads to induction of neural tissue(12). Here we use loss-of-function mutant mice to investigate the function of follistatin in mammals. We find that follistatin-deficient mice are retarded in their growth, have decreased mass of the diaphragm and intercostal muscles, shiny taut skin, skeletal defects of the hard palate and the thirteenth pair of ribs, their whisker and tooth development is abnormal, they fail to breathe, and die within hours of birth. These defects are more widespread than those seen in activin-deficient mutant mite, indicating that follistatin may modulate the actions of several members of the transforming growth factor-beta family.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	MATZUK, MM (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.			Vogel, Otto Hannes/0000-0002-0960-3508; Bradley, Allan/0000-0002-2349-8839				ALBANO RM, 1994, DEVELOPMENT, V120, P803; CHISAKA O, 1992, NATURE, V335, P516; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; HASHIMOTO M, 1992, J BIOL CHEM, V267, P7203; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; MICHEL U, 1990, BIOCHEM BIOPH RES CO, V173, P401, DOI 10.1016/S0006-291X(05)81072-1; MICHEL U, 1991, BIOCHEM BIOPH RES CO, V180, P223, DOI 10.1016/S0006-291X(05)81280-X; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PIERARDFRANCHIM.C, 1992, J PATHOL, V167, P2223; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAMIREZSOLIS R, 1993, CELL, V83, P279; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P652; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; VANDENEIJNDENVA.AJ, 1992, DEV BIOL, V154, P356; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397	23	488	514	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					360	363		10.1038/374360a0	http://dx.doi.org/10.1038/374360a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885475				2022-12-24	WOS:A1995QN63000060
J	PORTER, JA; VONKESSLER, DP; EKKER, SC; YOUNG, KE; LEE, JJ; MOSES, K; BEACHY, PA				PORTER, JA; VONKESSLER, DP; EKKER, SC; YOUNG, KE; LEE, JJ; MOSES, K; BEACHY, PA			THE PRODUCT OF HEDGEHOG AUTOPROTEOLYTIC CLEAVAGE ACTIVE IN LOCAL AND LONG-RANGE SIGNALING	NATURE			English	Article							POLARITY GENE HEDGEHOG; DROSOPHILA-EMBRYO; TRANSFORMATION; CUTICLE; VECTORS; LARVAL	THE secreted protein products of the hedgehog (hh) gene family are associated with local and long-range signalling activities that are responsible far developmental patterning in multiple systems, including Drosophila embryonic and larval tissues(1-8) and vertebrate neural tube, limbs and somites(9-15). In a process that is critical for full biological activity, the hedgehog protein (Hh) undergoes autoproteolysis to generate two biochemically distinct products, an 18K amino-terminal fragment, N, and a 25K carboxy-terminal fragment, C (ref. 16); mutations that block autoproteolysis impair Hh function. We have identified the site of autoproteolytic cleavage and find that it is broadly conserved throughout the hedgehog family. Knowing the site of cleavage, we were able to test the function of the N and C cleavage products in Drosophila assays. We show here that the N product is the active species in both local and long-range signalling. Consistent with this, all twelve mapped hedgehog mutations either affected the structure of the N product directly or otherwise blocked the release of N from the Hh precursor as a result of deletion or alteration of sequences in the C domain.	UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of Southern California	PORTER, JA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.			Ekker, Stephen/0000-0003-0726-4212				ASHBURNER M, 1989, DROSOPHILA LABORATOR; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHANG DT, 1994, DEVELOPMENT, V120, P3339; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOONIN EV, IN PRESS TRENDS BIOC; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1988, GENETICS, V120, P1061; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDERSLICE P, 1988, J BIOL CHEM, V263, P10583; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x	26	439	468	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					363	366		10.1038/374363a0	http://dx.doi.org/10.1038/374363a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885476				2022-12-24	WOS:A1995QN63000061
J	GONZALES, R; SANDE, M				GONZALES, R; SANDE, M			WHAT WILL IT TAKE TO STOP PHYSICIANS FROM PRESCRIBING ANTIBIOTICS IN ACUTE BRONCHITIS	LANCET			English	Editorial Material							ERYTHROMYCIN				GONZALES, R (corresponding author), SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110, USA.							BRICKFIELD FX, 1986, J FAM PRACTICE, V23, P119; DUNLAY J, 1987, J FAM PRACTICE, V25, P137; FRANKS P, 1984, J FAM PRACTICE, V19, P185; HOWIE JGR, 1970, LANCET, V2, P1099; KAYSER FH, 1990, EUR J CLIN MICROBIOL, V9, P810, DOI 10.1007/BF01967379; MASON EO, 1992, ANTIMICROB AGENTS CH, V36, P1703, DOI 10.1128/AAC.36.8.1703; NORDENSTAM I, 1992, SWEDISH STATISTICS M; ORR PH, 1993, J FAM PRACTICE, V36, P507; PARKINSON AJ, 1994, J INFECT DIS, V170, P461, DOI 10.1093/infdis/170.2.461; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; VERHEIJ TJM, 1990, FAM PRACT, V7, P175, DOI 10.1093/fampra/7.3.175; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; WILLIAMSON HA, 1984, J FAM PRACTICE, V19, P185	13	93	95	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					665	666		10.1016/S0140-6736(95)90861-7	http://dx.doi.org/10.1016/S0140-6736(95)90861-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885119				2022-12-24	WOS:A1995QM73200002
J	HAMILTON, MI; DICK, R; CRAWFORD, L; THOMPSON, NP; POUNDER, RE; WAKEFIELD, AJ				HAMILTON, MI; DICK, R; CRAWFORD, L; THOMPSON, NP; POUNDER, RE; WAKEFIELD, AJ			IS PROXIMAL DEMARCATION OF ULCERATIVE-COLITIS DETERMINED BY THE TERRITORY OF THE INFERIOR MESENTERIC-ARTERY	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; VASCULITIS	The sharp demarcation between diseased and normal mucosa often observed in ulcerative colitis remains unexplained by current hypotheses of disease pathogenesis. To investigate whether this demarcation occurs at the watershed of vascular territories, the colonic arterial anatomy of 10 patients with ulcerative colitis was studied by in-vitro angiography and macroscopic and histological examination of total colectomy specimens. Of the 10 perfusion-fixed colectomy specimens studied, 7 had pancolitis associated with a complete marginal artery (Arteria marginalis coli) that spanned the entire length of the large bowel. 3 specimens had sharply demarcated disease in which the marginal artery arose from the inferior mesenteric artery and ended abruptly at the point of mucosal demarcation. The colon proximal to this point was histologically normal. These findings suggest that the proximal extent of colitis is determined by the limit of the marginal artery. We suggest that some characteristic of the mucosal microvasculature in the territory of the inferior mesenteric artery, possibly embryological in origin, predisposes the dependent colon to develop ulcerative colitis.	ROYAL FREE HOSP,SCH MED,INFLAMMATORY BOWEL DIS STUDY GRP,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT RADIOL,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								BACANER MB, 1966, GASTROENTEROLOGY, V51, P764; COLLINS WJ, 1979, GASTROENTEROLOGY, V77, P1091; DHILLON AP, 1992, HISTOPATHOLOGY, V21, P127, DOI 10.1111/j.1365-2559.1992.tb00360.x; GAFFNEY PR, 1993, GASTROENTEROLOGY, V104, pA703; HAMILTON WK, 1972, EMBRYOLOGY, P268; HOLLISHEAD WH, 1956, ANATOMY SURGEONS, P503; HULTEN L, 1977, GASTROENTEROLOGY, V72, P388; JEWELL DP, 1992, ULCERATIVE COLITIS C, P1; LUNDERQUIST A, 1967, AMER J ROENTGENOL RA, V99, P18, DOI 10.2214/ajr.99.1.18; MISIEWICZ JJ, 1987, ATLAS CLIN GASTROENT; NELSON J, 1986, NEUROLOGY, V36, P719, DOI 10.1212/WNL.36.5.719; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P202, DOI 10.1016/S0091-6749(05)80067-3; SHUBICH M G, 1976, Arkhiv Patologii, V38, P60; TALBOT RW, 1986, MAYO CLIN PROC, V61, P140, DOI 10.1016/S0025-6196(12)65200-8; THOMPSON NP, IN PRESS GASTROENTER; TSUCHIYA M, 1980, ANGIOLOGY, V31, P147, DOI 10.1177/000331978003100301; WAKEFIELD AJ, 1989, LANCET, V2, P1057	17	31	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					688	690		10.1016/S0140-6736(95)90867-6	http://dx.doi.org/10.1016/S0140-6736(95)90867-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885124				2022-12-24	WOS:A1995QM73200008
J	SEGALAT, L; ELKES, DA; KAPLAN, JM				SEGALAT, L; ELKES, DA; KAPLAN, JM			MODULATION OF SEROTONIN-CONTROLLED BEHAVIORS BY G(O) IN CAENORHABDITIS-ELEGANS	SCIENCE			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEIN; NERVOUS-SYSTEM; ALPHA-SUBUNIT; NEMATODE; MYRISTOYLATION; STIMULATION; GENES	Seven transmembrane receptors and their associated heterotrimeric guanine nucleotide-binding proteins (G proteins) have been proposed to play a key role in modulating the activities of neurons and muscles. The physiological function of the Caenorhabditis elegans G protein G(o) has been genetically characterized. Mutations in the goa-l gene, which encodes an a subunit of G(o) (G alpha(o)), cause behavioral defects similar to those observed in mutants that lack the neurotransmitter serotonin (5-HT), and goa-1 mutants are partially resistant to exogenous 5-HT. Mutant animals that lack G alpha(o) and transgenic animals that overexpress G alpha(o) [goa-l(xs) animals] have reciprocal defects in locomotion, feeding, and egg laying behaviors. In normal animals, all of these behaviors are regulated by 5-HT. These results demonstrate that the level of G(o) activity is a critical determinant of several C. elegans behaviors and suggest that G(o) mediates many of the behavioral effects of 5-HT.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NINDS NIH HHS [NS32196] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032196] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FINNEY M, 1987, THESIS MIT; HAGA K, 1992, J BIOL CHEM, V267, P2222; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JORGENSEN E, COMMUNICATION; JORGENSEN EO, UNPUB; KAPLAN J, UNPUB; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; LOGETHETIS DE, 1987, NATURE, V325, P321; MARDER E, 1989, SEMIN NEUROSCI, V1, P1; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SEGALAT L, UNPUB; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THOMAS JH, 1990, GENETICS, V124, P855; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; TRENT C, 1983, GENETICS, V104, P619; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	37	253	258	1	18	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1648	1651		10.1126/science.7886454	http://dx.doi.org/10.1126/science.7886454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886454				2022-12-24	WOS:A1995QM39700038
J	SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; RAO, G; GUIDA, P; SKOULTCHI, AI; DEPINHO, RA				SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; RAO, G; GUIDA, P; SKOULTCHI, AI; DEPINHO, RA			AN AMINO-TERMINAL DOMAIN OF MXI1 MEDIATES ANTI-MYC ONCOGENIC ACTIVITY AND INTERACTS WITH A HOMOLOG OF THE YEAST TRANSCRIPTIONAL REPRESSOR SIN3	CELL			English	Article							C-MYC; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MAX; PROTEIN; EXPRESSION; GENE; RECOGNITION; ACTIVATION; HELIX	Documented interactions among members of the Myc superfamily support a yin-yang model for the regulation of Myc-responsive genes in which transactivation-competent Myc-Max heterodimers are opposed by repressive Mxi1-Max or Mad-Max complexes. Analysis of mouse mxi1 has led to the identification of two mxi1 transcript forms possessing open reading frames that differ in their capacity to encode a short aminoterminal alpha-helical domain. The presence of this segment dramatically augments the suppressive potential of Mxi1 and allows for association with a mammalian protein that is structurally homologous to the yeast transcriptional repressor SIN3, These findings provide a mechanistic basis for the antagonistic actions of Mxi1 on Myc activity that appears to be mediated in part through the recruitment of a putative transcriptional repressor.	ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DIV DERMATOL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	SCHREIBERAGUS, N (corresponding author), ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461, USA.			DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000194] Funding Source: NIH RePORTER; NCI NIH HHS [RT32CA-09173] Funding Source: Medline; NIA NIH HHS [2T32AG00194] Funding Source: Medline; NIGMS NIH HHS [T32GM07128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDELHOFF S, 1994, ONCOGENE, V9, P665; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO GJ, 1992, FASEB J, V6, P30565; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; Maxam A M, 1980, Methods Enzymol, V65, P499; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J., 1989, MOL CLONING LAB MANU; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRICH R, 1989, P NATL ACAD SCI USA, V86, P10018, DOI 10.1073/pnas.86.24.10018; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V83, P5455; YOSHIMOTO H, 1992, MOL GEN GENET, V233, P327, DOI 10.1007/BF00587597; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, CELL, V79; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	55	343	350	1	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					777	786		10.1016/0092-8674(95)90356-9	http://dx.doi.org/10.1016/0092-8674(95)90356-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889571	Bronze			2022-12-24	WOS:A1995QM39900014
J	CROSS, SM; SANCHEZ, CA; MORGAN, CA; SCHIMKE, MK; RAMEL, S; IDZERDA, RL; RASKIND, WH; REID, BJ				CROSS, SM; SANCHEZ, CA; MORGAN, CA; SCHIMKE, MK; RAMEL, S; IDZERDA, RL; RASKIND, WH; REID, BJ			A P53-DEPENDENT MOUSE SPINDLE CHECKPOINT	SCIENCE			English	Article							WILD-TYPE P53; MITOTIC CHROMOSOME TRANSMISSION; CELL-CYCLE EVENTS; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; SV40-TRANSFORMED CELLS; GENE AMPLIFICATION; DNA CONTENT; CARCINOMA; MITOSIS	Cell cycle checkpoints enhance genetic fidelity by causing arrest at specific stages of the cell cycle when previous events have not been completed. The tumor suppressor p53 has been implicated in a G(1) checkpoint. To investigate whether p53 also participates in a mitotic checkpoint, cultured fibroblasts from p53-deficient mouse embryos were exposed to spindle inhibitors. The fibroblasts underwent multiple rounds of DNA synthesis without completing chromosome segregation, thus forming tetraploid acid octaploid cells. Deficiency of p53 was also associated with the development of tetraploidy in vivo. These results suggest that murine p53 is a component of a spindle checkpoint that ensures the maintenance of diploidy.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; ERSTA HOSP,DEPT SURG,S-11635 STOCKHOLM,SWEDEN; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Ersta Sjukhus; University of Washington; University of Washington Seattle			Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X	NATIONAL CANCER INSTITUTE [R01CA055814] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA55814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNDTJOVIN DJ, 1977, J HISTOCHEM CYTOCHEM, V25, P585, DOI 10.1177/25.7.70450; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARBER HN, 1942, P ROY SOC LOND B BIO, V131, P258; BLOUNT PL, 1994, CANCER RES, V54, P2292; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BROWN M, 1991, COLD SH Q B, V56, P359; BUNN PA, 1982, BLOOD, V59, P528; BURHOLT DR, 1989, CANCER RES, V49, P3355; CARDER P, 1993, ONCOGENE, V8, P1397; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; GONG J, 1994, CANCER RES, V54, P428; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1985, GENETICS, V110, P381; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAKOBSEN A, 1983, CYTOMETRY, V4, P170, DOI 10.1002/cyto.990040211; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIRKLAND JA, 1967, CANCER, V20, P1934, DOI 10.1002/1097-0142(196711)20:11<1934::AID-CNCR2820201122>3.0.CO;2-4; KNOEFEL W T, 1987, Cancer Research, V47, P221; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUHAR SG, 1991, ONCOGENE, V6, P1499; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVAN A, 1956, ANN NY ACAD SCI, V63, P774, DOI 10.1111/j.1749-6632.1956.tb50892.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LIEBMANN J, 1994, CANCER CHEMOTH PHARM, V33, P331; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOPES NM, 1993, CANCER CHEMOTH PHARM, V32, P235, DOI 10.1007/BF00685842; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MURRAY AW, 1991, COLD SPRING HARB SYM, V56, P399; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; RAMEL S, IN PRESS PANCREAS; RASKIND WH, 1992, CANCER RES, V52, P2946; REIDER CL, 1989, MECHANISMS CHROMOSOM, P185; ROBERTS JR, 1990, CANCER RES, V50, P710; SCHIMKE RT, 1991, COLD SPRING HARB SYM, V56, P417; SHACKNEY SE, 1989, CANCER RES, V49, P3344; SHAPIRO JR, 1985, CANCER METAST REV, V4, P107, DOI 10.1007/BF00050691; WANG RJ, 1976, EXP CELL RES, V101, P331, DOI 10.1016/0014-4827(76)90385-2; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WIJKSTROM H, 1984, CANCER, V53, P1718, DOI 10.1002/1097-0142(19840415)53:8<1718::AID-CNCR2820530817>3.0.CO;2-E; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	53	690	696	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1353	1356		10.1126/science.7871434	http://dx.doi.org/10.1126/science.7871434			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871434				2022-12-24	WOS:A1995QK06800047
J	BUSSIERE, DE; BASTIA, D; WHITE, SW				BUSSIERE, DE; BASTIA, D; WHITE, SW			CRYSTAL-STRUCTURE OF THE REPLICATION TERMINATOR PROTEIN FROM BACILLUS-SUBTILIS AT 2.6-ANGSTROM	CELL			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; NUCLEOTIDE-SEQUENCE; LAMBDA-REPRESSOR; DNA; BINDING; OPERATOR; INVITRO; FORK	The crystal structure of the replication terminator protein (RTP) of B. subtilis has been determined at 2.6 Angstrom resolution. As previously suggested by both biochemical and biophysical studies, the molecule exists as a symmetric dimer and is in the alpha+beta protein-folding class. The protein has several uncommon features, including an antiparallel coiled-coil, which serves as the dimerization domain, and both an alpha-helix and a beta-ribbon suitably positioned to interact with the major and minor grooves of B-DNA. A site has been identified on the surface of RTP that is biochemically and positionally suitable for interaction with the replication-specific helicase. Other features of the structure are consistent with the polar contrahelicase mechanism of the protein. A model of the interaction between RTP and its cognate DNA is presented.	DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL & MOLEC BIOL PROGRAM,DURHAM,NC 27710	Duke University; Duke University			White, Stephen W/N-8164-2018		NIGMS NIH HHS [GM49264] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1988, X PLOR SYSTEM XRAY C; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; HIASA H, 1992, J BIOL CHEM, V267, P11379; HOSHINO T, 1987, P NATL ACAD SCI USA, V84, P653, DOI 10.1073/pnas.84.3.653; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KRALICEK AV, 1993, BIOCHEMISTRY-US, V32, P10216, DOI 10.1021/bi00089a043; KRALICEK AV, 1991, BIOCHEM J, V275, P823, DOI 10.1042/bj2750823; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; LANGLEY DB, 1993, MOL MICROBIOL, V10, P771, DOI 10.1111/j.1365-2958.1993.tb00947.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LEWIS PJ, 1989, J BACTERIOL, V171, P3564, DOI 10.1128/jb.171.6.3564-3567.1989; LEWIS PJ, 1991, RES MICROBIOL, V142, P893, DOI 10.1016/0923-2508(91)90070-Q; LEWIS PJ, 1990, J MOL BIOL, V244, P73; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MACALLISTER T, 1990, P NATL ACAD SCI USA, V72, P2905; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEHTA PP, 1992, J BIOL CHEM, V267, P18885; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; NICHOLLS A, 1993, GRASP; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PABO CO, 1982, NATURE, V298, P441, DOI 10.1038/298441a0; Pathak D., 1992, CURR OPIN STRUC BIOL, V2, P116, DOI [10.1016/0959-440X(92)90186-B, DOI 10.1016/0959-440X(92)90186-B]; PODJARNY AD, 1987, ANNU REV BIOPHYS BIO, V16, P351; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SAHOO T, 1995, IN PRESS EMBO J, V14; SATO Y, 1991, J BACTERIOL, V173, P7732, DOI 10.1128/jb.173.23.7732-7735.1991; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHARP KA, 1994, CURR OPIN STRUC BIOL, V4, P234, DOI 10.1016/S0959-440X(94)90314-X; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUEOKA N, 1968, COLD SPRING HARB SYM, V33, P695, DOI 10.1101/SQB.1968.033.01.078; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS AS, 1984, CELL, V39, P683, DOI 10.1016/0092-8674(84)90475-6; WHITE SW, 1988, STRUCT FUNC GENET, V5, P281; WONACOTT AJ, 1977, ROTATION METHOD CRYS, P75; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	62	75	75	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					651	660						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867072				2022-12-24	WOS:A1995QJ60200017
J	LI, W; OHLMEYER, JT; LANE, ME; KALDERON, D				LI, W; OHLMEYER, JT; LANE, ME; KALDERON, D			FUNCTION OF PROTEIN KINASE-A IN HEDGEHOG SIGNAL-TRANSDUCTION AND DROSOPHILA IMAGINAL DISC DEVELOPMENT	CELL			English	Article							POLARITY GENE HEDGEHOG; SEGMENT-POLARITY; CATALYTIC SUBUNIT; PATCHED GENE; EXPRESSION; WINGLESS; TRANSCRIPTION; MUTATIONS; DIRECTS; EMBRYO	Reduced protein kinase A (PKA) activity in anterior imaginal disc cells leads to cell-autonomous induction of decapentaplegic (dpp), wingless (wg), and patched (ptc) transcription that is independent of hedgehog (hh) gene activity. The resulting nonautonomous adult wing and leg pattern duplications are largely due to induced dpp and wg expression and resemble phenotypes elicited by ectopic hh expression. Inhibition of PKA in anterior cells close to the posterior compartment can substitute for hh activity to promote growth of imaginal discs, whereas overexpression of PKA can counteract transcriptional induction of ptc by hh in these cells. PKA therefore appears to be an integral component of the mechanism by which hh regulates the expression of key patterning molecules in imaginal discs.			LI, W (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.		Li, Willis X/AAL-7212-2020; Li, Willis/ABC-5695-2020	Li, Willis X/0000-0001-9041-7341; Li, Willis/0000-0001-9041-7341	NIGMS NIH HHS [GM41815] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041815] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER NE, 1988, DEVELOPMENT, V102, P489; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRYANT PJ, 1980, GENETICS BIOL DROS C, V2, P230; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COHEN B, 1993, DEVELOPMENT, V117, P597; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HANNAH-ALAVA ALOHA, 1958, J MORPH, V103, P281, DOI 10.1002/jmor.1051030205; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SAMPEDRO J, 1991, NATURE, V353, P187, DOI 10.1038/353187a0; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223	52	284	296	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					553	562		10.1016/0092-8674(95)90509-X	http://dx.doi.org/10.1016/0092-8674(95)90509-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867063	hybrid			2022-12-24	WOS:A1995QJ60200007
J	PARK, IS; HAUSINGER, RP				PARK, IS; HAUSINGER, RP			REQUIREMENT OF CARBON-DIOXIDE FOR IN-VITRO ASSEMBLY OF THE UREASE NICKEL METALLOCENTER	SCIENCE			English	Article							KLEBSIELLA-AEROGENES UREASE; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE OXIDASE; MOLECULAR CHARACTERIZATION; BINDING PROTEIN; PURIFICATION; ACTIVATION; GENE; UREE	Assembly of protein metallocenters is not well understood. Urease offers a tractable system for examination of this process. Formation of the urease metallocenter in vivo is known to require four accessory proteins: UreD, postulated to be a urease-specific molecular chaperone; UreE, a nickel(II)-binding protein; and UreF and UreG, of unknown function. Activation of purified Klebsiella aerogenes urease apoprotein was accomplished in vitro by providing carbon dioxide (half-maximal activation at similar to 0.2 percent carbon dioxide) in addition to nickel ion. Activation coincided with carbon dioxide incorporation into urease in a pH-dependent reaction (pK(a) greater than or equal to 9, where K-a is the acid constant). The concentration of carbon dioxide also affected the amount of activation of UreD-urease apoprotein complexes. These results suggest that carbon dioxide binding to urease apoprotein generates a ligand that facilitates productive nickel binding.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University; Michigan State University				Hausinger, Robert/0000-0002-3643-2054	NIDDK NIH HHS [DK45686] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045686] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Butler J. N., 1982, CARBON DIOXIDE EQUIL, DOI 10.1016/0146-6380(83)90006-2; DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; DONG JG, 1992, P NATL ACAD SCI USA, V89, P9789, DOI 10.1073/pnas.89.20.9789; FERNANDEZMACULE.JC, 1993, BIOCHEM BIOPH RES CO, V193, P1168; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Hausinger R.P., 1993, BIOCH NICKEL, V12, P23; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; Sumner JB, 1926, J BIOL CHEM, V69, P435; TODD MJ, 1989, J BIOL CHEM, V264, P15835; WANG S, 1994, INORG CHEM, V33, P1589, DOI 10.1021/ic00086a006; WEATHERBURN MW, 1967, ANAL CHEM, V39, P971, DOI 10.1021/ac60252a045	18	140	148	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1156	1158		10.1126/science.7855593	http://dx.doi.org/10.1126/science.7855593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855593				2022-12-24	WOS:A1995QJ23700033
J	HE, JL; FURMANSKI, P				HE, JL; FURMANSKI, P			SEQUENCE SPECIFICITY AND TRANSCRIPTIONAL ACTIVATION IN THE BINDING OF LACTOFERRIN TO DNA	NATURE			English	Article							NUCLEAR-LOCALIZATION; ENRICHED POPULATION; CELLS; PROTEIN; INFECTION; FRAGMENTS; AFFINITY; INVITRO; IRON	LACTOFERRIN, an iron-binding glycoprotein found in high concentrations in human milk and other epithelial secretions' and in the secondary (specific) granules of neutrophils(2), is thought to be responsible for primary defence against microbial infection, mainly as a result of lactoferrin sequestration of iron required for microbial growth(3). Many other functions have been attributed to lactoferrin, including immunomodulation and cell growth regulation (reviewed in ref. 4). Some of these functions appear to be at least in part independent of the iron-binding activity of lactoferrin, It also has been consistently observed that lactoferrin interacts avidly with nucleic acids(5-7). Lactoferrin enhancement of the activity of natural killer and lymphokine-activated killer cells in vitro is inhibited by RNA and DNA(8). Lactoferrin taken up by K562 human myelogenous leukaemia cells appears in the nucleus where it is bound to DNA(9) The report here that binding of lactoferrin to DNA occurs under stringent conditions with distinct sequence specificity, and that interaction between lactoferrin and these sequences intracellularly leads to transcriptional activation.	NYU,DEPT BIOL,NEW YORK,NY 10003	New York University								AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BENNETT RM, 1983, J CLIN INVEST, V71, P611, DOI 10.1172/JCI110807; BENNETT RM, 1981, J IMMUNOL, V127, P1211; BEZAULT J, 1994, CANCER RES, V54, P2310; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARRE C, 1992, J CELL PHYSIOL, V153, P477, DOI 10.1002/jcp.1041530306; GREEN I, 1971, P SOC EXP BIOL MED, V137, P1311; HASHIZUME S, 1983, BIOCHIM BIOPHYS ACTA, V763, P377, DOI 10.1016/0167-4889(83)90099-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUTCHENS TW, 1991, PEDIATR RES, V29, P243, DOI 10.1203/00006450-199103000-00005; LONNERDAL B, 1988, NUTR RES, V8, P853; Lyer S, 1993, EUR J CLIN NUTR, V47, P232; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MIYAUCHI J, 1987, CELL TISSUE RES, V247, P249; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; SLEBENLIST U, 1984, CELL, V37, P381; SPIK G, 1978, BRIT MED J, V5, P69; WALMER DK, 1992, ENDOCRINOLOGY, V131, P1458, DOI 10.1210/en.131.3.1458; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978; WEINBERG ED, 1992, LIFE SCI, V50, P1289, DOI 10.1016/0024-3205(92)90279-X; ZHANG XY, 1992, ANAL BIOCHEM, V201, P366, DOI 10.1016/0003-2697(92)90353-9; ZIERE GJ, 1993, J BIOL CHEM, V268, P27069; ZUCALI JR, 1987, BLOOD, V69, P33; ZUCALI JR, 1987, BLOOD, V70, pA191	27	314	333	2	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					721	724		10.1038/373721a0	http://dx.doi.org/10.1038/373721a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854459				2022-12-24	WOS:A1995QH92800061
J	LEGALL, JR; LEMESHOW, S; LELEU, G; KLAR, J; HUILLARD, J; RUE, M; TERES, D; ARTIGAS, A				LEGALL, JR; LEMESHOW, S; LELEU, G; KLAR, J; HUILLARD, J; RUE, M; TERES, D; ARTIGAS, A			CUSTOMIZED PROBABILITY-MODELS FOR EARLY SEVERE SEPSIS IN ADULT INTENSIVE-CARE PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPTIC SHOCK; FAILURE; TRIAL	Objective.-To develop customized versions of the Simplified Acute Physiology Score II (SAPS II) and the 24-hour Mortality Probability Model II (MPM II24) to estimate the probability of mortality for intensive care unit patients with early severe sepsis. Design and Setting.-Logistic regression models developed for patients with severe sepsis in a database of adult medical and surgical intensive care units in 12 countries. Patients.-Of 11 458 patients in the intensive care unit for at least 24 hours, 1130 had severe sepsis based on criteria of the American College of Chest Physicians and the Society of Critical Care Medicine (systemic inflammatory response syndrome in response to infection, plus hypotension, hypoperfusion, or multiple organ dysfunction). Results.-In patients with severe sepsis, mortality was higher (48.0% vs 19.6% among other patients) and 28-day survival was lower. The customized SAPS II was well calibrated (P=.92 for the goodness-of-fit test) and discriminated well (area under the receiver operating characteristic [ROC] curve, 0.78). Performance in the validation sample was equally good (P=.85 for the goodness-of-fit test; area under the ROC curve, 0.79). The customized MPM II24 was well calibrated (P=.92 for the goodness-of-fit test) and discriminated well (area under the ROC curve, 0.79). Performance in the validation sample was equally good (P=.52 for the goodness-of-fit test; area under the ROC curve, 0.75). The models are independent of each other; either can be used alone to estimate the probability of mortality of patients with severe sepsis. Conclusions.-Customization provides a simple technique to apply existing models to a subgroup of patients. Accurately assessing the probability of hospital mortality is a useful adjunct for clinical trials.	FAC MED LARIBOISIERE,PARIS,FRANCE; UNIV MASSACHUSETTS,SCH PUBL HLTH,AMHERST,MA 01003; BAYSTATE MED CTR,SPRINGFIELD,MA 01107; HOSP SABADELL,SABADELL,SPAIN	UDICE-French Research Universities; Universite Paris Cite; University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center; Autonomous University of Barcelona; Parc Tauli Hospital Universitari			Rue, Montserrat/B-5663-2009	Rue, Montserrat/0000-0002-7862-9365				[Anonymous], 1992, CRIT CARE MED, V20, P864; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HOSMER DW, 1994, REANIMATION URGENCES, V3, P173; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1987, NEW ENGL J MED, V317, P659	14	136	141	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					644	650		10.1001/jama.273.8.644	http://dx.doi.org/10.1001/jama.273.8.644			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844875				2022-12-24	WOS:A1995QG74800030
J	MOSIALOS, G; BIRKENBACH, M; YALAMANCHILI, R; VANARSDALE, T; WARE, C; KIEFF, E				MOSIALOS, G; BIRKENBACH, M; YALAMANCHILI, R; VANARSDALE, T; WARE, C; KIEFF, E			THE EPSTEIN-BARR-VIRUS TRANSFORMING PROTEIN LMP1 ENGAGES SIGNALING PROTEINS FOR THE TUMOR-NECROSIS-FACTOR RECEPTOR FAMILY	CELL			English	Article							FACTOR TNF RECEPTOR; LYMPHOCYTE GROWTH TRANSFORMATION; MEMBRANE-PROTEIN; CELL-LINES; NASOPHARYNGEAL CARCINOMA; MONOCLONAL-ANTIBODIES; NUCLEAR PROTEIN-2; HODGKINS-DISEASE; B TRANSFORMATION; SOLUBLE FORM	The cytoplasmic C-terminus of Epstein-Barr virus (EBV) latent infection membrane protein 1 (LMP1) is essential for B lymphocyte growth transformation and is now shown to interact with a novel human protein (LMP1-associated protein 1 [LAP1]). LAP1 is homologous to a murine protein, tumor necrosis factor receptor-associated factor 2 (TRAF2), implicated in growth signaling from the p80 TNFR. A second novel protein (EBI6), induced by EBV infection, is the human homolog of a second murine TNFR-associated protein (TRAF1). LMP1 expression causes LAP1 and EBI6 to localize to LMP1 clusters in lymphoblast plasma membranes, and LMP1 coimmunoprecipitates with these proteins. LAP1 binds to the p80 TNFR, CD40, and the lymphotoxin-p receptor, while EBI6 associates with the pan TNFR. The interaction of LMP1 with these TNFR family-associated proteins is further evidence for their role in signaling and links LMP1-mediated transformation to signal transduction from the TNFR family.	UNIV CHICAGO, MARJORIE B KOVLER VIRAL ONCOL LABS, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA	University of Chicago; University of California System; University of California Riverside	MOSIALOS, G (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, DEPT MED, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R35CA047006, K11CA001341, R01CA047006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008548] Funding Source: NIH RePORTER; NCI NIH HHS [5K11CA01341, CA47006] Funding Source: Medline; NIAID NIH HHS [AI08548-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BOUSSIOTIS VA, 1994, P NATL ACAD SCI USA, V91, P7007, DOI 10.1073/pnas.91.15.7007; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CARDE P, 1990, EUR J CANCER, V26, P474, DOI 10.1016/0277-5379(90)90019-P; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESTROV Z, 1993, J EXP MED, V177, P763, DOI 10.1084/jem.177.3.763; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FROESE P, 1987, J IMMUNOL, V139, P2081; GALIBERT L, 1994, J IMMUNOL, V152, P22; GIBBONS DL, 1994, EUR J IMMUNOL, V24, P1879, DOI 10.1002/eji.1830240825; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOODING LR, 1992, CELL, V71, P5; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HARPER JW, 1993, CELL, V75, P805; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1990, VIROLOGY, P1889; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LONGNECKER R, 1993, J VIROL, V67, P5068, DOI 10.1128/JVI.67.8.5068-5074.1993; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MARCHINI A, 1991, J VIROL, V65, P5991, DOI 10.1128/JVI.65.11.5991-6000.1991; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MILLER G, 1990, VIROLOGY, P1921; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OGRADY JT, 1994, AM J PATHOL, V144, P21; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PFREUNDSCHUH M, 1989, ONKOLOGIE, V12, P30, DOI 10.1159/000216681; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; ROBERTSON ES, 1994, J VIROL, V68, P1449, DOI 10.1128/JVI.68.3.1449-1458.1994; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; SAELAND S, 1993, J EXP MED, V178, P113, DOI 10.1084/jem.178.1.113; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TOMKINSON B, 1992, J VIROL, V66, P2893, DOI 10.1128/JVI.66.5.2893-2903.1992; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TRUMPER L, 1994, ANN ONCOL, V5, pS93, DOI 10.1093/annonc/5.suppl_1.S93; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WARE CF, 1991, J IMMUNOL, V147, P4229; WARE CF, 1995, CURRENT TOPICS MICRO, V198; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508	83	882	925	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					389	399		10.1016/0092-8674(95)90489-1	http://dx.doi.org/10.1016/0092-8674(95)90489-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859281	Bronze			2022-12-24	WOS:A1995QG47000005
J	STRUBIN, M; NEWELL, JW; MATTHIAS, P				STRUBIN, M; NEWELL, JW; MATTHIAS, P			OBF-1, A NOVEL B-CELL-SPECIFIC COACTIVATOR THAT STIMULATES IMMUNOGLOBULIN PROMOTER ACTIVITY THROUGH ASSOCIATION WITH OCTAMER-BINDING PROTEINS	CELL			English	Article							REMOTE ENHANCER POSITION; TRANSCRIPTION FACTOR; POU-DOMAIN; CONSERVED REGION; GENETIC-EVIDENCE; CYCLE REGULATION; TATA ELEMENT; HOMEO DOMAIN; HELA-CELLS; STEM-CELLS	Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity. Using a genetic screen in yeast, we have isolated a cell-derived cDNAs encoding Oct-binding factor 1 (OBF-1), a novel protein that specifically associates with Oct-1 and Oct-2. Biochemical studies demonstrate that OBF-1 has no intrinsic DNA-binding activity and recognizes the POU domains of Oct-1 and Oct-2, but not those of Oct-4 and Oct-6. The OBF-1 mRNA is expressed in a highly cell-specific manner, being most abundant in B cells and essentially absent In most of the other cells or tissues tested. Furthermore, expression of OBF-1 in HeLa cells selectively stimulates the activity of a natural immunoglobulin promoter in an octamer site-dependent manner. Thus, OBF-1 has all the properties expected for a B cell-specific transcriptional coactivator protein.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research	STRUBIN, M (corresponding author), UNIV GENEVA,MED CTR,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND.							ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DREYFUS M, 1987, EMBO J, V6, P1685, DOI 10.1002/j.1460-2075.1987.tb02418.x; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUC.MM, 1990, EMBO J, V9, P1625; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TANESE N, 1993, COLD SPRING HARB SYM, V58, P179, DOI 10.1101/SQB.1993.058.01.022; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0	58	353	361	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					497	506		10.1016/0092-8674(95)90500-6	http://dx.doi.org/10.1016/0092-8674(95)90500-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859290	Bronze			2022-12-24	WOS:A1995QG47000016
J	MURPHY, TH; BARABAN, JM; WIER, WG; BLATTER, LA				MURPHY, TH; BARABAN, JM; WIER, WG; BLATTER, LA			VISUALIZATION OF QUANTAL SYNAPTIC TRANSMISSION BY DENDRITIC CALCIUM IMAGING	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPAL SLICES; PHORBOL ESTERS; CURRENTS; NEURONS; VARIABILITY; RESPONSES; SPINES; NMDA; CA2+	As changes in synaptic strength are thought to be critical for learning and memory, it would be useful to monitor the activity of individual identified synapses on mammalian central neurons. Calcium imaging of cortical neurons grown in primary culture was used to visualize the activation of individual postsynaptic elements by miniature excitatory synaptic currents elicited by spontaneous quantal release. This approach revealed that the probability of spontaneous activity differed among synapses on the same dendrite. Furthermore, synapses that undergo changes in activity induced by glutamate or phorbol ester treatment were identified.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	MURPHY, TH (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA.		Murphy, Timothy/AAW-1975-2021; Wier, Withrow/AAE-2451-2020; Murphy, Timothy H/I-4982-2014; Blatter, Lothar/AAC-8431-2020	Murphy, Timothy/0000-0002-0093-4490; Murphy, Timothy H/0000-0002-0093-4490; Baraban, Jay/0000-0002-8165-2638				AMARAL DG, 1990, PROG BRAIN RES, V83, P1; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLATTER LA, 1992, AM J PHYSIOL, V263, pH576, DOI 10.1152/ajpheart.1992.263.2.H576; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FABER DS, 1992, SCIENCE, V258, P1494, DOI 10.1126/science.1279813; FINCH DM, 1990, BRAIN RES, V518, P269, DOI 10.1016/0006-8993(90)90979-L; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; KOCH C, 1993, J NEUROSCI, V13, P413; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TF, UNPUB; MURPHY TH, 1992, J NEUROSCI, V12, P4834; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; ROBITAILLE R, 1991, NEUROSCIENCE, V40, P571, DOI 10.1016/0306-4522(91)90142-B; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YOSHIKAMI D, 1984, NATURE, V310, P53, DOI 10.1038/310053a0	30	72	73	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	1994	263	5146					529	532		10.1126/science.7904774	http://dx.doi.org/10.1126/science.7904774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	7904774				2022-12-24	WOS:A1994MT96600036
J	GALE, JL; THAPA, PB; WASSILAK, SGF; BOBO, JK; MENDELMAN, PM; FOY, HM				GALE, JL; THAPA, PB; WASSILAK, SGF; BOBO, JK; MENDELMAN, PM; FOY, HM			RISK OF SERIOUS ACUTE NEUROLOGICAL ILLNESS AFTER IMMUNIZATION WITH DIPHTHERIA-TETANUS-PERTUSSIS VACCINE - A POPULATION-BASED CASE-CONTROL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE REACTIONS; DISORDERS; CHILDREN	Objective.-To evaluate the association between serious acute neurological illness and receipt of whole-cell pertussis vaccine, given as diphtheria-tetanus-pertussis (DTP) vaccine. Design.-Population-based case-control study. Setting.-Outpatient and inpatient hospital settings, physician practices, and the general population in Washington and Oregon states. Subjects.-A total of 424 confirmed cases of neurological illness were identified prospectively during a 12-month period by statewide active surveillance from the population of 218 000 children 1 to 24 months of age living in Washington and Oregon (estimated 368 000 DTP immunizations given). Each case child was matched to two population control children by birth date (+/-5 days), gender, and county of birth. Written immunization records were used to determine whether illness occurred within 7 days of immunization in case children, or within 7 days of the same reference date in control children, thus qualifying as exposed. Main Outcome Measures.-Outpatient and inpatient cases of complex febrile seizures, seizures without fever, infantile spasms, and acute encephalitis/encephalopathy confirmed by an expert panel masked to immunization history. Results.-The estimated odds ratio (OR) for onset of serious acute neurological illness within 7 days for young children exposed to DTP vaccine was 1.1 (95% confidence interval [CI], 0.6 to 2.0). When the analysis was restricted to children with encephalopathy or complicated seizures and adjusted for factors possibly affecting vaccine administration, the OR was 3.6 (95% Cl, 0.8 to 15.2). Odds ratios for specific study diagnoses varied, but all CIs included 1. No elevated risk was observed for the largest group of illnesses studied, nonfebrile seizures (OR, 0.5; 95% CI, 0.2 to 1.5). Conclusions.-This study did not find any statistically significant increased risk of onset of serious acute neurological illness in the 7 days after DTP vaccine exposure for young children.	UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; CTR DIS CONTROL,ATLANTA,GA 30333	University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA	GALE, JL (corresponding author), UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195, USA.				PHS HHS [200-87-0506] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELLMAN MH, 1983, LANCET, V1, P1031; BOBO JK, 1993, PEDIATRICS, V91, P308; BRESLOW NE, 1980, STAT METHODS CANC RE, P176; BYERS RK, 1948, PEDIATRICS, V1, P437; CHERRY JD, 1988, PEDIATRICS S, V81, P959; CODY CL, 1981, PEDIATRICS, V68, P650; CORSELLIS JAN, 1983, NEUROPATH APPL NEURO, V9, P261, DOI 10.1111/j.1365-2990.1983.tb00113.x; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GLOBUS JH, 1949, JAMA-J AM MED ASSOC, V141, P507, DOI 10.1001/jama.1949.02910080007003; GRIFFIN MR, 1990, JAMA-J AM MED ASSOC, V263, P1641, DOI 10.1001/jama.263.12.1641; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; Madsen T, 1933, J AMER MED ASSOC, V101, P187, DOI 10.1001/jama.1933.02740280007003; MARCUSE EK, 1990, VACCINE, V8, P531, DOI 10.1016/0264-410X(90)90003-5; Miller D, 1985, Dev Biol Stand, V61, P389; MILLER D, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P145; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; NICOLL A, 1989, MANUAL INFECTIONS IM, P207; POLLOCK TM, 1983, LANCET, V1, P753; SHIELDS WD, 1988, J PEDIATR-US, V113, P801, DOI 10.1016/S0022-3476(88)80004-0; SUTHERLAND JM, 1953, ARCH DIS CHILD, V28, P149, DOI 10.1136/adc.28.138.149; WALKER AM, 1988, PEDIATRICS, V81, P345; WENTZ KR, 1991, PEDIATRICS, V87, P287; 1990, BRIT JOINT COMMITTEE, P20; 1989, CANADIAN IMMUNIZATIO, P78; 1991, ADVERSE EFFECTS PERT; 1991, PEDIATRICS, V88, P397	26	64	69	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					37	41		10.1001/jama.271.1.37	http://dx.doi.org/10.1001/jama.271.1.37			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	7903109				2022-12-24	WOS:A1994MN72500028
J	SCHNEIDERMAUNOURY, S; TOPILKO, P; SEITANIDOU, T; LEVI, G; COHENTANNOUDJI, M; POURNIN, S; BABINET, C; CHARNAY, P				SCHNEIDERMAUNOURY, S; TOPILKO, P; SEITANIDOU, T; LEVI, G; COHENTANNOUDJI, M; POURNIN, S; BABINET, C; CHARNAY, P			DISRUPTION OF KROX-20 RESULTS IN ALTERATION OF RHOMBOMERE-3 AND RHOMBOMERE-5 IN THE DEVELOPING HINDBRAIN	CELL			English	Article							SEGMENT-SPECIFIC EXPRESSION; DEVELOPING MOUSE HINDBRAIN; DEVELOPING CHICK HINDBRAIN; CRANIAL NEURAL CREST; ZINC-FINGER GENE; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; EMBRYO HINDBRAIN; VERTEBRATE HEAD; REGION	The zinc finger gene Krox-20 is transcribed in two alternate segments (rhombomeres) of the developing hindbrain. To investigate its function, we have used homologous recombination to generate mice carrying an in-frame insertion of the E. coli lacZ gene within Krox-20. Analysis of the beta-galactosidase pattern in heterozygous embryos confirmed the known profile with expression restricted to rhombomeres (r) 3 and 5. Mice homozygous for the mutation die during the first two weeks after birth. Anatomical analysis of the hindbrain and of the cranial nerves during embryogenesis, combined with the determination of the expression patterns of rhombomere-specific genes, demonstrated that Krox-20 inactivation results in a marked reduction or elimination of r3 and r5. We conclude that Krox-20, although not required for the initial delimitation of r3 and r5, plays an important role in the process of segmentation governing hindbrain development.	ECOLE NORMALE SUPER, CNRS, UNITE RECH ASSOCIEE 1337, F-75230 PARIS 05, FRANCE; INST SCI TUMORI, CTR BIOTECNOL AVANZATE, I-16132 GENOA, ITALY; INST PASTEUR, CNRS, UNITE RECH ASSOCIEE 361, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	SCHNEIDERMAUNOURY, S (corresponding author), ECOLE NORMALE SUPER, INSERM, UNITE 368, F-75230 PARIS 05, FRANCE.		Levi, Giovanni/B-4416-2013; Schneider-Maunoury, Sylvie/K-6795-2017	Schneider-Maunoury, Sylvie/0000-0002-0797-4735; Cohen-Tannoudji, Michel/0000-0002-6405-2657; Charnay, Patrick/0000-0002-3847-6042; Levi, Giovanni/0000-0002-7041-6787	NICHD NIH HHS [N01-HD-6-2915] Funding Source: Medline; Telethon [94] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GILARDI P, 1991, BIOCHIMIE, V73, P85, DOI 10.1016/0300-9084(91)90079-G; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1991, J NEUROBIOL, V22, P742, DOI 10.1002/neu.480220709; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KALLEN B, 1956, KLUNG FYSIOGRAF SALL, V26, P1; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LEDOUARIN N, 1982, DEV CELL BIOL, V12; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MARK M, 1993, DEVELOPMENT, V119, P319; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SOFRONIEW MV, 1985, RAT NERVOUS SYSTEM, V1, P471; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; Vaage S., 1969, ERG ANAT ENTWICKLU, V41, P1; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILKINSON DG, 1990, SEMINARS DEV BIOL, V1, P127	50	382	385	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1199	1214		10.1016/0092-8674(93)90329-O	http://dx.doi.org/10.1016/0092-8674(93)90329-O			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7903221				2022-12-24	WOS:A1993MM89300018
J	EKBOM, A; HSIEH, CC; YUEN, J; TRICHOPOULOS, D; MCLAUGHLIN, J; LAN, SJ; ADAMI, HO				EKBOM, A; HSIEH, CC; YUEN, J; TRICHOPOULOS, D; MCLAUGHLIN, J; LAN, SJ; ADAMI, HO			RISK OF EXTRAHEPATIC BILEDUCT CANCER AFTER CHOLECYSTECTOMY	LANCET			English	Article							SCLEROSING CHOLANGITIS; ULCERATIVE-COLITIS; CARCINOMA; CHOLANGIOCARCINOMA; CYSTS	The aetiology of cancer of the extrahepatic bile duct is unknown. Gallstones have been proposed to be a risk factor on the basis of ecological and epidemiological evidence. As gallstones are formed in the gallbladder, the occurrence of extrahepatic bileduct cancer in patients after cholecystectomy is of interest. All patients (62 734) who had had a cholecystectomy during 1965-1983 within the Uppsala Health Care Region, Sweden, were followed up to the end of 1987. Excluding the first year of follow-up, 23 cancers of the extrahepatic bileduct occurred vs 26.3 expected for a standardised incidence ratio (SIR) of 0.88 (95% confidence interval [CI] 0.56-1.31). 10 years or more after operation there was a greater reduction of risk (SIR = 0.27; 95% CI 0.06-0.80). Similar patterns were observed for men and women, and among patients who had undergone cholecystectomy only compared with those who had had their common bileducts explored. To assess surveillance bias the incidence of primary liver cancer was also analysed: SIR = 1.15; 95% CI 0.91-1.44 overall, and 10 years or more after cholecystectomy SIR = 0.98; 95% CI 0.66-1.40. This study shows a reduced risk of extrahepatic bileduct cancer 10 or more years after cholecystectomy, indicating that gallstones may be a cause of this cancer.	NCI,BIOSTAT BRANCH,BETHESDA,MD 20892; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	EKBOM, A (corresponding author), UNIV HOSP UPPSALA,CANC EPIDEMIOL UNIT,S-75185 UPPSALA,SWEDEN.		Yuen, Jonathan/AAI-2035-2021	Yuen, Jonathan/0000-0003-2944-9226	NATIONAL CANCER INSTITUTE [R01CA044683] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1CA44683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILAR JC, 1964, BIOMETRICS, V20, P639; BRETT M, 1976, INT J EPIDEMIOL, V5, P335, DOI 10.1093/ije/5.4.335; CARBONI M, 1986, SCAND J GASTROENTERO, V21, P461, DOI 10.3109/00365528609015163; CETTA F, 1991, ANN SURG, V213, P315, DOI 10.1097/00000658-199104000-00006; DAY NE, 1984, IARC SCI PUBL, V56, P339; DONALDSON DR, 1975, BR J CLIN PRACT, V33, P297; Drinka P, 1985, Wis Med J, V84, P16; EKBOM A, 1993, GASTROENTEROLOGY, V105, P142, DOI 10.1016/0016-5085(93)90019-9; FLANIGAN DP, 1977, CANCER-AM CANCER SOC, V40, P880, DOI 10.1002/1097-0142(197708)40:2<880::AID-CNCR2820400242>3.0.CO;2-X; FRAUMENI JF, 1982, CANCER EPIDEMIOL, P683; GLENN F, 1974, ANN SURG, V179, P528, DOI 10.1097/00000658-197405000-00003; HERBA MJ, 1986, AM J ROENTGENOL, V147, P513, DOI 10.2214/ajr.147.3.513; JARHULT J, 1981, ACTA CHIR SCAND, V147, P147; KATO K, 1989, JPN J CANCER RES, V80, P932, DOI 10.1111/j.1349-7006.1989.tb01629.x; LEBORGNE J, 1984, ANN CHIR, V38, P369; MIRMADJLESSI SH, 1987, DIGEST DIS SCI, V32, P145, DOI 10.1007/BF01297102; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; ROBBINS S, 1988, AM J GASTROENTEROL, V83, P675; ROSSI RL, 1987, ANN SURG, V205, P377, DOI 10.1097/00000658-198704000-00006; SCHWARTZ DA, 1986, AM J GASTROENTEROL, V81, P76; SRIVATANAKUL P, 1991, INT J CANCER, V48, P821, DOI 10.1002/ijc.2910480606; TODANI T, 1979, CANCER-AM CANCER SOC, V44, P1134, DOI 10.1002/1097-0142(197909)44:3<1134::AID-CNCR2820440350>3.0.CO;2-T; WARREN KW, 1987, DISEASES LIVER, P1289; WEE A, 1985, HUM PATHOL, V16, P719, DOI 10.1016/S0046-8177(85)80158-1; WELTON JC, 1979, LANCET, V1, P791; YEN S, 1987, CANCER, V59, P2112, DOI 10.1002/1097-0142(19870615)59:12<2112::AID-CNCR2820591226>3.0.CO;2-H; 1991, CANCER INCIDENCE SWE	27	45	47	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1262	1265		10.1016/0140-6736(93)92359-2	http://dx.doi.org/10.1016/0140-6736(93)92359-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901583				2022-12-24	WOS:A1993MH56600009
J	MURPHY, DGM; DECARLI, C; DALY, E; HAXBY, JV; ALLEN, G; WHITE, BJ; MCINTOSH, AR; POWELL, CM; HORWITZ, B; RAPOPORT, SI; SCHAPIRO, MB				MURPHY, DGM; DECARLI, C; DALY, E; HAXBY, JV; ALLEN, G; WHITE, BJ; MCINTOSH, AR; POWELL, CM; HORWITZ, B; RAPOPORT, SI; SCHAPIRO, MB			X-CHROMOSOME EFFECTS ON FEMALE BRAIN - A MAGNETIC-RESONANCE-IMAGING STUDY OF TURNERS-SYNDROME	LANCET			English	Article							INACTIVATION; MEMORY	Many neuropsychiatric disorders differ between the sexes in incidence, symptoms, and age at onset. To investigate the effects of X-chromosome aneuploidy and of sex steroid deficiency during childhood on brain structure and function, we used neuropsychological tests and quantitative magnetic resonance imaging (MRI) to study the brains of eighteen women with Turner's syndrome (TS) and nineteen healthy control women of similar age. Nine TS subjects had mosaic 45,X karyotypes, and 9 had non-mosaic 45,X. The TS group had significantly lower scores than the controls for all the Wechsler adult intelligence scale tests, except verbal comprehension and reading level. The greatest difference was in visuospatial construction (mean 90 [SD 12] vs 118 [13], p < 0.0001). The TS subjects also had a greater discrepancy than controls between verbal and performance intelligence quotients (9 [8] vs -5 [9], p<0.001). We found that TS subjects had significantly smaller values than controls in MRI-measured volumes of hippocampus, caudate, lenticular, and thalamic nuclei, and parieto-occipital brain matter, on both sides. Women with mosaic TS had values between the full TS and control groups for cerebral hemisphere and lenticular and thalamic nuclei volume and for verbal ability. Within the mosaic TS group, visuospatial ability was significantly correlated with the percentage of lymphocytes that had the 45,X karyotype. Hippocampal volume and memory test scores were significantly lower in mosaic and non-mosaic 45,X TS subjects than in controls. We postulate that in human beings the X chromosome plays an important part in the development and ageing of grey matter in striatum, diencephalon, and cerebral hemispheres.	NIDDKD,CHEM BIOL LAB,CYTOGENET UNIT,BETHESDA,MD; NIH,MED GENET PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA	MURPHY, DGM (corresponding author), NIA,NEUROSCI LAB,BLDG 10,ROOM 6C-414,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		DeCarli, Charles/B-5541-2009; daly, eileen m/B-6716-2011; McIntosh, Anthony R/G-4955-2011	McIntosh, Anthony/0000-0002-1784-5662; Daly, Eileen/0000-0003-3625-3467				BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; HARNDEN DG, 1985, ISCN 1985 INT SYSTEM; Jastak J., 1978, WIDE RANGE ACHIEVEME; LYON MF, 1988, AM J HUM GENET, V42, P8; MIZOGUCHI K, 1992, NEUROSCI LETT, V138, P157, DOI 10.1016/0304-3940(92)90495-S; MONEY JOHN, 1966, J MED GENET, V3, P47, DOI 10.1136/jmg.3.1.47; MURPHY DGM, 1992, ARCH NEUROL-CHICAGO, V49, P839, DOI 10.1001/archneur.1992.00530320063013; RESKENIELSEN E, 1982, CORTEX, V18, P181, DOI 10.1016/S0010-9452(82)80001-4; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; TELLEGEN A, 1967, J CONSULT PSYCHOL, V31, P499, DOI 10.1037/h0024963; TORANALLERAND CD, 1991, PSYCHONEUROENDOCRINO, V16, P7, DOI 10.1016/0306-4530(91)90068-5; Verma RS, 1989, HUMAN CHROMOSOMES MA, p[5, 47]; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Wechsler D., 2008, WECHSLER ADULT INTEL; 1985, SAS USERS GUIDE BASI	17	156	156	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1197	1200		10.1016/0140-6736(93)92184-U	http://dx.doi.org/10.1016/0140-6736(93)92184-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901528				2022-12-24	WOS:A1993MG27400008
J	TAKAHASHI, T; MOMIYAMA, A				TAKAHASHI, T; MOMIYAMA, A			DIFFERENT TYPES OF CALCIUM CHANNELS MEDIATE CENTRAL SYNAPTIC TRANSMISSION	NATURE			English	Article							METABOTROPIC GLUTAMATE RECEPTOR; OMEGA-AGA-IVA; SELECTIVE MODULATION; NERVE-TERMINALS; NEURONS; CONOTOXIN; HIPPOCAMPUS; RELEASE; INVITRO	SYNAPTIC transmission is mediated by calcium entry through voltage-dependent calcium channels in presynaptic nerve terminals1,2. Various types of calcium channel have been characterized in neuronal somata3-6, but it is not clear which subtypes induce transmitter release at central synapses. The N-type Ca2+ channel blocker omega-conotoxin GVIA (omega-CgTx) suppresses the excitatory postsynaptic responses only partially7,8, whereas potassium-induced release of glutamate from brain synaptosomes can be blocked by omega-Aga-VIA (ref. 9), a blocker of P-type calcium channels5,10 and possibly of other types of calcium channels11,12. Here we test type-specific calcium-channel blockers on postsynaptic currents recorded from neurons in thin slices of rat central nervous system13. Inhibitory postsynaptic currents in cerebellar and spinal neurons and excitatory postsynaptic currents in hippocampal neurons are markedly suppressed by omega-Aga-IVA and reduced to a lesser extent by omega-CgTx. The L-type calcium channel blocker nicardipine had no effect. Our results indicate that at least two types of calcium channel mediate synaptic transmission in the mammalian central nervous system.	KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 606,JAPAN	Kyoto University			Takahashi, Tomoyuki/G-5951-2015	Takahashi, Tomoyuki/0000-0002-8771-7666				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; AUGUSTINE GJ, 1986, J PHYSIOL-LONDON, V381, P619, DOI 10.1113/jphysiol.1986.sp016347; COX DH, 1992, J NEUROSCI, V12, P906; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; Katz B., 1969, RELEASE NEURAL TRANS; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Sather W. A., 1992, Society for Neuroscience Abstracts, V18, P10; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833, DOI 10.1152/jn.1992.68.3.833; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358; TAKAHASHI T, 1992, J PHYSIOL-LONDON, V450, P593, DOI 10.1113/jphysiol.1992.sp019145; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P	25	643	657	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					156	158		10.1038/366156a0	http://dx.doi.org/10.1038/366156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	7901765				2022-12-24	WOS:A1993MG21600057
J	ATEENYIAGABA, C				ATEENYIAGABA, C			CONJUNCTIVAL SQUAMOUS-CELL CARCINOMA-ASSOCIATED WITH HIV-INFECTION IN KAMPALA, UGANDA	LANCET			English	Note								The incidence of conjunctival squamous-cell carcinoma in Kampala, Uganda, was steady at around 6 per million per year from 1970 until 1988, but has increased six-fold since then to 35 per million per year in 1992. Among 48 patients with conjunctival tumours seen at the ophthalmology clinic of the New Mulago Hospital from 1990 to 1991, 75% were HIV seropositive, compared with a 19% seropositivity rate among 48 matched controls (relative risk 13.0, 95% Cl 4.5-39.4, p<0.0001). The recent epidemic of conjunctival tumours in Uganda (and in neighbouring countries) appears to be largely due to the epidemic of HIV infection. Other factors that may contribute to the high incidence of these tumours in equatorial Africa may be exposure to ultraviolet light and conjunctival papillomavirus infection.			ATEENYIAGABA, C (corresponding author), MAKERERE UNIV,SCH MED,DEPT OPHTHALMOL,POB 7022,KAMPALA,UGANDA.							KESTELYN P, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91562-O; KIM RY, 1990, AM J OPHTHALMOL, V109, P231, DOI 10.1016/S0002-9394(14)75997-5; TEMPLETON A, 1973, RECENT RESULTS CANC, V43, P203; TRITTEN JJ, 1994, KLIN MONATSBL AUGENH, V204, P453, DOI 10.1055/s-2008-1045463; WINWARD KE, 1989, AM J OPHTHALMOL, V107, P554, DOI 10.1016/0002-9394(89)90508-4	5	113	118	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					695	696		10.1016/S0140-6736(95)90870-6	http://dx.doi.org/10.1016/S0140-6736(95)90870-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885126				2022-12-24	WOS:A1995QM73200011
J	MARCHETTI, M; ARICO, B; BURRONI, D; FIGURA, N; RAPPUOLI, R; GHIARA, P				MARCHETTI, M; ARICO, B; BURRONI, D; FIGURA, N; RAPPUOLI, R; GHIARA, P			DEVELOPMENT OF A MOUSE MODEL OF HELICOBACTER-PYLORI INFECTION THAT MIMICS HUMAN-DISEASE	SCIENCE			English	Article							PEPTIC-ULCERATION; CHRONIC GASTRITIS; IMMUNE-RESPONSE; PROTEIN	The human pathogen Helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer. The pathogenesis of H. pylori infection in vivo was studied by adapting fresh clinical isolates of bacteria to colonize the stomachs of mice. A gastric pathology resembling human disease was observed in infections With cytotoxin-producing strains but not with noncytotoxic strains. Oral immunization with purified H. pylori antigens protected mice from bacterial infection. This mouse model will allow the development of therapeutic agents and vaccines against H. pylori infection in humans.	BIOCINE SPA,IMMUNOBIOL RES INST SIENA,I-53100 SIENA,ITALY; UNIV SIENA,IST PATOL SPECIALE MED,I-53100 SIENA,ITALY	University of Siena				Figura, Natale/0000-0003-0318-4565				CANTORNA MT, 1990, CAN J MICROBIOL, V36, P237, DOI 10.1139/m90-041; CHEN M, 1994, INT J MED MICROBIOL, V280, P155; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; DUNN BE, 1990, J BIOL CHEM, V265, P2659; EULER AR, 1990, J CLIN MICROBIOL, V28, P2285, DOI 10.1128/JCM.28.10.2285-2290.1990; FERRERO RL, 1994, INFECT IMMUN, V62, P4981, DOI 10.1128/IAI.62.11.4981-4989.1994; FIOCCA R, 1989, ACTA GASTRO-ENT BELG, V52, P324; FOX JG, 1991, REV INFECT DIS, V13, pS671; GHIARA P, UNPUB; KARITA M, 1994, AM J GASTROENTEROL, V89, P208; KRAKOWKA S, 1987, INFECT IMMUN, V55, P2789, DOI 10.1128/IAI.55.11.2789-2796.1987; LEE A, 1993, LANCET, V341, P280, DOI 10.1016/0140-6736(93)92624-3; LEE A, 1990, GASTROENTEROLOGY, V99, P1315, DOI 10.1016/0016-5085(90)91156-Z; MACCHIA G, 1993, MOL MICROBIOL, V9, P645, DOI 10.1111/j.1365-2958.1993.tb01724.x; MEGRAUD F, 1993, GASTROENTEROL CLIN N, V22, P73; MICHETTI P, 1994, GASTROENTEROLOGY, V107, P1002, DOI 10.1016/0016-5085(94)90224-0; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; TSUDA M, 1994, INFECT IMMUN, V62, P3586, DOI 10.1128/IAI.62.8.3586-3589.1994; WARREN JR, 1983, LANCET, V2, P1273; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995; 1994, JAMA-J AM MED ASSOC, V272, P65	25	513	545	2	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1655	1658		10.1126/science.7886456	http://dx.doi.org/10.1126/science.7886456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886456				2022-12-24	WOS:A1995QM39700040
J	BURGE, MR; BOYLE, PJ				BURGE, MR; BOYLE, PJ			DIETARY THERAPY IN TYPE-II DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BURGE, MR (corresponding author), UNIV NEW MEXICO,SCH MED,ALBUQUERQUE,NM 87131, USA.							BANTLE JP, 1993, DIABETES CARE, V16, P1301, DOI 10.2337/diacare.16.9.1301; CRAPO PA, 1994, JOSLINS DIABETES MEL, P415; FREEMAN WL, 1988, PRIMARY CARE, V15, P327; HANSEN BC, 1988, DIABETES CARE, V11, P183, DOI 10.2337/diacare.11.2.183; HUGHES TA, 1984, AM J MED, V77, P7, DOI 10.1016/0002-9343(84)90429-7; REAVEN GM, 1980, DIABETOLOGIA, V19, P409, DOI 10.1007/BF00281817; 1994, DIABETES CARE, V17, P519; 1987, DIABETES CARE, V10, P639	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					898	898		10.1001/jama.273.11.898	http://dx.doi.org/10.1001/jama.273.11.898			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869567				2022-12-24	WOS:A1995QL40200035
J	VANDAELE, PLA; STOLK, RP; BURGER, H; ALGRA, D; GROBBEE, DE; HOFMAN, A; BIRKENHAGER, JC; POLS, HAP				VANDAELE, PLA; STOLK, RP; BURGER, H; ALGRA, D; GROBBEE, DE; HOFMAN, A; BIRKENHAGER, JC; POLS, HAP			BONE-DENSITY IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS - THE ROTTERDAM STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, NON-INSULIN-DEPENDENT; BONE DENSITY; FRACTURES; DIABETES MELLITUS, INSULIN-DEPENDENT; SEX FACTORS	HORMONE-BINDING GLOBULIN; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; ELDERLY WOMEN; MASS; FRACTURES; ESTROGENS; MEN; OSTEOPOROSIS	Objective: To investigate the relation between noninsulin-dependent diabetes mellitus and bone mineral density at the lumbar spine and hip. Design: Population-based study with a cross-sectional survey, Setting: A district of Rotterdam, the Netherlands. Participants: 5931 residents (2481 men, 3450 women) of the district aged 55 years or more. Measurements: Participants were classified as having non-insulin-dependent diabetes mellitus if they were receiving antidiabetic medication or if they had a serum glucose level of 11.1 mmol/L or more after a nonfasting oral glucose tolerance test. Bone mineral density, measured at the lumbar spine and proximal femur using dual-energy x-ray absorptiometry and the frequency of nonvertebral fractures during the preceding 5 years were compared between persons with and without non-insulin-dependent diabetes mellitus. Results: 243 men and 335 women had non-insulin-dependent diabetes mellitus. Both men and women with this condition had substantially higher mean bone mineral density values at all four sites measured than those with normal glucose tolerance. The increase could not be explained by age; obesity; use of estrogens, thiazides, or loop diuretics; impairment in abilities of daily living; smoking; or osteoarthritis. Women with non-insulin-dependent diabetes mellitus reported having had fewer fractures in the 5 preceding years than women without this condition (adjusted odds ratio, 0.63; 95% CI, 0.44 to 0.90). The frequency of fractures in men was similar for those with and without noninsulin-dependent diabetes mellitus (adjusted odds ratio, 0.96; CI, 0.60 to 1.52). Conclusions: Men and women with non-insulin-dependent diabetes mellitus have increased bone mineral density. Non-insulin-dependent diabetes mellitus in women is associated with a lower frequency of nonvertebral fractures.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			Stolk, Ronald P/B-2341-2013; Grobbee, Diederick/C-7651-2014	Stolk, Ronald P/0000-0002-0518-1205; Grobbee, Diederick/0000-0003-4472-4468				[Anonymous], 1985, DIABETES MELLITUS RE; BARRETTCONNOR E, 1992, JAMA-J AM MED ASSOC, V268, P3333; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; BIRKELAND KI, 1993, J CLIN ENDOCR METAB, V76, P275, DOI 10.1210/jc.76.2.275; CLEGHORN DB, 1992, J EPIDEMIOL COMMUN H, V46, P133, DOI 10.1136/jech.46.2.133; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DELEEUW I, 1977, DIABETES, V26, P1130, DOI 10.2337/diabetes.26.12.1130; ERNST M, 1987, CALCIFIED TISSUE INT, V40, P27, DOI 10.1007/BF02555725; GIACCA A, 1988, BONE, V9, P29, DOI 10.1016/8756-3282(88)90024-5; HAFFNER SM, 1993, METABOLISM, V42, P735, DOI 10.1016/0026-0495(93)90241-F; HEATH H, 1980, NEW ENGL J MED, V303, P567, DOI 10.1056/NEJM198009043031008; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; ISAIA G, 1987, ACTA DIABETOL LAT, V24, P305, DOI 10.1007/BF02742962; ISHIDA H, 1985, METABOLISM, V34, P797, DOI 10.1016/0026-0495(85)90101-5; JOHNSTON CC, 1985, METABOLISM, V34, P544, DOI 10.1016/0026-0495(85)90192-1; Kellgren, 1963, EPIDEMIOLOGY CHRONIC, V2; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502; LINDSAY R, 1991, BAILLIERE CLIN OB GY, V5, P837, DOI 10.1016/S0950-3552(05)80291-3; MCNAIR P, 1988, DAN MED BULL, V35, P109; MEEMA HE, 1967, CAN MED ASSOC J, V96, P132; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MURPHY S, 1993, BONE MINER, V20, P133, DOI 10.1016/S0169-6009(08)80022-0; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; PEIRIS AN, 1993, J CLIN ENDOCR METAB, V76, P279, DOI 10.1210/jc.76.2.279; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PLYMATE SR, 1988, J CLIN ENDOCR METAB, V67, P460, DOI 10.1210/jcem-67-3-460; PREZIOSI P, 1993, J CLIN ENDOCR METAB, V76, P283, DOI 10.1210/jcem.76.2.8432770; REID IR, 1993, AM J PHYSIOL, V265, P655; RUWAARD D, 1993, VOLKSGEZONDHEID TOEK, P303; SAMBROOK PN, 1988, J RHEUMATOL, V15, P1415; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SMYTHE HA, 1987, J RHEUMATOL, V14, P91; VANHEMERT AM, 1989, CLIN ENDOCRINOL, V31, P499; WAKASUGI M, 1993, BONE, V14, P29, DOI 10.1016/8756-3282(93)90252-6; WEINSTOCK RS, 1989, J BONE MINER RES, V4, P97; YKIJARVINEN H, 1994, LANCET, V343, P91, DOI 10.1016/S0140-6736(94)90821-4; 1987, MEASURING OBESITY CL	38	251	255	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					409	414		10.7326/0003-4819-122-6-199503150-00002	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856988				2022-12-24	WOS:A1995QM26600002
J	BROWN, K; GERSTBERGER, S; CARLSON, L; FRANZOSO, G; SIEBENLIST, U				BROWN, K; GERSTBERGER, S; CARLSON, L; FRANZOSO, G; SIEBENLIST, U			CENTRAL OF I-KAPPA-B-ALPHA PROTEOLYSIS BY SITE-SPECIFIC, SIGNAL-INDUCED PHOSPHORYLATION	SCIENCE			English	Article							ONCOPROTEIN BCL-3; INHIBITION; PROTEINS; COMMON	I kappa B-alpha inhibits transcription factor NF-kappa B by retaining it in the cytoplasm. Various stimuli, typically those associated with stress or pathogens, rapidly inactivate I kappa B-alpha. This liberates NF-kappa B to translocate to the nucleus and initiate transcription of genes important for the defense of the organism. Activation of NF-kappa B correlates with phosphorylation of I kappa B-alpha and requires the proteolysis of this inhibitor. When either serine-32 or serine-36 of I kappa B-alpha was mutated, the protein did not undergo signal-induced phosphorylation or degradation, and NF-kappa B could not be activated. These results suggest that phosphorylation at one or both of these residues is critical for activation of NF-kappa B.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Franzoso, Guido/GRR-8628-2022	Franzoso, Guido/0000-0002-0778-988X				BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWN KS, UNPUB; DEMARTIN R, 1994, EMBO J, V12, P2773; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x	19	1324	1365	1	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1485	1488		10.1126/science.7878466	http://dx.doi.org/10.1126/science.7878466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878466				2022-12-24	WOS:A1995QL49700034
J	KIRCHNER, J; CONNOLLY, CM; SANDMEYER, SB				KIRCHNER, J; CONNOLLY, CM; SANDMEYER, SB			REQUIREMENT OF RNA-POLYMERASE-III TRANSCRIPTION FACTORS FOR IN-VITRO POSITION-SPECIFIC INTEGRATION OF A RETROVIRUS-LIKE ELEMENT	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TY1 TRANSPOSITION; DNA; INVITRO; GENES; SEQUENCE; REGION; ENDONUCLEASE; NONRANDOM; HOTSPOTS	The yeast retroviruslike element Ty3 inserts at the transcription initiation sites of genes transcribed by RNA polymerase III (Pol III). An in vitro integration assay was developed with the use of Ty3 viruslike particles and a modified SUP2 tyrosine transfer RNA (tRNA(Tyr)) gene target. Integration was position-specific and required Ty3 integrase, Pol III transcription extract, and a transcriptionally competent tRNA gene. Use of individual transcription factor (TF) IIIB-, TFIIIC-, and Pol III-containing fractions showed that TFIIIB and TFIIIC, together, were sufficient for position-specific Ty3 integration, but not for transcription. This report demonstrates that in vitro integration of a retroelement can be targeted by cellular proteins.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					PHS HHS [33281] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLISON DS, 1983, CELL, V34, P655, DOI 10.1016/0092-8674(83)90398-7; BAKER RE, 1986, J BIOL CHEM, V261, P5275; CANNON PM, 1994, J VIROL, V68, P4768, DOI 10.1128/JVI.68.8.4768-4775.1994; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHALKER DL, 1990, GENETICS, V126, P837; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; EIBEL H, 1984, NATURE, V307, P386, DOI 10.1038/307386a0; ENGLEMAN A, 1992, J VIROL, V66, P6361; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1994, RNA POLYM, V3, pCH5; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; JI H, 1993, CELL, V73, P1007, DOI 10.1016/0092-8674(93)90278-X; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KIRCHNER J, 1993, J VIROL, V67, P19, DOI 10.1128/JVI.67.1.19-28.1993; Kirchner J., UNPUB; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LIEBMAN SW, 1993, GENETICS, V133, P499; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; MILOT E, 1994, VIROLOGY, V201, P408, DOI 10.1006/viro.1994.1310; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; NATSOULIS G, 1989, GENETICS, V123, P269; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SHIN CG, 1994, J VIROL, V68, P1633, DOI 10.1128/JVI.68.3.1633-1642.1994; TADDEO B, 1994, J VIROL, V68, P8401, DOI 10.1128/JVI.68.12.8401-8405.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; WIKERCHEN M, 1995, J VIROL, V69, P376; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473	37	182	188	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1488	1491		10.1126/science.7878467	http://dx.doi.org/10.1126/science.7878467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878467	Green Submitted			2022-12-24	WOS:A1995QL49700035
J	WANG, Q; SHEN, JX; SPLAWSKI, I; ATKINSON, D; LI, ZZ; ROBINSON, JL; MOSS, AJ; TOWBIN, JA; KEATING, MT				WANG, Q; SHEN, JX; SPLAWSKI, I; ATKINSON, D; LI, ZZ; ROBINSON, JL; MOSS, AJ; TOWBIN, JA; KEATING, MT			SCN5A MUTATIONS ASSOCIATED WITH AN INHERITED CARDIAC-ARRHYTHMIA, LONG QT SYNDROME	CELL			English	Article							HYPERKALEMIC PERIODIC PARALYSIS; MUSCLE SODIUM-CHANNEL; ALPHA-SUBUNIT; PARAMYOTONIA-CONGENITA; HUMAN CHROMOSOME-3; GENE; INACTIVATION; LINKAGE; FAMILIES; CLONING	Long QT syndrome (LQT) is an inherited disorder that causes sudden death from cardiac arrhythmias, specifically torsade de pointes and ventricular fibrillation. We previously mapped three LQT loci: LQT1 on chromosome 11p15.5, LQT2 on 7q35-36, and LQT3 on 3p21-24. Here we report genetic linkage between LQT3 and polymorphisms within SCN5A, the cardiac sodium channel gene. Single strand conformation polymorphism and DNA sequence analyses reveal identical intragenic deletions of SCN5A in affected members of two unrelated LQT families. The deleted sequences reside in a region that is important for channel inactivation. These data suggest that mutations in SCN5A cause chromosome 3-linked LQT and indicate a likely cellular mechanism for this disorder.	UNIV UTAH, HLTH SCI CTR, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, ECCLES PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, DIV CARDIOL, SALT LAKE CITY, UT 84112 USA; UNIV ROCHESTER, MED CTR, DEPT COMMUNITY & PREVENT MED, ROCHESTER, NY 14627 USA; UNIV ROCHESTER, MED CTR, DEPT MED, ROCHESTER, NY 14627 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Rochester; University of Rochester; Baylor College of Medicine; Baylor College of Medicine	WANG, Q (corresponding author), UNIV UTAH, HLTH SCI CTR, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA.		Towbin, Jeffrey A./J-5595-2019	Towbin, Jeffrey A./0000-0002-6585-714X	NHLBI NIH HHS [R01-HL48074, R01-HL51618, R01-HL33843] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051618, R01HL033843] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; ATTWELL D, 1979, PFLUG ARCH EUR J PHY, V379, P137, DOI 10.1007/BF00586939; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; CHIN H, 1991, GENOMICS, V11, P914, DOI 10.1016/0888-7543(91)90014-6; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; EBERS GC, 1991, ANN NEUROL, V30, P810, DOI 10.1002/ana.410300610; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1995, CYTOGENET CELL GENET, V68, P67; HONERJAGER P, 1981, REV PHYSIOL BIOCH P, V92, P1; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LERCHE H, 1993, J PHYSIOL-LONDON, V470, P13, DOI 10.1113/jphysiol.1993.sp019843; MAGOVCEVIC I, 1992, GENOMICS, V12, P125, DOI 10.1016/0888-7543(92)90414-N; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MCCLATCHEY AI, 1992, NAT GENET, V2, P148, DOI 10.1038/ng1092-148; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; ROMANO C, 1965, LANCET, V1, P658; RUDOLPH JA, 1992, NAT GENET, V2, P144, DOI 10.1038/ng1092-144; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SEINO S, 1992, GENOMICS, V13, P1375, DOI 10.1016/0888-7543(92)90078-7; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WANG Q, 1994, BIOTECHNIQUES, V17, P282; WARD O C, 1964, J Ir Med Assoc, V54, P103; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; YANG NB, 1994, P NATL ACAD SCI USA, V91, P12785, DOI 10.1073/pnas.91.26.12785; ZIPES DP, 1987, AM J CARDIOL, V59, pE26, DOI 10.1016/0002-9149(87)90198-6	42	1312	1366	1	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					805	811		10.1016/0092-8674(95)90359-3	http://dx.doi.org/10.1016/0092-8674(95)90359-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889574	Bronze			2022-12-24	WOS:A1995QM39900017
J	LIAO, SM; ZHANG, JH; JEFFREY, DA; KOLESKE, AJ; THOMPSON, CM; CHAO, DM; VILJOEN, M; VANVUUREN, HJJ; YOUNG, RA				LIAO, SM; ZHANG, JH; JEFFREY, DA; KOLESKE, AJ; THOMPSON, CM; CHAO, DM; VILJOEN, M; VANVUUREN, HJJ; YOUNG, RA			A KINASE-CYCLIN PAIR IN THE RNA-POLYMERASE-II HOLOENZYME	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL DOMAIN; YEAST; PROTEIN; BINDING; CTD; PURIFICATION; ACTIVATION; SYSTEM; RESCUE	THE RNA polymerase II holoenzyme consists of RNA polymerase II, a subset of general transcription factors, and regulatory proteins known as SRB proteins(1,2). The genes encoding SRB proteins were isolated as suppressors of mutations in the RNA polymerase II carboxy-terminal domain (CTD3,4). The CTD and SRB proteins have been implicated in the response to transcriptional regulators(1-11). We report here the isolation of two new SRB genes, SRB10 and SRB11, which encode kinase- and cyclin-like proteins, respectively, Genetic and biochemical evidence indicates that the SRB10 and SRB11 proteins form a kinase-cyclin pair in the holoenzyme, The SRB10/11 kinase is essential for a normal transcriptional response to galactose induction in vivo. Holoenzymes lacking SRB10/11 kinase function are strikingly deficient in CTD phosphorylation, Although defects in the kinase substantially affect transcription in vivo, purified holoenzymes lacking SRB10/11 kinase function do not show defects in defined in vitro transcription systems, suggesting that the factors necessary to elicit the regulatory role of the SRB10/11 kinase are missing in these systems, These results indicate that the SRB10/11 kinase is involved in CTD phosphorylation and suggest that this modification has a role in the response to transcriptional regulators in vivo.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; UNIV STELLENBOSCH, DEPT MICROBIOL, STELLENBOSCH 7600, SOUTH AFRICA	Massachusetts Institute of Technology (MIT); Stellenbosch University	LIAO, SM (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		zhang, jianhua/D-3404-2009; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Viljoen-Bloom, Marinda/0000-0002-4825-2392; Zhang, Jianhua/0000-0002-2128-9574; Chao, David/0000-0001-9198-337X				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEES JM, 1991, GENE EXPRESSION, V1, P149; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUROSKY RT, 1994, MOL CELL BIOL, V14, P3446, DOI 10.1128/MCB.14.5.3446; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	30	369	376	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	1995	374	6518					193	196		10.1038/374193a0	http://dx.doi.org/10.1038/374193a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877695				2022-12-24	WOS:A1995QL39700068
J	WEAVER, HA; AHEARN, MF; ARPIGNY, C; BOICE, DC; FELDMAN, PD; LARSON, SM; LAMY, P; LEVY, DH; MARSDEN, BG; MEECH, KJ; NOLL, KS; SCOTTI, JV; SEKANINA, Z; SHOEMAKER, CS; SHOEMAKER, EM; SMITH, TE; STERN, SA; STORRS, AD; TRAUGER, JT; YEOMANS, DK; ZELLNER, B				WEAVER, HA; AHEARN, MF; ARPIGNY, C; BOICE, DC; FELDMAN, PD; LARSON, SM; LAMY, P; LEVY, DH; MARSDEN, BG; MEECH, KJ; NOLL, KS; SCOTTI, JV; SEKANINA, Z; SHOEMAKER, CS; SHOEMAKER, EM; SMITH, TE; STERN, SA; STORRS, AD; TRAUGER, JT; YEOMANS, DK; ZELLNER, B			THE HUBBLE-SPACE-TELESCOPE (HST) OBSERVING CAMPAIGN ON COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article								The Hubble Space Telescope made systematic observations of the split comet P/Shoemaker-Levy 9 (SL9) (P designates a periodic comet) starting in July 1993 and continuing through mid-July 1994 when the fragments plunged into Jupiter's atmosphere. Deconvolutions of Wide Field Planetary Camera images indicate that the diameters of some fragments may have been as large as similar to 2 to 4 kilometers, assuming a geometric albedo of 4 percent, but significantly smaller values (that is, <1 kilometer) cannot be ruled out. Most of the fragments (or nuclei) were embedded in circularly symmetric inner comae from July 1993 until late June 1994, implying that there was continuous, but weak, cometary activity. At least a few nuclei fragmented into separate, condensed objects well after the breakup of the SL9 parent body, which argues against the hypothesis that the SL9 fragments were swarms of debris with no dominant, central bodies. Spectroscopic observations taken on 14 July 1994 showed an outburst in magnesium ion emission that was followed closely by a threefold increase in continuum emission, which may have been caused by the electrostatic charging and subsequent explosion of dust as the comet passed from interplanetary space into the jovian magnetosphere. No OH emission was detected, but the derived upper limit on the H2O production rate of similar to 10(27) molecules per second does not necessarily imply that the object was water-poor.	UNIV MARYLAND,DEPT ASTRON,COLLEGE PK,MD 20742; UNIV LIEGE,INST ASTROPHYS,B-4000 LIEGE,BELGIUM; SW RES INST,DIV 15,SAN ANTONIO,TX 78228; JOHNS HOPKINS UNIV,DEPT PHYS & ASTRON,BALTIMORE,MD 21218; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; LAB ASTRON SPATIALE TRAVERSE SIPHON,F-13376 MARSEILLE 12,FRANCE; HARVARD SMITHSONIAN CTR ASTROPHYS,CAMBRIDGE,MA 02138; UNIV HAWAII,INST ASTRON,HONOLULU,HI 96822; JET PROPULS LAB,PASADENA,CA 91109; NO ARIZONA UNIV,DEPT PHYS & ASTRON,FLAGSTAFF,AZ 86011; US GEOL SURVEY,FLAGSTAFF,AZ 86001; SW RES INST,DIV 15,BOULDER EXTENS OFF,BOULDER,CO 80302; GEORGIA SO UNIV,DEPT PHYS,STATESBORO,GA 30460	University System of Maryland; University of Maryland College Park; University of Liege; Southwest Research Institute; Johns Hopkins University; University of Arizona; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of Hawaii System; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Northern Arizona University; United States Department of the Interior; United States Geological Survey; University System of Georgia; Georgia Southern University	WEAVER, HA (corresponding author), SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218, USA.		Noll, Keith/C-8447-2012; Weaver, Harold A/D-9188-2016; Meech, Karen/CAH-1412-2022; Levy, David/GPS-4945-2022; Boice, Daniel/C-4831-2018	Weaver, Harold A/0000-0003-0951-7762; Boice, Daniel/0000-0001-6423-3768				Acuna M. H., 1983, PHYSICS JOVIAN MAGNE, P1, DOI [10. 1017/cbo9780511564574. 003, DOI 10.1017/CBO9780511564574.003]; ALLEN CW, 1976, ASTROPHYSICAL QUANTI, P162; Bobrovnikoff N. T., 1954, ASTRON J, V59, P357; BROWN WL, 1982, SCIENCE, V218, P525, DOI 10.1126/science.218.4572.525; COCHRAN AL, IN PRESS ICARUS; DEISEMME AH, 1982, COMETS, P85; DESSLER AJ, 1994, GEOPHYS RES LETT, V21, P1043, DOI 10.1029/94GL01294; FULLE M, 1990, NATURE, V359, P42; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; JEWITT D, 1986, ASTROPHYS J, V310, P937, DOI 10.1086/164745; JEWITT D, 1994, 5999 INT STR UN CIRC; LANDOLT AU, 1983, ASTRON J, V88, P439, DOI 10.1086/113329; MEECH KJ, 1993, ASTRON J, V106, P1222, DOI 10.1086/116721; SEKANINA Z, 1994, ASTRON ASTROPHYS, V289, P607; SEKANINA Z, 1994, HYPERVELOCITY IMPACT; SEKANINA Z, 1994, 6020 INT ASTR UN CIR; WALLACE LV, 1958, ASTRON J, V63, P213, DOI 10.1086/107729; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEISSMAN P, COMMUNICATION; WYCKOFF S, 1985, NATURE, V316, P241, DOI 10.1038/316241a0	20	75	75	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1282	1288		10.1126/science.7871424	http://dx.doi.org/10.1126/science.7871424			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871424				2022-12-24	WOS:A1995QK06800029
J	GIBSON, F; WALSH, J; MBURU, P; VARELA, A; BROWN, KA; ANTONIO, M; BEISEL, KW; STEEL, KP; BROWN, SDM				GIBSON, F; WALSH, J; MBURU, P; VARELA, A; BROWN, KA; ANTONIO, M; BEISEL, KW; STEEL, KP; BROWN, SDM			A TYPE-VII MYOSIN ENCODED BY THE MOUSE DEAFNESS GENE SHAKER-1	NATURE			English	Article							SYNDROME TYPE-I; ARTIFICIAL CHROMOSOME LIBRARY; YEAST; RECOMBINATION; CONSTRUCTION; LINKAGE; MAPS	GENETIC deafness is common, affecting about 1 in 2,000 births(1). Many of these show primary abnormalities of the sensory neuroepithelia of the inner ear, as do several hearing-impaired mouse mutants, suggesting that genes involved in sensory transduction could be affected. Here we report the identification of one such gene, the mouse shaker-1 (sh1) gene. Shaker-1 homozygotes show hyperactivity, head-tossing and circling due to vestibular dysfunction, together with typical neuroepithelial-type cochlear defects involving dysfunction and progressive degeneration of the organ of Corti(2-7). The sh1 gene encodes an unconventional myosin molecule of the type VII family. Three mutations are described, two missense mutations and a splice acceptor site mutation, all in the region encoding the myosin head. The myosin type VII molecule encoded by sh1 is the first molecule to be identified that is known, by virtue of its mutations, to be involved in auditory transduction.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT BIOCHEM & MOLEC GENET, LONDON W2 1PG, ENGLAND; BOYS TOWN NATL RES HOSP, OMAHA, NE 68131 USA; MRC, INST HEARING RES, NOTTINGHAM NG7 2RD, ENGLAND	Imperial College London; Boys Town National Research Hospital								BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BROWN KA, 1992, GENOMICS, V13, P189, DOI 10.1016/0888-7543(92)90219-I; BURKE DT, 1991, MAMM GENOME, V1, P65, DOI 10.1007/BF00350849; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; DEOL MS, 1956, PROC R SOC SER B-BIO, V145, P206, DOI 10.1098/rspb.1956.0028; DIBB NJ, 1985, J MOL BIOL, V183, P543, DOI 10.1016/0022-2836(85)90170-6; EVANS KL, 1993, HUM MOL GENET, V2, P115, DOI 10.1093/hmg/2.2.115; Fraser G. R, 1976, BIG 4 CAUSES POVERTY; GIBSON F, 1994, BIOTECHNIQUES, V16, P453; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GREENFIELD A J, 1987, Genomics, V1, P153, DOI 10.1016/0888-7543(87)90007-3; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KIKUCHI K, 1965, ACTA OTOLARYNG STOCK, V60, P287; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LETTS VA, 1994, MOUSE GENOME, V92, P116; Lord EM, 1929, AM NAT, V63, P435, DOI 10.1086/280276; MIKAELIAN DO, 1964, ARCHIV OTOLARYNGOL, V80, P418; MOOSEKER M, 1993, CURR BIOL, V3, P245, DOI 10.1016/0960-9822(93)90346-P; RINCHIK EM, 1990, P NATL ACAD SCI USA, V87, P896, DOI 10.1073/pnas.87.3.896; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SOLC CF, IN PRESS AUD NEUROSC; STEEL KP, 1983, ARCH OTOLARYNGOL, V109, P22; STEEL KP, 1992, DEV AUDITORY VESTIBU, V2, P221; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	28	521	529	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	1995	374	6517					62	64		10.1038/374062a0	http://dx.doi.org/10.1038/374062a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870172				2022-12-24	WOS:A1995QK07900052
J	CRUMP, BJ; PANTON, R; DRUMMOND, MF; MARCHMENT, M; HAWKES, RA				CRUMP, BJ; PANTON, R; DRUMMOND, MF; MARCHMENT, M; HAWKES, RA			TRANSFERRING THE COSTS OF EXPENSIVE TREATMENTS FROM SECONDARY TO PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article								General practitioners, especially fundholders, are becoming increasingly concerned about being asked to prescribe treatments for their patients that are outside their therapeutic experience. They are concerned about the clinical responsibility for such prescribing and the effects on their budgets. In some specialties transferring the costs of expensive treatments from secondary to primary care (cost shifting) has become partly institutionalised because of the separate sources of funding for drugs prescribed in the two sectors. With increased efforts to control the rising costs of the drugs budget and the emergence of new expensive treatments, cost shifting will be a challenge to clinicians and purchasers as they strive for rational, cost effective prescribing. A review of the funding mechanisms for drugs prescribing and of the relation between the licensing process and the decision to support the use of a treatment in primary or secondary care is needed.	KEELE UNIV,NEWCASTLE LYME ST5 5BC,STAFFS,ENGLAND; UNIV YORK,YORK YO1 5DD,N YORKSHIRE,ENGLAND; PREMIER HLTH TRUST,BURTON TRENT DE14 2AU,STAFFS,ENGLAND	Keele University; University of York - UK	CRUMP, BJ (corresponding author), S BIRMINGHAM HLTH AUTHOR,BIRMINGHAM B15 3DP,W MIDLANDS,ENGLAND.							DRUMMOND M, 1993, PHARMACOECONOMICS, V4, P173, DOI 10.2165/00019053-199304030-00003; 1993, CRDC1 STAND GROUP HL	2	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					509	512		10.1136/bmj.310.6978.509	http://dx.doi.org/10.1136/bmj.310.6978.509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888896	Green Published			2022-12-24	WOS:A1995QJ59800030
J	PAN, WH; LI, LA; TSAI, MJ				PAN, WH; LI, LA; TSAI, MJ			TEMPERATURE EXTREMES AND MORTALITY FROM CORONARY HEART-DISEASE AND CEREBRAL INFARCTION IN ELDERLY CHINESE	LANCET			English	Article							SEASONAL-VARIATION	We studied the relation between outdoor temperature and mortality rates from cardiovascular disease in Taiwan from 1981 to 1991. In 11 years, there were 30 085, 21 750, and 39 818 deaths from coronary artery disease, cerebral infarction, and cerebral haemorrhage, respectively, among 7.6 million residents aged 25 and over in selected areas where climate was recorded. A temperature-mortality relation was especially apparent in the elderly. A U-shaped relation was observed between temperature and mortality from coronary artery disease and cerebral infarction. The range corresponding to least deaths from coronary artery disease (26-29 degrees C) and cerebral infarction (27-29 degrees 0) was higher than that in countries with colder climates. In the elderly, the risk of cerebral infarction at 32 degrees C was 66% higher than that at 27-29 degrees C; the risk increased by 3.0% per 1 degrees C reduction from 27-29 degrees C. The risk of coronary artery disease at 32 degrees C was 22% higher than that at 26-29 degrees C; below 26-29 degrees C, the risk increased by 2.8% per 1 degrees C reduction. Mortality from cerebral haemorrhage decreased with increasing temperature at a rate of 3.3% per 1 degrees C. These results imply a pathophysiological difference between thromboembolic and haemorrhagic cardiovascular diseases. Poor thermoregulation in older people may precipitate cardiovascular disease events.	ACAD SINICA,INST STAT,TAIPEI 115,TAIWAN; NATL TAIWAN UNIV,COLL PUBL HLTH,INST EPIDEMIOL,TAIPEI 10764,TAIWAN	Academia Sinica - Taiwan; National Taiwan University	PAN, WH (corresponding author), ACAD SINICA,INST BIOMED SCI,DIV EPIDEMIOL & PUBL HLTH,TAIPEI 115,TAIWAN.		Pan, Wen-Harn/F-9972-2010	Pan, Wen-Harn/0000-0001-9136-0658				Clark R.P., 1985, MAN HIS THERMAL ENV; DOUGLAS AS, 1991, SCOT MED J, V36, P76, DOI 10.1177/003693309103600304; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; KEATINGE WR, 1986, AM J MED, V81, P795, DOI 10.1016/0002-9343(86)90348-7; KUNST AE, 1993, AM J EPIDEMIOL, V137, P331, DOI 10.1093/oxfordjournals.aje.a116680; NATSUME K, 1992, INT J BIOMETEOROL, V36, P1, DOI 10.1007/BF01208726; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; WOO J, 1991, NEUROEPIDEMIOLOGY, V10, P260, DOI 10.1159/000110282; WOODHOUSE PR, 1993, AGE AGEING, V22, P273, DOI 10.1093/ageing/22.4.273; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	10	203	218	1	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					353	355		10.1016/S0140-6736(95)90341-0	http://dx.doi.org/10.1016/S0140-6736(95)90341-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845116				2022-12-24	WOS:A1995QF72200009
J	GALLAY, P; SWINGLER, S; AIKEN, C; TRONO, D				GALLAY, P; SWINGLER, S; AIKEN, C; TRONO, D			HIV-I INFECTION OF NONDIVIDING CELLS - C-TERMINAL TYROSINE PHOSPHORYLATION OF THE VIRAL MATRIX PROTEIN IS A KEY REGULATOR	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR LOCATION; PLASMA-MEMBRANE; GROWTH-FACTOR; DNA; ACID; TRANSCRIPTION; SEQUENCE; IMPORT; CYCLE	The HIV-1 matrix (MA) protein contains two subcellular localization signals with opposing effects. A myristoylated N-terminus governs particle assembly at the plasma membrane, and a nucleophilic motif facilitates import of the viral preintegration complex into the nucleus of nondividing cells. Here, we show that myristoylation acts as the MA dominant targeting signal in HIV-1 producer cells. During virus assembly, a subset of MA is phosphorylated on the C-terminal tyrosine by a virion-associated cellular protein kinase. Tyrosine-phosphorylated MA is then preferentially transported to the nucleus of target cells. An MA tyrosine mutant virus grows normally in dividing cells, but is blocked for nuclear import in terminally differentiated macrophages. MA tyrosine phosphorylation thus reveals the karyophilic properties of this protein within the HIV-1 preintegration complex, thereby playing a critical role for infection of nondividing cells.			GALLAY, P (corresponding author), SALK INST BIOL STUDIES, INFECT DIS LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AIDEN C, 1994, CELL, V76, P853; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARTNER S, 1990, RETROVIRUSES, V8, P1017; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; GULIZIA J, 1994, J VIROL, V68, P2021, DOI 10.1128/JVI.68.3.2021-2025.1994; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUMPHRIES EH, 1972, J VIROL, V10, P82, DOI 10.1128/JVI.10.1.82-87.1972; HUMPHRIES EH, 1974, J VIROL, V14, P531, DOI 10.1128/JVI.14.3.531-546.1974; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; LIN PH, 1991, METHOD ENZYMOL, V198, P251; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; MYERS G, 1992, HUMAN RETROVIRUSES A; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHAROVA N, 1991, AIDS RES HUM RETROV, V7, P303, DOI 10.1089/aid.1991.7.303; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; SUGASAWA K, 1990, J VIROL, V64, P4820, DOI 10.1128/JVI.64.10.4820-4829.1990; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; YU XF, 1992, J VIROL, V66, P5667, DOI 10.1128/JVI.66.9.5667-5670.1992; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	45	297	306	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					379	388		10.1016/0092-8674(95)90488-3	http://dx.doi.org/10.1016/0092-8674(95)90488-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859280	Bronze			2022-12-24	WOS:A1995QG47000004
J	MATIC, I; RAYSSIGUIER, C; RADMAN, M				MATIC, I; RAYSSIGUIER, C; RADMAN, M			INTERSPECIES GENE EXCHANGE IN BACTERIA - THE ROLE OF SOS AND MISMATCH REPAIR SYSTEMS IN EVOLUTION OF SPECIES	CELL			English	Article							ESCHERICHIA-COLI K-12; CONSTITUTIVELY ACTIVATED RECA; SALMONELLA-TYPHIMURIUM; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; CODON USAGE; STRAINS; PROTEIN; INDUCTION; MUTANTS	Analysis of interspecies matings between S. typhimurium and E. coli indicates that the genetic barrier that separates these (and perhaps many other) related species is primarily recombinational. The structural component of this barrier is genomic sequence divergence. The mismatch repair enzymes act as potent inhibitors of interspecies recombination, whereas the SOS system acts as an inducible positive regulator. Interspecies mating triggers a RecBC-dependent SOS response in female bacteria that increases recombination mainly through overproduction of the RecA protein. Mismatch repair acts to reduce the mutation rate and recombination between similar sequences, whereas SOS acts to increase both. These opposing activities allow mismatch repair and SOS systems to determine both the rate of accumulation of sequence divergence and the extent of genetic isolation, which are the key components of the speciation process.			MATIC, I (corresponding author), INST JACQUES MONOD,MUTAGENESE LAB,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE.		; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0002-7034-4365; Radman, Miroslav/0000-0003-0216-3148				BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BAGDASARIAN M, 1986, P NATL ACAD SCI USA, V83, P5723, DOI 10.1073/pnas.83.15.5723; BARON LS, 1968, BACTERIOL REV, V32, P362, DOI 10.1128/MMBR.32.4_Pt_1.362-369.1968; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BOULAIN JC, 1986, MOL GEN GENET, V205, P339, DOI 10.1007/BF00430448; BUVINGER WE, 1984, J BACTERIOL, V159, P618, DOI 10.1128/JB.159.2.618-623.1984; CAILLETFAUQUET P, 1984, EMBO J, V3, P707, DOI 10.1002/j.1460-2075.1984.tb01873.x; CASAREGOLA S, 1982, MOL GEN GENET, V185, P430, DOI 10.1007/BF00334135; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; DIMPFL J, 1989, GENETICS, V123, P255; ECHOLS H, 1981, CELL, V25, P1, DOI 10.1016/0092-8674(81)90223-3; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; GROSS MD, 1981, MUTAT RES, V91, P107, DOI 10.1016/0165-7992(81)90081-6; HEINEMANN JA, 1991, TRENDS GENET, V7, P181, DOI 10.1016/0168-9525(91)90122-7; HERRLICH P, 1984, HUM GENET, V67, P360, DOI 10.1007/BF00291392; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; JACOB F, 1961, SEXUALITY GENETICS B, P93; JONES AL, 1992, MOL MICROBIOL, V6, P605, DOI 10.1111/j.1365-2958.1992.tb01507.x; JYSSUM K., 1960, ACTA PATHOL ET MICROBIOL SCAND, V48, P113; KAHN PL, 1968, J BACTERIOL, V96, P205; KARU AE, 1982, MOL GEN GENET, V185, P275, DOI 10.1007/BF00330798; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRICKER MC, 1992, P NATL ACAD SCI USA, V89, P1075, DOI 10.1073/pnas.89.3.1075; KUAN CT, 1992, J BACTERIOL, V174, P6872, DOI 10.1128/JB.174.21.6872-6877.1992; Kucherlapati R, 1988, GENETIC RECOMBINATIO, P1; KUSHNER SR, 1971, P NATL ACAD SCI USA, V67, P824; LEHNER AF, 1985, GENETICS, V110, P365; LEHNER AF, 1984, J BACTERIOL, V160, P682, DOI 10.1128/JB.160.2.682-686.1984; LENSKI RE, 1992, ENCY MICROBIOLOGY, V2, P125; LICHTEN M, 1984, P NATL ACAD SCI-BIOL, V81, P7180, DOI 10.1073/pnas.81.22.7180; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LLOYD RG, 1983, MOL GEN GENET, V190, P156, DOI 10.1007/BF00330339; LLOYD RG, 1978, J BACTERIOL, V134, P929, DOI 10.1128/JB.134.3.929-935.1978; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; MAHAJAN SK, 1988, GENETIC RECOMBINATIO, P87; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MATIC I, 1994, GENETICS, V136, P17; MAYNARDSMITH J, 1991, NATURE, V349, P29; Mayr E., 1982, GROWTH BIOL THOUGHT; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; Miller J.H., 1972, EXPT MOL GENETICS; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MOUNT DW, 1972, J BACTERIOL, V112, P886, DOI 10.1128/JB.112.2.886-893.1972; NINIO J, 1991, GENETICS, V129, P957; OHKI M, 1969, COLD SPRING HARB SYM, V33, P651; OISHI M, 1988, RECOMBINATION GENETI, P445; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PETIT MA, 1991, GENETICS, V129, P327; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RADMAN M, 1980, PHOTOCHEM PHOTOBIOL, V32, P823, DOI 10.1111/j.1751-1097.1980.tb04062.x; RADMAN M, 1993, GENOME ANAL, V7, P139; RADMAN M, 1993, CHROMOSOMA, V102, P369, DOI 10.1007/BF00360400; Radman M, 1974, MOL ENV ASPECTS MUTA, P128; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RAYSSIGUIER C, 1991, BIOCHIMIE, V73, P371, DOI 10.1016/0300-9084(91)90103-8; REENAN RAG, 1992, GENETICS, V132, P963; Roberts Michael S., 1993, Genetics, V134, P401; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; RYDER L, 1994, J BACTERIOL, V176, P1570, DOI 10.1128/jb.176.6.1570-1577.1994; SANDERSON KE, 1972, BACTERIOL REV, V36, P608, DOI 10.1128/MMBR.36.4.608-637.1972; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SEDGWICK SG, 1982, MOL GEN GENET, V185, P93, DOI 10.1007/BF00333796; SEDGWICK SG, 1988, J BACTERIOL, V170, P1610, DOI 10.1128/jb.170.4.1610-1616.1988; SERVICE RF, 1994, SCIENCE, V263, P1559, DOI 10.1126/science.8128240; SHARP PM, 1987, MOL BIOL EVOL, V4, P222; SHARP PM, 1991, J MOL EVOL, V33, P23, DOI 10.1007/BF02100192; SHEN P, 1986, GENETICS, V112, P441; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; SIEGEL EC, 1982, MUTAT RES, V92, P25; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH NH, 1990, J BACTERIOL, V172, P2209, DOI 10.1128/jb.172.5.2209-2216.1990; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TROBNER W, 1984, MOL GEN GENET, V198, P177, DOI 10.1007/BF00328720; VERMA N, 1989, J BACTERIOL, V171, P5694, DOI 10.1128/jb.171.10.5694-5701.1989; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WHITTAM TS, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P223; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	86	245	252	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					507	515		10.1016/0092-8674(95)90501-4	http://dx.doi.org/10.1016/0092-8674(95)90501-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859291	Bronze			2022-12-24	WOS:A1995QG47000017
J	SONGYANG, Z; CARRAWAY, KL; ECK, MJ; HARRISON, SC; FELDMAN, RA; MOHAMMADI, M; SCHLESSINGER, J; HUBBARD, SR; SMITH, DP; ENG, C; LORENZO, MJ; PONDER, BAJ; MAYER, BJ; CANTLEY, LC				SONGYANG, Z; CARRAWAY, KL; ECK, MJ; HARRISON, SC; FELDMAN, RA; MOHAMMADI, M; SCHLESSINGER, J; HUBBARD, SR; SMITH, DP; ENG, C; LORENZO, MJ; PONDER, BAJ; MAYER, BJ; CANTLEY, LC			CATALYTIC SPECIFICITY OF PROTEIN-TYROSINE KINASES IS CRITICAL FOR SELECTIVE SIGNALING	NATURE			English	Article							SUBSTRATE-SPECIFICITY; PHOSPHORYLATION; DOMAINS; INVITRO; ANTIGEN; SITES	How do distinct protein-tyrosine kinases activate specific downstream events? Src-homology-2 (SH2) domains on tyrosine kinases or targets of tyrosine kinases recognize phosphotyrosine in a specific sequence context and thereby provide some specificity(1-3). The role of the catalytic site of tyrosine kinases in determining target specificity has not been fully investigated. Here we use a degenerate peptide library to show that each of nine tyrosine kinases investigated has a unique optimal peptide substrate. We find that the cytosolic tyrosine kinases preferentially phosphorylate peptides recognized by their own SH2 domains or closely related SH2 domains (group I; ref. 3), whereas receptor tyrosine kinases preferentially phosphorylate peptides recognized by subsets of group In SH2 domains(3). The importance of these findings for human disease is underscored by our observation that a point mutation in the RET receptor-type tyrosine kinase, which causes multiple endocrine neoplasia type 2B, results in a shift in peptide substrate specificity.	BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP, MOLEC MED LAB, BOSTON, MA 02115 USA; UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA; NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts University; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; New York University; Columbia University; University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020; Cantley, Lewis C/D-1800-2014	Mohammadi, Moosa/0000-0003-2434-9437; Cantley, Lewis C/0000-0002-1298-7653; Lorenzo, Maria Jesus/0000-0003-4416-0615; Feldman, Ricardo A./0000-0001-6090-0439; Eng, Charis/0000-0002-3693-5145				ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DUYSTER J, IN PRESS P NATN ACAD; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUNTER T, 1982, J BIOL CHEM, V257, P4843; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TILT JH, 1994, J BIOL CHEM, V269, P7423; TINKER DA, 1992, ANTICANCER RES, V12, P123; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	25	817	843	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					536	539		10.1038/373536a0	http://dx.doi.org/10.1038/373536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845468				2022-12-24	WOS:A1995QF72400063
J	HENRIKSEN, TB; BEK, KM; HEDEGAARD, M; SECHER, NJ				HENRIKSEN, TB; BEK, KM; HEDEGAARD, M; SECHER, NJ			METHODS AND CONSEQUENCES OF CHANGES IN USE OF EPISIOTOMY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERINEAL MANAGEMENT TRIAL; INFORMATION; DELIVERY; RATES	Objectives-To evaluate the use of feedback by graphical profiles of rates of episiotomy and the impact on clinical practice and perineal state after spontaneous vaginal deliveries assisted by midwives with different attitudes towards episiotomy. Design-Observation period in labour ward followed by feedback to midwives about their own and other midwives' use of episiotomies. The periods before and after the intervention were compared. Subjects-All women (n = 3919) delivering during the two periods who had been assisted by one of 30 midwives; each midwife supervised at least 20 deliveries during each period. Main outcome measures-Overall rates of episiotomies and indications, incidence of intact perineums, perineal lacerations, and tears of anal sphincter. Results-The overall rate of episiotomy during the observation period was 37.1% (615). During the second period the rate was 6.6% lower (95% confidence interval 3.6% to 9.6%), corresponding to a relative decrease of 17.8% (10.1% to 24.7%). Higher rates of episiotomy during the observation period were associated with larger reductions in the second period. The decrease could be explained by less use of episiotomy in deliveries with rigid perineum or impending perineal tear. Compared with the observation period, in the second period 3.2% more women (0.3% to 6.3%) had an intact perineum after delivery and 3.4% (0.4% to 6.2%) experienced perineal tears. The overall incidence of tears of the anal sphincter remained unchanged. Women had a slightly reduced incidence of tears of the anal sphincter, however, if they were delivered by midwives who reduced a medium or high initial rate of episiotomy and a tendency towards an increased incidence of tears if they were assisted by midwives who reduced low initial rates (around 20%) of episiotomy. Conclusions-Changes in the use of episiotomy induced by awareness of clinical practice among midwives seem to increase the incidence of parturients with intact perineum without a concomitant rise in tears of the anal sphincter. To avoid the increase of such tears these changes should probably be restricted to midwives with rates of episiotomies above 30%.			HENRIKSEN, TB (corresponding author), AARHUS UNIV HOSP, DEPT OBSTET & GYNAECOL, PERINATAL EPIDEMIOL RES UNIT, DK-8000 AARHUS C, DENMARK.							BUEKENS P, 1985, BRIT J OBSTET GYNAEC, V92, P820, DOI 10.1111/j.1471-0528.1985.tb03052.x; BUEKENS P, 1993, BRIT MED J, V306, P623, DOI 10.1136/bmj.306.6878.623; Elwood JM, 1988, CAUSAL RELATIONSHIPS, Vxi, P332; GLEICHER N, 1984, Journal of the American Medical Association, V252, P3273, DOI 10.1001/jama.252.23.3273; HARRISON RF, 1984, BRIT MED J, V288, P1971, DOI 10.1136/bmj.288.6435.1971; Hemminki E, 1992, Qual Assur Health Care, V4, P133; HENRIKSEN TB, 1992, BRIT J OBSTET GYNAEC, V99, P950, DOI 10.1111/j.1471-0528.1992.tb13695.x; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANTEL N, 1959, J NATL CANCER I, V22, P719; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; MYERS SA, 1988, NEW ENGL J MED, V319, P1511, DOI 10.1056/NEJM198812083192304; SCHULTZ WCMW, 1990, J PSYCHOSOM OBST GYN, V11, P119, DOI 10.3109/01674829009084408; SHIONO P, 1990, OBSTET GYNECOL, V75, P765; SLEEP J, 1987, BRIT MED J, V295, P749, DOI 10.1136/bmj.295.6601.749; SLEEP J, 1984, BRIT MED J, V289, P587, DOI 10.1136/bmj.289.6445.587; SZCZEPURA A, 1987, BRIT MED J, V294, P875, DOI 10.1136/bmj.294.6576.875; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; THRANOV I, 1990, ACTA OBSTET GYN SCAN, V69, P11, DOI 10.3109/00016349009021032; YATES JM, 1984, BRIT MED J, V288, P1335; 1993, LANCET, V342, P1517; 1990, SPSS PC PLUS ADV STA, pB39	22	38	39	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	1994	309	6964					1255	1258		10.1136/bmj.309.6964.1255	http://dx.doi.org/10.1136/bmj.309.6964.1255			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888844	Green Published			2022-12-24	WOS:A1994PT03300017
J	PLOWMAN, GD; GREEN, JM; CULOUSCOU, JM; CARLTON, GW; ROTHWELL, VM; BUCKLEY, S				PLOWMAN, GD; GREEN, JM; CULOUSCOU, JM; CARLTON, GW; ROTHWELL, VM; BUCKLEY, S			HEREGULIN INDUCES TYROSINE PHOSPHORYLATION OF HER4/P180(ERBB4)	NATURE			English	Article							GROWTH-FACTOR; EGF RECEPTOR; P185ERBB2; CLONING	THE HER4/ERBB4 gene encodes a 180K transmembrane protein (HER4/p180erbB4) that is structurally related to the 185K product (HER2/p185erbB2) of the HER2/ERBB2 proto-oncogene1. A 45K heparin-binding glycoprotein (p45) has been characterized that specifically activates the intrinsic tyrosine kinase activity of HER4 (ref. 2). This HER4 ligand shares several features with the heregulin family of proteins, including molecular mass, ability to induce differentiation of breast cancer cells, activation of tyrosine phosphorylation in MDA-MB453 cells, and amino-terminal protein sequence. Heregulin exists as multiple isoforms and all are presumed to interact directly with HER2 (refs 3-6). We have used binding and phosphorylation studies with recombinant ligand on cell lines expressing recombinant receptors, and report here that heregulin, like p45, is a specific ligand for HER4. Furthermore, heregulin fails to induce phosphorylation of HER2 in the absence of HER4. These findings suggest that activation of the HER4 receptor is involved in signal transduction by heregulin.			PLOWMAN, GD (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.		PLOWMAN, Greg D/E-2012-2011					CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	13	467	520	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					473	475		10.1038/366473a0	http://dx.doi.org/10.1038/366473a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	7902537				2022-12-24	WOS:A1993MK09800067
J	SUNDNES, KO; HAIMANOT, AT				SUNDNES, KO; HAIMANOT, AT			EPIDEMIC OF LOUSE-BORNE RELAPSING FEVER IN ETHIOPIA	LANCET			English	Article							TETRACYCLINE; PENICILLIN	During summer 1991 an outbreak of louse-borne relapsing fever occurred simultaneously in two transit camps established for prisoners of war being returned from Eritrea at the end of the Ethiopian civil war. Only antibiotic treatment was given at the Bahr Dar camp where the frequency of cases increased for 20 days. Vector control by delousing in addition to antibiotics was given at Mekele camp where the frequency of cases fell over a similar period. This difference was significant (p < 0.001). Furthermore, there was a significant correlation between the decreasing proportion of camp inhabitants that had not been deloused at Mekele camp each day and the numbers of patients with fever (r = 0.89, p < 0.001). Taken together, these results confirm that effective control of an epidemic of louse-borne relapsing fever is dependent on efficient vector control in addition to antibiotic treatment.	INT COMM RED CROSS,MEKELE DELEGAT,ADDIS ABABA,ETHIOPIA; WHO,MALARIA UNIT,CH-1211 GENEVA 27,SWITZERLAND	World Health Organization								BRYCESON AD, 1970, Q J MED, V39, P129; GEBREHIWOT T, 1992, ETHIOPIAN MED J, V30, P175; MEKASHA A, 1992, J TROP MED HYG, V95, P206; PERINE PL, 1983, AM J TROP MED HYG, V32, P1096, DOI 10.4269/ajtmh.1983.32.1096; RIJKELS DF, 1971, TROP GEOGR MED, V23, P335; WARRELL DA, 1983, J INFECT DIS, V147, P898, DOI 10.1093/infdis/147.5.898	6	42	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1213	1215		10.1016/0140-6736(93)92190-5	http://dx.doi.org/10.1016/0140-6736(93)92190-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901534				2022-12-24	WOS:A1993MG27400014
J	ASCHERIO, A; RIMM, EB; STAMPFER, MJ; GIOVANNUCCI, EL; WILLETT, WC				ASCHERIO, A; RIMM, EB; STAMPFER, MJ; GIOVANNUCCI, EL; WILLETT, WC			DIETARY-INTAKE OF MARINE N-3 FATTY-ACIDS, FISH INTAKE, AND THE RISK OF CORONARY-DISEASE AMONG MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; HEART-DISEASE; MYOCARDIAL-INFARCTION; ADIPOSE-TISSUE; CONSUMPTION; MORTALITY; GREENLAND	Background. It has been hypothesized that a diet containing n-3 fatty acids from fish reduces the risk of coronary heart disease, but few large epidemiologic studies have examined this question. Methods. In 1986, 44,895 male health professionals, 40 to 75 years of age, who were free of known cardiovascular disease completed detailed and validated dietary questionnaires as part of the Health Professionals Followup Study. During six years of follow-up, we documented 1543 coronary events in this group: 264 deaths from coronary disease, 547 nonfatal myocardial infarctions, and 732 coronary-artery bypass or angioplasty procedures. Results. After controlling for age and several coronary risk factors, we observed no significant associations between dietary intake of n-3 fatty acids or fish intake and the risk of coronary disease, For men in the top fifth of the group in terms of intake of n-3 fatty acids (median, 0.58 g per day), the multivariate relative risk of coronary heart disease was 1.12 (95 percent confidence interval, 0.96 to 1.31), as compared with the men in the bottom fifth (median, 0.07 g per day). For men who consumed six or more servings of fish per week, as compared with those who consumed one serving per month or less, the multivariate relative risk of coronary disease was 1.14 (95 percent confidence interval, 0.86 to 1.51). The risk of death due to coronary disease among men who ate any amount of fish, as compared with those who ate no fish, was 0.74 (95 percent confidence interval, 0.44 to 1.23), but the risk did not decrease as fish consumption increased. Conclusions, Although the possibility of residual confounding by unmeasured factors cannot be entirely excluded, these data suggest that increasing fish intake from one to two servings per week to five to six servings per week does not substantially reduce the risk of coronary heart disease among men who are initially free of cardiovascular disease.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	ASCHERIO, A (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANG HO, 1980, AM J CLIN NUTR, V33, P2657, DOI 10.1093/ajcn/33.12.2657; BRR ML, 1989, LANCET, V2, P757; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; CURB JD, 1985, NEW ENGL J MED, V313, P821; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GABH Rose, 1982, WHO MONOGRAPH SERIES; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6; HIRAI A, 1980, LANCET, V2, P1132; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; KROMANN N, 1980, ACTA MED SCAND, V208, P401; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MIETTINEN TA, 1982, BRIT MED J, V285, P993, DOI 10.1136/bmj.285.6347.993; MORRIS MC, 1992, CIRCULATION, V86, P463; NORELL SE, 1986, BRIT MED J, V293, P426, DOI 10.1136/bmj.293.6544.426; RAPER NR, 1992, 50 DEP AGR HOM EC RE; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1992, AM J EPIDEMIOL, V135, P114; RIMM EB, 1993, NEW ENGL J MED, V328, P450; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHMIDT EB, 1994, DRUGS, V47, P405, DOI 10.2165/00003495-199447030-00003; SCHRADE W, 1961, J ATHEROSCLER RES, V1, P47, DOI 10.1016/S0368-1319(61)80053-7; SEIDELIN KN, 1992, AM J CLIN NUTR, V55, P1117, DOI 10.1093/ajcn/55.6.1117; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WOOD DA, 1984, LANCET, V2, P117, DOI 10.1016/S0140-6736(84)91044-4; WOOD DA, 1987, LANCET, V1, P117; 1963, AGR HDB DEP AGR, V8	32	427	429	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					977	982		10.1056/NEJM199504133321501	http://dx.doi.org/10.1056/NEJM199504133321501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885425				2022-12-24	WOS:A1995QT73700001
J	SHABAT, D; ITZHAKY, H; REYMOND, JL; KEINAN, E				SHABAT, D; ITZHAKY, H; REYMOND, JL; KEINAN, E			ANTIBODY CATALYSIS OF A REACTION OTHERWISE STRONGLY DISFAVOURED IN WATER	NATURE			English	Article							HYDROLYSIS; ETHERS	SEVERAL examples have been reported recently(1) of antibody catalysis(2) of reactions that are strongly disfavoured because of the high free energy of the transition state, Here we shaw that catalytic antibodies can be used to promote a particularly useful kind of reaction from a synthetic point of view: one involving an intermediate that is highly unstable in water, We show that an antibody elicited against the quaternary ammonium ion 4a (Fig, 1) catalyses the protonation of the enol ether 1 to form, with complete enantioselectivity, an oxocarbonium intermediate. This species is highly reactive in water, and would normally react with a water molecule to give the corresponding ketone 2, But the antibody provides a hydrophobic environment that allows the oxocarbonium ion instead to undergo an intramolecular reaction to form an enantiomerically pure ketal 3, This result shows that catalytic antibodies can exclude solvent molecules entirely from crucial steps on the reaction pathway.	TECHNION ISRAEL INST TECHNOL, DEPT CHEM, IL-32000 HAIFA, ISRAEL; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Technion Israel Institute of Technology; Scripps Research Institute				Reymond, Jean-Louis/0000-0003-2724-2942				BANAIT NS, 1991, J AM CHEM SOC, V113, P7951, DOI 10.1021/ja00021a021; EVANS DA, 1982, J AM CHEM SOC, V104, P1737, DOI 10.1021/ja00370a050; JAHANGIRI GK, 1994, J AM CHEM SOC, V116, P11264, DOI 10.1021/ja00104a008; JENKS WP, 1987, CATALYSIS CHEM ENZYM, P52; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LEWIS C, 1993, J AM CHEM SOC, V115, P1410, DOI 10.1021/ja00057a025; POTHIER N, 1992, HELV CHIM ACTA, V75, P604, DOI 10.1002/hlca.19920750217; REYMOND JL, 1994, ANGEW CHEM INT EDIT, V33, P475, DOI 10.1002/anie.199404751; REYMOND JL, 1993, J AM CHEM SOC, V115, P3909, DOI 10.1021/ja00063a009; REYMOND JL, 1991, ANGEW CHEM INT EDIT, V30, P1711, DOI 10.1002/anie.199117111; SCHMIR GL, 1965, J AM CHEM SOC, V87, P5692, DOI 10.1021/ja00952a030; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SCHUSTER M, 1994, J AM CHEM SOC, V116, P1135, DOI 10.1021/ja00082a047; SINHA SC, 1993, J AM CHEM SOC, V115, P4893, DOI 10.1021/ja00064a061; SINHA SC, 1993, P NATL ACAD SCI USA, V90, P11910, DOI 10.1073/pnas.90.24.11910	15	39	39	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					143	146		10.1038/374143a0	http://dx.doi.org/10.1038/374143a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	QL397	7877686				2022-12-24	WOS:A1995QL39700052
J	ARANY, Z; NEWSOME, D; OLDREAD, E; LIVINGSTON, DM; ECKNER, R				ARANY, Z; NEWSOME, D; OLDREAD, E; LIVINGSTON, DM; ECKNER, R			A FAMILY OF TRANSCRIPTIONAL ADAPTER PROTEINS TARGETED BY THE E1A ONCOPROTEIN	NATURE			English	Article							TISSUE-SPECIFIC EXTINGUISHER; REGULATORY SUBUNIT; TSE1 ENCODES; CYCLIC-AMP; ACTIVATION; KINASE; GENE	THE cellular protein p300 is a target of the adenoviral E1A oncoprotein and is thought to participate in preventing the G0/G1 transition in the cell cycle, activating certain enhancers and stimulating differentiation pathways(1). CBP is a protein that is associated with and coactivates the transcription factor CREB, mediating the induction by cyclic AMP of certain responsive promoters(2-4). The sequences of p300 and CBP are highly related(4,5). We show here that p300, like CBP2, can stimulate transcription, This activity is directly aml specifically inhibited by E1A. We also find that CBP exists in a DNA-bound complex containing a member of the CREB family and that E1A and CBP interact with one another in vivo. In keeping with the idea that E1A functionally targets CBP, cAMP-dependent transcription is repressed by E1A. Thus, p300 and CBP define a family of transcriptional adaptor proteins that are specifically targeted by the E1A oncoprotein.			ARANY, Z (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.							ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V30, P226; BARBEAU D, 1994, ONCOGENE, V9, P359; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KATO J, 1994, J CELL SCI, V79, P487; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; VAIRO G, 1990, J BIOL CHEM, V265, P2692; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	16	507	513	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					81	84		10.1038/374081a0	http://dx.doi.org/10.1038/374081a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870178				2022-12-24	WOS:A1995QK07900058
J	JANSEN, A; VANHAGEN, M; DREXHAGE, HA				JANSEN, A; VANHAGEN, M; DREXHAGE, HA			DEFECTIVE MATURATION AND FUNCTION OF ANTIGEN-PRESENTING CELLS IN TYPE-1 DIABETES	LANCET			English	Note							MICE	Macrophages and dendritic cells are important as antigen-presenting cells in the islet autoimmune response. We report decreased maturation of dendritic cells from blood monocytes of 61 patients with type 1 diabetes compared with 31 healthy controls (medians 26 and 35%, respectively, p=0.0005). The dendritic cells also had reduced ability to cluster (96 and 124 clusters, respectively, p=0.0005), and to stimulate autologous and allogeneic T cells. Because optimum antigen presentation is primarily required for tolerance induction rather than for immunisation, the defective maturation and function of diabetic dendritic cells might be the basis for disturbed activation of regulatory (suppressor) T cells.	ERASMUS UNIV ROTTERDAM,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam								CLARESALZLER MJ, 1992, J CLIN INVEST, V90, P741, DOI 10.1172/JCI115946; FAUSTMAN D, 1991, SCIENCE, V254, P1756, DOI 10.1126/science.1763324; INABA K, 1986, J EXP MED, V163, P247, DOI 10.1084/jem.163.2.247; JANSEN A, 1994, DIABETES, V43, P667, DOI 10.2337/diabetes.43.5.667; KNIGHT SC, 1985, P NATL ACAD SCI USA, V82, P4495, DOI 10.1073/pnas.82.13.4495; LANGMUIR PB, 1993, INT IMMUNOL, V5, P169, DOI 10.1093/intimm/5.2.169; LETY MA, 1992, CLIN IMMUNOL IMMUNOP, V64, P188, DOI 10.1016/0090-1229(92)90199-X; MOOIJ P, 1993, J ENDOCRINOL, V140, P503; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SERREZE DV, 1993, J IMMUNOL, V150, P2534	10	119	119	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					491	492		10.1016/S0140-6736(95)90586-3	http://dx.doi.org/10.1016/S0140-6736(95)90586-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861877				2022-12-24	WOS:A1995QH92900013
J	MARSHALL, M; LOCKWOOD, A; GATH, D				MARSHALL, M; LOCKWOOD, A; GATH, D			SOCIAL-SERVICES CASE-MANAGEMENT FOR LONG-TERM MENTAL-DISORDERS - A RANDOMIZED CONTROLLED TRIAL	LANCET			English	Article							NEEDS; CARE; ILL	Case management arose in the USA as a solution to the difficulties of providing community care to people with severe mental disorders. The basic principle of the approach is that a case manager takes responsibility for a client; arranges an assessment of need, a comprehensive service plan, delivery of suitable services, and monitoring and assessment of services delivered. The case-management approach has been widely accepted, to the extent that recent legislation has made case-management the cornerstone of community care in the UK. We did a randomised controlled trial to evaluate a social services case-management team for people with long-term mental disorders. Subjects were referred from hostels for the homeless, night shelters, a general-practitioner clinic for the homeless, the Oxford City Council homelessness unit, and local voluntary-sector group homes. Of 103 subjects referred, 80 consented to be randomised to treatment or control groups. At 14-month follow-up, as assessed by standardised interviews, there were no significant differences between groups in number of needs, quality of life, employment status, quality of accommodation, social behaviour, or severity of psychiatric symptoms. In the case-management group there was a significant reduction in deviant behaviour on a standardised behaviour rating scale (REHAB) (mean=0.79; 95% CI 0.26-1.32). It is unfortunate, in view of the limited effectiveness we have shown, that social services case-management was not evaluated in randomised controlled trials before its implementation in the UK.			MARSHALL, M (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baker R., 1983, USERS MANUAL REHABIL; BREWIN CR, 1988, PSYCHOL MED, V18, P457, DOI 10.1017/S0033291700007996; BREWIN CR, 1987, PSYCHOL MED, V17, P971, DOI 10.1017/S0033291700000787; FORD R, 1993, IMPLEMENTING CASE MA; FRANKLIN JL, 1987, AM J PUBLIC HEALTH, V77, P674, DOI 10.2105/AJPH.77.6.674; Griffiths R, 1988, COMMUNITY CARE AGEND; Holloway F, 1991, Int J Soc Psychiatry, V37, P2, DOI 10.1177/002076409103700102; HOLLOWAY F, 1991, BRIT J PSYCHIAT, V159, P142, DOI 10.1192/bjp.159.1.142; KRAWIECKA M, 1977, ACTA PSYCHIAT SCAND, V55, P299, DOI 10.1111/j.1600-0447.1977.tb00174.x; Lear G, 1993, Nurs Times, V89, P26; LEHMAN AF, 1983, ARCH GEN PSYCHIAT, V40, P369; Marshall M., 1994, PHILOS PSYCHOL PSYCH, V1, P27; MARSHALL M, 1994, IN PRESS PSYCHOL MED; ROSSLER W, 1992, ACTA PSYCHIAT SCAND, V86, P445, DOI 10.1111/j.1600-0447.1992.tb03295.x; SEGAL S, 1977, COMMUNITY BASED SHEL; Shepherd G, 1990, Health Trends, V22, P59; THORNICROFT G, 1991, International Review of Psychiatry, V3, P125, DOI 10.3109/09540269109067527; 1986, MAKING REALITY COMMU	18	67	68	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					409	412		10.1016/S0140-6736(95)90399-2	http://dx.doi.org/10.1016/S0140-6736(95)90399-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QG904	7853949				2022-12-24	WOS:A1995QG90400007
J	WINDELER, J; LANGE, S				WINDELER, J; LANGE, S			EVENTS PER PERSON YEAR - A DUBIOUS CONCEPT	BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CLINICAL-TRIALS; FRACTURE RATE; CALCIUM; THERAPY; WOMEN	In 1982 a new measure was introduced in research into osteoporosis and is now used everywhere in the literature. The so called ''fracture rate'' relates the number of fractures (single in some patients, multiple in others) to the cumulative time of observation of all patients. This concept, however, has no sound basis. Counting events instead of patients usually violates basic statistical assumptions and invalidates the use of common statistical tests and estimators. Its clinical interpretation is rather dubious. The use of such a measure impedes the search for valid and clinically meaningful outcome criteria and should be abandoned.	RUHR UNIV BOCHUM,MED INFORMAT & BIOMATH ABT,BOCHUM,GERMANY	Ruhr University Bochum	WINDELER, J (corresponding author), UNIV HEIDELBERG,INST MED BIOMETRIE,NEUENHEIMER FELD 305,D-69120 HEIDELBERG,GERMANY.							ANDERSEN B, 1990, METHODOLOGICAL ERROR, P152; ARMITAGE P, 1987, STATISTICAL METHODS; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; PAK C Y C, 1990, Journal of Bone and Mineral Research, V5, pS149; PALMIERI GMA, 1989, CALCIFIED TISSUE INT, V45, P137, DOI 10.1007/BF02556055; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802; RYAN PJ, 1992, ANN RHEUM DIS, V51, P1063, DOI 10.1136/ard.51.9.1063; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; STORM T, 1990, NEW ENGL J MED, V323, P1210; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	19	68	68	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					454	456		10.1136/bmj.310.6977.454	http://dx.doi.org/10.1136/bmj.310.6977.454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873955	Green Published			2022-12-24	WOS:A1995QJ24200027
J	STRITTMATTER, SM; FANKHAUSER, C; HUANG, PL; MASHIMO, H; FISHMAN, MC				STRITTMATTER, SM; FANKHAUSER, C; HUANG, PL; MASHIMO, H; FISHMAN, MC			NEURONAL PATHFINDING IS ABNORMAL IN MICE LACKING THE NEURONAL GROWTH CONE PROTEIN GAP-43	CELL			English	Article							IMMUNO-CYTOCHEMICAL LOCALIZATION; CALMODULIN-BINDING-PROTEIN; CENTRAL NERVOUS-SYSTEM; PRENATAL RAT-BRAIN; NEURITE OUTGROWTH; TYROSINE-HYDROXYLASE; OPTIC CHIASM; PC12 CELLS; MOUSE; GUIDANCE	GAP-43 has been termed a ''growth'' or ''plasticity'' protein because it is expressed at high levels in neuronal growth cones during development and during axonal regeneration. By homologous recombination, we generated mice lacking GAP-43. The mice die in the early postnatal period. GAP-43-deficient retinal axons remain trapped in the chiasm for 6 days, unable to navigate past this midline decision point. Over the subsequent weeks of life, most GAP-43-deficient axons do enter the appropriate tracts, and the adult CNS is grossly normal. There is no evidence for interference with nerve growth rate, and cultured neurons extend neurites and growth cones in a fashion indistinguishable from controls. Thus, the GAP-43 protein is not essential for axonal outgrowth or growth cone formation pet se, but is required at certain decision points, such as the optic chiasm. This is compatible with the hypothesis that GAP-43 serves to amplify pathfinding signals from the growth cone.	HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, DEPT NEUROL, BOSTON, MA 02129 USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT NEUROBIOL, NEW HAVEN, CT 06520 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University; Yale University	STRITTMATTER, SM (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, DEV BIOL LAB, BOSTON, MA 02129 USA.		Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ARGIRO V, 1982, J NEUROSCI, V2, P503; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; BOVOLENTA P, 1987, J NEUROSCI, V7, P1447; COLELLO RJ, 1992, J COMP NEUROL, V317, P357, DOI 10.1002/cne.903170404; DAVIES A, 1984, J COMP NEUROL, V223, P124, DOI 10.1002/cne.902230110; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GRABCZYK E, 1990, EUR J NEUROSCI, V2, P822, DOI 10.1111/j.1460-9568.1990.tb00393.x; HONIG MG, 1993, DEV BIOL, V156, P454, DOI 10.1006/dbio.1993.1092; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KROGER S, 1990, J NEUROSCI, V10, P3118; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Robertson E. J., 1987, TERATOCARCINOMAS EMB; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SHEA TB, 1991, J NEUROSCI, V11, P1685; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; SPECHT LA, 1981, J COMP NEUROL, V199, P233, DOI 10.1002/cne.901990207; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SRETAVAN DW, 1994, NEURON, V12, P957, DOI 10.1016/0896-6273(94)90307-7; SRETAVAN DW, 1993, NEURON, V10, P761, DOI 10.1016/0896-6273(93)90176-R; STITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1994, J CELL SCI, V107, P195; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; WIZENMANN A, 1993, DEVELOPMENT, V117, P725; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	47	342	348	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					445	452		10.1016/0092-8674(95)90495-6	http://dx.doi.org/10.1016/0092-8674(95)90495-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859286	hybrid			2022-12-24	WOS:A1995QG47000011
J	CROFTS, N; STEWART, T; HEARNE, P; PING, XY; BRESCHKIN, AM; LOCARNINI, SA				CROFTS, N; STEWART, T; HEARNE, P; PING, XY; BRESCHKIN, AM; LOCARNINI, SA			SPREAD OF BLOODBORNE VIRUSES AMONG AUSTRALIAN PRISON ENTRANTS	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-C VIRUS; INTRAVENOUS-DRUG-USERS; HIV TRANSMISSION; UNITED-STATES; PREVALENCE; INFECTION; VACCINATION; ANTIBODIES; HEROIN; JAIL	Objectives-To assess spread of bloodborne viruses among prison entrants in Victoria, Australia. Design-Voluntary confidential testing of all prison entrants for markers of exposure to bloodborne viruses with collection of minimal data on demography and risk factors over 12 months. Setting-Her Majesty's Prisons, Pentridge and Fairlea, Victoria, Australia. Subjects-3429 male and 198 female prison entrants (> 99% of all prison entrants); 344 entered prison and were tested more than once. Main outcome measures-Prevalence and incidence of antibodies to HIV, hepatitis B, and hepatitis C viruses, and minimal data on risk factors. Results-1562 (46%) gave a history of use of injected drugs, 1171 (33%) had antibody to hepatitis B core antigen, 1418 (39%) were anti-hepatitis C positive including 914 (64%) of the men who injected drugs, 91 (2.5%) were positive for hepatitis B surface antigen, and 17 (0.47%) were positive for antibody to HIV. Incidence rates for infection with hepatitis B and C virus were 12.6 and 18.3 per 100 person years, respectively; in men who injected drugs and were aged less than 30 years (29% of all prison entrants) these were 21 and 41 per 100 person years. Seroconversion to hepatitis B or C was associated with young age and shorter stay in prison. Only 5% of those who were not immune to hepatitis B reported hepatitis B immunisation. Conclusions-Hepatitis B and C are spreading rapidly through some populations of injecting drug users in Victoria, particularly among men aged less than 30 years at risk of imprisonment in whom rates of spread are extreme; this group constitutes a sizeable at risk population for spread of HIV. This spread is occurring in a context of integrated harm reduction measures outside prisons for prevention of viral spread but few programmes within or on transition from prisons; it poses an urgent challenge to these programmes.	PENTRIDGE HOSP,HER MAJESTYS PRISON,COBURG,VIC 3058,AUSTRALIA; FAIRFIELD HOSP,DEPT VIROL,VICTORIAN INFECT DIS REFERENCE LAB,FAIRFIELD,VIC 3078,AUSTRALIA	Victorian Infectious Diseases Reference Laboratory	CROFTS, N (corresponding author), MACFARLANE BURNET CTR MED RES,EPIDEMIOL & INT HLTH UNIT,POB 65,FAIRFIELD,VIC 3078,AUSTRALIA.							BAYAS JM, 1993, VACCINE, V11, P1441, DOI 10.1016/0264-410X(93)90174-V; BELL J, 1990, MED J AUSTRALIA, V152, P361, DOI 10.5694/j.1326-5377.1990.tb125185.x; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1991, AIDS, V8, P1345; BRESLOW NE, 1980, STATISTICAL METHODS; CHRISTIE B, 1993, BRIT MED J, V307, P151; CLAYTON D, 1993, STAT MODELS EPIDEMIO, P81; CROFTS N, 1993, MED J AUSTRALIA, V159, P237, DOI 10.5694/j.1326-5377.1993.tb137822.x; DECKER MD, 1985, J INFECT DIS, V152, P214, DOI 10.1093/infdis/152.1.214; DOBINSON I, 1986, J DRUG ISSUES, V16, P249, DOI 10.1177/002204268601600211; DONOGHOE M C, 1989, AIDS Care, V1, P51, DOI 10.1080/09540128908260235; GAUGHWIN MD, 1991, AIDS, V5, P845, DOI 10.1097/00002030-199107000-00008; GAUGHWIN MD, 1992, HIV AIDS AUSTR PRISO; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; HOLSEN DS, 1993, EUR J CLIN MICROBIOL, V12, P673, DOI 10.1007/BF02009378; INDERMAUER D, 1988, AUSTR NZ J CRIMINOLO, V3, P144; INDERMAUER D, 1990, SUBSTANCE ABUSE HIST; Kaldor J, 1993, Drug Alcohol Rev, V12, P175, DOI 10.1080/09595239300185611; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219; SUGITANI M, 1992, LANCET, V339, P1018, DOI 10.1016/0140-6736(92)90538-E; THOMPSON SC, 1993, MED J AUSTRALIA, V159, P562, DOI 10.5694/j.1326-5377.1993.tb138023.x; VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129; WATSON PG, 1973, MED J AUSTRALIA, V2, P421, DOI 10.5694/j.1326-5377.1973.tb115203.x; WOLK J, 1990, MED J AUSTRALIA, V152, P453, DOI 10.5694/j.1326-5377.1990.tb125302.x; 1993, NATIONAL HIV AIDS ST; 1990, NATIONAL HIV SEROPRE	29	132	134	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					285	288		10.1136/bmj.310.6975.285	http://dx.doi.org/10.1136/bmj.310.6975.285			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866168	Green Published			2022-12-24	WOS:A1995QF71700022
J	NATAZUKA, T; MANABE, Y; KONO, M; MURAYAMA, T; MATSUI, T; CHIHARA, K				NATAZUKA, T; MANABE, Y; KONO, M; MURAYAMA, T; MATSUI, T; CHIHARA, K			ASSOCIATION BETWEEN NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND NON-HODGKINS-LYMPHOMA	BRITISH MEDICAL JOURNAL			English	Article									KOBE UNIV,SCH MED,DEPT MED,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT RADIOL,KOBE 650,JAPAN; FUKUI MED SCH,DEPT OTOLARYNGOL,FUKUI,JAPAN	Kobe University; Kobe University; University of Fukui			Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				BIERMAN PJ, 1991, HEMATOLOGY BASIC PRI, P963; JACKSON RM, 1987, OTOLARYNG HEAD NECK, V97, P469, DOI 10.1177/019459988709700507; OTTER R, 1989, EUR J CANCER CLIN ON, V25, P1203, DOI 10.1016/0277-5379(89)90416-1; RAGOZZINO MW, 1983, J CHRON DIS, V36, P363, DOI 10.1016/0021-9681(83)90167-4; STOWENS D, 1981, LANCET, V2, P989	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1269	1269		10.1136/bmj.309.6964.1269	http://dx.doi.org/10.1136/bmj.309.6964.1269			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888850	Green Published			2022-12-24	WOS:A1994PT03300023
J	SCHNEIDER, DL; BARRETTCONNOR, EL; MORTON, DJ				SCHNEIDER, DL; BARRETTCONNOR, EL; MORTON, DJ			THYROID-HORMONE USE AND BONE-MINERAL DENSITY IN ELDERLY WOMEN - EFFECTS OF ESTROGEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE THERAPY; PREMENOPAUSAL WOMEN; LEVOTHYROXINE; HYPOTHYROIDISM; METABOLISM	Objective.-To determine the effect of long-term use of thyroid hormone on bone mineral density (BMD) in elderly women and the potential mitigating effects of estrogen replacement therapy. Design.-Cross-sectional, community-based study. Setting.-Rancho Bernardo, Calif. Participants.-A total of 991 white women aged 50 to 98 years who participated in a study of osteoporosis. Main Outcome Measures.-Bone mineral density at the ultradistal radius and midshaft radius using single-photon absorptiometry and at the hip and lumbar spine using dual-energy x-ray absorptiometry. Results.-A total of 196 women taking thyroid hormone for a mean duration of 20.4 years were compared with 795 women who were not using thyroid hormone. Women taking daily thyroxine-equivalent doses of 200 mu g or more had significantly lower BMD levels at the midshaft radius and hip compared with those taking less than 200 mu g. Daily doses of 1.6 mu g/kg and greater were associated with lower bone mass at ail four sites compared with nonuse, whereas doses less than 1.6 mu g/kg were not associated with lower BMD levels. These associations were independent of age, body mass index, smoking status, and use of thiazides, corticosteroids, and estrogen. Women taking both estrogen and a thyroid hormone dose of 1.6 mu g/kg or greater had significantly higher BMD levels at all four sites than women taking the same thyroid hormone dose alone. Women taking both thyroid hormone and estrogen had BMD levels comparable with those observed in women taking only estrogen. Conclusions.-Long-term thyroid hormone use at thyroxine-equivalent doses of 1.6 mu g/kg or greater was associated with significant osteopenia at the ultradistal radius, midshaft radius, hip, and lumbar spine. Estrogen use appears to negate thyroid hormone-associated loss of bone density in postmenopausal women,	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07181] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; AUWERX J, 1986, Q J MED, V60, P737; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; CHRISTIANSEN C, 1991, OSTEOPOROSIS INT, V1, P7; CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338; COLSTON KW, 1989, J BONE MINER RES, V4, P625; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DIAMOND T, 1990, J CLIN ENDOCR METAB, V72, P1184; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; GILMAN AG, 1980, GOODMAN GILMANS PHAR, P1406; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; MUNDY GR, 1976, J CLIN INVEST, V58, P529, DOI 10.1172/JCI108497; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; ROSENBAUM RL, 1982, ANN INTERN MED, V96, P53, DOI 10.7326/0003-4819-96-1-53; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SIMONSEN LLP, 1993, PHARM TIMES, V59, P29; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1988, SAS STAT USERS GUIDE	23	135	137	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1245	1249		10.1001/jama.271.16.1245	http://dx.doi.org/10.1001/jama.271.16.1245			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	7848399				2022-12-24	WOS:A1994NG36200023
J	SCHECHTER, M; HARRISON, LH; HALSEY, NA; TRADE, G; SANTINO, M; MOULTON, LH; QUINN, TC				SCHECHTER, M; HARRISON, LH; HALSEY, NA; TRADE, G; SANTINO, M; MOULTON, LH; QUINN, TC			COINFECTION WITH HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I AND HIV IN BRAZIL - IMPACT ON MARKERS OF HIV DISEASE PROGRESSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS-DRUG-USERS; HTLV-II; HOMOSEXUAL MEN; LEUKEMIA; INFECTION; RETROVIRUS; AIDS; LYMPHOCYTES; LYMPHOMA; CLINICS	Objectives.-To study the effect of human T-cell lymphtropic virus type I (HTLV-1) on markers of human immunodeficiency virus (HIV) disease progression. Design.-A retrospective, nested case-control study. Setting.-A university hospital outpatient HIV clinic in Rio de Janeiro, Brazil. Participants.-Human immunodeficiency virus-seropositive adults participating in a prospective HIV cohort study. Main Outcome Measures.-The HIV clinical stage, CD4+ lymphocyte counts, and other laboratory parameters in 27 individuals infected with HIV and HTLV-1 (coinfection) and 99 age-matched, HIV-seropositive, HTLV-seronegative controls (single infection). Results.-Variables independently associated with coinfection included higher CD4+ lymphocyte count (odds ratio [OR], 2.3; 95% confidence limits [CL], 1.3, 4.1), higher CD4+ percentage (OR, 2.0; 95% CL, 1.3, 3.2), beta2-Microglobulin level of 254 nmol/L or more (OR, 6.8; 95% CL, 1.3, 35.4), World Health Organization stages 3 and 4 (OR, 4.4; 95% CL, 1.1, 18.0), and reporting a parenteral risk factor (OR, 7.4; 95% CL, 1.4, 38.9). When stratified by p24 antigenemia, coinfection was associated with an estimated 82% higher CD4+ lymphocyte count (P<.05). Conclusion.-Coinfection was associated with higher CD4+ lymphocyte counts, more advanced clinical disease, and higher beta2-MiCroglobulin levels than HIV infection alone. The higher mean CD4+ lymphocyte count does not appear to offer immunologic benefit. Caution should be exercised when using CD4+ lymphocytes as a surrogate marker in studies of HIV infection in-populations where HTLV-I is prevalent. Further studies are needed to address whether current CD4+ lymphocyte values for the initiation of antiretroviral therapy and chemoprophylaxis against opportunistic infections in HIV infection are appropriate in coinfection.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,ROOM 5515,615 N WOLFE ST,BALTIMORE,MD 21205; UNIV FED RIO DE JANEIRO,HOSP UNIV CLEMENTINO FRAGA FILHO,DEPT PREVENT MED,INFECT DIS SERV,RIO JANEIRO,BRAZIL; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; NIAID,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Universidade Federal do Rio de Janeiro; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University				Moulton, Lawrence/0000-0001-7041-7387				[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; BARTHOLOMEW C, 1987, LANCET, V2, P1469; BARTHOLOMEW C, 1990, 6TH INT C AIDS SAN F; BOLLINGER RC, 1992, J INFECT DIS, V165, P913, DOI 10.1093/infdis/165.5.913; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; CLEGHORN FR, 1992, ARCH INTERN MED, V152, P1372, DOI 10.1001/archinte.152.7.1372; DESORMEAUX J, 1991, 7TH INT C AIDS FLOR; GALLO RC, 1991, J INFECT DIS, V164, P235, DOI 10.1093/infdis/164.2.235; HERSHOW RC, 1993, 9TH INT C AIDS BERL; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HJELLE B, 1991, J INFECT DIS, V163, P435, DOI 10.1093/infdis/163.3.435; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HORTA B L, 1992, Boletin de la Oficina Sanitaria Panamericana, V113, P131; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KRIMER A, 1990, HUMAN RETROVIROLOGY, P79; LAL RB, 1991, J CLIN MICROBIOL, V29, P2253, DOI 10.1128/JCM.29.10.2253-2258.1991; LIMA LAA, 1993, AIDS, V7, P295, DOI 10.1097/00002030-199302000-00031; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAGLIUCA A, 1990, LANCET, V336, P383, DOI 10.1016/0140-6736(90)91931-Y; PARK LP, 1992, J ACQ IMMUN DEF SYND, V5, P1124; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUINN TC, 1989, NEW ENGL J MED, V320, P1005, DOI 10.1056/NEJM198904133201509; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; ROSENBLATT JD, 1987, LEUKEMIA, V1, P397; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; SCHECHTER M, 1992, 8TH INT C AIDS AMST; VILLIGER PM, 1991, J IMMUNOL, V146, P550; WEISS SH, 1989, 5 INT C AIDS MONTR; WEISS SH, 1992, 1992 ANN M SPONS LAB; WELLES SL, 1992, 5TH P INT C HUM RETR; WIKTOR SZ, 1992, J INFECT DIS, V165, P920, DOI 10.1093/infdis/165.5.920; WIKTOR SZ, 1991, LANCET, V337, P327, DOI 10.1016/0140-6736(91)90947-N; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P2110, DOI 10.1073/pnas.89.6.2110; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; 1989, MMWR MORB MORTAL WKL, V38, P845	40	83	86	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					353	357		10.1001/jama.271.5.353	http://dx.doi.org/10.1001/jama.271.5.353			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	7904317				2022-12-24	WOS:A1994MR98300029
J	PAGE, C				PAGE, C			SODIUM CROMOGLYCATE, A TACHYKININ ANTAGONIST	LANCET			English	Editorial Material											PAGE, C (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED,SACKLER INST PULM PHARMACOL,LONDON SE5 8RX,ENGLAND.							BASRAN G S, 1983, European Journal of Pharmacology, V86, P143; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; CROSSMAN DC, 1993, J APPL PHYSIOL, V75, P167, DOI 10.1152/jappl.1993.75.1.167; DIXON M, 1979, BRIT J PHARMACOL, V67, P567; MYERS DJ, 1986, AM REV RESPIR DIS, V133, P1150; SPINA D, 1991, BRIT J PHARMACOL, V103, P1268, DOI 10.1111/j.1476-5381.1991.tb12335.x; STOKES TC, 1981, BR J DIS CHEST, V75, P11	7	10	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					70	70		10.1016/S0140-6736(94)90812-5	http://dx.doi.org/10.1016/S0140-6736(94)90812-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903775				2022-12-24	WOS:A1994MQ09200007
J	CLERICI, M; LUCEY, DR; BERZOFSKY, JA; PINTO, LA; WYNN, TA; BLATT, SP; DOLAN, MJ; HENDRIX, CW; WOLF, SF; SHEARER, GM				CLERICI, M; LUCEY, DR; BERZOFSKY, JA; PINTO, LA; WYNN, TA; BLATT, SP; DOLAN, MJ; HENDRIX, CW; WOLF, SF; SHEARER, GM			RESTORATION OF HIV-SPECIFIC CELL-MEDIATED IMMUNE-RESPONSES BY INTERLEUKIN-12 IN-VITRO	SCIENCE			English	Article							LYMPHOCYTE MATURATION FACTOR; STIMULATORY FACTOR; RECOMBINANT INTERLEUKIN-2; HETERODIMERIC CYTOKINE; IDENTIFICATION; PURIFICATION; INDUCTION; SYNERGY; PEPTIDE	Peripheral blood mononuclear cells (PBMCs) from many asymptomatic individuals infected with human immunodeficiency virus-type 1 (HIV) are unresponsive as measured by in vitro T cell proliferation and interleukin-2 (IL-2) production to influenza virus and synthetic peptides of HIV envelope (Env). Strong influenza virus- and Env-stimulated IL-2 responses and T cell proliferation were restored when cultures were stimulated in the presence of IL-12. Interferon-gamma production by PBMCs from HIV seropositive (HIV+) patients was also restored with IL-12. Furthermore, in vitro antigen-specific production of IL-2 and proliferation of PBMCs from HIV- donors were suppressed by antibody to IL-12, but were not enhanced by addition of exogenous IL-12. Thus, IL-12 may be limiting in PBMCs from HIV+ but not HIV- individuals. These findings demonstrate that IL-12 can restore HIV-specific cell-mediated immunity in vitro in HIV-infected individuals and suggest a potential use of IL-12 in augmenting the diminished immunologic functions associated with HIV infection.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10,ROOM 4B-17,BETHESDA,MD 20892; GENET INST INC,CAMBRIDGE,MA 02140; NCI,METAB BRANCH,BETHESDA,MD 20892; NIAID,PARASIT DIS LAB,BETHESDA,MD 20892; WILFORD HALL USAF MED CTR,HIV UNIT,LACKLAND AFB,TX 78236	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Air Force			Wynn, Thomas A/AAO-3523-2021; Wynn, Thomas A/C-2797-2011; Hendrix, Craig W/G-4182-2014	Wynn, Thomas A/0000-0002-7244-8731; Hendrix, Craig W/0000-0002-5696-8665; Clerici, Mario/0000-0001-5920-6191				ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; CHEHIMI J, 1992, J EXP MED, V175, P789, DOI 10.1084/jem.175.3.789; CHEHIMI J, 1993, 9TH INT C AIDS BERL, P24; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; CLERICI M, IN PRESS J CLIN INVE; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DOLAN MJ, 1993, 9TH INT C AIDS BERL, P45; GATELY MK, 1991, J IMMUNOL, V147, P874; GATELY MK, 1986, J IMMUNOL, V136, P1274; GATELY MK, 1992, CELL IMMUNOL, V143, P127, DOI 10.1016/0008-8749(92)90011-D; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MACOTONIA SE, 1993, INT IMMUNOL, V5, P1119; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; NAUME B, 1993, CYTOKINE, V5, P38, DOI 10.1016/1043-4666(93)90022-W; PINTO LH, UNPUB; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; WOLF SF, 1991, J IMMUNOL, V146, P3074; WONG HL, 1988, CELL IMMUNOL, V111, P39, DOI 10.1016/0008-8749(88)90049-4	33	409	426	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1721	1724		10.1126/science.7903123	http://dx.doi.org/10.1126/science.7903123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	7903123				2022-12-24	WOS:A1993ML22000038
J	HABER, DA				HABER, DA			TELOMERES, CANCER, AND IMMORTALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN FIBROBLASTS				HABER, DA (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02129, USA.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428	7	25	30	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					955	956		10.1056/NEJM199504063321412	http://dx.doi.org/10.1056/NEJM199504063321412			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877656				2022-12-24	WOS:A1995QP89300012
J	HALDER, G; CALLAERTS, P; GEHRING, WJ				HALDER, G; CALLAERTS, P; GEHRING, WJ			INDUCTION OF ECTOPIC EYES BY TARGETED EXPRESSION OF THE EYELESS GENE IN DROSOPHILA	SCIENCE			English	Article							MEDIATED ENHANCER DETECTION; HOMEOBOX-CONTAINING GENE; BASE-PAIRS; HOX CODES; MELANOGASTER; ANTENNAPEDIA; REGION; TRANSFORMATIONS; CHROMOSOME; VERTEBRAE	The Drosophila gene eyeless (ey) encodes a transcription factor with both a paired domain and a homeodomain. It is homologous to the mouse Small eye (Pax-6) gene and to the Aniridia gene in humans. These genes share extensive sequence identity, the position of three intron splice sites is conserved, and these genes are expressed similarly in the developing nervous system and in the eye during morphogenesis. Loss-of-function mutations in both the insect and in the mammalian genes have been shown to lead to a reduction or absence of eye structures, which suggests that ey functions in eye morphogenesis. By targeted expression of the ey com plementary DNA in various imaginal disc primordia of Drosophila, ectopic eye structures were induced on the wings, the legs, and on the antennae. The ectopic eyes appeared morphologically normal and consisted of groups of fully differentiated ommatidia with a complete set of photoreceptor cells. These results support the proposition that ey is the master control gene for eye morphogenesis, Because homologous genes are present in vertebrates, ascidians, insects, cephalopods, and nemerteans, ey may function as a master control gene throughout the metazoa.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel			Callaerts, Patrick/I-8118-2013; Halder, Georg/F-2966-2015	Halder, Georg/0000-0001-7580-3236; Callaerts, Patrick/0000-0003-4530-4561				[Anonymous], COMMUNICATION; ASHBURNER M, 1989, LABORATORY MANUAL; BACHILLER D, 1994, EMBO J, V13, P1930, DOI 10.1002/j.1460-2075.1994.tb06462.x; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOSSY B, 1984, EMBO J, V3, P2537, DOI 10.1002/j.1460-2075.1984.tb02169.x; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRIDGES CB, 1935, Z BIOL, V4, P401; CALLAERTS P, UNPUB; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; Dickson Barry, 1993, P1327; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; GAUSZ J, 1986, GENETICS, V112, P65; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GIBSON G, 1988, DEVELOPMENT, V102, P657; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; HALL LMC, 1983, J MOL BIOL, V169, P83, DOI 10.1016/S0022-2836(83)80176-4; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOCHMANN B, 1971, GENETICS, V62, P235; Hoge MA, 1915, AM NAT, V49, P47, DOI 10.1086/279455; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAMKA M, 1992, DEVELOPMENT, V116, P8412; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, P1133; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Meinertzhagen Ian A., 1993, P1363; MIRKOVITCH J, 1986, J MOL BIOL, V190, P255, DOI 10.1016/0022-2836(86)90296-2; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SERIKAKU MA, 1994, GENETICS, V138, P1137; Spemann H., 1938, EMBRYONIC DEV INDUCT; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; WOLFF R, 1993, DEV DROSOPHILA MELAN, P1277; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	53	1155	1198	3	167	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1788	1792		10.1126/science.7892602	http://dx.doi.org/10.1126/science.7892602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892602				2022-12-24	WOS:A1995QN70200029
J	JO, K; TOPAL, MD				JO, K; TOPAL, MD			DNA TOPOISOMERASE AND RECOMBINASE ACTIVITIES IN NAE-I RESTRICTION-ENDONUCLEASE	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; RECOGNITION SITES; ECORII; CONFORMATION; INTEGRATION; SPERMIDINE; ACTIVATION; MECHANISM; CLEAVAGE; BINDING	Nae I endonuclease must bind to two DNA sequences for cleavage. Examination of the amino acid sequence of Nae I uncovered similarity to the active site of human DNA ligase I, except for leucine 43 in Nae I instead of the lysine essential for ligase activity. Changing leucine 43 to lysine 43 (L43K) changed Nae I activity: Nae I-L43K relaxed supercoiled DNA to yield DNA topoisomers and recombined DNA to give dimeric molecules. Interruption of the reactions of Nae I and Nae I-L43K with DNA demonstrated transient protein-DNA covalent complexes. These findings imply coupled endonuclease and ligase domains and link Nae I endonuclease to the topoisomerase and recombinase protein families.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARBER W, 1990, J STRUCT BIOL, V104, P107, DOI 10.1016/1047-8477(90)90064-J; BAXTER BK, 1993, BIOCHEMISTRY-US, V32, P8291, DOI 10.1021/bi00083a033; CHANG S, 1977, P NATL ACAD SCI USA, V74, P4811, DOI 10.1073/pnas.74.11.4811; COLUMNA EA, 1993, ENVIRON MOL MUTAGEN, V22, P26, DOI 10.1002/em.2850220106; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; CRAIG NL, 1988, ANNU REV GENET, V22, P77; GABBARA S, 1992, J BIOL CHEM, V267, P18623; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HOLTZ JK, 1994, J BIOL CHEM, V269, P27286; Kornberg A., 1991, DNA REPLICATION; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PICHEL JG, 1993, ONCOGENE, V8, P3333; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; ROBERTS RJ, 1976, CRC CR REV BIOCH MOL, V4, P123, DOI 10.3109/10409237609105456; SAUER B, 1990, New Biologist, V2, P441; SCHIESTL RH, 1991, P NATL ACAD SCI USA, V88, P7585, DOI 10.1073/pnas.88.17.7585; THRESHER R, 1992, METHOD ENZYMOL, V211, P481; TOPAL MD, 1993, NUCLEIC ACIDS RES, V21, P2599, DOI 10.1093/nar/21.11.2599; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019; YANG CC, 1994, BIOCHEMISTRY-US, V33, P14918, DOI 10.1021/bi00253a031	27	54	55	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1817	1820		10.1126/science.7892605	http://dx.doi.org/10.1126/science.7892605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892605				2022-12-24	WOS:A1995QN70200038
J	KUMAR, J; YU, H; SHEETZ, MP				KUMAR, J; YU, H; SHEETZ, MP			KINECTIN, AN ESSENTIAL ANCHOR FOR KINESIN-DRIVEN VESICLE MOTILITY	SCIENCE			English	Article							CYTOPLASMIC DYNEIN; AXONAL-TRANSPORT; MOTOR; MICROTUBULES; CELLS; ORGANELLES; PROTEINS; MOVEMENT; GRANULES; INVITRO	The membrane anchor for the molecular motor kinesin is a critical site involved in intracellular membrane trafficking. Monoclonal antibodies specific for the; cytoplasmic surface of chick brain microsomes were used to define proteins involved in microtubule-dependent transport. One of four antibodies tested inhibited plus-end-directed vesicle motility by approximately 90 percent even as a monovalent Fab fragment and reduced kinesin binding to vesicles. This antibody bound to the cytoplasmic domain of kinectin, an integral membrane protein of the endoplasmic reticulum that binds to kinesin. Thus, kinectin acted as a membrane anchor protein for kinesin-driven vesicle motility.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University			Yu, Hanry/C-7375-2011; Yu, Hanry/C-1031-2013; Yu, Hanry/L-6050-2019	Yu, Hanry/0000-0002-0339-3685; Yu, Hanry/0000-0002-0339-3685	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023345] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 23345] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BURKHARDT JK, 1993, J CELL SCI, V104, P151; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; KUMAR J, UNPUB; LACEY ML, 1994, CELL MOTIL CYTOSKEL, V28, P205, DOI 10.1002/cm.970280304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SHEETZ MP, 1986, J CELL SCI, P181; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; YU H, 1992, J BIOL CHEM, V267, P20457; YU H, IN PRESS MOL BIOL CE	29	135	137	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1834	1837		10.1126/science.7892610	http://dx.doi.org/10.1126/science.7892610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892610				2022-12-24	WOS:A1995QN70200043
J	MATZUK, MM; KUMAR, TR; BRADLEY, A				MATZUK, MM; KUMAR, TR; BRADLEY, A			DIFFERENT PHENOTYPES FOR MICE DEFICIENT IN EITHER ACTIVINS OR ACTIVIN RECEPTOR-TYPE-II	NATURE			English	Article							EXPRESSION; GENE; RAT; INHIBIN	ACTIVINS are believed to initiate a signal transduction cascade by binding to serine/threonine kinase receptors types I and II1-3. Activins(4) bind to several different receptors in vitro(1-3), but the significance of this interaction in vivo has not been confirmed. To test the function of the type II activin receptor (ActRcII) in mammalian development and reproduction, we generated a null mutation in the ActRcII gene in mice using embryonic stem cell technology. We expected ActRcII-deficient mice to phenocopy activin-deficient mice. A few ActRcII-deficient mice had skeletal and facial abnormalities reminiszzcent of the Pierre-Robin syndrome in humans(5,6), but most lacked these defects and developed into adults; their follicle-stimulating hormone was suppressed, and their reproductive performance was defective. These findings confirm a role of ActRcII in activin signalling in pituitary gonadotrophs. The striking lack of overlap between phenotypes of ActRcII-deficient and activin-deficient mice suggests that the ligands that signal through ActRcII during embryonic development are not activins.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	MATZUK, MM (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.			Bradley, Allan/0000-0002-2349-8839				Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAMERON VA, 1994, ENDOCRINOLOGY, V134, P799, DOI 10.1210/en.134.2.799; CAOUETTELABERGE L, 1994, PLAST RECONSTR SURG, V93, P934, DOI 10.1097/00006534-199404001-00006; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CLARKE L, 1988, TERATOLOGY, V38, P565, DOI 10.1002/tera.1420380604; DEWINTER JP, 1992, MOL CELL ENDOCRINOL, V83, pR1, DOI 10.1016/0303-7207(92)90201-G; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; FENG ZM, 1993, ENDOCRINOLOGY, V132, P2593, DOI 10.1210/en.132.6.2593; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; KAIPIA A, 1994, ENDOCRINOLOGY, V134, P2165, DOI 10.1210/en.134.5.2165; KUMAR TR, 1992, MOL ENDOCRINOL, V6, P81, DOI 10.1210/me.6.1.81; MATHER JP, 1990, ENDOCRINOLOGY, V127, P3206, DOI 10.1210/endo-127-6-3206; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1992, BIOCHEM BIOPH RES CO, V185, P404, DOI 10.1016/S0006-291X(05)81000-9; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAMIREZSOLIS R, 1993, CELL, V83, P279; RITZEN EM, 1989, TESTIS, P269; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHIKONE T, 1994, MOL ENDOCRINOL, V8, P983, DOI 10.1210/me.8.8.983; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; VALE W, 1990, PEPTIDE GROWTH FACTO, V2, P211; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WOODRUFF TK, 1990, ENDOCRINOLOGY, V127, P3196, DOI 10.1210/endo-127-6-3196	28	480	515	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					356	360		10.1038/374356a0	http://dx.doi.org/10.1038/374356a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885474				2022-12-24	WOS:A1995QN63000059
J	ALLANDER, T; GRUBER, A; NAGHAVI, M; BEYENE, A; SODERSTROM, T; BJORKHOLM, M; GRILLNER, L; PERSSON, MAA				ALLANDER, T; GRUBER, A; NAGHAVI, M; BEYENE, A; SODERSTROM, T; BJORKHOLM, M; GRILLNER, L; PERSSON, MAA			FREQUENT PATIENT-TO-PATIENT TRANSMISSION OF HEPATITIS-C VIRUS IN A HEMATOLOGY WARD	LANCET			English	Article							POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; NON-A; REGION; INFECTION; ANTIBODY; GENOME; RNA	Blood transfusion is a well-documented route of transmission of hepatitis C virus (HCV). However, a persisting high frequency of HCV infections was recorded in our haematology ward even after screening of blood donors had been introduced. We investigated the viral strains in 37 patients with haematological malignant diseases who had developed hepatitis C when treated in the ward during 1990-93. 17 of the patients acquired hepatitis C despite being transfused only with blood components screened by second-generation anti-HCV tests. The viral strains were characterised by PCR genotyping and nucleotide sequencing of the hypervariable region of the E2 gene. Five clusters of closely related or identical viruses were found involving 2, 3, 4, 6, and 15 patients, respectively. Blood components could be ruled out as the common source of infection because no donor had given blood to all patients sharing a specific strain, and even donors whose blood had been given to several patients were negative for HCV RNA. All patients in each cluster had been treated in the ward during overlapping periods. These findings suggest that despite strict hygienic control, HCV transmission occurred between patients treated in the same hospital setting, as has previously been reported in a smaller group of haemodialysis patients.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT MED,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT LAB MED,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital				Persson, Mats/0000-0002-5118-6584				ALLANDER T, 1994, J MED VIROL, V43, P415, DOI 10.1002/jmv.1890430417; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ARICO M, 1994, BLOOD, V84, P2919; CHANT K, 1994, NEW S WALES PUBLIC H, V5, P47; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FEUCHT HH, 1994, MICROBIOL IMMUNOL, V38, P157, DOI 10.1111/j.1348-0421.1994.tb01758.x; GRUBER A, 1993, ANN ONCOL, V4, P229, DOI 10.1093/oxfordjournals.annonc.a058462; HIGASHI Y, 1993, VIROLOGY, V197, P659, DOI 10.1006/viro.1993.1641; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; TAKAMATSU K, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93229-I; WIDELL A, 1994, J MED VIROL, V44, P272, DOI 10.1002/jmv.1890440311; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409	17	188	189	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					603	607		10.1016/S0140-6736(95)90518-9	http://dx.doi.org/10.1016/S0140-6736(95)90518-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898176				2022-12-24	WOS:A1995QM07500006
J	RIMM, EB; CHAN, J; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC				RIMM, EB; CHAN, J; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC			PROSPECTIVE-STUDY OF CIGARETTE-SMOKING, ALCOHOL-USE, AND THE RISK OF DIABETES IN MEN	BRITISH MEDICAL JOURNAL			English	Article							BODY-FAT DISTRIBUTION; MIDDLE-AGED MEN; GLUCOSE-TOLERANCE; INSULIN RESISTANCE; PHYSICAL-ACTIVITY; FOLLOW-UP; MELLITUS; WOMEN; CONSUMPTION; POPULATION	Objective-To examine the association between smoking, alcohol consumption, and the incidence of non-insulin dependent diabetes mellitus in men of middle years and older. Design-Cohort questionnaire study of men followed up for six years from 1986. Setting-The health professionals' follow up study being conducted across the United States. Subjects-41 810 male health professionals aged 40-75 years and free of diabetes, cardiovascular disease, and cancer in 1986 and followed up for six years. Main outcome meausre-Incidence of non-insulin dependent diabetes mellitus diagnosed in the six years. Results-During 230 769 person years of follow up 509 men were newly diagnosed with diabetes. After controlling for known risk factors men who smoked 25 or more cigarettes daily had a relative risk of diabetes of 1 . 94 (95% confidence interval 1 . 25 to 3 . 03) compared with non-smokers. Men who consumed higher amounts of alcohol had a reduced risk of diabetes (P for trend <0 . 001). Compared with abstainers men who drank 30 . 0-49 . 9 g of alcohol daily had a relative risk of diabetes of 0 . 61 (95% confidence interval 0 . 44 to 0 . 91). Conclusions-Cigarette smoking may be an independent, modifiable risk factor for non-insulin dependent diabetes mellitus. Moderate alcohol consumption among healthy people may be associated with increased insulin sensitivity and a reduced risk of diabetes.			RIMM, EB (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; Chan, June/0000-0002-7620-569X	NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANES D, 1987, AM J PUBLIC HEALTH, V77, P439, DOI 10.2105/AJPH.77.4.439; ALDOORI WH, IN PRESS GUT; ARKY RA, 1989, ENDOCRIN METAB CLIN, V18, P75, DOI 10.1016/S0889-8529(18)30389-X; BALKAU B, 1991, J CLIN EPIDEMIOL, V44, P465, DOI 10.1016/0895-4356(91)90209-R; BALKAU B, 1991, AM J EPIDEMIOL, V134, P1469, DOI 10.1093/oxfordjournals.aje.a116056; BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BUTLER WJ, 1982, AM J EPIDEMIOL, V116, P971, DOI 10.1093/oxfordjournals.aje.a113499; CHAN JM, 1994, DIABETES CARE, V17, P1; CHRISTIANSEN C, 1994, BRIT J NUTR, V71, P449, DOI 10.1079/BJN19940151; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; EISEN SA, 1993, ARCH INTERN MED, V153, P2457, DOI 10.1001/archinte.153.21.2457; FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115; FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GIN H, 1992, DIABETES CARE, V15, P546, DOI 10.2337/diacare.15.4.546; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; HARRIS MI, 1985, DIABETES AM DIABETES, V6; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HODGE AM, 1993, AM J EPIDEMIOL, V137, P178, DOI 10.1093/oxfordjournals.aje.a116658; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; JANZON L, 1983, DIABETOLOGIA, V25, P86; JARRETT RJ, 1989, EPIDEMIOL REV, V11, P151, DOI 10.1093/oxfordjournals.epirev.a036034; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; MACMAHON B, 1982, CANCER-AM CANCER SOC, V50, P2676; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; MEDALIE JH, 1975, ARCH INTERN MED, V135, P811, DOI 10.1001/archinte.135.6.811; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; PYORALA K, 1985, ACTA MED SCAND S, V701, P38; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211; Rothman K, 1986, MODERN EPIDEMIOLOGY; SEIDELL JC, 1991, AM J EPIDEMIOL, V133, P257, DOI 10.1093/oxfordjournals.aje.a115870; SHAPER AG, 1988, LANCET, V2, P1267; SHIMOKATA H, 1989, JAMA-J AM MED ASSOC, V261, P1169, DOI 10.1001/jama.261.8.1169; SPARROW D, 1986, DIABETES, V35, P411, DOI 10.2337/diabetes.35.4.411; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; WHITTEMORE AS, 1983, J CHRON DIS, V36, P251, DOI 10.1016/0021-9681(83)90059-0; WILSON PWF, 1986, AM J MED, V80, P3, DOI 10.1016/0002-9343(86)90532-2; 1989, USDA AGR HDB, V8; 1994, MONTHLY VITAL STATIS, V43	48	434	456	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					555	559		10.1136/bmj.310.6979.555	http://dx.doi.org/10.1136/bmj.310.6979.555			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888928	Green Published, Green Submitted			2022-12-24	WOS:A1995QK70000016
J	GRAYSON, ML; GIBBONS, GW; BALOGH, K; LEVIN, E; KARCHMER, AW				GRAYSON, ML; GIBBONS, GW; BALOGH, K; LEVIN, E; KARCHMER, AW			PROBING TO BONE IN INFECTED PEDAL ULCERS - A CLINICAL SIGN OF UNDERLYING OSTEOMYELITIS IN DIABETIC-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THERAPEUTIC CONSIDERATIONS; UNSUSPECTED OSTEOMYELITIS; DIAGNOSIS; FOOT; FEATURES; IN-111; SCINTIGRAPHY; DISEASE	Objective.-To assess a bedside technique for diagnosing osteomyelitis. Design.-We prospectively assessed infected pedal ulcers for detectable bone by probing with a sterile, blunt, stainless steel probe. We then examined the relationship between detection of bone and the presence or absence of osteomyelitis that was defined histopathologically and/or clinically. Setting.-A tertiary care center. Patients.-Seventy-five hospitalized diabetic patients with a total of 76 infected foot ulcers were studied. Results.-Osteomyelitis was diagnosed in 50 instances (66%) and was excluded in 26 instances. Bone was detected by probing in 33 of 50 ulcers with contiguous osteomyelitis; in contrast, bone was probed in only four of 26 ulcers without contiguous osteomyelitis (P<.001). Bone detected on probing was visible in only three instances. Palpating bone on probing the pedal ulcer had a sensitivity of 66% for osteomyelitis, a specificity of 85%, a positive predictive value of 89%, and a negative predictive value of 56%. Conclusions.-Palpation of bone in the depths of infected pedal ulcers in patients with diabetes is strongly correlated with the presence of underlying osteomyelitis. If bone is palpated on probing, specialized roentgenographic and radionuclide tests to diagnose osteomyelitis are unnecessary. Probing for bone should be included in the initial assessment of all diabetic patients with infected pedal ulcers.	NEW ENGLAND DEACONESS HOSP,DEPT MED,DIV INFECT DIS,BOSTON,MA 02215; NEW ENGLAND DEACONESS HOSP,DEPT SURG,DIV VASC SURG,BOSTON,MA 02215; NEW ENGLAND DEACONESS HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School								BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BELTRAN J, 1990, SKELETAL RADIOL, V19, P37; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; GIBBONS GW, 1984, MANAGEMENT DIABETIC, P97; GRAYSON ML, 1994, CLIN INFECT DIS, V18, P683, DOI 10.1093/clinids/18.5.683; Karchmer A W, 1994, Curr Clin Top Infect Dis, V14, P1; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; MAURER AH, 1986, RADIOLOGY, V161, P221, DOI 10.1148/radiology.161.1.3763871; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; NEWMAN LG, 1991, JAMA-J AM MED ASSOC, V266, P1246, DOI 10.1001/jama.266.9.1246; NEWMAN LG, 1992, DIABETES CARE, V15, P1527, DOI 10.2337/diacare.15.11.1527; PARK HM, 1982, J NUCL MED, V23, P569; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; ROSAI J, 1989, ACKERMANS SURGICAL P, P1463; SCHAUWECKER DS, 1988, J NUCL MED, V29, P1651; SELDIN DW, 1985, J NUCL MED, V26, P988; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P316, DOI 10.1056/NEJM197002052820606; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P260, DOI 10.1056/NEJM197001292820507; WILLIAMSON MR, 1991, MAGN RESON IMAGING, V9, P945, DOI 10.1016/0730-725X(91)90540-3; YUH WTC, 1989, AM J ROENTGENOL, V152, P795, DOI 10.2214/ajr.152.4.795	22	342	353	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					721	723		10.1001/jama.273.9.721	http://dx.doi.org/10.1001/jama.273.9.721			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853630				2022-12-24	WOS:A1995QH81400031
J	CHENG, RH; KUHN, RJ; OLSON, NH; ROSSMANN, MG; CHOI, HK; SMITH, TJ; BAKER, TS				CHENG, RH; KUHN, RJ; OLSON, NH; ROSSMANN, MG; CHOI, HK; SMITH, TJ; BAKER, TS			NUCLEOCAPSID AND GLYCOPROTEIN ORGANIZATION IN AN ENVELOPED VIRUS	CELL			English	Article							SEMLIKI-FOREST VIRUS; ROSS RIVER VIRUS; SINDBIS VIRUS; CORE PROTEIN; NUCLEOTIDE-SEQUENCE; 3-DIMENSIONAL STRUCTURE; ELECTRON MICROGRAPHS; SERINE PROTEINASE; SPHERICAL VIRUSES; DEDUCED SEQUENCE	Alphaviruses are a group of icosahedral, positive-strand RNA, enveloped viruses. The membrane bilayer, which surrounds the similar to 400 Angstrom diameter nucleocapsid, is penetrated by 80 spikes arranged in a T = 4 lattice. Each spike is a trimer of heterodimers consisting of glycoproteins E1 and E2. Cryoelectron microscopy and image reconstruction of Ross River virus showed that the T = 4 quaternary structure of the nucleocapsid consists of pentamer and hexamer clusters of the capsid protein, but not dimers, as have been observed in several crystallographic studies. The E1-E2 heterodimers form one-to-one associations with the nucleocapsid monomers across the lipid bilayer. Knowledge of the atomic structure of the capsid protein and our reconstruction allows us to identify capsid-protein residues that interact with the RNA, the glycoproteins, and adjacent capsid-proteins.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus			Smith, Thomas J/K-9086-2013; Kuhn, Richard/AAR-2722-2021; Cheng, Holland/A-8973-2008	Smith, Thomas J/0000-0003-3528-6793; Kuhn, Richard/0000-0003-4148-1026; , Timothy/0000-0001-6543-8968	NIAID NIH HHS [AI33982, P01 AI035212, AI11217] Funding Source: Medline; NIGMS NIH HHS [R37 GM033050, GM33050, R01 GM033050] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035212, R01AI011217, R29AI033982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033050, R37GM033050] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDROUBI A, 1992, ULTRAMICROSCOPY, V46, P175, DOI 10.1016/0304-3991(92)90013-A; ALIPERTI G, 1978, VIROLOGY, V90, P366, DOI 10.1016/0042-6822(78)90321-5; ANTHONY RP, 1991, J VIROL, V65, P1187, DOI 10.1128/JVI.65.3.1187-1194.1991; BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BARTH BU, 1992, J VIROL, V66, P7560, DOI 10.1128/JVI.66.12.7560-7564.1992; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHENG RH, 1992, VIROLOGY, V186, P655, DOI 10.1016/0042-6822(92)90032-K; CHENG RH, 1994, STRUCTURE, V2, P271; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; COOMBS K, 1987, J MOL BIOL, V195, P359, DOI 10.1016/0022-2836(87)90657-7; COOMBS K, 1987, VIRUS RES, V7, P131, DOI 10.1016/0168-1702(87)90075-X; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DALGARNO L, 1983, VIROLOGY, V129, P170, DOI 10.1016/0042-6822(83)90404-X; DALRYMPLE JM, 1976, VIROLOGY, V69, P93, DOI 10.1016/0042-6822(76)90197-5; DOHERTY R. L., 1963, AUSTRALIAN J SCI, V26, P183; FARAGHER SG, 1988, VIROLOGY, V163, P509, DOI 10.1016/0042-6822(88)90292-9; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GAROFF H, 1974, VIROLOGY, V61, P493, DOI 10.1016/0042-6822(74)90285-2; GAROFF H, 1974, P NATL ACAD SCI USA, V71, P3988, DOI 10.1073/pnas.71.10.3988; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; GEIGENMULLERGNI.U, 1993, J VIROL, V7, P1620; HAHN CS, 1988, P NATL ACAD SCI USA, V85, P5997, DOI 10.1073/pnas.85.16.5997; HARRISON S C, 1974, Journal of Supramolecular Structure, V2, P486, DOI 10.1002/jss.400020233; HARRISON SC, 1992, J MOL BIOL, V226, P277, DOI 10.1016/0022-2836(92)90141-6; HARRISON SC, 1984, TRENDS BIOCHEM SCI, V9, P345, DOI 10.1016/0968-0004(84)90057-4; HARRISON SC, 1971, J MOL BIOL, V60, P523, DOI 10.1016/0022-2836(71)90186-0; HELENIUS A, 1980, EUR J BIOCHEM, V106, P613, DOI 10.1111/j.1432-1033.1980.tb04609.x; HOLMES KC, 1994, STRUCTURE, V2, P589, DOI 10.1016/S0969-2126(00)00061-7; HORZINEK M, 1969, J VIROL, V4, P514, DOI 10.1128/JVI.4.4.514-520.1969; JACROT B, 1987, ANIMAL VIRUS STRUCTU, P89; KAARIAINEN L, 1971, VIROLOGY, V43, P291, DOI 10.1016/0042-6822(71)90246-7; Kay B. H., 1989, The arboviruses: epidemiology and ecology. Volume IV., P93; KENNEY JM, 1994, STRUCTURE, V2, P823, DOI 10.1016/S0969-2126(94)00083-2; KUHN RJ, 1991, VIROLOGY, V182, P430, DOI 10.1016/0042-6822(91)90584-X; LEE HR, 1994, VIROLOGY, V202, P390, DOI 10.1006/viro.1994.1355; LOPEZ S, 1994, J VIROL, V68, P1316, DOI 10.1128/JVI.68.3.1316-1323.1994; MARSHALL ID, 1984, CURRENT TOPICS VECTO, P31; MAYNE JT, 1984, VIROLOGY, V134, P338, DOI 10.1016/0042-6822(84)90302-7; METSIKKO K, 1990, J VIROL, V64, P4678; OLSON NH, 1989, ULTRAMICROSCOPY, V30, P281, DOI 10.1016/0304-3991(89)90057-0; PAREDES AM, 1993, P NATL ACAD SCI USA, V90, P9095, DOI 10.1073/pnas.90.19.9095; PAREDES AM, 1993, VIROLOGY, V187, P329; RICE CM, 1982, J MOL BIOL, V154, P325, DOI 10.1016/0022-2836(82)90067-5; RICE CM, 1981, P NATL ACAD SCI-BIOL, V78, P2062, DOI 10.1073/pnas.78.4.2062; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SIMMONS DT, 1974, J MOL BIOL, V86, P397, DOI 10.1016/0022-2836(74)90027-8; STRAUSS EG, 1978, J VIROL, V28, P466, DOI 10.1128/JVI.28.2.466-474.1978; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; STUBBS MJ, 1991, J MOL BIOL, V221, P39, DOI 10.1016/0022-2836(91)80200-E; TONG L, 1992, ACTA CRYSTALLOGR A, V48, P430, DOI 10.1107/S0108767391014630; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; UBOL S, 1991, J VIROL, V65, P6913, DOI 10.1128/JVI.65.12.6913-6921.1991; VENIENBRYAN C, 1994, J MOL BIOL, V236, P572, DOI 10.1006/jmbi.1994.1166; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0; VRATI S, 1986, VIROLOGY, V151, P222, DOI 10.1016/0042-6822(86)90044-9; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WANG KS, 1991, VIROLOGY, V181, P694, DOI 10.1016/0042-6822(91)90903-O; WEISS B, 1994, NUCLEIC ACIDS RES, V22, P780, DOI 10.1093/nar/22.5.780; WENGLER G, 1992, VIROLOGY, V191, P880, DOI 10.1016/0042-6822(92)90263-O; ZIEMIECKI A, 1978, J MOL BIOL, V122, P259, DOI 10.1016/0022-2836(78)90189-4	64	276	279	1	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					621	630						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867069				2022-12-24	WOS:A1995QJ60200014
J	FLEMING, DM; CROSS, KW				FLEMING, DM; CROSS, KW			RESPIRATORY SYNCYTIAL VIRUS OR INFLUENZA	LANCET			English	Article							INFECTION; OUTBREAK	We compared data from clinical surveillance of acute respiratory infections in elderly people reported by a network of sentinel general practitioners, virus isolate data for respiratory syncytial virus (RSV) and influenza A and B viruses, and registered deaths, during the past four winters. Cases of acute respiratory disease (ARD) and deaths (3-week moving averages) showed strong similarity in timing. Periods of high incidence of ARD and numbers of deaths were followed within 2-3 weeks by reports of high numbers of RSV or influenza virus isolates. The epidemic period in December, 1989, was followed by high numbers of both virus isolates, but in all other epidemic periods one virus predominated. The lethality of epidemics due to RSV or influenza A or B varied both within and between years. These analyses suggest that RSV is as important as influenza viruses in causing morbidity and excess deaths among elderly people. RSV was prevalent at the end of each of the past four years in the UK; its importance as a cause of excess deaths would therefore be concealed in any analysis based on several years' experience. By contrast, the inconsistency of epidemics due to influenza viruses makes excess deaths due to these viruses easily recognisable. Integrated clinical and viriological surveillance is essential if epidemics due to RSV, influenza virus, or any other virus are to be correctly interpreted.			FLEMING, DM (corresponding author), RCGP,BIRMINGHAM RES UNIT,LORDSWOOD HOUSE,54 LORDSWOOD RD,BIRMINGHAM B17 9DB,ENGLAND.							ADAMS F, 1849, GENUINE WORKS HIPPOC, P203; AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208; ALDERSON MR, 1988, MORTALITY MORBIDITY, P122; ANDERSON TW, 1970, LANCET, V1, P291; Curwen M, 1990, POPUL TRENDS, P31; Curwen M., 1990, HLTH TRENDS, V22, P169; DAB W, 1991, EUR J EPIDEMIOL, V7, P579, DOI 10.1007/BF00218667; FLEMING DM, IN PRESS EUR J EPIDE; Fleming DM, 1991, 53 ROYAL COLL GEN PR; GARVIE DG, 1980, BRIT MED J, V281, P1253, DOI 10.1136/bmj.281.6250.1253-a; Graman P S, 1989, Semin Respir Infect, V4, P253; JOSEPH CA, 1992, COMMUN DIS REV, V2, P149; KUNST AE, 1990, INT J EPIDEMIOL, V20, P971; MARTIN AJ, 1978, LANCET, V1, P1035; NOAH ND, 1989, EPIDEMIOL INFECT, V102, P175, DOI 10.1017/S0950268800029848; OSTERWEIL D, 1990, J AM GERIATR SOC, V38, P659, DOI 10.1111/j.1532-5415.1990.tb01425.x; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600, DOI 10.1164/ajrccm/145.3.600; 1988, MORTALITY STATISTICS	18	137	139	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1507	1510		10.1016/S0140-6736(05)80082-0	http://dx.doi.org/10.1016/S0140-6736(05)80082-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902899				2022-12-24	WOS:A1993MM40200009
J	ZIEGLER, JL				ZIEGLER, JL			ENDEMIC KAPOSIS-SARCOMA IN AFRICA AND LOCAL VOLCANIC SOILS	LANCET			English	Article							ELEPHANTIASIS; PATHOGENESIS; UGANDA; AIDS	Endemic Kaposi's sarcoma (KS) in Africa has been attributed to a geographically-determined environmental factor. Endemic KS, a chronic nodular condition predominantly affecting the feet and legs, is believed to arise in the lymphatic endothelium and is associated with chronic lymphoedema. As such, KS bears a resemblance to podoconiosis (non-filarial elephantiasis). The prevalence of both conditions in highland areas close to volcanoes suggests a shared pathogenetic relationship to exposure to volcanic soils. The lymphatics and lymph nodes of patients with podoconiosis contain particulate alumino-silicates in macrophages consistent with the theory that ultrafine clay minerals are absorbed through the feet. The resulting chronic lymphatic irritation, inflammation, and collagenosis causes obstruction and lymphoedema. The geographical proximity of endemic KS to areas containing volcanic clay minerals, its lympho-endothelial origin, predilection for the feet and legs, and its prevalence among rural peasants and cultivators, suggest a common aetiology. Other features point to the participation of a low-grade, possibly sexually-transmitted, infective agent that becomes more pathogenic in the presence of immunosuppression. Damage to the dermal lymphatics of the feet and legs by absorbed clays could impair local immunity to such an agent. Endemic KS would then occur in exposed individuals who harbour the KS infective agent and are susceptible to the KS phenotype (males).	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								ALLISON AC, 1966, J EXP MED, V124, P141, DOI 10.1084/jem.124.2.141; BAYLEY AC, 1991, CANCER SURV, V10, P53; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; BLAND JM, 1977, E AFR J MED RES, V4, P47; BRONSON DM, 1988, KAPOSIS SARCOMA TEXT, P24; BRYCESON AD, 1970, T ROY SOC TROP MED H, V64, P380, DOI 10.1016/0035-9203(70)90174-4; COLLEY MH, 1989, AM J SURG PATHOL, V13, P803, DOI 10.1097/00000478-198909000-00011; DESMONDHELLMANN SD, 1991, J ACQ IMMUN DEF SYND, V4, P647; DIGIOVANNA JJ, 1981, AM J MED, V71, P779, DOI 10.1016/0002-9343(81)90364-8; DORFMAN RF, 1988, KAPOSIS SARCOMA PATH, P71; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; FYFE NCM, 1985, T ROY SOC TROP MED H, V79, P645, DOI 10.1016/0035-9203(85)90180-4; GAAFAR S, 1969, J PATHOL, V100, P9; GIGASE PL, 1986, VIRUS ASS CANCERS AF, P549; HUTT MSR, 1984, BRIT MED BULL, V40, P355, DOI 10.1093/oxfordjournals.bmb.a072004; KALENGAYI NMR, 1986, VIRUS ASS CANCERS AF, P559; KENNEDY TP, 1989, ARCH BIOCHEM BIOPHYS, V269, P359, DOI 10.1016/0003-9861(89)90118-5; KESTENS L, 1985, INT J CANCER, V36, P49, DOI 10.1002/ijc.2910360109; Kungu A, 1981, Antibiot Chemother (1971), V29, P38; OTU AA, 1986, J ROY SOC MED, V79, P510, DOI 10.1177/014107688607900905; PETERMAN TA, 1991, CANCER SURV, V10, P23; PRICE EW, 1972, T ROY SOC TROP MED H, V66, P150, DOI 10.1016/0035-9203(72)90063-6; PRICE EW, 1976, T ROY SOC TROP MED H, V70, P288, DOI 10.1016/0035-9203(76)90078-X; Price EW, 1990, PODOCONIOSIS NONFILA; SCHMID H, 1973, TROP GEOGR MED, V25, P266; TAYLOR JF, 1972, BRIT J CANCER, V26, P483, DOI 10.1038/bjc.1972.66; TAYLOR JF, 1971, INT J CANCER, V8, P122, DOI 10.1002/ijc.2910080116; Templeton A C, 1981, Pathol Annu, V16, P315; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WILSON M, 1993, IGNEOUS PETROGENESIS, P549	31	111	112	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1348	1351		10.1016/0140-6736(93)92252-O	http://dx.doi.org/10.1016/0140-6736(93)92252-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901641				2022-12-24	WOS:A1993MJ03900015
J	SCHWARTZ, RS				SCHWARTZ, RS			MOLECULAR MEDICINE - JUMPING GENES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Keller E. F., 1983, FEELING ORGANISM; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0	3	9	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					941	944		10.1056/NEJM199504063321408	http://dx.doi.org/10.1056/NEJM199504063321408			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877653				2022-12-24	WOS:A1995QP89300008
J	HARRIS, MA; SULLIVAN, CE				HARRIS, MA; SULLIVAN, CE			SLEEP PATTERN AND SUPPLEMENTARY OXYGEN REQUIREMENTS IN INFANTS WITH CHRONIC NEONATAL LUNG-DISEASE	LANCET			English	Note							AROUSAL RESPONSES	Seven infants with chronic neonatal lung disease and baseline oxygen saturation greater than 90% were studied with overnight polysomnography in their prescribed oxygen environment, and on a second night with 0.25 L/min additional oxygen. All had sleep fragmentation and decreased rapid-eye-movement (REM) sleep, which was reversed after the increased oxygen. Sleep duration (p<0.003), percentage REM sleep (p<0.001), and mean REM sleep period length (p<0.001) were increased, and arousals in REM sleep decreased (p<0.05), with improved oxygenation. We conclude that, in infants with chronic neonatal lung disease, arousal mechanisms minimise oxygen desaturation but induce sleep disruption.	ROYAL ALEXANDRA HOSP CHILDREN,DAVID READ PAEDIAT SLEEP DISORDERS CTR,MATL SIDS COUNCIL,SYDNEY,NSW,AUSTRALIA				Harris, Margaret-Anne/G-9627-2014					COONS S, 1987, SLEEP ITS DISORDERS, P17; ISSA FG, 1987, J APPL PHYSIOL, V62, P1832, DOI 10.1152/jappl.1987.62.5.1832; SCHER MS, 1992, SLEEP, V15, P195, DOI 10.1093/sleep/15.3.195; SELL EJ, 1988, BRONCHOPULMONARY DYS, P403; VOHR BR, 1982, AM J DIS CHILD, V136, P443, DOI 10.1001/archpedi.1982.03970410061015; WARD SLD, 1992, PEDIATRICS, V89, P860; WILLIAMS GR, 1989, AUST PAEDIATR J, V25, P370	7	33	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					831	832		10.1016/S0140-6736(95)92966-5	http://dx.doi.org/10.1016/S0140-6736(95)92966-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898231				2022-12-24	WOS:A1995QQ19500011
J	REAUME, AG; DESOUSA, PA; KULKARNI, S; LANGILLE, BL; ZHU, DG; DAVIES, TC; JUNEJA, SC; KIDDER, GM; ROSSANT, J				REAUME, AG; DESOUSA, PA; KULKARNI, S; LANGILLE, BL; ZHU, DG; DAVIES, TC; JUNEJA, SC; KIDDER, GM; ROSSANT, J			CARDIAC MALFORMATION IN NEONATAL MICE LACKING CONNEXIN43	SCIENCE			English	Article							GAP JUNCTION PROTEIN; MOUSE PREIMPLANTATION EMBRYOS; RAT-HEART; EXPRESSION; COMMUNICATION; CELLS; CHICK; MYOCARDIUM; PREGNANCY; TISSUES	Gap junctions are made up of connexin proteins, which comprise a multigene family in mammals. Targeted mutagenesis of connexin43 (Cx43), one of the most prevalent connexin proteins, showed that its absence was compatible with survival of mouse embryos to term, even though mutant cell lines showed reduced dye coupling in vitro. However, mutant embryos died at birth, as a result of a failure in pulmonary gas exchange caused by a swelling and blockage of the right ventricular outflow tract from the heart. This finding suggests that Cx43 plays an essential role in heart development but that there is functional compensation among connexins in other parts of the developing fetus.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV WESTERN ONTARIO, DEPT ZOOL, LONDON, ON N6A 5B7, CANADA; UNIV WESTERN ONTARIO, MOLEC GENET UNIT, LONDON, ON N6A 5B7, CANADA; MAX BELL RES CTR, TORONTO GEN DIV, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, DEPT PATHOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto			De Sousa, Paul A/H-7416-2013	De Sousa, Paul A/0000-0003-0745-2504; Juneja, Subhash/0000-0002-8536-5724				BASTIDE B, 1993, CIRC RES, V73, P1138, DOI 10.1161/01.RES.73.6.1138; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEVILACQUA A, 1989, P NATL ACAD SCI USA, V86, P5444, DOI 10.1073/pnas.86.14.5444; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BISHOP SP, 1990, CIRC RES, V66, P84, DOI 10.1161/01.RES.66.1.84; BOCKMAN DE, 1987, AM J ANAT, V180, P332; BRITZCUNNINGHAM SH, 1993, MOL BIOL CELL, V4, P329; CAVENEY S, 1985, ANNU REV PHYSIOL, V47, P319; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CLARK EB, 1989, AM J PHYSIOL, V257, pH55, DOI 10.1152/ajpheart.1989.257.1.H55; DEALY CN, 1994, DEV DYNAM, V199, P156, DOI 10.1002/aja.1001990208; DESOUSA PA, 1993, DEVELOPMENT, V117, P1355; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FISHMAN GI, 1991, CIRC RES, V68, P782, DOI 10.1161/01.RES.68.3.782; GOURDIE RG, 1993, CIRC RES, V72, P278, DOI 10.1161/01.RES.72.2.278; GOURDIE RG, 1993, J CELL SCI, V105, P985; GOURDIE RG, 1992, ANAT EMBRYOL, V185, P363; GREEN CR, 1988, BIOESSAYS, V8, P7, DOI 10.1002/bies.950080103; GROS D, 1994, CIRC RES, V74, P839, DOI 10.1161/01.RES.74.5.839; HURLE JM, 1979, J ANAT, V129, P427; KANTER HL, 1992, CIRC RES, V70, P438, DOI 10.1161/01.RES.70.2.438; KANTER HL, 1993, CIRC RES, V73, P344, DOI 10.1161/01.RES.73.2.344; LAIRD DW, 1990, J CELL SCI, V97, P109; LANGILLE BL, 1981, CIRC RES, V48, P481, DOI 10.1161/01.RES.48.4.481; Larsen WJ, 1993, HUMAN EMBRYOLOGY; LEE S, 1987, CELL, V51, P851, DOI 10.1016/0092-8674(87)90108-5; MCLACHLIN JR, 1986, DEV BIOL, V117, P146, DOI 10.1016/0012-1606(86)90357-X; MEDA P, 1993, ENDOCRINOLOGY, V133, P2371, DOI 10.1210/en.133.5.2371; MINKOFF R, 1993, CIRC RES, V73, P71, DOI 10.1161/01.RES.73.1.71; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAUS CCG, 1992, CELL MOL NEUROBIOL, V12, P163, DOI 10.1007/BF00713370; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; NISHI M, 1991, DEV BIOL, V146, P117, DOI 10.1016/0012-1606(91)90452-9; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PEXEIDER T, 1975, ADV ANAT EMBRYOL CEL, V51, P6; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; RISEK B, 1991, DEVELOPMENT, V113, P165; RISEK B, 1992, DEVELOPMENT, V116, P639; RUANGVORAVAT CP, 1992, DEV DYNAM, V194, P261, DOI 10.1002/aja.1001940403; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; SAFFITZ JE, 1994, CIRC RES, V74, P1065, DOI 10.1161/01.RES.74.6.1065; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; VALDIMARSSON G, 1993, MOL REPROD DEV, V36, P7, DOI 10.1002/mrd.1080360103; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; VANKEMPEN MJA, 1991, CIRC RES, V68, P1638, DOI 10.1161/01.RES.68.6.1638; VUILLEMIN M, 1989, AM J ANAT, V184, P114, DOI 10.1002/aja.1001840203; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WURST W, 1993, GENE TARGETING PRACT, P31	52	1040	1080	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1831	1834		10.1126/science.7892609	http://dx.doi.org/10.1126/science.7892609			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892609				2022-12-24	WOS:A1995QN70200042
J	MUSTARD, JF; SUNSHINE, JM				MUSTARD, JF; SUNSHINE, JM			SEEING THROUGH THE DUST - MARTIAN CRUSTAL HETEROGENEITY AND LINKS TO THE SNC METEORITES	SCIENCE			English	Article							REFLECTANCE SPECTRA; SURFACE	Through the application of new analytical techniques to high spatial resolution imaging spectrometer data, the ferrous mineralogy of major volcanic terrains on Mars is shown to consist of significant fractions of both low- and high-calcium pyroxene. Changes in the relative abundances of these pyroxenes are observed for units of different age and morphology, even in regions with higher degrees of alteration and contamination from dust. Volcanic rocks with these characteristics are uncommon on Earth but are typical of the basaltic SNC meteorites (shergottites, nakhlites, and chassignites) thought to be from Mars, Thus, it is possible to infer, even through the veil of dust, that the SNC meteorites have mineralogic affinities to major volcanic provinces on Mars and are therefore truly representative of the heterogeneity observed on the surface of the ''red planet.''	SETS TECHNOL,MILILANI,HI 96789		MUSTARD, JF (corresponding author), BROWN UNIV,DEPT GEOL SCI,BOX 1846,PROVIDENCE,RI 02912, USA.			Sunshine, Jessica/0000-0002-9413-8785				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; BIBRING JP, 1989, NATURE, V341, P591, DOI 10.1038/341591a0; BURNS RG, 1993, MINERALOGICAL APPLIC; CLARK BC, 1982, J GEOPHYS RES, V87, P59, DOI 10.1029/JB087iB12p10059; CLOUTIS EA, 1991, J GEOPHYS RES, V96, P18819; ERARD S, 1991, P LUNAR PLANET C, V21, P461; LONGHI J, 1991, P LUNAR PLANET SCI C, V19, P451; LONGHI J, 1992, MARS, pCH6; MCGETCHIN TR, 1978, ICARUS, V34, P512, DOI 10.1016/0019-1035(78)90042-8; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MCSWEEN HY, 1983, GEOCHIM COSMOCHIM AC, V47, P1501, DOI 10.1016/0016-7037(83)90309-5; MOUGINISMARK PJ, 1992, MARS, pCH13; MUSTARD JF, 1993, J GEOPHYS RES-PLANET, V98, P3387, DOI 10.1029/92JE02682; MUSTARD JF, 1993, LUNAR PLANET SCI, V24, P1039; MUSTARD JF, 1992, AM MINERAL, P345; PINET, 1994, GEOPHYS RES LETT, V21, P887; PINET P, 1990, J GEOPHYS RES-SOLID, V95, P14435, DOI 10.1029/JB095iB09p14435; Roush T.L., 1993, REMOTE GEOCHEMICAL A, P367; SCHUBERG G, 1992, MARS, pCH5; SINGER RB, 1993, RESOURCES NEAR EARTH, P709; SODERBLOM LA, 1992, MARS, pCH17; SUNSHINE JM, 1993, J GEOPHYS RES-PLANET, V98, P9075, DOI 10.1029/93JE00677; SUNSHINE JM, 1990, J GEOPHYS RES-SOLID, V95, P6955, DOI 10.1029/JB095iB05p06955; SUNSHINE JM, 1993, ICARUS, V105, P79, DOI 10.1006/icar.1993.1112; SUNSHINE JM, 1993, LUNAR PLANET SCI, V24, P1379; TARANTOLA A, 1982, REV GEOPHYS, V20, P219, DOI 10.1029/RG020i002p00219	26	96	96	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1623	1626		10.1126/science.7886449	http://dx.doi.org/10.1126/science.7886449			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886449				2022-12-24	WOS:A1995QM39700029
J	LINDPAINTNER, K; PFEFFER, MA; KREUTZ, R; STAMPFER, MJ; GRODSTEIN, F; LAMOTTE, F; BURING, J; HENNEKENS, CH				LINDPAINTNER, K; PFEFFER, MA; KREUTZ, R; STAMPFER, MJ; GRODSTEIN, F; LAMOTTE, F; BURING, J; HENNEKENS, CH			A PROSPECTIVE EVALUATION OF AN ANGIOTENSIN-CONVERTING-ENZYME GENE POLYMORPHISM AND THE RISK OF ISCHEMIC-HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSERTION DELETION POLYMORPHISM; MYOCARDIAL-INFARCTION; CARDIOMYOPATHY; CHOLESTEROL; EXPRESSION	Background. In a previous study, men with a history of myocardial infarction were found to have an increased prevalence of homozygosity for the deletional allele (D) of the angiotensin-converting-enzyme (ACE) gene, The D allele is associated with higher levels of ACE, which may predispose a person to ischemic heart disease. We investigated the association between the ACE genotype and the incidence of myocardial infarction, as well as other manifestations of ischemic heart disease, in a large, prospective cohort of U.S. male physicians, Methods. In the Physicians' Health Study, ischemic heart disease as defined by angina, coronary revascularization, or myocardial infarction developed in 1250 men by 1992, They were matched with 2340 controls according to age and smoking history. Zygosity for the deletion-insertion (D-I) polymorphism of the ACE gene was determined by an assay based on the polymerase chain reaction, Data were analyzed for both matched pairs and unmatched samples, with adjustment for the effects of known or suspected risk factors by conditional and non-conditional logistic regression, respectively. Results. The ACE genotype was not associated with the occurrence of either ischemic heart disease or myocardial infarction, The adjusted relative risk associated with the D allele was 1.07 (95 percent confidence interval, 0.96 to 1.19; P = 0.24) for ischemic heart disease and 1.05 (95 percent confidence interval, 0.89 to 1.25; P = 0.56) for myocardial infarction, if an additive mode of inheritance is assumed, Additional analyses assuming dominant and recessive effects of the D allele also failed to show any association, as did the examination of low-risk subgroups, Conclusions. In a large, prospectively followed population of U.S. male physicians, the presence of the D allele of the ACE gene conferred no appreciable increase in the risk of ischemic heart disease or myocardial infarction.	BRIGHAM & WOMENS HOSP,DIV CARDIOVASC DIS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health			Kreutz, Reinhold/AEV-0507-2022	Kreutz, Reinhold/0000-0002-4818-211X	NCI NIH HHS [CA42182, CA40360] Funding Source: Medline; NHLBI NIH HHS [K04-HL03138-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360, R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, NEW ENGL J MED; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BOHN M, 1993, CLIN GENET, V44, P298; BOHN M, 1993, CLIN GENET, V44, P292; BRITTON S, 1973, AM J PHYSIOL, V225, P1226, DOI 10.1152/ajplegacy.1973.225.5.1226; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; EVANS AE, 1994, Q J MED, V87, P211; FABRIS B, 1990, CLIN EXP PHARMACOL P, V17, P309, DOI 10.1111/j.1440-1681.1990.tb01326.x; HERBERT PN, 1985, J CLIN INVEST, V76, P403, DOI 10.1172/JCI111986; HERMAN B, 1983, AM J EPIDEMIOL, V118, P514, DOI 10.1093/oxfordjournals.aje.a113657; HIRSCH AT, 1991, CIRC RES, V59, P475; HOIT BD, 1986, CIRCULATION, V74, P712, DOI 10.1161/01.CIR.74.4.712; HUBERT C, 1991, J BIOL CHEM, V266, P15377; JORDE LB, 1988, AM J CARDIOL, V62, P708, DOI 10.1016/0002-9149(88)91207-6; LINDPAINTNER K, 1993, J MOL CELL CARDIOL, V25, P133, DOI 10.1006/jmcc.1993.1017; LINDPAINTNER K, 1993, CLIN RES, V41, pA216; Magrini F, 1988, Am J Med, V84, P55, DOI 10.1016/0002-9343(88)90205-7; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; MOCHIZUKI T, 1992, J CLIN INVEST, V89, P490, DOI 10.1172/JCI115611; OHISHI M, 1993, NAT GENET, V5, P324, DOI 10.1038/ng1293-324; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIDKER PM, 1993, CIRCULATION, V87, P1969, DOI 10.1161/01.CIR.87.6.1969; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; ROSNER B, 1978, INT J EPIDEMIOL, V7, P367, DOI 10.1093/ije/7.4.367; RUIZ J, 1994, P NATL ACAD SCI USA, V91, P3662, DOI 10.1073/pnas.91.9.3662; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SHANMUGAM V, 1993, PCR METH APPL, V3, P120; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TIRET L, 1992, AM J HUM GENET, V51, P197; TIRET L, 1993, LANCET, V341, P991, DOI 10.1016/0140-6736(93)91075-W; UNDERWOOD DA, 1985, AM J CARDIOL, V55, P631, DOI 10.1016/0002-9149(85)90126-2; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N	39	861	893	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					706	711		10.1056/NEJM199503163321103	http://dx.doi.org/10.1056/NEJM199503163321103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854377				2022-12-24	WOS:A1995QL78800003
J	ALLMAN, RM; GOODE, PS; PATRICK, MM; BURST, N; BARTOLUCCI, AA				ALLMAN, RM; GOODE, PS; PATRICK, MM; BURST, N; BARTOLUCCI, AA			PRESSURE ULCER RISK-FACTORS AMONG HOSPITALIZED-PATIENTS WITH ACTIVITY LIMITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SORES; SUPPORT; COHORT	Objective.-To identify specific demographic, medical, functional status, and nutritional characteristics that predict the development of stage 2 or greater pressure ulcers among patients whose activity is limited to bed or chair. Design.-Prospective inception cohort study. Setting.-Tertiary care, urban, university teaching hospital. Patients.-A total of 286 patients fulfilling the following criteria: admitted to the hospital within the previous 3 days, age 55 years or more, expected to be confined to bed or chair for at least 5 days or had a hip fracture, and without a stage 2 or greater pressure ulcer. Main Outcome Measure.-Time to in-hospital development of a stage 2 or greater pressure ulcer. Results.-Total cumulative incidence of pressure ulcers was 12.9% (n=37) after a median time of 9 days from admission to final skin examination. Age of 75 years or more, dry skin, nonblanchable erythema (a stage 1 pressure ulcer), previous pressure ulcer history, immobility, fecal incontinence, depleted triceps skinfold, lymphopenia (lymphocyte count <1.50x10(9)/L), and decreased body weight (<58 kg) were significantly associated with pressure ulcer development by univariate Kaplan-Meier survival analyses (P<.05 by log-rank test). Risk ratios (and 95% confidence intervals) for predictors (P less than or equal to.05) of pressure ulcer development after multivariable Cox regression analysis included the following: nonblanchable erythema, 7.52 (1.00 to 59.12); lymphopenia, 4.86 (1.70 to 13.89); immobility, 2.36 (1.14 to 4.85); dry skin, 2.31 (1.02 to 5.21); and decreased body weight, 2.18 (1.05 to 4.52). The 3-week cumulative incidence of pressure ulcers with none, one, two, or three or more of these characteristics was 0%, 11.4%, 39.6%, and 67.9%, respectively (P<.001 by log-rank test). Conclusions.-These results suggest that nonblanchable erythema, lymphopenia, immobility, dry skin, and decreased body weight are independent and significant risk factors for pressure ulcers in hospitalized patients whose activity is limited to bed or chair.	UNIV ALABAMA, DEPT MED, DIV GERONTOL & GERIATR MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOSTAT, BIRMINGHAM, AL 35294 USA; DEPT VET AFFAIRS MED CTR, BIRMINGHAM, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	ALLMAN, RM (corresponding author), UNIV ALABAMA, CTR AGING, 933 S 19TH ST, 201 CH-19, BIRMINGHAM, AL 35294 USA.		Allman, Richard M/D-5964-2011; Allman, Richard M./O-1693-2019	Allman, Richard M./0000-0002-1850-6515	NIA NIH HHS [5-R01-AG07178-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007178] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allman R M, 1989, Decubitus, V2, P30; ALLMAN RM, 1987, ANN INTERN MED, V107, P641, DOI 10.7326/0003-4819-107-5-641; ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; ANDERSEN KE, 1982, BMJ-BRIT MED J, V284, P1370, DOI 10.1136/bmj.284.6326.1370; [Anonymous], 1989, Decubitus, V2, P24; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; Braden B J, 1989, Decubitus, V2, P44; Braden BJ, 1989, DECUB J SKIN ULCERS, V2, P50; BRANDEIS GH, 1994, J AM GERIATR SOC, V42, P388, DOI 10.1111/j.1532-5415.1994.tb07486.x; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; EXTONSMITH A, 1961, LANCET, V2, P1124; Gilchrest BA., 1984, SKIN AGING PROCESSES; Gosnell D J, 1989, Decubitus, V2, P32; GOSNELL DJ, 1973, NURS RES, V22, P55; GURALNIK JM, 1988, J AM GERIATR SOC, V36, P807, DOI 10.1111/j.1532-5415.1988.tb04264.x; KEMP MG, 1993, RES NURS HEALTH, V16, P89, DOI 10.1002/nur.4770160203; KNAUS WA, 1981, JAMA-J AM MED ASSOC, V246, P2711, DOI 10.1001/jama.246.23.2711; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LOWTHIAN PT, 1976, BEDSORE BIOMECHANICS, P141; Norton D, 1975, INVESTIGATION GERIAT, P193; OKAMOTO GA, 1983, ARCH PHYS MED REHAB, V64, P20; Pennington JAT, 1985, FOOD VALUES PORTIONS; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; SHURAN M, 1986, GERIATRICS, V41, P48; SMITH DM, 1991, J GEN INTERN MED, V6, P81, DOI 10.1007/BF02599399; Stotts N A, 1988, Decubitus, V1, P24; WEINSIER R, 1989, HDB CLIN NUTRITION; 1992, PHS920047 US DEP HLT; 1985, 5TH PATIENT TYPE CLA	32	223	239	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					865	870		10.1001/jama.273.11.865	http://dx.doi.org/10.1001/jama.273.11.865			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869557				2022-12-24	WOS:A1995QL40200024
J	CAVANAUGH, AH; HEMPEL, WM; TAYLOR, LJ; ROGALSKY, V; TODOROV, G; ROTHBLUM, LI				CAVANAUGH, AH; HEMPEL, WM; TAYLOR, LJ; ROGALSKY, V; TODOROV, G; ROTHBLUM, LI			ACTIVITY OF RNA-POLYMERASE-I TRANSCRIPTION FACTOR UBF BLOCKED BY RB GENE-PRODUCT	NATURE			English	Article							CELL DIFFERENTIATION; PROTEIN; PHOSPHORYLATION; TRANSACTIVATION; BINDING; GROWTH	THE protein encoded by the retinoblastoma susceptibility gene (Rb) functions as a tumour suppressor and negative growth regulator(1). As actively growing cells require the ongoing synthesis of ribosomal RNA, we considered that Rb might interact with the ribosomal DNA transcription apparatus, Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket(2); and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro. This last observation was confirmed by affinity chromatography and immunoprecipitation, which demonstrated an interaction between Rb and UBF. These results indicate that there is an additional mechanism by which Rb suppresses cell growth, namely that Rb directly represses transcription of the rRNA genes.	GEISINGER MED CLIN,SIGFRIED & JANET WEIS CTR RES,DANVILLE,PA 17822; MT SINAI MED CTR,DIV NEOPLAST DIS,NEW YORK,NY 10029	Geisinger Medical Center; Icahn School of Medicine at Mount Sinai								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; NEVINS JR, 1992, SCIENCE, V258, P424; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; ROGALSKY V, 1993, BIOCHEM BIOPH RES CO, V192, P1139, DOI 10.1006/bbrc.1993.1535; ROGALSKY V, 1991, ANN NY ACAD SCI, V628, P323, DOI 10.1111/j.1749-6632.1991.tb17264.x; SCHNAPP G, 1994, EMBO J, V23, P190; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WAND CY, 1993, SCIENCE, V280, P1330	17	297	299	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					177	180		10.1038/374177a0	http://dx.doi.org/10.1038/374177a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877691				2022-12-24	WOS:A1995QL39700063
J	HORNE, JA; REYNER, LA				HORNE, JA; REYNER, LA			SLEEP-RELATED VEHICLE ACCIDENTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To assess the incidence, time of day, and driver morbidity associated with vehicle accidents where the most likely cause was the driver falling asleep at the wheel. Design-Two surveys were undertaken, in southwest England and the midlands, by using police databases or on the spot interviews. Subjects-Drivers involved in 679 sleep related vehicle accidents. Results-Of all vehicle accidents to which the police were summoned, sleep related vehicle accidents comprised 16% on major roads in southwest England, and over 20% on midland motorways. During the 24 hour period there were three major peaks: at around 0200, 0600, and 1600. About half these drivers were men under 30 years; few such accidents involved women. Conclusions-Sleep related vehicle accidents are largely dependent on the time of day and account for a considerable proportion of vehicle accidents, especially those on motorways and other monotonous roads. As there are no norms for the United Kingdom on road use by age and sex for time of day with which to compare these data, we cannot determine what the hourly exposure upsilon risk factors are for these subgroups. The findings are in close agreement with those from other countries.			HORNE, JA (corresponding author), LOUGHBOROUGH UNIV TECHNOL,DEPT HUMAN SCI,SLEEP RES LAB,LOUGHBOROUGH LE11 3TU,LEICS,ENGLAND.			Albery, Ian/0000-0002-5626-8677				AKERSTEDT T, 1994, J SLEEP RES, V3, P194; BRENDEL DH, 1990, PSYCHOPHYSIOLOGY, V27, P677, DOI 10.1111/j.1469-8986.1990.tb03193.x; HORNE JA, 1988, WHY WE SLEEP; LANGLOIS PH, 1986, CHRONOBIOL INT, V2, P131; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; MONK TH, 1991, SLEEPINESS SLEEP PER, P325; PACK AM, 1994, SLEEP RES, V23, P141; ZOMER J, 1990, SLEEP 90, P448; ZULLEY J, 1994, 248 KAR I STRESS RES, P104; 1994, ROAD ACCIDENTS GB 19	11	559	575	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					565	567		10.1136/bmj.310.6979.565	http://dx.doi.org/10.1136/bmj.310.6979.565			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888930	Green Published			2022-12-24	WOS:A1995QK70000018
J	LEE, JW; RYAN, F; SWAFFIELD, JC; JOHNSTON, SA; MOORE, DD				LEE, JW; RYAN, F; SWAFFIELD, JC; JOHNSTON, SA; MOORE, DD			INTERACTION OF THYROID-HORMONE RECEPTOR WITH A CONSERVED TRANSCRIPTIONAL MEDIATOR	NATURE			English	Article							26-S PROTEASE; TRANSACTIVATION; ACTIVATION; MODULATOR; DOMAIN; YEAST	THE thyroid-hormone receptors are hormone-dependent transcription factors that control expression of many target genes(1,2). This regulation is presumably a consequence of hormone-dependent contacts between the receptors and the basal transcription machinery(3). We used the yeast two-hybrid system(4,5) to identify a candidate human transcriptional mediator that interacts with both the thyroid-hormone receptor and the retinoid-X receptor in a ligand-dependent fashion. This protein, Trip1 (for thyroid-hormone-receptor Interacting protein), shares striking sequence conservation with the yeast transcriptional mediator Sug1 (refs 6, 7). Here we show that Trip1 can functionally substitute for Sug1 in yeast, and that both proteins interact in vitro with the thyroid-hormone receptor, acid with the transcriptional activation domains of yeast GAL4 and of herpes virus VP16.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LEE, JW (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,WELLMAN 9,BOSTON,MA 02114, USA.							BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BRENT GA, 1991, REV PHYSL, V53, P17; CARTER ME, 1994, MOL CELL BIOL, V14, P360; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; LEE JW, IN PRESS MOL ENDOCR; Moore DD, 1995, GLOB MOB SURV; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0	20	392	404	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					91	94		10.1038/374091a0	http://dx.doi.org/10.1038/374091a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870181				2022-12-24	WOS:A1995QK07900061
J	D'SOUZA-SCHOREY, C; LI, GP; COLOMBO, MI; STAHL, PD				D'SOUZA-SCHOREY, C; LI, GP; COLOMBO, MI; STAHL, PD			A REGULATORY ROLE FOR ARF6 IN RECEPTOR-MEDIATED ENDOCYTOSIS	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; GOLGI MEMBRANES; MUTAGENESIS; EXPRESSION; COATOMER; CELLS	Adenosine diphosphate-ribosylation factor 6 (ARF6), ARF6 mutants, and ARF1 were transiently expressed in Chinese hamster ovary cells, and the effects on receptor-mediated endocytosis were assessed. Overexpressed ARF6 localized to the cell periphery and led to a redistribution of transferrin receptors to the cell surface and a decrease in the rate of uptake of transferrin. Similar results were obtained when a mutant defective in guanosine triphosphate hydrolysis was expressed. Expression of a dominant negative mutant, ARF6(T27N), resulted in an intracellular distribution of transferrin receptors and an inhibition of transferrin recycling to the cell surface. In contrast, overexpression of ARF1 had little or no effect on these parameters of endocytosis.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Li, Guangpu/GRS-5397-2022; Stahl, Philip/D-6315-2012					BALCH WE, 1992, J BIOL CHEM, V267, P13053; BERON W, UNPUB; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DSOUZASCHOREY C, UNPUB; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LI GP, 1993, J BIOL CHEM, V268, P24475; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Sambrook J., 1989, MOL CLONING LAB MANU; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; Whitney J. A., 1993, Molecular Biology of the Cell, V4, p445A; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	25	365	369	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	1995	267	5201					1175	1178		10.1126/science.7855600	http://dx.doi.org/10.1126/science.7855600			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855600				2022-12-24	WOS:A1995QJ23700040
J	PAPHASSARANG, C; TOMSON, G; CHOPRAPAWON, C; WEERASURIYA, K				PAPHASSARANG, C; TOMSON, G; CHOPRAPAWON, C; WEERASURIYA, K			THE LAO NATIONAL DRUG POLICY - LESSONS ALONG THE JOURNEY	LANCET			English	Article									KAROLINSKA INST,DEPT INT HLTH & SOCIAL MED,INT HLTH CARE RES UNIT,S-17177 STOCKHOLM,SWEDEN; THAILAND HLTH RES INST,BANGKOK,THAILAND; UNIV COLOMBO,FAC MED,DEPT PHARMACOL,COLOMBO,SRI LANKA; MINIST PUBL HLTH,DEPT FOOD & DRUG,VIANGCHAN,LAOS	Karolinska Institutet; University of Colombo								CHETLEY A, 1994, LANCET, V343, P967; DUMOULIN J, 1994, LAO DRUG DATA BASE; FUNCK B, 1993, CHALLENGE EC REFORMM, P123; Hall P, 1975, CHANGE CHOICE CONFLI; HOGERZEIL HV, 1993, LANCET, V343, P1408; KINTANAR QL, 1992, PRESCRIPTION CHANGE, P32; MANGLA B, 1993, LANCET, V342, P608, DOI 10.1016/0140-6736(93)91424-K; PAPHASSARANG C, 1992, NATIONAL DRUG POLICY; PONGPRADITH S, 1993, DIARRHOEAL DISEASE C; REICH MR, 1994, HLTH POLICY PLANN, V9, P1; ROBLES A, 1992, PRESCRIPTION CHANGE; TOMSON G, 1986, LANCET, V2, P620; TOMSON G, 1992, NAIONAL DRUG POLICY; 1988, GUIDELINES DEV NATIO; 1994, REPORT BIENNIUM 1992; 1993, INVESTING HLTH WORLD; 1993, NATIONAL DRUG POLICY; 1994, LAO SOCIAL INDICATOR; 1992, ETHICAL CRITERIA MED	19	23	23	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					433	435		10.1016/S0140-6736(95)90408-5	http://dx.doi.org/10.1016/S0140-6736(95)90408-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853957				2022-12-24	WOS:A1995QG90400016
J	LUYAO, GL; GREENBERG, ER				LUYAO, GL; GREENBERG, ER			CHANGES IN PROSTATE-CANCER INCIDENCE AND TREATMENT IN USA	LANCET			English	Article							UNITED-STATES; SURVIVAL	We examined time trends and geographical variations in the detection and treatment of prostate cancer in USA, based on information from white men aged 50 to 79 who resided in areas covered by the Surveillance, Epidemiology, and End Results (SEER) program of the United States National Cancer Institute. Prostate-cancer incidence and treatment rates were determined for the 9 population-based cancer registries which participate in the SEER program. Prostate-cancer mortality rates were assessed from data compiled by the National Center for Health Statistics. Prostate cancer incidence rates increased by 6.4% per year between 1983 and 1989. The increase appeared to be due to detection of early-stage disease; there was no increase in the incidence rate of metastatic cancer. Incidence rates varied widely among the SEER program areas: in 1989 from 267.9 per 100 000 in Connecticut to 606.8 in Seattle. Radical prostatectomy rates more than tripled between 1983 and 1989 in the SEER areas as a whole. Among men aged 70-79, the rate of prostatectomy increased by nearly 35% per year. There was a five-fold variation among SEER areas in radical prostatectomy rates in 1989, with a low of 43.4 per 100 000 in Connecticut and a high of 224.4 in Seattle. Prostate cancer mortality rates did not increase during the period of study; there was little variation among areas in prostate-cancer mortality rates, and no apparent correlation between the incidence and mortality rates for an area. Increases in rates of prostate cancer incidence and prostate surgery have occurred in the United States without clear evidence that screening and prostectomy are effective in reducing mortality. Moreover, much of the growth in incidence and radical prostatectomy rates has occurred among older men, who appear least likely to benefit from early detection and surgery of occult prostate cancer.	DARTMOUTH COLL, SCH MED, CTR EVALUAT CLIN SCI, 7251 STRASENBURGH HALL, HANOVER, NH 03755 USA; DARTMOUTH COLL, NORRIS COTTON CANC CTR, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center				Lu-Yao, Grace/0000-0002-6017-9175	AHRQ HHS [HS06336] Funding Source: Medline; NCI NIH HHS [CA 23108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKNER M, 1985, J CHRON DIS, V38, P225, DOI 10.1016/0021-9681(85)90065-7; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; DEVESA SS, 1987, J NATL CANCER I, V79, P701; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; GARNICK MB, 1993, ANN INTERN MED, V118, P804, DOI 10.7326/0003-4819-118-10-199305150-00008; GIBBONS R P, 1988, NCI (National Cancer Institute) Monographs, P123; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; GOLDBLOOM R, 1991, CAN MED ASSOC J, V145, P413; GREENBERG ER, 1982, J NATL CANCER I, V68, P743; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LANGE PH, 1993, JAMA-J AM MED ASSOC, V269, P95, DOI 10.1001/jama.269.1.95; LEPOR H, 1988, NATL CANCER I MONOGR, V7, P117; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MILLER BA, 1992, CANCER STATISTICS RE; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; WALSH PC, 1987, J UROLOGY, V138, P823, DOI 10.1016/S0022-5347(17)43385-4; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676; WHITMORE WF, 1993, CANCER-AM CANCER SOC, V71, P970, DOI 10.1002/1097-0142(19930201)71:3+<970::AID-CNCR2820711412>3.0.CO;2-6; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P642; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P110; 1989, GUIDE CLIN PREVENTIV, P63; 1987, JAMA-J AM MED ASSOC, V258, P2727; 1993, J NATL CANCER I, V85, P947	28	207	207	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	1994	343	8892					251	254		10.1016/S0140-6736(94)91109-6	http://dx.doi.org/10.1016/S0140-6736(94)91109-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905093	hybrid			2022-12-24	WOS:A1994MT44000007
J	REES, M				REES, M			ON MENSTRUAL BLEEDING WITH HORMONE REPLACEMENT THERAPY	LANCET			English	Editorial Material							PROGESTOGEN; WOMEN				REES, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.							ANDERSSON K, 1992, OBSTET GYNECOL, V79, P963; CHRISTIANSEN C, 1990, BRIT J OBSTET GYNAEC, V97, P1087, DOI 10.1111/j.1471-0528.1990.tb02495.x; COOPE J, 1992, MATURITAS, V15, P151, DOI 10.1016/0378-5122(92)90249-4; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HAWTHORN RJS, 1991, BRIT J OBSTET GYNAEC, V98, P939, DOI 10.1111/j.1471-0528.1991.tb13519.x; MACLENNAN AH, 1993, MED J AUSTRALIA, V159, P102, DOI 10.5694/j.1326-5377.1993.tb137744.x; REES MCP, 1991, BRIT J OBSTET GYNAEC, V98, P106, DOI 10.1111/j.1471-0528.1991.tb10322.x; REES MCP, 1993, WOMENS PROBLEMS GENE, P171; SPORRONG T, 1992, BRIT J OBSTET GYNAEC, V99, P399, DOI 10.1111/j.1471-0528.1992.tb13757.x; STALAND B, 1981, MATURITAS, V3, P14	10	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					250	250		10.1016/S0140-6736(94)91108-8	http://dx.doi.org/10.1016/S0140-6736(94)91108-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905092				2022-12-24	WOS:A1994MT44000006
J	PERSSON, MG; ZETTERSTROM, O; AGRENIUS, V; IHRE, E; GUSTAFSSON, LE				PERSSON, MG; ZETTERSTROM, O; AGRENIUS, V; IHRE, E; GUSTAFSSON, LE			SINGLE-BREATH NITRIC-OXIDE MEASUREMENTS IN ASTHMATIC-PATIENTS AND SMOKERS	LANCET			English	Note							GUINEA-PIGS; HUMANS	Exhaled nitric oxide (NO) concentrations were measured in asthmatic outpatients and in non-smoking and smoking healthy controls. In single exhalations, NO showed a peak suggestive of airway origin in both controls and asthmatic patients. The peak NO concentration was higher in asthmatic patients and lower in smokers than in non-smoking controls (p<0.05). The findings support a role for NO in the host defence response in asthma and suggest that NO measurements can discriminate between different types of lung disorders.	KAROLINSKA INST,DEPT PHYSIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,INST ENVIRONM SCI,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA HOSP,DEPT THORAC MED,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital			Gustafsson, Lars E/E-6950-2013					BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BOUSQUET J, 1992, ALLERGY, V47, P129, DOI 10.1111/j.1398-9995.1992.tb00952.x; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; JORENS PG, 1993, EUR RESPIR J, V6, P258; NORMAN V, 1965, NATURE, V205, P915, DOI 10.1038/205915b0; PERSSON MG, 1993, AM REV RESPIR DIS, V148, P1210, DOI 10.1164/ajrccm/148.5.1210; PERSSON MG, 1993, ACTA PHYSIOL SCAND, V149, P461, DOI 10.1111/j.1748-1716.1993.tb09643.x; PERSSON MG, 1993, EUR J PHARMACOL, V249, P7	9	413	425	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					146	147		10.1016/S0140-6736(94)90935-0	http://dx.doi.org/10.1016/S0140-6736(94)90935-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904005				2022-12-24	WOS:A1994MQ86900011
J	URNOVITZ, HB; CLERICI, M; SHEARER, GM; GOTTFRIED, TD; ROBISON, DJ; LUTWICK, LI; MONTAGNIER, L; LANDERS, DV				URNOVITZ, HB; CLERICI, M; SHEARER, GM; GOTTFRIED, TD; ROBISON, DJ; LUTWICK, LI; MONTAGNIER, L; LANDERS, DV			HIV-1 ANTIBODY SERUM NEGATIVITY WITH URINE POSITIVITY	LANCET			English	Note								7 individuals who were negative for HIV-1 antibody in a licensed serum enzyme immunoassay (EIA) were positive in a urine EIA and western blot (WB). Follow-up in individuals by use of a cell-mediated immune response showed 1 positive and 1 negative for HIV-1 peptide reactivity. In a second study, 4 out of 5 subjects positive by urine EIA and indeterminate or negative by serum WB were HIV-1 peptide positive in the cell-mediated immune test. Comparison of cell-mediated responses with urine antibody responses may help to resolve discrepant HIV-1 results.	MAIMONIDES HOSP,BROOKLYN,NY 11219; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; INST PASTEUR,F-75724 PARIS 15,FRANCE; NCI,BETHESDA,MD 20892	Maimonides Medical Center; University of California System; University of California San Francisco; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	URNOVITZ, HB (corresponding author), CALYPTE BIOMED CORP,BERKELEY,CA 94710, USA.			Clerici, Mario/0000-0001-5920-6191				BAUER G, 1992, LANCET, V340, P559, DOI 10.1016/0140-6736(92)91763-X; CAO YZ, 1988, LANCET, V1, P831; CHAMARET S, 1992, 8 INT C AIDS AMST; CHEINGSONGPOPOV R, 1993, LANCET, V341, P1659, DOI 10.1016/0140-6736(93)90789-J; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553	8	24	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1458	1459		10.1016/0140-6736(93)92934-L	http://dx.doi.org/10.1016/0140-6736(93)92934-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902483				2022-12-24	WOS:A1993ML21700010
J	GARATTINI, S; GARATTINI, L				GARATTINI, S; GARATTINI, L			PHARMACEUTICAL PRESCRIPTIONS IN 4 EUROPEAN COUNTRIES	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), MARIO NEGRI INST PHARMACOL RES,CTR ECON SANIT A VALENTI,I-20157 MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297					0	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1191	1192		10.1016/0140-6736(93)92181-R	http://dx.doi.org/10.1016/0140-6736(93)92181-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901525				2022-12-24	WOS:A1993MG27400005
J	MUERS, M				MUERS, M			UNDERSTANDING BREATHLESSNESS	LANCET			English	Editorial Material							AIR HUNGER				MUERS, M (corresponding author), KILLINGBECK HOSP,RESP UNIT,LEEDS,ENGLAND.							BANZETT RB, 1990, RESP PHYSIOL, V81, P1, DOI 10.1016/0034-5687(90)90065-7; BANZETT RB, 1989, RESP PHYSIOL, V76, P53, DOI 10.1016/0034-5687(89)90017-0; CAMPBELL EJ, 1969, CLIN SCI, V36, P323; DAVIS JN, 1967, CLIN SCI, V33, P249; FOWLER WS, 1954, J APPL PHYSIOL, V6, P539, DOI 10.1152/jappl.1954.6.9.539; GANDEVIA SC, 1993, J PHYSIOL-LONDON, V470, P85, DOI 10.1113/jphysiol.1993.sp019849; HOWELL JBL, 1990, THORAX, V45, P287, DOI 10.1136/thx.45.4.287; HOWELL JBL, 1970, HERRINGBREUER CENTEN, P287; HOWELL JBL, 1990, BREATHLESSNESS, P221; MCCLOSKEY DI, 1981, HDB PHYSL NERVOUS SY, V2, P1415; Merton P A, 1964, Symp Soc Exp Biol, V18, P387	11	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1190	1191		10.1016/0140-6736(93)92180-2	http://dx.doi.org/10.1016/0140-6736(93)92180-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901524				2022-12-24	WOS:A1993MG27400004
J	GLYNN, RJ; FIELD, TS; ROSNER, B; HEBERT, PR; TAYLOR, JO; HENNEKENS, CH				GLYNN, RJ; FIELD, TS; ROSNER, B; HEBERT, PR; TAYLOR, JO; HENNEKENS, CH			EVIDENCE FOR A POSITIVE LINEAR RELATION BETWEEN BLOOD-PRESSURE AND MORTALITY IN ELDERLY PEOPLE	LANCET			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; HYPERTENSION; RISK; REDUCTION; SURVIVAL	Many studies of blood pressure in the elderly have found higher death rates in groups with the lowest blood pressure than in those with intermediate values. In a large community study, we examined whether these findings are real or artifacts of short follow-up, co-morbidity, or low blood pressure in people near death. In 1982-83, we assessed drug use, medical history, disability, physical function, and blood pressure in 3657 residents of East Boston, Massachusetts, aged 65 and older. We identified all deaths (1709) up to 1992 and followed up survivors for an average of 10.5 (range 9.5-11.0) years. After adjustment for confounding variables (including frailty and disorders such as congestive heart failure and myocardial infarction) and exclusion of deaths within the first 3 years of follow-up, higher systolic pressure predicted linear increases in cardiovascular (p<0.0001) and total (p<0.0007) mortality. Higher diastolic pressure predicted increases in cardiovascular (p=0.006) but not total (p=0.48) mortality. These results differed from those for the first 3 years, during which groups with the lowest systolic and diastolic pressures had the highest death rates. In the long term, lower blood pressure in old age, as in middle age, is associated with better survival. Short-term findings may differ because of associations of co-morbidity and frailty with blood pressure near death. Overall, the findings support recommendations to treat high blood pressure in elderly people.	BRIGHAM & WOMENS HOSP, E BOSTON NEIGHBOURHOOD HLTH CTR, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	GLYNN, RJ (corresponding author), BRIGHAM & WOMENS HOSP, DIV PREVENT MED, BOSTON, MA 02215 USA.				NIA NIH HHS [AG12106, AG02107] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; [Anonymous], 1991, JAMA, V265, P3255; Benfante R, 1992, Ann Epidemiol, V2, P273; BISHOP YM, 1980, DISCRETE MULTIVARIAT, P492; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BULPITT CJ, 1992, J HYPERTENSION S7, V10, P545; COOPE J, 1988, J HUM HYPERTENS, V2, P79; COOPE J, 1987, LANCET, V1, P1380; CORNONIHUNTLEY JC, 1986, NIH862443 PUBL; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; FRY J, 1974, LANCET, V2, P431; GLYNN RJ, 1993, AM J EPIDEMIOL, V138, P365, DOI 10.1093/oxfordjournals.aje.a116869; HARRIS T, 1985, HYPERTENSION, V7, P118, DOI 10.1161/01.HYP.7.1.118; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; HUGHES MD, 1993, BIOMETRICS, V49, P1056, DOI 10.2307/2532247; LANGER RD, 1989, BRIT MED J, V298, P1356, DOI 10.1136/bmj.298.6684.1356; LINDHOLM L, 1986, FAM PRACT, V3, P3, DOI 10.1093/fampra/3.1.3; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; SIEGEL D, 1987, AM J EPIDEMIOL, V126, P385, DOI 10.1093/oxfordjournals.aje.a114670; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; TAYLOR JO, 1991, AM J EPIDEMIOL, V134, P489, DOI 10.1093/oxfordjournals.aje.a116121; 1994, HLTH US 1993; 1978, J CHRON DIS, V31, P651	30	148	150	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	1995	345	8953					825	829		10.1016/S0140-6736(95)92964-9	http://dx.doi.org/10.1016/S0140-6736(95)92964-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898229				2022-12-24	WOS:A1995QQ19500009
J	MENDEL, JE; KORSWAGEN, HC; LIU, KS; HAJDUCRONIN, YM; SIMON, MI; PLASTERK, RHA; STERNBERG, PW				MENDEL, JE; KORSWAGEN, HC; LIU, KS; HAJDUCRONIN, YM; SIMON, MI; PLASTERK, RHA; STERNBERG, PW			PARTICIPATION OF THE PROTEIN G(O) IN MULTIPLE ASPECTS OF BEHAVIOR IN C-ELEGANS	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NUCLEOTIDE-BINDING PROTEIN; ESCHERICHIA-COLI; ALPHA-SUBUNITS; GS-ALPHA; EXPRESSION; MUTANTS; G0; GO; RECEPTORS	The goa-1 gene encoding the alpha subunit of the heterotrimeric guanosine triphosphate-binding protein (G protein) G(o) from Caenorhabditis elegans is expressed in most neurons, and in the muscles involved in egg laying and male mating, Reduction-of-function mutations in goa-1 caused a variety of behavioral defects including hyperactive movement, premature egg laying, and male impotence, Expression of the activated G(o) alpha subunit (G alpha(o)) in transgenic nematodes resulted in lethargic movement, delayed egg laying, and reduced mating efficiency, Induced expression of activated G alpha(o) in adults was sufficient to cause these phenotypes, indicating that G alpha(o) mediates behavior through its role in neuronal function and the functioning of specialized muscles.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL,PASADENA,CA 91125; NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; Netherlands Cancer Institute			Korswagen, Hendrik/I-8782-2012	Sternberg, Paul/0000-0002-7699-0173				BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1983, GENETICS, V103, P43; HUFF RM, 1985, J BIOL CHEM, V260, P864; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1995, IN PRESS METHODS CEL; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; SCHMIDT CJ, 1989, CELL REGUL, V1, P125, DOI 10.1091/mbc.1.1.125; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; STRETTON AOW, 1985, TRENDS NEUROSCI, V8, P294, DOI 10.1016/0166-2236(85)90105-5; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TRENT C, 1983, GENETICS, V104, P619; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4561, DOI 10.1073/pnas.83.12.4561; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	33	204	210	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1652	1655		10.1126/science.7886455	http://dx.doi.org/10.1126/science.7886455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886455				2022-12-24	WOS:A1995QM39700039
J	SCHOTLAND, J; SHUPLIAKOV, O; WIKSTROM, M; BRODIN, L; SRINIVASAN, M; YOU, ZB; HERRERAMARSCHITZ, M; ZHANG, WQ; HOKFELT, T; GRILLNER, S				SCHOTLAND, J; SHUPLIAKOV, O; WIKSTROM, M; BRODIN, L; SRINIVASAN, M; YOU, ZB; HERRERAMARSCHITZ, M; ZHANG, WQ; HOKFELT, T; GRILLNER, S			CONTROL OF LAMPREY LOCOMOTOR NEURONS BY COLOCALIZED MONOAMINE TRANSMITTERS	NATURE			English	Article							SPINAL-CORD; RAT STRIATUM; 5-HYDROXYTRYPTAMINE; SEROTONIN; DOPAMINE; AFTERHYPERPOLARIZATION; INVIVO	NEURONS in the central nervous system (CNS) often store more than one neurotransmitter(1,2), but as yet the functional significance of this type of coexistence is poorly understood. 5-Hydroxytryptamine (5-HT) modulates calcium-dependent K+ channels (K-Ca) responsible for the postspike afterhyperpolarization in different regions of the CNS3,4. In lamprey, 5-HT neurons control apamine-sensitive K-Ca channels in spinal locomotor network interneurons(4-6), thereby in addition regulating the duration of locomotor bursts(7,8). We report here that these spinal 5-HT neurons also contain dopamine. Like 5-HT, dopamine causes a reduction of the afterhyperpolarization, but in this case it is due to a reduction of calcium entry during the action potential, which results in a reduced activation of Kc,. 5-HT and dopamine are both released from these midline neurons, and both reduce the afterhyperpolarization through two distinctly different, but complementary cellular mechanisms. The net effect of dopamine (10-100 mu M) on the locomotor network is similar to that of 5-HT, and the effects of dopamine and 5-HT are additive at the network level.	KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,DEPT NEUROPHYSIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,DEPT PHARMACOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet			Shupliakov, Oleg/R-9148-2016	Shupliakov, Oleg/0000-0001-5352-6848				BRODIN L, 1990, BRAIN RES, V508, P172, DOI 10.1016/0006-8993(90)91134-3; BRODIN L, 1986, NEUROSCI LETT, V67, P53, DOI 10.1016/0304-3940(86)90207-7; CHRISTENSON J, 1989, NEUROSCI LETT, V100, P188, DOI 10.1016/0304-3940(89)90682-4; CHURCH PJ, 1993, J NEUROSCI, V13, P2790; Cuello A. C., 1982, COTRANSMISSION; CUMMING P, 1992, J NEUROCHEM, V59, P1905, DOI 10.1111/j.1471-4159.1992.tb11026.x; DEDEK J, 1979, J NEUROCHEM, V33, P687, DOI 10.1111/j.1471-4159.1979.tb05213.x; HARRISWARRICK RM, 1985, J EXP BIOL, V116, P27; HARRISWARRICK RM, 1985, NEUROSCIENCE, V14, P1127, DOI 10.1016/0306-4522(85)90282-9; HERRERAMARSCHIT.M, 1992, AMINO ACIDS, V2, P157; HILL RH, 1985, BRAIN RES, V358, P40, DOI 10.1016/0006-8993(85)90946-1; HOKFELT T, 1987, SYNAPTIC FUNCTION, P179; MATSUSHIMA T, 1992, J NEUROPHYSIOL, V67, P1683, DOI 10.1152/jn.1992.67.6.1683; NOMIKOS GG, 1992, NEUROPSYCHOPHARMACOL, V7, P7; SCHOTLAND JL, 1993, EXP BRAIN RES, V93, P391; SCHWINDT PC, 1992, J NEUROPHYSIOL, V67, P216, DOI 10.1152/jn.1992.67.1.216; SHARP T, 1986, J NEUROCHEM, V47, P113; STEINBUSCH HWM, 1991, NATO ASI SERIES, V58; VANDONGEN PAM, 1986, BRAIN RES, V366, P320; VANDONGEN PAM, 1985, J COMP NEUROL, V234, P501, DOI 10.1002/cne.902340408; VERHOFSTAD AAJ, 1983, CYTOCHEMISTRY PRACTI; VIGH B, 1983, CELL TISSUE RES, V231, P615, DOI 10.1007/BF00218119; WALLEN P, 1989, J NEUROPHYSIOL, V61, P759, DOI 10.1152/jn.1989.61.4.759	23	87	89	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					266	268		10.1038/374266a0	http://dx.doi.org/10.1038/374266a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885446				2022-12-24	WOS:A1995QM38700051
J	CHIBA, A; SNOW, P; KESHISHIAN, H; HOTTA, Y				CHIBA, A; SNOW, P; KESHISHIAN, H; HOTTA, Y			FASCICLIN-III AS A SYNAPTIC TARGET RECOGNITION MOLECULE IN DROSOPHILA	NATURE			English	Article							CELL-ADHESION MOLECULE; GROWTH CONE GUIDANCE; NEURONAL RECOGNITION; GENETIC-ANALYSIS; MOTONEURONS; MUSCLES; MELANOGASTER; MUTATIONS; COLLAPSE; PROTEIN	FASCICLIN III, a cell adhesion molecule of the immunoglobulin superfamily(1-3), is expressed by motor neuron RP3 and its synaptic targets (muscle cells 6 and 7) during embryonic neuromuscular development of Drosophila(4). We report here that RP3 often incorrectly innervates neighbouring non-target muscle cells when these cells misexpress fasciclin In, but still innervates normal targets in the fasciclin III null mutant, Fasciclin III manipulations do not influence target selections by other motor neurons, including fasciclin III-expressing RP1, We propose that fasciclin III acts as a synaptic target recognition molecule for motor neuron RP3, and also that its absence can be compensated for by other molecule(s).	UNIV TOKYO,GRAD SCH SCI,DEPT PHYS,TOKYO 113,JAPAN; NATL INST BASIC BIOL,CELLULAR COMMUN LAB,OKAZAKI,AICHI 444,JAPAN; SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); State University of New York (SUNY) System; State University of New York (SUNY) Albany; Yale University								BROADIE K, 1993, NATURE, V361, P350, DOI 10.1038/361350a0; CASH S, 1992, J NEUROSCI, V12, P2051; CHIBA A, 1993, J NEUROSCI, V13, P714; CRIPPS RM, 1994, J CELL BIOL, V126, P689, DOI 10.1083/jcb.126.3.689; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; KANIA A, 1993, NEURON, V11, P673, DOI 10.1016/0896-6273(93)90078-6; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, TRENDS NEUROSCI, V16, P278, DOI 10.1016/0166-2236(93)90182-L; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCALLISTER L, 1992, DEVELOPMENT, V115, P267; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RUBIN GM, 1982, SCIENCE, V218, P341; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WASSENBERG DR, 1987, J BIOL CHEM, V262, P10741; WHITLOCK KE, 1993, DEVELOPMENT, V117, P1251; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	29	110	110	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					166	168		10.1038/374166a0	http://dx.doi.org/10.1038/374166a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877688				2022-12-24	WOS:A1995QL39700060
J	KOBE, B; DEISENHOFER, J				KOBE, B; DEISENHOFER, J			A STRUCTURAL BASIS OF THE INTERACTIONS BETWEEN LEUCINE-RICH REPEATS AND PROTEIN LIGANDS	NATURE			English	Article							PORCINE RIBONUCLEASE INHIBITOR; CRYSTAL-STRUCTURE; MOTIF	THE leucine-rich repeat is a recently characterized structural motif(1) used in molecular recognition processes as diverse as signal transduction, cell adhesion, cell development, DNA repair and RNA processing(2). We present here the crystal structure at 2.5 Angstrom resolution of the complex between ribonuclease A and ribonculease inhibitor, a protein built entirely of leucine-rich repeats, The unusual non-globular structure of ribonuclease inhibitor, its solvent-exposed parallel beta-sheet and the conformational flexibility of the structure are used in the interaction; they appear to be the principal reasons for the effectiveness of leucine-rich repeats as protein-binding motifs, The structure can serve as a model for the interactions of other proteins containing leucine-rich repeats with their ligands.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Kobe, Bostjan/D-1292-2009	Kobe, Bostjan/0000-0001-9413-9166				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AVEY HP, 1967, NATURE, V11, P557; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BIRDSALL DL, 1992, J BIOL CHEM, V267, P22230; BORKAKOTI N, 1983, EUR J BIOCHEM, V132, P89, DOI 10.1111/j.1432-1033.1983.tb07329.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DAVIES D R, 1992, Current Biology, V2, P254, DOI 10.1016/0960-9822(92)90369-L; FOMINAYA JM, 1992, J BIOL CHEM, V267, P24655; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KARTHA G, 1967, NATURE, V213, P862, DOI 10.1038/213862a0; KOBE B, 1994, J MOL BIOL, V241, P288, DOI 10.1006/jmbi.1994.1502; KOBE B, 1993, J MOL BIOL, V231, P137, DOI 10.1006/jmbi.1993.1263; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NACHMAN J, 1990, BIOCHEMISTRY-US, V29, P928, DOI 10.1021/bi00456a012; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROTH JS, 1956, BIOCHIM BIOPHYS ACTA, V21, P34, DOI 10.1016/0006-3002(56)90091-9; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; VOCENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	30	565	604	3	38	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					183	186		10.1038/374183a0	http://dx.doi.org/10.1038/374183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877692				2022-12-24	WOS:A1995QL39700065
J	MCGRATH, MA; HALL, DT; MATHESON, PL; WEAVER, HA; TRAUGER, JT; SMITH, TE; THOMAS, N; GLADSTONE, R; SCHNEIDER, NM; HARRIS, WM; LIVENGOOD, TA; PRANGE, R; FESTOU, MC				MCGRATH, MA; HALL, DT; MATHESON, PL; WEAVER, HA; TRAUGER, JT; SMITH, TE; THOMAS, N; GLADSTONE, R; SCHNEIDER, NM; HARRIS, WM; LIVENGOOD, TA; PRANGE, R; FESTOU, MC			RESPONSE OF THE IO-PLASMA TORUS TO COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article								Spectroscopic and imaging observations of the lo plasma torus were made in June and July 1994 in conjunction with the encounter of periodic comet Shoemaker-Levy 9 with Jupiter, Characteristic emissions from sulfur and oxygen ions showed a decline of about 30 percent in the extreme ultraviolet and an increase of about 40 percent in the far ultraviolet relative to preimpact observations. Changes in the extreme ultraviolet may be indicative of small changes in the torus electron temperature as a result of quenching of electrons by dust associated with the comet passage. However, no new emission features indicative of fragment dust within the torus were detected. The characteristic torus morphology seen in ground-based imaging was typical of that observed in the past.	JOHNS HOPKINS UNIV,DEPT PHYS & ASTRON,BALTIMORE,MD 21218; UNIV SO CALIF,DEPT AEROSP ENGN,LOS ANGELES,CA 90089; JET PROPULS LAB,PASADENA,CA 91109; MAX PLANCK INST AERON,W-3411 KATLENBURG DUHM,GERMANY; SW RES INST,SAN ANTONIO,TX 78238; UNIV COLORADO,ASTRON & SPACE PHYS LAB,BOULDER,CO 80309; UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771; INST ASTROPHYS SPATIALE,ORSAY,FRANCE; OBSERV MIDI PYRENEES,NATL CTR SCI RES,F-31400 TOULOUSE,FRANCE	Johns Hopkins University; University of Southern California; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Max Planck Society; Southwest Research Institute; University of Colorado System; University of Colorado Boulder; University of Michigan System; University of Michigan; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	MCGRATH, MA (corresponding author), SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218, USA.		Weaver, Harold A/D-9188-2016; Livengood, Timothy A/C-8512-2012	Weaver, Harold A/0000-0003-0951-7762; SCHNEIDER, NICHOLAS/0000-0001-6720-5519				CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; DEPATER I, 1994, B AM ASTRON SOC, V26, P4; DESSLER AJ, 1994, GEOPHYS RES LETT, V21, P1043, DOI 10.1029/94GL01294; GRUN E, 1994, GEOPHYS RES LETT, V21, P1035, DOI 10.1029/94GL00701; Grun E., 1984, PLANETARY RINGS; HALL DT, 1994, ASTROPHYS J, V426, pL51, DOI 10.1086/187337; HERBERT F, 1994, GEOPHYS RES LETT, V21, P1047, DOI 10.1029/94GL00884; HORANYI M, 1994, GEOPHYS RES LETT, V21, P1039, DOI 10.1029/94GL01326; MCGRATH MA, 1993, ASTROPHYS J, V415, pL55, DOI 10.1086/187031; MOOS HW, 1985, ASTROPHYS J, V294, P369, DOI 10.1086/163304; MORFILL GE, 1993, J GEOPHYS RES-SPACE, V98, P1435, DOI 10.1029/92JA01951; SCHNEIDER NM, 1991, SCIENCE, V253, P1394, DOI 10.1126/science.253.5026.1394; SCHNEIDER NM, UNPUB; SEKANINA Z, 1994, ASTRON ASTROPHYS, V289, P607; THOMAS N, 1993, J GEOPHYS RES-PLANET, V98, P18737, DOI 10.1029/93JE01461; TRAUGER JT, 1984, SCIENCE, V226, P337, DOI 10.1126/science.226.4672.337; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424	17	10	10	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1313	1317		10.1126/science.7871429	http://dx.doi.org/10.1126/science.7871429			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871429				2022-12-24	WOS:A1995QK06800034
J	AKERLEY, BJ; COTTER, PA; MILLER, JF				AKERLEY, BJ; COTTER, PA; MILLER, JF			ECTOPIC EXPRESSION OF THE FLAGELLAR REGULON ALTERS DEVELOPMENT OF THE BORDETELLA HOST INTERACTION	CELL			English	Article							VIRULENCE FACTORS; SALMONELLA-TYPHIMURIUM; SENSORY TRANSDUCTION; REPRESSED GENE; BVG-LOCUS; PERTUSSIS; SEQUENCES; PROTEINS; BRONCHISEPTICA; IDENTIFICATION	Signal transduction molecules within the two-component family represent a conserved adaptation for the control of genes involved in pathogenesis. The Bordetella virulence control locus, bvgAS, activates and represses gene expression in response to environmental signals. While infection requires virulence gene activation, the role of gene repression during infection is not understood. By altering regulatory genes and reversing regulatory connections, we found evidence that the BvgAS-repressed genes responsible for motility are neither required nor expressed during colonization of the host. Expression of this Bvg(-) phase-specific phenotype in the Bvg(+) growth phase resulted in a defect in tracheal colonization. Therefore, BvgAS promotes virulence both by activating genes required for colonization and by repressing genes that inhibit the development of infection.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles			Akerley, Brian/AAD-6668-2020; Akerley, Brian/B-7343-2008; Akerley, Brian/ABH-6977-2020	Akerley, Brian/0000-0002-8142-7035; Akerley, Brian/0000-0002-8142-7035; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008747] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08747, AI07323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERLEY BJ, 1993, J BACTERIOL, V175, P3468, DOI 10.1128/jb.175.11.3468-3479.1993; AKERLEY BJ, 1992, J BACTERIOL, V174, P980, DOI 10.1128/jb.174.3.980-990.1992; ARICO B, 1989, P NATL ACAD SCI USA, V86, P6671, DOI 10.1073/pnas.86.17.6671; ARICO B, 1991, MOL MICROBIOL, V5, P2481, DOI 10.1111/j.1365-2958.1991.tb02093.x; BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BEATTIE DT, 1992, INFECT IMMUN, V60, P571, DOI 10.1128/IAI.60.2.571-577.1992; BEATTIE DT, 1990, J BACTERIOL, V172, P6997, DOI 10.1128/jb.172.12.6997-7004.1990; BEHLAU I, 1993, J BACTERIOL, V175, P4475, DOI 10.1128/JB.175.14.4475-4484.1993; BOUCHER PE, 1994, J MOL BIOL, V241, P363, DOI 10.1006/jmbi.1994.1513; COTTER PA, 1994, INFECT IMMUN, V62, P3381, DOI 10.1128/IAI.62.8.3381-3390.1994; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENG P, 1990, J GEN MICROBIOL, V136, P337, DOI 10.1099/00221287-136-2-337; GRAF J, 1994, J BACTERIOL, V176, P6986, DOI 10.1128/JB.176.22.6986-6991.1994; HARLOW E, 1988, ANTIBODIES LABORATOR; JONES BD, 1992, INFECT IMMUN, V60, P2475, DOI 10.1128/IAI.60.6.2475-2480.1992; KOMEDA Y, 1982, J BACTERIOL, V150, P16, DOI 10.1128/JB.150.1.16-26.1982; LACEY B. W., 1960, JOUR HYG, V58, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XY, 1994, J BACTERIOL, V176, P7345, DOI 10.1128/JB.176.23.7345-7351.1994; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MILLER JF, 1992, J BACTERIOL, V174, P970, DOI 10.1128/jb.174.3.970-979.1992; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MULLER M, 1993, NUCLEIC ACIDS RES, V21, P3320, DOI 10.1093/nar/21.14.3320; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; REID JL, 1987, GENE, V57, P239; ROY CR, 1991, J BACTERIOL, V173, P2385, DOI 10.1128/JB.173.7.2385-2392.1991; ROY CR, 1990, P NATL ACAD SCI USA, V87, P3763, DOI 10.1073/pnas.87.10.3763; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARLATO V, 1990, P NATL ACAD SCI USA, V87, P6753, DOI 10.1073/pnas.87.17.6753; SCHMITT CK, 1994, J BACTERIOL, V176, P368, DOI 10.1128/JB.176.2.368-377.1994; SILVERMAN M, 1977, J BACTERIOL, V120, P1196; STAINER DW, 1971, J GEN MICROBIOL, V63, P211; STIBITZ S, 1989, NATURE, V338, P266, DOI 10.1038/338266a0; STIBITZ S, 1991, J BACTERIOL, V173, P4288, DOI 10.1128/JB.173.14.4288-4296.1991; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; UHL MA, 1994, P NATL ACAD SCI USA, V91, P1163, DOI 10.1073/pnas.91.3.1163; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983	39	211	219	2	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					611	620		10.1016/0092-8674(95)90515-4	http://dx.doi.org/10.1016/0092-8674(95)90515-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867068	Bronze			2022-12-24	WOS:A1995QJ60200013
J	GILBERT, SP; WEBB, MR; BRUNE, M; JOHNSON, KA				GILBERT, SP; WEBB, MR; BRUNE, M; JOHNSON, KA			PATHWAY OF PROCESSIVE ATP HYDROLYSIS BY KINESIN	NATURE			English	Article							ADP RELEASE; MICROTUBULES; MOVEMENT; MYOSIN; MOTOR; IDENTIFICATION; SUBFRAGMENT-1; ACTOMYOSIN; MOLECULES; MOTILITY	Direct measurement of the kinetics of kinesin dissociation from microtubules, the release of phosphate and ADP from kinesin, and rebinding of kinesin to the microtubule have defined the mechanism for the kinesin ATPase cycle. The processivity of ATP hydrolysis is ten molecules per site at low salt concentration but is reduced to one ATP per site at higher salt concentration. Kinesin dissociates from the microtubule after ATP hydrolysis. This step is rate-limiting. The subsequent rebinding of kinesin ADP to the microtubule is fast, so kinesin spends only a small fraction of its duty cycle in the dissociated state. These results provide an explanation for the motility differences between skeletal myosin and kinesin.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; MRC National Institute for Medical Research				Webb, Martin/0000-0002-0134-9621	NIGMS NIH HHS [R01 GM026726] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026726] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GREENE LE, 1980, J BIOL CHEM, V255, P543; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SADHU A, 1992, J BIOL CHEM, V267, P11352; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TAYLOR EW, 1992, HEART CARDIOVASCULAR, P1281; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	24	256	257	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					671	676		10.1038/373671a0	http://dx.doi.org/10.1038/373671a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854446	Green Accepted			2022-12-24	WOS:A1995QH92800045
J	LELLOUCH, E; PAUBERT, G; MORENO, R; FESTOU, MC; BEZARD, B; BOCKELEEMORVAN, D; COLOM, P; CROVISIER, J; ENCRENAZ, T; GAUTIER, D; MARTEN, A; DESPOIS, D; STROBEL, DF; SIEVERS, A				LELLOUCH, E; PAUBERT, G; MORENO, R; FESTOU, MC; BEZARD, B; BOCKELEEMORVAN, D; COLOM, P; CROVISIER, J; ENCRENAZ, T; GAUTIER, D; MARTEN, A; DESPOIS, D; STROBEL, DF; SIEVERS, A			CHEMICAL AND THERMAL RESPONSE OF JUPITER ATMOSPHERE FOLLOWING THE IMPACT OF COMET SHOEMAKER-LEVY-9	NATURE			English	Article							MILLIMETER	July 1994, the collisions of the fragments of comet Shoemaker-Levy 9 with Jupiter resulted in dramatic changes in the planet's atmosphere. Observations of the events suggest that the composition and thermal properties of the atmosphere were considerably modified at the impact sites, with the changes persisting for times lasting from minutes to weeks (see, for example, refs 1-4). Here we report observations of the impact sites at millimetre wavelengths, which reveal strong emission lines associated with carbon monoxide, carbonyl sulphide and carbon monosulphide. The abundance of carbon monoxide in the jovian atmosphere is normally very low(5); carbonyl sulphide and carbon monosulphide, on the other hand, have not hitherto been detected, We find that the largest fragments (G and K) each produced approximately 10(14) g of carbon monoxide, 3 x 10(12) g of carbonyl sulphide and 3 x 10(11) g of carbon monosulphide, most probably by shock-induced chemical reactions(6). Our observations also place firm constraints on the thermal response of Jupiter's stratosphere to the impacts.	IRAM, E-18012 GRANADA, SPAIN; OBSERV MIDI PYRENEES, F-31400 TOULOUSE, FRANCE; OBSERV BORDEAUX, F-33270 FLOIRAC, FRANCE; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Johns Hopkins University	LELLOUCH, E (corresponding author), OBSERV PARIS, F-92195 MEUDON, FRANCE.		Strobel, Darrell5/AAO-6643-2021	Strobel, Darrell5/0000-0002-0944-8675; Bezard, Bruno/0000-0002-5433-5661; Gorski, Andrzej/0000-0002-0863-6041				ALLEN M, 1992, ICARUS, V100, P527, DOI 10.1016/0019-1035(92)90115-N; BJORAKER GL, IN PRESS B AM ASTR S; BOCKELEEMORVAN D, IN PRESS B AM ASTR S; BROOKE T, IN PRESS B AM ASTR S; BROSSMAN AW, IN PRESS B AM ASTR S; ENCRENAZ T, IN PRESS B AM ASTR S; GLADSTONE GR, 1987, SP494 NASA, P221; GRIFFIN MJ, 1986, ICARUS, V65, P244, DOI 10.1016/0019-1035(86)90137-5; GRIFFITH CA, IN PRESS B AM ASTR S; JESSBERGER EK, 1991, COMETS POST HALLEY E, V2, P1075; LELLOUCH E, 1984, ASTRON ASTROPHYS, V135, P365; MAILLARD JP, IN PRESS GEOPHYS RES; MARTIN TZ, IN PRESS B AM ASTR S; MEADOWS V, IN PRESS B AM ASTR S; MOSES JI, IN PRESS B AM ASTR S; NOLL KS, 1988, ASTROPHYS J, V324, P1210, DOI 10.1086/165975; NOLL KS, IN PRESS SCIENCE; ORTON GS, IN PRESS SCIENCE; WEST R, IN PRESS B AM ASTR S; ZAHNLE K, 1994, ICARUS, V108, P1, DOI 10.1006/icar.1994.1038; ZAHNLE K, IN PRESS B AM ASTR S	21	66	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	1995	373	6515					592	595		10.1038/373592a0	http://dx.doi.org/10.1038/373592a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854414				2022-12-24	WOS:A1995QG99700047
J	WHITTINGTON, MA; TRAUB, RD; JEFFERYS, JGR				WHITTINGTON, MA; TRAUB, RD; JEFFERYS, JGR			SYNCHRONIZED OSCILLATIONS IN INTERNEURON NETWORKS DRIVEN BY METABOTROPIC GLUTAMATE-RECEPTOR ACTIVATION	NATURE			English	Article							CAT VISUAL-CORTEX; RAT HIPPOCAMPUS; PYRAMIDAL NEURONS; INHIBITORY NEURONS; OLFACTORY SYSTEM; RESPONSES; FREQUENCY; INVITRO; HUMANS; EEG	PARTIALLY synchronous 40-Hz oscillations of cortical neurons have been implicated in cognitive function. Specifically, coherence of these oscillations between different parts of the cortex may provide conjunctive properties(1,2) to solve the 'binding problem': associating features detected by the cortex into unified perceived objects. Here we report an emergent 40-Hz oscillation in networks of inhibitory neurons connected by synapses using GABA(A) (gamma-aminobutyric acid) receptors in slices of rat hippocampus and neocortex. These network inhibitory postsynaptic potential oscillations occur in response to the activation of metabotropic glutamate receptors. The oscillations can entrain pyramidal cell discharges. The oscillation frequency is determined both by the net excitation of interneurons and by the kinetics of the inhibitory postsynaptic potentials between them. We propose that interneuron network oscillations, in conjunction with intrinsic membrane resonances and long-loop (such as thalamocortical) interactions, contribute to 40-Hz rhythms in vivo.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND; IBM CORP,DIV RES,TJ WATSON RES CTR,YORKTOWN HTS,NY 10598; COLUMBIA UNIV,DEPT NEUROL,NEW YORK,NY 10032	Imperial College London; International Business Machines (IBM); Columbia University			Jefferys, John G R/AAF-1164-2021; Jefferys, John/E-6132-2012	Jefferys, John G R/0000-0003-0106-4412; Jefferys, John/0000-0003-0106-4412; Whittington, Miles Adrian/0000-0002-0247-1362	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BRESSLER SL, 1980, ELECTROEN CLIN NEURO, V50, P19, DOI 10.1016/0013-4694(80)90319-3; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; EECKMAN FH, 1990, BRAIN RES, V528, P238, DOI 10.1016/0006-8993(90)91663-2; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; KATSUMARU H, 1988, EXP BRAIN RES, V72, P363; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; MILES R, 1993, J PHYSIOL-LONDON, V463, P461, DOI 10.1113/jphysiol.1993.sp019605; NUNEZ A, 1992, NEUROSCIENCE, V51, P7, DOI 10.1016/0306-4522(92)90464-D; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; ROPERT N, 1990, J PHYSIOL-LONDON, V428, P707, DOI 10.1113/jphysiol.1990.sp018236; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; STERIADE M, 1993, NEUROSCIENCE, V56, P1, DOI 10.1016/0306-4522(93)90556-U; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501	28	1222	1238	2	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					612	615		10.1038/373612a0	http://dx.doi.org/10.1038/373612a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854418				2022-12-24	WOS:A1995QG99700054
J	HENG, MCY; HENG, SY; ALLEN, SG				HENG, MCY; HENG, SY; ALLEN, SG			COINFECTION AND SYNERGY OF HUMAN IMMUNODEFICIENCY VIRUS-1 AND HERPES-SIMPLEX VIRUS-1	LANCET			English	Article							LYMPHOCYTES-T; HUMAN CYTOMEGALOVIRUS; LANGERHANS CELLS; HIV-1; TYPE-1; MACROPHAGES; REPLICATION; EXPRESSION; GENE; TRANSACTIVATION	The human immunodeficiency virus (HIV-1) uses the CD4 molecule, expressed by T helper cells and activated macrophages, as a receptor for entry into host cells. In tissues co-infected with herpes simplex type 1 (HSV-1), HIV-1 virions were observed to infect keratinocytes, which, because they lack the CD4 molecule, are normally incapable of being infected by HIV-1. Although a number of other viruses have been reported to enhance HIV-1 viral transcription in vitro, this is the first in-vivo report to our knowledge of reciprocal enhancement of viral replication associated with co-infection of keratinocytes and macrophages by HIV-1 and HSV-1 in patients with AIDS and non-genital herpes simplex lesions. The virions in the coinfected cells were larger, morphologically atypical, and appear to be hybrids; most contain the HIV-1 envelope necessary for infectivity. The increased viral load and the proximity of the virions to the cutaneous surface may lead to increased risk of transcutaneous transmission of both viruses. These findings point to the need for incorporation of suppressive treatment for herpes simplex in the treatment of AIDS.			HENG, MCY (corresponding author), VET AFFAIRS MED CTR,UCLA SAN FERNANDO VALLEY INTERNAL MED PROGRAM,DEPT MED,DIV DERMATOL,SEPULVEDA,CA 91343, USA.							COOPER DA, 1993, AIDS, V7, P197, DOI 10.1097/00002030-199302000-00007; CROWE S, 1987, AIDS RES HUM RETROV, V3, P135, DOI 10.1089/aid.1987.3.135; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; HO WZ, 1991, J ACQ IMMUN DEF SYND, V4, P1098; HO WZ, 1990, J GEN VIROL, V71, P97, DOI 10.1099/0022-1317-71-1-97; KEET IPM, 1990, GENITOURIN MED, V66, P330; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LI XL, 1990, J VIROL, V64, P1383, DOI 10.1128/JVI.64.3.1383-1387.1990; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; NELSON JA, 1988, VIROLOGY, V165, P280; POPOVIC M, 1987, LANCET, V2, P916; RANDO RF, 1987, ONCOGENE, V1, P13; RAPPERSBERGER K, 1988, INTERVIROLOGY, V29, P185; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988	20	152	155	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					255	258		10.1016/S0140-6736(94)91110-X	http://dx.doi.org/10.1016/S0140-6736(94)91110-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905094				2022-12-24	WOS:A1994MT44000008
J	BRISCO, MJ; CONDON, J; HUGHES, E; NEOH, SH; SYKES, PJ; SESHADRI, R; TOOGOOD, I; WATERS, K; TAURO, G; EKERT, H; MORLEY, AA				BRISCO, MJ; CONDON, J; HUGHES, E; NEOH, SH; SYKES, PJ; SESHADRI, R; TOOGOOD, I; WATERS, K; TAURO, G; EKERT, H; MORLEY, AA			OUTCOME PREDICTION IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA BY MOLECULAR QUANTIFICATION OF RESIDUAL DISEASE AT THE END OF INDUCTION	LANCET			English	Article							POLYMERASE CHAIN-REACTION; LYMPHOPROLIFERATIVE DISORDERS; OLIGONUCLEOTIDE PROBES; INVITRO AMPLIFICATION; GENE REARRANGEMENTS; LEUKEMIA; LINEAGE; RELAPSE; CELLS; PCR	Methods to detect and quantify minimal residual disease (MRD) after chemotherapy for acute lymphoblastic leukaemic (ALL) could improve treatment by identifying patients who need more or less intensive therapy. We have used a clone-specific polymerase chain reaction to detect rearranged immunoglobulin heavy-chain gene from the leukaemic clone, and quantified the clone by limiting dilution analysis. MRD was successfully quantified, by extracting DNA from marrow slides, from 88 of 181 children with ALL, who had total leucocyte counts below 100 x 10(9)/L at presentation and were enrolled in two clinical trials, in 1980-84 and 1985-89, Leukaemia was detected in the first remission marrow of 38 patients, in amounts between 6.7 x 10(2) and 9.9 x 10(-7) cells; 26 of these patients relapsed. Of 50 patients with no MRD detected, despite study of 522-496 000 genomes, only 6 relapsed. The association between MRD detection and outcome was significant for patients in each trial. In the first trial, patients relapsed at all levels of detected MRD, whereas in the later trial, in which treatment was more intensive and results were better, the extent of MRD was closely related to the probability of relapse (5 of 5 patients with >10(-3) MRD, 4 of 10 with 10(-3)to 2 x 10(-5), 0 of 3 with levels below 2 x 10(-5), and 2 of 26 with no MRD detected). Early quantification of leukaemic cells after chemotherapy may be a successful strategy for predicting outcome and hence individualising treatment in childhood ALL, because the results indicate both in-vivo drug sensitivity of the leukaemia and the number of leukaemic cells that remain to be killed by post-induction therapy.	FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT HAEMATOL,BEDFORD PK,SA 5042,AUSTRALIA; WOMENS & CHILDRENS HOSP,ADELAIDE,SA,AUSTRALIA	Flinders University South Australia; Womens & Childrens Hospital Australia				Sykes, Pam/0000-0001-9239-7639				BEISHUIZEN A, 1991, NEW ENGL J MED, V324, P772; BIONDI A, 1992, LEUKEMIA, V6, P282; BOURGUIN A, 1990, P NATL ACAD SCI USA, V87, P8536, DOI 10.1073/pnas.87.21.8536; BRISCO MJ, 1991, BRIT J HAEMATOL, V79, P211, DOI 10.1111/j.1365-2141.1991.tb04524.x; BRISCO MJ, 1993, LEUKEMIA, V7, P1514; BRISCO MJ, 1990, BRIT J HAEMATOL, V75, P163, DOI 10.1111/j.1365-2141.1990.tb02643.x; DAURIOL L, 1989, LEUKEMIA, V3, P155; DEANE M, 1991, BRIT J HAEMATOL, V77, P274, DOI 10.1111/j.1365-2141.1991.tb08570.x; EKERT H, 1990, CANCER THERAPY CONTR, V1, P87; HANSENHAGGE TE, 1989, BLOOD, V74, P1762; JONSSON OG, 1990, BLOOD, V76, P2072; KIYOI H, 1991, BONE MARROW TRANSPL, V8, P59; MACINTYRE EA, 1990, J CLIN INVEST, V86, P2125, DOI 10.1172/JCI114951; MCCARTHY KP, 1990, J CLIN PATHOL, V43, P429, DOI 10.1136/jcp.43.5.429; NEALE GAM, 1991, BLOOD, V78, P739, DOI 10.1182/blood.V78.3.739.bloodjournal783739; NIZET Y, 1991, BRIT J HAEMATOL, V79, P205, DOI 10.1111/j.1365-2141.1991.tb04523.x; POTTER MN, 1993, BRIT J HAEMATOL, V83, P412, DOI 10.1111/j.1365-2141.1993.tb04665.x; RALPH QM, 1993, BLOOD, V82, P202, DOI 10.1182/blood.V82.1.202.bloodjournal821202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SYKES PJ, 1992, BIOTECHNIQUES, V13, P444; TRAINOR KJ, 1991, BLOOD, V78, P192; TRAINOR KJ, 1990, BLOOD, V75, P2220; VANDENVELDE C, 1991, NOUV REV FR HEMATOL, V33, P25; VEELKEN H, 1991, BLOOD, V78, P1318; WASSERMAN R, 1992, BLOOD, V79, P223; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705; YOKOTA S, 1991, BLOOD, V77, P331	29	257	297	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					196	200		10.1016/S0140-6736(94)90988-1	http://dx.doi.org/10.1016/S0140-6736(94)90988-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904666				2022-12-24	WOS:A1994MT33200007
J	KHARITONOV, SA; YATES, D; ROBBINS, RA; LOGANSINCLAIR, R; SHINEBOURNE, EA; BARNES, PJ				KHARITONOV, SA; YATES, D; ROBBINS, RA; LOGANSINCLAIR, R; SHINEBOURNE, EA; BARNES, PJ			INCREASED NITRIC-OXIDE IN EXHALED AIR OF ASTHMATIC-PATIENTS	LANCET			English	Article							HUMANS	Nitric oxide (NO) gas is produced by various cells within the lower respiratory tract, including inflammatory and epithelial cells, and is detectable in the exhaled air of normal human subjects. We have measured exhaled NO in patients with asthma, since several cell types that are activated in asthma can produce NO after induction. NO was measured reproducibly by a slow vital capacity manoeuvre and an adapted chemiluminescence analyser. NO was detectable in exhaled air of 67 control subjects (mean peak concentration 80.2 [SE 4.1] ppb) and was significantly reduced by inhalation of the specific NO synthase inhibitor N(G)-monomethyl-L-arginine. 61 non-steroid-treated asthmatic subjects had significantly higher peak expired NO concentrations than controls (283 [16] ppb, p < 0.001) but 52 asthmatic patients receiving inhaled corticosteroids had levels similar to controls (101 [71 ppb). High exhaled NO concentrations in asthmatic patients may reflect induction of NO synthase, which is known to be inhibited by steroids. Measurement of exhaled NO concentrations may be clinically useful in detection and management of cytokine-mediated inflammatory lung disorders.	NATL HEART & LUNG INST, DEPT THORAC MED, LONDON SW3 6HP, ENGLAND; ROYAL BROMPTON HOSP, DEPT BIOMED ENGN, LONDON SW3 6HP, ENGLAND; ROYAL BROMPTON HOSP, DEPT PAEDIAT, LONDON SW3 6HP, ENGLAND	Imperial College London; Royal Brompton Hospital; Royal Brompton Hospital				Barnes, Peter/0000-0002-5122-4018				ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; BARNES PJ, 1993, EUR RESPIR J, V6, P163; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; DINHXUAN AT, 1992, EUR RESPIR J, V5, P757; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; JORENS PG, 1991, EUR J PHARMACOL, V200, P205, DOI 10.1016/0014-2999(91)90573-9; KOBZIK L, 1993, AM REV RESPIR DIS, V147, pA515; KUO HP, 1992, EUR J PHARMACOL, V221, P385; LIU SF, 1993, BIOCHEM BIOPH RES CO, V196, P1208, DOI 10.1006/bbrc.1993.2380; NAKAYAMA DK, 1992, AM J RESP CELL MOL, V7, P471, DOI 10.1165/ajrcmb/7.5.471; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROBBINS RA, 1993, LIFE SCI, V52, P709, DOI 10.1016/0024-3205(93)90232-R; SPRINGALL DR, 1993, AM REV RESPIR DIS, V147, pA515; WARD JK, 1993, J CLIN INVEST, V92, P736, DOI 10.1172/JCI116644; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0	16	1217	1245	1	68	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	1994	343	8890					133	135		10.1016/S0140-6736(94)90931-8	http://dx.doi.org/10.1016/S0140-6736(94)90931-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904001				2022-12-24	WOS:A1994MQ86900007
J	OZONOFF, D				OZONOFF, D			LEAD ON THE RANGE	LANCET			English	Editorial Material							INDOOR FIRING RANGE; EXPOSURE; INSTRUCTORS; ABSORPTION				OZONOFF, D (corresponding author), BOSTON UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02215 USA.			Ozonoff, David/0000-0002-4281-4171				BICKIS U, 1988, AM J PUBLIC HEALTH, V78, P95, DOI 10.2105/AJPH.78.1.95; BREWER F, 1989, J OCCUP ENVIRON MED, V31, P409; FISCHBEIN A, 1992, ISRAEL J MED SCI, V28, P560; FISCHBEIN A, 1993, CLIN IMMUNOL IMMUNOP, V66, P163, DOI 10.1006/clin.1993.1020; FISHERFISCHBEIN J, 1987, JAMA-J AM MED ASSOC, V257, P803, DOI 10.1001/jama.257.6.803; GEORGE PM, 1993, NEW ZEAL MED J, V106, P422; GOLDBERG RL, 1991, J OCCUP ENVIRON MED, V33, P718, DOI 10.1097/00043764-199106000-00013; LANDRIGAN PJ, 1975, JAMA-J AM MED ASSOC, V234, P394, DOI 10.1001/jama.234.4.394; MAIZLISH N, 1990, AM J PUBLIC HEALTH, V80, P931, DOI 10.2105/AJPH.80.8.931; MILLER CH, 1984, OCCUP HLTH, V36, P8; MUSKETT CJ, 1980, ANN OCCUP HYG, V23, P283, DOI 10.1093/annhyg/23.3.283; NOVOTNY T, 1987, AM J PUBLIC HEALTH, V77, P1225, DOI 10.2105/AJPH.77.9.1225; Smith D L, 1976, J Soc Occup Med, V26, P139, DOI 10.1093/occmed/26.4.139; SVENSSON BG, 1992, INT ARCH OCC ENV HEA, V64, P219, DOI 10.1007/BF00378278; TRIPATHI RK, 1991, AM J PUBLIC HEALTH, V81, P753, DOI 10.2105/AJPH.81.6.753; TRIPATHI RK, 1990, AM IND HYG ASSOC J, V51, P28, DOI 10.1080/15298669091369286; VALWAY SE, 1989, AM J PUBLIC HEALTH, V79, P1029, DOI 10.2105/AJPH.79.8.1029	17	12	12	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	1994	343	8888					6	7		10.1016/S0140-6736(94)90871-0	http://dx.doi.org/10.1016/S0140-6736(94)90871-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905076				2022-12-24	WOS:A1994MN93700007
J	KING, GN; HEALY, CM; GLOVER, MT; KWAN, JTC; WILLIAMS, DM; LEIGH, IM; WORTHINGTON, HV; THORNHILL, MH				KING, GN; HEALY, CM; GLOVER, MT; KWAN, JTC; WILLIAMS, DM; LEIGH, IM; WORTHINGTON, HV; THORNHILL, MH			INCREASED PREVALENCE OF DYSPLASTIC AND MALIGNANT LIP LESIONS IN RENAL-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALLOGRAFT RECIPIENTS; SKIN-CANCER; CARCINOMA; TUMORS	Background. Renal-transplant recipients are known to have increased rates of skin cancer associated with exposure to the sun. Little is known, however, about the prevalence and histologic features of lesions of the lips in these patients, or about risk factors for such lesions. Methods. We examined the lips of 160 renal-transplant recipients (105 men and 55 women; mean [+/-SD] age, 48+/-13 years) and 160 normal subjects matched with the transplant recipients for age, sex, and skin type. The mean length of time between transplantation and the examination was 69+/-52 months; 58 percent of the recipients had received their grafts more than 60 months earlier. Results. Among the 160 renal-transplant recipients, 21 (13 percent) had leukoplakia; in 2 (1.2 percent) the leukoplakia contained squamous-cell carcinoma. In contrast, only one normal subject (0.6 percent) had leukoplakia. Histologically, 13 of the 21 leukoplakias (62 percent) in the renal-transplant recipients who underwent biopsy were dysplastic, and 2 (10 percent) contained squamous-cell carcinoma. Actinic change was evident in 91 percent of the dysplastic lesions but not in the nondysplastic lesions (P<0.001). Exposure to the sun and smoking were risk factors for dysplastic and malignant lip lesions in the renal-transplant recipients (P<0.001 and P=0.003, respectively). Among these recipients, only men had dysplastic or malignant lip lesions (P=0.006); lipstick was used frequently by 73 percent of the women. The clinical appearance of lip lesions did not predict the presence of dysplasia or cancer. Conclusions. Renal-transplant recipients have an increased prevalence of leukoplakia, dysplasia, and cancer of the lip.	UNIV LONDON LONDON HOSP,COLL MED,DEPT DERMATOL,LONDON E1 2AD,ENGLAND; UNIV LONDON LONDON HOSP,COLL MED,DEPT NEPHROL,LONDON E1 2AD,ENGLAND; UNIV LONDON LONDON HOSP,COLL MED,INST DENT SURG,JOINT DEPT ORAL PATHOL,LONDON E1 2AD,ENGLAND; UNIV MANCHESTER,DEPT ORAL HLTH,MANCHESTER,LANCS,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; University of Manchester	KING, GN (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,DEPT ORAL MED & PERIODONTOL,LONDON E1 2AD,ENGLAND.		Healy, Claire M/AGL-9755-2022; Worthington, Helen/U-8971-2019	Healy, Claire M/0000-0003-0583-6360; Worthington, Helen/0000-0002-4851-7469; Thornhill, Martin/0000-0003-0681-4083; Healy, Claire M/0000-0001-7940-4611				BARR BBB, 1989, LANCET, V1, P124; BLESSING K, 1989, HISTOPATHOLOGY, V14, P129, DOI 10.1111/j.1365-2559.1989.tb02123.x; BLOHME I, 1985, TRANSPLANTATION, V39, P23; BLOHME I, 1984, TRANSPLANTATION, V37, P165, DOI 10.1097/00007890-198402000-00010; Bouquot J E, 1987, Quintessence Int, V18, P277; BOYLE J, 1984, LANCET, V1, P702; BUNNEY MH, 1987, LANCET, V2, P151; DOUGLASS CW, 1984, ORAL SURG ORAL MED O, V57, P631, DOI 10.1016/0030-4220(84)90286-X; HARDIE IR, 1980, SURGERY, V87, P177; HOXTELL EO, 1977, ARCH DERMATOL, V113, P436, DOI 10.1001/archderm.113.4.436; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KRAMER I R H, 1978, Oral Surgery Oral Medicine Oral Pathology, V46, P518; LINDQVIST C, 1981, COMMUNITY DENT ORAL, V9, P247, DOI 10.1111/j.1600-0528.1981.tb00339.x; LUTZNER M, 1980, J INVEST DERMATOL, V75, P353, DOI 10.1111/1523-1747.ep12531131; MARSHALL V, 1974, TRANSPLANTATION, V17, P272, DOI 10.1097/00007890-197403000-00006; PATHAK MA, 1987, DERMATOLOGY GENERAL, V1, P1507; PENN I, 1980, CLIN PLAST SURG, V7, P361; PENN I, 1993, HEMATOL ONCOL CLIN N, V7, P431, DOI 10.1016/S0889-8588(18)30250-8; ROGERS GS, 1988, J AM ACAD DERMATOL, V18, P1039, DOI 10.1016/S0190-9622(88)70101-2	19	94	96	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1052	1057		10.1056/NEJM199504203321602	http://dx.doi.org/10.1056/NEJM199504203321602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898522				2022-12-24	WOS:A1995QT18700002
J	KHAMASHTA, MA; CUADRADO, MJ; MUJIC, F; TAUB, NA; HUNT, BJ; HUGHES, GRV				KHAMASHTA, MA; CUADRADO, MJ; MUJIC, F; TAUB, NA; HUNT, BJ; HUGHES, GRV			THE MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTICARDIOLIPIN ANTIBODIES; DIFFERENT INTENSITIES; VENOUS THROMBOSIS; ANTICOAGULANT; WARFARIN; FEATURES; TRIAL	Background. The anti phospholipid-anti body syndrome is a thrombophilic disorder in which venous or arterial thrombosis, or both, may occur in patients with antiphospholipid antibodies. The optimal treatment of these patients is unclear. We assessed the efficacy of warfarin, low-dose aspirin, or both in the secondary prevention of thrombosis in patients with the syndrome. Methods. One hundred forty-seven patients (124 [84 percent] of whom were female) with the antiphospholipid-antibody syndrome and a history of thrombosis were studied retrospectively. The syndrome was primary in 62 patients and was associated with systemic lupus erythematosus in 66 patients and lupus-like disease in 19. Each patient's history was reviewed. Results. One hundred one patients (69 percent) had a total of 186 recurrences of thrombosis. The median time between the initial thrombosis and the first recurrence was 12 months (range, 0.5 to 144 months). Treatment with high-intensity warfarin (producing an international normalized ratio of greater than or equal to 3) with or without law-dose aspirin (75 mg per day) was significantly more effective (P<0.001 by the log-rank test) than treatment with low-intensity warfarin (producing an international normalized ratio of <3) with or without low-dose aspirin or treatment with aspirin alone in preventing further thrombotic events (recurrence rates per patient-year, 0.013, 0.23, and 0.18, respectively). The rate of recurrence of thrombosis was highest (1.30 per patient-year) during the first six months after the cessation of warfarin therapy. Complications involving bleeding occurred in 29 patients during warfarin therapy and were severe in 7 (0.071 and 0.017 occurrence per patient-year, respectively). Conclusions. The risk of recurrent thrombosis in patients with the antiphospholipid-antibody syndrome is high. Long-term anticoagulation therapy in which the international normalized ratio is maintained at or above 3 is advisable in these patients.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, RAYNE INST, LUPUS & ARTHRITIS RES UNIT, LONDON SE1 7EH, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, DEPT PUBL HLTH MED, LONDON SE1 7EH, ENGLAND; ST THOMAS HOSP, CTR HEMOPHILIA, LONDON, ENGLAND	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust								ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P1014; ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P482; ARMITAGE P, 1994, STATISTICAL METHODS, P144; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; ASHERSON RA, 1991, ANN RHEUM DIS, V50, P805, DOI 10.1136/ard.50.11.805; ASHERSON RA, 1985, ANN RHEUM DIS, V44, P823, DOI 10.1136/ard.44.12.823; BARBUI T, 1994, LUPUS, V3, P303, DOI 10.1177/096120339400300419; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; COX DR, 1972, J R STAT SOC B, V34, P187; DERKSEN RHWM, 1993, ANN RHEUM DIS, V52, P689, DOI 10.1136/ard.52.9.689; EXNER T, 1975, PATHOLOGY, V7, P319, DOI 10.3109/00313027509081688; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; HARRIS E N, 1987, British Journal of Rheumatology, V26, P19; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HIRSH J, 1994, CIRCULATION, V89, P1469, DOI 10.1161/01.CIR.89.3.1469; HUGHES GRV, 1983, BRIT MED J, V287, P1088, DOI 10.1136/bmj.287.6399.1088; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016/S0140-6736(94)90008-6; LEVINE SR, 1992, STROKE S1, V23, P29; LIE JT, 1989, J RHEUMATOL, V16, P713; LOCKSHIN MD, 1993, RHEUM DIS CLIN N AM, V19, P235; MACHIN SJ, 1991, J CLIN PATHOL, V44, P885; MACKWORTHYOUNG CG, 1989, ANN RHEUM DIS, V48, P362, DOI 10.1136/ard.48.5.362; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; RIVIER G, 1994, LUPUS, V3, P85, DOI 10.1177/096120339400300205; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VIANNA JL, 1994, AM J MED, V96, P3, DOI 10.1016/0002-9343(94)90108-2; VLACHOYIANNOPOULOS PG, 1994, LUPUS, V3, P91, DOI 10.1177/096120339400300206; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707	33	1130	1153	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					993	997		10.1056/NEJM199504133321504	http://dx.doi.org/10.1056/NEJM199504133321504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885428	Bronze			2022-12-24	WOS:A1995QT73700004
J	JADHAV, S				JADHAV, S			THE GHOSTBUSTERS OF PSYCHIATRY	LANCET			English	Editorial Material											JADHAV, S (corresponding author), UCL, DEPT PSYCHIAT, LONDON, ENGLAND.		jadhav, sushrut/B-8249-2009	jadhav, sushrut/0000-0001-5325-8687				BLUE I, 1994, BRIT J PSYCHIAT, V165, P9, DOI 10.1192/bjp.165.1.9; COLEMAN J, 1994, TREATING SURVIVORS S; Good B, 1994, MED RATIONALITY EXPE; HALE AS, 1994, BRIT J PSYCHIAT, V165, P386, DOI 10.1192/bjp.165.3.386; JADHAV S, 1994, PSYCHIATR B, V18, P572; Kakar Sudhir., 1982, SHAMANS MYSTICS DOCT; LEWIS IM, 1966, MAN, V1, P307, DOI 10.2307/2796794; LITTLEWOOD R, 1991, LANCET, V337, P1013, DOI 10.1016/0140-6736(91)92668-R; MULHERN S, 1991, PSYCHIAT CLIN N AM, V14, P769; Turner V.W., 1964, MAGIC FAITH HEALING; Vitebsky, 1993, DIALOGUES DEAD DISCU; WEISS MG, 1992, BRIT J PSYCHIAT, V160, P819, DOI 10.1192/bjp.160.6.819	12	7	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 1	1995	345	8953					808	810		10.1016/S0140-6736(95)92959-2	http://dx.doi.org/10.1016/S0140-6736(95)92959-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QQ195	7898225				2022-12-24	WOS:A1995QQ19500004
J	COOPER, C; KANIS, JA; COMPSTON, J				COOPER, C; KANIS, JA; COMPSTON, J			HOW TO ASSESS DRUG EFFICACY IN OSTEOPOROSIS	LANCET			English	Editorial Material							POPULATION		UNIV SHEFFIELD,SCH MED,DEPT HUMAN METAB & CLIN BIOCHEM,WHO COLLABORATING CTR METAB BONE DIS,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND; UNIV CAMBRIDGE,SCH MED,DEPT MED,CAMBRIDGE,ENGLAND	University of Sheffield; World Health Organization; University of Cambridge	COOPER, C (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; COOPER C, 1992, TRENDS ENDOCRIN MET, V3, P224, DOI 10.1016/1043-2760(92)90032-V; KANIS JA, 1993, DRUG AGING, V3, P391, DOI 10.2165/00002512-199303050-00001; KLEEREKOPER M, 1990, OSTEOPOROSIS INT, V1, P155; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; 1994, GUIDELINES PRECLINIC; 1994, WHO TECH REPORT SERI, V843	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					743	744		10.1016/S0140-6736(95)90635-5	http://dx.doi.org/10.1016/S0140-6736(95)90635-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891482				2022-12-24	WOS:A1995QN70100006
J	BABA, TW; JEONG, YS; PENNINCK, D; BRONSON, R; GREENE, MF; RUPRECHT, RM				BABA, TW; JEONG, YS; PENNINCK, D; BRONSON, R; GREENE, MF; RUPRECHT, RM			PATHOGENICITY OF LIVE, ATTENUATED SIV AFTER MUCOSAL INFECTION OF NEONATAL MACAQUES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; INDEPENDENT DOWN-REGULATION; VIRION-ASSOCIATED PROTEIN; CELL-SURFACE CD4; MUTATIONAL ANALYSIS; NEF-PROTEIN; THROMBOCYTOPENIC PURPURA; RHESUS MACAQUES; HOMOSEXUAL MEN	Adult macaques do not develop disease after infection with a nef deletion mutant of the simian immunodeficiency virus (SIV) and are protected against challenge with pathogenic virus. This finding led to the proposal to use nef-deleted viruses as live, attenuated vaccines to prevent human acquired immunodeficiency syndrome (AIDS). In contrast, neonatal macaques developed persistently high levels of viremia after oral exposure to an SIV nef, vpr, and negative regulatory element (NRE) deletion mutant. Severe hemolytic anemia, thrombocytopenia, and CD4(+) T cell depletion were observed, indicating that neither nef nor vpr determine pathogenicity in neonates. Because such constructs have retained their pathogenic potential, they should not be used as candidate live, attenuated virus vaccines against human AIDS.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,VIRAL PATHOGENESIS LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT PEDIAT,DIV NEWBORN MED,BOSTON,MA 02111; MASSACHUSETTS GEN HOSP,DEPT OBSTET & GYNECOL,BOSTON,MA 02114; TUFTS UNIV,SCH VET MED,DEPT RADIOL,GRAFTON,MA 01536; TUFTS UNIV,SCH VET MED,DEPT VET PATHOL,BOSTON,MA 02111	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Tufts University; Harvard University; Massachusetts General Hospital; Tufts University; Tufts University			Abrams, William R/A-5782-2008		PHS HHS [R01-A135533, R01-A132330] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AYEHUNIE S, UNPUB; BABA T, UNPUB; BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; BABA TW, 1993, J WOMENS HEALTH, V2, P231; BACHELERIE F, 1990, J VIROL, V64, P3059, DOI 10.1128/JVI.64.6.3059-3062.1990; BARRY PA, 1990, J MED PRIMATOL, V19, P327; BOLOGNESI DP, 1994, J NIH RES, V6, P55; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; CHINNECK JW, 1994, COMPUT OPER RES, V21, P1, DOI 10.1016/0305-0548(94)90057-4; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DENNY TN, 1990, PEDIATR RES, V27, pA155; Desrosiers R.C., 1994, J NIH RES, V6, P54; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P1457, DOI 10.1089/aid.1992.8.1457; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1994, AIDS RES HUM RETROV, V10, P221; DESROSIERS RC, 1994, 7TH ANN M NAT COOP V; FAZELY F, 1993, J ACQ IMMUN DEF SYND, V6, P107; FERNIE S, 1994, J TOXICOL ENV HLTH, V45, P53; FORSTER SM, 1987, AIDS, V1, P235; FOX CH, 1993, CURRENT PROTOCOLS IM; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; GOLDSWEIG HG, 1986, AM J HEMATOL, V21, P243, DOI 10.1002/ajh.2830210303; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HU SL, 1993, HIV MOL ORG PATHOGEN; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KLEGANOFF SJ, 1994, P NATL ACAD SCI USA, V91, P10615; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; LAIRMORE MD, 1990, AIDS RES HUM RETROV, V6, P1233, DOI 10.1089/aid.1990.6.1233; LAIRMORE MD, 1993, AIDS RES HUM RETROV, V9, P565, DOI 10.1089/aid.1993.9.565; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LITTMAN DR, 1994, CURR BIOL, V4, P618, DOI 10.1016/S0960-9822(00)00135-4; LU YC, 1989, J VIROL, V63, P4115, DOI 10.1128/JVI.63.9.4115-4119.1989; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; Mann J., 1992, AIDS WORLD GLOBAL RE; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MORRIS L, 1982, ANN INTERN MED, V96, P714, DOI 10.7326/0003-4819-96-6-714; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; OHKAWA S, 1990, FASEB J, V4, pA2264; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; RASZKA WV, 1994, PEDIATR INFECT DIS J, V13, P70, DOI 10.1097/00006454-199401000-00015; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; RUPRECHT RM, 1990, J ACQ IMMUN DEF SYND, V3, P591; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; RUPRECHT RM, 1994, DNA CELL BIOL, V13, P59, DOI 10.1089/dna.1994.13.59; SAVONA S, 1985, ANN INTERN MED, V102, P737, DOI 10.7326/0003-4819-102-6-737; SCHREIBNER ZA, 1983, BLOOD S, V92, pA117; SHIBATA R, 1990, J MED PRIMATOL, V19, P217; SHIBATA R, 1990, J VIROL, V64, P742, DOI 10.1128/JVI.64.2.742-747.1990; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SOSA MAG, 1991, AIDS RES HUM RETROV, V7, P859, DOI 10.1089/aid.1991.7.859; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TOY PTCY, 1985, AM J HEMATOL, V19, P145, DOI 10.1002/ajh.2830190206; TRAINADORGE V, 1992, AIDS RES HUM RETROV, V8, P97, DOI 10.1089/aid.1992.8.97; VIGLIANTI GA, 1988, J VIROL, V62, P4523, DOI 10.1128/JVI.62.12.4523-4532.1988; WALSH C, 1985, ANN INTERN MED, V103, P542, DOI 10.7326/0003-4819-103-4-542; WEBER JN, 1987, LANCET, V1, P121; WEISS R, 1984, RNA TUMOR VIRUSES; WILLIAMSHERMAN D, 1993, 9TH INT C AIDS BERL; WYAND MS, 1994, 1994 C ADV AIDS VACC; YU M, 1994, J NIH RES, V6, P20; YU XF, 1988, NATURE, V335, P262, DOI 10.1038/335262a0; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813	72	453	466	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1820	1825		10.1126/science.7892606	http://dx.doi.org/10.1126/science.7892606			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892606				2022-12-24	WOS:A1995QN70200039
J	KLINGMULLER, U; LORENZ, U; CANTLEY, LC; NEEL, BG; LODISH, HF				KLINGMULLER, U; LORENZ, U; CANTLEY, LC; NEEL, BG; LODISH, HF			SPECIFIC RECRUITMENT OF SH-PTP1 TO THE ERYTHROPOIETIN RECEPTOR CAUSES INACTIVATION OF JAK2 AND TERMINATION OF PROLIFERATIVE SIGNALS	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MOTH-EATEN; KINASE; PHOSPHORYLATION; DOMAIN; CELLS; SH2; DIFFERENTIATION; TRANSDUCTION; SUPERFAMILY	The binding of erythropoietin (EPO) to its receptor (EPO-R) activates the protein tyrosine kinase JAK2. The mechanism of JAK2 inactivation has been unclear. We show that the hematopoietic protein tyrosine phosphatase SH-PTP1 (also called HCP and PTP1C) associates via its SH2 domains with the tyrosine-phosphorylated EPO-R. In vitro binding studies suggest that Y429 in the cytoplasmic domain of the EPO-R is the binding site for SH-PTP1. Mutant EPO-Rs lacking Y429 are unable to bind SH-PTP1; cells expressing such mutants are hypersensitive to EPO and display prolonged EPO-induced autophosphorylation of JAK2. Our results suggest that activation of SH-PTP1 by binding to the EPO-R plays a major role in terminating proliferative signals.	BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02215 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	KLINGMULLER, U (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Cantley, Lewis C/D-1800-2014; Klingmüller, Ursula/G-8477-2013	Cantley, Lewis C/0000-0002-1298-7653; Klingmüller, Ursula/0000-0001-9845-3099; Lorenz, Ulrike/0000-0002-7933-6855	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASE RD, 1994, J BIOL CHEM, V269, P10467; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANZANT G, 1989, EXP HEMATOL, V17, P81; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	843	871	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					729	738		10.1016/0092-8674(95)90351-8	http://dx.doi.org/10.1016/0092-8674(95)90351-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889566	Bronze			2022-12-24	WOS:A1995QM39900009
J	KLONOFFCOHEN, HS; EDELSTEIN, SL				KLONOFFCOHEN, HS; EDELSTEIN, SL			A CASE-CONTROL STUDY OF ROUTINE AND DEATH SCENE SLEEP POSITION AND SUDDEN-INFANT-DEATH-SYNDROME IN SOUTHERN CALIFORNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COT DEATH; PRONE; RISK; EPIDEMIOLOGY	Objective.-To investigate whether infants who died of sudden infant death syndrome (SIDS) were routinely placed in different sleep positions compared with healthy infants in a multiethnic diverse population in the United States. Design.-A population-based case-control study. Setting.-Five counties in Southern California including Los Angeles, Orange, San Bernardino, Riverside, and San Diego. Participants.-Parents of 200 white, African-American, Hispanic, and Asian infants who died of SIDS between January 1989 and December 1992 and parents of 200 healthy, living infants matched on the basis of birth hospital, birth date, race, and gender. Information was obtained from detailed telephone interviews with the parents and validated with obstetric and pediatric records. Main Outcome Measures.-Routine sleep position, type of bedding, and objects in bed were determined for both case and control infants, while the last-placed and found sleep and face positions at death were reported for SIDS infants. Results.-Approximately 66% of SIDS infants and 64% of comparison infants routinely slept on their abdomens (P=.91). At the time of death, 80% of cases were found sleeping on their abdomens. There was no difference in routine sleep position for SIDS infants and comparison infants (odds ratio=0.76; 95% confidence interval, 0.42 to 1.38), while simultaneously adjusting for birth weight (in grams), medical conditions at birth, breast-feeding, passive smoking, maternal recreational drug use, prenatal care, and infant vomiting. Hispanic parents routinely placed their infants on their abdomens less frequently than white parents (P<.01). However, the prone sleep position (face down) was the most commonly found sleep position at death in both Hispanic and non-Hispanic infants. Conclusions.-Routine prone sleep position was not associated with an increased risk of SIDS in this study population. The results need to be confirmed with other parents of SIDS infants interviewed before the height of publicity regarding prone sleep position in the United States.			KLONOFFCOHEN, HS (corresponding author), UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, DIV EPIDEMIOL, 9500 GILMAN DR, 0607, LA JOLLA, CA 92037 USA.							BEAL S, 1991, MED J AUSTRALIA, V155, P507, DOI 10.5694/j.1326-5377.1991.tb93882.x; BEAL SM, 1991, J PAEDIATR CHILD H, V27, P334, DOI 10.1111/j.1440-1754.1991.tb00414.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BECKWITH J, 1988, SUDDEN INFANT DEATH; CAMERON MH, 1986, AUST PAEDIATR J, V22, P37; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; DREWS CD, 1990, INT J EPIDEMIOL, V19, P405, DOI 10.1093/ije/19.2.405; DWYER T, 1992, J EPIDEMIOL COMMUN H, V46, P98, DOI 10.1136/jech.46.2.98; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; GOULD JB, 1988, ANN NY ACAD SCI, V533, P62, DOI 10.1111/j.1749-6632.1988.tb37234.x; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; HOFFMAN HJ, 1992, CLIN PERINATOL, V19, P717, DOI 10.1016/S0095-5108(18)30427-5; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; KLEINBAUM D, 1982, OBSERVATIONAL RES; KROUS H F, 1988, Pediatrician, V15, P231; MCGLASHAN ND, 1988, LANCET, V2, P106; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS9, DOI 10.1111/j.1440-1754.1992.tb02732.x; NELSON EAS, 1989, AUST PAEDIATR J, V25, P202; NICHOLL JP, 1989, J EPIDEMIOL COMMUN H, V43, P133, DOI 10.1136/jech.43.2.133; PETERSON D R, 1988, Pediatrician, V15, P198; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; SENECAL J, 1987, ARCH FR PEDIATR, V44, P131; STEELE R, 1966, CAN MED ASSOC J, V94, P1165; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; 1991, CALIFORNIA MORBIDITY	32	35	35	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					790	794		10.1001/jama.273.10.790	http://dx.doi.org/10.1001/jama.273.10.790			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861573				2022-12-24	WOS:A1995QJ75000030
J	ECKMAN, MH; GREENFIELD, S; MACKEY, WC; WONG, JB; KAPLAN, S; SULLIVAN, L; DUKES, K; PAUKER, SG				ECKMAN, MH; GREENFIELD, S; MACKEY, WC; WONG, JB; KAPLAN, S; SULLIVAN, L; DUKES, K; PAUKER, SG			FOOT INFECTIONS IN DIABETIC-PATIENTS - DECISION AND COST-EFFECTIVENESS ANALYSES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY AMPUTATIONS; ORAL ANTIMICROBIAL THERAPY; PEDAL OSTEOMYELITIS; CONVENIENT APPROXIMATION; PERSONAL-COMPUTER; BONE-SCINTIGRAPHY; LIFE EXPECTANCY; SOFT-TISSUE; CIPROFLOXACIN; DIAGNOSIS	Objective.-To examine the cost-effectiveness of approaches to the diagnosis and treatment of patients with type II (non-insulin-dependent) diabetes mellitus (NIDDM) who have foot infections and suspected osteomyelitis. Design.-Decision and cost-effectiveness analyses were performed using a Markov model. We examined the prevalence of osteomyelitis, the major complications and efficacies of long-term antibiotic therapy and surgery, and the performance characteristics of four diagnostic tests (roentgenography, technetium Tc 99m bone scanning, indium In 111-labeled white blood cell scanning, and magnetic resonance imaging). Data were drawn from the English-language literature using MEDLINE searches and bibliographies from selected articles. Setting.-Primary care. Patients.-Patients with NIDDM who had foot infections and suspected osteomyelitis but no signs of systemic toxicity. Interventions.-following hospitalization for surgical debridement and intravenous antibiotic therapy: (1) treatment for presumed soft-tissue infection, (2) culture-guided empiric treatment for presumed osteomyelitis, (3) 71 combinations of diagnostic tests preceding antibiotic therapy for osteomyelitis, (4) 71 combinations of tests preceding amputation, and (5) immediate amputation. Main Outcome Measures.-Quality-adjusted life expectancy, average costs. Results.-Culture-guided empiric treatment for osteomyelitis with 10 weeks of oral antibiotic therapy has similar effectiveness to testing followed by a long course of antibiotic therapy if any test result is positive. However, empiric treatment is the least expensive strategy. Conclusions.-Noninvasive testing adds significant expense to the treatment of patients with NIDDM in whom pedal osteomyelitis is suspected, and such testing may result in little improvement in health outcomes. In patients without systemic toxicity, a 10-week course of culture-guided oral antibiotic therapy following surgical debridement may be as effective as and less costly than other approaches.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, PRIMARY CARE OUTCOMES RES INST, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT SURG, DIV VASC SURG, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts Medical Center; Tufts University	ECKMAN, MH (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CLIN DECIS MAKING, BOX 302, 750 WASHINGTON AVE, BOSTON, MA 02111 USA.			Greenfield, Sheldon/0000-0003-4628-1998; Kaplan, Sherrie/0000-0002-8644-5849; Wong, John/0000-0003-4203-9010; Eckman, Mark/0000-0001-8253-269X; Sullivan, Lisa/0000-0003-0726-7149	AHRQ HHS [HS-06665] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		APELQVIST J, 1989, DIABETIC MED, V6, P526, DOI 10.1111/j.1464-5491.1989.tb01221.x; BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BELTRAN J, 1990, SKELETAL RADIOL, V19, P37; BENTON GS, 1985, SURG GYNECOL OBSTET, V161, P523; BILD DE, 1989, DIABETES CARE, V12, P24, DOI 10.2337/diacare.12.1.24; BLACK J, 1987, J INFECT DIS, V155, P968, DOI 10.1093/infdis/155.5.968; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; CHRISTENSEN S, 1976, ACTA ORTHOP SCAND, V47, P329, DOI 10.3109/17453677608992001; CONNELL FA, 1991, MMWR-MORBID MORTAL W, V40, P737; DAVIS H, 1989, ANN INTERN MED, V111, P1041, DOI 10.7326/0003-4819-111-12-1041; De Frang R D, 1991, Ann Vasc Surg, V5, P202, DOI 10.1007/BF02016758; DESAI Y, 1986, BRIT J SURG, V73, P392, DOI 10.1002/bjs.1800730527; DURHAM JR, 1989, AM J SURG, V158, P127, DOI 10.1016/0002-9610(89)90360-7; EDMONDS ME, 1986, Q J MED, V60, P763; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Geiss Linda S., 1993, Morbidity and Mortality Weekly Report, V42, P1; Gentry L O, 1990, Infect Dis Clin North Am, V4, P485; GENTRY LO, 1991, ANN INTERN MED, V114, P986, DOI 10.7326/0003-4819-114-11-986; GENTRY LO, 1988, J ANTIMICROB CHEMOTH, V21, P115, DOI 10.1093/jac/21.suppl_C.115; GENTRY LO, 1990, ANTIMICROB AGENTS CH, V34, P40, DOI 10.1128/AAC.34.1.40; Geroulakos G, 1991, Eur J Vasc Surg, V5, P655, DOI 10.1016/S0950-821X(05)80901-6; GREENFIELD S, 1994, DIABETES CARE, V17, P32; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HARRIS MI, 1985, NIH851468 US DEP HLT; Hobson M I, 1990, J R Coll Surg Edinb, V35, P113; HUGHES C E, 1987, Clinical Therapeutics, V10, P36; JONES EW, 1987, DIABETIC MED, V4, P475, DOI 10.1111/j.1464-5491.1987.tb00912.x; KAHN KL, 1986, J CLIN GASTROENTEROL, V8, P346, DOI 10.1097/00004836-198606002-00005; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; LAU J, 1983, MED DECIS MAKING, V3, P39, DOI 10.1177/0272989X8300300110; LEVEY AS, 1987, ANN INTERN MED, V107, P697, DOI 10.7326/0003-4819-107-5-697; LIPSKY B, 1989, 29TH INT C ANT AG CH; Lipsky B A, 1990, Clin Geriatr Med, V6, P747; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; LIPSKY BA, 1990, ARCH INTERN MED, V150, P790, DOI 10.1001/archinte.150.4.790; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; LOUIE TJ, 1976, ANN INTERN MED, V85, P461, DOI 10.7326/0003-4819-85-4-461; LUSK RH, 1977, J INFECT DIS, V135, pS111, DOI 10.1093/infdis/135.Supplement.S111; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MALONE JM, 1981, ARCH SURG-CHICAGO, V116, P93; MAURER AH, 1986, RADIOLOGY, V161, P221, DOI 10.1148/radiology.161.1.3763871; MOSKOWITZ AJ, 1988, ANN INTERN MED, V108, P435, DOI 10.7326/0003-4819-108-3-435; MOSKOWITZ AJ, 1986, MED DECIS MAKING, V6, P267; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; MUSHLIN AI, 1994, J GEN INTERN MED, V9, P1, DOI 10.1007/BF02599133; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; NEWMAN LG, 1991, JAMA-J AM MED ASSOC, V266, P1246, DOI 10.1001/jama.266.9.1246; NIX DE, 1987, AM J MED, V82, P146; OCONNOR GT, 1993, MED DECIS MAKING, V13, P87, DOI 10.1177/0272989X9301300201; PARK HM, 1982, J NUCL MED, V23, P569; PAUKER SG, 1981, ARCH INTERN MED, V141, P1831, DOI 10.1001/archinte.141.13.1831; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; POTTS JR, 1979, AM J SURG, V138, P924, DOI 10.1016/0002-9610(79)90323-4; ROSENBERG JM, 1984, AM J SURG, V147, P486, DOI 10.1016/0002-9610(84)90010-2; SANFORD JP, 1994, ANTIMICROBIAL THERAP; SAPICO FL, 1980, J CLIN MICROBIOL, V12, P413, DOI 10.1128/JCM.12.3.413-420.1980; SCHAUWECKER DS, 1988, J NUCL MED, V29, P1651; SEGALL GM, 1989, CLIN NUCL MED, V14, P255, DOI 10.1097/00003072-198904000-00003; SELDIN DW, 1985, J NUCL MED, V26, P988; SINGER RB, 1976, MED RISKS, pCH9; STIEFELD SM, 1991, ORTHOP CLIN N AM, V22, P439; STIRNEMANN P, 1987, J CARDIOVASC SURG, V28, P152; TU JV, 1993, AM REV RESPIR DIS, V148, P370, DOI 10.1164/ajrccm/148.2.370; Wagner F W Jr, 1981, Foot Ankle, V2, P64; WAGNER FW, 1986, SURGERY FOOT, P423; WALKER RC, 1991, MAYO CLIN PROC, V66, P1249, DOI 10.1016/S0025-6196(12)62477-X; WANG A, 1990, MAGN RESON IMAGING, V8, P805, DOI 10.1016/0730-725X(90)90017-V; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WASSERMAN Y, 1993, PHYSICIANS FEE REFER, P62; WEINSTEIN D, 1993, FOOT ANKLE, V14, P18, DOI 10.1177/107110079301400104; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WHEAT J, 1985, AM J MED, V78, P218, DOI 10.1016/0002-9343(85)90388-2; WHEAT LJ, 1986, ARCH INTERN MED, V146, P1935, DOI 10.1001/archinte.146.10.1935; WILSON KH, 1985, SOUTHERN MED J, V78, P223, DOI 10.1097/00007611-198502000-00035; YAMAMOTO F, 1980, PROGNOSIS SURGICAL D, P88; YUH WTC, 1989, AM J ROENTGENOL, V152, P795, DOI 10.2214/ajr.152.4.795; ZIMMERMAN J, 1980, SCAND J INFECT DIS, V12, P79, DOI 10.3109/inf.1980.12.issue-1.15; ZLATKIN MB, 1987, RADIOL CLIN N AM, V25, P1095; [No title captured]; 1990, PHS901101 US DEP HLT, P10	82	188	191	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					712	720		10.1001/jama.273.9.712	http://dx.doi.org/10.1001/jama.273.9.712			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853629				2022-12-24	WOS:A1995QH81400030
J	ECKHARDT, M; MUHLENHOFF, M; BETHE, A; KOOPMAN, J; FROSCH, M; GERARDYSCHAHN, R				ECKHARDT, M; MUHLENHOFF, M; BETHE, A; KOOPMAN, J; FROSCH, M; GERARDYSCHAHN, R			MOLECULAR CHARACTERIZATION OF EUKARYOTIC POLYSIALYLTRANSFERASE-1	NATURE			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; N-CAM; NERVE; NCAM; POLYSACCHARIDE; EXPRESSION; ANTIBODY; BINDING; CLONING	POLYSIALIC acid (PSA) is a dynamically regulated product of posttranslational modification of the neural cell adhesion molecule, NCAM(1,2). Presence of the large anionic carbohydrate modulates NCAM binding properties and, by increasing the intercellular space, influences interactions between other cell surface molecules(1-5). PSA expression underlies cell type- and developmental-specific alterations(6) and correlates with stages of cellular motility(6-8), In the adult, PSA becomes restricted to regions of permanent neural plasticity and regenerating neural and muscle tissues(6,9,10). Recent data implicate its important function in spatial learning and memory(11,12), and in tumour biology(13-16). Here we describe the molecular characterization of polysialyltransferase-1, the key enzyme of eukaryotic PSA synthesis. In reconstitution experiments, the newly cloned enzyme induces PSA synthesis in all NCAM-expressing cell lines. Our data therefore represent convincing evidence that the polycondensation of alpha-2,8-linked sialic acids in mammals is the result of a single enzymatic activity and provide a new basis for studying the functional role of PSA in neuro- and tumour biology.	HANNOVER MED SCH,INST MED MIKROBIOL,D-30625 HANNOVER,GERMANY; NETHERLANDS CANC INST,DEPT TUMOR BIOL,1006 CX AMSTERDAM,NETHERLANDS	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Netherlands Cancer Institute			Frosch, Matthias/H-2411-2013					ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; BLERHUIZEN MFA, 1993, GENE DEV, V7, P468; BLOCH RJ, 1992, J CELL BIOL, V116, P449, DOI 10.1083/jcb.116.2.449; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DANILOFF JK, 1986, J CELL BIOL, V103, P929, DOI 10.1083/jcb.103.3.929; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GERARDYSCHAHN R, 1994, INT J CANCER S, V8, P38; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; KERN WF, 1993, LEUKEMIA LYMPHOMA, V12, P1, DOI 10.3109/10428199309059565; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOMMINOTH P, 1991, AM J PATHOL, V139, P297; LANDMESSER L, 1992, J NEUROBIOL, V23, P1131, DOI 10.1002/neu.480230906; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MCCOY RD, 1984, J BIOL CHEM, V260, P12659; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TAKAMATSU K, 1994, CANCER RES, V54, P2598; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TOMLINSON S, 1985, J VIROL, V55, P374, DOI 10.1128/JVI.55.2.374-378.1985; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487	31	269	278	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					715	718		10.1038/373715a0	http://dx.doi.org/10.1038/373715a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854457				2022-12-24	WOS:A1995QH92800059
J	FERRARI, S; RIZZOLI, R; CHEVALLEY, T; SLOSMAN, D; EISMAN, JA; BONJOUR, JP				FERRARI, S; RIZZOLI, R; CHEVALLEY, T; SLOSMAN, D; EISMAN, JA; BONJOUR, JP			VITAMIN-D-RECEPTOR-GENE POLYMORPHISMS AND CHANGE IN LUMBAR-SPINE BONE-MINERAL DENSITY	LANCET			English	Note							WOMEN; MASS; DETERMINANTS; CALCIUM; TWIN	Common vitamin-D-receptor (VDR) gene allelic variants predict bone mineral density. We analysed VDR alleles and rate of change of lumbar-spine bone mineral density over 18 months in 72 elderly subjects. 9 BB homozygotes lost bone mineral density but 26 homozygotes for the alternative genotype (bb) did not (mean change -2.3 [SE 1.0] vs 0.9 [0.7]% per year, p<0.05), irrespective of calcium intake. Among 37 heterozygotes (Bb), however, change in bone mineral density correlated with calcium intake (r=035, p<0.03). This association between a marker and rate of bone loss in the elderly suggests that the effect of calcium intake on maintenance of bone mass could relate to VDR gene polymorphisms.	WHO,COLLABORATING CTR OSTEOPOROSIS & BONE DIS,DEPT MED,DIV CLIN PATHOPHYSIOL,GENEVA,SWITZERLAND; UNIV HOSP GENEVA,DEPT RADIOL,DIV NUCL MED,CH-1211 GENEVA,SWITZERLAND	World Health Organization; University of Geneva			Eisman, John A/C-2886-2014; Chevalley, Thierry/AAQ-1412-2021; Ferrari, Serge/ABD-2730-2020	Chevalley, Thierry/0000-0003-3338-1148; Ferrari, Serge/0000-0002-1372-4417				CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHEVALLEY T, 1994, OSTEOPOROSIS INT, V4, P245, DOI 10.1007/BF01623348; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DEQUEKER J, 1987, BONE, V8, P207, DOI 10.1016/8756-3282(87)90166-9; Kelly P J, 1990, Osteoporos Int, V1, P56, DOI 10.1007/BF01880417; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476	10	235	240	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					423	424		10.1016/S0140-6736(95)90404-2	http://dx.doi.org/10.1016/S0140-6736(95)90404-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853953				2022-12-24	WOS:A1995QG90400012
J	BIGRIGG, A; HAFFENDEN, DK; SHEEHAN, AL; CODLING, BW; READ, MD				BIGRIGG, A; HAFFENDEN, DK; SHEEHAN, AL; CODLING, BW; READ, MD			EFFICACY AND SAFETY OF LARGE-LOOP EXCISION OF THE TRANSFORMATION ZONE	LANCET			English	Article							DIATHERMY EXCISION	Large-loop excision of the transformation zone (LLETZ) has become a popular treatment for women with cervical intraepithelial neoplasia (CIN) before long-term effectiveness and safety have been fully evaluated. Women who took part in a 1990 study of the procedure have been followed-up by cervical cytology for longer than 2 years. The rate of recurrences and residual lesions was 5.0% in the first year and 0.6% in the second year. LLETZ was also effective when used as a repeat procedure, although the negative histology rate was much higher (4.7% for initial procedures and 20% for repeat procedures). 250 women from the original study group of 1000 answered a questionnaire on fertility and menstrual symptoms 3 years after LLETZ. We found no differences between these women and controls of the same age, living in the same geographical area, with a history of negative cervical smears. LLETZ is a safe and effective procedure with no effect on menstruation or fertility.	GLOUCESTERSHIRE ROYAL HOSP,DEPT OBSTET & GYNAECOL,GLOUCESTER,ENGLAND; ST MICHAELS HOSP,DEPT HISTOPATHOL,BRISTOL,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,DEPT HISTOPATHOL,GLOUCESTER,ENGLAND	Gloucestershire Royal Hospital; Gloucestershire Royal Hospital	BIGRIGG, A (corresponding author), UNIV BRISTOL,SOUTHMEAD HOSP,DEPT OBSTET & GYNAECOL,BRISTOL BS10 5NB,AVON,ENGLAND.							Altman D.G., 1991, PRACTICAL STAT MED R, DOI [DOI 10.1002/SIM.4780101015, 10.1002/sim.4780101015]; BIGRIGG MA, 1990, LANCET, V336, P229, DOI 10.1016/0140-6736(90)91746-W; BIGRIGG MA, 1991, BRIT MED J, V302, P577, DOI 10.1136/bmj.302.6776.577; COPPLESON M, 1981, GYNAECOLOGIC ONCOLOG, P428; HAMMOND RH, 1990, BRIT MED J, V301, P1344, DOI 10.1136/bmj.301.6765.1344; KITCHENER HC, 1991, BRIT J OBSTET GYNAEC, V98, P1112, DOI 10.1111/j.1471-0528.1991.tb15363.x; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MACINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MURDOCH JB, 1991, INT J GYNECOL CANCER, V1, P105, DOI 10.1111/j.1525-1438.1991.tb00024.x	9	112	116	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					32	34		10.1016/S0140-6736(94)90881-8	http://dx.doi.org/10.1016/S0140-6736(94)90881-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905048				2022-12-24	WOS:A1994MN93700017
J	RIFAT, SL				RIFAT, SL			ALUMINUM HYPOTHESIS LIVES	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE				RIFAT, SL (corresponding author), NIAGARA HLTH SERV DEPT, DIV EPIDEMIOL, ST CATHARINES, ON, CANADA.							BIRCHALL JD, 1989, NATURE, V338, P146, DOI 10.1038/338146a0; BIRCHALL JD, 1988, LANCET, V2, P1008, DOI 10.1016/S0140-6736(88)90754-4; BIRCHALL JD, 1991, ALZHEIMERS DISEASE E, P70; COMMENGES D, 1992, NEUROBIOL AGING S1, V13, pS116; DOLL R, 1993, AGE AGEING, V22, P138, DOI 10.1093/ageing/22.2.138; DRISCOLL CT, 1988, J ENVIRON ENG-ASCE, V114, P21, DOI 10.1061/(ASCE)0733-9372(1988)114:1(21); EDWARDSON JA, 1993, LANCET, V342, P211, DOI 10.1016/0140-6736(93)92301-9; JACQMIN H, IN PRESS AM J EPIDEM; KRAUS AS, 1992, CAN J PUBLIC HEALTH, V83, P97; LANDSBERG JP, 1992, NATURE, V360, P65, DOI 10.1038/360065a0; MCLACHLAN DRC, 1991, CAN MED ASSOC J, V145, P793; MICHEL P, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P387	12	12	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	1994	343	8888					3	4		10.1016/S0140-6736(94)90868-0	http://dx.doi.org/10.1016/S0140-6736(94)90868-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905047				2022-12-24	WOS:A1994MN93700004
J	SANDLE, GI; MCNICHOLAS, CM; LOMAX, RB				SANDLE, GI; MCNICHOLAS, CM; LOMAX, RB			POTASSIUM CHANNELS IN COLONIC CRYPTS	LANCET			English	Note							EPITHELIAL-CELL LINE; MEMBRANE; TRANSPORT; CA-2+; CAMP	A characteristic feature of intestinal epithelia is their ability to secrete chloride (Cl-), a process that occurs mainly in intestinal crypts and is the critical transport event in secretory diarrhoea. Increased potassium (K+) channel activity in the basolateral membrane has an important role in the Cl-secretory process by hyperpolarising the cell and maintaining a favourable electrochemical driving force for Cl- exit at the apical membrane. We have shown, using patch-clamp techniques, that the basolateral membrane of human colonic crypt cells contains low conductance K+ channels that are voltage and calcium (Ca2+) sensitive and blocked by barium (Ba2+). These K+ channels are regulated by cytosolic cyclic adenosine monophosphate (cAMP) and Ca2+, intracellular second messengers that also stimulate Cl- secretion. This population of human intestinal K+ channels may be a target for the pharmacological control of Cl- secretory diarrhoea.			SANDLE, GI (corresponding author), UNIV MANCHESTER,HOPE HOSP,SCH MED,DEPT MED,SALFORD M6 8HD,LANCS,ENGLAND.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; McNicholas-Bevensee, Carmel/0000-0002-7013-8764	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRETT KE, 1993, ADV COMP ENV PHYSL, V16, P215; Binder HJ, 1987, PHYSL GASTROINTESTIN, P1389; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAWKER PC, 1978, GASTROENTEROLOGY, V74, P1241; LOO DDF, 1989, J MEMBRANE BIOL, V110, P19, DOI 10.1007/BF01870989; MANDEL KG, 1986, J BIOL CHEM, V261, P704; RAMBAUD JC, 1986, CLIN GASTROENTEROL, V15, P603; WEYER A, 1985, J CLIN INVEST, V76, P1828	10	60	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					23	25		10.1016/S0140-6736(94)90878-8	http://dx.doi.org/10.1016/S0140-6736(94)90878-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905044				2022-12-24	WOS:A1994MN93700014
J	CULOTTA, E; KOSHLAND, DE				CULOTTA, E; KOSHLAND, DE			P53 SWEEPS THROUGH CANCER-RESEARCH	SCIENCE			English	Editorial Material																			0	89	98	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					1958	1961		10.1126/science.7903477	http://dx.doi.org/10.1126/science.7903477			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	7903477				2022-12-24	WOS:A1993MN10800012
J	ROSAHL, TW; GEPPERT, M; SPILLANE, D; HERZ, J; HAMMER, RE; MALENKA, RC; SUDHOF, TC				ROSAHL, TW; GEPPERT, M; SPILLANE, D; HERZ, J; HAMMER, RE; MALENKA, RC; SUDHOF, TC			SHORT-TERM SYNAPTIC PLASTICITY IS ALTERED IN MICE LACKING SYNAPSIN-I	CELL			English	Article							SQUID GIANT SYNAPSE; PROTEIN-KINASE-II; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; PHOSPHORYLATION; VESICLES; CALMODULIN; GENE; POTENTIATION; HIPPOCAMPUS	Synapsin I, the major phosphoprotein of synaptic vesicles, is thought to play a central role in neurotransmitter release. Here we introduce a null mutation into the murine synapsin I gene by homologous recombination. Mice with no detectable synapsin I manifest no apparent changes in well-being or gross nervous system function. Thus, synapsin I is not essential for neurotransmitter release. Electrophysiology reveals that mice lacking synapsin I exhibit a selective increase in paired pulse facilitation, with no major alterations in other synaptic parameters such as long-term potentiation. In addition to potential redundant functions shared with other proteins, synapsin I in normal mice may function to limit increases in neurotransmitter release elicited by residual Ca2+ after an initial stimulus.	UNIV TEXAS, HLTH SCI CTR, SW MED SCH, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ROSAHL, TW (corresponding author), UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT MOLEC GENET, DALLAS, TX 75235 USA.			Hammer, Robert E./0000-0001-5487-7551				BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENNETT AF, 1991, BIOCHEM J, V276, P793, DOI 10.1042/bj2760793; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; FYKSE EM, 1993, IN PRESS J NEUROSCI; GREENE RW, 1991, PROG NEUROBIOL, V36, P329, DOI 10.1016/0301-0082(91)90005-L; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HAYES NVL, 1991, BIOCHEM J, V275, P93, DOI 10.1042/bj2750093; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; KAHLE JS, 1989, BRAIN RES, V482, P159, DOI 10.1016/0006-8993(89)90554-4; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MCGUINNESS TL, 1989, J NEUROSCI, V9, P4138; MCNAUGHTON BL, 1980, BRAIN RES, V199, P1, DOI 10.1016/0006-8993(80)90226-7; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NICHOLS RA, 1992, J NEUROCHEM, V58, P783, DOI 10.1111/j.1471-4159.1992.tb09788.x; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; PRINCE DA, 1992, P NATL ACAD SCI USA, V89, P8586, DOI 10.1073/pnas.89.18.8586; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Sambrook J., 1989, MOL CLONING LAB MANU; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SIKORSKI AF, 1991, BRAIN RES BULL, V27, P195, DOI 10.1016/0361-9230(91)90067-T; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUDHOF TC, 1991, NEUROSCI YEAR, V2, P146; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P2238; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P213, DOI 10.1085/jgp.76.2.213; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	46	280	291	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 19	1993	75	4					661	670		10.1016/0092-8674(93)90487-B	http://dx.doi.org/10.1016/0092-8674(93)90487-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7902212	Bronze			2022-12-24	WOS:A1993MH74900012
J	MARTIN, J; MAYHEW, M; LANGER, T; HARTL, FU				MARTIN, J; MAYHEW, M; LANGER, T; HARTL, FU			THE REACTION CYCLE OF GROEL AND GROES IN CHAPERONIN-ASSISTED PROTEIN-FOLDING	NATURE			English	Article							ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; MOLECULAR CHAPERONE; ATP HYDROLYSIS; PURIFICATION; COOPERATIVITY; SURFACE	The reaction mechanism of protein folding by the chaperonin GroEL and its regulator GroES has been defined. GroES and substrate protein counteract each other's effects on GroEL: whereas GroES stabilizes GroEL in the ADP-bound state, binding of unfolded polypeptide within the cavity of the GroEL cylinder triggers ADP and GroES release. Upon ADP-ATP exchange, GroES reassociates with GroEL and ATP hydrolysis discharges the bound protein for folding. Partially folded protein rebinds to the chaperonin, thus perpetuating the cycle until folding is complete.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	Langer, Thomas/0000-0003-1250-1462				BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MCLENNAN NF, 1993, MOL MICROBIOL, V7, P49, DOI 10.1111/j.1365-2958.1993.tb01096.x; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522	31	265	268	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					228	233		10.1038/366228a0	http://dx.doi.org/10.1038/366228a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	7901770				2022-12-24	WOS:A1993MH32500052
J	MARTIN, J; GEROMANOS, S; TEMPST, P; HARTL, FU				MARTIN, J; GEROMANOS, S; TEMPST, P; HARTL, FU			IDENTIFICATION OF NUCLEOTIDE-BINDING REGIONS IN THE CHAPERONIN PROTEINS GROEL AND GROES	NATURE			English	Article							ESCHERICHIA-COLI; ATP HYDROLYSIS; COOPERATIVITY; PURIFICATION; F1-ATPASE; GENES; SITE	THE chaperonin GroEL, a tetradecameric cylinder consisting of subunits of M(r) approximately 60,000 (60K), and its cofactor GroES, a heptameric ring of 10K subunits, mediate protein folding in the cytosol of Escherichia coli1-3. In the presence of nucleotide, GroES forms a 1:1 complex with GroEL which binds unfolded protein in its central cavity and releases it to allow folding upon ATP hydrolysis4-7. Using labelling with azido-ATP, we have identified a protease-stable nucleotide-binding domain of M(r) 40K in the GroEL subunits (residues 153-531). Azido-ATP is crosslinked to the highly conserved Tyr 477, indicating that this residue is close to the purine ring of the bound nucleotide. Surprisingly, GroES also binds ATP cooperatively and with an affinity comparable to that of GroEL. Azido-nucleotide labelling of GroES subunits occurs at the conserved Tyr 71 in a protease-stable 6.5K domain (starting at residue 33). Proteinase K cleavage at residue 32 is prevented when GroES is bound to GroEL. ATP binding to GroES may be important in charging the seven subunits of the interacting GroEL ring with ATP to facilitate cooperative ATP binding and hydrolysis for substrate protein release.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019					Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P327; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GEROMANOS S, IN PRESS TECHNIQUES, V5; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KNIGHT KL, 1985, J BIOL CHEM, V260, P185; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	29	94	99	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					279	282		10.1038/366279a0	http://dx.doi.org/10.1038/366279a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	7901771				2022-12-24	WOS:A1993MH32500068
J	SHINDO, M; ARAI, K; SOKAWA, Y; OKUNO, T				SHINDO, M; ARAI, K; SOKAWA, Y; OKUNO, T			HEPATIC HEPATITIS-C VIRUS-RNA AS A PREDICTOR OF A LONG-TERM RESPONSE TO INTERFERON-ALPHA THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C VIRUSES; HEPATITIS C; RNA, VIRAL; INTERFERON-ALPHA; HEPATITIS, CHRONIC ACTIVE	POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; CONTROLLED TRIAL; VIRAL SEQUENCES; ALFA THERAPY; NON-A; SERUM; LIVER; GENOTYPES; PLACEBO	Objective: To identify predictors of a long-term response to interferon-alpha therapy in chronic hepatitis C and to determine whether hepatitis C virus (HCV) was eradicated in patients with chronic hepatitis C who had a long-term response to therapy. Design: A retrospective analysis. Setting: In- and outpatient liver clinic of a municipal hospital in Japan. Patients: 47 patients with chronic hepatitis C who responded to interferon-alpha were divided into two groups: 22 patients with a long-term response (serum aminotransferase levels remained normal for > 1 year after therapy) and 25 patients with a short-term response (serum aminotransferase levels increased again after therapy). Measurements: Genotyping of HCV, titers of HCV RNA in liver and serum samples (using the reverse transcriptase-polymerase chain reaction), histologic activity index, and liver histologic tests during and 1 year after therapy. Results: Among the 22 long-term responders, HCV RNA was no longer detectable in liver and serum samples of 21 (95%) at the end of therapy and remained undetectable in the serum of 20 (98%) and in the liver of 19 (86%) 1 year after therapy. Liver histologic tests improved substantially immediately after therapy and 1 year after therapy in the long-term responders; however, 18 (82%) of these patients still had mild, chronic hepatitis. Among the 25 short-term responders, HCV RNA was still detected in the liver of 19 (76%) and in the serum of 9 (36%) at the end of therapy. Multivariate logistic regression analysis showed that the persistent presence of hepatic HCV RNA at the end of therapy was the strongest predictor of relapse. Conclusion: These findings suggest that HCV infection was eradicated in most of the long-term responders to interferon-alpha therapy because HCV RNA could no longer be detected in their serum and liver samples and because a significant improvement gradually occurred in their liver histologic results. The persistent presence of hepatic HCV RNA at the end of therapy was the most important predictor of relapse.	KYOTO INST TECHNOL, KYOTO, JAPAN	Kyoto Institute of Technology	SHINDO, M (corresponding author), AKASHI MUNICIPAL HOSP, DEPT INTERNAL MED, 1-33 TAKASHOMACHI, AKASHI, HYOGO 673, JAPAN.							BALART LA, 1993, GASTROENTEROLOGY, V104, P1472, DOI 10.1016/0016-5085(93)90358-J; CAMPS J, 1994, J HEPATOL, V21, P4, DOI 10.1016/S0168-8278(94)80129-0; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS GL, 1994, J HEPATOL, V21, P1, DOI 10.1016/S0168-8278(94)80128-2; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DAVIS GL, 1990, HEPATOLOGY, V12, P905; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIBISCEGLIE AM, 1993, GASTROENTEROLOGY, V105, P858, DOI 10.1016/0016-5085(93)90905-R; FONG TL, 1991, J CLIN INVEST, V88, P1058, DOI 10.1172/JCI115368; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; HAGIWARA H, 1993, GASTROENTEROLOGY, V104, P877, DOI 10.1016/0016-5085(93)91025-D; KANAI K, 1992, LANCET, V339, P1543, DOI 10.1016/0140-6736(92)91311-U; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SERFATY L, 1994, J HEPATOL, V21, P12, DOI 10.1016/S0168-8278(94)80130-4; SHINDO M, 1992, J INFECT DIS, V166, P424, DOI 10.1093/infdis/166.2.424; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	24	103	103	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					586	591		10.7326/0003-4819-122-8-199504150-00005	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887552				2022-12-24	WOS:A1995QR52500005
J	DORN, A; STOFFEL, R; MATILE, H; BUBENDORF, A; RIDLEY, RG				DORN, A; STOFFEL, R; MATILE, H; BUBENDORF, A; RIDLEY, RG			MALARIAL HAEMOZOIN BETA-HEMATIN SUPPORTS HEME POLYMERIZATION IN THE ABSENCE OF PROTEIN	NATURE			English	Article							PLASMODIUM-FALCIPARUM; HEMOGLOBIN DEGRADATION; FERRIPROTOPORPHYRIN-IX; CHLOROQUINE; PARASITES; PIGMENT; CULTURE	MALARIAL parasites growing inside erythrocytes digest up to 80% of the host cell's haemoglobin within a lysosomal organelle, the digestive vacuole(1,2). They sequester the potentially toxic haem (Fe (II) protohaematoporphyrin) that is released during this process into an insoluble pigment called haemozoin, which consists of polymerized Fe(III) protohaematoporphyrin subunits(3). We have studied this process of haem polymerization, which was previously reported to be enzyme-mediated and the target of the quinoline antimalarial drugs chloroquine and quinine(4). Here we show that, rather than being enzyme-mediated, haem polymerization is actually a chemical process, dependent only on the presence of haem-derived material associated with haemozoin and not on protein. This discovery does not invalidate haem polymerization as a target for drug intervention and the mechanism by which haemozoin formation is initiated is still not understood, but our view of this process and of the action of chloroquine must be reconsidered.	F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES SPECT,CH-4002 BASEL,SWITZERLAND	Roche Holding	DORN, A (corresponding author), F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES INFECT DIS,CH-4002 BASEL,SWITZERLAND.							ASHONG JO, 1989, T ROY SOC TROP MED H, V83, P167, DOI 10.1016/0035-9203(89)90631-7; COHEN P, 1971, J CLIN INVEST, V50, P762, DOI 10.1172/JCI106547; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FITCH CD, 1987, J BIOL CHEM, V262, P15552; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1992, PARASITOL TODAY, V8, P280, DOI 10.1016/0169-4758(92)90146-S; GOMAN M, 1982, MOL BIOCHEM PARASIT, V25, P391; GUSHIMANA Y, 1993, BIOPHYS CHEM, V47, P153, DOI 10.1016/0301-4622(93)85033-E; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; SLATER AFG, 1993, Patent No. 9211279; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840	15	347	351	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					269	271		10.1038/374269a0	http://dx.doi.org/10.1038/374269a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885447	Green Published			2022-12-24	WOS:A1995QM38700052
J	NOAKES, PG; GAUTAM, M; MUDD, J; SANES, JR; MERLIE, JP				NOAKES, PG; GAUTAM, M; MUDD, J; SANES, JR; MERLIE, JP			ABERRANT DIFFERENTIATION OF NEUROMUSCULAR-JUNCTIONS IN MICE LACKING S-LAMININ LAMININ BETA-2	NATURE			English	Article							ORIGINAL SYNAPTIC SITES; ACETYLCHOLINE-RECEPTOR; SKELETAL-MUSCLE; BASAL LAMINA; PROTEIN; IDENTIFICATION; INNERVATION; SYNAPSIN; REGIONS; CELLS	SYNAPSE formation requires a complex interchange of information between the pre- and postsynaptic partners. At the skeletal neuromuscular junction, some of this information is contained in the basal lamina (BL), which runs through the synaptic cleft between the motor nerve terminal and the muscle fibre. During regeneration following injury, components of synaptic BL can trigger several features of postsynaptic differentiation in the absence of the nerve terminal, and of presynaptic differentiation in the absence of the muscle fibre(1-3). One nerve-derived component of synaptic BL, agrin, is known to affect postsynaptic differentiation3, but no muscle-derived components have yet been shown to influence motor nerve terminals. A candidate for such a role is s-laminin (also called laminin beta 2), a homologue of the B1 (beta 1) chain of the widely distributed BL glycoprotein, laminin(30). s-laminin is synthesized by muscle cells(5) and concentrated in synaptic BL(4). In vitro, recombinant s-laminin fragments are selectively adhesive for motor neuron-like cells, inhibit neurite outgrowth promoted by other matrix molecules, and act as a 'stop signal' for growing neurites(6,7). By generating and characterizing mice with a targeted mutation of the s-laminin gene, we show here that s-laminin regulates formation of motor nerve terminals.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Noakes, Peter/X-9825-2019	Noakes, Peter/0000-0001-9821-8478; Gautam, Medha/0000-0002-5418-4322				BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; COVAULT J, 1986, J CELL BIOL, V102, P716, DOI 10.1083/jcb.102.3.716; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; GREEN TL, 1992, J BIOL CHEM, V267, P2014; GREENGARD P, 1993, SCIENCE, V259, P708; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUTCHINSON DO, 1993, BRAIN, V116, P633, DOI 10.1093/brain/116.3.633; INOUE A, 1992, J BIOL CHEM, V267, P10613; JIRMANOVA I, 1975, J NEUROCYTOL, V4, P141, DOI 10.1007/BF01098779; KARNOVSKY MJ, 1964, J CELL BIOL, V23, P217, DOI 10.1083/jcb.23.2.217; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PORTER BE, IN PRESS NEURON; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; SCOTT LJC, 1988, J NEUROSCI, V8, P932; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313	30	400	406	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					258	262		10.1038/374258a0	http://dx.doi.org/10.1038/374258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885444				2022-12-24	WOS:A1995QM38700049
J	HELM, TN				HELM, TN			EVALUATION OF ALOPECIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HELM, TN (corresponding author), SUNY BUFFALO,BUFFALO,NY, USA.							BERGFELD WF, 1994, CONSULTANT, V34, P1390; HELM TN, 1992, INT J DERMATOL, V31, P437, DOI 10.1111/j.1365-4362.1992.tb02680.x; STECK WD, 1978, CUTIS, V21, P543; WHITING DA, 1993, J AM ACAD DERMATOL, V28, P755, DOI 10.1016/0190-9622(93)70106-4	4	1	1	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					897	898						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869566				2022-12-24	WOS:A1995QL40200034
J	MAGRATH, I				MAGRATH, I			BONE-MARROW TRANSPLANTATION FOR LEUKEMIA - A LAME STALKING HORSE FOR USE OF HIGH-TECHNOLOGY MEDICAL-CARE	LANCET			English	Editorial Material											MAGRATH, I (corresponding author), NIH, LYMPHOMA BIOL SECT, BETHESDA, MD 20892 USA.							DICKE KA, 1993, ANN ONCOL, V4, pS81, DOI 10.1093/annonc/4.suppl_1.S81; GORIN NC, 1993, ANN ONCOL, V4, pS59, DOI 10.1093/annonc/4.suppl_1.S59; HAIOUN C, 1994, J CLIN ONCOL, V12, P2543, DOI 10.1200/JCO.1994.12.12.2543; KANTARJIAN HM, 1993, BLOOD, V82, P691; SEBBAN C, 1994, J CLIN ONCOL, V12, P2580, DOI 10.1200/JCO.1994.12.12.2580; 1994, GAOPEMD9410 US GEN A	6	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 11	1995	345	8950					601	602		10.1016/S0140-6736(95)90516-2	http://dx.doi.org/10.1016/S0140-6736(95)90516-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898174				2022-12-24	WOS:A1995QM07500004
J	HIOM, K; WEST, SC				HIOM, K; WEST, SC			BRANCH MIGRATION DURING HOMOLOGOUS RECOMBINATION - ASSEMBLY OF A RUVAB-HOLLIDAY JUNCTION COMPLEX IN-VITRO	CELL			English	Article							ESCHERICHIA-COLI RUVA; DNA-REPAIR; PHYSICAL-PROPERTIES; PROTEINS; PURIFICATION; GENES	The RuvA and RuvB proteins of E. coli promote the branch migration or movement of Holliday junctions during genetic recombination and DNA repair. Using small synthetic Holliday junctions in which the crossover point is confined near one end of the DNA molecule, we show that RuvAB-mediated branch migration occurs with a defined polarity. The assembly of RuvA and RuvB on the Holliday junction has been investigated by sedimentation analysis and by DNase I footprinting. We find that RuvA protein binds and protects all four strands of DNA at the crossover point, whereas RuvB protein binds the DNA asymmetrically. The polarity of branch migration is defined by the asymmetric assembly of the RuvAB branch migration complex relative to the junction and is consistent with a model in which RuvAB drives branch migration by passing the DNA through the hexameric rings of RuvB.			HIOM, K (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			West, Stephen/0000-0001-8848-9418				BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; MURCHIE AIH, 1990, NUCLEIC ACIDS RES, V18, P2599, DOI 10.1093/nar/18.9.2599; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SAMBROOK E, 1989, MOL CLONING LABORATO; SARGENTINI NJ, 1989, MUTAT RES, V215, P115, DOI 10.1016/0027-5107(89)90224-8; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1994, J BIOL CHEM, V269, P26552; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315	26	68	69	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					787	793		10.1016/0092-8674(95)90357-7	http://dx.doi.org/10.1016/0092-8674(95)90357-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889572	Bronze			2022-12-24	WOS:A1995QM39900015
J	DALESSANDRO, U; OLALEYE, BO; MCGUIRE, W; LANGEROCK, P; BENNETT, S; AIKINS, MK; THOMSON, MC; CHAM, MK; CHAM, BA; GREENWOOD, BM				DALESSANDRO, U; OLALEYE, BO; MCGUIRE, W; LANGEROCK, P; BENNETT, S; AIKINS, MK; THOMSON, MC; CHAM, MK; CHAM, BA; GREENWOOD, BM			MORTALITY AND MORBIDITY FROM MALARIA IN GAMBIAN CHILDREN AFTER INTRODUCTION OF AN IMPREGNATED BEDNET PROGRAM	LANCET			English	Article							AFRICA; NETS; STRATEGY; TRIAL	After the success of a controlled trial of insecticide-treated bednets in lowering child mortality, The Gambia initiated a National Insecticide Impregnated Bednet Programme (NlBP) in 1992 with the objective of introducing this form of malaria control into all large villages in The Gambia. Five areas (population 115 895) were chosen as sentinel sites for evaluation of the NlBP. During the first year of intervention a 25% reduction was achieved in ail-cause mortality in children 1-9 years old living in treated villages (rate ratio 0.75 [95% CI 0.57-0.98], p=0.04). If one area where the programme was ineffective was excluded, the was 38% (0.62 [0.46-0.83), p=0.001). A in rates of parasitaemia and high-density parasitaemia, an increase in mean packed-cell volume (rate ratio 0.75 [95% Cl 0.59-0.98], p=0.04) and an improvement in the nutritional status of children living in treated villages were also detected. In a country such as The Gambia, where nets were widely used and which has a good primary health care system, it is possible to achieve insecticide-treatment of bednets at a national level with a significant reduction in child mortality; but at a cost which the country cannot afford.	MRC LABS,BANJUL,GAMBIA; JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC INFECT DIS GRP,OXFORD,ENGLAND; LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON,ENGLAND; MINIST HLTH & SOCIAL WELF,BANJUL,GAMBIA	MRC Laboratory Molecular Biology; University of Oxford; University of London; London School of Hygiene & Tropical Medicine			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; McGuire, William/0000-0001-8572-3467				ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O; ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P31, DOI 10.1016/0035-9203(93)90173-N; ALONSO PL, 1987, ANN TROP PAEDIATR, V7, P187, DOI 10.1080/02724936.1987.11748504; Bryan J.H., 1987, Parassitologia (Rome), V29, P221; DALESSANDRO U, 1994, B WORLD HEALTH ORGAN, V72, P391; EWBANK DC, 1993, INT J EPIDEMIOL, V22, pS8, DOI 10.1093/ije/22.Supplement_1.S8; GIGLIOLI G, 1972, B WORLD HEALTH ORGAN, V46, P181; GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q; GREENWOOD BM, 1983, T R SOC TROP MED S2, V87, P3; MAURITSEN RH, 1984, THESIS U WASHINGTON; SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; THOMPSON BH, 1993, CIRCULATION, V88, P638; WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	17	326	330	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					479	483		10.1016/S0140-6736(95)90582-0	http://dx.doi.org/10.1016/S0140-6736(95)90582-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861874				2022-12-24	WOS:A1995QH92900009
J	RICHARDS, C; RICHARDS, H; PHEBY, D				RICHARDS, C; RICHARDS, H; PHEBY, D			SKIN-CANCER - HOW ACCURATE ARE LOCAL DATA	BRITISH MEDICAL JOURNAL			English	Article									BRISTOL & DIST HLTH AUTHOR,DEPT PUBL HLTH MED,BRISTOL BS2 8EE,AVON,ENGLAND; S WESTERN REG CANC REGISTRY,BRISTOL BS8 2PR,AVON,ENGLAND	University of Bristol								BENN RT, 1982, INT J EPIDEMIOL, V11, P362, DOI 10.1093/ije/11.4.362; Boyle P, 1991, CANC REGISTRATION PR, V95; 1990, REV NATIONAL CANCER; 1992, HLTH NATION SPECIFIC; 1993, PUBLIC HLTH COMMON D	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					503	503		10.1136/bmj.310.6978.503	http://dx.doi.org/10.1136/bmj.310.6978.503			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888891	Green Published			2022-12-24	WOS:A1995QJ59800024
J	WHITE, MA; NICOLETTE, C; MINDEN, A; POLVERINO, A; VANAELST, L; KARIN, M; WIGLER, MH				WHITE, MA; NICOLETTE, C; MINDEN, A; POLVERINO, A; VANAELST, L; KARIN, M; WIGLER, MH			MULTIPLE RAS FUNCTIONS CAN CONTRIBUTE TO MAMMALIAN-CELL TRANSFORMATION	CELL			English	Article							ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; MAP KINASE; GROWTH-FACTOR; HA-RAS; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; IN-VITRO; RAF-1; YEAST	We have developed a generalized approach, using two hybrid interactions, to isolate Ha-Ras effector loop mutations that separate the ability of Ha-Ras to interact with different downstream effecters. These mutations attenuate or eliminate Ha-ras(G12V) transformation of mammalian cells, but retain complementary activity, as demonstrated by synergistic induction of foci of growth-transformed cells, and by the ability to activate different downstream components. The transformation defect of Ha-ras(G12V, E37G) is rescued by a mutant, raf1, that restores interaction. These results indicate that multiple cellular components, including Raf1, are activated by Ha-Ras and contribute to Ha-Ras-induced mammalian cell transformation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego	WHITE, MA (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Wigler, Michael/0000-0003-4396-1971				BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEL PL, 1994, IN PRESS METH ENZYMO; BOLLAG G, 1994, ANN REV CELL BIOL, V7, P601; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUADRADO A, 1993, ONCOGENE, V8, P2443; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PORRAS A, 1994, J BIOL CHEM, V269, P12741; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; Sambrook J., 1989, MOL CLONING LAB MANU; Sherman F., 1986, METHODS YEAST GENETI; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOTTON D, 1993, J BIOL CHEM, V268, P17975; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	58	632	638	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					533	541		10.1016/0092-8674(95)90507-3	http://dx.doi.org/10.1016/0092-8674(95)90507-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867061	Bronze			2022-12-24	WOS:A1995QJ60200005
J	STEBBINS, CE; BORUKHOV, S; ORLOVA, M; POLYAKOV, A; GOLDFARB, A; DARST, SA				STEBBINS, CE; BORUKHOV, S; ORLOVA, M; POLYAKOV, A; GOLDFARB, A; DARST, SA			CRYSTAL-STRUCTURE OF THE GREA TRANSCRIPT CLEAVAGE FACTOR FROM ESCHERICHIA-COLI	NATURE			English	Article							RNA-POLYMERASE; ELONGATION-FACTOR; PROTEIN; ERRORS; MAPS	TRANSCRIPTION elongation factors stimulate the activity of DNA-dependent RNA polymerases by increasing the overall elongation rate and the completion of RNA chains. One group of such factors, which includes Escherichia coli GreA, GreB and eukaryotic SII (TFIIS), acts by inducing hydrolytic cleavage of the transcript within the RNA polymerase, followed by relase of the 3'-terminal fragment(1-5). Here we report the crystal structure of GreA at 2.2 Angstrom resolution. The structure contains an amino-terminal domain consisting of an antiparallel alpha-helical coiled-coil dimer which extends into solution, reminiscent of the coiled coil in seryl-tRNA synthetases(6). A site near the tip of the coiled-coil 'finger' plays a direct role in the transcript cleavage reaction by contacting the 3'-end of the transcript. The structure exhibits an unusual asymmetric charge distribution which indicates the manner in which GreA interacts with the RNA polymerase elongation complex.	ROCKEFELLER UNIV,NEW YORK,NY 10021; PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016	Rockefeller University			Borukhov, Sergei/AAF-3195-2019; Stebbins, Erec/N-2565-2018	Borukhov, Sergei/0000-0002-3517-3003; Stebbins, Erec/0000-0001-6229-5308				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DARST SA, 1994, J MOL BIOL, V242, P582, DOI 10.1006/jmbi.1994.1603; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; MARKS GL, 1992, NUCLEIC ACIDS RES, V20, P3785, DOI 10.1093/nar/20.14.3785; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REIONES D, 1992, J BIOL CHEM, V26, P3795; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P359; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V16, P6443; WOODY AYM, 1984, BIOCHEMISTRY-US, V23, P2843, DOI 10.1021/bi00308a001; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	26	116	121	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					636	640		10.1038/373636a0	http://dx.doi.org/10.1038/373636a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854424				2022-12-24	WOS:A1995QG99700061
J	WALD, NJ; BOWER, C				WALD, NJ; BOWER, C			FOLIC-ACID, PERNICIOUS-ANEMIA, AND PREVENTION OF NEURAL-TUBE DEFECTS	LANCET			English	Editorial Material											WALD, NJ (corresponding author), MED COLL ST BARTHOLOMEWS HOSP,WOLFSON INST PREVENT MED,LONDON,ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; WALD NJ, 1994, CIBA F SYMP, V181, P192; 1992, MMWR, V41, P1; 1994, BRIT MED J, V208, P223; 1991, LANCET, V338, P132; 1992, FOLIC ACID PREVENTIO	6	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					307	307		10.1016/S0140-6736(94)91156-8	http://dx.doi.org/10.1016/S0140-6736(94)91156-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905138				2022-12-24	WOS:A1994MU98500002
J	RIJLI, FM; MARK, M; LAKKARAJU, S; DIERICH, A; DOLLE, P; CHAMBON, P				RIJLI, FM; MARK, M; LAKKARAJU, S; DIERICH, A; DOLLE, P; CHAMBON, P			A HOMEOTIC TRANSFORMATION IS GENERATED IN THE ROSTRAL BRANCHIAL REGION OF THE HEAD BY DISRUPTION OF HOXA-2, WHICH ACTS AS A SELECTOR GENE	CELL			English	Article							HOMEOBOX GENE; NEURAL CREST; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; CHICK-EMBRYO; EXPRESSION; HINDBRAIN; SEGMENTATION; ORIGIN; MORPHOGENESIS	The Hoxa-2 gene was disrupted by homologous recombination. Homozygous mutant mice died at birth. Defects were found in the branchial region of the head, which corresponds to the Hoxa-2 rostral expression domain. While rhombomeric and neural crest cell (NCC) segmentation was not affected, mesenchymal NCC derivatives of the second arch were lacking, and second arch mesenchymal NCC identity was changed to first arch identity, resulting in homeotic transformation of second to first arch skeletal elements. These results reveal the existence of a skeletogenic ground pattern program common to at least the mesenchymal NCC that originated from rhombomeres 2 and 4. The appearance of an atavistic reptilian pterygoquadrate element in Hoxa-2 mutants suggests that this ground pattern is intermediate between reptiles and mammals. The ground pattern program appears to be modified in the mouse first arch by a Hox-independent process, whereas Hoxa-2 acts as a selector gene in the second arch.			RIJLI, FM (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL, GENET MOLEC EUCARYOTES LAB, CNRS, F-67085 STRASBOURG, FRANCE.		Dolle, Pascal/A-8037-2010; RIJLI, Filippo/AAP-2516-2020	Dolle, Pascal/0000-0002-9294-9090; RIJLI, Filippo/0000-0003-0515-0182				ALLIN EF, 1975, J MORPHOL, V147, P403, DOI 10.1002/jmor.1051470404; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CLARKE JDW, 1993, DEVELOPMENT, V118, P151; de Beer G.R, 1971, DEV VERTEBRATE SKULL; DEDOUARIN N, 1993, DEV BIOL, V159, P24; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GAUNT SJ, 1993, DEVELOPMENT, V117, P769; GAUNT SJ, 1988, DEVELOPMENT S, V104, P71; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; Hall B.K., 1999, EVOLUTIONARY DEV BIO; HALL BK, 1982, J CRAN GENET DEV BIO, V2, P309; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; LANGILLE RM, 1989, BIOL REV, V64, P73, DOI 10.1111/j.1469-185X.1989.tb00672.x; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MARK M, 1993, DEVELOPMENT, V119, P319; MORRISSKAY G, 1991, J CRAN GENET DEV BIO, V11, P181; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; OLSON EC, 1959, EVOLUTION, V13, P344, DOI 10.2307/2406111; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; Stadtmuller F., 1936, HDB VERGLEICHENDEN A, V4, P839; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; VERSLUYS VJ, 1936, HDB VERGLEICHENDEN A, V4, P699; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802	44	516	522	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1333	1349		10.1016/0092-8674(93)90620-6	http://dx.doi.org/10.1016/0092-8674(93)90620-6			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7903601				2022-12-24	WOS:A1993MP86900012
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSAL TO REQUIRE EVIDENCE OF EFFECTIVENESS OF SPERMICIDES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-24	WOS:A1995QP89000008
J	TAKEI, K; MCPHERSON, PS; SCHMID, SL; DECAMILLI, P				TAKEI, K; MCPHERSON, PS; SCHMID, SL; DECAMILLI, P			TUBULAR MEMBRANE INVAGINATIONS COATED BY DYNAMIN RINGS ARE INDUCED BY GTP-GAMMA-S IN NERVE-TERMINALS	NATURE			English	Article							FROG NEUROMUSCULAR JUNCTION; SYNAPTIC VESICLE MEMBRANE; I PROTEIN-I; BINDING PROTEINS; MECHANOCHEMICAL ENZYME; TRANSMITTER RELEASE; ENDOCYTOSIS; DROSOPHILA; PHOSPHOPROTEIN; MICROTUBULES	THE mechanisms through which synaptic vesicle membranes are reinternalized after exocytosis remain a matter of debate(1-5). Because several vesicular transport steps require GTP hydrolysis(6-9), GTP-gamma S may help identify intermediates in synaptic vesicle recycling. In GTP-gamma S-treated nerve terminals, we observed tubular invaginations of the plasmalemma that were often, but not always, capped by a clathrin-coated bud, Strikingly, the walls of these tubules were decorated by transverse electron-dense rings that were morphologically similar to structures formed by dynamin around tubular templates(10,11). Dynamin is a GTPase implicated in synaptic vesicle endocytosis(12-14) and here we show that the wails of these membranous tubules, but not their distal ends, were positive for dynamin immunoreactivity, These findings demonstrate that dynamin and clathrin act at different sites in the formation of endocytic vesicles, They strongly support a role for dynamin in the fission reaction and suggest that stabilization of the GTP-bound conformation of dynamin leads to tubule formation by progressive elongation of the vesicle stalk.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED RES INST, NEW HAVEN, CT 06510 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Yale University; Yale University; Scripps Research Institute				Schmid, Sandra/0000-0002-1690-7024; Takei, Kohji/0000-0002-6555-9425				CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NUOFFER C, 1994, REV BIOCH, V63, P949; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TAKEI K, 1992, J NEUROSCI, V12, P489; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617	35	643	652	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					186	190		10.1038/374186a0	http://dx.doi.org/10.1038/374186a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877693				2022-12-24	WOS:A1995QL39700066
J	GIBBONS, A				GIBBONS, A			LANGUAGES LAST STANDS	SCIENCE			English	Editorial Material																			0	4	4	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1272	1272		10.1126/science.7871421	http://dx.doi.org/10.1126/science.7871421			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871421				2022-12-24	WOS:A1995QK06800023
J	SALLER, DN; LESSER, KB; HARREL, U; ROGERS, BB; OYER, CE				SALLER, DN; LESSER, KB; HARREL, U; ROGERS, BB; OYER, CE			THE CLINICAL UTILITY OF THE PERINATAL AUTOPSY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To evaluate the clinical utility of the perinatal autopsy in determining the cause of a perinatal death. Design.-Retrospective observational survey. Setting.-University-affiliated, private, tertiary care hospital, limited to obstetrics, gynecology, and neonatology. Subjects.-All fetal deaths and neonatal deaths from 1990 and 1991 at Women and Infants Hospital, Providence, RI, were reviewed. Fetal deaths with a gestational age of less than 20 weeks and neonatal deaths occurring more than 48 hours after birth were excluded. Main Outcome Measures.-A clinical medical record review assessed the clinical diagnosis. Pathology records were reviewed independently. The clinical and autopsy diagnoses were compared and categorized as follows: (1) confirm (clinical and autopsy diagnoses concordant); (2) change (clinical and autopsy diagnoses discordant); (3) add (significant unexpected findings noted on the autopsy although the clinical diagnosis was not altered); (4) autopsy inconclusive; (5) autopsy not done or not available. Results.-Of 168 perinatal deaths, an autopsy was not obtained in 26.2% and was inconclusive in 24.2% of cases with an autopsy. Of 94 patients with conclusive autopsies, in 55.3%, the pathologic diagnosis confirmed the clinical diagnosis, and in 44.7%, it changed or significantly added to the clinical diagnosis. Conclusions.-These findings support the clinical relevance of the perinatal autopsy. As few published reports directly address the specific yield of the autopsy among fetal and neonatal deaths, these results may be useful in counseling patients who are considering a perinatal autopsy.	UNIV ROCHESTER,STRONG MEM HOSP,SCH MED,DEPT PEDIAT,ROCHESTER,NY 14642; BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,DEPT OBSTET & GYNECOL,PROVIDENCE,RI; BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,DEPT PATHOL,PROVIDENCE,RI; UNIV ARIZONA,DEPT OBSTET & GYNECOL,TUCSON,AZ; CHILDRENS MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Rochester; Brown University; Women & Infants Hospital Rhode Island; Brown University; Women & Infants Hospital Rhode Island; University of Arizona	SALLER, DN (corresponding author), UNIV ROCHESTER,STRONG MEM HOSP,SCH MED,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,BOX 8668,ROCHESTER,NY 14642, USA.							CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P5; FRETTS RC, 1992, OBSTET GYNECOL, V79, P35; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; LUNDBERG GD, 1994, JAMA-J AM MED ASSOC, V271, P317, DOI 10.1001/jama.1994.03510280079038; MCKUSICK VA, 1992, MENDELIAN INHERITANC, pR21; MEIER PR, 1986, OBSTET GYNECOL, V67, P349; RAO MG, 1990, AM J CLIN PATHOL, V93, P486, DOI 10.1093/ajcp/93.4.486; SHEN-SCHWARZ S, 1989, Pediatric Pathology, V9, P1	9	83	86	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					663	665		10.1001/jama.273.8.663	http://dx.doi.org/10.1001/jama.273.8.663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844878				2022-12-24	WOS:A1995QG74800033
J	MADICO, G; GILMAN, RH; CHECKLEY, W; CABRERA, L; KOHLSTADT, I; KACENA, K; DIAZ, JF; BLACK, R				MADICO, G; GILMAN, RH; CHECKLEY, W; CABRERA, L; KOHLSTADT, I; KACENA, K; DIAZ, JF; BLACK, R			COMMUNITY INFECTION RATIO AS AN INDICATOR FOR TUBERCULOSIS-CONTROL	LANCET			English	Article								The epidemiology of tuberculosis remains poorly understood. We investigated the relative importance of within-household and community transmission of infection among children aged 6 months to 14 years living in a Peruvian shanty-town. The prevalence of Mycobacterium tuberculosis exposure among 175 contact children (sharing a household with a person who had confirmed pulmonary tuberculosis) and 382 control children (living in nearby households free of active tuberculosis) was defined as the proportion of children with a positive purified protein derivative (PPD) skin-test. 97 (55%) contact children and 129 (34%) controls were PPD positive. Living in a contact household (odds ratio 1.74, 95% CI 1.11-2.73) and age (1.11, 1.06-1.18) were significant risk factors for PPD positivity. We calculated the community infection ratio (CIR) as the odds ratio of PPD-positive controls to PPD-positive contacts: [GRAPHICS] A low CIR therefore suggests mainly household spread of infection, whereas a high value suggests frequent transmission outside the household. The adjusted odds ratio (for age, sex, within-household correlation, and household size) was 0.40 (95% CI 0.26-0.64), compared with values of 0.18-0.37 in studies elsewhere. Currently recommended tuberculosis control strategies are suitable for areas with low CIRs. Different strategies may be needed for areas, such as that we studied, with high values.	AB PRISMA,LIMA,PERU; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH & BIOSTAT,BALTIMORE,MD 21205	Johns Hopkins University				Madico, Guillermo/0000-0002-8323-8262; Black, Robert/0000-0001-9926-7984; Checkley, William/0000-0003-1106-8812				ASPIN J, 1953, Tubercle, V34, P20, DOI 10.1016/S0041-3879(53)80042-5; Brown K. H., 1981, Nutrition Research, V1, P33, DOI 10.1016/S0271-5317(81)80006-1; CAREY V, 1993, BIOMETRIKA, V80, P517, DOI 10.2307/2337173; COMSTOCK GW, 1967, AM REV RESPIR DIS, V95, P935; DESPREZ R, 1990, PRINCIPLES PRACTICE, P1880; FLEISS JL, 1991, STATISTICAL METHODS, P76; GETCHELL WS, 1992, AM J TROP MED HYG, V47, P721, DOI 10.4269/ajtmh.1992.47.721; GLASSROTH J, 1980, NEW ENGL J MED, V302, P1441, DOI 10.1056/NEJM198006263022603; GRYZBOWSKI S, 1975, B INT UNION TUBERC, V50, P90; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; MENZIES R, 1992, AM REV RESPIR DIS, V145, P621, DOI 10.1164/ajrccm/145.3.621; NARAIN SR, 1966, B WORLD HEALTH ORGAN, V34, P639; QAQISH BF, 1992, BIOMETRICS, V48, P939, DOI 10.2307/2532359; ROSE CE, 1979, AM REV RESPIR DIS, V119, P603; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; STYBLO K, 1989, REV INF DIS S2, V2, pS339; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489	18	44	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					416	419		10.1016/S0140-6736(95)90401-8	http://dx.doi.org/10.1016/S0140-6736(95)90401-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853950				2022-12-24	WOS:A1995QG90400009
J	GABUNIA, L; VEKUA, A				GABUNIA, L; VEKUA, A			A PLIOPLEISTOCENE HOMINID FROM DMANISI, EAST GEORGIA, CAUCASUS	NATURE			English	Article								ARCHAEOLOGICAL excavations at the mediaeval site of Dmanisi (East Georgia) revealed that the town was built on a series of deposits yielding Late Villafranchian mammalian fossils and led to the discovery in late 1991 of a well preserved early human mandible. Dmanisi, where excavations are being carried out by a joint expedition of the Archaeological Research Centre of the Georgian Academy of Sciences and the Romisch-Germanisches Zentralmuseum (Mainz, Germany), is located southwest of Tbilisi, at about 44 degrees 20' N, 41 degrees 20' E (Fig. 1). The fossils date Ifo the latest Pliocene (or perhaps to the earliest Pleistocene), probably between 1.8 and 1.6 million years ago (Myr). Here we identify the mandible as belonging to the species Home erectus, of which it is the earliest known representative in western Eurasia. It shows a number of similarities to the African and Chinese representatives of this species.			GABUNIA, L (corresponding author), GEORGIAN ACAD SCI, INST PALEOBIOL, 9 SULKHAN SABA, TBILISI 380007, GEORGIA.							AN ZH, 1989, QUATERNARY RES, V32, P213, DOI 10.1016/0033-5894(89)90077-X; BOSINSKI G, 1991, JB ROMISCH GERMAN ZE, V36, P76; BOSINSKI G, 1991, JB ROMISCH GERMANISC, V36, P93; Brown Barbara, 1993, P161; GABUNIA L, 1993, DMANISI MAN ACCOMPAN, P1; MAJSURADZE G, 1991, JB ROMISCH GERMAN ZE, V36, P74; MUSKHELISHVITI A, IN PRESS JB ROMISCH; Rightmire G. P., 1990, EVOLUTION HOMO ERECT; ROEBROEKS W, 1994, CURR ANTHROPOL, V35, P301, DOI 10.1086/204279; SOLOGASHVILI D, IN PRESS JB ROMISCH; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; VEROSUB KL, 1991, 1 EUROPEENS, P237; Walker Alan, 1993, P63; WEIDENREICH F, 1937, PALAEONTOL SINICA D, V1, P1; Wood B., 1991, HOMINID CRANIAL REMA, V4	15	230	239	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					509	512		10.1038/373509a0	http://dx.doi.org/10.1038/373509a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845461				2022-12-24	WOS:A1995QF72400055
J	BUCKLEY, NA; DAWSON, AH; WHYTE, IM; OCONNELL, DL				BUCKLEY, NA; DAWSON, AH; WHYTE, IM; OCONNELL, DL			RELATIVE TOXICITY OF BENZODIAZEPINES IN OVERDOSE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TEMAZEPAM	Objective-To assess the sedative effects in overdose of temazepam and oxazepam compared with other benzodiazepines to determine if this explains reported differences in fatal toxicity. Design-Cohort study of patients admitted with benzodiazepine poisoning. Setting-Newcastle, Australia. Subjects-303 patients who had ingested benzodiazepine alone or in combination with alcohol and presented to a general hospital which served a well defined geographical area. Main outcome measures-Degree of sedation: Glasgow coma score, McCarron Score, and whether patients were stuporose or comatose. Results-Oxazepam produced less and temazepam more sedation than other benzodiazepines. Unadjusted odds ratios for coma with oxazepam and temazepam compared with other benzodiazepines were 0.0 (95% confidence interval 0.0 to 0.85) and 1.86 (0.68 to 4.77) respectively, chi(2) = 7.08, 2df, P = 0.03. After adjustment for potentially confounding effects of age, dose ingested, and coingestion of alcohol, the odds ratios were 0.22 (0.0 to 1.43) for oxazepam and 1.94 (0.57 to 6.23) for temazepam. Similar results were obtained for other measures of sedation. Conclusions-These results were in accordance with fatal toxicity indices derived from coroners' data on mortality and rates of prescription. The relative safety of benzodiazepines in overdose should be a consideration when they are prescribed.	UNIV NEWCASTLE, DEPT PHARMACOL, NEWCASTLE, NSW 2298, AUSTRALIA; NEWCASTLE MATER MISERICORDIAE HOSP, NEWCASTLE, NSW 2298, AUSTRALIA; UNIV NEWCASTLE, CTR CLIN EPIDEMIOL & BIOSTAT, NEWCASTLE, NSW, AUSTRALIA	University of Newcastle; Calvary Mater Newcastle Hospital; University of Newcastle	BUCKLEY, NA (corresponding author), UNIV NEWCASTLE, DEPT CLIN TOXICOL, NEWCASTLE, NSW 2298, AUSTRALIA.		Dawson, Andrew/D-5085-2012; Dawson, Andrew H/U-8041-2019; Whyte, Ian/A-1621-2010; Buckley, Nicholas A/D-4030-2012	Dawson, Andrew/0000-0002-8047-397X; Dawson, Andrew H/0000-0002-8047-397X; Whyte, Ian/0000-0001-7693-3948; Buckley, Nicholas A/0000-0002-6326-4711				ALEXANDER B, 1991, J SUBST ABUSE TREAT, V8, P9, DOI 10.1016/0740-5472(91)90022-3; BUCKLEY NA, IN PRESS MED J AUST; BUSTO U, 1980, AM J PSYCHIAT, V137, P224; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; CROME P, 1993, ACTA PSYCHIAT SCAND, V87, P33, DOI 10.1111/j.1600-0447.1993.tb05371.x; Dwyer P S, 1984, Hum Toxicol, V3 Suppl, p145S; FORREST ARW, 1986, LANCET, V2, P226; FUCCELLA LM, 1977, EUR J CLIN PHARMACOL, V12, P383, DOI 10.1007/BF00562455; GAUDREAULT P, 1991, DRUG SAFETY, V6, P247, DOI 10.2165/00002018-199106040-00003; GREENBLATT DJ, 1989, ARCH GEN PSYCHIAT, V46, P326; HOJER J, 1989, J INTERN MED, V226, P117; JOHNS MW, 1977, BRIT MED J, V1, P1128, DOI 10.1136/bmj.1.6069.1128; MARTIN CD, 1986, J ANAL TOXICOL, V10, P77, DOI 10.1093/jat/10.2.77; MCCARRON MM, 1982, JAMA-J AM MED ASSOC, V248, P55, DOI 10.1001/jama.248.1.55; MEHTA C, 1993, LOGXACT VERSION 1 1; MITLER MM, 1981, PHARMACOTHERAPY, V1, P3; SERFATY M, 1993, BRIT J PSYCHIAT, V163, P386, DOI 10.1192/bjp.163.3.386; 1994, DATA AUSTR DRUG UTIL	18	52	55	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	1995	310	6974					219	221		10.1136/bmj.310.6974.219	http://dx.doi.org/10.1136/bmj.310.6974.219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866122	Green Published			2022-12-24	WOS:A1995QE49600020
J	VAGERO, D; LEON, D				VAGERO, D; LEON, D			ISCHEMIC-HEART-DISEASE AND LOW-BIRTH-WEIGHT - A TEST OF THE FETAL-ORIGINS HYPOTHESIS FROM THE SWEDISH-TWIN-REGISTRY	LANCET			English	Article							ADULT LIFE; HEIGHT; MORTALITY; GROWTH; INFANCY; COHORT; DEATH	Twins constitute a population with lower than average birth weight for reasons that are not a consequence of social disadvantage. The hypothesis that ischaemic heart disease (IHD) is linked to low birth weight was tested by analysing whether or not 8174 female and 6612 male Swedish twins had a higher mortality compared to the general Swedish population. The association between adult body height and IHD mortality was also analysed in a nested case-control study among monozygotic and dizygotic twins. Ischaemic heart disease mortality was not higher among twins (women: relative risk [RR] 0.99; 95% confidence limits [CL] 0.89-1.10; men: RR 0.85; CL 0.79-0.92). However, the shorter twin in a twin pair was more likely to die of heart disease than the taller (odds ratio [OR] 1.15, CL 1.03-1.25). We suggest that postnatal influences may well be as important as prenatal influences in producing any effect on ischaemic heart disease mortality and that the type of growth retardation in utero experienced by twins may not constitute a risk for ischaemic heart disease in adulthood.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	VAGERO, D (corresponding author), UNIV STOCKHOLM, SWEDISH INST SOCIAL RES, S-10691 STOCKHOLM, SWEDEN.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762; Vagero, Denny/0000-0002-1854-2292				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; CAMPELL D, 1988, TWINNING TWINS; CEDERLOF R, 1966, TWIN METHOD EPIDEMIO; CEDERLOF R, 1977, ACTA MED SCAND, V202, pS49; FISCHBEIN S, 1990, 29 U STOCKH DEP SOC; FLEIGNER JR, 1984, AUSTR NZ J OBS GYNEC, V24, P192; ILLSLEY R, 1955, BRIT MED J, V2, P1520, DOI 10.1136/bmj.2.4955.1520; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; MACINTYRE S, 1988, SOC SCI MED, V27, P327, DOI 10.1016/0277-9536(88)90266-3; MARMOT MG, 1984, LANCET, V1, P1003; MOILANEN I, 1989, GROWTH DEVELOP AGING, V53, P145; NAEYE RL, 1964, PEDIATRICS, V33, P546; NOTKOLA V, 1985, LIVING CONDITIONS CH; PECK AMN, 1989, J EPIDEMIOL COMMUN H, V43, P380, DOI 10.1136/jech.43.4.380; PHILLIPS DIW, 1993, LANCET, V341, P1008, DOI 10.1016/0140-6736(93)91086-2; VAGERO D, 1994, IN PRESS PREMATURE A; WILSON R, 1986, HUMAN GROWTH COMPREH, V3; WILSON RS, 1974, ANN HUM BIOL, V1, P57, DOI 10.1080/03014467400000061; WILSON RS, 1979, ANN HUM BIOL, V6, P205, DOI 10.1080/03014467900007212; WILSON RS, 1974, ANN HUM BIOL, V1, P175, DOI 10.1080/03014467400000191; [No title captured]	26	122	122	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	1994	343	8892					260	263		10.1016/S0140-6736(94)91112-6	http://dx.doi.org/10.1016/S0140-6736(94)91112-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905096				2022-12-24	WOS:A1994MT44000010
J	MASTRO, TD; SATTEN, GA; NOPKESORN, T; SANGKHAROMYA, S; LOGINI, IM				MASTRO, TD; SATTEN, GA; NOPKESORN, T; SANGKHAROMYA, S; LOGINI, IM			PROBABILITY OF FEMALE-TO-MALE TRANSMISSION OF HIV-1 IN THAILAND	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; INFECTION; PARTNERS; CHILDREN; VIREMIA; TYPE-1; ADULTS; AIDS	The epidemic of human immunodeficiency virus type 1 (HIV-1) infection in Thailand has allowed an estimate to be made of the probability of female-to-male HIV-1 transmission per sexual contact. In a study of 1115 21 year-old male military conscripts, of whom 77 (6.9%) were HIV-1 seropositive, sex with female prostitutes was identified as the principal mode of HIV-1. transmission. With a mathematical model including data on conscript's age at first sexual contact, frequency of sex with female prostitutes, and province of origin; as well as province-specific HIV-1 seroprevalence of prostitutes, we estimated the probability of HIV-1 transmission per sexual contact to be 0.031 (95% confidence limits [CL] 0.025-0.040). Allowing for random error in the self-reported frequency of contacts, the estimate was 0.056 (95% CL 0.041-0.075). The transmission probability was significantly greater among men with a history of sexually-transmitted diseases. These estimates are substantially higher than analogous estimates made in North America. This high per-act probability of heterosexual transmission helps to explain the rapid spread of HIV-1 in the emerging epidermic in Thailand and perhaps in other countries where HIV-1 transmission is predominately heterosexual.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA; SOMDEJ PRANARESUAN MAHARAJ HOSP,PHITSANULOKE,THAILAND; EMORY UNIV,SCH PUBL HLTH,DIV BIOSTAT,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Emory University	MASTRO, TD (corresponding author), HIV AIDS COLLABORAT,88-7 SOI BAMRASNARADURA,TIVANON RD,NONTHABURI 11000,THAILAND.			Satten, Glen/0000-0001-7275-5371				CAMERON DW, 1989, LANCET, V2, P403; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; EISENBERG B, 1989, STAT MED, V8, P83, DOI 10.1002/sim.4780080109; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; HAVERKOS HW, 1992, JAMA-J AM MED ASSOC, V268, P1855, DOI 10.1001/jama.1992.03490140063023; HORSBURGH CR, 1989, LANCET, V2, P637; JEWELL NP, 1990, BIOMETRICS, V46, P1133, DOI 10.2307/2532454; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1199, DOI 10.1093/oxfordjournals.aje.a115832; LIMPAKARNJANARA.K, 1993, 9 INT C AIDS BERL; MYERS G, 1992, HUMAN RETROVIRUSES A; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SATTEN GA, IN PRESS STAT MED; SIRAYSIRISOPANA N, 1992, 8 INT C AIDS AMST; SIRISOPANA N, 1993, 9 INT C AIDS BERL; TAYLOR DN, 1984, SEX TRANSM DIS, V11, P148, DOI 10.1097/00007435-198407000-00005; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; [No title captured]; 1993, WHOGPACNPEVA931 PUBL	25	177	179	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					204	207		10.1016/S0140-6736(94)90990-3	http://dx.doi.org/10.1016/S0140-6736(94)90990-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904668				2022-12-24	WOS:A1994MT33200009
J	WALD, NJ; LAW, M; WATT, HC; WU, TS; BAILEY, A; JOHNSON, AM; CRAIG, WY; LEDUE, TB; HADDOW, JE				WALD, NJ; LAW, M; WATT, HC; WU, TS; BAILEY, A; JOHNSON, AM; CRAIG, WY; LEDUE, TB; HADDOW, JE			APOLIPOPROTEINS AND ISCHEMIC-HEART-DISEASE - IMPLICATIONS FOR SCREENING	LANCET			English	Article							CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION; SERUM; RISK; CHOLESTEROL; MEN	Apolipoproteins and lipids are established risk factors of ischaemic heart disease (IHD) but their efficacy as screening tests is not known. We therefore examined the mortality from IHD and serum concentrations of lipids and apolipoproteins in a prospective study of 21 520 men aged 35-64 years. Serum apo B was the apolipoprotein most strongly associated with IHD risk; a decrease in apo B of 10% was associated with 22% lower risk of IHD. However, measurement of apo B alone detected only 17% of all IHD deaths at the cost of a 5% false-positive rate. Combining apo B with apo Al and apo (a) increased the detection rate to 19%. With systolic blood pressure, smoking, and family history of IHD the detection rate increased to 28%. We conclude that screening for IHD by measuring apo B alone or with apo Al and apo (a) is too poor to discriminate between recommending drug therapy or lifestyle change for some and not others. It is not advisable to screen for IHD by measuring any combination of cholesterol, apo B, apo Al, apo (a) and the other risk factors. The primary aim in prevention of ischaemic heart disease should be to lower the risk factors in the population.	BUPA MED RES, LONDON WC2, ENGLAND; FDN BLOOD RES, SCARBOROUGH, ME USA	Foundation for Blood Research (FBR)	WALD, NJ (corresponding author), ST BARTHOLOMEWS HOSP, MED COLL, DEPT ENVIRONM & PREVENT MED, WOLFSON INST PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; H, V/M-5550-2014; Wald, Nicholas/AAY-8924-2021					BUCOLO G, 1973, CLIN CHEM, V19, P476; CREMER P, 1988, KLIN WOCHENSCHR, V66, P42; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; IRISH GR, 1987, CLIN CHEM, V33, P1267; IRISH GR, 1987, CLIN CHEM, V33, P1266; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; LAW MR, IN PRESS BMJ; MACIEJKO JJ, 1987, CLIN CHEM, V33, P2065; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, CORONARY HEART DIS E, P358; WARNICK GR, 1982, CLIN CHEM, V28, P1379; ZHAO SP, 1991, CLIN CHEM, V37, P1139	18	235	239	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	1994	343	8889					75	79		10.1016/S0140-6736(94)90814-1	http://dx.doi.org/10.1016/S0140-6736(94)90814-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903777				2022-12-24	WOS:A1994MQ09200009
J	RADER, DJ; IKEWAKI, K; DUVERGER, N; FEUERSTEIN, I; ZECH, L; CONNOR, W; BREWER, HB				RADER, DJ; IKEWAKI, K; DUVERGER, N; FEUERSTEIN, I; ZECH, L; CONNOR, W; BREWER, HB			VERY-LOW HIGH-DENSITY-LIPOPROTEINS WITHOUT CORONARY ATHEROSCLEROSIS	LANCET			English	Article							APOLIPOPROTEIN-A-I; ISCHEMIC HEART-DISEASE; INVIVO METABOLISM; PARTICLES; DEFICIENCY; MUTATION; GENE	Epidemiological studies have established that concentrations of plasma high-density lipoproteins (HDL) are inversely associated with premature atherosclerosis, but the physiological basis of this relationship remains unknown. We investigated 5 probands with very low plasma HDL. None had clinical or biochemical findings typical of the known genetic disorders with low HDL nor had evidence of premature coronary atherosclerosis by sensitive diagnostic methods. All 5 probands and the son of 1 of them had rapid catabolism of the HDL apolipoproteins A-I and A-II. These results indicate that not all people with low HDL are necessarily at risk of premature coronary heart disease and that further investigation is required before decisions can be made about their management.	OREGON HLTH SCI UNIV, DEPT MED, CLIN NUTR & LIPID METAB SECT, PORTLAND, OR 97201 USA	Oregon Health & Science University	RADER, DJ (corresponding author), NHLBI, MOLEC DIS BRANCH, BLDG 10, ROOM 7N117, BETHESDA, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040566] Funding Source: NIH RePORTER; NCRR NIH HHS [RR334] Funding Source: Medline; NIDDK NIH HHS [DK40566] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREWER HB, 1988, CLIN CHEM, V34, pB4; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRINTON EA, 1989, J CLIN INVEST, V84, P262, DOI 10.1172/JCI114149; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; FRUCHART JC, 1992, CLIN CHEM, V38, P793; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; LIPTON MJ, 1991, CIRCULATION, V84, pI72; MATSUNAGA T, 1991, P NATL ACAD SCI USA, V88, P2793, DOI 10.1073/pnas.88.7.2793; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; Norum K, 1989, METABOLIC BASIS INHE, P1181; PARRA HJ, 1990, CLIN CHEM, V36, P1431; RADER DJ, 1992, J LIPID RES, V33, P755; RADER DJ, 1991, J LIPID RES, V32, P1849; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SPRECHER DL, 1984, CLIN CHEM, V30, P2084; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; WARNICK GR, 1979, CLIN CHEM, V25, P596	21	56	56	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1455	1458		10.1016/0140-6736(93)92933-K	http://dx.doi.org/10.1016/0140-6736(93)92933-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902482				2022-12-24	WOS:A1993ML21700009
J	MOSSEL, DAA; STRUIJK, CB				MOSSEL, DAA; STRUIJK, CB			FOOD-BORNE ILLNESS 1993 - UPDATING WILSON TRIAD	LANCET			English	Editorial Material											MOSSEL, DAA (corresponding author), UNIV UTRECHT,EIJKMAN FDN,UTRECHT,NETHERLANDS.							CHRISTIAN JHB, 1980, FOOD RES Q, V40, P13; Lund B. M., 1993, Food Technology International, Europe, P196; Mossel D. A. A., 1988, Animal & Human Health, V1, P13; Mossel D. A. A., 1987, Elimination of pathogenic organisms from meat and poultry., P305; MOSSEL DAA, 1989, LETT APPL MICROBIOL, V9, P207, DOI 10.1111/j.1472-765X.1989.tb00327.x; MOSSEL DAA, 1992, INT J FOOD MICROBIOL, V15, P1, DOI 10.1016/0168-1605(92)90131-L; MOSSEL DAA, 1990, FOOD TECHNOL-CHICAGO, V44, P63; POTTER ME, 1984, JAMA-J AM MED ASSOC, V252, P2048, DOI 10.1001/jama.252.15.2048; RAMPLING A, 1993, LANCET, V342, P317, DOI 10.1016/0140-6736(93)91466-Y; VANNETTEN P, 1992, PREDICTIVE MICROBIOL, P181; Wilson GS, 1933, LANCET, V2, P829; WILSON GS, 1935, MRC SPEC REP SER, V206	12	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1254	1254		10.1016/0140-6736(93)92357-Y	http://dx.doi.org/10.1016/0140-6736(93)92357-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901581				2022-12-24	WOS:A1993MH56600007
J	LEE, HS; CROSS, SJ; RAWLES, JM; JENNINGS, KP				LEE, HS; CROSS, SJ; RAWLES, JM; JENNINGS, KP			PATIENTS WITH SUSPECTED MYOCARDIAL-INFARCTION WHO PRESENT WITH ST DEPRESSION	LANCET			English	Article							NON-Q-WAVE; NATURAL-HISTORY; UNSTABLE ANGINA; CHEST PAIN; SEGMENT; THROMBOLYSIS; ELECTROCARDIOGRAM; MYOGLOBIN	Patients with suspected myocardial infarction who present with ST depression have a high mortality which is not reduced by thrombolytic therapy. Despite this, there are few data on these patients. We studied the electrocardiographic and clinical characteristics of these patients, the diagnostic and prognostic value of the presenting electrocardiogram (ECG), and the reasons for the high mortality and apparent lack of thrombolytic efficacy. We studied all patients with suspected infarction admitted during 1990 with ST depression. Of the 136 patients (84 men, mean [SD] age 68 [11] years), 74 (54%) had confirmed infarction and 73 (54%) had previous infarction. 1-year mortality was 26% for all patients, 31% for those with confirmed infarcts, and 19% for those in whom infarction was subsequently excluded. Patients with infarction had more severe ST depression (mean 2.5 mm [SD 1.5]) and more ECG leads with ST depression (mean 4.7 leads [1.81]) compared with patients without infarction (1.4 mm [0.8], p < 0.001; 3.6 leads [1.7], p < 0.001). Sensitivity and specificity for the subsequent diagnosis of infarction with ST depression were 20% and 97%, respectively, for at least 4 mm; and 21% and 95%, respectively, for at least 7 leads. 1-year mortality was low in patients with 1 mm ST depression (14%) or no more than 2 leads (11%), but high in patients with at least 2 mm ST depression (39%, p < 0.001) and at least 3 leads (30%, p = 0.08). Patients with suspected infarction and ST depression had a high mean age, high incidence of previous infarction, and poor prognosis. The presenting ECG is helpful in predicting prognosis, and ST depression of at least 4 mm or involving at least 7 leads is highly specific for diagnosis of infarction.	UNIV ABERDEEN, MED ASSESSMENT RES UNIT, ABERDEEN AB9 1FX, SCOTLAND; ABERDEEN ROYAL INFIRM, DEPT CARDIOL, ABERDEEN AB9 2ZB, SCOTLAND	University of Aberdeen; University of Aberdeen								ABBOTT JA, 1973, AM J MED, V55, P608, DOI 10.1016/0002-9343(73)90182-4; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BERLAND J, 1986, AM HEART J, V111, P481, DOI 10.1016/0002-8703(86)90052-9; BOSSAERT L, 1991, EUR HEART J, V12, P965; CHOUHAN L, 1991, AM J CARDIOL, V68, P446, DOI 10.1016/0002-9149(91)90776-H; GHEORGHIADE M, 1991, AM HEART J, V122, P1548, DOI 10.1016/0002-8703(91)90270-R; GIBSON RS, 1986, CIRCULATION, V73, P1186, DOI 10.1161/01.CIR.73.6.1186; KAGEN LJ, 1978, CRC CR REV CL LAB SC, V9, P273, DOI 10.3109/10408367809150922; LEE HS, 1992, BRIT HEART J, V68, P145; MAIR J, 1992, BRIT HEART J, V68, P462; METCALFE MJ, 1990, BRIT HEART J, V63, P267; MIRANDA CP, 1991, CIRCULATION, V84, P2357, DOI 10.1161/01.CIR.84.6.2357; ODEMUYIWA O, 1985, BRIT HEART J, V54, P479; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; PRUITT RD, 1963, PROG CARDIOVASC DIS, V6, P85, DOI 10.1016/S0033-0620(63)80023-7; RAUNIO H, 1979, AM HEART J, V98, P176, DOI 10.1016/0002-8703(79)90219-9; SCHECHTMAN KB, 1989, CIRCULATION, V80, P1148, DOI 10.1161/01.CIR.80.5.1148; SCRUTINIO D, 1991, AM J CARDIOL, V68, pB99, DOI 10.1016/0002-9149(91)90391-W; SERNERI GGN, 1990, LANCET, V335, P615; SUGIURA M, 1969, JPN HEART J, V10, P203; WILLICH SN, 1987, AM HEART J, V114, P1110, DOI 10.1016/0002-8703(87)90186-4	22	71	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1204	1207		10.1016/0140-6736(93)92186-W	http://dx.doi.org/10.1016/0140-6736(93)92186-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901530				2022-12-24	WOS:A1993MG27400010
J	LIN, D; SUGAWARA, T; STRAUSS, JF; CLARK, BJ; STOCCO, DM; SAENGER, P; ROGOL, A; MILLER, WL				LIN, D; SUGAWARA, T; STRAUSS, JF; CLARK, BJ; STOCCO, DM; SAENGER, P; ROGOL, A; MILLER, WL			ROLE OF STEROIDOGENIC ACUTE REGULATORY PROTEIN IN ADRENAL AND GONADAL STEROIDOGENESIS	SCIENCE			English	Article							CHAIN CLEAVAGE ENZYME; LEYDIG TUMOR-CELLS; MITOCHONDRIAL PROTEINS; CHOLESTEROL; HYPERPLASIA; PRECURSORS; MOVEMENT; PATIENT; GENES	Congenital lipoid adrenal hyperplasia is an autosomal recessive disorder that is characterized by impaired synthesis of all adrenal and gonadal steroid hormones. In three unrelated individuals with this disorder, steroidogenic acute regulatory protein, which enhances the mitochondrial conversion of cholesterol into pregnenolone, was mutated and nonfunctional, providing genetic evidence that this protein is indispensable for normal adrenal and gonadal steroidogenesis.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104; TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & CELL BIOL,LUBBOCK,TX 79430; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; UNIV VIRGINIA,HLTH SCI CTR,DEPT PEDIAT,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143	University of Pennsylvania; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Virginia; University of Virginia; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LIN, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,CHILD HLTH RES CTR,CORE LAB,SAN FRANCISCO,CA 94143, USA.		Miller, Walter L/J-3696-2012; Rogol, A.D./H-5871-2019	Rogol, A.D./0000-0002-7526-3142; Clark, Barbara/0000-0003-1558-1904	NICHD NIH HHS [HD 06274, HD 28825, HD 07688] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028825] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; DEGENHART HJ, 1972, ACTA ENDOCRINOL-COP, V71, P215; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HAUFFA BP, 1985, CLIN ENDOCRINOL, V23, P481, DOI 10.1111/j.1365-2265.1985.tb01107.x; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KOIZUMI S, 1977, CLIN CHIM ACTA, V77, P301; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LIN D, 1993, GENOMICS, V18, P643, DOI 10.1016/S0888-7543(05)80367-2; LIN D, 1991, J CLIN INVEST, V88, P1955, DOI 10.1172/JCI115520; Lin D.Y., UNPUB; MELLON SH, 1994, J CLIN ENDOCR METAB, V78, P1003, DOI 10.1210/jc.78.5.1003; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; SAENGER P, 1995, J CLIN ENDOCR METAB, V80, P200, DOI 10.1210/jc.80.1.200; SAKAI Y, 1994, J CLIN ENDOCR METAB, V79, P1198, DOI 10.1210/jc.79.4.1198; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; STOCCO DM, 1993, ENDOCRINOLOGY, V132, P959, DOI 10.1210/en.132.3.959; STRAUSS JF, 1995, ENDOCRINOLOGY, V3, P2171; SUGAWARA T, IN PRESS P NATL ACAD; TOAFF ME, 1982, ENDOCRINOLOGY, V111, P1785, DOI 10.1210/endo-111-6-1785	23	792	818	0	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1828	1831		10.1126/science.7892608	http://dx.doi.org/10.1126/science.7892608			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892608				2022-12-24	WOS:A1995QN70200041
J	ANSARI, AZ; BRADNER, JE; OHALLORAN, TV				ANSARI, AZ; BRADNER, JE; OHALLORAN, TV			DNA-BEND MODULATION IN A REPRESSOR-TO-ACTIVATOR SWITCHING MECHANISM	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; MER PROMOTER; COMPLEX; DISTORTION; DIRECTION	RECENT discoveries of activator proteins that distort DNA but bear no obvious activation domains have focused attention on the role of DNA structure in transcriptional regulation(1). Here we describe how the transcription factor MerR can mediate repression as well as activation through stereospecific modulation of DNA structure. The repressor form of MerR binds between the -10 and -35 promoter elements of the bacterial mercury-detoxification genes, P-T, allowing RNA polymerase to form an inactive complex with P-T and MerR at this stress-inducible promoter(2,3). Upon mercuric ion binding, Hg-MerR converts this polymerase complex into the transcriptionally active or 'open' form(2-4). We show here that MerR bends DNA towards itself in a manner similar to the bacterial catabolite-activator protein CAP, namely at two loci demarked by DNase I sensitivity, and that the activator conformation, Hg-MerR, relaxes these bends. This activator-induced unbending, when coupled with the previously described untwisting of the operator(5), remodels the promoter and makes it a better template for the poised polymerase.	NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University; Northwestern University			O'Halloran, Thomas/ABE-6125-2021; Ansari, Aseem/AAF-4945-2019	O'Halloran, Thomas/0000-0001-8732-5059; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; ANSARI AZ, 1994, TRANSCRIPTION MECHAN, P369; BOROWIEC JA, 1986, BIOCHEMISTRY-US, V25, P5051, DOI 10.1021/bi00366a012; BURKHOFF AM, 1989, NATURE, V331, P455; COMESS KM, 1994, BIOCHEMISTRY-US, V33, P4175, DOI 10.1021/bi00180a010; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; HIDALGO E, 1993, EMBO J, V13, P138; HOGAN ME, 1989, P NATL ACAD SCI USA, V86, P9273, DOI 10.1073/pnas.86.23.9273; HUNTER CA, 1993, J MOL BIOL, V256, P1025; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; LAHM A, 1991, NUCLEIC ACIDS MOL BI, V5, P171; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; Ptashne M, 1986, GENETIC SWITCH, P13; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	31	184	186	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					371	375						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885478				2022-12-24	WOS:A1995QN63000063
J	ROWE, PC; BOUHOLAIGAH, I; KAN, JS; CALKINS, H				ROWE, PC; BOUHOLAIGAH, I; KAN, JS; CALKINS, H			NEURALLY-MEDIATED HYPOTENSION AN UNRECOGNIZED CAUSE OF CHRONIC FATIGUE	LANCET			English	Note							HEAD-UP TILT; UNEXPLAINED SYNCOPE	Neurally mediated hypotension is now recognised as a common cause of otherwise unexplained recurrent syncope, but has not been reported in association with chronic fatigue. We describe seven consecutive non-syncopal adolescents with chronic post-exertional fatigue, four of whom satisfied strict criteria for chronic fatigue syndrome. Upright tilt-table testing induced significant hypotension in all seven (median systolic blood pressure 65 mm Hg, range 37-75), consistent with the physiology of neurally mediated hypotension. Four had prompt improvement. in their chronic fatigue when treated with atenolol or disopyramide. These observations suggest an overlap in the symptoms of chronic fatigue syndrome and neurally mediated hypotension.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21287 USA	Johns Hopkins University	ROWE, PC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21287 USA.							ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; CALKINS H, IN PRESS AM J MED; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KAPOOR WN, 1994, AM J MED, V97, P78, DOI 10.1016/0002-9343(94)90051-5; KENNY RA, 1986, LANCET, V1, P1352; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; MANU P, 1993, CIBA F SYMP, V173, P23; ROSS BA, 1991, AM HEART J, V122, P748, DOI 10.1016/0002-8703(91)90521-I; RUBIN AM, 1993, AM HEART J, V125, P476, DOI 10.1016/0002-8703(93)90029-9; SCHONDORF R, 1993, NEUROLOGY, V43, P132, DOI 10.1212/WNL.43.1_Part_1.132	10	186	198	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 11	1995	345	8950					623	624		10.1016/S0140-6736(95)90525-1	http://dx.doi.org/10.1016/S0140-6736(95)90525-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898182	hybrid			2022-12-24	WOS:A1995QM07500013
J	RUETER, SM; BURNS, CM; COODE, SA; MOOKHERJEE, P; EMESON, RB				RUETER, SM; BURNS, CM; COODE, SA; MOOKHERJEE, P; EMESON, RB			GLUTAMATE-RECEPTOR RNA EDITING IN-VITRO BY ENZYMATIC CONVERSION OF ADENOSINE TO INOSINE	SCIENCE			English	Article							B MESSENGER-RNA; CA2+ PERMEABILITY; STRUCTURAL DETERMINANTS; ION FLOW; CHANNELS; KAINATE; EXPRESSION	RNA encoding the B subunit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptor (GluR-B) undergoes a posttranscriptional modification in which a genomically encoded adenosine is represented as a guanosine in the GluR-B complementary DNA. In vitro editing of GluR-B RNA transcripts with HeLa cell nuclear extracts was found to result from an activity that converts adenosine to inosine in regions of double-stranded RNA by enzymatic base modification. This activity is consistent with that of a double-stranded RNA-specific adenosine deaminase previously described in Xenopus oocytes and widely distributed in mammalian tissues.	VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University				Emeson, Ronald/0000-0002-4585-1648	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ausubel F, 1989, MOL REPROD DEV, V1, P146; BASS B, 1993, RNA WORLD, pCH15; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BOULTER J, 1989, NEURON, V3, P589; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; EGEBJERG J, 1993, P NATL ACAD SCI USA, V90, P755, DOI 10.1073/pnas.90.2.755; EGEBJERG J, 1994, P NATL ACAD SCI USA, V91, P10270, DOI 10.1073/pnas.91.22.10270; ELLIOTT MS, 1984, J BIOL CHEM, V259, P2407; GARCIA GA, 1993, J MOL BIOL, V231, P489, DOI 10.1006/jmbi.1993.1296; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; NAKANISHI N, 1990, TOXICON, V28, P1333; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SHULDINER AR, 1993, PCR PROTOCOLS CURREN, P169; Silberklang M, 1979, Methods Enzymol, V59, P58; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WU JH, 1990, J BIOL CHEM, V265, P12312	26	117	125	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1491	1494		10.1126/science.7878468	http://dx.doi.org/10.1126/science.7878468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878468				2022-12-24	WOS:A1995QL49700036
J	WEST, RA; KARKOSCHKA, E; FRIEDSON, AJ; SEYMOUR, M; BAINES, KH; HAMMEL, HB				WEST, RA; KARKOSCHKA, E; FRIEDSON, AJ; SEYMOUR, M; BAINES, KH; HAMMEL, HB			IMPACT DEBRIS PARTICLES IN JUPITER STRATOSPHERE	SCIENCE			English	Article							OPTICAL-PROPERTIES; ICE; CIRCULATION; ULTRAVIOLET; CONSTANTS	The aftermath of the impacts of periodic comet Shoemaker-Levy 9 on Jupiter was studied With the Wide Field Planetary Camera 2 on the Hubble Space Telescope. The impact debris particles may owe their dark brown color to organic material rich in sulfur and nitrogen. The total volume of aerosol 1 day after the last impact is equal to the volume of a sphere of radius 0.5 kilometer. In the optically thick core regions, the particle mean radius is between 0.15 and 0.3 micrometer, and the aerosol is spread over many scale heights, from approximately 1 millibar to 200 millibars of pressure or more. Particle coagulation can account for the evolution of particle radius and total optical depth during the month following the impacts.	UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; UCL, LONDON, ENGLAND; MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA	University of Arizona; University of London; University College London; Massachusetts Institute of Technology (MIT)	WEST, RA (corresponding author), CALTECH, JET PROP LAB, DIV EARTH & SPACE SCI, PASADENA, CA 91109 USA.							BAINES KH, 1994, 26TH ANN M AM ASTR S; BJORAKER GL, 1994, 26TH ANN M AM ASTR S; CONRATH BJ, 1990, ICARUS, V83, P255, DOI 10.1016/0019-1035(90)90068-K; DRAINE BT, 1985, ASTROPHYS J SUPPL S, V57, P587, DOI 10.1086/191016; FIELD GB, IN PRESS ASTRON ASTR; GUSTAVSEN RL, 1989, THESIS WASHINGTON ST; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; KARKOSCHKA E, 1994, ICARUS, V111, P174, DOI 10.1006/icar.1994.1139; KHARE BN, 1994, CAN J CHEM, V72, P678, DOI 10.1139/v94-093; LANDRY B, 1991, ICARUS, V89, P377, DOI 10.1016/0019-1035(91)90184-U; LATTIMER JM, 1982, 1980 P C FORM PLAN S, P190; MARTONCHIK JV, 1984, APPL OPTICS, V23, P541, DOI 10.1364/AO.23.000541; MORENO F, IN PRESS GEOPHYS RES; NICHOLSON PD, UNPUB; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; ORTON G, 1995, SCIENCE, V267, P1277, DOI 10.1126/science.7871423; OWEN T, 1994, 26TH ANN M AM ASTR S; PRUPPACHER HR, 1978, MICROPHYSICS CLOUDS, P358; SASSON R, 1985, ICARUS, V64, P368, DOI 10.1016/0019-1035(85)90061-2; TINGLE TN, 1992, ORIGINS LIFE EVOL B, V21, P385; TREPTE CR, 1992, NATURE, V355, P626, DOI 10.1038/355626a0; WALLACE L, 1986, ASTROPHYS J, V172, P755; WARREN SG, 1986, APPL OPTICS, V25, P2650, DOI 10.1364/AO.25.002650; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WEST RA, 1992, ICARUS, V100, P245, DOI 10.1016/0019-1035(92)90033-4; ZHANLE K, COMMUNICATION	26	83	83	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1296	1301		10.1126/science.7871426	http://dx.doi.org/10.1126/science.7871426			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871426				2022-12-24	WOS:A1995QK06800031
J	KAWAI, K; OHASHI, PS				KAWAI, K; OHASHI, PS			IMMUNOLOGICAL FUNCTION OF A DEFINED T-CELL POPULATION TOLERIZED TO LOW-AFFINITY SELF-ANTIGENS	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; CLONAL DELETION; POSITIVE SELECTION; TRANSGENIC MICE; RECEPTOR; TOLERANCE; ANERGY; INDUCTION; ANTIBODY	IN the thymus there are two major mechanisms of T-lymphocyte tolerance: clonal deletion and clonal inactivation(1-3). One important problem underlying the mechanism of clonal inactivation is why unresponsive cells are maintained in the mature peripheral T-cell repertoire. Here we report that transgenic alpha beta T-cells may be tolerized to a self antigen Mls-1(a), but still retain proliferative responses for alternative peptide antigens and superantigens. These self-tolerant T cells can also provide immunopathological and memory cytotoxic function in vivo. We propose that high-affinity/avidity self-reactive T cells are deleted in the thymus, whereas lower-affinity/avidity interactions lead to unresponsiveness and define the 'resting threshold' for a given T cell. These low-affinity self-tolerant T cells remain functionally competent for high-affinity foreign antigens, and efficiently eliminate natural pathogens in vivo.	UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Kawai, Kazuhiro/D-4998-2011	Kawai, Kazuhiro/0000-0001-9375-0713; Ohashi, Pamela S./0000-0003-2915-9317				BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; RAMSDELL F, 1992, SCIENCE, V257, P1130, DOI 10.1126/science.257.5073.1130; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROCHA B, 1993, J EXP MED, V177, P1517, DOI 10.1084/jem.177.5.1517; ROCKEN M, 1992, NATURE, V359, P79, DOI 10.1038/359079a0; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1991, J EXP MED, V174, P1001, DOI 10.1084/jem.174.5.1001; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAN XJ, 1993, J IMMUNOL, V150, P3873; YUI K, 1990, P NATL ACAD SCI USA, V87, P7135, DOI 10.1073/pnas.87.18.7135	22	77	78	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					68	69		10.1038/374068a0	http://dx.doi.org/10.1038/374068a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870174				2022-12-24	WOS:A1995QK07900054
J	MILLAR, AJ; STRAUME, M; CHORY, J; CHUA, NH; KAY, SA				MILLAR, AJ; STRAUME, M; CHORY, J; CHUA, NH; KAY, SA			THE REGULATION OF CIRCADIAN PERIOD BY PHOTOTRANSDUCTION PATHWAYS IN ARABIDOPSIS	SCIENCE			English	Article							PLANTS; PHYTOCHROME; EXPRESSION; MUTANTS; CLOCK	Transgenic Arabidopsis plants expressing a luciferase gene fused to a circadian-regulated promoter exhibited robust rhythms in bioluminescence. The cyclic luminescence has a 24.7-hour period in white light but 30- to 36-hour periods under constant darkness. Either red or blue light shortened the period of the wild type to 25 hours. A phytochrome-deficient mutation lengthened the period in continuous red light but had little effect in continuous blue fight, whereas seedlings carrying mutations that activate light-dependent pathways in darkness maintained shorter periods in constant darkness. These results suggest that both phytochrome- and blue light-responsive photoreceptor pathways control the period of the circadian clock.	UNIV VIRGINIA,DEPT BIOL,NSF,CTR BIOL TIMING,CHARLOTTESVILLE,VA 22903; SALK INST,PLANT BIOL LAB,SAN DIEGO,CA 92186; ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; Salk Institute; Rockefeller University			Kay, Steve A/F-6025-2011; Millar, Andrew J/G-2423-2012	Kay, Steve A/0000-0002-0402-2878; Millar, Andrew J/0000-0003-1756-3654	NIGMS NIH HHS [GM44640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044640, R56GM044640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNIER G, 1993, PLANT CELL, V5, P1147, DOI 10.1105/tpc.5.10.1147; Bevington PR, 1969, DATA REDUCTION ERROR, P73; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; Edmunds LN, 1988, CELLULAR MOL BASES B; HARRIS PJC, 1976, PLANTA, V129, P253, DOI 10.1007/BF00398267; HORWITZ BA, 1978, PLANT SCI LETT, V13, P9, DOI 10.1016/0304-4211(78)90058-5; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; MCCLUNG CR, 1994, ARABIDOPSIS THALIANA; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1994, THESIS ROCKEFELLER U; MILLAR AJ, UNPUB; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; ROENNEBERG T, 1988, NATURWISSENSCHAFTEN, V75, P206, DOI 10.1007/BF00735584; SIMON E, 1976, PLANT PHYSIOL, V58, P421, DOI 10.1104/pp.58.3.421; Sweeney BM., 1987, RHYTHMIC PHENOMENA P	21	223	228	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1163	1166		10.1126/science.7855596	http://dx.doi.org/10.1126/science.7855596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855596				2022-12-24	WOS:A1995QJ23700036
J	HALEVY, O; NOVITCH, BG; SPICER, DB; SKAPEK, SX; RHEE, J; HANNON, GJ; BEACH, D; LASSAR, AB				HALEVY, O; NOVITCH, BG; SPICER, DB; SKAPEK, SX; RHEE, J; HANNON, GJ; BEACH, D; LASSAR, AB			CORRELATION OF TERMINAL CELL-CYCLE ARREST OF SKELETAL-MUSCLE WITH INDUCTION OF P21 BY MYOD	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; MYOGENIC DIFFERENTIATION; DEPENDENT KINASES; PROTEIN; EXPRESSION; E2F; P53; SUPPRESSION; ASSOCIATION; INHIBITION	Skeletal muscle differentiation entails the coordination of muscle-specific gene expression and terminal withdrawal from the cell cycle. This cell cycle arrest in the G(0) phase requires the retinoblastoma tumor suppressor protein (Rb). The function of Rb is negatively regulated by cyclin-dependent kinases (Cdks), which are controlled by Cdk inhibitors. Expression of MyoD, a skeletal muscle-specific transcriptional regulator, activated the expression of the Cdk inhibitor p21 during differentiation of murine myocytes and in nonmyogenic cells. MyoD-mediated induction of p21 did not require the tumor suppressor protein p53 and correlated with cell cycle withdrawal. Thus, MyoD may induce terminal cell cycle arrest during skeletal muscle differentiation by increasing the expression of p21.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PEDIAT HEMATOL ONCOL,BOSTON,MA 02115; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute			Hannon, Gregory/AAB-3568-2019; Rhee, James/V-9973-2019	Novitch, Bennett/0000-0002-2696-3708	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008214] Funding Source: NIH RePORTER; NIAMS NIH HHS [F32ARO8214-01A1] Funding Source: Medline; NICHD NIH HHS [N01-HD-6-2915] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CLEGG CH, 1987, J CELL BIOL, V105, P937, DOI 10.1083/jcb.105.2.937; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COPPOLA JA, 1990, ONCOGENE, V5, P1731; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DOTTO P, COMMUNICATION; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; NEVINS JR, 1992, SCIENCE, V258, P424; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOVITCH BG, UNPUB; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VOGELSTEIN B, COMMUNICATION; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	49	1090	1102	0	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1018	1021		10.1126/science.7863327	http://dx.doi.org/10.1126/science.7863327			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863327				2022-12-24	WOS:A1995QG99000037
J	LINTON, MF; ATKINSON, JB; FAZIO, S				LINTON, MF; ATKINSON, JB; FAZIO, S			PREVENTION OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE BY BONE-MARROW TRANSPLANTATION	SCIENCE			English	Article							HERITABLE HYPERLIPIDEMIC RABBITS; III HYPERLIPOPROTEINEMIA; LIVER-TRANSPLANTATION; DENSITY-LIPOPROTEIN; PLASMA-LIPOPROTEINS; MOUSE MACROPHAGES; APOPROTEIN-E; CELLS; HYPERCHOLESTEROLEMIA; CHOLESTEROL	Apolipoprotein E (apoE) deficiency causes severe hyperlipidemia and atherosclerosis in humans and in gene-targeted mice. Although the majority of apoE in plasma is of hepatic origin, apoE is synthesized by a variety of cell types, including macrophages. Because macrophages derive from hematopoietic cells, bone marrow transplantation was used to examine the potential of apoE synthesized by bone marrow-derived cells to correct the hyperlipidemia and atherosclerosis caused by apoE deficiency. After transplantation of bone marrow from mice with the normal apoE gene into apoE-deficient mice, apoE was detected in serum and promoted clearance of lipoproteins and normalization of serum cholesterol levels. ApoE-deficient mice given transplants of normal bone marrow showed virtually complete protection from diet-induced atherosclerosis.	VANDERBILT UNIV,MED CTR N,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232	Vanderbilt University	LINTON, MF (corresponding author), VANDERBILT UNIV,MED CTR N,SCH MED,DEPT MED,DIV ENDOCRINOL,ROOM AA 4206,NASHVILLE,TN 37232, USA.				NHLBI NIH HHS [HL-02925] Funding Source: Medline; NIDDK NIH HHS [DK-26657-15] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BASU SK, 1982, J BIOL CHEM, V257, P9788; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BRUNSTETTER MA, 1971, ARCH INTERN MED, V127, P1064, DOI 10.1001/archinte.127.6.1064; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; FAZIO S, 1993, TRENDS CARDIOVAS MED, V3, P191, DOI 10.1016/1050-1738(93)90005-Q; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; KERR WJ, COMMUNICATION; KLEIN J, 1983, IMMUNOGENETICS, V17, P553, DOI 10.1007/BF00366126; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1994, CIRCULATION, V90, P133; LINTON MF, UNPUB; LONGO DL, 1980, J EXP MED, V151, P1452, DOI 10.1084/jem.151.6.1452; LONGO DL, 1983, J IMMUNOL, V130, P2525; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PARADIS K, 1990, J PEDIATR GASTR NUTR, V11, P525, DOI 10.1097/00005176-199011000-00014; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; THIELE DL, 1989, J CLIN INVEST, V84, P1947, DOI 10.1172/JCI114383; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; YAMADA N, 1992, J CLIN INVEST, V89, P706, DOI 10.1172/JCI115639; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	37	399	418	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1034	1037		10.1126/science.7863332	http://dx.doi.org/10.1126/science.7863332			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863332				2022-12-24	WOS:A1995QG99000042
J	PARKER, SB; EICHELE, G; ZHANG, PM; RAWLS, A; SANDS, AT; BRADLEY, A; OLSON, EN; HARPER, JW; ELLEDGE, SJ				PARKER, SB; EICHELE, G; ZHANG, PM; RAWLS, A; SANDS, AT; BRADLEY, A; OLSON, EN; HARPER, JW; ELLEDGE, SJ			P53-INDEPENDENT EXPRESSION OF P21(CIP)1 IN MUSCLE AND OTHER TERMINALLY DIFFERENTIATING CELLS	SCIENCE			English	Article							CYCLIN-DEPENDENT KINASES; GENE MYF-5; PROTEIN; MYOD; MICE; FIBROBLASTS; P53; PROLIFERATION; NEUROGENESIS; INACTIVATION	Terminal differentiation is coupled to withdrawal from the cell cycle. The cyclin-dependent kinase inhibitor (CKI) p21(Cip1) is transcriptionally regulated by p53 and can induce growth arrest. CKIs are therefore potential mediators of developmental control of cell proliferation. The expression pattern of mouse p21 correlated with terminal differentiation of multiple cell lineages including skeletal muscle, cartilage, skin, and nasal epithelium in a p53-independent manner. Although the muscle-specific transcription factor MyoD is sufficient to activate p21 expression in 10T1/2 cells, p21 was expressed in myogenic cells of mice lacking the genes encoding MyoD and myogenin, demonstrating that p21 expression does not require these transcription factors. The p21 protein may function during development as an inducible growth inhibitor that contributes to cell cycle exit and differentiation.	BAYLOR COLL MED,HOWARD HUGHES MED INST,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT HUMAN & MOLEC GENET,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center				Bradley, Allan/0000-0002-2349-8839; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040339, R01AR039849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40339, AR39849] Funding Source: Medline; NIA NIH HHS [AG-11085] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRENNAN T, 1990, J CELL BIOL, V11, P929; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHRIST B, 1983, ANAT EMBRYOL, V166, P87, DOI 10.1007/BF00317946; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EDMONDSON D, 1989, GENE DEV, V3, P28; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDIERY WS, 1994, CANCER RES, V54, P1169; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P874; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; KAEHN K, 1988, ANAT EMBRYOL, V177, P191, DOI 10.1007/BF00321131; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LI Y, 1994, ONCOGENE, V9, P2261; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MICHIELI P, 1994, CANCER RES, V54, P3391; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAWLS A, UNPUB; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V344, P303; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang P. X., UNPUB	53	1052	1067	0	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1024	1027		10.1126/science.7863329	http://dx.doi.org/10.1126/science.7863329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863329				2022-12-24	WOS:A1995QG99000039
J	CHANG, HC; SOLOMON, NM; WASSARMAN, DA; KARIM, FD; THERRIEN, M; RUBIN, GM; WOLFF, T				CHANG, HC; SOLOMON, NM; WASSARMAN, DA; KARIM, FD; THERRIEN, M; RUBIN, GM; WOLFF, T			PHYLLOPOD FUNCTIONS IN THE FATE DETERMINATION OF A SUBSET OF PHOTORECEPTORS IN DROSOPHILA	CELL			English	Article							RECEPTOR TYROSINE KINASE; SEVENLESS PROTEIN; DEVELOPING EYE; COMPOUND EYE; CELL FATE; GENE; RAS; MELANOGASTER; ACTIVATION; EXPRESSION	phyllopod (phyl) encodes a novel protein required for fate determination of photoreceptors R1, R6, and R7, the last three photoreceptors to be recruited into the ommatidia of the developing Drosophila eye. Genetic data suggests that phyl acts downstream of Ras1, raf, and van to promote neuronal differentiation in this subset of photoreceptors. Ectopic expression of phyl in the cone cell precursors mimics the effect of ectopic activation of Ras1, suggesting that phyl expression is regulated by Ras1. phyl is also required for embryonic nervous system and sensory bristle development.			CHANG, HC (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BOWTELL DDL, 1991, P NATL ACAD SCI USA, V88, P6853, DOI 10.1073/pnas.88.15.6853; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson Barry, 1993, P1327; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HAY BA, 1994, DEVELOPMENT, V120, P2121; Jan Yuh Nung, 1993, P1207; KARPEN GH, 1992, GENETICS, V132, P737; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KUSSICK SJ, 1993, ONCOGENE, V8, P2791; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NILSSON DE, 1983, CELL TISSUE RES, V230, P401; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; WOLFF T, 1991, DEVELOPMENT, V113, P841; Wolff Tanya, 1993, P1277; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	41	95	98	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					463	472		10.1016/0092-8674(95)90497-2	http://dx.doi.org/10.1016/0092-8674(95)90497-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7888014	Bronze			2022-12-24	WOS:A1995QG47000013
J	LI, Y; LACERDA, DA; WARMAN, ML; BEIER, DR; YOSHIOKA, H; NINOMIYA, Y; OXFORD, JT; MORRIS, NP; ANDRIKOPOULOS, K; RAMIREZ, F; WARDELL, BB; LIFFERTH, GD; TEUSCHER, C; WOODWARD, SR; TAYLOR, BA; SEEGMILLER, RE; OLSEN, BR				LI, Y; LACERDA, DA; WARMAN, ML; BEIER, DR; YOSHIOKA, H; NINOMIYA, Y; OXFORD, JT; MORRIS, NP; ANDRIKOPOULOS, K; RAMIREZ, F; WARDELL, BB; LIFFERTH, GD; TEUSCHER, C; WOODWARD, SR; TAYLOR, BA; SEEGMILLER, RE; OLSEN, BR			A FIBRILLAR COLLAGEN GENE, COL11A1, IS ESSENTIAL FOR SKELETAL MORPHOGENESIS	CELL			English	Article							XI COLLAGEN; II COLLAGEN; V COLLAGEN; CARTILAGE; MICE; ORGANIZATION; EXPRESSION; CLONING; REVEALS; TISSUE	Mice that are homozygous for the autosomal recessive chondrodysplasia (cho) mutation die at birth with abnormalities in cartilage of limbs, ribs, mandible, and trachea. Limb bones of newborn cho/cho mice are wider at the metaphyses than normal bones and only about half the normal length. By linkage analysis, the cho gene and the gene encoding the alpha 1(XI) chain of cartilage collagen XI were mapped to the same region of chromosome 3. Deletion of a cytidine residue about 570 nt downstream of the translation initiation codon in cho alpha 1(XI) mRNA causes a reading frame shift and introduces a premature stop codon. The data demonstrate that collagen XI is essential for normal formation of cartilage collagen fibrils and the cohesive properties of cartilage. The results also suggest that the normal differentiation and spatial organization of growth plate chondrocytes is critially dependent on the presence of type XI collagen in cartilage extracellular matrix.	BRIGHAM & WOMENS HOSP,DIV GENET,BOSTON,MA 02115; OKAYAMA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,OKAYAMA 700,JAPAN; SHRINERS HOSP CRIPPLED CHILDRENS,RES DEPT,PORTLAND,OR 97201; MT SINAI MED CTR,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; BRIGHAM YOUNG UNIV,DEPT MICROBIOL,PROVO,UT 84602; BRIGHAM YOUNG UNIV,DEPT ZOOL,PROVO,UT 84602; JACKSON LAB,BAR HARBOR,ME 04609	Harvard University; Brigham & Women's Hospital; Okayama University; Icahn School of Medicine at Mount Sinai; Brigham Young University; Brigham Young University; Jackson Laboratory	LI, Y (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Oxford, Julia Thom/AAH-2842-2019	Oxford, Julia Thom/0000-0002-4850-3569	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036820, R37AR036820, R01AR036819, R37AR036819] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36820, AR36819] Funding Source: Medline; NIGMS NIH HHS [GM38862] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIER DR, 1993, MAMM GENOME, V4, P627, DOI 10.1007/BF00360898; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BROEK DL, 1985, J BIOL CHEM, V260, P555; BRUNNER HG, 1994, HUM MOL GENET, V3, P1561, DOI 10.1093/hmg/3.9.1561; BURTON BK, 1986, J PEDIATR-US, V109, P642, DOI 10.1016/S0022-3476(86)80228-1; DIETRICH W, 1992, GENETICS, V131, P423; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Eyre D, 1987, STRUCTURE FUNCTION C, P261; GAROFALO S, 1993, P NATL ACAD SCI USA, V90, P3825, DOI 10.1073/pnas.90.9.3825; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HAUSSER I, 1994, HUM GENET, V93, P394; HENRY I, 1988, Genomics, V3, P87, DOI 10.1016/0888-7543(88)90165-6; HEPWORTH W B, 1990, Pediatric Pathology, V10, P919; JACENKO O, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P327; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MONSON CB, 1981, J BONE JOINT SURG AM, V63, P637, DOI 10.2106/00004623-198163040-00015; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; OXFORD JT, 1994, EXP CELL RES, V213, P28, DOI 10.1006/excr.1994.1169; SEEGMILL.R, 1972, J ULTRA MOL STRUCT R, V38, P288, DOI 10.1016/S0022-5320(72)90006-8; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; SEEGMILLER RE, 1981, CONNECT TISSUE RES, V9, P69, DOI 10.3109/03008208109160242; SEEGMILLER RE, 1986, TERATOLOGY, V33, P339, DOI 10.1002/tera.1420330313; SELDIN MF, 1993, GENOME, V4, pS47; SHAW LM, 1990, TRENDS BIOCHEM SCI, V16, P191; SHEREN SB, 1986, COMP BIOCHEM PHYS B, V85, P5, DOI 10.1016/0305-0491(86)90214-2; SMITH GN, 1985, J BIOL CHEM, V260, P761; SPRANGER J, 1990, ADV HUM GENET, P1; STEPHENS TD, 1976, TERATOLOGY, V13, P317, DOI 10.1002/tera.1420130312; TAYLOR BA, 1989, GENOMICS, V5, P221, DOI 10.1016/0888-7543(89)90050-5; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X	36	281	290	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					423	430		10.1016/0092-8674(95)90492-1	http://dx.doi.org/10.1016/0092-8674(95)90492-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859283	Bronze			2022-12-24	WOS:A1995QG47000008
J	VIKKULA, M; MARIMAN, ECM; LUI, VCH; ZHIDKOVA, NI; TILLER, GE; GOLDRING, MB; VANBEERSUM, SEC; MALEFIJT, MCD; VANDENHOOGEN, FHJ; ROPERS, HH; MAYNE, R; CHEAH, KSE; OLSEN, BR; WARMAN, ML; BRUNNER, HG				VIKKULA, M; MARIMAN, ECM; LUI, VCH; ZHIDKOVA, NI; TILLER, GE; GOLDRING, MB; VANBEERSUM, SEC; MALEFIJT, MCD; VANDENHOOGEN, FHJ; ROPERS, HH; MAYNE, R; CHEAH, KSE; OLSEN, BR; WARMAN, ML; BRUNNER, HG			AUTOSOMAL-DOMINANT AND RECESSIVE OSTEOCHONDRODYSPLASIAS ASSOCIATED WITH THE COL11A2 LOCUS	CELL			English	Article							COLLAGEN; MUTATIONS; HUMANS	Identifying mutations that cause specific osteochondrodysplasias will provide novel insights into the function of genes that are essential for skeletal morphogenesis. We report here that an autosomal dominant form of Stickler syndrome, characterized by mild spondyloepiphyseal dysplasia, osteoarthritis, and sensorineural hearing loss, but no eye involvement, is caused by a splice donor site mutation resulting in ''in-frame'' exon skipping within the COL11A2 gene, encoding the alpha 2(XI) chain of the quantitatively minor fibrillar collagen XI. We also show that an autosomal recessive disorder with similar, but more severe, characteristics is linked to the COL11A2 locus and is caused by a glycine to arginine substitution In alpha 2(XI) collagen. The results suggest that mutations in collagen XI genes are associated with a spectrum of abnormalities in human skeletal development and support the conclusion of others, based on studies of murine chondrodysplasia, that collagen XI is essential for skeletal morphogenesis.	UNIV NIJMEGEN HOSP,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; UNIV HONG KONG,DEPT BIOCHEM,HONG KONG,HONG KONG; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; VANDERBILT UNIV,MED CTR,DIV GENET,NASHVILLE,TN 37232; MASSACHUSETTS GEN HOSP E,ARTHRITIS RES MED SERV,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA 02129; UNIV NIJMEGEN HOSP,DEPT ORTHOPED SURG,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT RHEUMATOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; University of Hong Kong; University of Alabama System; University of Alabama Birmingham; Vanderbilt University; Harvard University; Harvard Medical School; Radboud University Nijmegen; Radboud University Nijmegen	VIKKULA, M (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		van Beersum, Sylvia E.C./P-8653-2015; Brunner, Han/C-9928-2013; Vikkula, Miikka/Q-1038-2018; Cheah, Kathryn/C-4222-2009; /C-4359-2009	van Beersum, Sylvia E.C./0000-0002-4552-2908; Vikkula, Miikka/0000-0002-6236-338X; /0000-0002-1758-8854	NIAMS NIH HHS [AR03564, AR30481, ARO1925] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030481, K08AR001925, P01AR003564, R37AR030481] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRUNNER HG, 1994, HUM MOL GENET, V3, P1561, DOI 10.1093/hmg/3.9.1561; DOLZ R, 1990, ANN NY ACAD SCI, V580, P421, DOI 10.1111/j.1749-6632.1990.tb17948.x; Eyre D, 1987, STRUCTURE FUNCTION C, P261; GIEDION A, 1982, HELV PAEDIATR ACTA, V37, P361; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MAYNE R, 1993, J BIOL CHEM, V268, P9381; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SNEAD MP, 1994, IN PRESS EYE, V6; SPRANGER J, 1985, ENDOCRINE GENETICS G, P315; STICKLER GB, 1965, MAYO CLIN PROC, V40, P433; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; VIKKULA M, 1994, ANN MED, V26, P107; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79	20	282	290	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					431	437		10.1016/0092-8674(95)90493-X	http://dx.doi.org/10.1016/0092-8674(95)90493-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859284	Green Published, Bronze			2022-12-24	WOS:A1995QG47000009
J	LOUTAN, L; BOVIER, P; ALTHAUS, B; GLUCK, R				LOUTAN, L; BOVIER, P; ALTHAUS, B; GLUCK, R			INACTIVATED VIROSOME HEPATITIS-A VACCINE	LANCET			English	Article							SUPPRESSION	Immunopotentiating reconstituted influenza virosomes (IRIV) are efficient carrier systems for small virion particles such as hepatitis A virus (HAV). We evaluated immunogenicity and tolerability of an IRIV-HAV vaccine and the effectiveness of a booster by immunising 104 healthy HAV seronegative volunteers. A single dose was highly immunogenic, since 98% of volunteers had seroconverted after 2 weeks. Anti-HAV titres remained high, with 100% seroconversion rate 1 year later, when the booster was given. The vaccine was effective, with a 22-fold increase in geometric mean titres 1 month later. No serious adverse reactions were observed.	SWISS SERUM & VACCINE INST, DEPT MED & VIROL, BERN, SWITZERLAND		LOUTAN, L (corresponding author), UNIV GENEVA, HOP CANTONAL, DEPT MED, MED POLICLIN, COMMUNITY MED UNIT, CH-1211 GENEVA 14, SWITZERLAND.							AMBROSCH F, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P98; ANDRE FE, 1990, PROG MED VIROL, V37, P72; ANDRE FE, 1992, VACCINE, V10, pS160, DOI 10.1016/0264-410X(92)90576-6; ETLINGER HM, 1990, SCIENCE, V249, P423, DOI 10.1126/science.1696030; GLUCK R, 1992, J CLIN INVEST, V90, P2491, DOI 10.1172/JCI116141; GLUCK R, 1993, 3RD C INT TRAV MED P; GUPTA RK, 1993, VACCINE, V11, P293, DOI 10.1016/0264-410X(93)90190-9; HERZENBERG LA, 1982, J EXP MED, V155, P1730, DOI 10.1084/jem.155.6.1730; MILLINER DS, 1985, NEW ENGL J MED, V312, P165, DOI 10.1056/NEJM198501173120307; POOVORAWAN Y, IN PRESS J INFECT DI; SCHUTZE MP, 1989, J IMMUNOL, V142, P2635; 1992, LANCET, V339, P1198	12	75	77	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	1994	343	8893					322	324		10.1016/S0140-6736(94)91162-2	http://dx.doi.org/10.1016/S0140-6736(94)91162-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905144				2022-12-24	WOS:A1994MU98500008
J	CALNE, R; DAVIES, H				CALNE, R; DAVIES, H			ORGAN GRAFT TOLERANCE - THE LIVER EFFECT	LANCET			English	Editorial Material							TRANSPLANTATION; RECIPIENTS; CHIMERISM; ANTIGENS				CALNE, R (corresponding author), ADDENBROOKES HOSP,DEPT SURG,CAMBRIDGE CB2 2QQ,ENGLAND.							DAVIES HFS, 1989, TRANSPLANTATION, V47, P524; GONWA TA, 1988, TRANSPLANTATION, V46, P690, DOI 10.1097/00007890-198811000-00013; JAMIESON NV, 1991, TRANSPLANT INT, V4, P67, DOI 10.1111/j.1432-2277.1991.tb01950.x; KAMADA N, 1980, TRANSPLANTATION, V29, P429, DOI 10.1097/00007890-198005000-00021; MARGREITER R, 1988, TRANSPLANT P, V20, P522; RASMUSSEN A, 1993, 6TH C EUR SOC ORG TR; SRIWATANAWONGA V, 1993, THESIS U CAMBRIDGE; SRIWATANAWONGSA V, 1993, TRANSPLANT P, V25, P371; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; 1969, LANCET, V2, P940	12	75	75	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					67	68		10.1016/S0140-6736(94)90809-5	http://dx.doi.org/10.1016/S0140-6736(94)90809-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903772				2022-12-24	WOS:A1994MQ09200004
J	JOHNSTON, SRD; HAYNES, BP; SMITH, IE; JARMAN, M; SACKS, NPM; EBBS, SR; DOWSETT, M				JOHNSTON, SRD; HAYNES, BP; SMITH, IE; JARMAN, M; SACKS, NPM; EBBS, SR; DOWSETT, M			ACQUIRED TAMOXIFEN RESISTANCE IN HUMAN BREAST-CANCER AND REDUCED INTRA-TUMORAL DRUG CONCENTRATION	LANCET			English	Note								Reduced intra-tumoral drug concentrations have been investigated as a mechanism of tamoxifen resistance in 51 patients with locally recurrent breast cancer. Serum tamoxifen was similar in patients with acquired and de-novo resistance, but intra-tumoral concentrations were significantly lower in patients with acquired resistance. Tumour oestrogen-receptor concentrations at relapse did not support the hypothesis that selective outgrowth of oestrogen-receptor-negative cells is a major mechanism for acquired tamoxifen resistance. Reduced intra-tumoral tamoxifen levels during prolonged therapy may be an important mechanism for acquired resistance in breast cancer.	ROYAL MARSDEN HOSP,BREAST UNIT,LONDON SW3 6JJ,ENGLAND; INST CANC RES,DRUG DEV SECT,SUTTON SM2 5PX,SURREY,ENGLAND; MAYDAY UNIV HOSP,DEPT SURG,CROYDON,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Croydon University Hospital	JOHNSTON, SRD (corresponding author), ROYAL MARSDEN HOSP,ACAD DEPT BIOCHEM,LONDON SW3 6JJ,ENGLAND.							JENSEN EV, 1982, RECENT PROG HORM RES, V38, P1; JOHNSTON SRD, 1992, ANN ONCOL, V3, P503, DOI 10.1093/oxfordjournals.annonc.a058251; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; LANGANFAHEY SM, 1990, EUR J CANCER, V26, P883, DOI 10.1016/0277-5379(90)90191-U; MCCAGUE R, 1989, J MED CHEM, V32, P2527, DOI 10.1021/jm00132a006; OSBORNE CK, 1992, J CLIN ONCOL, V10, P304, DOI 10.1200/JCO.1992.10.2.304; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; SMITH IE, 1982, CANCER RES, V42, P3430	8	78	79	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1521	1522		10.1016/S0140-6736(05)80088-1	http://dx.doi.org/10.1016/S0140-6736(05)80088-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902904				2022-12-24	WOS:A1993MM40200015
J	HESSLER, NA; SHIRKE, AM; MALINOW, R				HESSLER, NA; SHIRKE, AM; MALINOW, R			THE PROBABILITY OF TRANSMITTER RELEASE AT A MAMMALIAN CENTRAL SYNAPSE	NATURE			English	Article							EXCITATORY POSTSYNAPTIC POTENTIALS; GROUP-IA SYNAPSES; TIME COURSE; TRANSMISSION; GLUTAMATE; RECEPTOR; CURRENTS	WHEN an action potential reaches a synaptic terminal, fusion of a transmitter-containing vesicle with the presynaptic membrane occurs with a probability (p(r)) of less than one1. Despite the fundamental importance of this parameter, p(r) has not been directly measured in the central nervous system. Here we describe a novel approach to determine p(r), monitoring the decrement of NMDA (N-methyl-D-aspartate)-receptor mediated synaptic currents in the presence of the use-dependent channel blocker MK-801 (ref. 2). On a single postsynaptic CA1 hippocampal slice neuron, two classes of synapses with a sixfold difference in p(r) are resolved. Synapses with low p(r) contribute to over half of transmission and are more sensitive to drugs enhancing transmitter release. Switching between these two classes of synapses provides the potential for large changes in synaptic efficacy and could underlie forms of activity-dependent plasticity.	UNIV IOWA,NEUROSCI PROGRAM,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa; University of Iowa			hessler, neal/A-7328-2010					ATWOOD HL, 1967, NATURE, V215, P57, DOI 10.1038/215057a0; CLAMANN HP, 1989, J NEUROPHYSIOL, V61, P403, DOI 10.1152/jn.1989.61.2.403; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; EDMONDS B, 1992, P ROY SOC B-BIOL SCI, V250, P279, DOI 10.1098/rspb.1992.0160; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HEUTTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307; JACK JJB, 1981, J PHYSIOL-LONDON, V321, P111, DOI 10.1113/jphysiol.1981.sp013974; JAHR CE, 1992, SCIENCE, V255, P470, DOI 10.1126/science.1346477; Katz B., 1969, RELEASE NEURAL TRANS; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIN JW, 1988, J NEUROSCI, V8, P1313; RAHAMIMOFF R, 1968, J PHYSIOL-LONDON, V195, P471, DOI 10.1113/jphysiol.1968.sp008468; REDMAN S, 1983, J PHYSIOL-LONDON, V343, P135, DOI 10.1113/jphysiol.1983.sp014885; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; ROSENMUND C, 1993, BIOPH SOC ABSTR, pA327; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; WALMSLEY B, 1988, J NEUROPHYSIOL, V60, P889, DOI 10.1152/jn.1988.60.3.889	20	472	474	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					569	572		10.1038/366569a0	http://dx.doi.org/10.1038/366569a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7902955				2022-12-24	WOS:A1993ML21800071
J	WALLACE, CJ				WALLACE, CJ			MAGNETIC-RESONANCE FOR DETECTION OF ABNORMALITIES IN PARTIAL EPILEPSY	LANCET			English	Editorial Material							HIPPOCAMPAL				WALLACE, CJ (corresponding author), FOOTHILLS PROV GEN HOSP,DEPT RADIOL SCI,CALGARY,AB,CANADA.							COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; CROSS JH, 1993, ARCH DIS CHILD, V69, P104, DOI 10.1136/adc.69.1.104; DUCHOWNY M, 1992, EPILEPSIA, V33, P298, DOI 10.1111/j.1528-1157.1992.tb02319.x; HIRSCHORN K A, 1991, Neurology, V41, P170; JACK CR, 1990, RADIOLOGY, V175, P423, DOI 10.1148/radiology.175.2.2183282; JACKSON GD, 1990, NEUROLOGY, V40, P1869, DOI 10.1212/WNL.40.12.1869; TSURUDA JS, 1992, ASNR M NOTES VANCOUV, P174	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1252	1252		10.1016/0140-6736(93)92354-V	http://dx.doi.org/10.1016/0140-6736(93)92354-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901578				2022-12-24	WOS:A1993MH56600004
J	BRENNER, MK; RILL, DR; HOLLADAY, MS; HESLOP, HE; MOEN, RC; BUSCHLE, M; KRANCE, RA; SANTANA, VM; ANDERSON, WF; IHLE, JN				BRENNER, MK; RILL, DR; HOLLADAY, MS; HESLOP, HE; MOEN, RC; BUSCHLE, M; KRANCE, RA; SANTANA, VM; ANDERSON, WF; IHLE, JN			GENE MARKING TO DETERMINE WHETHER AUTOLOGOUS MARROW INFUSION RESTORES LONG-TERM HEMATOPOIESIS IN CANCER-PATIENTS	LANCET			English	Article							HEMATOPOIETIC STEM-CELLS; HIGH-DOSE CHEMOTHERAPY; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; BONE-MARROW; TRANSPLANTATION; EXPRESSION; PROGENITORS; RECOVERY; RECONSTITUTION	The contribution of infused bone marrow cells to long-term haemopoietic recovery in patients undergoing autologous bone marrow transplantation is unknown. Such information would help to clarify the role of this procedure in cancer therapy and would aid in the development of strategies to reduce the risk of subsequent aplasia. By transferring a neomycin resistance marker gene into the marrow cells of 20 patients before transplantation, we were able to trace the pattern of haemopoietic reconstitution postinfusion. The marker gene was present and expressed in all haemopoietic lineages in vivo in 15 of 18 evaluable patients at 1 month post-transplantation, in 8 of 9 patients at 6 months, and in 5 of 5 at 1 year. The marker has remained detectable for up to 18 months-the duration of our study. Our findings indicate that harvested bone marrow consistently contributes to long-term multilineage recovery of haemopoiesis after autologous marrow transplantation in cancer patients. These results, provide a rationale for the continued exploration of more ablative preparative regimens with single or sequential autologous marrow transplants.	UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT MED, MEMPHIS, TN 38163 USA; GENET THERAPY INC, GAITHERSBURG, MD 20878 USA; USC, SCH MED, LOS ANGELES, CA 90033 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Novartis; University of Southern California; St Jude Children's Research Hospital	BRENNER, MK (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38105 USA.		Heslop, Helen/AAC-9500-2020; Brenner, Malcolm/Y-2509-2019		NATIONAL CANCER INSTITUTE [P30CA021765, U01CA058211] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58211, CA 21765, CA 59479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BODINE DM, 1991, EXP HEMATOL, V19, P206; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; CHOPRA R, 1991, J CLIN ONCOL, V9, P1840, DOI 10.1200/JCO.1991.9.10.1840; EKHTERAE D, 1990, BLOOD, V75, P365; GALE RP, 1989, LANCET, V2, P315; GIANNI AM, 1989, LANCET, V2, P580; GRAHAMPOLE J, 1991, BLOOD, V78, P1607; LAPORTE JP, 1991, LANCET, V338, P601, DOI 10.1016/0140-6736(91)90609-S; LI CL, 1992, J EXP MED, V175, P1443, DOI 10.1084/jem.175.6.1443; LOTHROP CD, 1991, BLOOD, V78, P237; MCMILLAN AK, 1990, BLOOD, V76, P480; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1990, BLOOD, V76, P271; RILL DR, 1992, BLOOD, V79, P2694; RILL DR, 1992, HUM GENE THER, V3, P129, DOI 10.1089/hum.1992.3.2-129; SCHUENING FG, 1991, BLOOD, V78, P2568; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SIENA S, 1991, BLOOD, V77, P400; STEWART FM, 1989, EXP HEMATOL, V17, P974; VANBEUSECHEM VW, 1992, P NATL ACAD SCI USA, V89, P7640, DOI 10.1073/pnas.89.16.7640; WIEDER R, 1991, BLOOD, V77, P448; 1989, LANCET, V2, P317	25	384	395	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1134	1137		10.1016/0140-6736(93)92122-A	http://dx.doi.org/10.1016/0140-6736(93)92122-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901474				2022-12-24	WOS:A1993MF19800008
J	AGUNDEZ, JAG; LEDESMA, MC; BENITEZ, J; LADERO, JM; RODRIGUEZLESCURE, A; DIAZRUBIO, E; DIAZRUBIO, M				AGUNDEZ, JAG; LEDESMA, MC; BENITEZ, J; LADERO, JM; RODRIGUEZLESCURE, A; DIAZRUBIO, E; DIAZRUBIO, M			CYP2D6 GENES AND RISK OF LIVER-CANCER	LANCET			English	Note							DEBRISOQUINE; AMPLIFICATION; PHENOTYPE	We have studied by use of PCR and Xbal and EcoRI restriction-fragment-length polymorphism whether mutations at the polymorphic CYP2D6 (debrisoquine hydroxylase) gene locus are associated with liver cancer. The frequency of CYP2D6 genes containing inactivating mutations was lower among 75 liver cancer patients than 200 healthy controls, and 40 cirrhotic subjects that did not develop liver cancer (frequency for carriers of two or more functional genes was 95% vs 74% vs 78%, respectively). Subjects who were homozygous for functional CYP2D6 genes appear to be at higher risk of developing primary liver cancer (odds ratio 6.40 [95% CI] 2.4-17.5).	UNIV EXTREMADURA,SCH MED,DEPT PHARMACOL,E-06071 BADAJOZ,SPAIN; UNIV COMPLUTENSE MADRID,SAN CARLOS UNIV HOSP,SERV ONCOL,MADRID,SPAIN; UNIV COMPLUTENSE MADRID,SAN CARLOS UNIV HOSP,SERV GASTROENTEROL,MADRID,SPAIN	Universidad de Extremadura; Complutense University of Madrid; Hospital Clinico San Carlos; Complutense University of Madrid; Hospital Clinico San Carlos			Agúndez, José A. G./A-5503-2008; Rodríguez-Lescure, Álvaro/AAB-7039-2019; Diaz-Rubio, Manuel/B-5359-2010; Ledesma, M  Carmen/K-1689-2017	Agúndez, José A. G./0000-0001-6895-9160; Rodríguez-Lescure, Álvaro/0000-0002-6823-5290; Ledesma, M  Carmen/0000-0001-5546-0598; Diaz-Rubio, Eduardo/0000-0003-2792-5348				AGUNDEZ JAG, 1994, CLIN PHARMACOL THER, V55, P10, DOI 10.1038/clpt.1994.3; AGUNDEZ JAG, IN PRESS CLIN PHARM; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P4790, DOI 10.1073/pnas.87.12.4790; BROLY F, 1991, DNA CELL BIOL, V10, P545, DOI 10.1089/dna.1991.10.545; CAPORASO N, 1991, PHARMACOGENETICS, V1, P4, DOI 10.1097/00008571-199110000-00003; CRESPI CL, 1991, CARCINOGENESIS, V12, P1197, DOI 10.1093/carcin/12.7.1197; HEIM M, 1990, LANCET, V336, P529, DOI 10.1016/0140-6736(90)92086-W; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; TYNDALE R, 1991, PHARMACOGENETICS, V1, P26, DOI 10.1097/00008571-199110000-00005; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035	10	61	69	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					830	831		10.1016/S0140-6736(95)92965-7	http://dx.doi.org/10.1016/S0140-6736(95)92965-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898230				2022-12-24	WOS:A1995QQ19500010
J	DUPONT, HL; CHAPPELL, CL; STERLING, CR; OKHUYSEN, PC; ROSE, JB; JAKUBOWSKI, W				DUPONT, HL; CHAPPELL, CL; STERLING, CR; OKHUYSEN, PC; ROSE, JB; JAKUBOWSKI, W			THE INFECTIVITY OF CRYPTOSPORIDIUM-PARVUM IN HEALTHY-VOLUNTEERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRINKING-WATER; INVITRO EXCYSTATION; OUTBREAK; OOCYSTS; IMMUNOCOMPETENT; GIARDIA; DISINFECTANTS; VIABILITY; OZONE; MICE	Background. Small numbers of Cryptosporidium parvum oocysts can contaminate even treated drinking water, and ingestion of oocysts can cause diarrheal disease in normal as well as immunocompromised hosts. Since the number of organisms necessary to cause infection in humans is unknown, we performed a study to determine the infective dose of the parasite in healthy adults. Methods. After providing informed consent, 29 healthy volunteers without evidence of previous C. parvum infection, as determined by the absence of anti-cryptosporidium-specific antibodies, were given a single dose of 30 to 1 million C. parvum oocysts obtained from a calf. They were then monitored for oocyst excretion and clinical illness for eight weeks. Household contacts were monitored for secondary spread. Reuslts. Of the 16 subjects who received an intended dose of 300 or more oocysts, 14 (88 percent) became infected. After a dose of 30 oocysts, one of five subjects (20 percent) became infected, whereas at a dose of 1000 or more oocysts, seven of seven became infected. The median infective dose, calculated by linear regression, was 132 oocysts. Of the 18 subjects who excreted oocysts after the challenge dose, 11 had enteric symptoms and 7 (39 percent) had clinical cryptosporidiosis, consisting of diarrhea plus at least one other enteric symptom. All recovered, and there were no secondary cases of diarrhea among household contacts. Conclusions. In healthy adults with no serologic evidence of past infection with C. parvum, a low dose of C. parvum oocysts is sufficient to cause infection.	UNIV TEXAS, SCH MED, HOUSTON, TX USA; UNIV TEXAS, SCH PUBL HLTH, HOUSTON, TX USA; UNIV ARIZONA, TUCSON, AZ USA; UNIV S FLORIDA, TAMPA, FL USA; US EPA, CINCINNATI, OH 45268 USA	University of Texas System; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Arizona; State University System of Florida; University of South Florida; United States Environmental Protection Agency			DuPont, Herbert/AAH-6776-2021	Okhuysen, Pablo/0000-0002-1596-3411	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002558] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR-02558] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANGUS KW, 1982, RES VET SCI, V33, P379, DOI 10.1016/S0034-5288(18)32320-8; ARROWOOD MJ, 1987, J PARASITOL, V73, P314, DOI 10.2307/3282084; BLACKLOW NR, 1979, J CLIN MICROBIOL, V10, P903, DOI 10.1128/JCM.10.6.903-909.1979; CAMPBELL AT, 1992, APPL ENVIRON MICROB, V58, P3488, DOI 10.1128/AEM.58.11.3488-3493.1992; CAMPBELL I, 1982, VET REC, V111, P414, DOI 10.1136/vr.111.18.414; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; DUPONT HL, 1992, CLIN INFECT DIS, V15, pS228, DOI 10.1093/clind/15.Supplement_1.S228; FINCH GR, 1993, APPL ENVIRON MICROB, V59, P4203, DOI 10.1128/AEM.59.12.4203-4210.1993; GOODGAME RW, 1993, J INFECT DIS, V167, P704, DOI 10.1093/infdis/167.3.704; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; ISAACRENTON JL, 1987, LANCET, V1, P973; JOKIPII L, 1985, GASTROENTEROLOGY, V89, P838, DOI 10.1016/0016-5085(85)90581-5; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; KUHLS TL, 1994, CLIN INFECT DIS, V18, P731, DOI 10.1093/clinids/18.5.731; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; Lederberg J., 1992, EMERGING INFECTIONS; LENGERICH EJ, 1993, J INFECT DIS, V167, P1252, DOI 10.1093/infdis/167.5.1252; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MADORE MS, 1987, J PARASITOL, V73, P702, DOI 10.2307/3282398; MOON HW, 1988, INFECT IMMUN, V56, P649, DOI 10.1128/IAI.56.3.649-653.1988; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; REGLI S, 1991, J AM WATER WORKS ASS, V83, P76, DOI 10.1002/j.1551-8833.1991.tb07252.x; RENDTORFF ROBERT C., 1954, AMER JOUR HYG, V59, P209; ROSE JB, 1991, AM J PUBLIC HEALTH, V81, P709, DOI 10.2105/AJPH.81.6.709; TANGERMANN RH, 1991, AM J EPIDEMIOL, V133, P471, DOI 10.1093/oxfordjournals.aje.a115914; UNGAR BLP, 1989, ARCH INTERN MED, V149, P894, DOI 10.1001/archinte.149.4.894; UNGAR BLP, 1986, J INFECT DIS, V153, P570, DOI 10.1093/infdis/153.3.570; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; WOODMANSEE DB, 1987, J PROTOZOOL, V34, P398, DOI 10.1111/j.1550-7408.1987.tb03199.x	31	690	738	2	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					855	859		10.1056/NEJM199503303321304	http://dx.doi.org/10.1056/NEJM199503303321304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7870140	Bronze			2022-12-24	WOS:A1995QP22800004
J	LORENZ, M; JUNG, S; RADBRUCH, A				LORENZ, M; JUNG, S; RADBRUCH, A			SWITCH TRANSCRIPTS IN IMMUNOGLOBULIN CLASS SWITCHING	SCIENCE			English	Article							HEAVY-CHAIN TRANSCRIPTS; RESTING B-CELLS; MAMMALIAN-CELLS; STEM-CELLS; RECOMBINATION; GENE; INDUCTION; INTERLEUKIN-4; REGION; REARRANGEMENT	B cells can exchange gene segments for the constant region of the immunoglobulin heavy chain, altering the class and effector function of the antibodies that they produce. Class switching is directed to distinct classes by cytokines, which induce transcription of the targeted DNA sequences. These transcripts are processed, resulting in spliced ''switch'' transcripts. Switch recombination can be directed to immunoglobulin G1 (IgG1) by the heterologous human metallothionein IIA promoter in mutant mice. Induction of the structurally conserved, spliced switch transcripts is sufficient to target switch recombination to IgG1, whereas transcription alone is not.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91120 JERUSALEM, ISRAEL	University of Cologne; Hebrew University of Jerusalem			Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716; Radbruch, Andreas/0000-0001-5753-0000				ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; BERTON MT, 1990, J EXP MED, V172, P375, DOI 10.1084/jem.172.1.375; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; ESSER C, 1989, EMBO J, V8, P483, DOI 10.1002/j.1460-2075.1989.tb03401.x; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; ILLGES H, 1992, MOL IMMUNOL, V29, P1265, DOI 10.1016/0161-5890(92)90063-4; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KEPRON MR, 1989, J IMMUNOL, V143, P334; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAYTON JE, 1984, J EXP MED, V160, P1850, DOI 10.1084/jem.160.6.1850; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MOWATT MR, 1986, J IMMUNOL, V136, P2674; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; SCHMITZ J, 1990, INT IMMUNOL, V144, P952; SCROCH P, 1993, PROG CLIN BIOL RES, V380, P113; SEVERINSON E, 1990, EUR J IMMUNOL, V20, P1079, DOI 10.1002/eji.1830200520; SEVERINSONGRONOWICZ E, 1979, J IMMUNOL, V123, P2057; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; SWAPAN KD, 1990, J BIOL CHEM, V265, P15267; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; XU LX, 1993, P NATL ACAD SCI USA, V90, P3705, DOI 10.1073/pnas.90.8.3705; Xu M, 1990, Dev Immunol, V1, P11, DOI 10.1155/1990/47659; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x	36	210	213	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1825	1828		10.1126/science.7892607	http://dx.doi.org/10.1126/science.7892607			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892607				2022-12-24	WOS:A1995QN70200040
J	CHEN, JJ; JACKSON, PK; KIRSCHNER, MW; DUTTA, A				CHEN, JJ; JACKSON, PK; KIRSCHNER, MW; DUTTA, A			SEPARATE DOMAINS OF P21 INVOLVED IN THE INHIBITION OF CDK KINASE AND PCNA	NATURE			English	Article							DNA-REPLICATION; P53	THE protein p21 (WAF1, CIP1 or sdi1), induced by the tumour-suppressor protein p53, interacts with and inhibits two different targets essential for cell-cycle progression(1-8). One of these is the cyclin-Cdk family of kinases and the other is the essential DNA replication factor, proliferating-cell nuclear antigen (PCNA). We report here that separate domains of p21 are responsible for interacting with and inhibiting the two targets. An amino-terminal domain inhibits cyclin-Cdk kinases and a carboxy-terminal domain inhibits PCNA. Using these separated domains, we have determined that p21 inhibits different biological systems through different targets. The PCNA-binding domain is sufficient for inhibition of DNA replication based on sinian virus 40, whereas the Cdk2-binding domain is sufficient for inhibition of DNA replication based on Xenopus egg extract and for growth suppression in transformed human cells.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV MOLEC ONCOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Jackson, Peter/0000-0002-1742-2539				DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1922, EMBO J, V11, P2189; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	16	525	543	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					386	388		10.1038/374386a0	http://dx.doi.org/10.1038/374386a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885482				2022-12-24	WOS:A1995QN63000067
J	SCHEFFZEK, K; KLEBE, C; FRITZWOLF, K; KABSCH, W; WITTINGHOFER, A				SCHEFFZEK, K; KLEBE, C; FRITZWOLF, K; KABSCH, W; WITTINGHOFER, A			CRYSTAL-STRUCTURE OF THE NUCLEAR RAS-RELATED PROTEIN RAN IN ITS GDP-BOUND FORM	NATURE			English	Article							ELONGATION-FACTOR TU; ESCHERICHIA-COLI; AMINO-ACIDS; REGULATOR; BINDING; DOMAIN; LOCATION; RAN/TC4; RCC1	THE Ran proteins constitute a distinct branch of the superfamily of Ras-related GTP-binding proteins(1) which function as molecular switches cycling between GTP-bound 'on' and GDP-bound 'off' states(2). Ran is located predominantly in the nucleus of eukaryotic cells(3) and is involved in the nuclear import of proteins(4,5) as well as in control of DNA synthesis and of cell-cycle progression(6-8). We report here the crystal structure at 2.3 Angstrom resolution of human Ran (M(r) 24K) complexed with GDP and Mg2+. This structure reveals a similarity with the Ras core (G-domain) but with significant variations in regions involved in GDP and Mg2+ coordination (switch I and switch II regions in Ras)(9,10), suggesting that there could be major conformational changes upon GTP binding. In addition to the G-domain, an extended chain and an alpha-helix were identified at the carboxy terminus. The amino-terminal (amino-acid residues (1)MAAQGEP(7)) stretch and the acidic tail ((211)DEDDDL(216)) appear to be flexible in the crystal structure.	MAX PLANK INST MOLEK PHYSIOL, STRUKT BIOL ABT, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, BIOPHYS ABT, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Max Planck Society								AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER A, 1993, XPLOR VERSION 3 1; CLARKE PR, IN PRESS J CELL SCI; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KOMBLUTH S, 1994, J CELL BIOL, V125, P705; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	30	172	176	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	1995	374	6520					378	381		10.1038/374378a0	http://dx.doi.org/10.1038/374378a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885480				2022-12-24	WOS:A1995QN63000065
J	ORRELL, MW; ODWYER, AM				ORRELL, MW; ODWYER, AM			DEMENTIA, AGING, AND THE STRESS-CONTROL SYSTEM	LANCET			English	Editorial Material							ALZHEIMERS		UNIV CAMBRIDGE, DEPT PSYCHIAT, CAMBRIDGE, ENGLAND	University of Cambridge	ORRELL, MW (corresponding author), UCL, SCH MED, DEPT PSYCHIAT, LONDON W1N 8AA, ENGLAND.			Orrell, Martin/0000-0002-1169-3530				AMADUCCI L, 1992, INT J GERIATR PSYCH, V7, P383, DOI 10.1002/gps.930070602; BRAYNE C, 1988, LANCET, V1, P1265; BROE GA, 1990, NEUROLOGY, V40, P1699; DODT C, 1991, J CLIN ENDOCR METAB, V72, P272, DOI 10.1210/jcem-72-2-272; ELLIOTT EM, 1993, BRAIN RES, V602, P84, DOI 10.1016/0006-8993(93)90245-I; FRENCH SL, 1992, AM J COMMUN PSYCHOL, V20, P243, DOI 10.1007/BF00940838; JORM AF, 1991, INT J EPIDEMIOL S2, V20, P43; MILLER AH, 1994, AM J PSYCHIAT, V151, P267; Mullan Michael J., 1993, International Review of Psychiatry, V5, P351, DOI 10.3109/09540269309037798; OBRIEN JT, 1993, INT J GERIATR PSYCH, V8, P887, DOI 10.1002/gps.930081103; SAPOLSKY RM, 1990, BIOL PSYCHIAT, V27, P937, DOI 10.1016/0006-3223(90)90032-W; SAPOLSKY RM, 1986, ENDOCR REV, V7, P285	12	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 18	1995	345	8951					666	667		10.1016/S0140-6736(95)90862-5	http://dx.doi.org/10.1016/S0140-6736(95)90862-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM732	7885120				2022-12-24	WOS:A1995QM73200003
J	TAKALA, AK; JERO, J; KELA, E; RONNBERG, PR; KOSKENNIEMI, E; ESKOLA, J				TAKALA, AK; JERO, J; KELA, E; RONNBERG, PR; KOSKENNIEMI, E; ESKOLA, J			RISK-FACTORS FOR PRIMARY INVASIVE PNEUMOCOCCAL DISEASE AMONG CHILDREN IN FINLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLUENZAE TYPE-B; STREPTOCOCCUS-PNEUMONIAE; HEMOPHILUS-INFLUENZAE; HAEMOPHILUS-INFLUENZAE; OTITIS-MEDIA; EPIDEMIOLOGY; INFECTIONS; POPULATION; INFANTS; COUNTY	Objective.-To study risk factors for invasive pneumococcal disease among children. Design.-A population-based, case-control study of 149 cases and 284 controls matched for age, sex, and place of residence. Setting.-Finland, November 1986 through November 1989. Patients and Controls.-Patients were identified from a prospective nationwide surveillance for invasive bacterial diseases among children (0 to 15 years of age) through a network of bacteriologic laboratories. Two matched controls were selected for 135 of the cases and one matched control for 14 of the cases from the respective cases' child health center or school. Questionnaires evaluating potential risk factors were mailed to families of cases and controls. Results.-An increased risk for invasive pneumococcal disease among children younger than 2 years was associated with day care center attendance (odds ratio [OR]=36; 95% confidence interval [CI], 5.7 to 233), family day care (OR=4.4; 95% CI, 1.7 to 12), and history of frequent otitis media (OR=8.8; 95% CI, 2.5 to 31). For those at least 2 years of age, existence of siblings younger than school-age indicated increased risk for invasive pneumococcal disease (OR=2.2; 95% CI, 1.1 to 4.4). Conclusions.-Day care center attendance is a major risk factor for invasive pneumococcal disease for children younger than 2 years, with significantly higher risk than the risk associated with family day care.			TAKALA, AK (corresponding author), NATL PUBL HLTH INST,DEPT INFECT DIS & EPIDEMIOL,MANNERHEIMINTIE 170A,SF-00300 HELSINKI,FINLAND.							ANDERSSON B, 1986, J INFECT DIS, V153, P232, DOI 10.1093/infdis/153.2.232; ANIANSSON G, 1990, MICROB PATHOGENESIS, V8, P315, DOI 10.1016/0882-4010(90)90090-D; BLACK S, 1994, 34TH INT C ANT AG CH; BLUESTONE CD, 1992, PEDIATR INFECT DIS J, V11, pS7, DOI 10.1097/00006454-199208001-00002; BROOME CV, 1981, REV INFECT DIS, V3, P277; BURMAN LA, 1985, REV INFECT DIS, V7, P133; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; COCHI SL, 1986, J PEDIATR-US, V108, P887, DOI 10.1016/S0022-3476(86)80922-2; CORTESE MM, 1992, ARCH INTERN MED, V152, P2277, DOI 10.1001/archinte.152.11.2277; DAGAN R, 1992, JAMA-J AM MED ASSOC, V268, P3328, DOI 10.1001/jama.268.23.3328; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; ESKOLA J, 1992, JAMA-J AM MED ASSOC, V268, P3323, DOI 10.1001/jama.268.23.3323; FADEN H, 1991, ANN OTO RHINOL LARYN, V100, P612, DOI 10.1177/000348949110000802; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GRAY BM, 1982, AM J EPIDEMIOL, V116, P692, DOI 10.1093/oxfordjournals.aje.a113452; HALL PG, 1988, REPORT COMMITTEE INF, P328; HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55; ISTRE GR, 1985, J PEDIATR-US, V106, P190, DOI 10.1016/S0022-3476(85)80285-7; JACOBS NM, 1979, PEDIATRICS, V64, P296; KARMA P, 1987, ANN OTO RHINOL LARYN, V96, pS1; KLEIN JO, 1981, REV INFECT DIS, V3, P246; LEHMANN D, 1992, J INFECT DIS, V165, pS20, DOI 10.1093/infdis/165-Supplement_1-S20; LUOTONEN J, 1981, SCAND J INFECT DIS, V13, P177, DOI 10.3109/inf.1981.13.issue-3.04; MCGOWAN JE, 1973, NEW ENGL J MED, V288, P1309, DOI 10.1056/NEJM197306212882501; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MICHAELS RH, 1976, J CLIN MICROBIOL, V4, P413; NOHYNEK H, 1991, AM J DIS CHILD, V145, P618, DOI 10.1001/archpedi.1991.02160060036016; PETERSEN GM, 1991, AM J EPIDEMIOL, V134, P1212, DOI 10.1093/oxfordjournals.aje.a116024; REICHLER M, 1991, 31ST INT C ANT AG CH; SABHARWAL H, 1992, OCT EUR RES C RES C; SHAPIRO ED, 1994, J INFECT DIS, V169, P212, DOI 10.1093/infdis/169.1.212; SIPILA M, 1988, ACTA OTO-LARYNGOL, V106, P94, DOI 10.3109/00016488809107375; SNIADAK D, 1993, 33RD INT C ANT AG CH; TAKALA AK, 1992, J INFECT DIS, V165, pS11, DOI 10.1093/infdis/165-Supplement_1-S11; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P189, DOI 10.1097/00006454-199303000-00003; TAKALA AK, 1989, J PEDIATR-US, V115, P694, DOI 10.1016/S0022-3476(89)80644-4; TAKALA AK, 1994, DEV CLIN USES HAEMOP; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; TODD JK, 1984, PEDIATR INFECT DIS J, V3, P159, DOI 10.1097/00006454-198403000-00021; VADHEIM CM, 1992, AM J EPIDEMIOL, V136, P221, DOI 10.1093/oxfordjournals.aje.a116488; VINTHER S, 1992, CLIN INFECT DIS, V15, P794; 1989, MMWR-MORBID MORTAL W, V38, P733	43	75	75	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					859	864		10.1001/jama.273.11.859	http://dx.doi.org/10.1001/jama.273.11.859			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869556				2022-12-24	WOS:A1995QL40200023
J	DWYER, T; PONSONBY, AL; BLIZZARD, L; NEWMAN, NM; COCHRANE, JA				DWYER, T; PONSONBY, AL; BLIZZARD, L; NEWMAN, NM; COCHRANE, JA			THE CONTRIBUTION OF CHANGES IN THE PREVALENCE OF PRONE SLEEPING POSITION TO THE DECLINE IN SUDDEN-INFANT-DEATH-SYNDROME IN TASMANIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COT DEATHS; RISK; AUSTRALIA	Objective.-To determine the independent contribution of changes in infant sleep position to the recent decline in sudden infant death syndrome (SIDS) rate in Tasmania. Design.-(1) A comparison of the whole population incidence of SIDS before and after an intervention to reduce the prevalence of prone sleeping position. (2) A within-cohort analysis of the contribution of sleep position and other exposures to the decline in SIDS after the intervention. Setting.-Tasmania, Australia. Participants.-(1) All SIDS cases from 1975 through 1992. (2) A sample of one in five infants born in Tasmania who at perinatal assessment were scored to be at higher risk for SIDS since January 1988. Of 5534 infants included in the study, 39 later died of SIDS. Interventions.-Multiple public health activities to reduce the prevalence of the prone infant sleeping position in Tasmania and verbal information on the association between prone position and SIDS to cohort participants from May 1, 1991. Main Outcome Measure.-Sudden infant death syndrome incidence. Results.-The Tasmanian SIDS rate decreased (P<.01) from 3.8 (95% confidence interval [CI], 3.5 to 4.2) deaths per 1000 live births from 1975 through 1990 to a rate of 1.5 (95% CI, 0.9 to 2.2) deaths per 1000 live births in 1991 through 1992. The SIDS mortality rate in the cohort by period of birth was 7.6 (95% CI, 4.9 to 10.3) deaths per 1000 live births for those born from May 1, 1988, through April 30, 1991, and 4.1 (95% CI, 1.3 to 7.0) deaths per 1000 infants for those born from May 1, 1998, through October 31, 1992. The prevalence of usual prone sleeping position at 1 month of age was 29.9% and 4.3% in these two cohorts, respectively (adjusted odds ratio, 0.11; 95% CI, 0.08 to 0.13). Logistic regression demonstrated that 70% of the SIDS rate reduction in the cohort could be accounted for by the decreased prevalence of the prone sleeping position. Other factors examined individually contributed to less than 10% of the SIDS rate reduction. Conclusions.-The major contributing factor to the recent SIDS rate decline in Tasmania has been the reduction in the proportion of infants usually sleeping prone.			DWYER, T (corresponding author), UNIV TASMANIA,MENZIES CRR POPULAT HLTH RES,GPO BOX 252C,HOBART,TAS 7000,AUSTRALIA.		Ponsonby, Anne-Louise/AAE-4351-2019	Ponsonby, Anne-Louise/0000-0002-6581-3657	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028979] Funding Source: NIH RePORTER; NICHD NIH HHS [001 HD28979-01A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAL S, 1991, MED J AUSTRALIA, V155, P507, DOI 10.5694/j.1326-5377.1991.tb93882.x; BEAL SM, 1991, J PAEDIATR CHILD H, V27, P334, DOI 10.1111/j.1440-1754.1991.tb00414.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BRESLOW NE, 1993, STATISTICAL METHODS, V2, P109; d'Espaignet E T, 1990, Paediatr Perinat Epidemiol, V4, P422, DOI 10.1111/j.1365-3016.1990.tb00670.x; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; EMERY JL, 1986, MED J AUSTRALIA, V144, P469, DOI 10.5694/j.1326-5377.1986.tb101052.x; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; HOFFMAN HJ, 1992, CLIN PERINATOL, V19, P717, DOI 10.1016/S0095-5108(18)30427-5; HOLBOROW P, 1991, NEW ZEAL MED J, V104, P296; JONES ME, 1994, EPIDEMIOLOGY, V5, P332, DOI 10.1097/00001648-199405000-00012; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; LEWIS J, 1993, LANCET, V341, P51, DOI 10.1016/0140-6736(93)92525-X; MITCHELL EA, 1991, J PAEDIATR CHILD H, V27, P319, DOI 10.1111/j.1440-1754.1991.tb00409.x; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS9, DOI 10.1111/j.1440-1754.1992.tb02732.x; MITCHELL EA, 1992, J PAEDIATR CHILD H S; PONSONBY AL, 1994, PREV MED, V23, P402, DOI 10.1006/pmed.1994.1055; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PONSONBY AL, 1994, NEW ENGL J MED, V330, P64; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P146; SALONEN JT, 1989, INT J EPIDEMIOL, V18, P595, DOI 10.1093/ije/18.3.595; SPIERS PS, 1994, ARCH PEDIAT ADOL MED, V148, P141, DOI 10.1001/archpedi.1994.02170020027004; WILLIAMS AL, 1990, AUST NZ J OBSTET GYN, V30, P98, DOI 10.1111/j.1479-828X.1990.tb03235.x; 1993, STATISTICAL METHODS, V2, P131; 1992, SURVEY INFANT SLEEPI; 1993, BIRTHS 1988 1992 AUS; 1993, FETAL INFANT DEATHS; 1993, DEATHS 1988 1992 AUS; 1991, 112TH SESS NHMRC COU; [No title captured]; 1990, SAS STAT USERS GUIDE, V2; 1994, FETAL INFANT DEATHS; 1991, J PAEDIATR CHILD HLT, V27, P323; 1990, SAS STAT USERS GUIDE, V1	38	129	130	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					783	789		10.1001/jama.273.10.783	http://dx.doi.org/10.1001/jama.273.10.783			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861572				2022-12-24	WOS:A1995QJ75000029
J	FALL, CHD; OSMOND, C; BARKER, DJP; CLARK, PMS; HALES, CN; STIRLING, Y; MEADE, TW				FALL, CHD; OSMOND, C; BARKER, DJP; CLARK, PMS; HALES, CN; STIRLING, Y; MEADE, TW			FETAL AND INFANT GROWTH AND CARDIOVASCULAR RISK-FACTORS IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; ADULT LIFE; HEART-DISEASE; HYPERTENSION; MORTALITY; INUTERO; DEATH	Objective-To examine whether cardiovascular risk factors in women are related to fetal and infant growth. Design-Follow up study of women born 1923-30 whose birth weights and weights at one year were recorded. Setting-Hertfordshire. Subjects-297 women born and still living in East Hertfordshire. Main outcome measures-Plasma glucose and insulin concentrations during a standard oral glucose tolerance test; fasting plasma proinsulin and 32-33 split proinsulin concentrations; blood pressure; fasting serum total, low density lipoprotein and high density lipoprotein cholesterol, triglyceride, and apolipoprotein A I and B concentrations; and plasma fibrinogen and factor VII concentrations. Results-Fasting plasma concentrations of glucose, insulin, and 32-33 split proinsulin fell with increasing birth weight (P=0.04, P-0.002, and P=0.0002 respectively, when current body mass index was allowed for). Glucose and insulin concentrations 120 minutes after an oral glucose load showed similar trends (P=0.03 and P=0.02). Systolic blood pressure, waist:hip ratio, and serum triglyceride concentrations also fell with increasing birth weight (P=0.08, P=0.07, and P=0.07 respectively), while serum high density lipoprotein cholesterol concentrations rose (P=0.04). At each birth weight women who currently had a higher body mass index had higher levels of risk factors. Conclusion-In women, as in men, reduced fetal growth leads to insulin resistance and the associated disorders: raised blood pressure and high serum triglyceride and low serum high density lipoprotein cholesterol concentrations. The highest values of these coronary risk factors occur in people who were small at birth and become obese. In contrast with men, low rates of infant growth did not predict levels of risk factors in women.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; ST BARTHOLOMEWS HOSP,WOLFSON INST PREVENT MED,MRC,EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; Queen Mary University London	FALL, CHD (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				[Anonymous], 1980, CLASSIFICATION OCCUP; Barker D, 1994, MOTHER BABIES DISEAS; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LUCAS A, 1991, CIBA F S, V156; MARTYN CN, IN PRESS BR HEART J; MCKEIGUE PM, 1994, DIABETIC MED S2, V11, pA17; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PHILLIPS DIW, 1994, DIABETIC MED, V11, P286, DOI 10.1111/j.1464-5491.1994.tb00273.x; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157	23	353	364	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					428	432		10.1136/bmj.310.6977.428	http://dx.doi.org/10.1136/bmj.310.6977.428			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873947	Green Published			2022-12-24	WOS:A1995QJ24200017
J	CROSS, AS				CROSS, AS			INDUCING AN ABSCESS	LANCET			English	Editorial Material							POLYSACCHARIDE; BACTEROIDES				CROSS, AS (corresponding author), WALTER REED ARMY INST RES,DEPT SOCIOL,WASHINGTON,DC 20307, USA.							BYCROFT BW, 1989, ANTIMICROB AGENTS CH, V33, P1516, DOI 10.1128/AAC.33.9.1516; DOMENICO P, 1993, J INFECT DIS, V168, P766, DOI 10.1093/infdis/168.3.766; ONDERDONK AB, 1977, J INFECT DIS, V136, P82, DOI 10.1093/infdis/136.1.82; RANNEY DF, 1985, SCIENCE, V227, P182, DOI 10.1126/science.3966151; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SHAPIRO ME, 1982, J EXP MED, V154, P1188; TAKAHASHI T, 1991, INFECT IMMUN, V59, P18, DOI 10.1128/IAI.59.1.18-23.1991; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; VERINGA EM, 1989, J ANTIMICROB CHEMOTH, V23, P577, DOI 10.1093/jac/23.4.577; WEINSTEIN WM, 1975, J INFECT DIS, V132, P282, DOI 10.1093/infdis/132.3.282	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					248	249		10.1016/S0140-6736(94)91106-1	http://dx.doi.org/10.1016/S0140-6736(94)91106-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905090				2022-12-24	WOS:A1994MT44000004
J	LADWIG, KH; ROLL, G; BREITHARDT, G; BUDDE, T; BORGGREFE, M				LADWIG, KH; ROLL, G; BREITHARDT, G; BUDDE, T; BORGGREFE, M			POSTINFARCTION DEPRESSION AND INCOMPLETE RECOVERY 6 MONTHS AFTER ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							CORONARY-ARTERY DISEASE; MORTALITY; LIFE	Patients who suffer from post-infarction depression are a high risk group with an increased mortality risk. The reasons for this are not known although it may be because such patients cannot cope with the chronic condition of cardiac disease. We designed a profile of clinical and behavioural outcome measurements representing recovery after myocardial infarction. 552 male survivors of acute myocardial infarction (29-65 years; mean=53) were grouped at study entry according to their depression status. 377 patients were reassessed after 6 months and were divided into the following subgroups: 50 (13.3%) patients had severe depression; 85 (22.5%) moderate depression and 242 (64.2%) low degrees of depression in the initial study. There were no substantial differences in baseline characteristics between the index group and the drop-out group. The unadjusted relative risk for follow-up angina pectoris among patients with depression (severe versus low) was 3.12 (95% CI 1.58 to 6.16) and was 5.55 (CI 2.87 to 10.71) for emotional instability. The relative risk for maintenance of smoking habits was 2.63 (CI 1.23 to 5.60) and was for work resumption 0.39 (CI 0.18 to 0.88). There was no association between depression and the occurrence of late potentials. After adjustment for univariate variables (age, social class, recurrent infarction, helplessness) only small and nonsignificant changes in the relative risks were found. However the inverse association of depression and work resumption was lost after adjustment. The investigation revealed that persistent postinfarction depression is an independent and important source of subsequent morbidity and long-acting reduced quality of life. Depression has adverse effects on illness behaviour and pain perception.	TECH UNIV MUNICH,PSYCHOSOMAT MED PSYCHOTHERAPIE & MED PSYCHOL POLIKLIN,MUNICH,GERMANY; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST MED INFORMAT & SYST FORSCH,MUNICH,GERMANY; UNIV MUNSTER,MED KLIN & POLIKLIN,W-4400 MUNSTER,GERMANY	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munster	LADWIG, KH (corresponding author), TECH UNIV MUNICH,INST PSYCHOSOMAT MED PSYCHOTHERAPIE & MED PSYCHOL,LANGER STR 3,D-81675 MUNICH,GERMANY.		Ladwig, Karl-Heinz/B-5351-2014	Ladwig, Karl-Heinz/0000-0003-0710-1720				AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; AHNVE J, 1988, AM HEART J, V117, P925; BORGGREFE M, 1990, European Heart Journal, V11, P403; BREITHARDT G, 1987, CIRCULATION, V75, P1091, DOI 10.1161/01.CIR.75.6.1091; Breslow N, 1980, STATISTICAL METHODS, V32; CARNEY RM, 1987, AM J CARDIOL, V60, P1273, DOI 10.1016/0002-9149(87)90607-2; CARNEY RM, 1988, J PSYCHOSOM RES, V32, P159, DOI 10.1016/0022-3999(88)90050-5; DALY LE, 1983, BMJ-BRIT MED J, V287, P324, DOI 10.1136/bmj.287.6388.324; DEMUYNCK RU, 1980, DIAGNOSE THERAPIE SO; FLETCHER AE, 1987, J CHRON DIS, V40, P557, DOI 10.1016/0021-9681(87)90014-2; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; GILPIN E, 1989, CIRCULATION, V80, P457; HAWIK OE, 1990, J PSYCHOSOM RES, V34, P271; KENNEDY GJ, 1987, PSYCHOSOM MED, V49, P410, DOI 10.1097/00006842-198707000-00010; LADWIG KH, 1992, J PSYCHOSOM RES, V36, P723, DOI 10.1016/0022-3999(92)90130-T; LADWIG KH, 1986, KARDIOVASKULARE HYPE; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; PYSZCZYNSKI T, 1987, PSYCHOL BULL, V102, P122, DOI 10.1037/0033-2909.102.1.122; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SILVERSTONE PH, 1990, J PSYCHOSOM RES, V34, P659, DOI 10.1016/0022-3999(90)90110-P; SIMSON MB, 1981, CIRCULATION, V64, P235, DOI 10.1161/01.CIR.64.2.235; YOUNG LD, 1988, CARDIOLOGY, V75, P10, DOI 10.1159/000174344; ZUNG WWK, 1984, J CLIN PSYCHIAT, V45, P26; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3	24	185	187	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					20	23		10.1016/S0140-6736(94)90877-X	http://dx.doi.org/10.1016/S0140-6736(94)90877-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MN937	7905043				2022-12-24	WOS:A1994MN93700013
J	ETSUDA, H; MIZUNO, K; ARAKAWA, K; SATOMURA, K; SHIBUYA, T; ISOJIMA, K				ETSUDA, H; MIZUNO, K; ARAKAWA, K; SATOMURA, K; SHIBUYA, T; ISOJIMA, K			ANGIOSCOPY IN VARIANT ANGINA - CORONARY-ARTERY SPASM AND INTIMAL INJURY	LANCET			English	Article							ACETYLCHOLINE; INVIVO; PIGS; PATHOGENESIS; VASOSPASM	Studies in pigs and dogs show that intimal injury is related to coronary artery spasm; it is not known whether intimal injury is related to coronary artery spasm in human beings. We examined intima at the site of coronary artery spasm by percutaneous transluminal coronary angioscopy in 10 of 13 consecutive patients with variant angina. Coronary artery spasms occurred spontaneously or were induced by intracoronary acetylcholine (10-100 mug). Angioscopy showed intimal injuries (haemorrhage, flap, thrombus, or ulcer) in 4 of the 10. We suggest that intimal injury is related to coronary artery spasm in human beings.	NATL DEF MED COLL,DEPT INTERNAL MED 1,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN	National Defense Medical College - Japan								EGASHIRA K, 1986, CIRCULATION, V74, P826, DOI 10.1161/01.CIR.74.4.826; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GANZ P, 1985, AM J CARDIOL, V56, P11; GERRITY RG, 1977, AM J PATHOL, V89, P313; GERTZ SD, 1981, CIRCULATION, V63, P476, DOI 10.1161/01.CIR.63.3.476; KASKI JC, 1989, J AM COLL CARDIOL, V14, P1456, DOI 10.1016/0735-1097(89)90382-3; LAM JYT, 1987, CIRCULATION, V75, P243, DOI 10.1161/01.CIR.75.1.243; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MACALPIN RN, 1980, AM J CARDIOL, V46, P143, DOI 10.1016/0002-9149(80)90616-5; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; MIZUNO K, 1989, J AM COLL CARDIOL, V13, P363, DOI 10.1016/0735-1097(89)90513-5; MIZUNO K, 1991, LANCET, V337, P809, DOI 10.1016/0140-6736(91)92514-3; NAGASAWA K, 1989, CIRC RES, V65, P272, DOI 10.1161/01.RES.65.2.272; OKAMOTO Y, 1991, Japanese Circulation Journal, V55, P95; SHIMOKAWA H, 1983, SCIENCE, V221, P560, DOI 10.1126/science.6408736; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; YASUE H, 1986, CIRCULATION, V74, P955, DOI 10.1161/01.CIR.74.5.955	19	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1322	1324		10.1016/0140-6736(93)92245-O	http://dx.doi.org/10.1016/0140-6736(93)92245-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901635				2022-12-24	WOS:A1993MJ03900008
J	HOWARD, R				HOWARD, R			SCHIZOPHRENIA AND THE GUT, AGAIN	LANCET			English	Editorial Material							LIPID-PEROXIDATION; PERMEABILITY				HOWARD, R (corresponding author), INST PSYCHIAT,LONDON SE5,ENGLAND.			Howard, Robert/0000-0002-3071-2338				BEAUCHAMP RO, 1983, CRC CR REV TOXICOL, V11, P169, DOI 10.3109/10408448309128255; HUMAD S, 1988, FREE RADICAL RES COM, V5, P101, DOI 10.3109/10715768809066917; KOVALEVA ES, 1989, ZH NEVROPATOL PSIKH, V89, P108; Kretschmer Ernst, 1925, PHYSIQUE CHARACTER; LAMBERT MT, 1989, BRIT J PSYCHIAT, V155, P619; PHILLIPS M, 1993, J CLIN PATHOL, V46, P861, DOI 10.1136/jcp.46.9.861; SMYTHIES JR, 1963, SCHIZOPHRENIA CHEM M; VANGOSSUM A, 1989, EUR RESPIR J, V2, P787; WEITZ ZW, 1991, LANCET, V337, P933, DOI 10.1016/0140-6736(91)91569-G; WOOD NC, 1987, BRIT J PSYCHIAT, V150, P853, DOI 10.1192/bjp.150.6.853	10	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1128	1129		10.1016/0140-6736(93)92118-D	http://dx.doi.org/10.1016/0140-6736(93)92118-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901470				2022-12-24	WOS:A1993MF19800004
J	WATKINS, H; MCKENNA, WJ; THIERFELDER, L; SUK, HJ; ANAN, R; ODONOGHUE, A; SPIRITO, P; MATSUMORI, A; MORAVEC, CS; SEIDMAN, JG; SEIDMAN, CE				WATKINS, H; MCKENNA, WJ; THIERFELDER, L; SUK, HJ; ANAN, R; ODONOGHUE, A; SPIRITO, P; MATSUMORI, A; MORAVEC, CS; SEIDMAN, JG; SEIDMAN, CE			MUTATIONS IN THE GENES FOR CARDIAC TROPONIN-T AND ALPHA-TROPOMYOSIN IN HYPERTROPHIC CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; CLINICAL MANIFESTATIONS; MISSENSE MUTATION; PATHO-PHYSIOLOGY; EXPRESSION; INTERRELATIONS; SEQUENCE; THERAPY; DISEASE; LOCUS	Background. Familial hypertrophic cardiomyopathy can be caused by mutations in the genes for beta cardiac myosin heavy chain, alpha-tropomyosin, or cardiac troponin T. It is not known how often the disease is caused by mutations in the tropomyosin and troponin genes, and the associated clinical phenotypes have not been carefully studied. Methods. Linkage between polymorphisms of the alpha-tropomyosin gene or the cardiac troponin T gene and hypertrophic cardiomyopathy was assessed in 27 families. In addition, 100 probands were screened for mutations in the alpha-tropomyosin gene, and 26 were screened for mutations in the cardiac troponin T gene. Life expectancy, the incidence of sudden death, and the extent of left ventricular hypertrophy were compared in patients with different mutations. Results. Genetic analyses identified only one alpha-tropomyosin mutation, identical to one previously described. Five novel mutations in cardiac troponin were identified, as well as a further example of a previously described mutation. The clinical phenotype of four troponin T mutations in seven unrelated families was similar and was characterized by a poor prognosis (life expectancy, approximately 35 years) and a high incidence of sudden death. The mean (+/-SD) maximal thickness of the left ventricular wall in subjects with cardiac troponin T mutations (16.7+/-5.5 mm) was significantly less than that in subjects with beta cardiac myosin heavy-chain mutations (23.7+/-7.7 mm, P<0.001). Conclusions. Mutations in alpha-tropomyosin are a rare cause of familial hypertrophic cardiomyopathy, accounting for approximately 3 percent of cases. Mutations in cardiac troponin T account for approximately 15 percent of cases of familial hypertrophic cardiomyopathy in this referral-center population. These mutations are characterized by relatively mild and sometimes subclinical hypertrophy but a high incidence of sudden death. Genetic testing may therefore be especially important in this group.	HOWARD HUGHES MED INST,BOSTON,MA; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; FRANZ VOLHARD KLIN,BERLIN,GERMANY; MAX DELBRUCK CTR,BERLIN,GERMANY; OSPED GALLIERA,DIV CARDIOL,GENOA,ITALY; KYOTO UNIV,DEPT INTERNAL MED,KYOTO,JAPAN; CLEVELAND CLIN FDN,CTR ANESTHESIOL RES,CLEVELAND,OH	Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; St Georges University London; Harvard University; Harvard Medical School; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ente Ospedaliero Ospedali Galliera; Kyoto University; Cleveland Clinic Foundation			McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016	Telethon [600] Funding Source: Medline	Telethon(Fondazione Telethon)		ANAN R, 1994, J CLIN INVEST, V93, P280, DOI 10.1172/JCI116957; CARRIER L, 1993, NAT GENET, V4, P311, DOI 10.1038/ng0793-311; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Cox D. R., 1984, ANAL SURVIVAL DATA; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; GEISTERFERLOWRA.AA, 1990, CELL, V62, P999; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P277; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P276; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P3, DOI 10.1006/jmcc.1994.1002; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE ET, 1980, STATISTICAL METHODS; MACRAE CA, 1994, CIRCULATION, V89, P33, DOI 10.1161/01.CIR.89.1.33; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MCKENNA WJ, 1989, DISEASES HEART, P933; MCKENNA WJ, 1995, METABOLIC MOL BASES, V3, P4253; MESNARD L, 1993, FEBS LETT, V328, P139, DOI 10.1016/0014-5793(93)80981-Y; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; PERRYMAN MB, 1992, J CLIN INVEST, V90, P271, DOI 10.1172/JCI115848; Solomon SD, 1993, J AM COLL CARDIOL, V22, P498, DOI 10.1016/0735-1097(93)90055-6; THIERFELDER L, 1993, P NATL ACAD SCI USA, V90, P6270, DOI 10.1073/pnas.90.13.6270; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOWNSEND PJ, 1994, GENOMICS, V21, P311, DOI 10.1006/geno.1994.1271; WATKINS H, 1993, NAT GENET, V3, P333, DOI 10.1038/ng0493-333; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WATKINS H, 1994, HUM MOL GENET, V3, P2267, DOI 10.1093/hmg/3.12.2267; WATKINS H, 1994, CURRENT PROTOCOLS HU; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	31	696	722	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1058	1064		10.1056/NEJM199504203321603	http://dx.doi.org/10.1056/NEJM199504203321603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898523				2022-12-24	WOS:A1995QT18700003
J	PETTIFOR, JM; BIKLE, DD; CAVALEROS, M; ZACHEN, D; KAMDAR, MC; ROSS, FP				PETTIFOR, JM; BIKLE, DD; CAVALEROS, M; ZACHEN, D; KAMDAR, MC; ROSS, FP			SERUM LEVELS OF FREE 1,25-DIHYDROXYVITAMIN-D IN VITAMIN-D TOXICITY	ANNALS OF INTERNAL MEDICINE			English	Note							D-BINDING PROTEIN; HYPERVITAMINOSIS-D; ASSAY; METABOLITES	Objective: To determine the serum level of free 1,25-dihydroxyvitamin D [1,25-(OH)(2)D] in patients with vitamin D toxicity and to assess the in vitro effect of differing concentrations of vitamin D metabolites on the free serum levels of 1,25-(OH)(2)D. Design: 1) A case study of patients hospitalized with Vitamin D toxicity after accidentally ingesting a veterinary vitamin D concentrate and 2) an in vitro experiment in which vitamin D metabolites in various concentrations were added to normal serum and their effect was noted on percentage of free 1,25-(OH)(2)D. Patients: 11 patients (age range, 8 to 69 years) were studied 10 to 40 days after hospitalization for hypercalcemia. Measurements: Serum total 25-hydroxyvitamin D (25-OHD) and 1,25-(OH)(2)D levels were measured by radioreceptor assays. The percentage of free 1,25(OH)(2)D was measured by centrifugal ultrafiltration isodialysis and was used to calculate actual free 1,25(OH)(2)D levels. In the in vitro studies, vitamin D metabolites [25-OHD; 24,25-(OH)(2)D; 25,26-(OH)(2)D; and 25-OHD-26,23 lactone] were added to normal serum in concentrations expected to occur with vitamin D toxicity. The percentage of free 1,25-(OH)(2)D was measured by isodialysis. Results: All patients presented with marked hypercalcemia (mean calcium level, 3.99 +/- 0.33 mmol/L). Serum 25-OHD levels ranged from 847 to 1652 nmol/L, and total 1,25-(OH)(2)D levels (mean, 106 +/- 86 pmol/L) were elevated in only three patients. The percentage of free 1,25-(OH)(2)D (mean, 1.023% +/- 0.366%) was elevated in all nine patients in whom it was measured. Actual free 1,25-(OH)(2)D levels (mean, 856 +/- 600 fmol/L) were elevated in six of the nine patients. Total 1,25(OH)(2)D levels were correlated with 25-OHD levels (r = 0.66; P= 0.03), whereas total and free 1,25-(OH)(2)D levels were highly correlated (r = 0.957; P < 0.001). In the in vitro studies, the percentage of free 1,25-(OH)(2)D increased after 25-OHD or 24,25-(OH)(2)D was added. Conclusions: Although the patients had normal or near-normal total 1,25-(OH)(2)D values, most patients had elevated free 1,25-(OH)(2)D levels. These findings suggest that elevated free 1,25-(OH)(2)D levers might play a role in the pathogenesis of hypercalcemia in vitamin D toxicity.	UNIV WITWATERSRAND, JOHANNESBURG, SOUTH AFRICA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; UNIV NATAL, DURBAN 4001, SOUTH AFRICA	University of Witwatersrand; University of California System; University of California San Francisco; University of Kwazulu Natal			Pettifor, John/M-4579-2019	Pettifor, John/0000-0003-1155-0334				BIKLE DD, 1985, J CLIN ENDOCR METAB, V61, P969, DOI 10.1210/jcem-61-5-969; BIKLE DD, 1984, J CLIN INVEST, V74, P1966, DOI 10.1172/JCI111617; BIKLE DD, 1986, J CLIN ENDOCR METAB, V63, P954, DOI 10.1210/jcem-63-4-954; BOUILLON R, 1977, J CLIN ENDOCR METAB, V45, P225, DOI 10.1210/jcem-45-2-225; CHAPUY MC, 1990, METABOLIC MOL BASIS, P1824; COUNTS SJ, 1975, ANN INTERN MED, V82, P196, DOI 10.7326/0003-4819-82-2-196; HADDAD JG, 1971, J CLIN ENDOCR METAB, V33, P992, DOI 10.1210/jcem-33-6-992; HORST RL, 1979, BIOCHEM BIOPH RES CO, V89, P286, DOI 10.1016/0006-291X(79)90976-8; HORST RL, 1981, J CLIN INVEST, V67, P274, DOI 10.1172/JCI110023; HUGHES MR, 1976, J CLIN INVEST, V58, P61, DOI 10.1172/JCI108459; JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801; MASON RS, 1980, CLIN CHEM, V26, P444; MAWER EB, 1985, CLIN SCI, V68, P135, DOI 10.1042/cs0680135; ORIORDAN JLH, 1982, VITAMIN D CHEM BIOCH, P751; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; SHEPARD RM, 1980, ARCH BIOCHEM BIOPHYS, V202, P43, DOI 10.1016/0003-9861(80)90404-X; VIETH R, 1990, BONE MINER, V11, P267, DOI 10.1016/0169-6009(90)90023-9	17	88	91	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					511	513		10.7326/0003-4819-122-7-199504010-00006	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872586				2022-12-24	WOS:A1995QP00800006
J	DUPIN, N; GRANDADAM, M; CALVEZ, V; GORIN, I; AUBIN, JT; HAVARD, S; LAMY, F; LEIBOWITCH, M; HURAUX, JM; ESCANDE, JP; AGUT, H				DUPIN, N; GRANDADAM, M; CALVEZ, V; GORIN, I; AUBIN, JT; HAVARD, S; LAMY, F; LEIBOWITCH, M; HURAUX, JM; ESCANDE, JP; AGUT, H			HERPESVIRUS-LIKE DNA-SEQUENCES IN PATIENTS WITH MEDITERRANEAN KAPOSIS-SARCOMA	LANCET			English	Note								DNA sequences closely related to herpesvirus-like sequences have been found in AIDS-associated Kaposi's sarcoma. Using PCR, we found herpesvirus-like DNA sequences in Kaposi's lesions and normal adjacent skin in five patients with Mediterranean Kaposi's sarcoma. We did not find these sequences in tissues from patients without Kaposi's sarcoma. Semi-quantitative PCR revealed many more herpesvirus-like sequences in Kaposi's lesions than in unaffected skin. Our results reinforce the hypothesis that an infectious agent closely related to gamma-herpesvirus is implicated in the pathogenesis of Mediterranean and AIDS-associated Kaposi's sarcoma.	GRP HOSP PITIE SALPETRIERE,VIROL LAB,CNRS,EP 57,F-75634 PARIS,FRANCE; TARNIER HOSP,DEPT DERMATOL,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			GRANDADAM, Marc/GNP-7470-2022	Dupin, Nicolas/0000-0002-6237-4951				CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; LAURE F, 1988, LANCET, V2, P538; SAIKI RK, 1988, SCIENCE, V39, P487; SCHULZ TF, 1995, NATURE, V373, P17, DOI 10.1038/373017a0; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	7	353	364	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					761	762		10.1016/S0140-6736(95)90642-8	http://dx.doi.org/10.1016/S0140-6736(95)90642-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891488				2022-12-24	WOS:A1995QN70100013
J	MCNAMEE, D				MCNAMEE, D			TAXOLS PEDIGREE	LANCET			English	Editorial Material																		1995, NATURE, V374, P11; 1995, NATURE, V374, P208	2	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					743	743		10.1016/S0140-6736(95)90634-7	http://dx.doi.org/10.1016/S0140-6736(95)90634-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891481				2022-12-24	WOS:A1995QN70100005
J	HURIE, MB; GENNIS, MA; HERNANDEZ, LV; DINDZANS, VJ; DAVIS, JP				HURIE, MB; GENNIS, MA; HERNANDEZ, LV; DINDZANS, VJ; DAVIS, JP			PREVALENCE OF HEPATITIS-B MARKERS AND MEASLES, MUMPS, AND RUBELLA ANTIBODIES AMONG JEWISH REFUGEES FROM THE FORMER SOVIET-UNION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SEROSURVEY; RECRUITS	Objective.-To assess the prevalence of hepatitis B virus (HBV) infection and immunity to measles, mumps, and rubella among refugees from the former Soviet Union (FSU). Design.-Descriptive study. Setting.-Soviet Immigrant Health Care Program, Sinai Samaritan Hospital, Milwaukee, Wis. Patients.-Consecutive sample of 496 Jewish refugees from the FSU presenting for new arrival screening from December 1, 1990, through January 11, 1993. Outcome Measures.-Hepatitis B surface antigen (HBsAg), hepatitis B core antibody, hepatitis B surface antibody, and measles, mumps, and rubella antibodies. Results.-At least one hepatitis B marker was detected in 22% of the refugees, and HBsAg was detected in 0.4%. The rate of HBV infection (any marker present) increased with increasing age, ranging from 4% among those aged 0 through 19 years to 31% among those aged 50 through 59 years (chi(2) test for trend, 13.5; P<.001). Among those aged 0 through 19 years, 19% lacked antibody to measles, 8% lacked antibody to mumps, and 13% lacked antibody to rubella. Refugees who were less than 30 years of age were more than twice as likely to lack antibodies to measles, mumps, or rubella compared with those who were 30 years of age or older (relative risk, 2.8; 95% confidence interval, 1.8 to 4.2; P<.001). Conclusions.-In our sample of Jewish refugees from the FSU (primarily Ukraine, Russia, and Belorussia), the rate of HBsAg positivity was low, suggesting that routine screening for HBV infection is not needed. Seronegativity to measles, mumps, and rubella was relatively common among those less than 30 years old. Those refugees who were born after 1957 should be given combined measles, mumps, and rubella vaccine unless their written documentation indicates previous receipt of these antigens according to the immunization schedule recommended in the United States.	UNIV WISCONSIN, SCH MED, SINAI SAMARITAN MED CTR, MILWAUKEE, WI USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI USA; UNIV WISCONSIN, DEPT PREVENT MED, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Milwaukee; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	HURIE, MB (corresponding author), BUR PUBL HLTH, WISCONSIN DIV HLTH, COMMUN DIS SECT, 1414 E WASHINGTON AVE, ROOM 167, MADISON, WI 53703 USA.							[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Brinton K, 1992, Nurse Pract, V17, P21, DOI 10.1097/00006205-199204000-00008; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; KNAUS W, 1981, INSIDE RUSSIAN MED, P137; MAYNARD JE, 1989, REV INFECT DIS, V11, pS574; MILLER B, 1990, TB NOTES         SUM, P9; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; SEALE JR, 1987, J ROY SOC MED, V80, P301, DOI 10.1177/014107688708000515; SOBESLAVSKY O, 1980, B WORLD HEALTH ORGAN, V58, P621; STRUEWING JP, 1993, AM J PUBLIC HEALTH, V83, P1717, DOI 10.2105/AJPH.83.12.1717; 1992, MMWR-MORBID MORTAL W, V41, P89; 1989, MMWR-MORBID MORTAL W, V38, P818; 1991, MMWR-MORBID MORTAL W, V40, P784; 1993, REFUGEE REP, V14, P8	14	6	6	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					954	956		10.1001/jama.273.12.954	http://dx.doi.org/10.1001/jama.273.12.954			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884955				2022-12-24	WOS:A1995QM17300031
J	LUCCHINI, R; SOGO, JM				LUCCHINI, R; SOGO, JM			REPLICATION OF TRANSCRIPTIONALLY ACTIVE CHROMATIN	NATURE			English	Article							RIBOSOMAL-RNA GENES; PSORALEN-CROSSLINKING; RDNA ENHANCER; DNA; FORK	IN eukaryotic cells, active genes and their regulatory sequences are organized into open chromatin conformations in which nucleosomes can be modified, disrupted or totally absent(1-3). It has been proposed that these characteristic chromatin structures and their associated factors might be directly inherited by the newly synthesized daughter strands during chromosome duplication(4-6). Here we show that in the yeast Saccharomyces cerevisiae, replication machinery entering upstream of a transcriptionally active ribosomal RNA gene generates two newly replicated coding regions regularly packaged into nucleosomes, indicating that the active chromatin structure cannot be directly inherited at the replication fork. Whereas the establishment of an exposed chromatin conformation at some newly replicated rRNA gene promoters can occur shortly after the passage of the replication fork, regeneration of the active chromatin structure along the coding region is always a post-replicative process involving disruption of preformed nucleosomes.			LUCCHINI, R (corresponding author), ETH HONGGERBERG,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND.							ALBERTS B, 1977, P INT S EUKARYOTIC G, P165; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; CHASMAN DI, 1990, GENE DEV, V4, P403; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; CONCONI A, 1984, J MOL BIOL, V178, P920, DOI 10.1016/0022-2836(84)90319-X; DAMMANN R, 1993, NUCLEIC ACIDS RES, V10, P2331; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KULKENS T, 1989, CURR GENET, V16, P351, DOI 10.1007/BF00340714; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LUCCHINI R, 1992, MOL CELL BIOL, V12, P4288, DOI 10.1128/MCB.12.10.4288; LUCCHINI R, 1994, MOL CELL BIOL, V14, P318, DOI 10.1128/MCB.14.1.318; MORROW BE, 1989, J BIOL CHEM, V264, P9061; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE AP, 1991, J CELL SCI, V99, P201	20	86	87	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					276	280		10.1038/374276a0	http://dx.doi.org/10.1038/374276a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885449				2022-12-24	WOS:A1995QM38700054
J	LINDPAINTNER, K				LINDPAINTNER, K			FINDING AN OBESITY GENE - A TALE OF MICE AND MAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											LINDPAINTNER, K (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.							ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	1	35	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					679	680		10.1056/NEJM199503093321012	http://dx.doi.org/10.1056/NEJM199503093321012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7845436				2022-12-24	WOS:A1995QK06600012
J	CLARKE, JT; PRANGE, R; BALLESTER, GE; TRAUGER, J; EVANS, R; REGO, D; STAPELFELDT, K; IP, W; GERARD, JC; HAMMEL, H; BALLAV, M; BENJAFFEL, L; BERTAUX, JL; CRISP, D; EMERICH, C; HARRIS, W; HORANYI, M; MILLER, S; STORRS, A; WEAVER, H				CLARKE, JT; PRANGE, R; BALLESTER, GE; TRAUGER, J; EVANS, R; REGO, D; STAPELFELDT, K; IP, W; GERARD, JC; HAMMEL, H; BALLAV, M; BENJAFFEL, L; BERTAUX, JL; CRISP, D; EMERICH, C; HARRIS, W; HORANYI, M; MILLER, S; STORRS, A; WEAVER, H			HST FAR-ULTRAVIOLET IMAGING OF JUPITER DURING THE IMPACTS OF COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article							HUBBLE-SPACE-TELESCOPE; POLAR AURORA	Hubble Space Telescope far-ultraviolet images of Jupiter during the Shoemaker-Levy 9 impacts show the impact regions darkening over the 2 to 3 hours after the impact, becoming darker and more extended than at longer wavelengths, which indicates that ultraviolet-absorbing gases or aerosols are more extended, more absorbing, and at higher altitudes than the absorbers of visible light, Transient auroral emissions were observed near the magnetic conjugate point of the K impact site just after that impact. The global auroral activity was fainter than average during the impacts, and a variable auroral emission feature was observed inside the southern auroral oval preceding the impacts of fragments Q1 and Q2.	UNIV PARIS 11, CNRS, INST ASTROPHYS SPATIALE, F-91405 ORSAY, FRANCE; CNRS, INST ASTROPHYS SPATIALE, F-75014 PARIS, FRANCE; JET PROPULS LAB, PASADENA, CA 91109 USA; MAX PLANCK INST AERON, D-37191 KATLENBURG DUHM, GERMANY; UNIV LIEGE, INST ASTROPHYS, B-4000 LIEGE, BELGIUM; MIT, CAMBRIDGE, MA 02139 USA; CNRS, SERV AERON, F-91371 VERRIERES LE BUISSON, FRANCE; UNIV COLORADO, ATMOSPHER & SPACE PHYS LAB, BOULDER, CO 80309 USA; UCL, DEPT PHYS & ASTRON, LONDON, ENGLAND; SPACE TELESCOPE SCI INST, BALTIMORE, MD 21218 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Max Planck Society; University of Liege; Massachusetts Institute of Technology (MIT); Centre National de la Recherche Scientifique (CNRS); University of Colorado System; University of Colorado Boulder; University of London; University College London; Space Telescope Science Institute	CLARKE, JT (corresponding author), UNIV MICHIGAN, SPACE PHYS RES LAB, ANN ARBOR, MI 48109 USA.		Crisp, David/F-6642-2017; Stapelfeldt, Karl R/D-2721-2012; Clarke, John/C-8644-2013; Weaver, Harold A/D-9188-2016	Crisp, David/0000-0002-4573-9998; Weaver, Harold A/0000-0003-0951-7762; Stapelfeldt, Karl/0000-0002-2805-7338; GERARD, Jean-Claude/0000-0002-8565-8746; Horanyi, Mihaly/0000-0002-5920-9226; Miller, Steven/0000-0002-7159-6871				BALLESTER G, UNPUB; BOLIN O, 1994, GEOPHYS RES LETT, V21, P1063, DOI 10.1029/94GL00890; BOSLOUGH MB, 1994, GEOPHYS RES LETT, V21, P1555, DOI 10.1029/94GL01582; CALDWELL J, 1992, SCIENCE, V257, P1512, DOI 10.1126/science.257.5076.1512; CLARKE JS, UNPUB; CLARKE JT, 1980, ASTROPHYS J, V241, pL179, DOI 10.1086/183386; Connerney J.E.P., 1992, PLANETARY RADIO EMIS, P13; CONNERNEY JEP, COMMUNICATION; CRAVENS TE, 1994, GEOPHYS RES LETT, V21, P1075, DOI 10.1029/94GL01070; DEPATER I, UNPUB; DESSLER AJ, 1994, B AM ASTRON SOC, V26, P1593; DOLS V, 1992, GEOPHYS RES LETT, V19, P1803, DOI 10.1029/92GL02104; FARRELL WM, 1994, GEOPHYS RES LETT, V21, P1067, DOI 10.1029/94GL01066; GERARD JC, 1993, J GEOPHYS RES-PLANET, V98, P18793, DOI 10.1029/93JE01334; GOMBOSI TI, 1989, J GEOPHYS RES, V94, P359, DOI 10.1029/JA094iA01p00359; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; HARRIS W, 6040 INT ASTR UN CIR; HARRIS WM, 1994, 6040 INT ASTR UN CIR; HARRIS WM, 1990, J GEOPHYS RES, V95, P10375; HERBERT F, 1994, GEOPHYS RES LETT, V21, P1047, DOI 10.1029/94GL00884; HOLTZMAN J, IN PRESS PUBL ASTRON; IP WH, 1994, GEOPHYS RES LETT, V21, P1051, DOI 10.1029/94GL01063; KELLOGG PJ, 1994, GEOPHYS RES LETT, V21, P1055, DOI 10.1029/94GL01293; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; PRANGE R, 1995, SCIENCE, V267, P1317, DOI 10.1126/science.7871430; PRYOR WR, 1991, ICARUS, V91, P161, DOI 10.1016/0019-1035(91)90135-G; SCOTTI JV, 1993, NATURE, V365, P733, DOI 10.1038/365733a0; SHOEMAKER CS, 1993, 5725 INT ASTR UN CIR; SOMMERIA J, UNPUB; TAUGER JT, 1994, ASTROPHYS J, V435, pL3; WAGENER R, 1985, ICARUS, V63, P222, DOI 10.1016/0019-1035(85)90007-7; WAGENER R, 1988, ICARUS, V74, P141, DOI 10.1016/0019-1035(88)90036-X; WAITE JH, 1994, J GEOPHYS RES-SPACE, V99, P14799, DOI 10.1029/94JA01005; WAITE JH, UNPUB; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; YEOMANS DK, 1993, 22197 MIN PLAN CIRC	37	59	59	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1302	1307		10.1126/science.7871427	http://dx.doi.org/10.1126/science.7871427			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871427				2022-12-24	WOS:A1995QK06800032
J	HALL, DT; STROBEL, DF; FELDMAN, PD; MCGRATH, MA; WEAVER, HA				HALL, DT; STROBEL, DF; FELDMAN, PD; MCGRATH, MA; WEAVER, HA			DETECTION OF AN OXYGEN ATMOSPHERE ON JUPITER MOON EUROPA	NATURE			English	Article							IO PLASMA TORUS; FREQUENCY REDISTRIBUTION; GALILEAN SATELLITES; ELECTRON-IMPACT; CROSS-SECTIONS; SPECTROSCOPY; EXCITATION; MOLECULES; UV	EUROPA, the second large satellite out from Jupiter, is roughly the size of Earth's Moon, but unlike the Moon, it has water ice on its surface(1), There have been Suggestions that an oxygen atmosphere should accumulate around such a body, through reactions which break up the water molecules and form molecular hydrogen and oxygen(2,3), The lighter H-2 molecules would escape from Europa relatively easily, leaving behind an atmosphere rich in oxygen, Here we report the detection of atomic oxygen emission from Europa, which we interpret as being produced by the simultaneous dissociation and excitation of atmospheric O-2 by electrons from Jupiter's magnetosphere, Europa's molecular oxygen atmosphere is very tenuous, with a surface pressure about 10(-11) that of the Earth's atmosphere at sea level.	SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218	Space Telescope Science Institute	HALL, DT (corresponding author), JOHNS HOPKINS UNIV,CTR ASTROPHYS SCI,34TH & CHARLES ST,BALTIMORE,MD 21218, USA.		Weaver, Harold A/D-9188-2016; Strobel, Darrell5/AAO-6643-2021	Weaver, Harold A/0000-0003-0951-7762; Strobel, Darrell5/0000-0002-0944-8675				BAGENAL F, 1994, J GEOPHYS RES-SPACE, V99, P11043, DOI 10.1029/93JA02908; Cheng A.F., 1986, SATELLITES, P403, DOI [10.2307/j.ctv1v3gr3r.13, DOI 10.2307/J.CTV1V3GR3R.13]; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; GLADSTONE GR, 1992, J GEOPHYS RES-SPACE, V97, P19519, DOI 10.1029/92JA00991; HAPKE B, 1981, ICARUS, V47, P361, DOI 10.1016/0019-1035(81)90184-6; ITIKAWA Y, 1989, J PHYS CHEM REF DATA, V18, P23, DOI 10.1063/1.555841; JOHNSON RE, 1983, GEOPHYS RES LETT, V10, P892, DOI 10.1029/GL010i009p00892; LAHER RR, 1990, J PHYS CHEM REF DATA, V19, P277, DOI 10.1063/1.555872; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LEE JS, 1980, ASTROPHYS J, V240, P185, DOI 10.1086/158222; MALIN MC, 1986, SATELLITES, P689; MEIER RR, 1991, SPACE SCI REV, V58, P1, DOI 10.1007/BF01206000; MEIER RR, 1982, PLANET SPACE SCI, V30, P439, DOI 10.1016/0032-0633(82)90053-8; NELSON RM, 1987, ICARUS, V72, P358, DOI 10.1016/0019-1035(87)90180-1; SHEMANSKY DE, 1988, J GEOPHYS RES, V93, P1773, DOI 10.1029/JA093iA03p01773; SITTLER EC, 1987, J GEOPHYS RES, V92, P5741, DOI 10.1029/JA092iA06p05741; VANHOOSIER ME, 1988, ASTROPHYS LETT COMM, V27, P163; YUNG YL, 1977, ICARUS, V20, P97; ZIPF EC, 1986, J PHYS B-AT MOL OPT, V19, P2199, DOI 10.1088/0022-3700/19/14/014; [No title captured]	20	278	280	0	55	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					677	679		10.1038/373677a0	http://dx.doi.org/10.1038/373677a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854447				2022-12-24	WOS:A1995QH92800046
J	OTT, M; SCHAEFFEL, F				OTT, M; SCHAEFFEL, F			A NEGATIVELY POWERED LENS IN THE CHAMELEON	NATURE			English	Article							ACCOMMODATION	CHAMELEONS are arboral Lizards that spot their prey visually and catch it by highly precise shots with their long sticky tongue, They scan their environment by large-amplitude independent saccadic eye movements; once an insect is detected, the head axis is aligned towards the target ('head tracking'(1), both eyes come forward to fixate the insect and, in a phase called 'initial protrusion'(2), the sticky tongue is loaded with tension by a special hyoid apparatus(3) and subsequently shot out of the mouth with great precision, Lenses placed in front of the eyes produce predictable errors in distance estimation(4), suggesting that chameleons rely on accommodation cues when measuring the distance to their prey, but focusing has never been measured directly, Using a new technique to measure accommodation(5), we now show that accommodation is precise enough to serve as the major distance cue. Because accurate focusing requires large retinal images, we have tested image magnification and find that it is higher than in any other vertebrate eye scaled to the same size, This is a result of a unique optical design: unlike other vertebrate eyes, the crystalline lens of the chameleon has negative refractive power, Although there is a trend among vertebrates to increase corneal power and to decrease lens power with higher visual acuity, only in the chameleon eye has this tendency led to a reversal of the sign of the power of the lens.	UNIV TUBINGEN,HOSP EYE,DEPT EXPTL OPHTHALMOL,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen								ALTEVOGT R, 1954, Z VERGL PHYSIOL, V36, P66, DOI 10.1007/BF00297854; [Anonymous], 1977, VISUAL SYSTEM VERTEB, DOI [DOI 10.1007/978-3-642-66468-7, 10.1007/978-3-642-66468-7_11, DOI 10.1007/978-3-642-66468-7_11]; CITRON MC, 1973, VISION RES, V13, P873, DOI 10.1016/0042-6989(73)90050-3; FLANDERS M, 1985, VISION RES, V25, P935, DOI 10.1016/0042-6989(85)90204-4; GLICKSTEIN M, 1970, SCIENCE, V192, P605; HARKNESS L, 1977, NATURE, V267, P346, DOI 10.1038/267346a0; Martin G.R., 1994, P5; Miller W.H., 1979, HDB SENSORY PHYSL, V7 / 6 / 6 A, P69, DOI [10.1007/978-3-642-66999-6_3, DOI 10.1007/978-3-642-66999-6]; OKEEFE LP, 1988, OPHTHAL PHYSL OPT, V8, P97, DOI 10.1111/j.1475-1313.1988.tb01086.x; SCHAEFFEL F, 1987, J COMP PHYSIOL A, V160, P375, DOI 10.1007/BF00613027; SCHAEFFEL F, 1988, VISION RES, V28, P639, DOI 10.1016/0042-6989(88)90113-7; SCHAEFFEL F, 1994, J OPT SOC AM A, V11, P487, DOI 10.1364/JOSAA.11.000487; SCHAEFFEL F, 1988, CLIN VISION SCI, V3, P83; WAGNER H, 1992, J COMP PHYSIOL A, V169, P515; WAINWRIGHT PC, 1992, J EXP BIOL, V168, P1; YOUNG T, 1801, PHILOS T R SOC LONDO, V19, P23	16	58	59	2	44	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					692	694		10.1038/373692a0	http://dx.doi.org/10.1038/373692a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854450				2022-12-24	WOS:A1995QH92800052
J	SCHMIDT, C; BLADT, F; GOEDECKE, S; BRINKMANN, V; ZSCHIESCHE, W; SHARPE, M; GHERARDI, E; BIRCHMEIER, C				SCHMIDT, C; BLADT, F; GOEDECKE, S; BRINKMANN, V; ZSCHIESCHE, W; SHARPE, M; GHERARDI, E; BIRCHMEIER, C			SCATTER FACTOR/HEPATOCYTE GROWTH-FACTOR IS ESSENTIAL FOR LIVER DEVELOPMENT	NATURE			English	Article							MET RECEPTOR; EPITHELIAL INTERACTIONS; MOLECULAR-CLONING; TYROSINE KINASE; HEPATOCYTE; IDENTIFICATION; CELLS; MOTILITY; GENE	POLYPEPTIDE growth factors are important effecters of cell growth and differentiation in vitro and are thought to be critical for processes such as specification of cell fate, tissue growth and organogenesis in vivo, Scatter factor(1-3)/hepatocyte growth factor(4,5) (SF/HGF) is the prototype of an emerging family of growth factors that resemble in their domain structure and mechanism of activation the blood proteinase plasminogen(6,7). The cellular responses of SF/HGF are mediated by the c-Met tyrosine kinase receptor(8-10). Here we report that mice lacking SF/HGF fail to complete development and die in utero. The mutation affects the embryonic liver, which is reduced in size and shows extensive loss of parenchymal cells, In addition, development of the placenta, particularly of trophoblast cells, is impaired. Thus, SF/HGF is essential for the development of several epithelial organs.	MAX PLANCK GESELL,MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY; UNIV CAMBRIDGE,SCH MED,MRC CTR,ICRF,CELL INTERACT LAB,CAMBRIDGE CB2 2QH,ENGLAND	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; MRC Laboratory Molecular Biology; University of Cambridge			Gherardi, Ermanno/AAB-9608-2022; Brinkmann, Volker/A-6015-2009	GHERARDI, ERMANNO/0000-0002-0016-2945				BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; DENK H, 1985, EXP CELL RES, V161, P161, DOI 10.1016/0014-4827(85)90500-2; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HILBERG F, 1993, NATURE, V385, P179; KUEHN R, 1991, Science (Washington D C), V254, P707; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145	29	1179	1248	2	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					699	702		10.1038/373699a0	http://dx.doi.org/10.1038/373699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854452				2022-12-24	WOS:A1995QH92800054
J	ASSAD, JA; MAUNSELL, JHR				ASSAD, JA; MAUNSELL, JHR			NEURONAL CORRELATES OF INFERRED MOTION IN PRIMATE POSTERIOR PARIETAL CARTER	NATURE			English	Article							SACCADE-RELATED ACTIVITY; LATERAL INTRAPARIETAL AREA; ASSOCIATION CORTEX; EYE POSITION; 7A	FOR many types of behaviours, it is necessary to monitor the position or movement of objects that are temporarily occluded. The primate posterior parietal cortex contains neurons that are active during visual guidance tasks: in some cases, even if the visual target disappears transiently(1,2). It has been proposed that activity of this sort could be related to current or planned eye movements(1,2), but it might also provide a more generalized abstract representation of the spatial disposition of targets, even when they are not visible. We have recorded from monkey posterior parietal cortex while the animal viewed a visual stimulus that disappeared, and then, depending on experimental context, could be inferred to be either moving or stationary. During this temporary absence of the stimulus, about half of the neurons were found to be significantly more active on those trials in which the stimulus could be presumed to be moving rather than stationary. The activity was thus present in the absence of either sensory input or motor output, suggesting that it may indeed constitute a generalized representation of target motion.			ASSAD, JA (corresponding author), BAYLOR COLL MED,DIV NEUROSCI S603,HOUSTON,TX 77030, USA.		Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439	NEI NIH HHS [R01 EY005911] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; CRIST CF, 1988, J NEUROSCI METH, V26, P117, DOI 10.1016/0165-0270(88)90160-4; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; NEWSOME WT, 1988, J NEUROPHYSIOL, V60, P604, DOI 10.1152/jn.1988.60.2.604; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; ROBINSON DL, 1978, J NEUROPHYSIOL, V41, P910, DOI 10.1152/jn.1978.41.4.910	9	173	174	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					518	521		10.1038/373518a0	http://dx.doi.org/10.1038/373518a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845463				2022-12-24	WOS:A1995QF72400058
J	LAMBERT, M				LAMBERT, M			CONTROVERSIES IN MANAGEMENT - SHOULD CAROTID ENDARTERECTOMY BE PURCHASED - PURCHASERS NEED A BROADER PERSPECTIVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CEREBROVASCULAR-DISEASE; STROKE; ANGIOGRAPHY; OXFORDSHIRE				LAMBERT, M (corresponding author), WAKEFIELD HLTH AUTHOR, WHITE ROSE HOUSE, WAKEFIELD WF1 1LT, W YORKSHIRE, ENGLAND.			Lambert, Mark/0000-0003-3528-9070				ASPLUND K, 1993, CEREBROVASC DIS, V3, P34, DOI 10.1159/000108747; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BROWN MM, 1992, BMJ-BRIT MED J, V305, P1071, DOI 10.1136/bmj.305.6861.1071; CAMPLING EA, 1992, REPORT NATIONAL CONF; DENNIS M, 1991, BRIT MED J, V303, P636, DOI 10.1136/bmj.303.6803.636; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HOWARD G, 1991, J STROKE CEREBROVASC, V40, P166; MURIE JA, 1991, BRIT J SURG, V78, P397, DOI 10.1002/bjs.1800780406; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TURNIPSEED WD, 1993, SURGERY, V114, P643; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; 1991, CM1523; 1990, CM555	15	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	1995	310	6975					317	318		10.1136/bmj.310.6975.317	http://dx.doi.org/10.1136/bmj.310.6975.317			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866178	Green Published			2022-12-24	WOS:A1995QF71700041
J	TAYLOR, A; GOLDBERG, D; EMSLIE, J; WRENCH, J; GRUER, L; CAMERON, S; BLACK, J; DAVIS, B; MCGREGOR, J; FOLLETT, E; HARVEY, J; BASSON, J; MCGAVIGAN, J				TAYLOR, A; GOLDBERG, D; EMSLIE, J; WRENCH, J; GRUER, L; CAMERON, S; BLACK, J; DAVIS, B; MCGREGOR, J; FOLLETT, E; HARVEY, J; BASSON, J; MCGAVIGAN, J			OUTBREAK OF HIV-INFECTION IN A SCOTTISH PRISON	BRITISH MEDICAL JOURNAL			English	Article							INJECTING DRUG-USERS; HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; INMATES; AIDS; SEROPOSITIVITY; SURVEILLANCE	Objectives-To investigate the possible spread of HIV infection and its route of transmission among prison inmates. Design-In response to an outbreak of acute clinical hepatitis B and two seroconversions to HIV infection, counselling and testing for HIV were offered to all inmates over a two week period in July 1993. Information was sought about drug injecting, sexual behaviour, and previous HIV testing. Setting-HM Prison Glenochil in Scotland. Subjects-Adult male prisoners. Main outcome measures-Uptake of HIV counselling and testing; occurrence and mode of HIV transmission within the prison. Results-Of a total 378 inmates, 227 (60%) were counselled and 162 (43%) tested for HIV. Twelve (7%) of those tested were positive for antibody to HIV. One third (76) of those counselled had injected drugs at some time, of whom 33 (43%) had injected in Glenochil; all 12 seropositive men belonged to this latter group. Thirty two of these 33 had shared needles and syringes in the prison. A further two inmates who injected in the prison were diagnosed as positive for HIV two months previously. Evidence based on sequential results and time of entry into prison indicated that eight transmissions definitely occurred within prison in the first half of 1993. Conclusion-This is the first report of an outbreak of HIV infection occurring within a prison. Restricted access to injecting equipment resulted in random sharing and placed injectors at high risk of becoming infected with HIV. Measures to prevent further spread of infection among prison injectors are urgently required.	FORTH VALLEY HLTH BOARD,STIRLING FK8 1DX,SCOTLAND; RUCHILL HOSP,HIV & ADDICT RESOURCE CTR,GLASGOW,LANARK,SCOTLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND; RUCHILL HOSP,HIV & ADDICT CLIN DIRECTORATE,HIV COUNSELING CLIN,GLASGOW,LANARK,SCOTLAND; HLTH CTR,ALLOA FK10 1AB,CLACK,SCOTLAND; FALKIRK & DIST ROYAL INFIRM,FORTH VALLEY HLTH BOARD,FALKIRK FK1 5QE,SCOTLAND; ROYAL INFIRM,STIRLING FK8 2AU,SCOTLAND; SCOTTISH HOME & HLTH DEPT,EDINBURGH EH1 3DE,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh	TAYLOR, A (corresponding author), RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND.			Gruer, Laurence/0000-0002-1089-2896				BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; CASTRO K, 1991, 7 INT C AIDS FLOR 16, P314; CHOOPANYA K, 1991, AIDS, V5, P1509, DOI 10.1097/00002030-199112000-00014; CONTORREGI C, 1993, 9TH INT C AIDS BERL; COVELL RG, 1993, DRUG ALCOHOL DEPEN, V32, P9, DOI 10.1016/0376-8716(93)90017-K; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DOLAN K, 1994, 5TH P INT C RED DRUG; DOLAN K, 1992, 8TH INT C AIDS AMST; DYE S, 1991, BRIT MED J, V302, P1506, DOI 10.1136/bmj.302.6791.1506; FRERICHS RR, 1992, LANCET, V340, P1496, DOI 10.1016/0140-6736(92)92755-5; GELLERT GA, 1993, AM J PUBLIC HEALTH, V83, P1454, DOI 10.2105/AJPH.83.10.1454; GREEN ST, 1991, ANSWER SCOTTISH CTR; Hankins C, 1991, Can Dis Wkly Rep, V17, P233; HARDING TW, 1987, LANCET, V2, P1260; HORSBURGH CR, 1990, AM J PUBLIC HEALTH, V80, P209, DOI 10.2105/AJPH.80.2.209; KALL KI, 1990, AIDS, V4, P153, DOI 10.1097/00002030-199002000-00009; KENNEDY D, 1991, BRIT MED J, V312, P1507; MARTIN V, 1990, AIDS, V4, P1023, DOI 10.1097/00002030-199010000-00013; MCKEE KJ, 1992, SCOT MED J, V37, P132, DOI 10.1177/003693309203700502; NAIK TN, 1991, AIDS, V5, P117, DOI 10.1097/00002030-199101000-00026; POWER KG, 1992, BRIT J ADDICT, V87, P35; RICHARDSON C, 1993, AIDS, V7, P1485, DOI 10.1097/00002030-199311000-00013; TAYLOR A, 1994, INT J STD AIDS, V5, P105, DOI 10.1177/095646249400500205; TAYLOR A, 1993, BRIT MED J, V307, P623, DOI 10.1136/bmj.307.6904.623; Turnbull P. J., 1991, PRISON HIV AIDS RISK; VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129; 1989, MMWR-MORBID MORTAL W, V38, P1	30	172	174	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					289	292		10.1136/bmj.310.6975.289	http://dx.doi.org/10.1136/bmj.310.6975.289			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF717	7866169	Green Published			2022-12-24	WOS:A1995QF71700023
J	COWAN, FM; JOHNSON, AM; ASHLEY, R; COREY, L; MINDEL, A				COWAN, FM; JOHNSON, AM; ASHLEY, R; COREY, L; MINDEL, A			ANTIBODY TO HERPES-SIMPLEX VIRUS TYPE-2 AS SEROLOGICAL MARKER OF SEXUAL LIFE-STYLE IN POPULATIONS	BRITISH MEDICAL JOURNAL			English	Article							GENITAL HERPES; INFECTIONS; TRANSMISSION; PREVALENCE; FREQUENCY; RISK	Objectives-To examine the epidemiology of antibody to herpes simplex virus type 2 and to assess its suitability as a serological marker of sexual behaviour in populations with high and low prevalences. Design-Cross sectional survey. Setting-Department of genitourinary medicine and blood donation centre in central London. Subjects-Representative sample of 869 patients attending department between November 1990 and December 1991, and 1494 consecutive blood donors attending for donation between February and April 1992. Method-Participants had a blood sample taken for antibody testing with a novel type specific assay and completed a questionnaire. Results-Prevalence of antibody differed significantly between the two groups (188/833 (22.7%) clinic attenders; 102/1347 (7.6%) blood donors). In both populations antibody was strongly associated with sex, sexual orientation, years of sexual activity, number of lifetime sexual partners, and past infection with sexually transmitted diseases after other factors were controlled for. Only 130 (45%) of all those with antibody had symptoms suggestive of genital herpes, and 79 (27.4%) had had genital herpes diagnosed. Of those:without antibody to herpes simplex viruses type 1 and 2, 8.0% reported genital blisters or sores and 1.1% had had genital herpes diagnosed by a doctor. Conclusions-The strong relation between herpes simplex virus type 2 and sexual lifestyle suggests that the presence of antibody to the virus may be suitable for use as an objective, serological marker of patterns of sexual behaviour in different populations. These data show that only a minority of those infected with herpes simplex virus type 2 have a diagnosis of genital herpes or express clinical symptoms, making serological determinants of infection essential for epidemiological studies.	CHILDRENS HOSP & MED CTR, DEPT LAB MED, DIV VIROL, SEATTLE, WA 98105 USA	Seattle Children's Hospital	COWAN, FM (corresponding author), UCL, SCH MED, ACAD DEPT GENITOURINARY MED, MORTIMER ST, LONDON WC1E 6AV, ENGLAND.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436; Mindel, Adrian/0000-0002-8780-9982; Johnson, Anne/0000-0003-1330-7100; Cowan, Frances/0000-0003-3087-4422	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON IG, 1982, BRIT J VENER DIS, V58, P44; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COWAN FM, 1993, GENITOURIN MED, V69, P141; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LEE RM, 1990, AM BEHAV SCI, V33, P510, DOI 10.1177/0002764290033005002; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; SCOULAR A, 1990, GENITOURIN MED, V66, P226; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V268, P1702, DOI 10.1001/jama.268.13.1702; 1992, CMND1986; 1988, EGRET EPIDEMIOLOGICA; 1985, STATISTICAL PACKAGE	20	220	223	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1325	1329		10.1136/bmj.309.6965.1325	http://dx.doi.org/10.1136/bmj.309.6965.1325			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866079	Green Published			2022-12-24	WOS:A1994PT62500018
J	BURACK, JH; BARRETT, DC; STALL, RD; CHESNEY, MA; EKSTRAND, ML; COATES, TJ				BURACK, JH; BARRETT, DC; STALL, RD; CHESNEY, MA; EKSTRAND, ML; COATES, TJ			DEPRESSIVE SYMPTOMS AND CD4 LYMPHOCYTE DECLINE AMONG HIV-INFECTED MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FOLLOW-UP; AIDS; COHORT; HEALTH; RISK; MARKERS	Objective.-To investigate whether high levels of depressive symptomatology. at baseline predict more rapid decline of CD4 lymphocyte counts and progression of clinical disease in persons infected with the human immunodeficiency virus (HIV). Design.-Prospective cohort study with semiannual data collection waves and up to 66 months of follow-up. Setting.-Population-based probability sample of single men in areas of San Francisco with high case rates of the acquired immunodeficiency syndrome (AIDS). Subjects.-All 330 homosexual or bisexual men who by January 1985 had serological evidence of HIV infection but had not had an AIDS diagnosis. Analysis of CD4 lymphocyte change was performed for 277 subjects (83.9%) who had three or more CD4 lymphocyte counts recorded during the study period January 1985 through July 1990. Outcome Measures.-Depressive symptoms were assessed using the Center for Epidemiologic Studies-Depression scale (CES-D). All subjects were classified according to two indicators of depression: (1) as overall depressed using a cut point of 16 or higher on the complete CES-D, and (2) as affectively depressed using a cut point of more than 1 SD above the mean on a subscale of the CES-D measuring affective depression. Laboratory and symptom measures, antiretroviral use, demographics, and behavioral measures were also used. The primary outcome measure was the rate of change of the CD4 lymphocyte count. Secondary outcomes were AIDS-free survival and mortality. Results.-At baseline 65 subjects (19.7%) were classified as depressed on the overall scale and 53 (16.1%) were classified as depressed on the affective scale. The unadjusted mean rate of CD4 change was 38% greater for overall depressed subjects than for the overall nondepressed (-0.0812 vs -0.0588 x 10(9)/L [-81.2 vs -58.8/muL per year; P=.07) and 34% greater for affectively depressed subjects than for the affectively nondepressed (-0.0804 vs -0.0598 x 10(9)/L per year; P=.06). In hierarchical multivariate analysis controlling for antiretroviral use, symptoms, and other predictors, baseline overall depression was associated with an excess decline in CD4 count of -0.0285 x 10(9)/L per year (95% confidence interval, -0.0496 to -0.0073), and baseline affective depression was associated with an excess decline in CD4 count of -0.0236 x 10(9)/L per year (95% confidence interval, -0.0464 to -0.0008). Neither overall depression nor affective depression was significantly associated with earlier AIDS diagnosis or earlier mortality. Conclusions.-Overall depression and affective depression predicted a more rapid decline in CD4 lymphocyte counts; this association was not attributable to baseline physiological differences. While the mechanism of the association remains unknown and cannot be addressed directly by this study, the data suggest that it can be explained neither as simply a reflection of perceived somatic symptoms nor as the result of differences in recreational drug and alcohol use. Further study is necessary to determine whether treating depression can alter the course of HIV infection.	UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,74 NEW MONTGOMERY ST,SUITE 600,SAN FRANCISCO,CA 94105; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIMH NIH HHS [MH42459] Funding Source: Medline; PHS HHS [N01-A1-82515, N01-A1-32519] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASCHER MS, 1993, NATURE, V362, P103, DOI 10.1038/362103a0; BORNSTEIN RA, 1991, ARCH NEUROL-CHICAGO, V48, P704, DOI 10.1001/archneur.1991.00530190050015; COOKE M, 1991, APR C ADH AIDS CLIN; DEGRUTTOLA V, 1991, J AM STAT ASSOC, V86, P569, DOI 10.2307/2290384; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GLASER R, 1987, Brain Behavior and Immunity, V1, P107, DOI 10.1016/0889-1591(87)90013-4; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; HAYS RB, 1992, J CONSULT CLIN PSYCH, V60, P463, DOI 10.1037/0022-006X.60.3.463; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; HOOVER DR, 1992, J ACQ IMMUN DEF SYND, V5, P794; HOPKINS A, 1990, BMDP STATISTICAL SOF, P769; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; KATZ MH, 1992, ANN INTERN MED, V117, P797, DOI 10.7326/0003-4819-117-9-797_1; KEMENY ME, IN PRESS NEUROPSYCHI; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PERSKY VW, 1987, PSYCHOSOM MED, V49, P435, DOI 10.1097/00006842-198709000-00001; PIAZZA T, 1989, 3 U CAL CAL SURV RES; RABKIN JG, 1993, HOSP COMMUNITY PSYCH, V44, P162; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; Solomon G F, 1989, Psychiatr Med, V7, P47; VALENTINE F T, 1990, AIDS (London), V4, pS201; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P1037; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1987, MMWR MORB MORTAL S2S, V36, P1	30	268	270	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2568	2573		10.1001/jama.270.21.2568	http://dx.doi.org/10.1001/jama.270.21.2568			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	7901433				2022-12-24	WOS:A1993MJ26600023
J	PARSONS, CA; STASIAK, A; BENNETT, RJ; WEST, SC				PARSONS, CA; STASIAK, A; BENNETT, RJ; WEST, SC			STRUCTURE OF A MULTISUBUNIT COMPLEX THAT PROMOTES DNA BRANCH MIGRATION	NATURE			English	Article							ESCHERICHIA-COLI; RUVB PROTEINS; HOLLIDAY JUNCTION; HELICASE	THE RuvA and RuvB proteins of Escherichia coli, which are induced in response to DNA damage, are important in the formation of heteroduplex DNA during genetic recombination and related recombinational repair processes(1). In vitro studies show that RuvA binds Holliday junctions(2-5) and acts as a specificity factor that targets the RuvB ATPase, a hexameric ring protein(6,7), to the junction. Together, RuvA and RuvB promote branch migration, an ATP-dependent reaction that increases the length of the heteroduplex DNA(3,8-10). Electron microscopic visualization of RuvAB now provides a new insight into the mechanism of this process. We observe the formation of a tripartite protein complex in which RuvA binds the crossover and is sandwiched between two hexameric rings of RuvB. The Holliday junction within this complex adopts a square-planar structure. We propose a molecular model for branch migration, a unique feature of which is the role played by the two oppositely oriented RuvB ring motors.	IMPERIAL CANC RES FUND,GENET RECOMBINAT LAB,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV LAUSANNE,ULTRASTRUCT ANAL LAB,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne			Stasiak, Andrzej/E-5551-2010	Stasiak, Andrzej/0000-0002-0398-1989; West, Stephen/0000-0001-8848-9418; Bennett, Richard/0000-0001-7563-484X				ADAMS DE, 1995, J MOL BIOL, V247, P404, DOI 10.1006/jmbi.1995.0149; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; IYPE LE, 1994, J BIOL CHEM, V269, P24967; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; MCCULLOCH R, 1994, EMBO J, V13, P1844, DOI 10.1002/j.1460-2075.1994.tb06453.x; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17179; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6	22	161	161	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					375	378		10.1038/374375a0	http://dx.doi.org/10.1038/374375a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885479				2022-12-24	WOS:A1995QN63000064
J	ASHTON, CM; KUYKENDALL, DH; JOHNSON, ML; WRAY, NP; WU, L				ASHTON, CM; KUYKENDALL, DH; JOHNSON, ML; WRAY, NP; WU, L			THE ASSOCIATION BETWEEN THE QUALITY OF INPATIENT CARE AND EARLY READMISSION	ANNALS OF INTERNAL MEDICINE			English	Article						PATIENT READMISSION; QUALITY OF HEALTH CARE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); HOSPITALIZATION	DISEASE	Objective: To determine whether the quality of care during a hospital stay is associated with unplanned readmission within 14 days. Design: Case-control study. Setting: 12 Veterans Affairs hospitals. Patients: Men discharged after a hospitalization for diabetes (n = 593), chronic obstructive lung disease (n = 1172), or heart failure (n = 748). The ratio of controls (men without an unplanned readmission within 14 days to any Veterans Affairs hospital) to cases (men with such a readmission) was 3:1. Main Outcome Measures: Unplanned readmission to any of the 159 Veterans Affairs hospitals within 14 days of discharge. Quality of care during the index stay was assessed by chart review using disease-specific explicit criteria for the process of inpatient care, which were developed by panels composed of expert physicians. Adherence scores (the percentage of applicable criteria that were met) were calculated for the admission workup, evaluation and treatment, and readiness for discharge. Results: After adjustment was made for demographic characteristics, severity of illness, and need for care, adherence scores correlated with early unplanned readmission (P < 0.05). For patients with diabetes and heart failure, decreased readiness-for-discharge adherence scores correlated with increased risk for readmission (P = 0.001 and P = 0.016, respectively). In patients with obstructive lung disease, decreased admission-workup scores correlated with increased risk for readmission (P = 0.013). One of 7 readmissions in patients with diabetes, 1 of 5 readmissions in patients with heart failure, and 1 of 12 readmissions in patients with obstructive lung disease were attributable to substandard care. Conclusions: Lower quality of inpatient care increases the risk for unplanned early readmission in patients with heart failure, diabetes, or obstructive lung disease. Under certain circumstances, readmission is associated with remediable deficiencies in the process of inpatient care.	BAYLOR COLL MED, HOUSTON, TX 77030 USA	Baylor College of Medicine	ASHTON, CM (corresponding author), VET AFFAIRS MED CTR, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; ASHTON CM, 1994, J GEN INTERN MED, V9, P208, DOI 10.1007/BF02600126; ASHTON CM, 1994, MED CARE, V32, P755, DOI 10.1097/00005650-199408000-00001; ASHTON CM, 1987, MED CARE, V25, P1184, DOI 10.1097/00005650-198712000-00008; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; FEINGLASS J, 1991, HEALTH SERV RES, V26, P183; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, P211, DOI DOI 10.2307/2530193; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; HAYWARD RA, 1993, MED CARE, V31, P394, DOI 10.1097/00005650-199305000-00002; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P162; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUDKE RL, 1993, INQUIRY-J HEALTH CAR, V30, P95; MANHEIM LM, 1990, MED CARE, V28, P29, DOI 10.1097/00005650-199001000-00005; REED RL, 1991, J GEN INTERN MED, V6, P223, DOI 10.1007/BF02598964; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; SIMMER TL, 1991, MED CARE, V29, pJS31; THOMAS JW, 1991, MED CARE, V29, P377, DOI 10.1097/00005650-199104000-00006; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; WILLIAMS EI, 1988, BRIT MED J, V297, P784, DOI 10.1136/bmj.297.6651.784; WRAY NP, 1995, MED CARE, V33, P75, DOI 10.1097/00005650-199501000-00007; 1989, ANAL READMISSIONS US; 1989, SAS UNIX 607	23	280	289	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					415	421		10.7326/0003-4819-122-6-199503150-00003	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM266	7856989				2022-12-24	WOS:A1995QM26600003
J	AYER, DE; LAWRENCE, QA; EISENMAN, RN				AYER, DE; LAWRENCE, QA; EISENMAN, RN			MAD-MAX TRANSCRIPTIONAL REPRESSION IS MEDIATED BY TERNARY COMPLEX-FORMATION WITH MAMMALIAN HOMOLOGS OF YEAST REPRESSOR SIN3	CELL			English	Article							THYROID-HORMONE RECEPTOR; SACCHAROMYCES-CEREVISIAE; C-MYC; GENE-PRODUCT; PROTEIN; ACTIVATION; INTERACTS; HO; DIMERIZATION; EXPRESSION	The bHLH-ZIP protein Mad heterodimerizes with Max as a sequence-specific transcriptional repressor. Mad is rapidly induced upon differentiation, and the associated switch from Myc-Max to Mad-Max heterocomplexes seem to repress genes normally activated by Myc-Max. We have identified two related mammalian cDNAs that encode Mad-binding proteins. Both possess sequence homology with the yeast transcription repressor Sin3, including four conserved paired amphipathic helix (PAH) domains. mSin3A and mSin3B bind specifically to Mad and the related protein Mxi1. Mad-Max and mSin3 form ternary complexes in solution that specifically recognize the Mad-Max E box-binding site. Mad-mSin3 association requires PAHS of mSin3A/mSin3B and the first 25 residues of Mad, which contains a putative amphipathic alpha-helical region. Point mutations in this region eliminate interaction with mSin3 proteins and block Mad transcriptional repression. We suggest that Mad-Max represses transcription by tethering mSin3 to DNA as corepressors and that a transcriptional repression mechanism is conserved from yeast to mammals.			AYER, DE (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,ROOM A2-025,SEATTLE,WA 98104, USA.			Ayer, Donald/0000-0002-5595-3269	NATIONAL CANCER INSTITUTE [R01CA057138] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AUBLE DT, 1994, IN PRESS GENES DEV, V8; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENIKOFF S, 1987, GENETICS, V117, P711; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUDAK KA, 1994, GENETICS, V136, P475; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRICH R, 1989, P NATL ACAD SCI USA, V88, P10018; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VIDAL M, 1990, GENETICS, V125, P313; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HM, 1994, MOL GEN GENET, V245, P675, DOI 10.1007/BF00297274; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WANG HM, 1990, P NATL ACAD SCI USA, V87, P9761, DOI 10.1073/pnas.87.24.9761; WEINBERG RA, 1992, SCIENCE, V254, P1138; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YOSHIMOTO H, 1992, MOL GEN GENET, V233, P327, DOI 10.1007/BF00587597; ZAWEL L, 1992, CURR OPIN CELL BIOL, V4, P448; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, CELL, V79	61	530	538	1	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					767	776		10.1016/0092-8674(95)90355-0	http://dx.doi.org/10.1016/0092-8674(95)90355-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889570	Bronze			2022-12-24	WOS:A1995QM39900013
J	LISMAN, JE; IDIART, MAP				LISMAN, JE; IDIART, MAP			STORAGE OF 7+/-2 SHORT-TERM MEMORIES IN OSCILLATORY SUBCYCLES	SCIENCE			English	Article							RAT-ASSOCIATION CORTEX; PYRAMIDAL CELLS; RESPONSES; MONKEY	Psychophysical measurements indicate that human subjects can store approximately seven short-term memories. Physiological studies suggest that short-term memories are stored by patterns of neuronal activity. Here it is shown that activity patterns associated with multiple memories can be stored in a single neural network that exhibits nested oscillations similar to those recorded from the brain. Each memory is stored in a different high-frequency (''40 hertz'') subcycle of a low-frequency oscillation. Memory patterns repeat on each low-frequency (5 to 12 hertz) oscillation, a repetition that relies on activity-dependent changes in membrane excitability rather than reverberatory circuits. This work suggests that brain oscillations are a timing mechanism for controlling the serial processing of short-term memories.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT PHYS,WALTHAM,MA 02254	Brandeis University; Brandeis University	LISMAN, JE (corresponding author), BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254, USA.		idiart, marco/F-7389-2015	idiart, marco/0000-0002-7129-3520	NINDS NIH HHS [NS27337] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027337] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIT DJ, 1994, J NEUROSCI, V14, P6435; Amit DJ, 1989, MODELING BRAIN FUNCT, DOI 10.1017/CBO9780511623257; ANDRADE R, 1991, BRAIN RES, V548, P81, DOI 10.1016/0006-8993(91)91109-E; ARANEDA R, 1991, NEUROSCIENCE, V40, P399, DOI 10.1016/0306-4522(91)90128-B; Atkinson R. C., 1968, PSYCHOL LEARN MOTIV, V2, P89, DOI 10.1016/S0079-7421(08)60422-3; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BRAGIN A, 1995, J NEUROSCI, V15, P47; CAESER M, 1993, EUR J NEUROSCI, V5, P560, DOI 10.1111/j.1460-9568.1993.tb00521.x; CHANG HT, 1950, J NEUROPHYSIOL, V13, P235, DOI 10.1152/jn.1950.13.3.235; Fahle M., 1994, Society for Neuroscience Abstracts, V20, P319; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1982, J NEUROSCI, V2, P361; HEBB DO, 1949, ORG BEHAVIOR; Horn D, 1991, NEURAL COMPUT, V3, P31, DOI 10.1162/neco.1991.3.1.31; HORN D, 1994, ADV NEURAL INFORMATI, V4, P125; JOLIOT M, 1994, P NATL ACAD SCI USA, V91, P11748, DOI 10.1073/pnas.91.24.11748; KAUFMAN L, 1992, ELECTROENCEPHALOGR C, V82, P226; Koch C., 1994, SOME FURTHER IDEAS R, P93; KREITER AK, 1992, EUR J NEUROSCI, V4, P369, DOI 10.1111/j.1460-9568.1992.tb00884.x; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; NAKAMURA K, 1992, NEUROREPORT, V3, P117, DOI 10.1097/00001756-199201000-00031; Oberly HS, 1928, AM J PSYCHOL, V40, P295, DOI 10.2307/1414490; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; Skaggs W. E., 1993, Society for Neuroscience Abstracts, V19, P795; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; STERIADE M, 1991, P NATL ACAD SCI USA, V88, P4396, DOI 10.1073/pnas.88.10.4396; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; WINGFIELD A, 1972, SCIENCE, V176, P690, DOI 10.1126/science.176.4035.690; ZIPSER D, 1993, J NEUROSCI, V13, P3406	33	977	987	0	81	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1512	1515		10.1126/science.7878473	http://dx.doi.org/10.1126/science.7878473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878473				2022-12-24	WOS:A1995QL49700042
J	VONCKEN, JW; VANSCHAICK, H; KAARTINEN, V; DEEMER, K; COATES, T; LANDING, B; PATTENGALE, P; DORSEUIL, O; BOKOCH, GM; GROFFEN, J; HEISTERKAMP, N				VONCKEN, JW; VANSCHAICK, H; KAARTINEN, V; DEEMER, K; COATES, T; LANDING, B; PATTENGALE, P; DORSEUIL, O; BOKOCH, GM; GROFFEN, J; HEISTERKAMP, N			INCREASED NEUTROPHIL RESPIRATORY BURST IN BCR-NULL MUTANTS	CELL			English	Article							CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; NADPH OXIDASE; C-ABL; SUPEROXIDE PRODUCTION; NUCLEOTIDE EXCHANGE; B-CELL; PROTEIN; ONCOGENE; ACTIVATION	Philadelphia (Ph)-positive leukemias invariably contain a chromosomal translocation fusing BCR to ABL. The BCR-ABL protein is responsible for leukemogenesis. Here we show that exposure of bcr-null mutant mice to gram-negative endotoxin led to severe septic shock and increased tissue injury by neutrophils. Neutrophils of bcr (-/-) mice showed a pronounced increase in reactive oxygen metabolite production upon activation and were more sensitive to priming stimuli. Activated (-/-) neutrophils displayed a 3-fold increased p21(rac2) membrane translocation compared with (+/+) neutrophils. These results connect Bcr in vivo with the regulation of Rac-mediated superoxide production by the NADPH-oxidase system of leukocytes and suggest a link between Bcr function and the cell type affected in Ph-positive leukemia.	CHILDRENS HOSP LOS ANGELES, DEPT HEMATOL, LOS ANGELES, CA 90027 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Children's Hospital Los Angeles; Scripps Research Institute; Scripps Research Institute	VONCKEN, JW (corresponding author), CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, LOS ANGELES, CA 90027 USA.		Kaartinen, Vesa/AAU-5396-2021; Coates, Thomas/AAN-3556-2020; Heisterkamp, Nora/C-1698-2012	Coates, Thomas/0000-0001-9878-6029; Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NATIONAL CANCER INSTITUTE [R01CA050248] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NCI NIH HHS [CA50248] Funding Source: Medline; NHLBI NIH HHS [HL 48008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHMED S, 1994, J BIOL CHEM, V269, P17642; BEDI A, 1993, BLOOD, V81, P2898; BENNA JE, 1994, J BIOL CHEM, V269, P6729; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; DEFORGE LE, 1994, AM J PATHOL, V144, P599; DEMLING RH, 1990, CIRC SHOCK, V30, P297; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; EDWARDS SW, 1994, BIOCH PHYSL NEUTROPH, P235; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FIORETOS T, 1994, BLOOD, V83, P3441; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAAS OA, 1992, NATURE, V359, P414, DOI 10.1038/359414a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P473; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; HEWETT JA, 1992, LAB INVEST, V66, P347; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HIMMELFARB J, 1992, CYTOMETRY, V13, P83, DOI 10.1002/cyto.990130113; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LIU JX, 1993, ONCOGENE, V8, P101; LOFGREN R, 1993, J CELL BIOL, V123, P1597, DOI 10.1083/jcb.123.6.1597; LU D, 1993, BLOOD, V82, P1257; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MELO JV, 1993, BLOOD, V81, P158; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHAAFI RI, 1988, J LEUKOCYTE BIOL, V43, P18, DOI 10.1002/jlb.43.1.18; SHASBY DM, 1982, AM REV RESPIR DIS, V125, P443; SHIRATORI Y, 1990, HEPATOLOGY, V11, P83; SIMPSON R, 1993, ANN SURG, V218, P444, DOI 10.1097/00000658-199310000-00005; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1993, ADV RES TREATMENT, P295; WAKIYAMA H, 1993, CLIN EXP IMMUNOL, V92, P218; WATT SM, 1979, J CELL PHYSIOL, V100, P1, DOI 10.1002/jcp.1041000102; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; YOSHIKAWA T, 1994, CIRC SHOCK, V42, P53	52	152	156	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					719	728		10.1016/0092-8674(95)90350-X	http://dx.doi.org/10.1016/0092-8674(95)90350-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889565	Bronze			2022-12-24	WOS:A1995QM39900008
J	HINSHAW, JE; SCHMID, SL				HINSHAW, JE; SCHMID, SL			DYNAMIN SELF-ASSEMBLES INTO RINGS SUGGESTING A MECHANISM FOR COATED VESICLE BUDDING	NATURE			English	Article							GTP-BINDING PROTEINS; MECHANOCHEMICAL ENZYME; DROSOPHILA; MICROTUBULES; ENDOCYTOSIS; SHIBIRE; DOMAIN	DYNAMIN, a 100K member of the GTPase superfamily(1), is the mammalian homologue of the Drosophila shihire gene product(2,3). Mutations in shibire cause a defect in endocytosis Leading to accumulation of coated pits and deep invaginations at the plasma membrane of all tissues examined(4,5). Similarly, invaginated coated pits accumulate in mammalian cells overexpressing dominant-negative mutants of dynamin, establishing that dynamin is required for the formation of 'constricted' coated pits and for coated vesicle budding(6). Whether dynamin functions in the classic GTPase mode as a molecular switch to regulate events leading to coated vesicle budding or instead actively participates as a mechanochemical enzyme driving coated vesicle formation is unclear(7). Here we show that dynamin spontaneously self-assembles into rings and stacks of interconnected rings, comparable in dimension to the 'collars' observed at the necks of invaginated coated pits that accumulate at synaptic terminals in shibire flies(4). We propose that invaginated coated pits become constricted by the assembly of dynamin into rings around their necks. A concerted conformational change would then close the rings and pinch off the budding coated vesicles.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Schmid, Sandra/0000-0002-1690-7024				CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TSURUHARA T, 1990, CELL TISSUE RES, V259, P199, DOI 10.1007/BF00318441; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WARNOCK DE, IN PRESS EMBO J	17	649	662	4	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					190	192		10.1038/374190a0	http://dx.doi.org/10.1038/374190a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877694				2022-12-24	WOS:A1995QL39700067
J	SCHOENHERR, CJ; ANDERSON, DJ				SCHOENHERR, CJ; ANDERSON, DJ			THE NEURON-RESTRICTIVE SILENCER FACTOR (NRSF) - A COORDINATE REPRESSOR OF MULTIPLE NEURON-SPECIFIC GENES	SCIENCE			English	Article							SODIUM-CHANNEL GENE; NERVE GROWTH-FACTOR; BINDING-PROTEIN; SCG10 GENE; CELL LINE; EXPRESSION; DIFFERENTIATION; SEQUENCE; FAMILY; DNA	The neuron-restrictive silencer factor (NRSF) binds a DNA sequence element, called the neuron-restrictive silencer element (NRSE), that represses neuronal gene transcription in nonneuronal cells. Consensus NRSEs have been identified in 18 neuron-specific genes, Complementary DNA clones encoding a functional fragment of NRSF were isolated and found to encode a novel protein containing eight noncanonical zinc fingers. Expression of NRSF mRNA was detected in most nonneuronal tissues at several developmental stages, In the nervous system, NRSF mRNA was detected in undifferentiated neuronal progenitors, but not in differentiated neurons, NRSF represents the first example of a vertebrate silencer protein that potentially regulates a large battery of cell type-specific genes, and therefore may function as a master negative regulator of neurogenesis.	CALTECH,HOWARD HUGHES MED INST,DIV BIOL 21676,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23476] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BLAV HM, 1991, ANN REV BIOCH, V61, P1213; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEBER SM, 1990, J NEUROSCI, V10, P2451; LI L, P NATL ACAD SCI USA, V90, P1460; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MORITA H, 1992, ZOOL SCI, V9, P1; OU SKH, 1993, J IMMUNOL METHODS, V165, P75, DOI 10.1016/0022-1759(93)90108-J; PATHAK BG, 1984, NUCLEIC ACIDS RES, V22, P4748; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PFEIFFER SE, 1978, GLIAL CELL LINES, P287; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SCHOENHERR CS, UNPUB; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	35	905	930	1	59	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1360	1363		10.1126/science.7871435	http://dx.doi.org/10.1126/science.7871435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871435				2022-12-24	WOS:A1995QK06800049
J	STEER, P; ALAM, MA; WADSWORTH, J; WELCH, A				STEER, P; ALAM, MA; WADSWORTH, J; WELCH, A			RELATION BETWEEN MATERNAL HEMOGLOBIN CONCENTRATION AND BIRTH-WEIGHT IN DIFFERENT ETHNIC-GROUPS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMOGLOBIN CONCENTRATION; FOLATE SUPPLEMENTS; GROWTH-RETARDATION; PREGNANCY; IRON; ANEMIA; 2ND-TRIMESTER; HEMATOCRIT	Objective-To assess the relation of the lowest haemoglobin concentration in pregnancy with birth weight and the rates of low birth weight and preterm delivery in different ethnic groups. Design-Retrospective analysis of 153 602 pregnancies with ethnic group and birth weight recorded on a regional pregnancy database during 1988-91. The haemoglobin measurement used was the lowest recorded during pregnancy. Setting-North West Thames region. Subjects-115 262 white women, 22 206 Indo-Pakistanis, 4570 Afro-Caribbeans, 2642 mediterraneans, 3905 black Africans, 2351 orientals, and 2666 others. Main outcome measures-Birth weight and rates of low birth weight (<2500 g) and preterm delivery (<37 completed weeks). Results-Maximum mean birth weight in white women was achieved with a lowest haemoglobin concentration in pregnancy of 85-95 g/l; the lowest incidence of low birth weight and preterm labour occurred with a lowest haemoglobin of 95-105 g/l. A similar pattern occurred in all ethnic groups. Conclusions-The magnitude of the fall in haemoglobin concentration in pregnancy is related to birth weight; failure of the haemoglobin concentration to fall below 105 g/l indicates an increased risk of low birth weight and preterm delivery. This phenomenon is seen in all ethnic groups. Some ethnic groups have higher rates of low birth weight and preterm delivery than white women, and they also have higher rates of low haemoglobin concentrations. This increased rate of ''anaemia,'' however, does not account for their higher rates of low birth weight, which occurs at all haemoglobin concentrations.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL, LONDON EC1A 7BE, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT PUBL HLTH, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT OBSTET & GYNAECOL, LONDON W2 1PG, ENGLAND	University of London; Queen Mary University London; Imperial College London; Imperial College London	STEER, P (corresponding author), CHELSEA & WESTMINSTER HOSP, CHARING CROSS & WESTMINSTER MED SCH, ACAD DEPT OBSTET & GYNAECOL, LONDON SW10 9NH, ENGLAND.							Dieckmann WJ, 1934, ARCH INTERN MED, V53, P71, DOI 10.1001/archinte.1934.00160070076007; DUNLOP W, 1978, BRIT J OBSTET GYNAEC, V85, P938, DOI 10.1111/j.1471-0528.1978.tb15857.x; FENTON V, 1977, BRIT J HAEMATOL, V37, P145, DOI 10.1111/j.1365-2141.1977.tb08819.x; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; GOODLIN RC, 1982, J REPROD MED, V27, P639; HIBBARD BM, 1988, BRIT MED J, V297, P1324, DOI 10.1136/bmj.297.6659.1324; HORN E, 1988, BRIT MED J, V297, P1325, DOI 10.1136/bmj.297.6659.1325; HUISMAN A, 1986, ACTA OBSTET GYN SCAN, V65, P605, DOI 10.3109/00016348609158396; HYTTEN FE, 1963, J OBSTET GYN BR COMM, V70, P402; KLEBANOFF MA, 1989, JAMA-J AM MED ASSOC, V262, P511, DOI 10.1001/jama.262.4.511; KLEBANOFF MA, 1991, AM J OBSTET GYNECOL, V164, P59, DOI 10.1016/0002-9378(91)90626-3; KOLLER O, 1979, ACTA OBSTET GYN SCAN, V58, P9, DOI 10.3109/00016347909154904; LETSKY EA, 1994, HIGH RISK PREGNANCY, P337; LU ZM, 1991, OBSTET GYNECOL, V77, P190; MAHOMED K, 1993, PREGNANCY CHILDBIRTH; MAU G, 1977, J PERINAT MED, V5, P172, DOI 10.1515/jpme.1977.5.4.172; MURPHY JF, 1986, LANCET, V1, P992; PAINTIN D. B., 1966, Journal of Obstetrics and Gynaecology of the British Commonwealth, V73, P181, DOI 10.1111/j.1471-0528.1966.tb05144.x; SAGEN N, 1984, ACTA OBSTET GYN SCAN, V63, P245, DOI 10.3109/00016348409155506; TAYLOR DJ, 1979, BRIT J OBSTET GYNAEC, V86, P364, DOI 10.1111/j.1471-0528.1979.tb10611.x; 1978, BRIT MED J, V2, P1317; 1965, WHO TECH REP SER, V302, P5	22	208	218	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	1995	310	6978					489	491		10.1136/bmj.310.6978.489	http://dx.doi.org/10.1136/bmj.310.6978.489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888886	Green Published			2022-12-24	WOS:A1995QJ59800018
J	BUONOMANO, DV; MERZENICH, MM				BUONOMANO, DV; MERZENICH, MM			TEMPORAL INFORMATION TRANSFORMED INTO A SPATIAL CODE BY A NEURAL-NETWORK WITH REALISTIC PROPERTIES	SCIENCE			English	Article							RAT HIPPOCAMPUS; PAIRED-PULSE; DISCRIMINATION; FACILITATION; COMPUTATION; INVITRO; CORTEX; TIME; CA1	Neurons exhibit a wide range of properties in addition to postsynaptic potential (PSP) summation and spike generation. Although other neuronal properties such as paired-pulse facilitation (PPF) and slow PSPs are well characterized, their role in information processing remains unclear. It is possible that these properties contribute to temporal processing in the range of hundreds of milliseconds, a range relevant to most complex sensory processing. A continuous-time neural network model based on integrate-and-fire elements that incorporate PPF and slow inhibitory postsynaptic potentials (IPSPs) was developed here. The time constants of the PPF and IPSPs were estimated from empirical data and were identical and constant for all elements in the circuit. When these elements were incorporated into a circuit inspired by neocortical connectivity, the network was able to discriminate different temporal patterns. Generalization emerged spontaneously. These results demonstrate that known time-dependent neuronal properties enable a network to transform temporal information into a spatial code in a self-organizing manner-that is, with no need to assume a spectrum of time delays or to custom-design the circuit.			BUONOMANO, DV (corresponding author), UNIV CALIF SAN FRANCISCO, KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH010431] Funding Source: NIH RePORTER; NIMH NIH HHS [F32 MH10431] Funding Source: Medline; NINDS NIH HHS [NS-10414] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson J.A., 1988, NEUROCOMPUTING; ANDERSON JA, 1990, NEUROCOMPUTING, V2; ANTON PS, 1991, BIOL CYBERN, V65, P407, DOI 10.1007/BF00216975; Braitenberg V, 1967, Prog Brain Res, V25, P334; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUONOMANO DV, 1994, NEURAL COMPUT, V6, P38, DOI 10.1162/neco.1994.6.1.38; CARR CE, 1993, ANNU REV NEUROSCI, V16, P223, DOI 10.1146/annurev.ne.16.030193.001255; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; DOUGLAS RJ, 1990, J PHYSIOL-LONDON, V40, P735; GIBBON J, 1984, ANN NY ACAD SCI, V423, P52, DOI 10.1111/j.1749-6632.1984.tb23417.x; GROSSBERG S, 1989, NEURAL NETWORKS, V2, P79, DOI 10.1016/0893-6080(89)90026-9; Margoliash D., 1983, J NEUROSCI, V3, P133; MASON A, 1991, J NEUROSCI, V11, P72; MCCORMICK DA, 1989, J NEUROPHYSIOL, V62, P1018, DOI 10.1152/jn.1989.62.5.1018; MCCORMICK DA, 1990, SYNAPTIC ORG BRAIN, P33; MOORE JW, 1989, BIOL CYBERN, V62, P17, DOI 10.1007/BF00217657; NATHAN T, 1991, J NEUROPHYSIOL, V66, P1704, DOI 10.1152/jn.1991.66.5.1704; OGDEN G, 1978, PSYCHOL REV, V85, P172; Rumelhart D., 1986, PARALLEL DISTRIBUTED; SULLIVAN WE, 1982, J NEUROPHYSIOL, V48, P1033, DOI 10.1152/jn.1982.48.4.1033; Swadlow H. A., 1993, Society for Neuroscience Abstracts, V19, P1704; TALLAL P, 1993, ANN NY ACAD SCI, V682; TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896; WELKER E, 1993, EUR J NEUROSCI, V5, P691, DOI 10.1111/j.1460-9568.1993.tb00534.x; WOOD CC, 1976, J ACOUST SOC AM, V60, P1381, DOI 10.1121/1.381231; WORGOTTER F, 1991, J NEUROSCI, V11, P1959; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	27	320	322	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1028	1030		10.1126/science.7863330	http://dx.doi.org/10.1126/science.7863330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863330				2022-12-24	WOS:A1995QG99000040
J	VAADIA, E; HAALMAN, I; ABELES, M; BERGMAN, H; PRUT, Y; SLOVIN, H; AERTSEN, A				VAADIA, E; HAALMAN, I; ABELES, M; BERGMAN, H; PRUT, Y; SLOVIN, H; AERTSEN, A			DYNAMICS OF NEURONAL INTERACTIONS IN MONKEY CORTEX IN RELATION TO BEHAVIORAL EVENTS	NATURE			English	Article							CROSS-CORRELATION ANALYSIS; CAT STRIATE CORTEX; VISUAL-CORTEX; SYNCHRONIZATION; CONNECTIVITY; NETWORK	IT is possible that brain cortical function is mediated by dynamic modulation of coherent firing in groups of neurons. Indeed, a correlation of firing between cortical neurons, seen following sensory stimuli or during motor behaviour, has been described(1-5). However, the time course of modifications of correlation in relation to behaviour was not evaluated systematically. Here we show that correlated firing between single neurons, recorded simultaneously in the frontal cortex of monkeys performing a behavioural task, evolves within a fraction of a second, and in systematic relation to behavioural events. Moreover, the dynamic patterns of correlation depend on the distance between neurons, and can emerge even without modulation of the firing rates. These findings support the notion that neurons can associate rapidly into a functional group in order to perform a computational task, at the same time becoming dissociated from concurrently activated competing groups. Thus, they call for a revision of prevailing models of neural coding that rely solely on single neuron firing rates(6-8).	HEBREW UNIV JERUSALEM,CTR NEURAL COMPUTAT,IL-91010 JERUSALEM,ISRAEL; WEIZMANN INST SCI,CTR RES HIGHER BRAIN FUNCT,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Weizmann Institute of Science	VAADIA, E (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PHYSIOL,IL-91010 JERUSALEM,ISRAEL.		Vaadia, Eilon/E-9347-2011					ABELES M, 1993, BRAIN THEORY, P149; ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; AERTSEN A, 1994, PHYSICA D, V75, P103, DOI 10.1016/0167-2789(94)90278-X; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; Barlow H.B., 1992, INFORMATION PROCESSI, P169; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FETZ E, 1991, CEREB CORTEX, V9, P1; GRA CM, 1992, VIS NEUROSCI, V8, P37; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HANSEL D, 1992, PHYS REV LETT, V68, P718, DOI 10.1103/PhysRevLett.68.718; KANEKO K, 1990, PHYSICA D, V41, P137, DOI 10.1016/0167-2789(90)90119-A; KRUGER J, 1990, VISUAL NEUROSCI, V5, P135, DOI 10.1017/S0952523800000171; MICHALSKI A, 1983, EXP BRAIN RES, V51, P97; MURTHY VN, IN PRESS OSCILLATORY; NELSON JI, 1992, VISUAL NEUROSCI, V9, P21, DOI 10.1017/S0952523800006349; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; PALM G, 1988, BIOL CYBERN, V59, P1, DOI 10.1007/BF00336885; SELEMON LD, 1990, J COMP NEUROL, V297, P359, DOI 10.1002/cne.902970304; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; TOYAMA K, 1981, J NEUROPHYSIOL, V46, P191, DOI 10.1152/jn.1981.46.2.191; TSO DY, 1986, J NEUROSCI, V6, P1160; Vaadia E, 1992, INFORMATION PROCESSI, P81	24	603	613	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					515	518		10.1038/373515a0	http://dx.doi.org/10.1038/373515a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845462				2022-12-24	WOS:A1995QF72400057
J	GORE, SM; BIRD, AG; BURNS, SM; GOLDBERG, DJ; ROSS, AJ; MACGREGOR, J				GORE, SM; BIRD, AG; BURNS, SM; GOLDBERG, DJ; ROSS, AJ; MACGREGOR, J			DRUG INJECTION AND HIV PREVALENCE IN INMATES OF GLENOCHIL PRISON	BRITISH MEDICAL JOURNAL			English	Article							SAUGHTON-PRISON; SURVEILLANCE; EDINBURGH; JAIL	Objective-To determine prevalence of HIV infection and drug injecting behaviour among inmates of Glenochil Prison on a specified date a year after an outbreak of hepatitis B and HIV infection. Design-Cross sectional: voluntary, anonymous HIV salivary antibody surveillance and Linked self completion questionnaire on risk factors. Setting-Glenochil prison, Scotland, a year after an outbreak of hepatitis B and HIV transmission related to drug injection. Subjects-352 prisoners, of whom 295 (84%) took part; 284 questionnaires (96%) passed logical checks. Main outcome measures-HIV prevalence; proportion of all inmates who had ever injected drugs, had ever injected inside prison, had started injecting drugs while inside prison. Results-More than half (150/284) the current inmates were also in Glenochil Prison during the critical period of January to June 1993, when hepatitis B and HIV were transmitted. Similar proportions of current inmates and men who were also in Glenochil during the critical period were drug users (27% (75/278) v 30% (44/149)). A quarter of injecting drug users (18/72) had first injected inside prison, irrespective of whether they were in Glenochil in January to June 1993 and regardless of the calendar period when they first injected. Significantly more inmates from Glasgow (41%; 56/138) than from Edinburgh (21%; 7/34) or elsewhere (11%; 12/106) were injecting drug users. On testing for HIV, seven saliva samples out of 293 gave positive results-four were presumed to be from inmates known to be infected with HIV, and the others from injecting drug users from Glasgow, all of whom had been in Glenochil during January to June 1993, when two of the three had injected drugs and had been tested for HIV, with negative results. The ratio of overall (2.4%) to disclosed (1.4%) HIV prevalence was 1.7. For men who had injected drugs in Glenochil during January to June 1993, HIV prevalence was estimated at 29%. Conclusion-Between a quarter and a third of prisoners who injected drugs in Glenochil in January to June 1993 were infected with HIV. There is widespread ongoing risk of bloodborne virus infection within prisons, which is probably long standing but demands urgent attention.	CHURCHILL HOSP,DEPT IMMUNOL,OXFORD OX3 7LJ,ENGLAND; CITY HOSP EDINBURGH,REG VIRUS LAB,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND; CTR HIV RES,MRC,BIOSTAT INITIAT AIDS & HIV SCOTLAND,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND; HM PRISON & YOUNG OFFENDERS INST,ALLOA FK10 3AD,CLACK,SCOTLAND	University of Oxford	GORE, SM (corresponding author), INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							BIRD AG, 1993, AIDS, V7, P1277, DOI 10.1097/00002030-199309000-00025; BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; CARRELL S, 1994, SCOTSMAN        0808, P2; CHRISTIE B, 1993, BRIT MED J, V307, P151; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GORE SM, IN PRESS DEATHS CUST, V2; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289	9	84	88	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					293	296		10.1136/bmj.310.6975.293	http://dx.doi.org/10.1136/bmj.310.6975.293			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF717	7866170	Green Published			2022-12-24	WOS:A1995QF71700024
J	GUPTA, R; GUPTA, VP; AHLUWALIA, NS				GUPTA, R; GUPTA, VP; AHLUWALIA, NS			EDUCATIONAL STATUS, CORONARY HEART-DISEASE, AND CORONARY RISK FACTOR PREVALENCE IN A RURAL-POPULATION OF INDIA	BRITISH MEDICAL JOURNAL			English	Article							ASSOCIATION; MORTALITY; LEVEL; MEN	Objective-To define the association between educational level and prevalence of coronary heart disease and coronary risk factors in India. Design-Total community cross sectional survey with a doctor administered questionnaire, physical examination, and electrocardiography. Setting-A cluster of three villages in rural Rajasthan, western India. Subjects-3148 residents aged over 20 (1982 men, 1166 women) divided into various groups according to years of formal schooling. Results-Illiteracy and low educational levels were associated with less prestigious occupations (agricultural and farm labouring) and inferior housing. There was an inverse correlation of educational level with age (rank correlation: men -0.45, women -0.49). The prevalence of coronary heart disease (diagnosed by electrocardiography) was significantly higher among uneducated and less educated people and showed an inverse relation with education in both sexes. Among uneducated and less educated people there was a higher prevalence of the coronary risk factors smoking and hypertension. Educational level showed a significant inverse correlation with systolic and diastolic blood pressure. Logistic regression analysis with adjustment for age showed that educational level had an inverse relation with prevalence of electrocardiographically diagnosed coronary heart disease (odds ratio: men 0.82, women 0.53), hypertension (men 0.88, women 0.56), and smoking (men 0.73, women 0.65) but not with hypercholesterolaemia and obesity. The inverse relation of coronary heart disease with educational level abated after adjustment for smoking, physical activity, body mass index, and blood pressure (odds ratio: men 0.98, women 0.78). Conclusion-Uneducated and less educated people in rural India have a higher prevalence of coronary heart disease and of the coronary risk factors smoking and hypertension.	UNIV RAJASTHAN,DEPT STAT,JAIPUR 302004,RAJASTHAN,INDIA	University of Rajasthan	GUPTA, R (corresponding author), MONILEK HOSP & RES CTR,DEPT MED,JAWAHAR NAGAR,JAIPUR 302004,RAJASTHAN,INDIA.							ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; CHADHA SL, 1990, INDIAN J MED RES-B, V92, P424; Dewan B D, 1974, Indian Heart J, V26, P68; Gupta R, 1994, J Assoc Physicians India, V42, P24; Gupta S P, 1975, J Assoc Physicians India, V23, P885; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; JACOBSEN BK, 1988, AM J EPIDEMIOL, V127, P923, DOI 10.1093/oxfordjournals.aje.a114895; Jajoo U N, 1988, J Assoc Physicians India, V36, P689; Joshi P P, 1993, J Assoc Physicians India, V41, P579; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; Rose G, 1982, CARDIOVASCULAR SURVE; SARVOTHAM SG, 1968, CIRCULATION, V37, P839; 1993, ARCH INTERN MED, V153, P154; 1993, STATUS HLTH RAJASTHA, P3; 1989, STRONG HEART STUDY M; 1992, J CLIN EPIDEMIOL, V45, P841	21	126	129	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1332	1336		10.1136/bmj.309.6965.1332	http://dx.doi.org/10.1136/bmj.309.6965.1332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866081	Green Published			2022-12-24	WOS:A1994PT62500020
J	OGRADY, J; STEWART, S; ELTON, RA; KRAJEWSKI, AS				OGRADY, J; STEWART, S; ELTON, RA; KRAJEWSKI, AS			EPSTEIN-BARR-VIRUS IN HODGKINS-DISEASE AND SITE OF ORIGIN OF TUMOR	LANCET			English	Note							PERSISTENCE; CELLS	Epstein-Barr virus (EBV) may be involved in the pathogenesis of Hodgkin's disease. We investigated whether EBV in Hodgkin's disease is related to the site of origin of the tumour. In 40 patients with stage I disease, there was a significant association between EBV latent membrane protein (LMP-1) expression and presentation in neck lymph nodes. There was no association in stage II-IV disease (57 cases). Nodular sclerosing subtype was rarely associated with LMP-1 expression. In some cases of Hodgkin's disease of mixed cellularity or lymphocyte predominant subtype originating in the neck, EBV may be an important aetiological co-factor.	UNIV EDINBURGH,MED STAT UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	OGRADY, J (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ALLDAY MJ, 1988, LANCET, V1, P855; ARMSTRONG AA, 1992, LEUKEMIA, V6, P869; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; CHAN MKM, 1989, ACTA CYTOL, V33, P351; COATES PJ, 1991, J PATHOL, V164, P291, DOI 10.1002/path.1711640404; HO SC, 1990, HAEMATOL ONCOL, V8, P271; ISAACSON PG, 1992, J PATHOL, V2, P267; JARRETT RF, 1991, J CLIN PATHOL, V44, P844, DOI 10.1136/jcp.44.10.844; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107	10	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					265	266		10.1016/S0140-6736(94)91114-2	http://dx.doi.org/10.1016/S0140-6736(94)91114-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905098				2022-12-24	WOS:A1994MT44000012
J	SOLOMON, T; FELIX, JM; SAMUEL, M; DENGO, GA; SALDANHA, RA; SCHAPIRA, A; PHILLIPS, RE				SOLOMON, T; FELIX, JM; SAMUEL, M; DENGO, GA; SALDANHA, RA; SCHAPIRA, A; PHILLIPS, RE			HYPOGLYCEMIA IN PEDIATRIC ADMISSIONS IN MOZAMBIQUE	LANCET			English	Note							SEVERE FALCIPARUM-MALARIA; HYPOGLYCEMIA; CHILDREN; CHILDHOOD	We studied the incidence and clinical associations of hypoglycaemia in an acute medical paediatric service in Maputo, Mozambique. Of 603 children, 43 (7.1%) were hypoglycaemic. 16 of these with Plasmodium falciparum malaria had a shorter illness, and a higher incidence of convulsions and focal neurological signs than those with other diagnoses, but were less likely to die. Hypoglycaemia also complicated protein energy malnutrition, pneumonia, encephalitis, intestinal parasite infection, and nephrotic syndrome. 25 of the 603 children died: 7 (16.3%) of 43 with hypoglycaemia and 18 (3.2%) of 560 who were normoglycaemic, (relative risk of death 5.8 [95% confidence interval 2.25 to 14.93]). Hypoglycaemia is common in children in hospital in Mozambique, and should be suspected in any acutely-ill child regardless of the primary disease.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; UNIV EDUARDO MONDLANE,FAC MED,MAPUTO,MOZAMBIQUE; HOSP CENT MAPUTO,MAPUTO,MOZAMBIQUE; UNIV OXFORD,DEPT STAT,OXFORD,ENGLAND	University of Oxford; Eduardo Mondlane University; University of Oxford			Schapira, Allan/AAZ-8116-2020	Solomon, Tom/0000-0001-7266-6547; Saldanha, Richard/0000-0002-4137-3917	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNISH ML, 1990, NEW ENGL J MED, V322, P1357, DOI 10.1056/NEJM199005103221905; FILKINS JP, 1974, AM J PHYSIOL, V227, P778, DOI 10.1152/ajplegacy.1974.227.4.778; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; MOLYNEUX ME, 1989, AM J TROP MED HYG, V40, P470, DOI 10.4269/ajtmh.1989.40.470; PAGLIARA AS, 1973, J PEDIATR-US, V82, P558, DOI 10.1016/S0022-3476(73)80581-5; PAGLIARA AS, 1973, J PEDIATR-US, V82, P365, DOI 10.1016/S0022-3476(73)80109-X; TAYLOR TE, 1988, NEW ENGL J MED, V319, P1040, DOI 10.1056/NEJM198810203191602; WHARTON B, 1970, LANCET, V1, P171; WHITE NJ, 1987, LANCET, V1, P708; 1990, T R SOC TROP MED H S, P1; 1972, LANCET, V2, P143	11	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					149	150		10.1016/S0140-6736(94)90937-7	http://dx.doi.org/10.1016/S0140-6736(94)90937-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904007				2022-12-24	WOS:A1994MQ86900013
J	EPSTEIN, PR; FORD, TE; COLWELL, RR				EPSTEIN, PR; FORD, TE; COLWELL, RR			MARINE ECOSYSTEMS	LANCET			English	Article							TEMPERATURE; CHOLERA; WATER		HARVARD UNIV,DEPT ENVIRONM BIOL,CAMBRIDGE,MA 02138; UNIV MARYLAND,INST BIOTECHNOL,COLL PK,MD 20742	Harvard University; University System of Maryland; University of Maryland College Park	EPSTEIN, PR (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DIV SOCIAL & COMMUNITY MED,CAMBRIDGE,MA 02139, USA.			Ford, Timothy/0000-0001-5194-5459				[Anonymous], TOXIC PHYTOPLANKTON; BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; BYRD JJ, 1991, APPL ENVIRON MICROB, V57, P875, DOI 10.1128/AEM.57.3.875-878.1991; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Glantz M.H., 1991, TELECONNECTIONS LINK; Hayes R.L., 1991, WORLD RES REV, V3, P306; Houghton J.T., 1990, CLIMATE CHANGE IPCC; HUQ A, 1984, APPL ENVIRON MICROB, V48, P420, DOI 10.1128/AEM.48.2.420-424.1984; ISLAM S, 1990, J TROP MED HYG, V93, P133; MACKENZIE D, 1988, NEW SCI         0128, P30; MANABE S, 1993, NATURE, V364, P215, DOI 10.1038/364215a0; MEEHL GA, 1993, SCIENCE, V260, P1101, DOI 10.1126/science.260.5111.1101; SAMADI AR, 1983, T ROY SOC TROP MED H, V77, P853, DOI 10.1016/0035-9203(83)90306-1; SHERMAN L, 1993, LARGE MARINE ECOSYST, P301; SWERDLOW DL, 1992, LANCET, V340, P28, DOI 10.1016/0140-6736(92)92432-F; Valiela I., 1984, MARINE ECOLOGICAL PR, DOI 10.1007/978-1-4757-4125-4; YAN XH, 1992, SCIENCE, V258, P1643, DOI 10.1126/science.258.5088.1643	17	74	74	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1216	1219		10.1016/0140-6736(93)92191-U	http://dx.doi.org/10.1016/0140-6736(93)92191-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901535				2022-12-24	WOS:A1993MG27400015
J	MOL, CD; KUO, CF; THAYER, MM; CUNNINGHAM, RP; TAINER, JA				MOL, CD; KUO, CF; THAYER, MM; CUNNINGHAM, RP; TAINER, JA			STRUCTURE AND FUNCTION OF THE MULTIFUNCTIONAL DNA-REPAIR ENZYME EXONUCLEASE-III	NATURE			English	Article							ESCHERICHIA-COLI; RESOLUTION; SEQUENCE; CDNA; REFINEMENT; HOMOLOGY; COMPLEX	THE repair of DNA requires the removal of abasic sites, which are constantly generated in vivo both spontaneously(1) and by enzymatic removal of uracil(2), and of bases damaged by active oxygen species, alkylating agents and ionizing radiation The major apurinic/apyrimidinic (AP) DNA-repair endonuclease in Escherichia coli is the multifunctional enzyme exonuclease In, which also exhibits 3'-repair diesterase, 3'-->5' exonuclease, 3'-phosphomonoesterase and ribonuclease activities(5). We report here the 1.7 Angstrom resolution crystal structure of exonuclease III which reveals a 2-fold symmetric, four-layered ap fold,vith similarities to both deoxyribonuclease I-6 and RNase H-7. In the ternary complex determined at 2.6 Angstrom resolution, Mn2+ and dCMP bind to exonuclease III at one end of the alpha beta-sandwich, in a region dominated by positive electrostatic potential. Residues conserved among AP endonucleases from bacteria to man cluster within this active site and appear to participate in phosphate-bond cleavage at AP sites through a nucleophilic attack facilitated by a single bound metal ion.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SUNY ALBANY, CTR BIOCHEM & BIOPHYS, DEPT BIOL SCI, ALBANY, NY 12222 USA	Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KAYANA S, 1991, EUR J BIOCHEM, V198, P437; KUO CF, 1993, J MOL BIOL, V229, P239, DOI 10.1006/jmbi.1993.1021; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SAPORITO SM, 1988, J BACTERIOL, V170, P4542, DOI 10.1128/jb.170.10.4542-4547.1988; SEKI S, 1991, J BIOL CHEM, V266, P20797; TAYLOR AF, 1982, J BACTERIOL, V151, P351, DOI 10.1128/JB.151.1.351-357.1982; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V	24	338	363	1	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					381	386		10.1038/374381a0	http://dx.doi.org/10.1038/374381a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885481				2022-12-24	WOS:A1995QN63000066
J	DESSEN, A; QUEMARD, A; BLANCHARD, JS; JACOBS, WR; SACCHETTINI, JC				DESSEN, A; QUEMARD, A; BLANCHARD, JS; JACOBS, WR; SACCHETTINI, JC			CRYSTAL-STRUCTURE AND FUNCTION OF THE ISONIAZID TARGET OF MYCOBACTERIUM-TUBERCULOSIS	SCIENCE			English	Article							CATALASE-PEROXIDASE GENE; MYCOLIC ACID SYNTHESIS; RESISTANT STRAINS; SEQUENCES	Resistance to isoniazid in Mycobacterium tuberculosis can be mediated by substitution of alanine for serine 94 in the InhA protein, the drug's primary target. InhA was shown to catalyze the beta-nicotinamide adenine dinucleotide (NADH)-specific reduction of 2-trans-enoyl-acyl carrier protein, an essential step in fatty acid elongation. Kinetic analyses suggested that isoniazid resistance is due to a decreased affinity of the mutant protein for NADH. The three-dimensional structures of wild-type and mutant InhA, refined to 2.2 and 2.7 angstroms, respectively, revealed that drug resistance is directly related to a perturbation in the hydrogen-bonding network that stabilizes NADH binding.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine				Dessen, Andrea/0000-0001-6487-4020; Jacobs, William/0000-0003-3321-3080; Quemard, Annaik/0000-0002-5545-3424	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030189, R01AI033696, U01AI036849] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30189, AI33696, AI36849] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; HOWARD AJ, 1986, GUIDE DATA REDUCTION; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MCREE DE, 1993, PRACTICAL PROTEIN CR, P303; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; QUEMARD A, UNPUB; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SLABAS AR, 1986, BIOCHIM BIOPHYS ACTA, V877, P271, DOI 10.1016/0005-2760(86)90304-8; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TRONRUD DE, 1988, ACTA CRYSTALLOGR A, V43, P489; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Winder F, 1982, BIOL MYCOBACTERIA, V1, P354; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	27	380	397	2	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1638	1641		10.1126/science.7886450	http://dx.doi.org/10.1126/science.7886450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886450				2022-12-24	WOS:A1995QM39700034
J	MRAK, RE				MRAK, RE			TRIPOLAR MITOTIC FIGURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MRAK, RE (corresponding author), VET AFFAIRS MED CTR,LITTLE ROCK,AR 72205, USA.								0	2	2	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					718	718		10.1056/NEJM199503163321105	http://dx.doi.org/10.1056/NEJM199503163321105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854379				2022-12-24	WOS:A1995QL78800005
J	SZATHMARY, E; SMITH, JM				SZATHMARY, E; SMITH, JM			THE MAJOR EVOLUTIONARY TRANSITIONS	NATURE			English	Review							NATURAL-SELECTION; ORIGIN; CHROMOSOMES; MECHANISMS; TEMPLATES; MODELS; GROWTH; CELLS; LIFE	There is no theoretical reason to expect evolutionary lineages to increase in complexity with time, and no empirical evidence that they do so. Nevertheless, eukaryotic cells are more complex than prokaryotic ones, animals and plants are more complex than protists, and so on. This increase in complexity may have been achieved as a result of a series of major evolutionary transitions. These involved changes in the way information is stored and transmitted.	EOTVOS LORAND UNIV, DEPT PLANT TAXON & ECOL, ECOL MODELLING RES GRP, H-1083 BUDAPEST, HUNGARY; UNIV SUSSEX, SCH BIOL SCI, BRIGHTON BN1 9QG, E SUSSEX, ENGLAND	Eotvos Lorand University; University of Sussex	SZATHMARY, E (corresponding author), COLLEGIUM BUDAPEST, INST ADV STUDY, SZENTHAROMSAG U2, H-1014 BUDAPEST, HUNGARY.		Szathmáry, Eörs/A-5007-2011; Szathmary, Eors/AAS-1202-2021	Szathmary, Eors/0000-0001-5227-2997				BACHMANN PA, 1992, NATURE, V357, P57, DOI 10.1038/357057a0; Bell G., 1985, ORIGIN EVOLUTION SEX, P221; BENNER SA, 1987, COLD SPRING HARB SYM, V52, P53, DOI 10.1101/SQB.1987.052.01.009; Bickerton Derek, 1990, LANGUAGE SPECIES; Bonner JT., 1988, EVOLUTION COMPLEXITY; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI 10.1515/9781400858712; CAIRNS-SMITH A G, 1974, Biosystems, V5, P173, DOI 10.1016/0303-2647(74)90030-6; Cavalier-Smith T, 1985, EVOLUTION GENOME SIZ; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CHAMOV E, 1976, NATURE, V263, P125; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; CROW JF, 1991, BIOESSAYS, V13, P305, DOI 10.1002/bies.950130609; Dawkins R, 1976, SELFISH GENE; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; FAMULOK M, IN PRESS J AM CHEM S; Ganti T., 1979, THEORY BIOCH SUPERSY; Ganti T, 1975, BIOSYSTEMS, V7, P189, DOI [10.1016/0303-2647(75)90057-X, DOI 10.1016/0303-2647(75)90057-X]; Ganti T., 1987, PRINCIPLE LIFE; GOPNIK M, 1990, NATURE, V344, P715, DOI 10.1038/344715a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hinton G. E., 1987, Complex Systems, V1, P495; HURST LD, 1992, P ROY SOC B-BIOL SCI, V247, P189, DOI 10.1098/rspb.1992.0027; HURST LD, 1992, P ROY SOC B-BIOL SCI, V248, P135, DOI 10.1098/rspb.1992.0053; HUTSON V, 1993, P ROY SOC LOND B BIO, V283, P43; JABLONKA E, 1994, J THEOR BIOL, V170, P301, DOI 10.1006/jtbi.1994.1191; JABLONKA ELM, 1995, EPIGENETIC INHERITAN; JEON KW, 1991, SYMBIOSIS SOURCE EVO, P118; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; KACSER H, 1984, J MOL EVOL, V20, P38, DOI 10.1007/BF02101984; KING GAM, 1980, BIOSYSTEMS, V13, P23, DOI 10.1016/0303-2647(80)90003-9; KIRK DL, 1988, TRENDS GENET, V4, P32, DOI 10.1016/0168-9525(88)90063-7; KOCH AL, 1985, J MOL EVOL, V21, P270, DOI 10.1007/BF02102359; KOUFOPANOU V, 1994, AM NAT, V143, P907, DOI 10.1086/285639; LAZCANO A, 1988, J MOL EVOL, V27, P283, DOI 10.1007/BF02101189; Leigh E.G., 1971, ADAPTATION DIVERSITY; LEIGH EG, 1991, TRENDS ECOL EVOL, V6, P257, DOI 10.1016/0169-5347(91)90073-7; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Margulis L., 1993, SYMBIOSIS CELL EVOLU; Maynard Smith J., 1978, EVOLUTION SEX; MOLNAR I, 1993, ABSTR BOT, V17, P207; PINKER S, 1990, BEHAV BRAIN SCI, V13, P707, DOI 10.1017/S0140525X00081061; Pinker S, 1994, LANGUAGE INSTINCT NE; PRUDENT JR, 1994, SCIENCE, V264, P1924; Rasbach H., 1979, BER BAYER BOT GES, V50, P23; RENSCH B, 1966, EVOLUTION SPECIES LE; SMITH A, 1777, WEALTH NATIONS; Smith J. M., 1995, MAJOR TRANSITIONS EV; SMITH JM, 1983, PROC R SOC SER B-BIO, V219, P315, DOI 10.1098/rspb.1983.0076; SMITH JM, 1993, J THEOR BIOL, V164, P437, DOI 10.1006/jtbi.1993.1165; SZATHMARY E, 1989, J THEOR BIOL, V138, P55, DOI 10.1016/S0022-5193(89)80177-8; SZATHMARY E, 1990, NATURE, V344, P115, DOI 10.1038/344115a0; SZATHMARY E, 1993, P NATL ACAD SCI USA, V90, P9916, DOI 10.1073/pnas.90.21.9916; SZATHMARY E, 1987, J THEOR BIOL, V128, P463, DOI 10.1016/S0022-5193(87)80191-1; SZATHMARY E, 1991, TRENDS ECOL EVOL, V6, P366, DOI 10.1016/0169-5347(91)90228-P; SZATHMARY E, 1989, TRENDS ECOL EVOL, V4, P200, DOI 10.1016/0169-5347(89)90073-6; SZATHMARY E, 1993, J THEOR BIOL, V164, P447, DOI 10.1006/jtbi.1993.1166; Szathmary E., 1989, Oxford Surveys in Evolutionary Biology, V6, P169; SZATHMARY E, 1994, J THEOR BIOL, V169, P125, DOI 10.1006/jtbi.1994.1134; TARUMI K, 1987, B MATH BIOL, V49, P307, DOI 10.1016/S0092-8240(87)80026-5; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113; VONKLEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P923; WACHTERSHAUSER G, 1994, P NATL ACAD SCI USA, V91, P4283, DOI 10.1073/pnas.91.10.4283; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Williams G. C., 1966, P307; WILSON DS, 1989, J THEOR BIOL, V136, P337, DOI 10.1016/S0022-5193(89)80169-9; Wilson E.O., 1975, P1; WOLPERT L, 1990, BIOL J LINN SOC, V39, P109, DOI 10.1111/j.1095-8312.1990.tb00506.x; YCAS M, 1955, P NATL ACAD SCI USA, V41, P714, DOI 10.1073/pnas.41.10.714	72	646	660	3	209	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	1995	374	6519					227	232		10.1038/374227a0	http://dx.doi.org/10.1038/374227a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885442				2022-12-24	WOS:A1995QM38700040
J	PAN, DJ; RUBIN, GM				PAN, DJ; RUBIN, GM			CAMP-DEPENDENT PROTEIN-KINASE AND HEDGEHOG ACT ANTAGONISTICALLY IN REGULATING DECAPENTAPLEGIC TRANSCRIPTION IN DROSOPHILA IMAGINAL DISKS	CELL			English	Article							POLARITY GENE HEDGEHOG; EXPRESSION; WINGLESS; DISKS; COMPARTMENTS; DIRECTS; CELLS; EYE	Localized expression of decapentaplegic (dpp) is required for proper development of the Drosophila imaginal discs. Using genetic mosaics, we show that in the anterior compartment of appendage discs and anterior to the morphogenetic furrow in the eye disc, cells that lack cAMP-dependent protein kinase (PKA) activity ectopically express dpp. Pka(-) cells can influence the fate of neighboring cells to reorganize anterior patterns in appendages and trigger ectopic morphogenetic furrows in the developing retina. This organizing activity of Pka mutant cells depends on dpp activity. Our findings suggest that PKA is a component of a signaling pathway that represses dpp expression and that hh antagonizes this pathway to maintain dpp expression at the anterior-posterior compartment border and in the morphogenetic furrow.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BROWN NL, 1991, DEVELOPMENT, V113, P1245; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223	38	222	225	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					543	552		10.1016/0092-8674(95)90508-1	http://dx.doi.org/10.1016/0092-8674(95)90508-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867062	Bronze			2022-12-24	WOS:A1995QJ60200006
J	DEBELLO, WM; OCONNOR, V; DRESBACH, T; WHITEHEART, SW; WANG, SSH; SCHWEIZER, FE; BETZ, H; ROTHMAN, JE; AUGUSTINE, GJ				DEBELLO, WM; OCONNOR, V; DRESBACH, T; WHITEHEART, SW; WANG, SSH; SCHWEIZER, FE; BETZ, H; ROTHMAN, JE; AUGUSTINE, GJ			SNAP-MEDIATED PROTEIN-PROTEIN INTERACTIONS ESSENTIAL FOR NEUROTRANSMITTER RELEASE	NATURE			English	Article							SQUID GIANT SYNAPSE; MEMBRANE-FUSION; CALCIUM; TRANSPORT; SYNAPTOTAGMIN; POTENTIATION; DOCKING; FAMILY; YEAST	The constitutive fusion of transport vesicles with intracellular membranes requires soluble proteins called SNAPs(1). Certain presynaptic proteins(2-4) implicated in synaptic vesicle exocytosis(5) also bind SNAPs, suggesting that SNAPs participate in the calcium-regulated membrane fusion events mediating neurotransmitter release(6,7). Here we show that injection of recombinant SNAPs into the giant synapse of squid enhances transmitter release. Conversely, injection of peptides designed to mimic the sites at which SNAP interacts with its binding partners inhibits transmitter release downstream of synaptic vesicle docking. A SNAP-dependent protein complex must therefore mediate transmitter release, showing that transmitter release shares a common molecular mechanism with constitutive membrane fusion.	MARINE BIOL LAB,WOODS HOLE,MA 02543; MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,D-60528 FRANKFURT,GERMANY; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Marine Biological Laboratory - Woods Hole; Max Planck Society; Memorial Sloan Kettering Cancer Center	DEBELLO, WM (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710, USA.		Augustine, George James/J-9228-2013	Whiteheart, Sidney/0000-0001-5577-0473				ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; Katz B., 1969, RELEASE NEURAL TRANS; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; OCONNOR V, 1994, CELL, V75, P785; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V363, P318; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; SUDHOF TC, 1993, CELL, V75, P1; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	30	142	146	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					626	630		10.1038/373626a0	http://dx.doi.org/10.1038/373626a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854421				2022-12-24	WOS:A1995QG99700058
J	SHANN, F				SHANN, F			ANTIPYRETICS IN SEVERE SEPSIS	LANCET			English	Editorial Material							ASPIRIN; INFECTION; RABBITS				SHANN, F (corresponding author), ROYAL CHILDRENS HOSP,INTENS CARE UNIT,MELBOURNE,VIC,AUSTRALIA.		Shann, Frank/C-9510-2011					ADAM D, 1994, EUR J PEDIATR, V153, P394; Busser FJM, 1978, J VET PHARMACOL THER, V1, P69; ESPOSITO AL, 1984, AM REV RESPIR DIS, V130, P857; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; HSIA J, 1989, B NEW YORK ACAD MED, V65, P45; HUSSEINI RH, 1982, J INFECT DIS, V145, P520, DOI 10.1093/infdis/145.4.520; KUROSAWA S, 1987, J INFECT DIS, V155, P991, DOI 10.1093/infdis/155.5.991; MOGABGAB WJ, 1976, JAMA-J AM MED ASSOC, V235, P801, DOI 10.1001/jama.1976.03260340011003; STANLEY ED, 1975, JAMA-J AM MED ASSOC, V231, P1248, DOI 10.1001/jama.231.12.1248; VAUGHN LK, 1980, BRAIN RES BULL, V5, P69, DOI 10.1016/0361-9230(80)90285-3; VAUGHN LK, 1977, FED PROC, V36, P511; 1993, WHOARI9330	12	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					338	338		10.1016/S0140-6736(95)90337-2	http://dx.doi.org/10.1016/S0140-6736(95)90337-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845113				2022-12-24	WOS:A1995QF72200005
J	SELDIN, DC; LEDER, P				SELDIN, DC; LEDER, P			CASEIN KINASE II-ALPHA TRANSGENE-INDUCED MURINE LYMPHOMA - RELATION TO THEILERIOSIS IN CATTLE	SCIENCE			English	Article							INTRACELLULAR PROTOZOAN PARASITE; C-MYC GENE; E-MU-MYC; V-RAF; MICE BEARING; B-CELLS; N-MYC; TUMORS; TRANSFORMATION; PARVA	Infection of cattle with the protozoan parasite Theileria parva results in a fatal lymphoproliferative syndrome that is associated with the overexpression of casein kinase II. The role of this enzyme in the pathogenesis of lymphoproliferative disorders was investigated by expressing the catalytic subunit in lymphocytes of transgenic mice. Adult transgenic mice displayed a stochastic propensity to develop lymphoma; co-expression of a c-myc transgene in addition to casein kinase II resulted in neonatal leukemia. Thus, the casein kinase II gene can serve as an oncogene, and its dysregulated expression is capable of transforming lymphocytes in a two-step pathway with c-myc.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Seldin, David C/0000-0003-0168-2333	NHLBI NIH HHS [1-K08-HL0286-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; FRIEDRICH TD, 1989, BIOCHIM BIOPHYS ACTA, V992, P41, DOI 10.1016/0304-4165(89)90048-2; JOHANSSON M, 1993, BRIT J CANCER, V67, P1236, DOI 10.1038/bjc.1993.231; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KURIE JM, 1990, ONCOGENE, V5, P577; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Mertens F., 1991, CATALOG CHROMOSOME A; MOROY T, 1991, ONCOGENE, V6, P1941; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OLEMOIYOI OK, 1989, ANN NY ACAD SCI, V569, P174, DOI 10.1111/j.1749-6632.1989.tb27367.x; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; OLEMOIYOI OK, 1989, EXP PARASITOL, V69, P204, DOI 10.1016/0014-4894(89)90067-2; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WIRKNER U, 1994, GENOMICS, V19, P257, DOI 10.1006/geno.1994.1056; YANGFENG TL, 1990, GENOMICS, V8, P741, DOI 10.1016/0888-7543(90)90266-W; YANGFENG TL, 1994, GENOMICS, V19, P173, DOI 10.1006/geno.1994.1032	32	353	372	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					894	897		10.1126/science.7846532	http://dx.doi.org/10.1126/science.7846532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846532				2022-12-24	WOS:A1995QG20700061
J	BAIRD, RN				BAIRD, RN			CONTROVERSIES IN MANAGEMENT - SHOULD CAROTID ENDARTERECTOMY BE PURCHASED - TREATMENT AVOIDS MUCH MORBIDITY .19.	BRITISH MEDICAL JOURNAL			English	Article														Lambert, Mark/0000-0003-3528-9070				BAMFORD J, SEMINAR DISTRICT STR; BARNETT HJM, 1990, STROKE, V21, P2; BEEBE HG, 1989, STROKE, V20, P314; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; MAGEE TR, 1992, ANN ROY COLL SURG, V74, P430; MURIE JA, 1994, BRIT J SURG, V81, P827, DOI 10.1002/bjs.1800810612; PEARCE JMS, 1978, BRIT MED J, V1, P969, DOI 10.1136/bmj.1.6118.969; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; 1991, LANCET, V337, P1235; 1991, NEW ENGL J MED, V325, P445	10	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					316	317		10.1136/bmj.310.6975.316	http://dx.doi.org/10.1136/bmj.310.6975.316			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866177	Green Published			2022-12-24	WOS:A1995QF71700040
J	BLADIN, CF; ALEXANDROV, AV; SMURAWSKA, LT				BLADIN, CF; ALEXANDROV, AV; SMURAWSKA, LT			SHOULD PATIENTS WITH STROKE SEE A NEUROLOGIST	LANCET			English	Editorial Material											BLADIN, CF (corresponding author), UNIV TORONTO,STROKE RES UNIT,TORONTO M5S 1A1,ONTARIO,CANADA.		bladin, chris/B-9136-2013	Alexandrov, Andrei V/0000-0001-8871-1023				ASPLUND K, 1993, CEREBROVASC DIS, V3, P34, DOI 10.1159/000108747; HEWER RL, 1992, J NEUROL NEUROSUR PS, V55, P8; ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; NORRIS JW, 1982, LANCET, V1, P328; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; 1991, LANCET, V337, P1235; 1993, GUIDELINES CARE PATI; 1993, LANCET, V342, P1255; 1991, NEW ENGL J MED, V325, P445	10	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					69	70		10.1016/S0140-6736(94)90811-7	http://dx.doi.org/10.1016/S0140-6736(94)90811-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903774				2022-12-24	WOS:A1994MQ09200006
J	MCPHERSON, MA; DORMER, RL				MCPHERSON, MA; DORMER, RL			CYSTIC-FIBROSIS GENE AND MUCIN SECRETION	LANCET			English	Editorial Material							CELLS; CFTR				MCPHERSON, MA (corresponding author), UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES.							BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; DRUMM ML, 1993, PEDIATR PULMONOL, V250; KUVER R, 1993, PEDIATR PULMONOL S9, V254; MCPHERSON MA, 1986, LANCET, V2, P1007; MILLS CL, 1992, BIOCHEM BIOPH RES CO, V188, P1146, DOI 10.1016/0006-291X(92)91351-P; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; TSENG HC, 1993, 7TH ANN N AM CF C DA	7	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					7	7		10.1016/S0140-6736(94)90872-9	http://dx.doi.org/10.1016/S0140-6736(94)90872-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905085				2022-12-24	WOS:A1994MN93700008
J	WEBB, DJ; HAYNES, WG				WEBB, DJ; HAYNES, WG			ENDOTHELINS COME OF AGE	LANCET			English	Editorial Material							RECEPTOR; CLONING				WEBB, DJ (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.		Haynes, William G/D-5374-2013	Haynes, William G/0000-0003-1004-6136				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BENIGNI A, 1993, KIDNEY INT, V44, P440, DOI 10.1038/ki.1993.263; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CLOZEL M, 1993, CIRCULATION, V88, P316; HAYNES WG, 1993, CLIN SCI, V84, P485, DOI 10.1042/cs0840485; MCMAHON EG, 1991, J CARDIOVASC PHARM, V17, pS29, DOI 10.1097/00005344-199100177-00009; NISHIKIBE M, 1993, LIFE SCI, V52, P717, DOI 10.1016/0024-3205(93)90233-S; ROUX SP, 1993, CIRCULATION, V88, P170; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	10	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1439	1440		10.1016/0140-6736(93)92928-M	http://dx.doi.org/10.1016/0140-6736(93)92928-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902478				2022-12-24	WOS:A1993ML21700004
J	BERNHARD, JD				BERNHARD, JD			BRINGING ON THE BACON FOR MYIASIS	LANCET			English	Editorial Material											BERNHARD, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA 01605, USA.							BREWER TF, 1993, JAMA-J AM MED ASSOC, V270, P2087, DOI 10.1001/jama.270.17.2087; CANIZARES O, 1992, CLIN TROPICAL DERMAT, P404; JAMES AS, 1992, ARCH EMERG MED, V9, P58; LYELL A, 1983, J AM ACAD DERMATOL, P895; PAMPIGLIONE S, 1992, BRIT J DERMATOL, V126, P418, DOI 10.1111/j.1365-2133.1992.tb00698.x; SANUSI ID, 1989, J AM ACAD DERMATOL, V20, P941, DOI 10.1016/S0190-9622(89)70115-8	6	9	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1377	1378						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901678				2022-12-24	WOS:A1993MK09500006
J	MAHMOUD, HH; HURWITZ, CA; ROBERTS, WM; SANTANA, VM; RIBEIRO, RC; KRANCE, RA				MAHMOUD, HH; HURWITZ, CA; ROBERTS, WM; SANTANA, VM; RIBEIRO, RC; KRANCE, RA			TRETINOIN TOXICITY IN CHILDREN WITH ACUTE PROMYELOCYTIC LEUKEMIA	LANCET			English	Note							TRANS-RETINOIC ACID; DIFFERENTIATION THERAPY; LEUKEMIA; CANCER	Tretinoin is effective in acute promyelocytic leukaemia in adults. Data about its efficacy and safety in children are limited. We have treated 9 children with tretinoin at 45 mg/m2 per day. Pseudotumour cerebri or hyperleucocytosis occurred in 5 patients. Retinoic acid syndrome was seen in 3 cases. 1 of 2 children who developed hyperleucocytosis, pseudotumour cerebri, and retinoic acid syndrome died despite steroids and mechanical ventilation. Complete remissions with tretinoin alone were achieved in 5 patients. All 8 surviving children received consolidation chemotherapy. Our experience with tretinoin therapy suggests that toxicity is frequent in children.	UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	MAHMOUD, HH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 323 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.				NATIONAL CANCER INSTITUTE [P01CA020180] Funding Source: NIH RePORTER; NCI NIH HHS [CA 20180] Funding Source: Medline; PHS HHS [21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVVISATI G, 1991, HAEMATOLOGICA S4, V76, P16; CASTAIGNE S, 1990, BLOOD, V76, P1704; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAHN MJ, 1992, J NATL CANCER I, V84, P1669, DOI 10.1093/jnci/84.21.1669; KURZROCK R, 1993, J CLIN ONCOL, V11, P1489, DOI 10.1200/JCO.1993.11.8.1489; SMITH MA, 1992, J CLIN ONCOL, V10, P1666, DOI 10.1200/JCO.1992.10.11.1666; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307	10	77	79	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1394	1395		10.1016/0140-6736(93)92755-I	http://dx.doi.org/10.1016/0140-6736(93)92755-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901684				2022-12-24	WOS:A1993MK09500012
J	KAMOGAWA, Y; MINASI, LAE; CARDING, SR; BOTTOMLY, K; FLAVELL, RA				KAMOGAWA, Y; MINASI, LAE; CARDING, SR; BOTTOMLY, K; FLAVELL, RA			THE RELATIONSHIP OF IL-4-PRODUCING AND IFN-GAMMA-PRODUCING T-CELLS STUDIED BY LINEAGE ABLATION OF IL-4-PRODUCING CELLS	CELL			English	Article							STIMULATORY FACTOR-I; SIMPLEX VIRUS TYPE-1; EXPRESSES B-CELL; MONOCLONAL-ANTIBODY; THYMIDINE KINASE; MESSENGER-RNA; TH2 CLONES; IL-4; INTERLEUKIN-4; MICE	Subsets of CD4 T cells are defined by the cytokines that they produce; these cytokines determine the effector function of these cells. Cloned CD4 T cells fall into two subsets, producing either interferon-gamma (IFNgamma) or interleukin-4 (IL-4) in combination with other cytokines, and are called Th1 and Th2 cells, respectively. The lineage relationship between naive T cells and effector Th1- and Th2-type cells is unclear. We generated transgenic mice in which IL-4-producing cells express herpes simplex virus 1 thymidine kinase and are eliminated by ganciclovir (GANC). Activation of transgenic T cells in the presence of GANC eliminates IL-4 and IFNgamma production, showing that IL-4- and IFNgamma-producing cells express or have expressed IL-4. These results show that effector cells producing either IL-4 or IFNgamma have a common precursor, which expresses the IL-4 gene.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19106; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19106	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	KAMOGAWA, Y (corresponding author), YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510, USA.			Carding, Simon/0000-0002-2383-9701				ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BETZ M, 1990, J IMMUNOL, V145, P1046; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P1; Bottomly K, 1989, Semin Immunol, V1, P21; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; CARDING SR, 1989, EUR J IMMUNOL, V19, P231, DOI 10.1002/eji.1830190203; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HENKEL G, 1992, J IMMUNOL, V149, P3239; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; JONES B, 1983, EUR J IMMUNOL, V13, P678, DOI 10.1002/eji.1830130813; KILLAR L, 1987, J IMMUNOL, V138, P1674; KIM J, 1985, J EXP MED, V162, P188, DOI 10.1084/jem.162.1.188; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LANDAIS D, 1986, J IMMUNOL, V137, P3002; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MINASI LAE, 1993, J EXP MED, V177, P1451, DOI 10.1084/jem.177.5.1451; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURRAY JS, 1989, J EXP MED, V170, P2135, DOI 10.1084/jem.170.6.2135; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OTSUKA T, 1987, NUCLEIC ACIDS RES, V15, P333, DOI 10.1093/nar/15.1.333; PLATZER C, 1992, EUR J IMMUNOL, V22, P1179, DOI 10.1002/eji.1830220511; POWERS GD, 1988, J IMMUNOL, V140, P3352; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SIDERAS P, 1988, P NATL ACAD SCI USA, V85, P218, DOI 10.1073/pnas.85.1.218; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; STOUT RD, 1989, J IMMUNOL, V142, P760; STREET NE, 1990, J IMMUNOL, V144, P1629; SUMMERS WC, 1977, J VIROL, V24, P314, DOI 10.1128/JVI.24.1.314-318.1977; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAIN SL, 1988, J IMMUNOL, V141, P3445; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TITE JP, 1985, J IMMUNOL, V135, P25; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441	48	269	273	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					985	995		10.1016/0092-8674(93)90542-X	http://dx.doi.org/10.1016/0092-8674(93)90542-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	7902780	hybrid			2022-12-24	WOS:A1993MK96600018
J	PARRY, ML; ROSENZWEIG, C				PARRY, ML; ROSENZWEIG, C			FOOD-SUPPLY AND RISK OF HUNGER	LANCET			English	Article									COLUMBIA UNIV,NEW YORK,NY 10027; GODDARD INST SPACE STUDIES,NEW YORK,NY 10025	Columbia University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	PARRY, ML (corresponding author), UNIV OXFORD,ENVIRONM CHANGE UNIT,1A MANSFIELD RD,OXFORD OX1 3TB,ENGLAND.							[Anonymous], 1992, CLIMATE CHANGE SUPPL; Peart R.M., 1989, POTENTIAL EFFECTS GL; ROSENZWEIG C, 1993, 3 ENV CHANG UN ENV C; ROSENZWEIG C, IN PRESS IMPLICATION; 1989, DECISION SUPPORT SYS	5	24	26	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1345	1347		10.1016/0140-6736(93)92251-N	http://dx.doi.org/10.1016/0140-6736(93)92251-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901640				2022-12-24	WOS:A1993MJ03900014
J	WATLING, D; GUSCHIN, D; MULLER, M; SILVENNOINEN, O; WITTHUHN, BA; QUELLE, FW; ROGERS, NC; SCHINDLER, C; STARK, GR; IHLE, JN; KERR, IM				WATLING, D; GUSCHIN, D; MULLER, M; SILVENNOINEN, O; WITTHUHN, BA; QUELLE, FW; ROGERS, NC; SCHINDLER, C; STARK, GR; IHLE, JN; KERR, IM			COMPLEMENTATION BY THE PROTEIN-TYROSINE KINASE JAK2 OF A MUTANT-CELL LINE DEFECTIVE IN THE INTERFERON-GAMMA SIGNAL-TRANSDUCTION PATHWAY	NATURE			English	Article							IFN-GAMMA; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; RECEPTOR; ANTIGEN; DOMAIN	INTERFERONS (IFNs) alpha/beta (type I) and gamma (type II) bind to distinct cell surface receptors1, inducing transcription of overlapping sets of genes by intracellular pathways that have recently attracted much attention2,3. Previous studies using cell lines selected for their inability to respond to IFN-alpha (ref. 4) have shown that the protein kinase Tyk2 plays a central role in the IFN alpha/beta response5. Here we report the isolation of the cell line gamma1A, selected for its inability to express IFN-gamma-inducible cell-surface markers, that is deficient in all aspects of the IFN-gamma response tested, but responds normally to IFNs alpha and beta. The mutant cells can be complemented by the expression of another member of the JAK family of protein tyrosine kinases, JAK2 (refs 6-9). Unlike IFNs alpha and beta, IFN-gamma induces rapid tyrosine phosphorylation of JAK2 in wild-type cells, and JAK2 immunoprecipitates from these cells show tyrosine kinase activity. These responses are absent in gamma1A cells. JAK2 is therefore required for the response to IFN-gamma but not to IFNs alpha and beta.	NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; COLUMBIA UNIV, MED CTR, DEPT MOLEC MED, NEW YORK, NY 10032 USA; CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, CLEVELAND, OH 44195 USA	New York University; St Jude Children's Research Hospital; Columbia University; Cleveland Clinic Foundation	WATLING, D (corresponding author), IMPERIAL CANC RES FUND, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Guschin, Dmitry/U-3731-2019; witthuhn, bruce/GSE-3193-2022; Guschin, Dmitry/O-7594-2018	Guschin, Dmitry/0000-0002-4184-0001; Guschin, Dmitry/0000-0002-4184-0001; Rogers, Neil/0000-0001-8977-7585; Quelle, Frederick/0000-0002-1184-6170; Muller, Mathias/0000-0002-7879-3552				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1328; HARPUR AG, 1992, ONCOGENE, V7, P1347; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEWELL WA, 1986, P NATL ACAD SCI USA, V83, P8718, DOI 10.1073/pnas.83.22.8718; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STASHL N, 1993, CELL, V74, P587; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	27	478	486	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					166	170		10.1038/366166a0	http://dx.doi.org/10.1038/366166a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	7901766				2022-12-24	WOS:A1993MG21600060
J	SHERLOCK, S				SHERLOCK, S			EUROPEAN LIVERS	LANCET			English	Editorial Material											SHERLOCK, S (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT SURG,LONDON,ENGLAND.								0	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1127	1128		10.1016/0140-6736(93)92117-C	http://dx.doi.org/10.1016/0140-6736(93)92117-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901469				2022-12-24	WOS:A1993MF19800003
J	LUBITZ, J; BEEBE, J; BAKER, C				LUBITZ, J; BEEBE, J; BAKER, C			LONGEVITY AND MEDICARE EXPENDITURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; CARE; COMPRESSION; MORBIDITY; PAYMENTS; DEATH	Background. In the United States, the elderly account for over one third of health care spending. The total population over the age of 65 is projected to increase, as is life expectancy beyond the age of 65. We studied current patterns of Medicare expenses according to age at death and the possible effect of future demographic changes on Medicare spending. Methods. We used data from the Medicare program to estimate lifetime Medicare expenses for a sample of 129, 166 beneficiaries, 65 or older, who died in 1989 and 1990, according to age at death. Spending for nursing home care not covered by Medicare was excluded. (Nursing home costs represent about 20 percent of total health care spending for the elderly and increase with age.) Through simulation, we assessed the lifetime payments by Medicare for enrollees who turned 65 in 1990 and those who will do so in 2020. Results. Estimated lifetime Medicare payments (in 1990 dollars) ranged from $13,044 for persons who died at 65 years of age, to $56,094 for those who died at 80, to $65,633 for those who died at 101 or older. The payments associated with an additional year of life and the average annual payments over an enrollee's lifetime both decreased as the age at death increased. The estimated 7.9 percent increase in life expectancy beyond 65 years that will have taken place between 1990 and 2020 (19.1 years past the age of 65 in 2020, as compared with 17.7 years in 1990) was associated with an estimated increase of 2.0 percent in lifetime Medicare payments. Of the estimated $98 billion increase in total lifetime payments (in 1990 dollars) from the 1990 group to the 2020 group, 74.3 percent was due to the larger size of the original birth cohort who will reach the age of 65 in 2020, 22.5 percent to an increase in the proportion of that birth cohort projected to survive to 65 years of age, and 3.2 percent to improved life expectancy beyond 65. Conclusions. The effect on Medicare spending of increased longevity beyond the age of 65 may not be great. Total Medicare payments will be more substantially affected by the expected increase in the absolute number of elderly people.	HLTH ECON RES,WALTHAM,MA		LUBITZ, J (corresponding author), US HLTH CARE FINANCING ADM,OFF RES & DEMONSTRAT,ROOM 2504,OAK MEADOWS BLDG,6325 SECUR BLDG,BALTIMORE,MD 21207, USA.							FRIES JF, 1989, MILBANK Q, V67, P208, DOI 10.2307/3350138; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FUCHS VR, 1984, MILBANK FUND Q, V62, P143; GORNICK M, 1993, HEALTH AFFAIR, V12, P140, DOI 10.1377/hlthaff.12.2.140; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; Letsch S W, 1992, Health Care Financ Rev, V14, P1; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; MANTON KG, 1991, POPUL DEV REV, V7, P603; OLSHANSKY SJ, 1993, SCI AM, V268, P46, DOI 10.1038/scientificamerican0493-46; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; Peden E A, 1991, Health Care Financ Rev, V13, P75; RICE DP, 1983, VITAL HLTH STATIST 3, V23; ROOS NP, 1987, MILBANK Q, V65, P231, DOI 10.2307/3350021; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; Waldo D R, 1989, Health Care Financ Rev, V10, P111; 1993, 1993 BOARD TRUST ANN; 1993, CURRENT POPULATION R, V1104	17	152	153	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					999	1003		10.1056/NEJM199504133321506	http://dx.doi.org/10.1056/NEJM199504133321506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT737	7885430				2022-12-24	WOS:A1995QT73700006
J	PARR, BA; MCMAHON, AP				PARR, BA; MCMAHON, AP			DORSALIZING SIGNAL WNT-7A REQUIRED FOR NORMAL POLARITY OF D-V AND A-P AXES OF MOUSE LIMB	NATURE			English	Article							APICAL ECTODERMAL RIDGE; CHICK LIMB; PATTERN-FORMATION; BUD CELLS; MORPHOGENESIS; INFORMATION; OUTGROWTH; MESODERM; DOMAINS; EMBRYOS	FORMATION Of the vertebrate limb requires specification of cell position along three axes(1). Proximal-distal identity is regulated by the apical ectodermal ridge (AER) at the distal tip of the growing limb(2-6). Anterior-posterior identity is controlled by signals from the zone of polarizing activity (ZPA) within the posterior limb mesenchyme(7-9). Dorsal-ventral identity is regulated by ectodermally derived signals(10-14). Recent studies have begun to identify signalling molecules that may mediate these patterning activities. Members of the fibroblast growth factor (FGF) family are expressed in the AER and can mimic its proximal-distal signalling activity(15,16). Similarly, the gene Sonic hedgehog (Shh) is expressed in the ZPA, and Shh-expressing cells, like ZPA cells, can cause digit duplications when transplan ted to the anterior limb margin. In contrast, no signal has yet been identified for the dorsal-ventral axis, although Wnt-7a is expressed in the dorsal ectoderm, suggesting that it mag play such a role(19,20). To test this possibility, we have generated mice lacking Wnt-7a activity. The limb mesoderm of these mice shows dorsal-to-ventral transformations of cell fate, indicating that Wnt-7a is a dorsalizing signal. Many mutant mice also lack posterior digits, demonstrating that Wnt-7a is also required for anterior-posterior patterning. We propose that normal limb development requires interactions between the signalling systems for these two axes.			PARR, BA (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, 16 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020					ANDERSON R, 1993, DEVELOPMENT, V117, P1421; BULFONE A, 1993, MECH DEVELOP, V40, P129, DOI 10.1016/0925-4773(93)90071-5; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FINCH RA, 1971, J EXP ZOOL, V176, P397, DOI 10.1002/jez.1401760403; GEDUSPAN JS, 1987, DEV BIOL, V124, P398, DOI 10.1016/0012-1606(87)90492-1; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; GLOBUS M, 1976, DIFFERENTIATION, V6, P91, DOI 10.1111/j.1432-0436.1976.tb01474.x; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LYONS KM, 1990, DEVELOPMENT, V109, P833; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; PARR BA, 1993, DEVELOPMENT, V119, P247; REITER RS, 1982, DEV BIOL, V93, P28, DOI 10.1016/0012-1606(82)90235-4; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SMITH JC, 1978, NATURE, V272, P612, DOI 10.1038/272612a0; STARK RJ, 1974, DEV BIOL, V38, P51, DOI 10.1016/0012-1606(74)90258-9; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; YANG Y, IN PRESS CELL	31	595	611	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	1995	374	6520					350	353		10.1038/374350a0	http://dx.doi.org/10.1038/374350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885472				2022-12-24	WOS:A1995QN63000057
J	SHAPIRO, L; FANNON, AM; KWONG, PD; THOMPSON, A; LEHMANN, MS; GRUBEL, G; LEGRAND, JF; ALSNIELSEN, J; COLMAN, DR; HENDRICKSON, WA				SHAPIRO, L; FANNON, AM; KWONG, PD; THOMPSON, A; LEHMANN, MS; GRUBEL, G; LEGRAND, JF; ALSNIELSEN, J; COLMAN, DR; HENDRICKSON, WA			STRUCTURAL BASIS OF CELL-CELL ADHESION BY CADHERINS	NATURE			English	Article							INTERCELLULAR ADHERENS JUNCTIONS; EXPRESSION; IDENTIFICATION; MOLECULE	Crystal structures of the amino-terminal domain of N-cadherin provide a picture at the atomic level of a specific adhesive contact between cells. A repeated set of dimer interfaces is common to the structure in three lattices. These interactions combine to form a linear zipper of molecules that mirrors the linear structure of the intracellular filaments with which cadherins associate. This cell-adhesion zipper may provide a mechanism to marshal individual molecular adhesive interactions into strong bonds between cells.	COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; EUROPEAN MOLEC BIOL LAB,F-38042 GRENOBLE,FRANCE; EUROPEAN SYNCHROTRON RADIAT FACIL,F-38043 GRENOBLE,FRANCE; INST MAX VON LAUE PAUL LANGEVIN,F-38042 GRENOBLE,FRANCE; UNIV GRENOBLE 1,SPECTROMETRIE PHYS LAB,CNRS,URA 8,F-38402 ST MARTIN DHERES,FRANCE; RISO NATL LAB,DK-4000 ROSKILDE,DENMARK	Columbia University; Howard Hughes Medical Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF); Institut Laue-Langevin (ILL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Technical University of Denmark	SHAPIRO, L (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,630 W 168TH ST,NEW YORK,NY 10032, USA.		Shapiro, Lawrence/AAE-7172-2019					AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CAMPBELL RD, 1971, ORIGIN CONTINUITY DE; CCP4, 1979, CCP4 SUITE PROGRAMS; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FAWCETT DW, 1958, ATLAS FINE STRUCTURE, P365; FREUND AK, 1993, SPIE P, V1997, P223; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Galtsoff PS, 1925, J EXP ZOOL, V42, P183, DOI 10.1002/jez.1400420109; GRUBEL G, 1994, PHYSIQUE 4, V4, P27; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1979, BIOPOLYMERS, V22, P2577; KELLY DE, 1966, J CELL BIOL, V28, P51, DOI 10.1083/jcb.28.1.51; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACLARE JL, 1994, J SYNCHROTRON RADIAT, V1, P12, DOI 10.1107/S0909049594006564; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McNutt N S, 1970, Am J Cardiol, V25, P169, DOI 10.1016/0002-9149(70)90577-1; McNutt N S, 1973, Prog Biophys Mol Biol, V26, P45; Nagafuchi A, 1993, Semin Cell Biol, V4, P175, DOI 10.1006/scel.1993.1021; NICHOLLS A, 1989, PROTEINS, V11, P281; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; POKUTTA S, 1994, EUR J BIOCH; ROGERS DC, 1965, J ULTRA MOL STRUCT R, V13, P478, DOI 10.1016/S0022-5320(65)90010-9; SHAPIRO L, IN PRESS P NATN ACAD; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1990, COLD SH Q B, V55, P319; TONG KI, 1994, FEBS LETT, V352, P318; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; VOLK T, 1986, J CELL BIOL, V103, P1451, DOI 10.1083/jcb.103.4.1451; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7; [No title captured]	51	962	1003	1	80	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					327	337		10.1038/374327a0	http://dx.doi.org/10.1038/374327a0			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885471				2022-12-24	WOS:A1995QN63000051
J	MOTOYAMA, N; WANG, FP; ROTH, KA; SAWA, H; NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; SENJU, S; ZHANG, Q; FUJII, S; LOH, DY				MOTOYAMA, N; WANG, FP; ROTH, KA; SAWA, H; NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; SENJU, S; ZHANG, Q; FUJII, S; LOH, DY			MASSIVE CELL-DEATH OF IMMATURE HEMATOPOIETIC-CELLS AND NEURONS IN BCL-X-DEFICIENT MICE	SCIENCE			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; MUTANT CHIMERIC MICE; B-CELL; GENE; APOPTOSIS; PROTOONCOGENE; MECHANISMS; EXPRESSION; MUTATION; SYSTEM	bcl-x is a member of the bcl-2 gene family, which may regulate programmed cell death. Mice were generated that lacked Bcl-x. The Bcl-x-deficient mice died around embryonic day 13. Extensive apoptotic cell death was evident in postmitotic immature neurons of the developing brain, spinal cord, and dorsal root ganglia. Hematopoietic cells in the liver were also apoptotic. Analyses of bcl-x double-knockout chimeric mice showed that the maturation of Bcl-x-deficient lymphocytes was diminished. The life-span of immature lymphocytes, but not mature lymphocytes, was shortened. Thus, Bcl-x functions to support the viability of immature cells during the development oi the nervous and hematopoietic systems.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOL MOLEC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV CARDIOVASC MED,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			wang, fang/GYD-4295-2022; Sawa, Hirofumi/F-6954-2012; Sawa, Hirofumi/AAW-8816-2021	Sawa, Hirofumi/0000-0003-2569-2755; Roth, Kevin/0000-0002-0643-995X				ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FANG W, 1994, J IMMUNOL, V153, P4388; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HERMISTON ML, 1992, J HISTOCHEM CYTOCHEM, V40, P1283, DOI 10.1177/40.9.1506665; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; Kaufman MH, 1992, ATLAS MOUSE DEV, P128; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LEBRUN DP, 1993, AM J PATHOL, V142, P743; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LIN EY, 1993, J IMMUNOL, V151, P1979; MERRY DE, 1994, DEVELOPMENT, V120, P301; MOTOYAMA N, UNPUB; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NAKAYAMA K, UNPUB; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SAWYERS CL, 1994, CELL, V177, P121; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TUCKER RP, 1988, J COMP NEUROL, V271, P44, DOI 10.1002/cne.902710106; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VEISNOVACK D, 1994, AM J PATHOL, V145, P61; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	40	988	1013	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1506	1510		10.1126/science.7878471	http://dx.doi.org/10.1126/science.7878471			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878471				2022-12-24	WOS:A1995QL49700040
J	KRAPIVINSKY, G; GORDON, EA; WICKMAN, K; VELIMIROVIC, B; KRAPIVINSKY, L; CLAPHAM, DE				KRAPIVINSKY, G; GORDON, EA; WICKMAN, K; VELIMIROVIC, B; KRAPIVINSKY, L; CLAPHAM, DE			THE G-PROTEIN-GATED ATRIAL K+ CHANNEL I-KACH IS A HETEROMULTIMER OF 2 INWARDLY RECTIFYING K+-CHANNEL PROTEINS	NATURE			English	Article							SUBUNIT; HEART	Heart rate is slowed in part by acetylcholine-dependent activation of a cardiac potassium (K+) channel, I-KACh. Activated muscarinic receptors stimulate I-KACh via the G-protein beta gamma-subunits. It has been assumed that the inwardly rectifying K+-channel gene, GIRK1, alone encodes I-KACh. It is now shown that I-KACh is a heteromultimer of two distinct inwardly rectifying K+-channel subunits, GIRK1 and a newly cloned member of the family, CIR.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Wickman, Kevin/0000-0002-5179-9540; Clapham, David/0000-0002-4459-9428				AGULLARBRYAN L, 1995, BIOPHYS J, V68, pA234; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; KUBO Y, 1993, NATURE, V384, P802; LIM N, 1995, J GEN PHYSIOL, V105, P1; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; TUNG R T, 1992, Journal of the American College of Cardiology, V19, p245A; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	15	741	770	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					135	141		10.1038/374135a0	http://dx.doi.org/10.1038/374135a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877685				2022-12-24	WOS:A1995QL39700050
J	KLONOFFCOHEN, HS; EDELSTEIN, SL; LEFKOWITZ, ES; SRINIVASAN, IP; KAEGI, D; CHANG, JC; WILEY, KJ				KLONOFFCOHEN, HS; EDELSTEIN, SL; LEFKOWITZ, ES; SRINIVASAN, IP; KAEGI, D; CHANG, JC; WILEY, KJ			THE EFFECT OF PASSIVE SMOKING AND TOBACCO EXPOSURE THROUGH BREAST-MILK ON SUDDEN-INFANT-DEATH-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MATERNAL SMOKING; CIGARETTE-SMOKING; BIRTH-WEIGHT; RISK-FACTORS; PREGNANCY; HYPOXIA	Objective.-To examine the relationship between sudden infant death syndrome (SIDS) and smoking during pregnancy; postnatal tobacco smoke exposure from the mother, father, live-in adults, and day care providers; and postnatal smoke exposure from breast-feeding. Design.-Case-control study. Setting.-Five counties in Southern California. Participants.-A total of 200 white, African-American, Hispanic, and Asian parents of infants who died of SIDS between 1989 and 1992 were compared with 200 control parents who delivered healthy infants. Case infants were matched to control infants on the basis of birth hospital, birth date, gender, and race. All information was obtained from a detailed telephone interview and validated with medical records. Main Outcome Measures.-Risk of SIDS associated with passive smoking by the mother, father, live-in adults, and day care providers; smoking in the same room as the infant; total number of cigarettes smoked by all adults; and maternal smoking during the time period of breast-feeding. Results.-Conditional logistic regression resulted in overall adjusted odds ratios (ORs) for SIDS associated with passive smoke from the mother of 2.28, the father of 3.46, other live-in adults of 2.18, and all sources of 3.50 (95% confidence interval, 1.81 to 6.75), while simultaneously adjusting for birth weight, sleep position, prenatal care, medical conditions at birth, breast-feeding, and maternal smoking during pregnancy. A dose-response effect was noted for SIDS associated with increasing numbers of cigarettes, as well as total number of smokers. Breast-feeding was protective for SIDS among nonsmokers (OR=0.37) but not smokers (OR=1.38), when adjusting for potential confounders. Conclusions.-Passive smoking in the same room as the infant increases the risk for SIDS. Physicians should educate new and prospective parents about the risks of tobacco smoke exposure during pregnancy and the first year of the infant's life.			KLONOFFCOHEN, HS (corresponding author), UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, DIV EPIDEMIOL, 9500 GILMAN DR, 0607, LA JOLLA, CA 92093 USA.							AVERY ME, 1983, NEW ENGL J MED, V309, P107, DOI 10.1056/NEJM198307143090211; BERGMAN AB, 1976, PEDIATRICS, V58, P665; BULTERYS MG, 1990, PEDIATRICS, V86, P535; CARPENTE.RG, 1965, BRIT J PREV SOC MED, V19, P1; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; Golding J., 1985, SUDDEN INFANT DEATH; HAGLUND B, 1990, AM J PUBLIC HEALTH, V80, P29, DOI 10.2105/AJPH.80.1.29; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; KLONOFFCOHEN HS, 1995, JAMA-J AM MED ASSOC, V273, P790, DOI 10.1001/jama.273.10.790; KRAUS JF, 1989, INT J EPIDEMIOL, V18, P113, DOI 10.1093/ije/18.1.113; KROUS H F, 1988, Pediatrician, V15, P231; LI DK, 1991, AM J EPIDEMIOL, V134, P958, DOI 10.1093/oxfordjournals.aje.a116180; MALLOY MH, 1992, AM J PUBLIC HEALTH, V82, P1380, DOI 10.2105/AJPH.82.10.1380; MALLOY MH, 1988, AM J EPIDEMIOL, V128, P46, DOI 10.1093/oxfordjournals.aje.a114957; MCGLASHAN ND, 1989, SOC SCI MED, V29, P1015, DOI 10.1016/0277-9536(89)90059-2; MITCHELL E, 1991, NZ MED J, V106, P71; MITCHELL EA, 1987, NEW ZEAL MED J, V100, P269; MITCHELL EA, 1993, PEDIATRICS, V91, P893; MURPHY JF, 1982, J EPIDEMIOL COMMUN H, V36, P17, DOI 10.1136/jech.36.1.17; NAEYE RL, 1976, AM J DIS CHILD, V130, P1207, DOI 10.1001/archpedi.1976.02120120041005; PETERSON DR, 1981, AM J EPIDEMIOL, V113, P583, DOI 10.1093/oxfordjournals.aje.a113135; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PROTESTOS CD, 1973, ARCH DIS CHILD, V48, P835, DOI 10.1136/adc.48.11.835; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; STEELE R, 1966, CAN MED ASSOC J, V94, P1165; VANDENBERG M, 1985, NEW ZEAL MED J, V98, P1075; 1993, STATISTICS EPIDEMIOL; 1985, SAS USERS GUIDE VERS; 1988, MMWR-MORBID MORTAL W, V37, P644; 1986, HLTH CONSEQUENCES IN, P38	31	171	177	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					795	798		10.1001/jama.273.10.795	http://dx.doi.org/10.1001/jama.273.10.795			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861574				2022-12-24	WOS:A1995QJ75000031
J	GRAHAM, JR; DEPATER, I; JERNIGAN, JG; LIU, MC; BROWN, ME				GRAHAM, JR; DEPATER, I; JERNIGAN, JG; LIU, MC; BROWN, ME			THE FRAGMENT-R COLLISION - WM-KEEK-TELESCOPE OBSERVATIONS OF SL9	SCIENCE			English	Article								The W. M. Keck telescope was used to observe the impact of comet Shoemaker-Levy 9 (SL9) fragment R at a wavelength of 2.3 micrometers on 21 July 1994. The data showed three outbursts. The first flash lasted about 40 seconds and was followed 1 minute after its peak by a second flash that lasted about 3 minutes. A third, longer lasting flare began 6 minutes after the first flash and lasted for 10 minutes. At its maximum brightness, the flare outshone Jupiter. The two short flashes are probably associated with the initial meteor trail and the subsequent fireball, respectively. The bright flare occurred when the impact site rotated into view. These data show that the explosion ejected material at least 1300 kilometers above the visible cloud tops. The luminosity of the impact site during the long bright flare was probably maintained by the release of gravitational potential energy, as this material fell back onto the lower atmosphere.	UNIV CALIF BERKELEY, SPACE SCI LAB, BERKELEY, CA USA	University of California System; University of California Berkeley	GRAHAM, JR (corresponding author), UNIV CALIF BERKELEY, DEPT ASTRON, 601 CAMPBELL HALL, BERKELEY, CA 94720 USA.			Liu, Michael C/0000-0003-2232-7664; Brown, Michael E./0000-0002-8255-0545				AHRENS TJ, 1994, GEOPHYS RES LETT, V21, P1087, DOI 10.1029/94GL01325; ASPHAUG E, 1994, NATURE, V370, P120, DOI 10.1038/370120a0; BOSLOUGH MB, 1994, GEOPHYS RES LETT, V21, P1555, DOI 10.1029/94GL01582; CHEVALIER RA, 1994, ASTROPHYS J, V429, P863, DOI 10.1086/174371; FROGEL JA, 1978, ASTROPHYS J, V220, P75, DOI 10.1086/155883; JEWITT D, 1993, B AM ASTRON SOC, V25, P1042; MACLOW MM, 1994, ASTROPHYS J, V434, pL33, DOI 10.1086/187565; MATTHEWS K, 1994, INFRARED ARRAYS ASTR; TAKATA T, 1994, ICARUS, V109, P3, DOI 10.1006/icar.1994.1074; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; ZAHNLE K, 1994, ICARUS, V108, P1, DOI 10.1006/icar.1994.1038; Zahnle Kevin, COMMUNICATION; ZELDOVICH YB, 1967, PHYSICS SHOCK WAVES	13	33	33	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1320	1323						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871431				2022-12-24	WOS:A1995QK06800036
J	PUI, CH; BOYETT, JM; HANCOCK, ML; PRATT, CB; MEYER, WH; CRIST, WM				PUI, CH; BOYETT, JM; HANCOCK, ML; PRATT, CB; MEYER, WH; CRIST, WM			OUTCOME OF TREATMENT FOR CHILDHOOD-CANCER IN BLACK AS COMPARED WITH WHITE-CHILDREN - THE ST-JUDE-CHILDRENS-RESEARCH-HOSPITAL EXPERIENCE, 1962 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; BREAST-CANCER; RACIAL-DIFFERENCES; SOCIOECONOMIC-STATUS; SURVIVAL RATES; RACE; WOMEN; PLACE	Objective.-To determine whether there is a racial difference in prognosis among childhood cancers. Design.-An overall (30-year) survival analysis by race was followed by separate studies for ''early'' and ''recent'' treatment eras, defined by time points at which significantly improved outcome was demonstrated for specific tumor types, Stratified analyses were performed to adjust for recognized prognostic features. Setting.-Pediatric oncology research and treatment center. Patients.-The study included 798 black and 4507 white children with newly diagnosed malignancies treated from January 1962 through June 1992. These patients were accepted for treatment regardless of their financial status and were enrolled on disease-specific protocols. Results.-Across the 30-year study period, black children had a significantly poorer rate of survival than white children (P<.,001, log-rank test). In the early treatment era, a significant difference was seen for all forms of cancer combined (P<.001), with 10-year Kaplan-Meier estimates (+/-SE) of 37%+/-3% for black children and 50%+/-1% for white children. This difference largely reflected the poorer prognosis of black children with the most common childhood cancer, acute lymphoblastic leukemia. In the recent treatment era, there were no significant differences in treatment outcome by race for specific disease categories or for all forms of cancer combined, Ten-year survival rates were 67%+/-6% for black children and 66%+/-3% for white children, indicating a significantly greater improvement in the former group. Conclusion.-With equal access to effective contemporary treatment, black children with cancer fare as well as white children when treated with protocol-based therapy at a pediatric oncology research center.	ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, COLL MED, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	PUI, CH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180, P01CA023099] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765, P01 CA 23099, P01 CA 20180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; AZIZ H, 1988, AM J CLIN ONCOL-CANC, V11, P166, DOI 10.1097/00000421-198804000-00015; BAIN RP, 1987, AM J OBSTET GYNECOL, V157, P914, DOI 10.1016/S0002-9378(87)80089-3; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; BIRCH JM, 1988, BRIT MED J, V296, P1372, DOI 10.1136/bmj.296.6633.1372; BLATT J, 1992, AM J MED, V93, P57, DOI 10.1016/0002-9343(92)90680-A; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BORING CC, 1992, CA-CANCER J CLIN, V42, P7, DOI 10.3322/canjclin.42.1.7; BRODER S, 1993, STEM CELLS, V1, P3; COX DR, 1968, STATISTICAL ANAL SER, P229; DANSEY RD, 1988, CANCER, V61, P1908, DOI 10.1002/1097-0142(19880501)61:9<1908::AID-CNCR2820610931>3.0.CO;2-N; DAYAL H, 1987, J CHRON DIS, V40, P857, DOI 10.1016/0021-9681(87)90185-8; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; EVANS WE, 1991, SEMIN HEMATOL, V28, P15; FALLETTA JM, 1984, PROG CANCER RES THER, V27, P191; HOWARD J, 1992, CANCER, V69, P2349, DOI 10.1002/1097-0142(19920501)69:9&lt;2349::AID-CNCR2820690925&gt;3.0.CO;2-7; KALWINSKY DK, 1985, LEUKEMIA RES, V9, P817, DOI 10.1016/0145-2126(85)90300-5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; KLINGEMANN HG, 1986, BONE MARROW TRANSPL, V1, P87; KRAMER S, 1984, J CLIN ONCOL, V2, P917, DOI 10.1200/JCO.1984.2.8.917; LENNOX EL, 1979, BRIT MED J, V2, P567, DOI 10.1136/bmj.2.6190.567; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; MANTEL N, 1959, J NATL CANCER I, V22, P719; MEADOWS AT, 1983, CANCER INVEST, V1, P49, DOI 10.3109/07357908309040932; MILLER RW, 1989, PRINCIPLES PRACTICE, P3; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; OWNBY HE, 1985, J NATL CANCER I, V75, P55; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PUI CH, 1993, BLOOD, V82, P343; PUI CH, 1990, BLOOD, V76, P1449; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RAGLAND KE, 1991, AM J EPIDEMIOL, V133, P672; REAMAN GH, 1984, PROG CANCER RES THER, V27, P163; REINTGEN DS, 1982, JAMA-J AM MED ASSOC, V248, P1856, DOI 10.1001/jama.248.15.1856; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SATHER H, 1984, PROG CANCER RES THER, V27, P179; STEINHORN SC, 1986, AM J EPIDEMIOL, V124, P85, DOI 10.1093/oxfordjournals.aje.a114373; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; WALTERS TR, 1972, CANCER, V29, P210, DOI 10.1002/1097-0142(197201)29:1<210::AID-CNCR2820290131>3.0.CO;2-U; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; 1992, PEDIATRICS, V89, P597; 1990, TREATMENT EARLY BREA, P1	46	73	74	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					633	637		10.1001/jama.273.8.633	http://dx.doi.org/10.1001/jama.273.8.633			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844873				2022-12-24	WOS:A1995QG74800028
J	MIYAMOTO, S; AKIYAMA, SK; YAMADA, KM				MIYAMOTO, S; AKIYAMA, SK; YAMADA, KM			SYNERGISTIC ROLES FOR RECEPTOR OCCUPANCY AND AGGREGATION IN INTEGRIN TRANSMEMBRANE FUNCTION	SCIENCE			English	Article							FIBRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; CELL-ADHESION; TYROSINE PHOSPHORYLATION; FIBROBLASTS; ANTIBODIES; BINDING; PROTEIN; MATRIX; GROWTH	Integrin receptors mediate cell adhesion, signal transduction, and cytoskeletal organization. How a single transmembrane receptor can fulfill multiple functions was clarified by comparing roles of receptor occupancy and aggregation. Integrin occupancy by monovalent ligand induced receptor redistribution, but minimal tyrosine phosphorylation signaling or cytoskeletal protein redistribution. Aggregation of integrins by noninhibitory monoclonal antibodies on beads induced intracellular accumulations of pp125(FAK) and tensin, as well as phosphorylation, but no accumulation of other cytoskeletal proteins such as talin. Combining antibody-mediated clustering with monovalent ligand occupancy induced accumulation of seven cytoskeletal proteins, including alpha-actinin, talin, and F-actin, thereby mimicking multivalent interactions with fibronectin or polyvalent peptides. Integrins therefore mediate a complex repertoire of functions through the distinct effects of receptor aggregation, receptor occupancy, or both together.	NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yamada, Kenneth/0000-0003-1512-6805				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; CHERESH DA, 1992, CLIN LAB MED, V12, P217, DOI 10.1016/S0272-2712(18)30514-6; COUCHMAN JR, 1979, J CELL SCI, V39, P149; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GRINNELL F, 1986, EXP CELL RES, V162, P449, DOI 10.1016/0014-4827(86)90349-6; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; METZGER H, 1992, J IMMUNOL, V149, P1477; MIYAMOTO S, UNPUB; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8	28	815	825	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					883	885		10.1126/science.7846531	http://dx.doi.org/10.1126/science.7846531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846531				2022-12-24	WOS:A1995QG20700058
J	GAMES, D; ADAMS, D; ALESSANDRINI, R; BARBOUR, R; BERTHELETTE, P; BLACKWELL, C; CARR, T; CLEMENS, J; DONALDSON, T; GILLESPIE, F; GUIDO, T; HAGOPIAN, S; JOHNSONWOOD, K; KHAN, K; LEE, M; LEIBOWITZ, P; LIEBERBURG, I; LITTLE, S; MASLIAH, E; MCCONLOGUE, L; MONTOYAZAVALA, M; MUCKE, L; PAGANINI, L; PENNIMAN, E; POWER, M; SCHENK, D; SEUBERT, P; SNYDER, B; SORIANO, F; TAN, H; VITALE, J; WADSWORTH, S; WOLOZIN, B; ZHAO, J				GAMES, D; ADAMS, D; ALESSANDRINI, R; BARBOUR, R; BERTHELETTE, P; BLACKWELL, C; CARR, T; CLEMENS, J; DONALDSON, T; GILLESPIE, F; GUIDO, T; HAGOPIAN, S; JOHNSONWOOD, K; KHAN, K; LEE, M; LEIBOWITZ, P; LIEBERBURG, I; LITTLE, S; MASLIAH, E; MCCONLOGUE, L; MONTOYAZAVALA, M; MUCKE, L; PAGANINI, L; PENNIMAN, E; POWER, M; SCHENK, D; SEUBERT, P; SNYDER, B; SORIANO, F; TAN, H; VITALE, J; WADSWORTH, S; WOLOZIN, B; ZHAO, J			ALZHEIMER-TYPE NEUROPATHOLOGY IN TRANSGENIC MICE OVEREXPRESSING V717F BETA-AMYLOID PRECURSOR PROTEIN	NATURE			English	Article							SENILE PLAQUES; DISEASE; IDENTIFICATION; EXPRESSION; PATHOLOGY; DEPOSITS; PEPTIDE; CHAIN; BRAIN; GENE	ALZHEIMER'S disease (AD) is the most common cause of progressive intellectual failure in aged humans. AD brains contain numerous amyloid plaques surrounded by dystrophic neurites, and show profound synaptic loss, neurofibrillary tangle formation and gliosis. The amyloid plaques are composed of amyloid beta-peptide (A beta), a 40-42-amino-acid fragment of the beta-amyloid precursor protein (APP)(1). A primary pathogenic role for APP/A beta is suggested by missense mutations in APP that are tightly linked to autosomal dominant forms of AD(2,3). A major obstacle to elucidating and treating AD has been the lack of an animal model. Animals transgenic for APP have previously failed to show extensive AD-type neuropathology(4-10), but we now report the production of transgenic mice that express high levels of human mutant APP (with valine at residue 717 substituted by phenylalanine) and which progressively develop many of the pathological hallmarks of AD, including numerous extracellular thioflavin S-positive AP deposits, neuritic plaques, synaptic loss, astrocytosis and microgliosis. These mice support a primary role for APP/A beta in the genesis of AD and could provide a preclinical model for testing therapeutic drugs.	ATHENA NEUROSCI INC, San Francisco, CA 94080 USA; EXEMPLAR CORP, WORCESTER, MA 01605 USA; ELI LILLY & CO, LILLY RES LAB, INDIANAPOLIS, IN 46285 USA; SCRIPPS RES INST, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; NIMH, CLIN SCI LAB, BETHESDA, MD 20892 USA	Eli Lilly; Scripps Research Institute; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)				Mucke, Lennart/0000-0001-6256-9559				ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORK LC, 1988, J NEUROPATH EXP NEUR, V47, P629, DOI 10.1097/00005072-198811000-00006; DICKSON DW, 1990, ACTA NEUROPATHOL, V79, P486, DOI 10.1007/BF00296107; GAMES D, 1992, NEUROBIOL AGING, V13, P569, DOI 10.1016/0197-4580(92)90057-5; HARDY J, 1994, CLIN GERIATR MED, V10, P239, DOI 10.1016/S0749-0690(18)30343-4; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; Hogan B., 1986, MANIPULATING MOUSE E; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MANN DMA, 1992, NEURODEGENERATION, V1, P201; MASLIAH E, 1991, AM J PATHOL, V138, P235; MASLIAH E, 1991, ACTA NEUROPATHOL, V81, P428, DOI 10.1007/BF00293464; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; MCCONLOGUE L, 1994, NEUROBIOL AGING, V15, pS12; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; SANHU FA, 1991, J BIOL CHEM, V266, P21331; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SELKOE DJ, 1994, REV NEUROSCI, V17, P489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	29	2120	2283	2	169	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					523	527		10.1038/373523a0	http://dx.doi.org/10.1038/373523a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845465				2022-12-24	WOS:A1995QF72400060
J	DOCKE, WD; PROSCH, S; FIETZE, E; KIMEL, V; ZUCKERMANN, H; KLUG, C; SYRBE, U; KRUGER, DH; VONBAEHR, R; VOLK, HD				DOCKE, WD; PROSCH, S; FIETZE, E; KIMEL, V; ZUCKERMANN, H; KLUG, C; SYRBE, U; KRUGER, DH; VONBAEHR, R; VOLK, HD			CYTOMEGALOVIRUS REACTIVATION AND TUMOR-NECROSIS-FACTOR	LANCET			English	Note							FACTOR-ALPHA; IMMUNODEFICIENCY; CELLS	Tumour necrosis factor-alpha (TNF) stimulates cytomegalovirus (CMV) activity in a transfected human monocytic cell line. We assessed whether this finding is relevant in vivo by evaluating the frequency of active CMV infection in patients with diseases that enhance plasma TNF. In septic disease, peripheral blood mononuclear cells of almost all patients studied were positive for CMV. Furthermore, CMV antigenaemia and enhanced plasma TNF occurred in many patients with liver cirrhosis, common variable immunodeficiency, and B-cell chronic lymphocytic leukaemia. Thus, TNF may have a central role in CMV reactivation.	HUMBOLDT UNIV BERLIN,MED SCH CHARITE,INST VIROL,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,MED SCH CHARITE,DEPT SURG,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,MED SCH CHARITE,DEPT ANAESTHESIOL & INTENS CARE,D-10098 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	DOCKE, WD (corresponding author), HUMBOLDT UNIV BERLIN,MED SCH CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY.		volk, hans-dieter/AAV-8053-2021; Syrbe, Uta/T-7557-2017	volk, hans-dieter/0000-0002-7743-6668; Syrbe, Uta/0000-0001-8463-7890				CORDONNIER C, 1990, Revue de Pneumologie Clinique, V46, P244; DOCKE WD, 1991, LANCET, V338, P1597, DOI 10.1016/0140-6736(91)92422-X; FOA R, 1990, BLOOD, V76, P393; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; PROSCH S, 1992, J MED VIROL, V38, P246, DOI 10.1002/jmv.1890380404; RUBIN RH, 1990, REV INFECT DIS    S7, V12, P5754; STEIN J, 1993, J GEN VIROL, V74, P2333, DOI 10.1099/0022-1317-74-11-2333; TANAKA S, 1992, HEPATOLOGY, V16, P1409, DOI 10.1002/hep.1840160617; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; TLG H, 1992, GASTROENTEROLOGY, V103, P264	10	217	219	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					268	269		10.1016/S0140-6736(94)91116-9	http://dx.doi.org/10.1016/S0140-6736(94)91116-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905100				2022-12-24	WOS:A1994MT44000014
J	SACK, MN; RADER, DJ; CANNON, RO				SACK, MN; RADER, DJ; CANNON, RO			ESTROGEN AND INHIBITION OF OXIDATION OF LOW-DENSITY LIPOPROTEINS IN POSTMENOPAUSAL WOMEN	LANCET			English	Note							17-BETA ESTRADIOL	Oxidative modification of low-density lipoprotein (LDL) may be atherogenic. We studied the time of onset of LDL oxidation (lag) in 18 postmenopausal women before and after intraarterial infusion of 17beta-oestradiol, after 3 weeks' patch administration ir 12 of these women, and 1. month after discontinuation in 10. The lag increased from baseline after acute infusion (from 134 [SD 41] to 167 [36] min, p = 0.01) and after the patch (132 [31] to 178 [45] min, p = 0.009). After discontinuation of oestradiol, the lag returned to baseline. This study shows an antioxidant effect of physiological levels of 17beta-oestradiol, which may contribute to an anti-atherogenic action.	NHLBI,CARDIOL BRANCH,BLDG 10,ROOM 7B-15,BETHESDA,MD 20892; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892; GEORGETOWN UNIV HOSP,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University								ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CARR BR, 1992, WILLIAMS TXB ENDOCRI, P733; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOUGH JL, 1986, ARTERIOSCLEROSIS, V6, P57, DOI 10.1161/01.ATV.6.1.57; MAZIERE C, 1991, ATHEROSCLEROSIS, V89, P175, DOI 10.1016/0021-9150(91)90058-B; RIFICI VA, 1992, METABOLISM, V41, P1110, DOI 10.1016/0026-0495(92)90295-L; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	9	483	493	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					269	270		10.1016/S0140-6736(94)91117-7	http://dx.doi.org/10.1016/S0140-6736(94)91117-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905101	hybrid			2022-12-24	WOS:A1994MT44000015
J	HOOTON, TM; ROBERTS, MC; KENNY, GE				HOOTON, TM; ROBERTS, MC; KENNY, GE			MYCOPLASMA-GENITALIUM AND NONGONOCOCCAL URETHRITIS	LANCET			English	Editorial Material											HOOTON, TM (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,MADISON CLIN,SEATTLE,WA 98104, USA.							BOWIE WR, 1981, ANN INTERN MED, V95, P306, DOI 10.7326/0003-4819-95-3-306; BOWIE WR, 1989, SEXUALLY TRANSMITTED, P627; HANDSFIELD H H, 1976, Journal of the American Venereal Disease Association, V2, P5; HOERNER PJ, 1993, LANCET, V342, P582; Hooton T M, 1987, Infect Dis Clin North Am, V1, P165; HOOTON TM, 1988, LANCET, V1, P266; TAYLORROBINSON D, 1985, BRIT J EXP PATHOL, V66, P95	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					69	69		10.1016/S0140-6736(94)90810-9	http://dx.doi.org/10.1016/S0140-6736(94)90810-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903773				2022-12-24	WOS:A1994MQ09200005
J	KOSTER, T; ROSENDAAL, FR; DERONDE, H; BRIET, E; VANDENBROUCKE, JP; BERTINA, RM				KOSTER, T; ROSENDAAL, FR; DERONDE, H; BRIET, E; VANDENBROUCKE, JP; BERTINA, RM			VENOUS THROMBOSIS DUE TO POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - LEIDEN THROMBOPHILIA STUDY	LANCET			English	Article							INACTIVATION	We undertook a population-based case-control study to test the clinical importance of a hereditary abnormality in the coagulation system, characterised by poor anticoagulant response to activated protein C (APC), which is associated with familial thrombophilia. The abnormality was detected in 64 (21%) of 301 unselected consecutive patients younger than 70 years,with a first, objectively confirmed episode of deep-vein thrombosis and without underlying malignant disease. Among 301 healthy control subjects matched for age and sex, the frequency was 5% (14 subjects). Thus, there is a seven-fold increase in risk of deep-vein thrombosis in subjects with a poor response to APC (matched odds ratio 6.6 [95% CI 3.6-12.0]). In addition, there was a clear inverse relation between the degree of response to APC and thrombosis risk. In the families of the patients an autosomal dominant mode of transmission of the abnormality was confirmed. 9 of 10 thrombosis patients with a poor response to APC had 1 parent with a similar poor response, whereas 9 of 10 patients with normal tests had parents with equally normal tests. The abnormality was found in both parents of 1 patient with an extremely poor response to APC; this patient is probably homozygous for the abnormality. We conclude that the poor response to APC is the most important hereditary cause of venous thrombosis. Its high prevalence in a series of unselected patients will make testing of all thrombosis patients for this abnormality worth while.	UNIV HOSP LEIDEN, HEMOSTASIS & THROMBOSIS RES CTR, 2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	KOSTER, T (corresponding author), UNIV HOSP LEIDEN, DEPT CLIN EPIDEMIOL, BLDG 1, CO-P, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Bertina, Rogier/AGQ-5246-2022; Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BOYERNEUMANN C, IN PRESS THROMB HAEM; CLOUSE LH, 1986, NEW ENGL J MED, V314, P1298, DOI 10.1056/NEJM198605153142006; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1993, THROMB HAEMOSTASIS, V69, P529; DEUTZTERLOUW PP, 1990, CLIN CHIM ACTA, V186, P321, DOI 10.1016/0009-8981(90)90318-M; ESMON CT, 1983, BLOOD, V62, P1155; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB104, DOI 10.1016/S0735-1097(86)80012-2; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LOELIGER EA, 1984, ANTICOAGULANTS MYOCA, P157; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILETICH J, 1987, NEW ENGL J MED, V317, P919; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; SVENSSON PJ, 1993, THROMB HAEMOSTASIS, V69, P1252; SVENSSON PJ, 1993, THROMB HAEMOSTASIS, V69, P999; VANHINSBERGH VWM, 1985, BLOOD, V65, P444	18	1276	1296	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1503	1506		10.1016/S0140-6736(05)80081-9	http://dx.doi.org/10.1016/S0140-6736(05)80081-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902898				2022-12-24	WOS:A1993MM40200008
J	MANNS, A; CLEGHORN, FR; FALK, R; HANCHARD, B; JAFFE, ES; BARTHOLOMEW, C; HARTGE, P; BENICHOU, J; BLATTNER, WA				MANNS, A; CLEGHORN, FR; FALK, R; HANCHARD, B; JAFFE, ES; BARTHOLOMEW, C; HARTGE, P; BENICHOU, J; BLATTNER, WA			ROLE OF HTLV-I IN DEVELOPMENT OF NON-HODGKIN-LYMPHOMA IN JAMAICA AND TRINIDAD-AND-TOBAGO	LANCET			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; RISK-FACTORS; DETERMINANTS; RETROVIRUS; INFECTION; MODEL; AGE	Human T-cell lymphotropic virus type I (HTLV-I) has been implicated in the aetiology of adult T-cell leukaemia/lymphoma in Japan and elsewhere, particularly the Caribbean. We have carried out parallel case-control studies in Jamaica and in Trinidad and Tobago to quantify the role of HTLV-I in the development of non-Hodgkin lymphoma (NHL). 135 cases of NHL were enrolled in Jamaica and 104 in Trinidad and Tobago. Controls were selected from patients treated in the same wards or clinics at the same time as the cases. Overall, patients with NHL were 10 times more likely than were controls to be seropositive for HTLV-I (Jamaica odds ratio 10.3 [95% CI 6.0-18.0], Trinidad and Tobago 14.4 [7.6-27.2]). In both countries the association between NHL and HTLV-I was greatest for T-cell lymphomas (18.3 [9.5-35.6] and 63.3 [25-167]). Among T-cell lymphomas especially, there was no significant difference between men and women in the association between NHL and HTLV-I, but there was a significant inverse relation between age and likelihood of HTLV-I seropositivity. B-cell lymphomas were predominant in the older age groups and were not associated with HTLV-I seropositivity. These findings are consistent with the hypothesis that early life exposure to HTLV-I is important for risk of subsequent ATL. Prevention of vertical transmission of HTLV-I could reduce by 70-80% cases of NHL in people under 60 years in this region.	UNIV W INDIES, DEPT PATHOL, KINGSTON 7, JAMAICA; NCI, PATHOL LAB, BETHESDA, MD 20892 USA; NCI, DIV CANC ETIOL, EPIDEMIOL & BLOSTAT PROGRAM, BETHESDA, MD 20892 USA; DEPT MED, PORT OF SPAIN, TRINIDAD TOBAGO	University West Indies Mona Jamaica; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jaffe, Elaine/G-8981-2014		DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP031006] Funding Source: NIH RePORTER; NCI NIH HHS [NCI N01-CP-61002, NCI N01-CP-31006] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BARTHOLOMEW C, 1985, BMJ-BRIT MED J, V290, P1243, DOI 10.1136/bmj.290.6477.1243; BENICHOU J, 1990, BIOMETRICS, V46, P991, DOI 10.2307/2532443; BLATTNER WA, 1990, J ACQ IMMUN DEF SYND, V3, P1102; BLATTNER WA, 1990, HUMAN RETROVIROLOGY : HTLV, P251; BROOKS SEH, 1991, W INDIAN MED J, V40, P134; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CLEGHORN FR, 1990, HUMAN RETROVIROLOGY : HTLV, P185; DEVESA SS, 1992, CANCER RES, V52, pS5432; Francis D P, 1981, Prog Med Virol, V27, P127; GESSAIN A, 1984, LANCET, V1, P1183; GIBBS WN, 1987, ANN INTERN MED, V106, P361, DOI 10.7326/0003-4819-106-3-361; HANAOKA M, 1982, ACTA PATHOL JPN, V29, P2112; HOOVER EA, 1976, J NATL CANCER I, V57, P365, DOI 10.1093/jnci/57.2.365; JAFFE ES, 1992, MANUAL CLIN LABORATO, P288; KUREC AS, 1988, CLIN LAB MED, V8, P223, DOI 10.1016/S0272-2712(18)30708-X; LEVINE PH, 1992, CANCER EPIDEM BIOMAR, V1, P515; LIU MC, 1993, ONCOLOGY, V7, P66; MANN DL, 1987, SCIENCE, V236, P1103, DOI 10.1126/science.2883731; MILLER GJ, 1986, INT J CANCER, V38, P801, DOI 10.1002/ijc.2910380604; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; PRENTICE R, 1976, BIOMETRICS, V32, P599, DOI 10.2307/2529748; REZANKA LJ, 1992, CANCER INVEST, V10, P371, DOI 10.3109/07357909209024796; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Takatsuki K., 1977, TOPICS HEMATOLOGY, P73; 1988, MMWR, V37, P736; 1982, CANCER, V49, P211	30	61	62	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1447	1450		10.1016/0140-6736(93)92931-I	http://dx.doi.org/10.1016/0140-6736(93)92931-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902480				2022-12-24	WOS:A1993ML21700007
J	LEUNG, DYM; MEISSNER, HC; FULTON, DR; MURRAY, DL; KOTZIN, BL; SCHLIEVERT, PM				LEUNG, DYM; MEISSNER, HC; FULTON, DR; MURRAY, DL; KOTZIN, BL; SCHLIEVERT, PM			TOXIC SHOCK SYNDROME TOXIN-SECRETING STAPHYLOCOCCUS-AUREUS IN KAWASAKI SYNDROME	LANCET			English	Article							STREPTOCOCCAL PYROGENIC EXOTOXINS; SELECTIVE EXPANSION; GAMMA-GLOBULIN; DISEASE; V-BETA-2; AGR	Kawasaki syndrome (KS), the main cause of acquired heart disease in children, is associated with the selective expansion of Vbeta2+ T cells in peripheral blood. Our study suggests that KS may be caused by a superantigen-a staphylococcal or streptococcal toxin. Bacteria were cultured without knowledge of their origin, from the throat, rectum, axilla, and groin of 16 patients with untreated acute KS and 15 controls. Bacteria producing toxins were isolated from 13 of 16 KS patients but from only 1 of 15 controls (p<0.0001). Toxic shock syndrome toxin (TSST) -secreting Staphylococcus aureus was isolated from 11 of the 13 toxin-positive cultures, and streptococcal pyrogenic exotoxin (SPE) B and C were found in the other 2. These toxins are known to stimulate Vbeta2+ T cells. All TSST-producing KS isolates were tryptophan auxotrophs indicating they were clonally related. S aureus isolates from acute KS patients were unusual because they produced less lipase, haemolysin, and protease compared to other isolates (p<0.01). S aureus colonies from KS patients were white, and could be easily mistaken for coagulase-negative staphylococci, whereas colonies of non-KS isolates were gold. These observations suggest that the expansion of Vbeta2+ T cells in most patients with KS may be caused by a new clone of TSST-producing S aureus, and, in a minority of patients, SPEB-producing or SPEC-producing streptococci.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DENVER, CO 80206 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT PEDIAT, BOSTON, MA 02111 USA; UNIV MINNESOTA, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA	National Jewish Health; Tufts Medical Center; University of Minnesota System; University of Minnesota Twin Cities	LEUNG, DYM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, 1400 JACKSON ST, DENVER, CO 80206 USA.			Schlievert, Patrick/0000-0001-8314-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R01HL036611, R37HL037260, R55HL036611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37260, HL36611] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE J, 1993, J EXP MED, V177, P791, DOI 10.1084/jem.177.3.791; ABE J, 1992, P NATL ACAD SCI USA, V89, P4066, DOI 10.1073/pnas.89.9.4066; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHU MC, 1988, INFECT IMMUN, V56, P2702, DOI 10.1128/IAI.56.10.2702-2708.1988; DRAKE CG, 1992, J CLIN IMMUNOL, V12, P149, DOI 10.1007/BF00918083; HOKONOHARA M, 1987, JPN CIRC J, V51, P1353, DOI 10.1253/jcj.51.1353; HYNES WL, 1985, J MICROBIOL METH, V4, P25, DOI 10.1016/0167-7012(85)90004-1; KASS EH, 1988, J INFECT DIS, V158, P44, DOI 10.1093/infdis/158.1.44; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; LEE PK, 1989, J CLIN MICROBIOL, V27, P1890, DOI 10.1128/JCM.27.8.1890-1892.1989; LEE PK, 1992, J INFECT DIS, V165, P1056, DOI 10.1093/infdis/165.6.1056; Leung D Y, 1993, Curr Opin Rheumatol, V5, P41; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; LEUNG DYM, 1983, J IMMUNOL, V130, P2002; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MUSSER JM, 1990, P NATL ACAD SCI USA, V87, P225, DOI 10.1073/pnas.87.1.225; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; RECSEI P, 1986, MOL GEN GENET, V202, P58, DOI 10.1007/BF00330517; RIDER LG, 1991, LANCET, V337, P1100, DOI 10.1016/0140-6736(91)91751-F; SCHLIEVERT PM, 1982, ANN INTERN MED, V96, P937, DOI 10.7326/0003-4819-96-6-937; SCHLIEVERT PM, 1983, J INFECT DIS, V147, P236, DOI 10.1093/infdis/147.2.236; SUZUKI A, 1986, PEDIATR CARDIOL, V7, P3, DOI 10.1007/BF02315475; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; TODD JK, 1984, INFECT IMMUN, V45, P339, DOI 10.1128/IAI.45.2.339-344.1984; TOMAI MA, 1992, INFECT IMMUN, V60, P701, DOI 10.1128/IAI.60.2.701-705.1992; 1990, JAMA-J AM MED ASSOC, V44, P1218	27	310	333	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1993	342	8884					1385	1388		10.1016/0140-6736(93)92752-F	http://dx.doi.org/10.1016/0140-6736(93)92752-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901681				2022-12-24	WOS:A1993MK09500009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MONOCLONAL-ANTIBODY LICENSED FOR USE IN ANGIOPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,560 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-24	WOS:A1995QP89000007
J	BERN, C; NATHANAIL, L				BERN, C; NATHANAIL, L			IS MID-UPPER-ARM CIRCUMFERENCE A USEFUL TOOL FOR SCREENING IN EMERGENCY SETTINGS	LANCET			English	Article							CHILDREN	In refugee emergencies, rapid collection of nutritional data provides important information for public-health planning. In Rwandan refugee camps in eastern Zaire in August, 1994, a two-step procedure of screening for referral to supplementary feeding programmes was used-mid-upper-arm circumference (MUAC) followed by weight-for-height for children with MUAC of less than 12 cm. To assess the usefulness of this procedure, we analysed data from complete screening of 3681 children in three camps. The performance of MUAC varied with the cut-off chosen; a high cut-off of 14 cm allowed detection of 88% of children with low weight-for-height but at the cost of measuring more than 40% of children in the second step. MUAC preferentially selects younger children as malnourished, and misses older children with low weight-for-height. The groups of children chosen by low MUAC and by low weight-for-height have poor overlap, varying from 20% to 391 overlap depending on age. Thus two-step screening does not save as much time as might be expected and low MUAC cannot be used as a substitute for low weight-for-height. For decision-making in refugee settings, weight-for-height surveys or screening are probably more efficient strategies for data collection.	SAVE CHILDREN FUND,POLICY DEPT UNIT,LONDON,ENGLAND	Save the Children	BERN, C (corresponding author), CTR DIS CONTROL & PREVENT,DIV NUTR,MATERNAL & CHILD HLTH BRANCH,ATLANTA,GA 30341, USA.							[Anonymous], 1986, WEIGH MEASURE CHILDR; BRIEND A, 1986, BRIT MED J, V293, P373, DOI 10.1136/bmj.293.6543.373; DEONIS M, 1993, B WORLD HEALTH ORGAN, V71, P703; GAYLE HD, 1988, J TROP PEDIATRICS, V34, P213, DOI 10.1093/tropej/34.5.213; GOLAZ A, 1994, 43RD EP INT SERV ANN; HALL G, 1993, LANCET, V341, P1481, DOI 10.1016/0140-6736(93)90927-9; JELIFFE DB, 1969, J TROP PEDIATRICS, V15, P177; LINDTJORN B, 1985, LANCET, V2, P1229; REES DG, 1987, LANCET, V1, P87; YOUNG H, 1992, FOOD SCARCITY FAMINE; 1986, B WORLD HEALTH ORGAN, V64, P929; 1993, GUIDELINES SUPPLEMEN; IN PRESS REPORT EXPE; 1992, MMWR-MORBID MORTAL W, V41, P1	14	24	24	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					631	633		10.1016/S0140-6736(95)90527-8	http://dx.doi.org/10.1016/S0140-6736(95)90527-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898183				2022-12-24	WOS:A1995QM07500015
J	VERBEEK, S; IZON, D; HOFHUIS, F; ROBANUSMAANDAG, E; TERIELE, H; VANDEWETERING, M; OOSTERWEGEL, M; WILSON, A; MACDONALD, HR; CLEVERS, H				VERBEEK, S; IZON, D; HOFHUIS, F; ROBANUSMAANDAG, E; TERIELE, H; VANDEWETERING, M; OOSTERWEGEL, M; WILSON, A; MACDONALD, HR; CLEVERS, H			AN HMG-BOX-CONTAINING T-CELL FACTOR REQUIRED FOR THYMOCYTE DIFFERENTIATION	NATURE			English	Article							TRANSCRIPTION FACTOR; RECEPTOR GENES; MICE; LYMPHOCYTES; PROTEIN; DOMAIN; TCF-1; LEF-1; BLOCK	Two candidate genes for controlling thymocyte differentiation, T-cell factor-1 (Tcf-1) and lymphoid enhancer-binding factor (Lef-1), encode closely related DNA-binding HMG-box proteins(1,2). Their expression pattern is complex and largely overlapping during embryogenesis, yet restricted to lymphocytes postnatally(3). Here we generate two independent germline mutations in Tcf-1 and find that thymocyte development is (otherwise normal) mutant mice is blocked at the transition from the CD8(+), immature single-positive to the CD4(+)/CD8(+) double-positive stage. Is contrast to wild-type mice, most of the immature single-positive cells in the mutants are not in the cell cycle and the number of immunocompetent T cells in peripheral lymphoid organs is reduced. We conclude that Tcf-1 controls an essential step in thymocyte differentiation.	UNIV UTRECHT HOSP,DEPT IMMUNOL,3508 GA UTRECHT,NETHERLANDS; NETHERLANDS CANC INST,DIV IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; UNIV LAUSANNE,LUDWIG INST CANC RES,CH-1066 EPALINGES,SWITZERLAND	Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; Netherlands Cancer Institute; Ludwig Institute for Cancer Research; University of Lausanne			Wilson, Anne/A-7131-2011					CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; OOSTERWEGEL M, 1992, J EXP MED, V173, P1133; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, J BIOL CHEM, V267, P8530; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; WILSON A, 1994, J EXP MED, V179, P1355, DOI 10.1084/jem.179.4.1355	20	423	426	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					70	74		10.1038/374070a0	http://dx.doi.org/10.1038/374070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870176	Green Submitted			2022-12-24	WOS:A1995QK07900055
J	LEPAGE, T; COHEN, SM; DIAZBENJUMEA, FJ; PARKHURST, SM				LEPAGE, T; COHEN, SM; DIAZBENJUMEA, FJ; PARKHURST, SM			SIGNAL-TRANSDUCTION BY CAMP-DEPENDENT PROTEIN-KINASE-A IN DROSOPHILA LIMB PATTERNING	NATURE			English	Article							HEDGEHOG GENE; PATCHED GENE; POLARITY; TRANSCRIPTION; ORGANIZATION; EXPRESSION; DIRECTS; CELLS	INTERACTION between distinctly specified cells in adjacent compartments establishes organizing centres that control growth and specify cell fate in the developing limbs of Drosophila(1-5). Localized expression of the secreted Hedgehog protein (Hh) by cells in the posterior compartment(6-8) induces expression of the secreted signalling molecules decapentaplegic (dpp) or wingless (wg) in nearby anterior cells(2,3). wg and dpp in turn organize spatial pattern in the wing and leg imaginal discs(2,4,9). The Hh signal is thought to act by antagonizing the ability of the patched (ptc) gene product to repress log and dpp expression(10-14). Here we present evidence that removing activity of the gene encoding cyclic AMP-dependent protein kinase A (pka) is functionally equivalent to removing ptc activity or to providing cells with the Hh signal. These findings suggest that cyclic AMP-dependent protein kinase A is a component of the signal transduction pathway through which Hh and Ptc direct localized expression of dpp (or wg) and establish the compartment boundary organizer.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,A1-162,SEATTLE,WA 98104	European Molecular Biology Laboratory (EMBL); Fred Hutchinson Cancer Center			Cohen, Stephen M/G-9930-2011; Lepage, Thierry/V-4208-2019; Diaz-Benjumea, Fernando/K-7667-2014; Lepage, Thierry/AAF-8925-2019	Cohen, Stephen M/0000-0003-2858-9163; Lepage, Thierry/0000-0003-2889-5064; Diaz-Benjumea, Fernando/0000-0003-3007-2489; 				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FORBES AJ, 1993, DEVELOPMENT, P115; GRAU Y, 1987, DEV BIOL, V122, P186, DOI 10.1016/0012-1606(87)90344-7; HARTWELL L, 1994, NATURE, V371, P286, DOI 10.1038/371286a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; RAFERTY LA, 1991, DEVELOPMENT, V113, P27; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; STRADLER CD, 1994, REV BIOCH, V63, P101; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TOROK T, 1993, GENETICS, V35, P71; Watson S., 1994, G PROTEIN LINKED REC; XU T, 1993, DEVELOPMENT, V117, P1223	29	151	159	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					711	715		10.1038/373711a0	http://dx.doi.org/10.1038/373711a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854456				2022-12-24	WOS:A1995QH92800058
J	ALBEROLAILA, J; FORBUSH, KA; SEGER, R; KREBS, EG; PERLMUTTER, RM				ALBEROLAILA, J; FORBUSH, KA; SEGER, R; KREBS, EG; PERLMUTTER, RM			SELECTIVE REQUIREMENT FOR MAP KINASE ACTIVATION IN THYMOCYTE DIFFERENTIATION	NATURE			English	Article							T-CELL ACTIVATION; EXPRESSION; INVIVO; MICE	ENGAGEMENT of the T-cell receptor (TCR) with cognate ligands provokes different outcomes depending on the developmental stage of the T cell and on the properties of the ligand. In immature thymocytes TCR stimulation may result in maturation (positive selection) or death (negative selection), whereas in mature T cells it may induce proliferation, death or unresponsiveness(1-5). To investigate the different signals involved in these processes, we have analysed the role of the MAP kinase (MAPK) cascade, which is required for growth-factor-stimulated replication and for differentiation in other cell types(6-9), by expressing a catalytically inactive form of MAPK kinase (MEK-1) in thymocytes, thereby blocking MAPK activation, We find that positive selection of these cells is inhibited but that negative selection and TCR-induced proliferation are unaffected. Our results indicate that the intracellular signals regulating lineage commitment in T cells parallel those in photoreceptor cell specification in Drosophila(10) and vulval cell differentiation in Caenorhabditis elegans(11), suggesting that general rules for cell-type specification could apply among all metazoans.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	ALBEROLAILA, J (corresponding author), UNIV WASHINGTON,DEPT IMMUNOL,SL-15,SEATTLE,WA 98195, USA.			alberola-ila, Jose/0000-0003-2439-553X				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGERTON M, 1990, INT IMMUNOL, V2, P501, DOI 10.1093/intimm/2.6.501; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1992, J BIOL CHEM, V267, P25628; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; VONBOEHMER H, 1991, J EXP MED, V174, P1001, DOI 10.1084/jem.174.5.1001; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	29	360	362	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					620	623		10.1038/373620a0	http://dx.doi.org/10.1038/373620a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854419				2022-12-24	WOS:A1995QG99700056
J	JOLIET, V; DEMMA, M; PRYWES, R				JOLIET, V; DEMMA, M; PRYWES, R			INTERACTION WITH RAP74 SUBUNIT OF TFIIF IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION BY SERUM RESPONSE FACTOR	NATURE			English	Article							RNA POLYMERASE-II; TERNARY COMPLEX-FORMATION; INITIATION-FACTOR; DOMAIN; CDNA; SRF; DNA	A FEW general transcription factors, in particular TFIID and TFIIB, have been found to bind transcriptional activators(1). Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter. Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding. Further, RAP74's central charged cluster domain is required for binding to SRF's activation domain. Deletion of this domain impairs RAP74's ability to support SRF-activated transcription in vitro but has Little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription. The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University								ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P195; CHANG CH, 1993, J BIOL CHEM, V268, P20482; DALTON S, 1992, CELL, V88, P597; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1989, J BIOL CHEM, V284, P8913; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V386, P466; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LIU SH, 1993, J BIOL CHEM, V268, P21147; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273; ZHU H, 1994, J BIOL CHEM, V269, P3489	23	73	75	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					632	635		10.1038/373632a0	http://dx.doi.org/10.1038/373632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854423				2022-12-24	WOS:A1995QG99700060
J	SHAYWITZ, BA; SHAYWITZ, SE; PUGH, KR; CONSTABLE, RT; SKUDLARSKI, P; FULBRIGHT, RK; BRONEN, RA; FLETCHER, JM; SHANKWEILER, DP; KATZ, L; GORE, JC				SHAYWITZ, BA; SHAYWITZ, SE; PUGH, KR; CONSTABLE, RT; SKUDLARSKI, P; FULBRIGHT, RK; BRONEN, RA; FLETCHER, JM; SHANKWEILER, DP; KATZ, L; GORE, JC			SEX-DIFFERENCES IN THE FUNCTIONAL-ORGANIZATION OF THE BRAIN FOR LANGUAGE	NATURE			English	Article							SENSORY STIMULATION; ASYMMETRY	A MUCH debated question is whether sex differences exist in the functional organization of the brain for language(1-4). A long-held hypothesis posits that language functions are more likely to be highly lateralized in males and to be represented in both cerebral hemispheres in females(5,6), but attempts to demonstrate this have been inconclusive(7-17). Here we use echo-planar functional magnetic resonance imaging(18-21) to study 38 right-handed subjects (19 males and 19 females) during orthographic (letter recognition), phonological (rhyme) and semantic (semantic category) tasks. During phonological tasks, brain activation in males is lateralized to the left inferior frontal gyrus regions; in females the pattern of activation is very different, engaging more diffuse neural systems that involve both the left and right inferior frontal gyrus. Our data provide clear evidence for a sex difference in the functional organization of the brain for language and indicate that these variations exist at the level of phonological processing.	YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; HASKINS LABS INC,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT DIAGNOST RADIOL,NEW HAVEN,CT 06510; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77030; YALE UNIV,BECTON ENGIN & APPL SCI CTR,DEPT APPL PHYS,NEW HAVEN,CT 06520	Yale University; Yale University; Haskins Laboratories; Yale University; University of Texas System; Yale University	SHAYWITZ, BA (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,POB 208064,NEW HAVEN,CT 06510, USA.		Constable, R. Todd/ABE-8038-2021; Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019	Constable, R. Todd/0000-0001-5661-9521; 				BRADSHAW JL, 1978, BRAIN LANG, V5, P166, DOI 10.1016/0093-934X(78)90016-0; Bryden M.P., 1988, HDB DICHOTIC LISTENI, P1, DOI DOI 10.1002/ACP.2350040307; Demonet J. F., 1993, Human Brain Mapping, V1, P39, DOI 10.1002/hbm.460010105; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; DEMONET JF, 1994, BRAIN, V117, P671, DOI 10.1093/brain/117.4.671; EFRON R, 1990, DECLINE FALL HEMISPH, P1; FRACKOWIAK RSJ, 1994, TRENDS NEUROSCI, V17, P109, DOI 10.1016/0166-2236(94)90119-8; FRISTON KJ, 1994, HUMAN BRAIN MAPPING, V1, P69; HALPERN D, 1992, SEX DIFFERENCES COGN, P1; HAMPSON E, 1992, P357; HARSHMAN R, 1983, LANGUAGE BRAIN, V3; HELLIGE JB, 1993, HEMISPHERIC ASYMMETR, P1; HINES M, 1990, HORMONES BRAIN BEHAV, V1, P51; INGLIS J, 1981, SCIENCE, V212, P693, DOI 10.1126/science.7221560; KULYNYCH JJ, 1994, CEREB CORTEX, V4, P107, DOI 10.1093/cercor/4.2.107; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LACCINO J, 1993, LEFT BRAIN RIGHT BRA, P1; LEVY J, 1972, BIOL BEHAVIOR; LUKATELA G, 1991, J EXP PSYCHOL HUMAN, V17, P951, DOI 10.1037/0096-1523.17.4.951; MCCARTHY G, 1993, P NATL ACAD SCI USA, V90, P4952, DOI 10.1073/pnas.90.11.4952; MCGLONE J, 1977, BRAIN, V100, P775, DOI 10.1093/brain/100.4.775; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PETERSEN SE, 1993, ANNU REV NEUROSCI, V1, P509; PUGH KR, 1994, J EXP PSYCHOL HUMAN, V20, P807, DOI 10.1037/0096-1523.20.4.807; SHAYWITZ BA, 1995, HUM BRAIN MAPP, V2, P21; Talairach J., 1988, COPLANAR STEREOTAXIC; TENG EL, 1981, NEUROPSYCHOLOGIA, V19, P235, DOI 10.1016/0028-3932(81)90107-X; VOYER D, 1990, BRAIN COGNITION, V13, P18, DOI 10.1016/0278-2626(90)90037-O; WITELSON SF, 1992, J COMP NEUROL, V323, P326, DOI 10.1002/cne.903230303	30	973	997	1	82	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					607	609		10.1038/373607a0	http://dx.doi.org/10.1038/373607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG997	7854416				2022-12-24	WOS:A1995QG99700052
J	LI, P; ALLEN, H; BANERJEE, S; FRANKLIN, S; HERZOG, L; JOHNSTON, C; MCDOWELL, J; PASKIND, M; RODMAN, L; SALFELD, J; TOWNE, E; TRACEY, D; WARDWELL, S; WEI, FY; WONG, W; KAMEN, R; SESHADRI, T				LI, P; ALLEN, H; BANERJEE, S; FRANKLIN, S; HERZOG, L; JOHNSTON, C; MCDOWELL, J; PASKIND, M; RODMAN, L; SALFELD, J; TOWNE, E; TRACEY, D; WARDWELL, S; WEI, FY; WONG, W; KAMEN, R; SESHADRI, T			MICE DEFICIENT IN IL-1-BETA-CONVERTING ENZYME ARE DEFECTIVE IN PRODUCTION OF MATURE IL-1-BETA AND RESISTANT TO ENDOTOXIC-SHOCK	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; DEATH GENE CED-3; CELL-DEATH; APOPTOSIS; PROTEASE; PRECURSOR; RECEPTOR; SURVIVAL; IDENTIFICATION; MONOCYTOGENES	IL-1 beta-converting enzyme (ICE) cleaves pro-IL-1 beta to generate mature IL-1 beta. ICE is homologous to other proteins that have been implicated in apoptosis, including CED-3 and Nedd-2/Ich-1. We generated ICE-deficient mice and observed that they are overtly normal but have a major defect in the production of mature IL-1 beta after stimulation with lipopolysaccharide. IL-1 alpha production is also impaired. ICE-deficient mice are resistant to endotoxic shock. Thymocytes and macrophages from the ICE-deficient animals undergo apoptosis normally. ICE therefore plays a dominant role in the generation of mature IL-1 beta, a previously unsuspected role in production of IL-1 alpha, but has no autonomous function in apoptosis.			LI, P (corresponding author), BASF BIORES CORP,100 RES DR,WORCESTER,MA 01605, USA.							ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; AYALA JM, 1994, J IMMUNOL, V53, P2592; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sambrook J., 1989, MOL CLONING LAB MANU; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; STRANGE R, 1992, DEVELOPMENT, V115, P49; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Togni PD, 1994, SCIENCE, V264, P703; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	51	1277	1328	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					401	411		10.1016/0092-8674(95)90490-5	http://dx.doi.org/10.1016/0092-8674(95)90490-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859282	Bronze			2022-12-24	WOS:A1995QG47000006
J	ROSSING, P; TARNOW, L; NIELSEN, FS; BOELSKIFTE, S; BRENNER, BM; PARVING, HH				ROSSING, P; TARNOW, L; NIELSEN, FS; BOELSKIFTE, S; BRENNER, BM; PARVING, HH			SHORT STATURE AND DIABETIC NEPHROPATHY	BRITISH MEDICAL JOURNAL			English	Article							MICROALBUMINURIA; HYPERTENSION; HEIGHT		DANISH COMP CTR RES & EDUC,UNI C,DK-8200 AARHUS N,DENMARK; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	ROSSING, P (corresponding author), STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK.		rossing, peter/AAZ-3415-2021; rossing, peter/AAH-7879-2021	rossing, peter/0000-0002-1531-4294; Tarnow, Lise/0000-0002-8735-966X				BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRENNER BM, 1994, AM J KIDNEY DIS, V23, P171, DOI 10.1016/S0272-6386(12)80967-X; GOULD MM, 1993, BMJ-BRIT MED J, V306, P240, DOI 10.1136/bmj.306.6872.240; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156	5	64	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					296	297		10.1136/bmj.310.6975.296	http://dx.doi.org/10.1136/bmj.310.6975.296			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866171	Green Published			2022-12-24	WOS:A1995QF71700025
J	DEBONO, D				DEBONO, D			DIGOXIN IN EURHYTHMIC HEART-FAILURE - PROVED OR NOT PROVEN	LANCET			English	Editorial Material											DEBONO, D (corresponding author), UNIV LEICESTER,DEPT MED,DIV CARDIOL,LEICESTER LE1 7RH,ENGLAND.							NOBLE D, 1980, CARDIOVASC RES, V14, P495, DOI 10.1093/cvr/14.9.495; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PUGH SE, 1989, BRIT HEART J, V61, P529; SMITH T W, 1988, New England Journal of Medicine, V318, P358; SMITH TW, 1993, NEW ENGL J MED, V329, P51, DOI 10.1056/NEJM199307013290111; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; YUSUF S, 1992, AM J CARDIOL, V69, pG64, DOI 10.1016/0002-9149(92)91255-3; 1991, NEW ENGL J MED, V325, P293; 1987, NEW ENGL J MED, V316, P1429	9	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					128	129		10.1016/S0140-6736(94)90926-1	http://dx.doi.org/10.1016/S0140-6736(94)90926-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903996				2022-12-24	WOS:A1994MQ86900002
J	SUZUKI, S; NAKATOMI, Y; SATO, H; TSUKADA, H; ARAKAWA, M				SUZUKI, S; NAKATOMI, Y; SATO, H; TSUKADA, H; ARAKAWA, M			HAEMOPHILUS-PARAINFLUENZAE ANTIGEN AND ANTIBODY IN RENAL BIOPSY SAMPLES AND SERUM OF PATIENTS WITH IGA NEPHROPATHY	LANCET			English	Article							FC-RECEPTOR; VIRUS; DEPOSITION; PROTEINS	IgA nephropathy may be associated with colonisation with Haemophilus parainfluenzae. In patients with glomerular diseases, we examined renal-biopsy specimens for presence of bacterial antigen by immunofluorescence microscopy with rabbit antiserum against H parainfluenzae, and by enzyme-linked immunosorbent assay looked for IgA antibody against H parainfluenzae in patient sera. The rabbit antiserum recognised by immunoblotting four components of H parainfluenzae outer membranes (OMHP) of molecular weights 19.5, 30, 33, and 40 5 kDa. All 44 patients with IgA nephropathy and 2 of 3 9 patients with other glomerular diseases showed mesangial deposition of OMHP antigens (p<0.001). Patients with IgA nephropathy had significantly more IgA antibody against H parainfluenzae than did patients with other glomerular diseases. IgA antibody in the sera of patients with IgA nephropathy recognised by immunoblotting the same four components of OMHP as recognised by rabbit antiserum. Glomerular deposition of OMHP antigens and the presence of IgA antibody against OMHP in patients with IgA nephropathy suggest that H parainfluenzae has a role in the aetiology of this disease.	DENKA SELKEN CO LTD,DIV RES & DEV,NIIGATA,JAPAN		SUZUKI, S (corresponding author), NIIGATA UNIV,SCH MED,DEPT MED 2,ASAHIMACHI DORI,NIIGATA 951,JAPAN.							ANDRE PM, 1990, NEPHRON, V54, P185, DOI 10.1159/000185845; BERGER J, 1969, TRANSPL P, V1, P939; BORRADORI L, 1990, NEPHRON, V56, P35, DOI 10.1159/000186097; CLARKSON AR, 1984, CLIN NEPHROL, V21, P7; COPPO R, 1990, CLIN NEPHROL, V33, P72; DAMICO G, 1985, NEPHRON, V41, P1, DOI 10.1159/000183538; DAVIN JC, 1987, KIDNEY INT, V31, P1132, DOI 10.1038/ki.1987.119; GREGORY MC, 1988, LANCET, V1, P11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI KN, 1988, CLIN NEPHROL, V29, P229; LAWRENCE S, 1983, CLIN NEPHROL, V16, P280; MORTON DJ, 1989, J GEN MICROBIOL, V135, P445; NICHOLLS K, 1984, AM J KIDNEY DIS, V4, P128, DOI 10.1016/S0272-6386(84)80060-8; ROCCATELLO D, 1985, CLIN NEPHROL, V23, P159; SATO M, 1988, CLIN EXP IMMUNOL, V73, P295; SUZUKI S, 1992, AM J NEPHROL, V12, P22, DOI 10.1159/000168413; TOMINO Y, 1987, NEPHRON, V47, P258, DOI 10.1159/000184520; WOODROFFE AJ, 1980, KIDNEY INT, V18, P366, DOI 10.1038/ki.1980.147	18	111	120	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					12	16		10.1016/S0140-6736(94)90875-3	http://dx.doi.org/10.1016/S0140-6736(94)90875-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905040				2022-12-24	WOS:A1994MN93700011
J	TAKESHIMA, Y; SEYAMA, T; BENNETT, WP; AKIYAMA, M; TOKUOKA, S; INAI, K; MABUCHI, K; LAND, CE; HARRIS, CC				TAKESHIMA, Y; SEYAMA, T; BENNETT, WP; AKIYAMA, M; TOKUOKA, S; INAI, K; MABUCHI, K; LAND, CE; HARRIS, CC			P53 MUTATIONS IN LUNG CANCERS FROM NONSMOKING ATOMIC-BOMB SURVIVORS	LANCET			English	Note							GENE	Tobacco smoke contains many carcinogens and has been linked with the development of lung cancer. We sequenced the conserved regions of the p53 tumour suppressor gene in lung cancers from 17 non-smokers from Hiroshima, Japan; 9 were atomic-bomb survivors. The mutations were predominantly transitions (all G:C to A:T); there were no G:C to T:A transversions. By contrast, lung cancers from 77 Japanese smokers have a predominance of G:C to T:A transversions in which the guanine residues occur on the non-transcribed DNA strand. These findings further implicate tobacco smoke carcinogens in the molecular pathogenesis of lung cancer.	NCI,BLDG 37,ROOM 2C05,BETHESDA,MD 20892; HIROSHIMA UNIV,SCH MED,HIROSHIMA 730,JAPAN; RADIAT EFFECTS RES FDN,HIROSHIMA 730,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hiroshima University; Radiation Effects Research Foundation - Japan					NCI NIH HHS [NCI N01-CP-71128] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP071128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		EVANS MK, IN PRESS CANCER RES; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; MILLER CW, 1992, CANCER RES, V52, P1695; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2	10	108	109	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1520	1521		10.1016/S0140-6736(05)80087-X	http://dx.doi.org/10.1016/S0140-6736(05)80087-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902903				2022-12-24	WOS:A1993MM40200014
J	BAILEY, TC; FRASER, VJ; SPITZNAGEL, EL; DUNAGAN, WC				BAILEY, TC; FRASER, VJ; SPITZNAGEL, EL; DUNAGAN, WC			RISK-FACTORS FOR A POSITIVE TUBERCULIN SKIN-TEST AMONG EMPLOYEES OF AN URBAN, MIDWESTERN TEACHING HOSPITAL	ANNALS OF INTERNAL MEDICINE			English	Article						TUBERCULIN TEST; AGE FACTORS; RACIAL STOCKS; SOCIOECONOMIC FACTORS; TUBERCULOSIS	HEALTH-CARE WORKERS; MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL TRANSMISSION; INFECTION; OUTBREAK; PROGRAM	Objective: To determine the prevalence and incidence of and the relative risks for positive tuberculin skin tests among employees of a large, urban teaching hospital. Design: Retrospective cohort study. Setting: Barnes Hospital, St, Louis, Missouri. Participants: Hospital personnel employed at any time between January 1989 and July 1991. Results: 684 of 6070 employees screened (11.3% [95% CI, 10.4% to 12.1%]) had positive tuberculin skin tests. Factors associated with a positive result were age (odds ratio, 2.02 per decade [CI, 1.87 to 2.18]; P < 0.0001); black race (odds ratio, 1.58 [CI, 1.26 to 2.00]; P < 0.0001); Asian race (odds ratio, 16.7 [CI, 9.33 to 29.9]; P < 0.0001); Hispanic ethnicity (odds ratio, 9.45 [CI, 3.58 to 25.0]; P < 0.0001); and percentage of low-income persons within the employee's residential postal zone (odds ratio, 1.14 per 10% [CI, 1.05 to 1.23]; P = 0.001). Twenty-nine of 3106 employees who had at least two tests had skin-test conversions (0.93% [CI, 0.60% to 1.3%]); 15 of these conversions (52%) occurred among employees who had no direct contact with patients. Only the percentage of low-income persons within the employee's residential postal zone (odds ratio 1.39 [CI, 1.09 to 1.78]; P = 0.0075) was independently associated with conversion. Conclusions: The most important associations with a positive tuberculin skin test were older age, minority group status, and the proportion of low-income persons within the employee's residential postal zone. Skin-test conversion was independently associated only with the percentage of low-income persons in the employee's postal zone. Stratifying employees according to degree of contact with patients or according to departmental group was not useful in determining risk for a positive tuberculin skin test or for skin-test conversion. For certain groups of employees, an exposure to tuberculosis in the community probably poses a greater risk than exposure in the hospital setting.			BAILEY, TC (corresponding author), WASHINGTON UNIV, SCH MED, BOX 8217, 660 S EUCLID, ST LOUIS, MO 63110 USA.			Fraser, Victoria/0000-0001-6251-0733				ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306; AITKEN ML, 1987, AM REV RESPIR DIS, V136, P805, DOI 10.1164/ajrccm/136.4.805; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; BERMAN J, 1981, AM J PUBLIC HEALTH, V71, P1217, DOI 10.2105/AJPH.71.11.1217; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECKER MD, 1993, INFECT CONT HOSP EP, V14, P689, DOI 10.1086/646671; DIPERRI G, 1992, LANCET, V340, P682; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRASER VJ, 1994, INFECT CONT HOSP EP, V15, P95; FRASER VJ, 1993, INFECT CONT HOSP EP, V14, P623; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; HOGE CW, 1994, AM J EPIDEMIOL, V139, P520, DOI 10.1093/oxfordjournals.aje.a117035; JARVIS WR, 1995, ANN INTERN MED, V122, P142, DOI 10.7326/0003-4819-122-2-199501150-00011; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; LIFSON AR, 1993, J INFECT DIS, V168, P1048, DOI 10.1093/infdis/168.4.1048; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAAD I, 1989, INFECT CONT HOSP EP, V10, P465, DOI 10.1086/645922; RILEY RL, 1962, AM REV RESPIR DIS, V85, P511; SNIDER DE, 1984, AM J INFECT CONTROL, V12, P305, DOI 10.1016/0196-6553(84)90001-4; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STROUD L, 1993, INTERSCIENCE C ANTIM; 1990, MMWR-MORBID MORTAL W, V39, P9; 1994, FED REGISTER, V59, P54242	33	61	63	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					580	585		10.7326/0003-4819-122-8-199504150-00004	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887551				2022-12-24	WOS:A1995QR52500004
J	SANCHEZGUERRERO, J; LIANG, MH; KARLSON, EW; HUNTER, DJ; COLDITZ, GA				SANCHEZGUERRERO, J; LIANG, MH; KARLSON, EW; HUNTER, DJ; COLDITZ, GA			POSTMENOPAUSAL ESTROGEN THERAPY AND THE RISK FOR DEVELOPING SYSTEMIC LUPUS-ERYTHEMATOSUS	ANNALS OF INTERNAL MEDICINE			English	Note							LOW PLASMA ANDROGENS; PROSPECTIVE COHORT; WOMEN; GLOMERULONEPHRITIS; PATHOGENESIS; SURVIVAL; MICE	Objective: To examine the relation between postmenopausal hormone use and development of systemic lupus erythematosus. Design: Prospective cohort study. Setting: Nurses' Health Study. Patients: 69 435 women aged 30 to 55 years in 1976 who reported that they had completed menopause and did not have systemic lupus erythematosus or any connective tissue disease were followed every 2 years from 1976 to 1990. These women were classified as never- or ever-(current and past) users of postmenopausal hormones. Measurements: Incidence rates of systemic lupus erythematosus and classification criteria from the American College of Rheumatology that were confirmed by chart review. Results: With never-users of postmenopausal hormones as the reference group, age-adjusted relative risks for systemic lupus erythematosus (n = 45 women) were 2.1 (95% CI, 1.1 to 4.0) for ever-users, 2.5 (CI, 1.2 to 5.0) for current users, and 1.8 (CI, 0.8 to 4.1) for past users. A proportional increase in the risk for systemic lupus erythematosus was observed that was related to the duration of use of postmenopausal hormones (test for trend, P = 0.011). Conclusions: Postmenopausal hormone therapy is associated with an increased risk for developing systemic lupus erythematosus.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	FOGARTY INTERNATIONAL CENTER [F05TW004573] Funding Source: NIH RePORTER; FIC NIH HHS [5F05 TW04573-02] Funding Source: Medline; NCI NIH HHS [CA 40396] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALARCONSEGOVIA D, 1984, J RHEUMATOL, V11, P588; COHEN JHM, 1983, J IMMUNOL, V131, P2767; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JUNGERS P, 1982, ARTHRITIS RHEUM, V25, P454, DOI 10.1002/art.1780250415; KARLSON EW, 1995, IN PRESS ANN EPIDEMI; KELLEY VE, 1980, CLIN IMMUNOL IMMUNOP, V16, P142, DOI 10.1016/0090-1229(80)90198-1; LAHITA RG, 1981, J CLIN ENDOCR METAB, V53, P174, DOI 10.1210/jcem-53-1-174; LAHITA RG, 1987, ARTHRITIS RHEUM, V30, P241, DOI 10.1002/art.1780300301; MASI AT, 1978, ARTHRITIS RHEUM-US, V21, P480, DOI 10.1002/art.1780210413; ROTHMAN KJ, 1979, PHS NIH791649 PUBL; ROUBINIAN JR, 1979, J CLIN INVEST, V63, P902, DOI 10.1172/JCI109390; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; Silman AJ, 1993, EPIDEMIOLOGY RHEUMAT, P163; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tosteson Anna N. A., 1994, P405	18	165	177	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					430	433		10.7326/0003-4819-122-6-199503150-00005	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856991				2022-12-24	WOS:A1995QM26600005
J	COHN, MJ; IZPISUABELMONTE, JC; ABUD, H; HEATH, JK; TICKLE, C				COHN, MJ; IZPISUABELMONTE, JC; ABUD, H; HEATH, JK; TICKLE, C			FIBROBLAST GROWTH-FACTORS INDUCE ADDITIONAL LIMB DEVELOPMENT FROM THE FLANK OF CHICK-EMBRYOS	CELL			English	Article							APICAL ECTODERMAL RIDGE; POLARIZING ACTIVITY; EXPRESSION; RECEPTOR; BUD; MOUSE; CELLS; LOCALIZATION; GENES; FGF-4	Fibroblast growth factors (FGFs) act as signals in the developing limb and can maintain proliferation of limb bud mesenchyme cells. Remarkably, beads soaked in FGF-1, FGF-2, or FGF-4 and placed in the presumptive flank of chick embryos induce formation of ectopic limb buds, which can develop into complete limbs. The entire flank can produce additional limbs, but generally wings are formed anteriorly and legs posteriorly. FGF application activates Sonic hedgehog in cells with polarizing potential to make a discrete polarizing region. Hoxd-13 is also expressed in the ectopic bud, and an apical ectodermal ridge forms. A limb bud is thus established that can generate the appropriate signals to develop into a complete limb. The additional limbs have reversed polarity. This can be explained by the distribution of cells in the flank with potential polarizing activity. The results suggest that local production of an FGF may initiate limb development.	SALK INST BIOL STUDIES,GENE EXPRESS LABS,LA JOLLA,CA 92037; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	Salk Institute; University of Oxford; University of Birmingham	COHN, MJ (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DB,ENGLAND.			Abud, Helen/0000-0003-3792-4023	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; Balinsky B. I., 1933, ROUXS ARCH, V130, P704; BALINSKY BI, 1925, ROUX ARCH DEV BIOL, V143, P718; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CROSSLEY PH, 1995, IN PRESS DEVELOPMENT; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; IZPISUABELMONTE JC, 1992, DEVELOPMENT, V115, P553; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIORTSIS VASSILI, 1953, REV SUISSE ZOOL, V60, P301; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LOCATELLI P, 1924, B SOC MED CHIR PA, P36; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MESCHER AL, 1979, J EXP ZOOL, V207, P497, DOI 10.1002/jez.1402070318; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOLVEN A, 1990, DEVELOPMENT, V109, P279; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; OLIVER G, 1988, CELL, V55, P1017, DOI 10.1016/0092-8674(88)90246-2; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PETERS KG, 1992, DEVELOPMENT, V114, P233; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; SEARLS RL, 1964, DEV BIOL, V9, P35; SUMMERBELL D, 1973, NATURE, V224, P492; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; THOMAS KA, 1993, NEUROTROPHIC FACTORS, P285; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	48	484	491	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					739	746		10.1016/0092-8674(95)90352-6	http://dx.doi.org/10.1016/0092-8674(95)90352-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889567	Bronze			2022-12-24	WOS:A1995QM39900010
J	MURATA, Y; WHARTON, RP				MURATA, Y; WHARTON, RP			BINDING OF PUMILIO TO MATERNAL HUNCHBACK MESSENGER-RNA IS REQUIRED FOR POSTERIOR PATTERNING IN DROSOPHILA EMBRYOS	CELL			English	Article							3' UNTRANSLATED REGION; POLE CELL-FORMATION; C-ELEGANS; DETERMINANT NANOS; HEAD DEVELOPMENT; BICOID PROTEIN; BODY PATTERN; GENE NANOS; RNA; SEGMENTATION	Posterior patterning in Drosophila embryos is governed by nanos (nos), which acts by repressing the translation of maternal transcripts of the hunchback (hb) gene. Sites in hb mRNA that mediate this repression, named nanos response elements (NREs), have been identified. However, we know of no evidence of a direct interaction between nos, or any other protein, and the NRE. Here, we show that two proteins present in embryonic extracts, neither one nos, bind specifically to the NRE in vitro. Furthermore, we show that binding in vitro correlates with NRE function in vivo. One of the NRE-binding factors is encoded by pumilio (pum), a gene that, like nos, is essential for abdominal segmentation. These and other observations suggest that pum acts by recognizing the NRE and then recruiting nos. Presumably, the resulting complex inhibits some component of the translation machinery.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT MICROBIOL, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute	MURATA, Y (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT GENET, DURHAM, NC 27710 USA.							AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ARMEIN H, 1994, CELL, V76, P735; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEN WN, 1991, YEAST, V7, P309, DOI 10.1002/yea.320070314; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; HARLOW E, 1988, ANTIBODIES LABORATOR; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	47	335	342	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					747	756		10.1016/0092-8674(95)90353-4	http://dx.doi.org/10.1016/0092-8674(95)90353-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889568	Bronze			2022-12-24	WOS:A1995QM39900011
J	HAY, JC; FISETTE, PL; JENKINS, GH; FUKAMI, K; TAKENAWA, T; ANDERSON, RA; MARTIN, TFJ				HAY, JC; FISETTE, PL; JENKINS, GH; FUKAMI, K; TAKENAWA, T; ANDERSON, RA; MARTIN, TFJ			ATP-DEPENDENT INOSITIDE PHOSPHORYLATION REQUIRED FOR CA2+-ACTIVATED SECRETION	NATURE			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; CYTOSOLIC PROTEINS; CHROMAFFIN CELLS; PHOSPHOLIPASE-C; EXOCYTOSIS; MEMBRANES; ANTIBODY; FUSION	REGULATED fusion of secretory granules with the plasma membrane in secretory cells requires ATP, Ca2+ and cytosolic(1-3) as well as membrane(4) proteins. ATP-dependent steps in Ca2+-activated secretion from PC12 cells require three cytosolic PEP proteins (priming in exocytosis proteins, PEP1-3)(5,6), the identity of which will provide insights into the required ATP-using reactions. PEP3 was recently identified as phosphatidylinositol transfer protein (PtdInsTP)(6), and here we report that PEP1 consists of the type I phosphatidylinositol-4-phosphate 5-kinase (PtdInsP5K), The roles of PEP3/PtdInsTP and PEP1/PtdInsP5K in sequential phosphoinositide recruitment and phosphorylation explains their synergistic activity in ATP-dependent priming, Moreover, inhibition of Ca2+-activated secretion by PtdIns(4,5)P-2-specific antibodies and phospholipase C implies that 5-phosphorylated inositides play a novel, necessary role in the regulated secretory pathway. The results indicate that lipid kinase-mediated phosphorylation is an important basis for ATP use in the exocytotic pathway.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT PHARMACOL,MADISON,WI 53706; UNIV WISCONSIN,CELL & MOLEC BIOL PROGRAM,MADISON,WI 53706; UNIV TOKYO,DEPT MOLEC ONCOL,TOKYO 108,JAPAN	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Tokyo				Anderson, Richard/0000-0001-6265-8359				ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BITTNER MA, 1993, CELL MOL NEUROBIOL, V13, P649, DOI 10.1007/BF00711564; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; LISCOVITCH M, 1993, J BIOL CHEM, V269, P21403; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; SCHOLZ G, 1992, EUR J BIOCHEM, V210, P461, DOI 10.1111/j.1432-1033.1992.tb17443.x; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; WU YN, 1992, BIOCHEM J, V285, P697, DOI 10.1042/bj2850697	30	444	451	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					173	177		10.1038/374173a0	http://dx.doi.org/10.1038/374173a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877690				2022-12-24	WOS:A1995QL39700062
J	NEWTON, JN; REDBURN, J				NEWTON, JN; REDBURN, J			INCIDENCE OF MELANOMA IN 4 ENGLISH COUNTIES, 1989-92	BRITISH MEDICAL JOURNAL			English	Article									ANGLIA & OXFORD REG HLTH AUTHOR,OXFORD CANC INTELLIGENCE UNIT,OXFORD OX3 7LF,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND	University of Oxford; University of Oxford				Newton, John/0000-0002-5641-6457				[Anonymous], 1992, IARC MONOGRAPHS EVAL, V55; ARMITRAGE P, 1987, STATISTICAL METHODS; GRAHAMBROWN RAC, 1990, BRIT J DERMATOL, V122, P53, DOI 10.1111/j.1365-2133.1990.tb08239.x; SHARP L, 1993, CANCER REGISTRATION; 1994, CANCER STATISTICS RE	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					502	503		10.1136/bmj.310.6978.502	http://dx.doi.org/10.1136/bmj.310.6978.502			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888890	Green Published			2022-12-24	WOS:A1995QJ59800023
J	PARVIN, JD; MCCORMICK, RJ; SHARP, PA; FISHER, DE				PARVIN, JD; MCCORMICK, RJ; SHARP, PA; FISHER, DE			PRE-BENDING OF A PROMOTER SEQUENCE ENHANCES AFFINITY FOR THE TATA-BINDING FACTOR	NATURE			English	Article							CRYSTAL-STRUCTURE; MINOR-GROOVE; BOX COMPLEX; TFIID BINDS; DNA; PROTEIN; ELEMENTS	TATA-binding protein (TBP) binds the minor groove of the TATA element with the DNA bent 80 degrees towards the major groove(1-4). A constrained minicircle strategy(5) has been used to test the effect of DNA topology on the affinity of TBP for the TATA element. We report here that TBP bound to DNA which was slightly pre-bent towards the major groove with 100-fold higher affinity than unbent (linear) DNA of identical sequence and 300-foId higher affinity than DNA pre-bent towards the minor groove, Similar discrimination was observed with the holo-TFIID transcription complex. DNA topology, particularly bending, is determined by many factors including chromatin in cells and may, through changes in the affinity of the TATA factor, be important in the control of transcription.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Parvin, Jeffrey D/C-8955-2009					BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM JL, 1994, NAT STRUCT BIOL, V1, P621; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KUDDUS R, 1993, NUCLEIC ACIDS RES, V21, P1789, DOI 10.1093/nar/21.8.1789; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E	19	163	165	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					724	727		10.1038/373724a0	http://dx.doi.org/10.1038/373724a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854460				2022-12-24	WOS:A1995QH92800062
J	PERRY, IJ; BEEVERS, DG; WHINCUP, PH; BAREFORD, D				PERRY, IJ; BEEVERS, DG; WHINCUP, PH; BAREFORD, D			PREDICTORS OF RATIO OF PLACENTAL WEIGHT TO FETAL WEIGHT IN MULTIETHNIC COMMUNITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IRON-DEFICIENCY; ADULT LIFE; HYPERTENSION; PREGNANCY	Objective-To determine whether placental ratio is influenced by maternal ethnic origin, obesity, hypertension, and haematological indices of iron deficiency anaemia. Design-Observational study. Setting-District general hospital in Birmingham. Subjects-692 healthy nulliparous pregnant women, of whom 367 were European, 213 Asian, 99 Afro-Caribbean, and 13 of other or undocumented ethnic origin. Main outcome measures-Placental ratio and maternal body mass index, blood pressure, and haematological indices. Results-Though birth weight and placental weight were lower in Asian women than in other groups, mean placental ratio was similar in Asian (19.5% (SD 3.3%)), European (20.0% (4.0%)), and Afro-Caribbean women (20.4% (5.3%)). Gestational age at birth was the main predictor of placental ratio in the univariate analysis (r=-0.34, P < 0.001) and multivariate analysis. The only other significant predictor of placental ratio in multivariate analysis was maternal body mass index, which was positively associated with placental ratio (r=0.1, P=0.01). Mean (SD) placental ratio was not significantly higher in women who developed gestational hypertension (20.4% (4.5%)) and pre-eclampsia (23.3% (7.3%)) than in normal women (19.8% (3.8%)). No evidence of a relation between placental ratio and first antenatal visit haemoglobin concentration or mean cell volume was detected, and placental ratio was not associated with change in mean cell volume during pregnancy or with third trimester serum ferritin concentration. Conclusions-These data do not support the proposed association between poor maternal nutrition and increased placental ratio. The association between high placental ratio and adult hypertension may be confounded by genetic and environmental factors associated with maternal obesity (and possibly maternal hypertension).	DUDLEY RD GEN HOSP, DEPT MED, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND; DUDLEY RD GEN HOSP, DEPT HAEMATOL, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND		PERRY, IJ (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH, LONDON NW3 2PF, ENGLAND.			Whincup, Peter/0000-0002-5589-4107; Perry, Ivan/0000-0002-4965-9792	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADDISON GM, 1972, J CLIN PATHOL, V25, P326, DOI 10.1136/jcp.25.4.326; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; CHAMBERLAIN G, 1978, BRIT BIRTHS 1970, V2; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; EATON PM, 1984, BR J NUTR, V52, P477; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; ESKENAZI B, 1991, JAMA-J AM MED ASSOC, V266, P237; Fox H, 1988, HDB HYPERTENSION, V10, P16; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; HIMMELMANN A, 1994, J INTERN MED, V235, P347, DOI 10.1111/j.1365-2796.1994.tb01085.x; PERRY IJ, 1993, BRIT MED J, V307, P420, DOI 10.1136/bmj.307.6901.420; PERRY IJ, 1994, BRIT J OBSTET GYNAEC, V101, P587, DOI 10.1111/j.1471-0528.1994.tb13648.x; WHARTON PA, 1984, BRIT J NUTR, V52, P469, DOI 10.1079/BJN19840114; WHINCUP P, 1994, J HUM HYPERTENS, V8, P337; 1989, MINITAG STATISTICAL	17	83	85	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	1995	310	6977					436	439		10.1136/bmj.310.6977.436	http://dx.doi.org/10.1136/bmj.310.6977.436			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873949	Green Published			2022-12-24	WOS:A1995QJ24200019
J	FLYNN, JJ; WYSS, AR; CHARRIER, R; SWISHER, CC				FLYNN, JJ; WYSS, AR; CHARRIER, R; SWISHER, CC			AN EARLY MIOCENE ANTHROPOID SKULL FROM THE CHILEAN ANDES	NATURE			English	Article							OLIGOCENE; ARGENTINA; FOSSILS	PARTLY because of their poor fossil record, the relationships of neotropical platyrrhine monkeys to other groups of primates and to each other remain perhaps the most poorly known for any major primate clade(1). Here we report the discovery of a complete platyrrhine skull from the Andes of central Chile, by far the best preserved Tertiary primate cranium from South America. This find, coupled with recent phylogenetic analyses of higher groups of anthropoid primates(2-4), has the potential to revise substantially our understanding of platyrrhine interrelationships, indicating, among other points, significant modification to reconstruction of the ancestral platyrrhine morphotype and a likely African origin for New World monkeys. A 40Ar/39Ar radioisotopic date directly associated with the skull indicates an Early Miocene age(5), marking the first report of South American mammals of this age from outside Argentine Patagonia. Finally, this discovery demonstrates the enormous potential of vastly distributed, but virtually untapped, Andean volcaniclastic deposits to yield further insights into the origin and diversification of South American primates.	UNIV CALIF SANTA BARBARA, DEPT GEOL SCI, SANTA BARBARA, CA 93106 USA; UNIV CHILE, FAC CIENCIAS FIS & MATEMAT, DEPT GEOL, SANTIAGO, CHILE; INST HUMAN ORIGINS, CTR GEOCHRONOL, BERKELEY, CA 94709 USA	University of California System; University of California Santa Barbara; Universidad de Chile	FLYNN, JJ (corresponding author), FIELD MUSEUM NAT HIST, DEPT GEOL, ROOSEVELT RD & LAKE SHORE DR, CHICAGO, IL 60605 USA.							BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; DEQUEIROZ K, 1992, ANNU REV ECOL SYST, V23, P449, DOI 10.1146/annurev.ecolsys.23.1.449; FLEAGLE JG, 1990, J HUM EVOL, V19, P61, DOI 10.1016/0047-2484(90)90012-Z; FLEAGLE JG, 1987, J HUM EVOL, V16, P483, DOI 10.1016/0047-2484(87)90036-4; FLEAGLE JG, 1983, FOLIA PRIMATOL, V41, P240, DOI 10.1159/000156135; Fleagle JG, 1988, PRIMATE ADAPTATION E; FLEAGLE JG, 1990, J HUM EVOL, V19; FLYNN JJ, SEPM SPECIAL PUBLICA; Ford S.M., 1986, P73; GINGERICH PD, 1982, AM J PHYS ANTHROPOL, V58, P81, DOI 10.1002/ajpa.1330580110; HERSHKOVITZ P, 1974, FOLIA PRIMATOL, V21, P1, DOI 10.1159/000155594; Hershkovitz P., 1977, P1; HOFFSTETTER R, 1969, CR ACAD SCI D NAT, V269, P434; Hoffstetter R., 1980, P103; Jerison HJ., 1973, EVOLUTION BRAIN INTE; Kay R.F., 1980, International Journal of Primatology, V1, P21, DOI 10.1007/BF02692256; Kay R.F., 1994, EVOL ANTHROPOL, V3, P32; KAY RF, 1990, J HUM EVOL, V19, P175, DOI 10.1016/0047-2484(90)90016-5; Martin R.D., 1990, PRIMATE ORIGINS EVOL; PASCUAL R, 1990, J HUM EVOL, V19, P23, DOI 10.1016/0047-2484(90)90011-Y; Rosenberger A.L., 1981, P9; ROSENBERGER AL, 1990, J HUM EVOL, V19, P209, DOI 10.1016/0047-2484(90)90017-6; Rusconi C., 1935, Revista Argentina de Paleontologia y Antropologia Ameghinia, V1, P39; RUSCONI C, 1935, REV ARGENTINA PALEON, V1, P103; RUSCONI C, 1935, REV ARGENTINA PALEON, V1, P71; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; SIMONS EL, 1986, J HUM EVOL, V15, P205, DOI 10.1016/S0047-2484(86)80046-X; STEIGER RH, 1977, EARTH PLANET SC LETT, V36, P359, DOI 10.1016/0012-821X(77)90060-7; SWISHER CC, 1992, SCIENCE, V257, P954, DOI 10.1126/science.257.5072.954; TAUBER A, 1991, ACAD NAC CIENCIAS MI, V82; Taylor JR., 1982, INTRO ERROR ANAL, V2nd edition; Wyss A.R., 1994, American Museum Novitates, V3098, P1	32	64	70	0	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 16	1995	373	6515					603	607		10.1038/373603a0	http://dx.doi.org/10.1038/373603a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG997	7854415				2022-12-24	WOS:A1995QG99700051
J	WOODMAN, CBJ; THRELFALL, AG; BOGGIS, CRM; PRIOR, P				WOODMAN, CBJ; THRELFALL, AG; BOGGIS, CRM; PRIOR, P			IS THE 3-YEAR BREAST SCREENING INTERVAL TOO LONG - OCCURRENCE OF INTERVAL CANCERS IN NHS BREAST SCREENING PROGRAMS NORTH-WESTERN REGION	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TRIAL	Objective-To report the detection rate of interval cancers in women screened by the NHS breast screening programme. Design-Detection of interval cancers by computer Linkage of records held by the screening centres in the North Western Regional Health Authority with breast cancer registrations at the regional cancer registry. Setting-North Western Regional Health Authority. Subjects-137421 women screened between 1 March 1988 and 31 March 1992 who had a negative screening result. Results-297 invasive interval cancers were detected. The rate of detection of interval cancers expressed as a proportion of the underlying incidence was 31% in the first 12 months after screening, 52% between 12 and 24 months, and 82% between 24 and 36 months. Conclusion-The incidence of interval cancers in the third year after breast screening approaches that which would have been expected in the absence of screening and suggests that the three year interval between screens is too long.	WITHINGTON HOSP,MANCHESTER BREAST SCREENING SERV,MANCHESTER M20 0PT,LANCS,ENGLAND		WOODMAN, CBJ (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,CTR CANC EPIDEMIOL,MANCHESTER M20 4QL,LANCS,ENGLAND.							ANDERSSON I, 1978, AM J ROENTGENOL, V130, P349, DOI 10.2214/ajr.130.2.349; BASSETT LW, 1987, RADIOLOGY, V165, P95, DOI 10.1148/radiology.165.1.3628795; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FRISELL J, 1987, BREAST CANCER RES TR, V9, P219, DOI 10.1007/BF01806383; PATNICK J, 1994, NHS BREAST SCREENING, P16; PEETERS PHM, 1989, BRIT J CANCER, V59, P929, DOI 10.1038/bjc.1989.196; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1985, LANCET, V2, P829; VANDIJCK JAAM, 1993, CANCER, V72, P1933, DOI 10.1002/1097-0142(19930915)72:6<1933::AID-CNCR2820720623>3.0.CO;2-N; VERBEEK ALM, 1984, LANCET, V1, P1222	13	120	120	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					224	226		10.1136/bmj.310.6974.224	http://dx.doi.org/10.1136/bmj.310.6974.224			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866124	Green Published			2022-12-24	WOS:A1995QE49600022
J	OBRIEN, S; KANTARJIAN, H; ESTEY, E; KOLLER, C; ROBERTSON, B; BERAN, M; ANDREEFF, M; PIERCE, S; KEATING, M				OBRIEN, S; KANTARJIAN, H; ESTEY, E; KOLLER, C; ROBERTSON, B; BERAN, M; ANDREEFF, M; PIERCE, S; KEATING, M			LACK OF EFFECT OF 2-CHLORODEOXYADENOSINE THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA REFRACTORY TO FLUDARABINE THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HAIRY-CELL LEUKEMIA; PLASMA; AGENT	Background. Fludarabine and 2-chlorodeoxyadenosine are nucleoside analogues that have proved effective in patients with chronic lymphocytic leukemia (CLL). Although their mechanism of action is thought to be similar, a small number of patients who do not respond to fludarabine do respond to 2-chlorodeoxyadenosine. The extent to which 2-chlorodeoxyadenosine is effective in patients who do not respond to fludarabine is not known, however. Methods. We treated 28 patients with CLL refractory to fludarabine therapy with a continuous infusion of 2-chlorodeoxyadenosine at a daily dose of 4 mg per square meter of body-surface area for seven days. The treatment could be repeated monthly. The number of treatments ranged from one to five; patients who responded continued to receive treatment until the maximal response was achieved. Results. Two patients (7 percent) had partial remissions, but no patients had complete remissions. One other patient had a substantial response but had residual thrombocytopenia. The rate of response in most affected organs was 20 percent, but anemia or thrombocytopenia rarely improved. Myelosuppression was frequent, and 65 percent of the courses of 2-chlorodeoxyadenosine therapy were accompanied by febrile episodes or infections. Ten patients died within 60 days of starting therapy with 2-chlorodeoxyadenosine; eight deaths were related to infection. The median platelet count at the start of 2-chlorodeoxyadenosine therapy in these 10 patients was 24,000 per cubic millimeter, as compared with 109,000 per cubic millimeter in the other 18 patients. Five patients were alive after a median follow-up of 24 months. Conclusions. Patients with advanced CLL refractory to fludarabine therapy are unlikely to benefit from treatment with 2-chlorodeoxyadenosine. Although 20 percent of the patients have some response, thrombocytopenia and anemia are rarely corrected and may be made worse by 2-chlorodeoxyadenosine therapy.			OBRIEN, S (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 61,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; DANHAUSER L, 1986, CANCER CHEMOTH PHARM, V18, P145; DELANNOY A, 1993, NEW ENGL J MED, V328, P812; ESTEY EH, 1992, BLOOD, V79, P882; GANDHI V, 1993, LEUKEMIA LYMPHOMA, V10, P49, DOI 10.3109/10428199309147356; JULIUSSON G, 1993, J CLIN ONCOL, V11, P679, DOI 10.1200/JCO.1993.11.4.679; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; KEATING MJ, 1989, BLOOD, V74, P19; LILIEMARK J, 1991, BLOOD S, V78, pA33; LILIEMARK JO, 1985, CANCER RES, V45, P5952; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1988, BLOOD, V72, P1069; PLUNKETT W, 1993, CHRONIC LYMPHOCYTIC, V1, P197; ROBERTSON LE, 1993, BLOOD, V81, P143; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394	15	82	84	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					319	322		10.1056/NEJM199402033300504	http://dx.doi.org/10.1056/NEJM199402033300504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	7904047				2022-12-24	WOS:A1994MU48900004
J	CALLEBAUT, C; KRUST, B; JACOTOT, E; HOVANESSIAN, AG				CALLEBAUT, C; KRUST, B; JACOTOT, E; HOVANESSIAN, AG			T-CELL ACTIVATION ANTIGEN, CD26, AS A COFACTOR FOR ENTRY OF HIV IN CD4+ CELLS	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DIPEPTIDYL PEPTIDASE-IV; PRINCIPAL NEUTRALIZING DETERMINANT; HUMAN LYMPHOCYTES-T; ENVELOPE GLYCOPROTEIN; V3 DOMAIN; MONOCLONAL-ANTIBODIES; CD4-MEDIATED FUSION; SYNTHETIC PEPTIDES; AMINOPEPTIDASE-IV	The CD4 molecule is essential for binding HIV particles, but is not sufficient for efficient viral entry and infection. The cofactor was shown to be dipeptidyl peptidase IV (DPP IV), also known as CD26. This serine protease cleaves its substrates at specific motifs; such motifs are also highly conserved in the V3 loops of HIV-1, HIV-2, and related simian isolates. Entry of HIV-1 or HIV-2 into T lymphoblastoid and monocytoid cell lines was inhibited by a specific monoclonal antibody against DPP IV or specific peptide inhibitors of this protease. Co-expression of human CD4 and CD26 in murine NIH 3T3 cells rendered them permissive to infection by HIV-1 and HIV-2. These observations could provide the basis for developing simple and specific inhibitors of HIV and open a possibility for vaccine development.	INST PASTEUR, CNRS, UA 1157, UNITE VIROL & IMMUNOL CELLULAIRE, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				/0000-0002-5301-1569				ARDMAN B, 1990, J ACQ IMMUN DEF SYND, V3, P206; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BARNETT SW, 1993, J VIROL, V67, P1006, DOI 10.1128/JVI.67.2.1006-1014.1993; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; BAUVOIS B, 1992, EUR J IMMUNOL, V22, P923, DOI 10.1002/eji.1830220407; BAUVOIS B, 1991, LYMPHATIC TISSUES IN; BLAZQUEZ MV, 1992, J IMMUNOL, V149, P3073; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; Brown A J, 1991, AIDS, V5 Suppl 2, pS35, DOI 10.1097/00002030-199101001-00005; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CHOU SH, 1992, AIDS RES HUM RETROV, V8, P1611, DOI 10.1089/aid.1992.8.1611; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANG NH, 1990, J IMMUNOL, V145, P3963; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; DEMEESTER I, 1992, CLIN CHIM ACTA, V210, P23, DOI 10.1016/0009-8981(92)90042-O; DEPASQUALE A, 1989, ACTA HAEMATOL-BASEL, V81, P19; DEROSSI A, 1991, VIROLOGY, V184, P187; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; EBENBICHLER CF, 1993, AIDS, V7, P489, DOI 10.1097/00002030-199304000-00006; EIDEN LE, 1992, IMMUNOL TODAY, V13, P201, DOI 10.1016/0167-5699(92)90154-Y; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GOWDA SD, 1989, J IMMUNOL, V142, P773; GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992; HAFLER DA, 1989, J IMMUNOL, V142, P2590; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; HEGEN M, 1990, J IMMUNOL, V144, P2908; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HENDERSON LA, 1993, J BIOL CHEM, V268, P15291; HOLMBACK K, 1993, J VIROL, V67, P1612; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; KIDO H, 1988, J BIOL CHEM, V263, P18104; KINNEYTHOMAS E, 1988, AIDS, V2, P25; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Koito A, 1989, Int Immunol, V1, P613, DOI 10.1093/intimm/1.6.613; KREUTZ R, 1992, AIDS RES HUM RETROV, V8, P1619, DOI 10.1089/aid.1992.8.1619; KUDO M, 1985, J BIOCHEM, V97, P1211, DOI 10.1093/oxfordjournals.jbchem.a135166; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAURENTCRAWFORD AG, 1993, AIDS RES HUM RETROV, V9, P761, DOI 10.1089/aid.1993.9.761; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MASUDA T, 1990, J IMMUNOL, V145, P3240; MATTERN T, 1991, SCAND J IMMUNOL, V33, P737, DOI 10.1111/j.1365-3083.1991.tb02548.x; MCKEATING JA, 1992, VIROLOGY, V191, P732, DOI 10.1016/0042-6822(92)90249-O; MILICH L, 1993, J VIROL, V67, P5623, DOI 10.1128/JVI.67.9.5623-5634.1993; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; MUNOZ E, 1992, IMMUNOLOGY, V77, P43; MYERS G, 1992, HUMAN RETROVIRUSES A; NEHETE PN, 1993, J VIROL, V67, P6841, DOI 10.1128/JVI.67.11.6841-6846.1993; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PARDI R, 1992, IMMUNOL TODAY, V13, P224, DOI 10.1016/0167-5699(92)90159-5; QURESHI NM, 1990, AIDS, V4, P553, DOI 10.1097/00002030-199006000-00009; RAO PE, 1983, CELL IMMUNOL, V80, P310, DOI 10.1016/0008-8749(83)90119-3; REY MA, 1989, VIROLOGY, V173, P258, DOI 10.1016/0042-6822(89)90242-0; REYCUILLE MA, UNPUB; REYCUILLE MA, IN PRESS; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SCHON E, 1989, SCAND J IMMUNOL, V29, P127, DOI 10.1111/j.1365-3083.1989.tb01108.x; STEPHENS PE, 1990, NATURE, V343, P219, DOI 10.1038/343219b0; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TANAKA T, 1992, J IMMUNOL, V149, P481; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; UMEZAWA H, 1984, J ANTIBIOT, V37, P422, DOI 10.7164/antibiotics.37.422; VANHAM G, 1993, J ACQ IMMUN DEF SYND, V6, P749; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679; WEISS RA, 1992, SCIENCE CHALLENGING AIDS, P107; WERNER A, 1993, J VIROL, V67, P2566, DOI 10.1128/JVI.67.5.2566-2574.1993; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	79	234	241	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					2045	2050		10.1126/science.7903479	http://dx.doi.org/10.1126/science.7903479			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	7903479				2022-12-24	WOS:A1993MN10800042
J	HOGERZEIL, HV; BIMO; ROSSDEGNAN, D; LAING, RO; OFORIADJEI, D; SANTOSO, B; CHOWDHURY, AKA; DAS, AM; KAFLE, KK; MABADEJE, AFB; MASSELE, AY				HOGERZEIL, HV; BIMO; ROSSDEGNAN, D; LAING, RO; OFORIADJEI, D; SANTOSO, B; CHOWDHURY, AKA; DAS, AM; KAFLE, KK; MABADEJE, AFB; MASSELE, AY			FIELD-TESTS FOR RATIONAL DRUG-USE IN 12 DEVELOPING-COUNTRIES	LANCET			English	Article								Increasing efforts are being made to improve drug-use practices and prescribing behaviour in developing countries. An essential tool for such work is an objective and standard method of assessment. We present here a set of drug-use indicators produced and tested in twelve developing countries. We describe practical applications, which include the use of indicators to increase awareness among prescribers in Malawi and Bangladesh, to identify priorities for action (eg, polypharmacy in Indonesia and Nigeria, overuse of injections in Uganda, Sudan, and Nigeria, and low percentage of patients who understood the dosage schedule in Malawi), and to quantify the impact of interventions in Yemen, Uganda, Sudan, and Zimbabwe.	YAYASAN INDONESIA SEJAHTERA,DIV HLTH,JAKARTA,INDONESIA; HARVARD UNIV,SCH MED,DRUG POLICY GRP,BOSTON,MA 02115; MANAGEMENT SCI HLTH,INT NETWORK RAT USE DRUGS,BOSTON,MA; UNIV GHANA,SCH MED,CTR TROP CLIN PHARMACOL,ACCRA,GHANA; GADJAH MADA UNIV,DEPT CLIN PHARMACOL,YOGYAKARTA,INDONESIA; NATL INST PREVENT & SOCIAL MED,DEPT BIOSTAT,DHAKA,BANGLADESH; UNIV DHAKA,DEPT PHARM,DHAKA,BANGLADESH; TRIBHUVAN UNIV HOSP,DEPT CLIN PHARMACOL,KATMANDU,NEPAL; UNIV LAGOS,COLL MED,DEPT PHARMACOL,LAGOS,NIGERIA; MAHIMBILL MED CTR,DEPT CLIN PHARMACOL,DAR ES SALAAM,TANZANIA	Harvard University; Harvard Medical School; University of Ghana; Gadjah Mada University; University of Dhaka; Tribhuvan University; Institute of Medicine (IoM) - Nepal; University of Lagos	HOGERZEIL, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA 27,SWITZERLAND.			Ofori-Adjei, David/0000-0003-1912-4188; Massele, Amos/0000-0003-3816-2040				Bannenberg WJ, 1991, WHODAP9110; BATES JA, 1992, GUATEMALA FIELD TEST; Bimo, 1992, INRUD NEWS, V3, P9; Christensen Rene Flamsholt, 1990, STRATEGY IMPROVEMENT; Gelders S, 1992, MALAWI ESSENTIAL DRU; HOGERZEIL HV, 1989, LANCET, V1, P141; KAFLE KK, 1992, INRUD NEWS, V3, P15; LAING RO, 1990, TROP DOCT, V20, P101, DOI 10.1177/004947559002000303; Ofori-Adjei D, 1992, INRUD NEWS, V3, P9; ROSSDEGNAN D, 1992, SOC SCI MED, V35, P1329, DOI 10.1016/0277-9536(92)90037-Q; SALLET JP, 1992, ECUADOR FIELD TEST P; 1991, FIELD TESTING DRUG I; 1993, WHODAP931, P1; 1993, BASELINE SURVEY DRUG; 1987, 1985 C EXP NAIR; 1991, ESSENTIAL DRUGS SURV	16	162	178	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1408	1410		10.1016/0140-6736(93)92760-Q	http://dx.doi.org/10.1016/0140-6736(93)92760-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901689				2022-12-24	WOS:A1993MK09500017
J	CHAN, MK; MUKUND, S; KLETZIN, A; ADAMS, MWW; REES, DC				CHAN, MK; MUKUND, S; KLETZIN, A; ADAMS, MWW; REES, DC			STRUCTURE OF A HYPERTHERMOPHILIC TUNGSTOPTERIN ENZYME, ALDEHYDE FERREDOXIN OXIDOREDUCTASE	SCIENCE			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; ARCHAEBACTERIUM PYROCOCCUS-FURIOSUS; IRON-SULFUR PROTEIN; MOLYBDENUM COFACTOR; MACROMOLECULAR CRYSTALLOGRAPHY; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HEAT-STABILITY; ALPHA-HELICES; TUNGSTEN; CRYSTAL	The crystal structure of the tungsten-containing aldehyde ferredoxin oxidoreductase (AOR) from Pyrococcus furiosus, a hyperthermophilic archaeon (formerly archaebacterium) that grows optimally at 100 degrees C, has been determined at 2.3 angstrom resolution by means of multiple isomorphous replacement and multiple crystal form averaging. AOR consists of two identical subunits, each containing an Fe4S4 cluster and a molybdopterin-based tungsten cofactor that is analogous to the molybdenum cofactor found in a large class of oxotransferases. Whereas the general features of the tungsten coordination in this cofactor were consistent with a previously proposed structure, each AOR subunit unexpectedly contained two molybdopterin molecules that coordinate a tungsten by a total of four sulfur ligands, and the pterin system was modified by an intramolecular cyclization that generated a three-ringed structure. In comparison to other proteins, the hyperthermophilic enzyme AOR has a relatively small solvent-exposed surface area, and a relatively large number of both ion pairs and buried atoms. These properties may contribute to the extreme thermostability of this enzyme.	CALTECH, DIV CHEM & CHEM ENGN 14775CH, PASADENA, CA 91125 USA; UNIV GEORGIA, CTR METALLOENZYME STUDIES, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA	California Institute of Technology; University System of Georgia; University of Georgia			Kletzin, Arnulf/AAO-7366-2020	Kletzin, Arnulf/0000-0002-4500-2232; Adams, Michael/0000-0002-9796-5014	NIGMS NIH HHS [1F32 GM15006, GM50775] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015006, R01GM050775] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams M.W.W., 1994, ENCY INORGANIC CHEM, P4284; ADAMS MWW, 1992, ACS SYM SER, V498, P1; ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BEGUM NS, 1992, POLYHEDRON, V11, P2823; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; CONN JF, 1974, J AM CHEM SOC, V96, P7152, DOI 10.1021/ja00829a081; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DAVIES GJ, 1993, PROTEINS, V15, P283, DOI 10.1002/prot.340150306; DAY MW, 1992, PROTEIN SCI, V1, P1494, DOI 10.1002/pro.5560011111; ENERNARK JH, 1994, ADV INORG CHEM, V40, P1; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; HOLM RH, 1990, COORDIN CHEM REV, V100, P183, DOI 10.1016/0010-8545(90)85010-P; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JOHNSON JL, 1993, J BIOL CHEM, V268, P4848; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1991, FEMS MICROBIOL LETT, V77, P213; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARRASCH M, 1990, FEBS LETT, V274, P48, DOI 10.1016/0014-5793(90)81326-J; KENDRICK MJ, 1992, METALS BIOL SYSTEMS; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KLETZIN A, UNPUB; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1994, P NATL ACAD SCI USA, V91, P423, DOI 10.1073/pnas.91.1.423; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; MUKUND S, 1993, J BIOL CHEM, V268, P13592; MUKUND S, UNPUB; PERUTZ MF, 1975, NATURE, V255, P256, DOI 10.1038/255256a0; PERUTZ MF, 1978, SCIENCE, V201, P1187, DOI 10.1126/science.694508; Pilato R. S., 1993, BIOINORGANIC CATALYS, P131; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; REES DC, UNPUB; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; SOYKA R, 1990, HELV CHIM ACTA, V73, P808, DOI 10.1002/hlca.19900730407; STEIFEL EI, 1993, ACS SYM SER, V535, P1; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALKER JE, 1980, EUR J BIOCHEM, V108, P581, DOI 10.1111/j.1432-1033.1980.tb04753.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007	72	531	549	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1463	1469		10.1126/science.7878465	http://dx.doi.org/10.1126/science.7878465			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878465				2022-12-24	WOS:A1995QL49700027
J	CURRAN, ME; SPLAWSKI, I; TIMOTHY, KW; VINCENT, GM; GREEN, ED; KEATING, MT				CURRAN, ME; SPLAWSKI, I; TIMOTHY, KW; VINCENT, GM; GREEN, ED; KEATING, MT			A MOLECULAR-BASIS FOR CARDIAC-ARRHYTHMIA - HERG MUTATIONS CAUSE LONG QT SYNDROME	CELL			English	Article							EARLY AFTERDEPOLARIZATIONS; GENE; DNA; LINKAGE; IDENTIFICATION; HETEROGENEITY; FRAGMENTS; CHANNEL; LOCUS; DEATH	To identify genes involved in cardiac arrhythmia, we investigated patients with long QT syndrome (LQT), an inherited disorder causing sudden death from a ventricular tachyarrhythmia, torsade de pointes. We previously mapped LQT loci on chromosomes 11 (LQT1), 7(LQT2), and 3(LQT3). Here, linkage and physical mapping place LQT2 and a putative potassium channel gene, HERG, on chromosome 7q35-36. Single strand conformation polymorphism and DNA sequence analyses reveal HERG mutations in six LQT families, including two intragenic deletions, one splice-donor mutation, and three missense mutations. In one kindred, the mutation arose de novo. Northern blot analyses show that HERG is strongly expressed in the heart. These data indicate that HERG is LQT2 and suggest a likely cellular mechanism for torsade de pointes.	UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DIV CARDIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; LATTER DAY ST HOSP,DEPT MED,SALT LAKE CITY,UT 84037; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	CURRAN, ME (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.				NCRR NIH HHS [MO1-RR00064] Funding Source: Medline; NHLBI NIH HHS [R01-HL 48074] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BENHORIN J, 1993, SCIENCE, V260, P1960, DOI 10.1126/science.8316839; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; CURRAN M, 1993, J CLIN INVEST, V92, P799, DOI 10.1172/JCI116653; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; GREEN ED, 1995, IN PRESS GENOMICS; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; JANUARY CT, 1989, CIRC RES, V64, P977, DOI 10.1161/01.RES.64.5.977; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MARCHUK D, 1990, NUCLEIC ACIDS RES, V19, P1154; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PTACEK LJ, 1991, CELL, V67, P1021; ROMANO C, 1965, LANCET, V1, P658; ROY N, 1994, NAT GENET, V8, P113, DOI 10.1038/ng1094-113; Schwartz PJ, 1995, CARDIAC ELECTROPHYSI, P788; SCHWARTZ PJ, 1975, AM HEART J, V109, P378; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; SURAWICZ B, 1989, J AM COLL CARDIOL, V14, P172, DOI 10.1016/0735-1097(89)90069-7; TOWBIN JA, 1994, CIRCULATION, V90, P2635, DOI 10.1161/01.CIR.90.6.2635; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WARD O C, 1964, J Ir Med Assoc, V54, P103; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7	38	1818	1891	0	86	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					795	803		10.1016/0092-8674(95)90358-5	http://dx.doi.org/10.1016/0092-8674(95)90358-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889573	Bronze			2022-12-24	WOS:A1995QM39900016
J	COOK, DJ; GUYATT, GH; JAESCHKE, R; REEVE, J; SPANIER, A; KING, D; MOLLOY, DW; WILLAN, A; STREINER, DL				COOK, DJ; GUYATT, GH; JAESCHKE, R; REEVE, J; SPANIER, A; KING, D; MOLLOY, DW; WILLAN, A; STREINER, DL			DETERMINANTS IN CANADIAN HEALTH-CARE WORKERS OF THE DECISION TO WITHDRAW LIFE-SUPPORT FROM THE CRITICALLY ILL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; RESOURCE-ALLOCATION; RATIONING DECISIONS; RESUSCITATE ORDERS; MEDICAL-CARE; INEVITABILITY; VARIABILITY; TECHNOLOGY; DIRECTIVES; ATTITUDES	Objective.-To examine the attitudes of health care workers regarding the withdrawal or life support. Design.-Cross-sectional survey. Participants.-Attending staff, house staff, and intensive care unit (ICU) nurses in 37 Canadian university-affiliate hospitals. Main Outcome Measures.-Health care workers' ratings of the importance of 17 factors considered in the decision to withdraw life support, and their ratings of five levels of care ranging from comfort measures to intensive care in two of 12 different clinical scenarios. Results.-We surveyed 1361 respondents (149 of 167 potentially eligible ICU attending staff, 142 of 173 ICU house staff, and 1070 of 1455 ICU nurses, with response rates of 89%, 82% and 74%, respectively). The most important factors were likelihood of surviving the current episode, likelihood of long-term survival, premorbid cognitive function, and age of the patient. In choosing the level of care for the patient scenarios, the same option was chosen by more than 50% of respondents in only one of 12 scenarios; opposite extremes of care were chosen by more than 10% of the respondents in eight of 12 scenarios. Respondent characteristics affecting choices included the number of years since graduation, the city and province in which they worked, the number of beds in their ICU, and their assessment of the likelihood that they would withdraw life support in comparison with their colleagues (P<.001 for all comparisons). Conclusions.-While ICU health care workers consistently identify a number of patient factors as important in decisions to withdraw care, there is extreme variability, which may be explained in part by the values of individual health care providers.	MCMASTER UNIV, FAC HLTH SCI, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA; MCGILL UNIV, JEWISH GEN HOSP, DEPT SURG, MONTREAL, PQ H3T 1E2, CANADA	McMaster University; McMaster University; McGill University			Embrett, Mark G./H-4466-2014; Streiner, David/E-6563-2011	Embrett, Mark G./0000-0002-3969-0219; Streiner, David/0000-0003-0610-6271				ALEMAYEHU E, 1991, CAN MED ASSOC J, V144, P1133; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; BYTH PL, 1990, ETHICAL ATTITUDES ME; COOK DJ, 1992, CURRENT PULMONOLOGY; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2047; Feinstein AR, 1987, CLINIMETRICS, P141, DOI DOI 10.2307/J.CTT1XP3VBC.13; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT GH, 1986, CAN MED ASSOC J, V134, P889; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; LOEWY EH, 1987, NEW ENGL J MED, V317, P1465, DOI 10.1056/NEJM198712033172308; LUCE JM, 1988, CHEST, V94, P621, DOI 10.1378/chest.94.3.621; MCCRARY SV, 1989, JAMA-J AM MED ASSOC, V265, P2411; MOLLOY DW, 1993, HUM MED, V9, P70; MOLLOY DW, 1991, CAN MED ASSOC J, V145, P307; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; SCHROEDER SA, 1979, NEW ENGL J MED, V300, P1306, DOI 10.1056/NEJM197906073002304; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPRUNG CL, 1992, CRIT CARE MED, V20, P320; SPRUNG CL, 1990, JAMA-J AM MED ASSOC, V263, P2211, DOI 10.1001/jama.263.16.2211; VINCENT JL, 1990, INTENS CARE MED, V16, P256, DOI 10.1007/BF01705162; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	28	304	309	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					703	708		10.1001/jama.273.9.703	http://dx.doi.org/10.1001/jama.273.9.703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QH814	7853627				2022-12-24	WOS:A1995QH81400028
J	DAMMER, U; POPESCU, O; WAGNER, P; ANSELMETTI, D; GUNTHERODT, HJ; MISEVIC, GN				DAMMER, U; POPESCU, O; WAGNER, P; ANSELMETTI, D; GUNTHERODT, HJ; MISEVIC, GN			BINDING STRENGTH BETWEEN CELL-ADHESION PROTEOGLYCANS MEASURED BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article							SPONGE MICROCIONA-PROLIFERA; AGGREGATION FACTOR; MARINE SPONGE	Measurement of binding forces intrinsic to adhesion molecules is necessary to assess their contribution to the maintenance of the anatomical integrity of multicellular organisms. Atomic force microscopy was used to measure the binding strength between cell adhesion proteoglycans from a marine sponge. Under physiological conditions, the adhesive force between two cell adhesion molecules was found to be up to 400 piconewtons. Thus a single pair of molecules could hold the weight of 1600 cells. High intermolecular binding forces are likely to form the basis for the integrity of the multicellular sponge organism.	UNIV BASEL HOSP,DEPT RES,CH-4031 BASEL,SWITZERLAND; UNIV BASEL,INST PHYS,CH-4056 BASEL,SWITZERLAND; ETH ZURICH,INST BIOCHEM 2,CH-8092 ZURICH,SWITZERLAND	University of Basel; University of Basel; Swiss Federal Institutes of Technology Domain; ETH Zurich			Popescu, Octavian/O-2134-2019; Misevic, Gradimir/D-8294-2016; Popescu, Octavian/C-4027-2011; Popescu, Octavian/E-4942-2010; Anselmetti, Dario/F-1664-2011	Popescu, Octavian/0000-0002-2597-7155; Misevic, Gradimir/0000-0001-5047-2936; Popescu, Octavian/0000-0002-2597-7155; Anselmetti, Dario/0000-0002-8720-4369				ANSELMETTI D, 1994, EUROPHYS LETT, V27, P365, DOI 10.1209/0295-5075/27/5/006; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; CAUDWELL CB, 1973, BIOCHEMISTRY-US, V12, P3051; DAMMER U, 1994, IN PRESS MAR NATO AS; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; GUTIERREZ C, 1979, J IMMUNOL METHODS, V29, P57, DOI 10.1016/0022-1759(79)90125-X; HARMANSON GT, 1992, IMMOBILIZED AFFINITY; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HUMPHREYS S, 1977, J SUPRAMOL STR CELL, V7, P339, DOI 10.1002/jss.400070307; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; LECKBAND DE, 1992, SCIENCE, V255, P1419, DOI 10.1126/science.1542789; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; RICE DJ, 1983, J BIOL CHEM, V258, P6394; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; WAGNER P, UNPUB; WINTER WT, 1977, J MOL BIOL, V117, P761, DOI 10.1016/0022-2836(77)90068-7; [No title captured]	22	356	368	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1173	1175		10.1126/science.7855599	http://dx.doi.org/10.1126/science.7855599			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855599	Green Submitted			2022-12-24	WOS:A1995QJ23700039
J	WEBSTER, MA; MOLLON, JD				WEBSTER, MA; MOLLON, JD			COLOR CONSTANCY INFLUENCED BY CONTRAST ADAPTATION	NATURE			English	Article							MECHANISMS; ILLUMINANT	VISUAL sensitivity is controlled by at least two distinct types of adaptation: light adaptation adjusts sensitivity to the mean luminance and colour in the stimulus(1), and contrast adaptation adjusts sensitivity to the variations in luminance and colour(2-5). Light adaptation is thought to be important in maintaining the perceived colour of objects despite changes in illumination ('colour constancy'), compensating for the mean changes in the light reflected from scenes under different illuminants(6). But for naturalistic colour signals, we show here that changes in an illuminant can also alter colour contrasts in images (how colours are distributed around the mean) enough to alter the state of contrast adaptation. Thus perceived colour under different illuminants may also be noticeably influenced by contrast adaptation.	UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,CAMBRIDGE CB2 3EB,ENGLAND	University of Cambridge	WEBSTER, MA (corresponding author), UNIV NEVADA,DEPT PSYCHOL,RENO,NV 89557, USA.		Mollon, John/C-3520-2009; Mollon, John/U-2631-2019	Mollon, John/0000-0001-8533-033X; Mollon, John/0000-0001-8533-033X; Webster, Michael/0000-0001-8262-7525				AREND LE, 1993, J OPT SOC AM A, V10, P2134, DOI 10.1364/JOSAA.10.002134; ATICK JJ, 1993, VISION RES, V33, P123, DOI 10.1016/0042-6989(93)90065-5; BARLOW HB, 1989, VISION CODING EFFICI, P363; BRAINARD DH, 1992, J OPT SOC AM A, V9, P1433, DOI 10.1364/JOSAA.9.001433; BROWN RO, 1991, INVEST OPHTH VIS SCI, V32, P1214; COHEN J, 1964, PSYCHON SCI, V1, P369, DOI 10.3758/BF03342963; DZMURA M, 1986, J OPT SOC AM A, V3, P1662, DOI 10.1364/JOSAA.3.001662; FLANAGAN P, 1989, Investigative Ophthalmology and Visual Science, V30, P130; GEORGESON M A, 1985, Spatial Vision, V1, P103, DOI 10.1163/156856885X00125; JUDD DB, 1964, J OPT SOC AM, V54, P1031, DOI 10.1364/JOSA.54.001031; KRAUSKOPF J, 1986, VISION RES, V26, P23, DOI 10.1016/0042-6989(86)90068-4; KRAUSKOPF J, 1982, VISION RES, V22, P1123, DOI 10.1016/0042-6989(82)90077-3; MACLEOD DIA, 1979, J OPT SOC AM, V69, P1183, DOI 10.1364/JOSA.69.001183; MACLEOD DJA, 1985, CENTRAL PERIPHERAL M; STILES WS, 1959, P NATL ACAD SCI USA, V45, P100, DOI 10.1073/pnas.45.1.100; VONKRIES J, 1970, FESTSCHRIFT A LUDWIG; WEBSTER MA, 1991, NATURE, V349, P235, DOI 10.1038/349235a0; WEBSTER MA, 1993, J OPT SOC AM A, V10, P1332, DOI 10.1364/JOSAA.10.001332; WEBSTER MA, 1994, VISION RES, V34, P1993, DOI 10.1016/0042-6989(94)90028-0; WORTHEY JA, 1982, J OPT SOC AM, V72, P74, DOI 10.1364/JOSA.72.000074; WORTHEY JA, 1986, J OPT SOC AM A, V3, P1708, DOI 10.1364/JOSAA.3.001708; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; ZAIDI Q, 1993, BIOL CYBERN, V69, P415, DOI 10.1007/BF01185413; [No title captured]	24	98	98	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					694	698		10.1038/373694a0	http://dx.doi.org/10.1038/373694a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854451				2022-12-24	WOS:A1995QH92800053
J	ASHBY, EC; ASHFORD, NS; CAMPBELL, MJ				ASHBY, EC; ASHFORD, NS; CAMPBELL, MJ			POSTURE, BLOOD VELOCITY IN COMMON FEMORAL VEIN, AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM	LANCET			English	Note							COMPRESSION; THROMBOSIS	Might leg elevation and avoidance of poor postures provide better prophylaxis against venous thromboembolism than heparin or mechanical methods? 12 supine subjects tilted in 3 degrees increments from 6 degrees leg-down to 12 degrees leg-up showed linear increase in mean peak blood velocity and reduction in calibre in the common femoral vein (colour-duplex ultrasound). Between horizontal and 6 degrees leg-up, velocity was increased by 17% and diameter reduced by 14%.: A ranking of mean peak velocities in six postures (sitting; standing; trunk raised 35 degrees to legs which were first horizontal and then tilted up 6 degrees; supine, first horizontal then 6 degrees leg-up) showed significant increases in velocity between consecutive positions.	CHICHESTER HOSP,CHICHESTER,W SUSSEX,ENGLAND; UNIV SOUTHAMPTON,DEPT MED STAT,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton								ANDREWS B, 1993, BRIT J SURG, V80, P198, DOI 10.1002/bjs.1800800221; ASHBY EC, 1993, LANCET, V142, P1562; CLAGETT PG, 1988, ANN SURG, V208, P227; COMEROTA AJ, 1992, AM J SURG, V164, P265, DOI 10.1016/S0002-9610(05)81083-9; COMEROTA AJ, 1989, SURGERY, V106, P301; FLANC C, 1969, LANCET, V1, P477; MATHEWS JNS, 1990, BRIT MED J, V300, P230; MONETA GL, 1988, J VASC SURG, V8, P285; NICOLAIDES AN, 1992, 1991 EUR CONS STAT W; 1992, BRIT MED J, V305, P567	10	27	29	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					419	421		10.1016/S0140-6736(95)90402-6	http://dx.doi.org/10.1016/S0140-6736(95)90402-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853951				2022-12-24	WOS:A1995QG90400010
J	JENKINSON, D				JENKINSON, D			NATURAL COURSE OF 500 CONSECUTIVE CASES OF WHOOPING-COUGH - A GENERAL-PRACTICE POPULATION STUDY	BRITISH MEDICAL JOURNAL			English	Article							PERTUSSIS	Objective-To describe the natural course of whooping cough. Design-Observational study of a general practice population. Setting-Discrete semirural East Midlands practice of 11 500 patients. Subjects-500 consecutive cases of whooping cough diagnosed clinically during 1977-92. Main outcome measures-Incidence of vomiting, whooping, apnoea, admission to hospital, and complications; duration and frequency of paroxysms. Pattern of spread. Results-The incidence in the practice population was 4347/100 000 population compared with a notification rate for England and Wales of 717/100 000. Most cases were relatively mild. 284 patients vomited after paroxysms, 242 whooped, and 57 had apnoea. Duration and frequency of paroxysms varied widely. Female and unimmunised patients suffered more severe disease. Bordetella was isolated from fewer immunised patients (24/96 v 63/122 unimmunised). Infection was usually spread through contacts with someone with clinical whooping cough. Five patients developed pneumonia, three of whom had been immunised. Three patients required hospital admission. Conclusions-Most cases of whooping cough are relatively mild. Such cases are difficult to diagnose without a high index of suspicion because doctors are unlikely to hear the characteristic cough, which may be the only symptom. Parents can be reassured that a serious outcome is unlikely. Adults also get whooping cough, especially from their children, and get the same symptoms as children. The difficulty of early diagnosis and probability of missed cases reinforces the need to keep the incidence low through immunisation in order to protect infants, who are the most vulnerable.			JENKINSON, D (corresponding author), KEYWORTH HLTH CTR,NOTTINGHAM NG12 5JU,ENGLAND.							CHRISTIE AB, 1970, INFECT DIS, P726; GROB PR, 1981, BRIT MED J, V282, P1925, DOI 10.1136/bmj.282.6280.1925; JENKINSON D, 1978, BRIT MED J, V2, P577; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; JENKINSON D, 1983, BRIT MED J, V287, P185, DOI 10.1136/bmj.287.6386.185; Kendrick P, 1939, AM J HYG, V29, P133, DOI 10.1093/oxfordjournals.aje.a118485; MARCOVITCH H, 1986, BRIT MED J, V292, P360, DOI 10.1136/bmj.292.6517.360; MILLER C, 1976, BRIT MED J, V2, P117; MILLER E, 1992, CDR REV, V2, P152; VESSELINOVAJENK.CK, 1978, J EPIDEMIOL COMMUNIT, V32, P194; 1981, BRIT MED J, V232, P23	11	48	50	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					299	302		10.1136/bmj.310.6975.299	http://dx.doi.org/10.1136/bmj.310.6975.299			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866173	Green Published			2022-12-24	WOS:A1995QF71700028
J	CLAES, G; DROTT, C				CLAES, G; DROTT, C			HYPERHIDROSIS	LANCET			English	Editorial Material											CLAES, G (corresponding author), BORAS HOSP,DEPT SURG,BORAS,SWEDEN.							BYRNE J, 1990, BRIT J SURG, V77, P1046, DOI 10.1002/bjs.1800770931; CLAES G, 1993, SCAND J PLAST RECONS, V27, P29, DOI 10.3109/02844319309080288; EDMONDSON RA, 1992, ANN SURG, V215, P289, DOI 10.1097/00000658-199203000-00015; Hughes J, 1942, Proc R Soc Med, V35, P585; Kotzareff A, 1920, REV MED SUISSE ROM, V40, P111; KUX E, 1954, THORAKOSKOPISCHE EIN	6	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					247	248		10.1016/S0140-6736(94)91105-3	http://dx.doi.org/10.1016/S0140-6736(94)91105-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905089				2022-12-24	WOS:A1994MT44000003
J	MACPHERSON, AJS; KHOO, UY; BJARNASON, I				MACPHERSON, AJS; KHOO, UY; BJARNASON, I			INFLAMMATORY BOWEL-DISEASE OF MICE - AND MEN	LANCET			English	Editorial Material							CYTOKINE PRODUCTION				MACPHERSON, AJS (corresponding author), UNIV LONDON KINGS COLL, SCH MED, DEPT MED, LONDON WC2R 2LS, ENGLAND.							FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; MACDERMOTT RP, 1988, ADV IMMUNOL, V42, P285, DOI 10.1016/S0065-2776(08)60848-2; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5	8	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	1994	343	8890					130	131		10.1016/S0140-6736(94)90928-8	http://dx.doi.org/10.1016/S0140-6736(94)90928-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903998				2022-12-24	WOS:A1994MQ86900004
J	CHILD, J				CHILD, J			BATS IN MY BELFRY	LANCET			English	Editorial Material											CHILD, J (corresponding author), DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							AJELLO L, 1962, AM J TROP MED HYG, V11, P249, DOI 10.4269/ajtmh.1962.11.249; KING AA, 1993, J COMP PATHOL, V108, P1, DOI 10.1016/S0021-9975(08)80224-1; KLITE PD, 1965, AM J TROP MED HYG, V14, P433, DOI 10.4269/ajtmh.1965.14.433; LAFON M, 1986, LANCET, V2, P515; MEREDITH C D, 1971, South African Medical Journal, V45, P767; TAYLOR RL, 1962, AM J TROP MED HYG, V11, P790, DOI 10.4269/ajtmh.1962.11.790; 1990, RABIES B EUR, V14	7	4	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					5	6		10.1016/S0140-6736(94)90870-2	http://dx.doi.org/10.1016/S0140-6736(94)90870-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905056				2022-12-24	WOS:A1994MN93700006
J	HAYASHI, Y; MOMIYAMA, A; TAKAHASHI, T; OHISHI, H; OGAWAMEGURO, R; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S				HAYASHI, Y; MOMIYAMA, A; TAKAHASHI, T; OHISHI, H; OGAWAMEGURO, R; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S			ROLE OF A METABOTROPIC GLUTAMATE-RECEPTOR IN SYNAPTIC MODULATION IN THE ACCESSORY OLFACTORY-BULB	NATURE			English	Article							NERVOUS-SYSTEM; NEURONS; EXPRESSION; CLONING; BRAIN	VARIOUS functions of glutamate transmission are mediated by both ionotropic and metabotropic glutamate receptors1. The metabotropic glutamate receptors (mGluRs) consist of at least six different subtypes that are classified into three subgroups, mGluR1/mGluR5, mGluR2/mGluR3, and mGluR4/mGluR6 (refs 1-5), but their physiological roles are largely unknown. Here we report the identification of a very potent agonist for mGluR2/mGluR3, DCG-IV, and the specific localization of mGluR2 in granule cell dendrites that form dendrodendritic synapses with mitral cells in the accessory olfactory bulb. Using the DCG-IV agonist for mGluR2 in combination with slice patch-recording, we demonstrate that the granule cell mGluR2 presynaptically suppresses inhibitory GABA (gamma-aminobutyrate) transmission to the mitral cell. Our results indicate that mGluR2 in granule cells plays an important role in the persistent excitation of olfactory sensory transmission in the accessory olfactory bulb by relieving mitral cells from the GABA inhibition.	KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN	Kyoto University; Kyoto University; Kyoto University; Kyoto University			Takahashi, Tomoyuki/G-5951-2015; Shigemoto, Ryuichi/E-3628-2013; Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019	Takahashi, Tomoyuki/0000-0002-8771-7666; Shigemoto, Ryuichi/0000-0001-8761-9444; Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004				ABE T, 1992, J BIOL CHEM, V267, P13361; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; HAYASHI Y, 1992, BRIT J PHARMACOL, V107, P539, DOI 10.1111/j.1476-5381.1992.tb12780.x; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; ISHIDA M, 1993, BRIT J PHARMACOL, V109, P1169, DOI 10.1111/j.1476-5381.1993.tb13745.x; ITO S, 1991, J PHYSIOL-LONDON, V440, P67, DOI 10.1113/jphysiol.1991.sp018696; KAWAI M, 1992, EUR J PHARMACOL, V211, P195; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHFUNE Y, 1993, BIOORG MED CHEM LETT, V3, P15, DOI 10.1016/S0960-894X(00)80083-9; OHISHI H, 1993, J COMP NEUROL, V335, P252, DOI 10.1002/cne.903350209; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; RALL W, 1968, J NEUROPHYSIOL, V31, P884, DOI 10.1152/jn.1968.31.6.884; SHEPHERD GM, 1978, SCI AM, V238, P92, DOI 10.1038/scientificamerican0278-92; SHIGEMOTO R, 1993, NEUROSCI LETT, V153, P157, DOI 10.1016/0304-3940(93)90311-8; TAKAHASHI T, 1992, J PHYSIOL-LONDON, V450, P593, DOI 10.1113/jphysiol.1992.sp019145; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; VANDERKLOOT W, 1991, PROG NEUROBIOL, V36, P93, DOI 10.1016/0301-0082(91)90019-W	20	348	353	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					687	690		10.1038/366687a0	http://dx.doi.org/10.1038/366687a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	7903116				2022-12-24	WOS:A1993MM26500070
J	LEGUENNO, B				LEGUENNO, B			IDENTIFYING A HANTAVIRUS ASSOCIATED WITH ACUTE RESPIRATORY ILLNESS - A PCR VICTORY	LANCET			English	Editorial Material											LEGUENNO, B (corresponding author), INST PASTEUR,CTR NATL REFERENCE FIEVRES HEMORRAG VIRALES,F-75724 PARIS 15,FRANCE.							CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FRENCH GR, 1981, SCIENCE, V211, P1046, DOI 10.1126/science.6110243; GERDING MN, 1993, LANCET, V342, P495, DOI 10.1016/0140-6736(93)91620-2; KULZER P, 1993, LANCET, V342, P313, DOI 10.1016/0140-6736(93)91865-J; Lee HW., 1976, KOREAN J INTERN MED, V19, P371; LEE HW, 1978, J INFECT DIS, V137, P289; LLOYD G, 1990, CURRENT TOPICS CLIN; NEERURKAER V, 1993, LANCET, V342, P1059; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; 1993, MMWR, V42, P421	10	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1438	1439		10.1016/0140-6736(93)92927-L	http://dx.doi.org/10.1016/0140-6736(93)92927-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902477				2022-12-24	WOS:A1993ML21700003
J	ALMENDARES, J; SIERRA, M; ANDERSON, PK; EPSTEIN, PR				ALMENDARES, J; SIERRA, M; ANDERSON, PK; EPSTEIN, PR			CRITICAL REGIONS, A PROFILE OF HONDURAS	LANCET			English	Article									HARVARD UNIV,SCH MED,DEPT MED,CAMBRIDGE,MA 02138; COMIS NACL MOSCA BLANCA,MANAGUA,NICARAGUA; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard University; Harvard T.H. Chan School of Public Health								ANDERSON PK, IN PRESS IN PRESS P; CABALLERO R, 1993, TURRIALBA, P50; KASPERSON JX, CRITICAL ENV REGIONS; KIRCHHOFF LV, 1993, NEW ENGL J MED, V329, P639, DOI 10.1056/NEJM199308263290909; SKOLE D, 1993, SCIENCE, V260, P1905, DOI 10.1126/science.260.5116.1905; Twilley Robert R., 1993, P105; WALSH JF, 1993, PARASITOLOGY, V106, P655; 1993, 1993 WORLD BANK WORL; 1991, TECH REP SER WHO, V811	9	17	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1400	1402		10.1016/0140-6736(93)92758-L	http://dx.doi.org/10.1016/0140-6736(93)92758-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901687				2022-12-24	WOS:A1993MK09500015
J	MCCARTHY, M				MCCARTHY, M			UNLOCKING THE DATASETS	LANCET			English	Editorial Material											MCCARTHY, M (corresponding author), CAMDEN & ISLINGTON HLTH AUTHOR,DEPT PUBL HLTH,LONDON,ENGLAND.							[Anonymous], HIGH TECHNOLOGY MED; CHALMERS I, 1991, NEW ENGL J MED, V325, P1514; COX TM, 1993, LANCET, V342, P694, DOI 10.1016/0140-6736(93)91703-O; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; 1989, LANCET, V2, P195; 1993, ASSESSING EFFECTS HL	6	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1252	1253		10.1016/0140-6736(93)92355-W	http://dx.doi.org/10.1016/0140-6736(93)92355-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901579				2022-12-24	WOS:A1993MH56600005
J	EVANS, JM; OFALLON, WM; HUNDER, GG				EVANS, JM; OFALLON, WM; HUNDER, GG			INCREASED INCIDENCE OF AORTIC-ANEURYSM AND DISSECTION IN GIANT-CELL (TEMPORAL) ARTERITIS - A POPULATION-BASED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							BIOPSY; COUNTY	Objective: To determine the frequency of aneurysm and dissection of the aorta in patients with giant cell arteritis and to assess the effects of these events on these patients. Design: Population-based cohort study. Setting: A multispecialty and a primary care clinic in southern Minnesota. Patients: 96 residents of Olmsted County, Minnesota, who developed giant cell arteritis between 1950 and 1985, The presence of aortic aneurysm, dissection, or both was confirmed using computed tomography, ultrasonography, angiography, or autopsy. Results: 11 of the 96 patients were found to have thoracic aortic aneurysms. In 2 of these patients, the aneurysms were detected when giant cell arteritis was diagnosed. In the remaining 9 patients, the aneurysms occurred a median of 5.8 years after giant cell arteritis was diagnosed. Six of the 11 died suddenly of acute thoracic aortic dissection. Five patients who did not have thoracic aortic aneurysms developed isolated abdominal aortic aneurysms a median of 2.5 years after giant cell arteritis was diagnosed. The incidence of thoracic aortic aneurysm in patients with giant cell arteritis was 999 per 100 000 person-years; the incidence of abdominal aortic aneurysm in these patients was 555 per 100 000 person-years. Compared with all persons of the same age and sex living in Olmsted County, patients with giant cell arteritis were 17.3 times (95% CI, 7.9 to 33.0) more likely to develop thoracic aortic aneurysm and 2.4 times (CI, 0.8 to 5.5) more likely to develop isolated abdominal aortic aneurysm. Conclusions: Giant cell arteritis is associated with a markedly increased risk for the development of aortic aneurysm, which is often a late complication and may cause death.	MAYO CLIN & MAYO FDN, DEPT MED, DIV RHEUMATOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, DIV COMMUNITY MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic								AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; ANIA BJ, 1994, MAYO CLIN PROC, V69, P730, DOI 10.1016/S0025-6196(12)61089-1; BICKERSTAFF LK, 1982, SURGERY, V92, P1103; BOESEN P, 1987, ARTHRITIS RHEUM, V30, P294, DOI 10.1002/art.1780300308; CALAMIA KT, 1981, ARTHRITIS RHEUM, V24, P1414, DOI 10.1002/art.1780241113; CASELLI RJ, 1988, NEUROLOGY, V38, P352, DOI 10.1212/WNL.38.3.352; DEBAKEY ME, 1965, J THORAC CARDIOV SUR, V49, P130, DOI 10.1016/S0022-5223(19)33323-9; EVANS JM, 1994, ARTHRITIS RHEUM-US, V37, P1539, DOI 10.1002/art.1780371020; FABER LP, 1991, AM CANCER SOC TXB CL, P194; HEALEY LA, 1980, ARTHRITIS RHEUM, V23, P641, DOI 10.1002/art.1780230605; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; KLEIN RG, 1976, MAYO CLIN PROC, V51, P504; KLEIN RG, 1975, ANN INTERN MED, V83, P806, DOI 10.7326/0003-4819-83-6-806; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MAGAREY FR, 1950, J PATHOL BACTERIOL, V62, P445, DOI 10.1002/path.1700620318; MCMILLAN GC, 1950, ARCH PATHOL, V49, P63; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; NORDBORG E, 1990, J INTERN MED, V227, P233, DOI 10.1111/j.1365-2796.1990.tb00150.x; PONGE T, 1988, J RHEUMATOL, V15, P997; REID JVO, 1957, BRIT HEART J, V19, P206; ROCCELLA EJ, 1986, JAMA-J AM MED ASSOC, V256, P70; SPROUL EE, 1942, NY J MED, V42, P345	23	414	425	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					502	507		10.7326/0003-4819-122-7-199504010-00004	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872584				2022-12-24	WOS:A1995QP00800004
J	MADHAVAN, S; STOCKWELL, D; COHEN, H; ALDERMAN, MH				MADHAVAN, S; STOCKWELL, D; COHEN, H; ALDERMAN, MH			RENAL-FUNCTION DURING ANTIHYPERTENSIVE TREATMENT	LANCET			English	Article							BLOOD-PRESSURE; ESSENTIAL-HYPERTENSION; WORK SITE; DISEASE; RISK	To determine the association of renal function and the course of blood pressure in antihypertensive therapy, we studied the changes in serum creatinine as a measure of renal function and in-treatment blood pressure in black and white hypertensive patients. We measured serum creatinine in 2125 mild and moderately hypertensive men during treatment over an average of 5 years. Both unadjusted mean initial and final serum creatinine of 758 blacks (113 and 117 mu mol/L respectively) were significantly higher than those of 1367 whites (108 and 107 mu mol/L), with a small increase of 4 mu mol/L (p<0.01) for blacks and a fall of 0.9 mu mol/L (p>0.05) for whites. Less than 2% of all patients attained or remained at a final serum creatinine of 177 mu mol/L or more. Of this small group (3% blacks, 1.4% whites), 31% had proteinuria at entry. After stratification by in-treatment diastolic blood pressure (<95 and greater than or equal to 95 mm Hg) in each race, mean slopes of reciprocal serum creatinine were estimated, adjusting for age at entry, initial serum creatinine, diastolic pressure, and body-mass index by analysis of covariance. The two adjusted mean slopes did not differ significantly within each race. Multiple regression analysis confirmed that in-treatment diastolic pressure was not independently associated with final serum creatinine. The change in renal function was most likely a reflection of regression towards the mean, and does not support the view that antihypertensive treatment is an important determinant of renal function in mild-to-moderate hypertensive patients. Patients with substantial renal insufficiency may have pre-existing intrinsic renal disease.			MADHAVAN, S (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.			Cohen, Hillel/0000-0002-4524-0898				ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; BRAZY PC, 1990, KIDNEY INT, V37, P1113, DOI 10.1038/ki.1990.93; DUSTAN HP, 1987, AM J CARDIOL, V60, pI73; LUKE RG, 1993, HYPERTENSION, V21, P380, DOI 10.1161/01.HYP.21.3.380; MADHAVAN S, 1994, HYPERTENSION, V23, P395, DOI 10.1161/01.HYP.23.3.395; MITCH WE, 1976, LANCET, V2, P1326; NOLAN CR, 1992, RENAL ELECTROLYTE DI, V9, P447; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P1272, DOI 10.1001/jama.269.10.1272; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; ROLLINGTON F, 1987, AM J PUBLIC HEALTH, V77, P864; ROSANSKY SJ, 1990, ARCH INTERN MED, V150, P2073, DOI 10.1001/archinte.150.10.2073; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; SELDIN DW, 1992, KIDNEY PHYSL PATHOPH, P947; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; Snedecor G.W., 1980, STAT METHODS, V7; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250	19	66	67	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	1995	345	8952					749	751		10.1016/S0140-6736(95)90638-X	http://dx.doi.org/10.1016/S0140-6736(95)90638-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891485				2022-12-24	WOS:A1995QN70100009
J	DERMOTT, SF; SAGAN, C				DERMOTT, SF; SAGAN, C			TIDAL EFFECTS OF DISCONNECTED HYDROCARBON SEAS ON TITAN	NATURE			English	Article							SURFACE; DISSIPATION; OCEAN	THERMODYNAMIC and photochemical arguments(1-4) suggest that Titan, the largest satellite of Saturn, has a deep ocean of liquid hydrocarbons. At visible wavelengths, Titan's surface is obscured by a thick stratospheric haze, but radar observations(5-7) have revealed large regions of high surface reflectivity that are inconsistent with a global hydrocarbon ocean. Titan's surface has also been imaged at infrared wavelengths(8-10), and the highest-resolution data (obtained by the Hubble Space Telescope) show clear variations in surface albedo and/or topography(10). The natural interpretation of these observations is that Titan, like the Earth, has continents and oceans. But Titan's high orbital eccentricity poses a problem for this interpretation, as the effects of oceanic tidal friction would have circularized Titan's orbit for most configurations of oceans and continents(1,11). Here we argue that a more realistic topography, in which liquid hydrocarbons are confined to a number of disconnected seas or crater lakes, may satisfy both the dynamical and observational constraints.	CORNELL UNIV,PLANETARY STUDIES LAB,ITHACA,NY 14853	Cornell University	DERMOTT, SF (corresponding author), UNIV FLORIDA,DEPT ASTRON,POB 112055,GAINESVILLE,FL 32611, USA.							BURNS JA, 1986, SATELLITES, P117; Butler B. J, 1992, B AM ASTRON SOC, V24, P954; CHAPMAN CR, 1986, SATELLITES, P492; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; ENGEL S, 1994, B AM ASTRON SOC, V26, P1183; FLASAR FM, 1983, SCIENCE, V221, P55, DOI 10.1126/science.221.4605.55; GRIFFITH CA, 1993, NATURE, V364, P511, DOI 10.1038/364511a0; GROSSMAN AW, 1992, B AM ASTRON SOC, V24, P954; LAMBECK K, 1980, EARTHS VARIABLE ROTA, P295; LEMMON MT, 1993, ICARUS, V103, P329, DOI 10.1006/icar.1993.1074; LUNINE JI, 1993, REV GEOPHYS, V31, P133, DOI 10.1029/92RG02794; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; Merian J. R., 1828, BEWEGUNG TROPFBARER; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; PEALE SJ, 1980, ICARUS, V43, P65, DOI 10.1016/0019-1035(80)90088-3; SAGAN C, 1982, NATURE, V300, P731, DOI 10.1038/300731a0; SAGAN C, 1994, B AM ASTRON SOC, V26, P1183; SEARS WD, IN PRESS ICARUS; SEARS WD, 1994, B AM ASTRON SOC, V26, P1184; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; SMITH PH, 1994, B AM ASTRON SOC, V26, P1181; Turcotte D., 2014, GEODYNAMICS, V3rd edn.; WEBB DJ, 1982, CONTEMP PHYS, V23, P419, DOI 10.1080/00107518208237094	23	34	34	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					238	240		10.1038/374238a0	http://dx.doi.org/10.1038/374238a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885443				2022-12-24	WOS:A1995QM38700042
J	MAX, M; MCKINNON, PJ; SEIDENMAN, KJ; BARRETT, RK; APPLEBURY, ML; TAKAHASHI, JS; MARGOLSKEE, RF				MAX, M; MCKINNON, PJ; SEIDENMAN, KJ; BARRETT, RK; APPLEBURY, ML; TAKAHASHI, JS; MARGOLSKEE, RF			PINEAL OPSIN - A NONVISUAL OPSIN EXPRESSED IN CHICK PINEAL	SCIENCE			English	Article							VISUAL PIGMENT; RHODOPSIN; PROTEIN; SEQUENCE; GENES; CELL; ROD; PHYLOGENIES; RELEASE; CULTURE	Pineal opsin (P-opsin), an opsin from chick that is highly expressed in pineal but is not detectable in retina, was cloned by the polymerase chain reaction. It is likely that the P-opsin lineage diverged from the retinal opsins early in opsin evolution. The amino acid sequence of P-opsin is 42 to 46 percent identical to that of the retinal opsins. P-opsin is a seven-membrane spanning, G protein-linked receptor with a Schiff-base lysine in the seventh membrane span and a Schiff-base counterion in the third membrane span. The primary sequence of P-opsin suggests that it will be maximally sensitive to similar to 500-nanometer tight and produce a slow and prolonged phototransduction response consistent with the nonvisual function of pineal photoreception.	NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, NATL SCI FDN, CTR BIOL TIMING, EVANSTON, IL 60208 USA; HARVARD UNIV, SCH MED, HOWE LABS, BOSTON, MA 02114 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University; Harvard University; Harvard Medical School	MAX, M (corresponding author), HOFFMANN LA ROCHE INC, ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA.		Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878; Margolskee, Robert/0000-0002-9572-2887	NATIONAL EYE INSTITUTE [R01EY008467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039592, R01MH039592, F31MH010287] Funding Source: NIH RePORTER; NEI NIH HHS [EYO8467] Funding Source: Medline; NIMH NIH HHS [MH39592, MH10287] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APPLEBURY ML, 1994, MOL EVOLUTION PHYSL, P235; ARAKI M, 1992, DEV BRAIN RES, V65, P85, DOI 10.1016/0165-3806(92)90011-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DEGUCHI T, 1988, J NEUROSCI, V8, P22; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J, 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; IBBOTSON RE, 1992, P ROY SOC B-BIOL SCI, V247, P145, DOI 10.1098/rspb.1992.0021; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T, 1989, MOL CLONING; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MCLAUGHLIN SK, 1993, BIOTECHNIQUES, V15, P506; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; VIGH B, 1982, Z MIKROSK ANAT FORSC, V96, P113; WANG SZ, 1992, BIOCHEMISTRY-US, V31, P3309, DOI 10.1021/bi00128a002; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; YOKOYAMA R, 1990, P NATL ACAD SCI USA, V87, P9315, DOI 10.1073/pnas.87.23.9315; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1994, J NEUROCHEM, V62, P2001	39	139	142	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1502	1506		10.1126/science.7878470	http://dx.doi.org/10.1126/science.7878470			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878470				2022-12-24	WOS:A1995QL49700039
J	SIMINOSKI, K				SIMINOSKI, K			DOES THIS PATIENT HAVE A GOITER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THYROID SIZE; CLINICAL-ASSESSMENT; ULTRASOUND; FREQUENCY; IODINE; VOLUME; ACCURACY; DISEASE; GLAND				SIMINOSKI, K (corresponding author), UNIV ALBERTA, DEPT MED, DIV ENDOCRINOL & METAB, 362 HMRC, EDMONTON, AB T6G 2S2, CANADA.							BERGHOUT A, 1988, CLIN ENDOCRINOL, V28, P409, DOI 10.1111/j.1365-2265.1988.tb03672.x; BERGHOUT A, 1987, CLIN ENDOCRINOL, V26, P273, DOI 10.1111/j.1365-2265.1987.tb00784.x; BRANDER A, 1992, J CLIN ULTRASOUND, V20, P37, DOI 10.1002/jcu.1870200107; BROWN MC, 1978, ACTA RADIOL ONCOL, V17, P337, DOI 10.3109/02841867809127937; BURCH WM, 1987, CASE STUDIES ENDOCRI, P52; CLAIN A, 1986, HAMILTON BAILLEYS DE, P155; COOK IJ, 1989, AM J PHYSIOL, V257, pG748, DOI 10.1152/ajpgi.1989.257.5.G748; CROOKS J, 1967, LANCET, V2, P625; Daniels G, 1991, WERNER INGBARS THYRO, P572; Dingle P R, 1966, Clin Exp Immunol, V1, P277; EASTHAM RD, 1985, POCKET GUIDE DIFFERE, P220; EDWARDS CRW, 1990, MACLEODS CLIN EXAMIN, P66; GREENSPAN FS, 1991, BASIC CLIN ENDOCRINO, P213; GURNEY C, 1970, LANCET, V2, P1275; GUTEKUNST R, 1986, ACTA ENDOCRINOL-COP, V112, P494, DOI 10.1530/acta.0.1120494; GWINUP G, 1975, J CLIN ENDOCR METAB, V40, P37, DOI 10.1210/jcem-40-1-37; HEGEDUS L, 1990, DAN MED BULL, V37, P249; HEGEDUS L, 1985, CLIN ENDOCRINOL, V22, P287, DOI 10.1111/j.1365-2265.1985.tb03242.x; HEGEDUS L, 1985, CLIN ENDOCRINOL, V23, P423, DOI 10.1111/j.1365-2265.1985.tb01100.x; HEGEDUS L, 1987, DAN MED BULL, V34, P121; HENNESSY W B, 1964, Med J Aust, V1, P505; HINTZE G, 1991, ACTA ENDOCRINOL-COP, V124, P12, DOI 10.1530/acta.0.1240012; HOLLINGSWORTH DR, 1963, MEDICINE, V42, P47, DOI 10.1097/00005792-196301000-00003; HULL OH, 1955, ARCH PATHOL, V59, P291; Jaffe RH, 1930, ARCH PATHOL, V10, P887; JARLOV AE, 1991, J INTERN MED, V229, P159, DOI 10.1111/j.1365-2796.1991.tb00324.x; JARLOV AE, 1991, DAN MED BULL, V38, P87; KATLIC MR, 1985, ANN THORAC SURG, V39, P391, DOI 10.1016/S0003-4975(10)62645-8; KEARNS JE, 1967, TREATMENT HYPERTHYRO, P16; KILPATRICK R, 1963, BMJ-BRIT MED J, P29; LADENSON PW, 1991, WERNER INGBARS THYRO, P901; MACLENNAN R, 1969, ENDEMIC GOITER, P67; MALAMOS B, 1970, ENDOKRINOLOGIE, V56, P232; MANDART G, 1975, INT J NUCL MED BIOL, V2, P185, DOI 10.1016/S0047-0740(75)80009-X; MERCER R D, 1975, Cleveland Clinic Quarterly, V42, P319; PEREZ C, 1958, Bull World Health Organ, V18, P217; PERRILD H, 1990, AM J PSYCHIAT, V147, P1518; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SHAPIRA JD, 1990, ART SCI BEDSIDE DIAG, P236; Silink K, 1966, ENDEMIC GOITRE ALLIE, P33; SIMINOSKI K, 1994, HEAD NECK-J SCI SPEC, V16, P21, DOI 10.1002/hed.2880160106; SMITH RN, 1967, BRIT MED J, V1, P129, DOI 10.1136/bmj.1.5533.129; TAMAYO SG, 1993, J GEN INTERN MED, V8, P69, DOI 10.1007/BF02599986; TANNAHILL AJ, 1978, CLIN ENDOCRINOL, V8, P483, DOI 10.1111/j.1365-2265.1978.tb02185.x; TROTTER WR, 1962, BRIT J PREV SOC MED, V16, P16; TROWBRIDGE FL, 1975, PEDIATRICS, V56, P82; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILLIAMS RH, 1949, AM J MED, V7, P702, DOI 10.1016/0002-9343(49)90409-X; WINSA B, 1990, ACTA ENDOCRINOL-COP, V122, P722, DOI 10.1530/acta.0.1220722	50	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					813	817		10.1001/jama.273.10.813	http://dx.doi.org/10.1001/jama.273.10.813			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861577				2022-12-24	WOS:A1995QJ75000035
J	GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC				GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC			PHYSICAL-ACTIVITY, OBESITY, AND RISK FOR COLON-CANCER AND ADENOMA IN MEN	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-FAT DISTRIBUTION; COLORECTAL-CANCER; OCCUPATIONAL EXERCISE; ALCOHOL-CONSUMPTION; COLLEGE ALUMNI; GROWTH-FACTOR; BOWEL HABIT; YOUNG MEN; CELL-LINE; INSULIN	Objective: To determine whether physical inactivity and obesity increase risk for colon cancer and adenomas, which are precursors of cancer, and whether the abdominal distribution of obesity is an independent risk factor for these events. Design: Prospective cohort study. Setting: United States. Patients: 47 723 male health professionals, 40 to 75 years of age, who responded to a questionnaire mailed in 1986. Measurements: Questionnaires in 1986 about physical activity level and body mass index, and questionnaires in 1987 (31 055 respondents) about waist and hip circumferences. Between 1986 and 1992, 203 new patients were diagnosed with colon cancer and 586 were diagnosed with adenomas. Results: Physical activity was inversely associated with risk for colon cancer (high compared with low quintiles of average energy expenditure from leisure time activities: relative risk, 0.53 [95% CI, 0.32 to 0.88], P for trend = 0.03) after adjustment for age; history of colorectal polyp; previous endoscopy; parental history of colorectal cancer; smoking; body mass; use of aspirin; and intake of red meat, dietary fiber, folate, and alcohol. Body mass index was directly associated with risk for colon cancer independently of physical activity level. Waist circumference and waist-to-hip ratio were strong risk factors for colon cancer (waist-to-hip ratio greater than or equal to 0.99 compared with waist-to-hip ratio < 0.90: multivariate relative risk, 3.41 [CI, 1.52 to 7.66], P for trend = 0.01; waist circumference greater than or equal to 43 inches compared with waist circumference < 35 inches: relative risk, 2.56 [CI, 1.33 to 4.96], P for trend < 0.001). These associations persisted even after adjustment for body mass and physical activity. Similar associations were seen between obesity and physical inactivity and adenomas of 1 cm or more, but no association was observed for smaller adenomas. Height was also associated with a higher risk for colon cancer (height greater than or equal to 73 inches compared with height less than or equal to 68 inches: multivariate relative risk, 1.76 [CI, 1.13 to 2.74], P for trend = 0.02). Conclusions: The results support an inverse association between physical activity and risk for colon cancer, whereas height and obesity, particularly abdominal adiposity, are associated with an elevated risk.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	GIOVANNUCCI, E (corresponding author), CHANNING LABS, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ALBANES D, 1989, AM J PUBLIC HEALTH, V79, P744, DOI 10.2105/AJPH.79.6.744; ALBANES D, 1988, CANCER RES, V48, P1658; ALBANES D, 1990, NUTR CANCER, V14, P69, DOI 10.1080/01635589009514078; Albanes D, 1990, Epidemiology, V1, P65, DOI 10.1097/00001648-199001000-00014; ALBANES D, 1988, JNCI-J NATL CANCER I, V80, P772, DOI 10.1093/jnci/80.10.772; BALLARDBARBASH R, 1990, CANCER RES, V50, P3610; BINGHAM SA, 1989, GASTROENTEROLOGY, V97, P1389, DOI 10.1016/0016-5085(89)90381-8; BJORK J, 1993, SCAND J GASTROENTERO, V28, P879, DOI 10.3109/00365529309103129; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; BOYLE P, 1985, INT J CANCER, V36, P9, DOI 10.1002/ijc.2910360103; BROWNSON RC, 1989, AM J EPIDEMIOL, V130, P675, DOI 10.1093/oxfordjournals.aje.a115389; CHUTE CG, 1991, CANCER CAUSE CONTROL, V2, P117, DOI 10.1007/BF00053131; COENEN C, 1992, AM J GASTROENTEROL, V87, P292; DEVERDIER MG, 1990, INT J CANCER, V46, P985, DOI 10.1002/ijc.2910460606; DONAHUE RP, 1987, LANCET, V1, P821; FRASER G, 1993, CANCER CAUSE CONTROL, V4, P45, DOI 10.1007/BF00051713; FREDRIKSSON M, 1989, CANCER, V63, P1838; GARABRANT DH, 1984, AM J EPIDEMIOL, V119, P1005, DOI 10.1093/oxfordjournals.aje.a113805; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; GERHARDSSON M, 1988, INT J EPIDEMIOL, V17, P743, DOI 10.1093/ije/17.4.743; GERHARDSSON M, 1986, AM J EPIDEMIOL, V123, P775, DOI 10.1093/oxfordjournals.aje.a114306; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; GIOVANNUCCI E, 1995, IN PRESS CANCER CAUS; GIOVANNUCCI E, 1994, JNCI-J NATL CANCER I, V54, P2390; GRAHAM S, 1988, AM J EPIDEMIOL, V128, P490, DOI 10.1093/oxfordjournals.aje.a114997; HILL M, 1978, PATHOGENESIS COLOREC, P158; HIRSCH J, 1956, GASTROENTEROLOGY, V31, P274; HOPKINS WG, 1991, AM J EPIDEMIOL, V133, P73, DOI 10.1093/oxfordjournals.aje.a115805; HYAMS DE, 1974, BRIT MED J, V1, P107, DOI 10.1136/bmj.1.5898.107; KATO I, 1990, JPN J CANCER RES, V81, P1101, DOI 10.1111/j.1349-7006.1990.tb02520.x; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KLATSKY AL, 1988, AM J EPIDEMIOL, V128, P1007; KOENUMA M, 1989, JPN J CANCER RES, V80, P51, DOI 10.1111/j.1349-7006.1989.tb02244.x; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LEE IM, 1992, J NATL CANCER I, V84, P1326, DOI 10.1093/jnci/84.17.1326; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LEMARCHAND L, 1992, CANCER CAUSE CONTROL, V3, P349, DOI 10.1007/BF00146888; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LITTLE J, 1993, BRIT J CANCER, V67, P177, DOI 10.1038/bjc.1993.31; MILNE JS, 1972, GERONTOL CLIN, V14, P56, DOI 10.1159/000245372; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; NEUGUT AI, 1991, J NATL CANCER I, V83, P359, DOI 10.1093/jnci/83.5.359; OETTLE GJ, 1991, GUT, V32, P941, DOI 10.1136/gut.32.8.941; PAFFENBARGER RS, 1987, AM J CLIN NUTR, V45, P312, DOI 10.1093/ajcn/45.1.312; PETERS RK, 1989, CANCER RES, V49, P5459; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; POLEDNAK AP, 1976, CANCER, V38, P382, DOI 10.1002/1097-0142(197607)38:1<382::AID-CNCR2820380155>3.0.CO;2-V; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; REGENSTEINER JG, 1991, DIABETES CARE, V14, P1066, DOI 10.2337/diacare.14.11.1066; RICCARDI G, 1991, DIABETES CARE, V14, P1115, DOI 10.2337/diacare.14.12.1115; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; Rothman K, 1986, MODERN EPIDEMIOLOGY; SEVERSON RK, 1989, AM J EPIDEMIOL, V130, P522, DOI 10.1093/oxfordjournals.aje.a115366; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; SLATTERY ML, 1988, AM J EPIDEMIOL, V128, P989; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; VENA JE, 1985, AM J EPIDEMIOL, V122, P357, DOI 10.1093/oxfordjournals.aje.a114116; VENA JE, 1987, AM J CLIN NUTR, V45, P318, DOI 10.1093/ajcn/45.1.318; WATKINS LF, 1990, INT J CANCER, V45, P372, DOI 10.1002/ijc.2910450227; WHITTEMORE AS, 1990, JNCI-J NATL CANCER I, V82, P915, DOI 10.1093/jnci/82.11.915; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WILLETT W, 1990, NUTR EPIDEMIOLOGY, P217; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140; 1992, CANCER FACTS FIGURES	74	751	765	0	59	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					327	334		10.7326/0003-4819-122-5-199503010-00002	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847643				2022-12-24	WOS:A1995QJ08500002
J	BABBITT, PC; MRACHKO, GT; HASSON, MS; HUISMAN, GW; KOLTER, R; RINGE, D; PETSKO, GA; KENYON, GL; GERLT, JA				BABBITT, PC; MRACHKO, GT; HASSON, MS; HUISMAN, GW; KOLTER, R; RINGE, D; PETSKO, GA; KENYON, GL; GERLT, JA			FUNCTIONALLY DIVERSE ENZYME SUPERFAMILY THAT ABSTRACTS THE ALPHA-PROTONS OF CARBOXYLIC-ACIDS	SCIENCE			English	Article							ESCHERICHIA-COLI; MANDELATE RACEMASE; CRYSTAL-STRUCTURE; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-PUTIDA; LACTONIZING ENZYME; D-GALACTONATE; CARBON ACIDS; DNA-SEQUENCE; CLONING	Mandelate racemase and muconate lactonizing enzyme are structurally homologous but catalyze different reactions, each initiated by proton abstraction from carbon. The structural similarity to mandelate racemase of a previously unidentified gene product was used to deduce its function as a galactonate dehydratase. in this enzyme superfamily that has evolved to catalyze proton abstraction from carbon, three variations of homologous active site architectures are now represented: lysine and histidine bases in the active site of mandelate racemase, only a lysine base in the active site of muconate lactonizing enzyme, and only a histidine base in the active site of galactonate dehydratase. This discovery supports the hypothesis that new enzymatic activities evolve by recruitment of a protein catalyzing the same type of chemical reaction.	UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	University of Illinois System; University of Illinois Urbana-Champaign; Brandeis University; Harvard University; Harvard Medical School	BABBITT, PC (corresponding author), UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA.		Petsko, Gregory/AAO-7962-2020	Huisman, Gjalt/0000-0003-1955-1120	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040570] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40570, GM-34572] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRICH TL, 1987, GENE, V52, P185, DOI 10.1016/0378-1119(87)90045-X; BABBITT PC, UNPUB; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; BURLINGAME RP, M69160 GENB ACC; COOPER RA, 1978, ARCH MICROBIOL, V118, P199, DOI 10.1007/BF00415730; DEACON J, 1977, FEBS LETT, V77, P201, DOI 10.1016/0014-5793(77)80234-2; DOLNICK BJ, 1993, NUCLEIC ACIDS RES, V21, P1747, DOI 10.1093/nar/21.8.1747; DOLNICK BJ, COMMUNICATION; DONALD A, 1979, J BIOL CHEM, V254, P2132; EGAN SE, 1992, J BACTERIOL, V174, P4638, DOI 10.1128/JB.174.14.4638-4646.1992; EIGLMEIER K, 1987, MOL MICROBIOL, V1, P251, DOI 10.1111/j.1365-2958.1987.tb01931.x; Gerlt J.A., 1992, CURR OPIN STRUC BIOL, V2, P736; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; GOLDMAN A, 1987, J MOL BIOL, V194, P143, DOI 10.1016/0022-2836(87)90723-6; HASSON M, UNPB; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HUISMAN GW, 1994, SCIENCE, V265, P537, DOI 10.1126/science.7545940; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; JENSEN RA, 1987, COLD SPRING HARBOR S, V52; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LANDRO JA, 1994, BIOCHEMISTRY-US, V33, P635, DOI 10.1021/bi00169a003; LEBIODA L, 1988, NATURE, V333, P683, DOI 10.1038/333683a0; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; PETSKO GA, 1993, TRENDS BIOCHEM SCI, V18, P372, DOI 10.1016/0968-0004(93)90091-Z; RANSOM SC, 1988, BIOCHEMISTRY-US, V27, P540, DOI 10.1021/bi00402a006; SCHNEIDER D, 1993, J GEN MICROBIOL, V139, P2559, DOI 10.1099/00221287-139-11-2559; SHAFER SL, UNPUB; TAYLOR KT, 1991, THESIS U MARYLAND CO; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; WEDEKIND JH, IN PRESS BIOCHEMISTR	34	138	139	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	1995	267	5201					1159	1161		10.1126/science.7855594	http://dx.doi.org/10.1126/science.7855594			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855594				2022-12-24	WOS:A1995QJ23700034
J	AMIEL, SA				AMIEL, SA			GLUCAGON-LIKE PEPTIDE - A THERAPEUTIC GLIMMER	LANCET			English	Editorial Material											AMIEL, SA (corresponding author), GUYS HOSP,DIV MED,LONDON SE1 9RT,ENGLAND.							GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HIROTA M, 1990, DIABETES RES CLIN PR, V9, P179, DOI 10.1016/0168-8227(90)90110-F; KREYMANN B, 1987, LANCET, V2, P1300; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; NAUCK MA, 1993, J CLIN ENDOCR METAB, V76, P912, DOI 10.1210/jc.76.4.912; ORSKOV C, 1991, J CLIN INVEST, V87, P415, DOI 10.1172/JCI115012	7	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					4	5		10.1016/S0140-6736(94)90869-9	http://dx.doi.org/10.1016/S0140-6736(94)90869-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905051				2022-12-24	WOS:A1994MN93700005
J	ORLANDO, V; PARO, R				ORLANDO, V; PARO, R			MAPPING POLYCOMB-REPRESSED DOMAINS IN THE BITHORAX COMPLEX USING IN-VIVO FORMALDEHYDE CROSS-LINKED CHROMATIN	CELL			English	Article							POSITION-EFFECT VARIEGATION; HOMEOTIC GENE ULTRABITHORAX; ABDOMINAL-B DOMAIN; DROSOPHILA-MELANOGASTER; MOLECULAR-GENETICS; ANTENNAPEDIA GENE; CONTROL REGION; DNA-SEQUENCES; PROTEIN; EXPRESSION	The Polycomb group (Pc-G) proteins are responsible for keeping developmental regulators, like homeotic genes, stably and inheritably repressed during Drosophila development. Several similarities to a protein class involved in heterochromatin formation suggest that the Pc-G exerts its function at the higher order chromatin level. Here we have mapped the distribution of the Pc protein in the homeotic bithorax complex (BX-C) of Drosophila tissue culture cells. We have elaborated a method, based on the in vivo formaldehyde cross-linking technique, that allows a substantial enrichment for Pc-interacting sites by immunoprecipitation of the cross-linked chromatin with anti-Pc antibodies. We find that the Pc protein quantitatively covers large regulatory regions of repressed BX-C genes. Conversely, we find that the Abdominal-B gene is active in these cells and the region devoid of any bound Pc protein.			ORLANDO, V (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,IM NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BIENZ M, 1988, CELL, V53, P567, DOI 10.1016/0092-8674(88)90573-9; BLANCO J, 1985, BIOCHEMISTRY-US, V24, P8021, DOI 10.1021/bi00348a028; BOULET AM, 1988, GENE DEV, V2, P1600, DOI 10.1101/gad.2.12a.1600; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CASANOVA J, 1986, CELL, V47, P627, DOI 10.1016/0092-8674(86)90627-6; CASTELLIGAIR J, 1992, DEVELOPMENT, V114, P877; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DECAMILLIS M, 1992, GENE DEV, V6, P223, DOI 10.1101/gad.6.2.223; DELORENZI M, 1988, EMBO J, V7, P3223, DOI 10.1002/j.1460-2075.1988.tb03189.x; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; ENGSTROM Y, 1992, ROUX ARCH DEV BIOL, V201, P65, DOI 10.1007/BF00420417; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GOLDSCHMIDTCLERMONT M, 1980, NUCLEIC ACIDS RES, V8, P235, DOI 10.1093/nar/8.2.235; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HARDING K, 1988, EMBO J, V7, P205, DOI 10.1002/j.1460-2075.1988.tb02801.x; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; IRVINE KD, 1991, DEVELOPMENT, V111, P407; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; JOHNSON DH, 1991, PCR PRACTICAL APPROA; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KUZIORA MA, 1988, EMBO J, V7, P3233, DOI 10.1002/j.1460-2075.1988.tb03190.x; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LOCKE J, 1988, GENETICS, V120, P181; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MULLER J, 1991, EMBO J, V10, P3147, DOI 10.1002/j.1460-2075.1991.tb04876.x; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PARO R, 1983, EMBO J, V2, P853, DOI 10.1002/j.1460-2075.1983.tb01513.x; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SAKONJU S, 1984, GENETICS, V107, P593; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZHERRERO E, 1991, DEVELOPMENT, V111, P437; SAUNDERS RDC, 1989, NUCLEIC ACIDS RES, V17, P9027, DOI 10.1093/nar/17.22.9027; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SCHOUTEN JP, 1985, J BIOL CHEM, V260, P9929; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; SIMON J, 1992, DEVELOPMENT, V114, P493; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; ZAVORTINK M, 1989, GENE DEV, V3, P1969, DOI 10.1101/gad.3.12a.1969; ZHANG CC, 1991, DEVELOPMENT, V113, P1171; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	71	305	316	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1187	1198		10.1016/0092-8674(93)90328-N	http://dx.doi.org/10.1016/0092-8674(93)90328-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7903220				2022-12-24	WOS:A1993MM89300017
J	ADAMSON, BB; GALLACHER, SJ; BYARS, J; RALSTON, SH; BOYLE, IT; BOYCE, BF				ADAMSON, BB; GALLACHER, SJ; BYARS, J; RALSTON, SH; BOYLE, IT; BOYCE, BF			MINERALIZATION DEFECTS WITH PAMIDRONATE THERAPY FOR PAGETS-DISEASE	LANCET			English	Note							BONE	Bone biopsy samples were taken from 20 patients with Paget's disease before and after intravenous pamidronate therapy. In 10 patients given 180 or 360 mg during 6 or 9 weeks, bone turnover decreased as measured biochemically and histologically, but osteomalacia developed in 1 patient and mineralisation defects in 3. 10 other patients received 45 mg every 3 months for 1 year. Bone turnover decreased biochemically but not histologically, and osteoid thickness increased, suggesting impaired mineralisation. Despite overall efficacy, pamidronate has a narrow therapeutic range between resorption inhibition and mineralisation defects. Short courses given to achieve biochemical remission should be administered with caution.	UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW,SCOTLAND; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284	University of Glasgow; University of Texas System; University of Texas Health San Antonio	BOYCE, BF (corresponding author), UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT PATHOL,GLASGOW,SCOTLAND.							ANDERSON DC, 1987, BRIT MED J, V294, P1486, DOI 10.1136/bmj.294.6585.1486; BOYCE BF, 1984, LANCET, V1, P821; BYCE BF, 1992, J CLIN PATHOL, V45, P502; CANTRILL JA, 1990, CLIN ENDOCRINOL, V32, P507, DOI 10.1111/j.1365-2265.1990.tb00892.x; FENTON AJ, 1991, CLIN ENDOCRINOL, V34, P197, DOI 10.1111/j.1365-2265.1991.tb00294.x; FLEISCH H, 1987, CLIN ORTHOP RELAT R, V217, P72; GALLACHER SJ, 1991, ANN RHEUM DIS, V50, P930, DOI 10.1136/ard.50.12.930; HARINCK HIJ, 1987, CLIN ORTHOP RELAT R, V217, P79	8	107	108	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1459	1460		10.1016/0140-6736(93)92935-M	http://dx.doi.org/10.1016/0140-6736(93)92935-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902484				2022-12-24	WOS:A1993ML21700011
J	KUKS, JBM; COOK, MJ; FISH, DR; STEVENS, JM; SHORVON, SD				KUKS, JBM; COOK, MJ; FISH, DR; STEVENS, JM; SHORVON, SD			HIPPOCAMPAL SCLEROSIS IN EPILEPSY AND CHILDHOOD FEBRILE SEIZURES	LANCET			English	Article							TEMPORAL-LOBE EPILEPSY; CONVULSIONS; RISK	The connection between hippocampal sclerosis and childhood febrile seizures (CFS) is a contentious issue in the study of epilepsy. We investigated 107 patients with drug-resistant epilepsy by high-resolution volumetric magnetic resonance imaging (MRI). 20 had a history of CFS, 45 had focal (26) or diffuse (19) hippocampal volume loss (HVL). The frequency of CFS was significantly (p < 0.001) higher in the patients with HVL, especially of the diffuse pattern, compared to other epileptic patients without HVL and to the general population. Furthermore, the severity of HVL was greatest in those with a history of CFS. No other clinical or demographic features were associated with either a history of CFS or HVL. The frequency of CFS in patients with other structural congenital causes of epilepsy did not differ from that in a general population. Although these findings show that hippocampal sclerosis is strongly associated with a history of CFS, they do not indicate whether this is a causal relationship. If CFS do cause some cases of hippocampal sclerosis, this can not be the only mechanism, as 64% of those with HVL gave no history of CFS. As diffuse HVL is more strongly associated with a history of CFS than focal HVL, it is also possible that CFS convert pre-existing congenital focal abnormalities into diffuse hippocampal sclerosis. Given the possibility that CFS may cause hippocampal damage and epilepsy, they require urgent medical intervention.	UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND; ST MARYS HOSP, LONDON, ENGLAND; STATE UNIV HOSP GRONINGEN, DEPT NEUROL, GRONINGEN, NETHERLANDS	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Imperial College London; University of Groningen			Cook, Mark J/A-7096-2010; Shorvon, Simon D/A-2019-2009	Cook, Mark J/0000-0002-8875-4135; 				AICARDI J, 1983, DELGADO, P115; ANNEGERS JF, 1979, NEUROLOGY, V29, P297, DOI 10.1212/WNL.29.3.297; BABB TL, 1984, EPILEPSIA, V25, P721, DOI 10.1111/j.1528-1157.1984.tb03483.x; Brown W., 1987, SURGICAL TREATMENT E, P511; BRUTON CJ, 1988, NEUROPATHOLOGY TEMPO, P1; Cook M. J., 1992, Epilepsia, V33, P72; COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; DAM AM, 1982, ACTA NEUROL SCAND, V66, P601, DOI 10.1111/j.1600-0404.1982.tb04528.x; FALCONER MA, 1971, EPILEPSIA, V12, P13, DOI 10.1111/j.1528-1157.1971.tb03912.x; FISH D, 1991, NEUROLOGY, V41, P1781, DOI 10.1212/WNL.41.11.1781; GASTAUT H, 1959, EPILEPSIA, V1, P56, DOI 10.1111/j.1528-1157.1959.tb04249.x; Hauser WA, 1981, FEBRILE SEIZURES, P5; JACK CR, 1992, ANN NEUROL, V31, P138, DOI 10.1002/ana.410310204; LENCZ T, 1992, ANN NEUROL, V31, P629, DOI 10.1002/ana.410310610; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; RASMUSSEN T, 1979, EPILEPSIA, V20, P395, DOI 10.1111/j.1528-1157.1979.tb04819.x; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; Scheibel A B, 1991, Adv Neurol, V55, P59; VERITY CM, 1993, BMJ-BRIT MED J, V307, P225, DOI 10.1136/bmj.307.6898.225; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373	21	131	135	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1993	342	8884					1391	1394						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901683				2022-12-24	WOS:A1993MK09500011
J	JAVAHERI, S; PARKER, TJ; WEXLER, L; MICHAELS, SE; STANBERRY, E; NISHYAMA, H; ROSELLE, GA				JAVAHERI, S; PARKER, TJ; WEXLER, L; MICHAELS, SE; STANBERRY, E; NISHYAMA, H; ROSELLE, GA			OCCULT SLEEP-DISORDERED BREATHING IN STABLE CONGESTIVE-HEART-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Article						HEART FAILURE, CONGESTIVE; VENTRICULAR FUNCTION, LEFT; SLEEP APNEA SYNDROMES; CHEYNE-STOKES RESPIRATION; OXYHEMOGLOBINS	CHEYNE-STOKES RESPIRATION; APNEA; ABNORMALITIES; VENTILATION; OXYGEN	Objective: To determine the prevalence and effect of sleep-disordered breathing in ambulatory patients with stable, optimally treated congestive heart failure. Design: A prospective, longitudinal study. Setting: Referral sleep laboratory of a Department of Veterans Affairs medical center. Patients: 42 of the 48 eligible patients with stable congestive heart failure and left ventricular systolic dysfunction (left ventricular ejection fraction less than or equal to 45%). Measurements: After an adaptation night, polysomnography and Holter monitoring were done in the sleep laboratory. Arterial blood gases and pH were measured, and cardiac radionuclide ventriculography and pulmonary, renal, and thyroid function tests were done. Results: Patients were divided into two groups. Group I (n = 23) had an hourly rate of apnea and hypopnea (apnea-hypopnea index) of 20 episodes per hour or less; group II (n = 19 [45%; CI, 30% to 60%]) had an index of more than 20 episodes per hour. In group II, the index varied from 26.5 to 82.2 episodes per hour (mean +/- SD, 44 +/- 13 episodes per hour; CI, 38 to 51 episodes per hour). Group II had significantly more arousals (24 +/- 12 compared with 3 +/- 3 in group I) that were directly attributable to episodes of apnea and hypopnea, longer periods of time with an arterial oxyhemoglobin saturation of less than 90% (23% +/- 24% of total sleep time compared with 2% +/- 4%), lower arterial oxyhemoglobin saturation during sleep (74% +/- 13% compared with 87% +/- 4%), lower left ventricular ejection fraction (22% +/- 9% compared with 30% +/- 10%), and a significantly increased number of episodes of nocturnal ventricular arrhythmias. Multiple regression analyses showed that left Ventricular systolic dysfunction was an independent risk factor for sleep apnea in patients with congestive heart failure. Conclusions: The prevalence of severe occult sleep-disordered breathing is high in ambulatory patients with stable, optimally treated chronic congestive heart failure. The breathing episodes are associated with severe nocturnal arterial blood oxyhemoglobin desaturation and excessive arousals. Severe untreated sleep-disordered breathing may adversely affect left ventricular function, resulting in a vicious cycle that could contribute to death in patients with congestive heart failure. Prospective, longitudinal studies on survival are needed.	VET AFFAIRS MED CTR, SERV PHARM, CINCINNATI, OH 45220 USA; UNIV CINCINNATI, COLL MED, CINCINNATI, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	JAVAHERI, S (corresponding author), VET AFFAIRS MED CTR, PULM SECT 111F, SLEEP DISORDERS LAB, 3200 VINE ST, CINCINNATI, OH 45220 USA.							Ancoli-Israel S, 1989, Clin Geriatr Med, V5, P347; [Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1992, SLEEP, V15, P174; BLUMBERG H, 1980, J AUTONOM NERV SYST, V2, P223, DOI 10.1016/0165-1838(80)90013-2; BRADLEY TD, 1992, CLIN CHEST MED, V13, P459; CHERNIACK NS, 1981, NEW ENGL J MED, V305, P325; DARK DS, 1987, CHEST, V91, P833, DOI 10.1378/chest.91.6.833; DOWDELL WT, 1990, AM REV RESPIR DIS, V141, P871, DOI 10.1164/ajrccm/141.4_Pt_1.871; DOWDELL WT, 1992, AM REV RESPIR DIS, V145, P137, DOI 10.1164/ajrccm/145.1.137; FINDLEY LJ, 1985, SOUTH MED J, V78, P11, DOI 10.1097/00007611-198501000-00004; FLEMONS WW, 1994, PRINCIPLES PRACTICE, P824; FLETCHER EC, 1992, HYPERTENSION, V19, P555, DOI 10.1161/01.HYP.19.6.555; FRANCIS GS, 1986, AM J CARDIOL, V57, pB3, DOI 10.1016/0002-9149(86)90991-4; HANLY P, 1993, CHEST, V104, P1079, DOI 10.1378/chest.104.4.1079; HANLY PJ, 1989, ANN INTERN MED, V111, P777, DOI 10.7326/0003-4819-111-10-777; HANLY PJ, 1989, CHEST, V96, P480, DOI 10.1378/chest.96.3.480; Harrison TR, 1934, ARCH INTERN MED, V53, P891, DOI 10.1001/archinte.1934.00160120085009; HARVEY RM, 1971, CHEST, V59, P82, DOI 10.1378/chest.59.1.82; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; JAVAHERI S, 1990, RESP PHYSIOL, V81, P359, DOI 10.1016/0034-5687(90)90116-G; MASSUMI RA, 1968, CHEST, V54, P21; PACKER M, 1985, CIRCULATION, V72, P681, DOI 10.1161/01.CIR.72.4.681; PHILLIPSON EA, 1994, TXB RESP MED, P2301; PICKERING TG, 1978, AM J MED, V65, P575, DOI 10.1016/0002-9343(78)90844-6; REES PJ, 1979, LANCET, V2, P1315; ROSE CE, 1983, AM J PHYSIOL, V245, pH924, DOI 10.1152/ajpheart.1983.245.6.H924; ROTH T, 1994, PRINCIPLES PRACTICE, P40; SKATRUD JB, 1983, J APPL PHYSIOL, V55, P813, DOI 10.1152/jappl.1983.55.3.813; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; YASUMA F, 1989, JPN CIRC J, V53, P1506, DOI 10.1253/jcj.53.1506; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZARET BL, 1992, HEART DISEASE TXB CA, P276; 1988, SAS STAT USERS GUIDE	36	205	230	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					487	492		10.7326/0003-4819-122-7-199504010-00002	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872582				2022-12-24	WOS:A1995QP00800002
J	HUANG, YQ; LI, JJ; KAPLAN, MH; POIESZ, B; KATABIRA, E; ZHANG, WC; FEINER, D; FRIEDMANKIEN, AE				HUANG, YQ; LI, JJ; KAPLAN, MH; POIESZ, B; KATABIRA, E; ZHANG, WC; FEINER, D; FRIEDMANKIEN, AE			HUMAN HERPESVIRUS-LIKE NUCLEIC-ACID IN VARIOUS FORMS OF KAPOSIS-SARCOMA	LANCET			English	Note								The association between a new human herpesvirus-like agent and various forms of Kaposi's sarcoma was examined by PCR. The DNA sequences of this agent were detected in 7 of 8 classic Kaposi's sarcoma specimens, 12 of 12 AIDS-associated specimens from the United States, and 7 of 10 specimens from African endemic Kaposi's sarcoma. Polymorphism of the herpesvirus-like DNA in the Kaposi's tissue from different populations was observed by both single-strand conformational polymorphism and direct sequencing. Furthermore, the presence and expression of the virus was detected in some Kaposi's tumours by Southern and northern blotting. This herpesvirus may be involved in the pathogenesis of different kinds of Kaposi's sarcoma seen among distinct and unrelated populations.	NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; N SHORE UNIV HOSP,DEPT MED,MANHASSET,NY; SUNY HLTH SCI CTR,CTR REG ONCOL,SYRACUSE,NY 13210; MULAGO HOSP,DEPT MED,WHO,KAMPALA,UGANDA	New York University; New York University; Northwell Health; North Shore University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Mulago National Referral Hospital; World Health Organization				Friedman Kien, Alvin/0000-0002-5854-2852				ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Buchbinder Aby, 1992, Current Opinion in Oncology, V4, P867, DOI 10.1097/00001622-199210000-00009; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; LI JJ, 1992, J CLIN MICROBIOL, V30, P1051, DOI 10.1128/JCM.30.5.1051-1055.1992; Miles Steven A., 1992, Current Opinion in Oncology, V4, P875, DOI 10.1097/00001622-199210000-00010; NICOLAIDES A, 1994, ANTICANCER RES, V14, P921; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	8	406	413	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					759	761		10.1016/S0140-6736(95)90641-X	http://dx.doi.org/10.1016/S0140-6736(95)90641-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891487	hybrid			2022-12-24	WOS:A1995QN70100012
J	GERGEN, P; MCQUILLAN, GM; KIELY, M; EZZATIRICE, TM; SUTTER, RW; VIRELLA, G				GERGEN, P; MCQUILLAN, GM; KIELY, M; EZZATIRICE, TM; SUTTER, RW; VIRELLA, G			A POPULATION-BASED SEROLOGIC SURVEY OF IMMUNITY TO TETANUS IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIPHTHERIA IMMUNITY; VACCINATION; CHILDREN; REVACCINATION; IMMUNIZATION; ADULTS	Background. Vaccination rates are frequently considered a surrogate measure of protection. To provide more accurate estimates, serum levels of antibody against tetanus were measured as part of the third National Health and Nutrition Examination Survey (NHANES III), which studied a representative sample of the civilian, noninstitutionalized population of the United States. Methods. We measured tetanus antitoxin using a solid-phase enzyme immunoassay in serum samples from 10,618 persons six years of age and older who were examined during phase 1 of NHANES III in 1988 to 1991. Results. Overall, 69.7 percent of Americans six years of age and older had protective levels of tetanus antibodies (>0.15 IU per milliliter). The rate decreased from 87.7 percent among those 6 to 11 years of age to 27.8 percent among those 70 years of age or older, Among children 6 to 16 years of age, 82.2 percent had protective levels of tetanus antibodies, with little variation according to race or ethnicity. More men than women were immune (79.0 percent vs. 62.4 percent). Mexican Americans had a significantly lower rate of immunity (57.9 percent, P<0.05) than either non-Hispanic whites (72.7 percent) or non-Hispanic blacks (68.1 percent). Those with a history of military service, higher levels of education, or incomes above the poverty level were more likely to have protective antibody levels. Although the prevalence of immunity declined rapidly starting at the age of 40 years, most of the 107 cases of tetanus (with 20 deaths) reported in 1989 and 1990 occurred in persons 60 years of age or older, Conclusions. Despite the fact that effective vaccines against tetanus have been available since the 1940s, many Americans do not have immunity to tetanus, and the rates are lowest among the elderly There is an excellent correlation between vaccination rates (96 percent) and immunity (96 percent) among six-year-olds. However, antibody levels decline over time, and one fifth of older children (10 to 16 years of age) do not have protective antibody levels.	NIAID,BETHESDA,MD 20892; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,HYATTSVILLE,MD 20782; US MATERNAL & CHILD HLTH BUR,ROCKVILLE,MD; CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,ATLANTA,GA 30333; MED UNIV S CAROLINA,DEPT MICROBIOL & IMMUNOL,CHARLESTON,SC 29425	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Medical University of South Carolina								BALESTRA DJ, 1993, J GEN INTERN MED, V8, P405, DOI 10.1007/BF02599616; CROSSLEY K, 1979, JAMA-J AM MED ASSOC, V242, P2298, DOI 10.1001/jama.242.21.2298; EZZATI T, 1993, 1992 P SURV RES METH, P339; HINMAN AR, 1991, AM J DIS CHILD, V145, P559, DOI 10.1001/archpedi.1991.02160050085023; KAHN HA, 1989, STATISTICAL METHODS; KHARE M, 1994, IN PRESS 1994 P SURV; MARKS JS, 1979, PEDIATRICS, V64, P304; MYERS MG, 1982, JAMA-J AM MED ASSOC, V248, P2478, DOI 10.1001/jama.248.19.2478; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; PETER G, 1994, 1994 RED BOOK REPORT, P458; Prevots Rebecca, 1992, Morbidity and Mortality Weekly Report, V41, P1; RUBEN FL, 1973, B WORLD HEALTH ORGAN, V48, P175; SHAH BV, 1991, SUDAAN USERS MANUAL; SIMONSEN O, 1989, DAN MED BULL, V36, P24; SIMONSEN O, 1986, J BIOL STAND, V14, P231, DOI 10.1016/0092-1157(86)90008-9; SIMONSEN O, 1986, ACTA PATH MICRO IM C, V94, P77; SIMONSEN O, 1984, LANCET, V2, P1240; SUTTER RW, 1990, AM J EPIDEMIOL, V131, P132, DOI 10.1093/oxfordjournals.aje.a115466; VIRELLA G, 1991, J CLIN LAB ANAL, V5, P43, DOI 10.1002/jcla.1860050108; VOLK VK, 1962, PUBLIC HEALTH REP, V77, P185, DOI 10.2307/4591451; WEISS BP, 1983, AM J PUBLIC HEALTH, V73, P802, DOI 10.2105/AJPH.73.7.802; 1994, MMWR-MORBID MORTAL W, V43, P282; 1994, MMWR-MORBID MORTAL W, V43, P57; 1992, DHHS PHS921387 NAT C; 1994, MMWR-MORBID MORTAL W, V43, P1; 1989, CURRENT POPULATION P, V60; 1994, MMWR-MORBID MORTAL W, V42, P985; 1988, CURRENT POPULATION P, V60; 1993, STATE IMMUNIZATION 1; 1993, 1993 WORLD BANK DEV, P8; 1991, CURRENT POPULATION P, V60; 1992, MMWR-MORBID MORTAL W, V41, P67; 1994, MMWR-MORBID MORTAL W, V43, P556	33	249	255	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					761	766		10.1056/NEJM199503233321201	http://dx.doi.org/10.1056/NEJM199503233321201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862178	Green Published			2022-12-24	WOS:A1995QN44200001
J	SMALL, GW; MAZZIOTTA, JC; COLLINS, MT; BAXTER, LR; PHELPS, ME; MANDELKERN, MA; KAPLAN, A; LARUE, A; ADAMSON, CF; CHANG, L; GUZE, BH; CORDER, EH; SAUNDERS, AM; HAINES, JL; PERICAKVANCE, MA; ROSES, AD				SMALL, GW; MAZZIOTTA, JC; COLLINS, MT; BAXTER, LR; PHELPS, ME; MANDELKERN, MA; KAPLAN, A; LARUE, A; ADAMSON, CF; CHANG, L; GUZE, BH; CORDER, EH; SAUNDERS, AM; HAINES, JL; PERICAKVANCE, MA; ROSES, AD			APOLIPOPROTEIN-E TYPE-4 ALLELE AND CEREBRAL GLUCOSE-METABOLISM IN RELATIVES AT RISK FOR FAMILIAL ALZHEIMER-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON EMISSION TOMOGRAPHY; SENILE DEMENTIA; ONSET; GENE; CHROMOSOME-14; RELIABILITY; PREVALENCE; EPSILON-4; PATTERNS; REGIONS	Objective.-Cerebral parietal hypometabolism and left-right asymmetry occur early in the course of Alzheimer disease (AD), and the apolipoprotein E type 4 allele (APOE epsilon 4) is a risk factor for familial AD. To determine if APOE epsilon 4 is associated with lowered brain function in nondemented relatives at risk for familiar AD, we studied 12 relatives with APOE epsilon 4 and 19 relatives without APOE epsilon 4. We also compared them with seven patients with probable AD. Design.-After grouping subjects according to diagnosis and genotype, brain function measures were compared among groups. Setting.-University medical center. Patients.-At-risk subjects had mild memory complaints, normal cognitive performance, and at least two relatives with AD. Subjects with APOE epsilon 4 did not differ from those without APOE epsilon 4 in mean age at examination (56.4 vs 55.5 years) or in neuropsychological performance (mean Mini-Mental State Examination score, 28.8 vs 29.3). Main Outcome Measures.-Cerebral glucose metabolism was measured using positron emission tomography and fludeoxyglucose F 18. Results.-Parietal metabolism was significantly lower and left-right parietal asymmetry was significantly higher in at-risk subjects with APOE epsilon 4 compared with those without APOE epsilon 4, Patients with dementia had significantly lower parietal metabolism than did at-risk subjects with APOE epsilon 4. Conclusions.-These results suggest that the inheritance of APOE epsilon 4 is associated with reduced cerebral parietal metabolism and increased asymmetry in nondemented relatives at risk for probable AD, Longitudinal study will determine if glucose metabolic measures provide a means to monitor experimental treatment responses during the early phases of the disorder.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT RADIOL SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV BRAIN MAPPING,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,CTR ALZHEIMERS DIS,LOS ANGELES,CA 90024; VET AFFAIRS MED CTR,LOS ANGELES,CA; UNIV CALIF IRVINE,DEPT PHYS,IRVINE,CA; UNIV NEW MEXICO,DEPT PSYCHIAT,ALBUQUERQUE,NM; DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZHEIMERS DIS RES CTR,DURHAM,NC; DUKE UNIV,MED CTR,DIV NEUROL,DURHAM,NC; DUKE UNIV,MED CTR,DIV NEUROBIOL,DURHAM,NC; MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Irvine; University of New Mexico; Duke University; Duke University; Duke University; Harvard University; Massachusetts General Hospital	SMALL, GW (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024, USA.		Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728	NIA NIH HHS [U24 AG021886, AG10123, AG05128] Funding Source: Medline; NIMH NIH HHS [1R29 MH46424] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH046424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U24AG021886, P30AG010123] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AZARI NP, 1993, J CEREBR BLOOD F MET, V13, P438, DOI 10.1038/jcbfm.1993.58; BACHMAN DL, 1992, NEUROLOGY, V42, P115, DOI 10.1212/WNL.42.1.115; BARRIO JR, 1981, J NUCL MED, V22, P372; BAXTER LR, 1987, PSYCHIAT RES, V21, P237, DOI 10.1016/0165-1781(87)90028-X; Benton A, 1978, PSYCHOL ASSESSMENT R; BLASS JP, 1993, ALZ DIS ASSOC DIS, V6, P205; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; DAVIS PC, 1992, NEUROLOGY, V42, P1676, DOI 10.1212/WNL.42.9.1676; DELEON MJ, 1993, AM J NEURORADIOL, V14, P897; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILEWSKI MJ, 1990, PSYCHOL AGING, V5, P482, DOI 10.1037/0882-7974.5.4.482; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRADY CL, 1988, J CLIN EXP NEUROPSYC, V10, P576, DOI 10.1080/01688638808402796; GRADY CL, 1993, NEUROBIOL AGING, V14, P35, DOI 10.1016/0197-4580(93)90018-7; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HART RP, 1987, PSYCHOL AGING, V2, P111, DOI 10.1037/0882-7974.2.2.111; HAXBY JV, 1990, ARCH NEUROL-CHICAGO, V47, P753, DOI 10.1001/archneur.1990.00530070043010; HENRY TR, 1990, J CEREBR BLOOD F MET, V10, P748, DOI 10.1038/jcbfm.1990.128; HERHOLZ K, 1993, J NUCL MED, V34, P1460; HIXSON JE, 1990, J LIPID RES, V31, P545; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; KILLIANY RJ, 1993, ARCH NEUROL-CHICAGO, V50, P949, DOI 10.1001/archneur.1993.00540090052010; KUHL DE, 1987, J CEREB BLOOD FLOW M, V7, pS406; LIU CK, 1992, NEUROLOGY, V42, P138, DOI 10.1212/WNL.42.1.138; MASUR DM, 1989, J CLIN EXP NEUROPSYC, V11, P615, DOI 10.1080/01688638908400920; MAX W, 1993, NEUROLOGY, V43, pS6; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAZZIOTTA J C, 1986, P493; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MULLERGARTNER HW, 1992, J CEREBR BLOOD F MET, V12, P571, DOI 10.1038/jcbfm.1992.81; Osterrieth P., 1944, ARCH PSYCHOL-GENEVE, V30, P206; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; PHELPS ME, 1981, J CEREB BLOOD FLOW M, V2, P113; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; SAMBROOK J, 1989, MOL CLONING LABORATO, pB24; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SMALL GW, 1989, ARCH GEN PSYCHIAT, V46, P527; SMALL GW, 1992, PSYCHIAT RES-NEUROIM, V45, P177, DOI 10.1016/0925-4927(92)90025-Y; SMALL GW, 1994, INT PSYCHOGERIATR, V6, P21; SMALL GW, 1988, ARCH GEN PSYCHIAT, V46, P945; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STORANDT M, 1984, ARCH NEUROL-CHICAGO, V41, P497, DOI 10.1001/archneur.1984.04050170043013; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CMG, 1991, INT J EPIDEMIOL S2, V20, pS48; VANGORP WG, 1990, DEV NEUROPSYCHOL, V6, P279, DOI 10.1080/87565649009540467; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; Wechsler D., 2008, WECHSLER ADULT INTEL; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; 1988, ALZ DIS ASSOC DIS, V2, P4; 1993, LANCET, V342, P737	59	497	512	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					942	947		10.1001/jama.273.12.942	http://dx.doi.org/10.1001/jama.273.12.942			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM173	7884953				2022-12-24	WOS:A1995QM17300029
J	HALANYCH, KM; BACHELLER, JD; AGUINALDO, AMA; LIVA, SM; HILLIS, DM; LAKE, JA				HALANYCH, KM; BACHELLER, JD; AGUINALDO, AMA; LIVA, SM; HILLIS, DM; LAKE, JA			EVIDENCE FROM 18S RIBOSOMAL DNA THAT THE LOPHOPHORATES ARE PROTOSTOME ANIMALS	SCIENCE			English	Article							SEQUENCES; ORIGIN; PHYLOGENY; RNA	The suspension-feeding metazoan subkingdom Lophophorata exhibits characteristics of both deuterostomes and protostomes. Because the morphology and embryology of lophophorates are phylogenetically ambiguous, their origin is a major unsolved problem of metazoan phylogenetics. The complete 18S ribosomal DNA sequences of all three lophophorate phyla were obtained and analyzed to clarify the phylogenetic relationships of this subkingdom. Sequence analyses show that lophophorates are protostomes closely related to mollusks and annelids, This conclusion deviates from the commonly held view of deuterostome affinity.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	HALANYCH, KM (corresponding author), UNIV TEXAS, DEPT ZOOL, AUSTIN, TX 78712 USA.		Hillis, David/L-5421-2019; Halanych, Ken M/A-9480-2009; Hillis, David M/B-4278-2008	Halanych, Ken M/0000-0002-8658-9674; 				BACKELJAU T, 1993, CLADISTICS, V9, P167, DOI 10.1111/j.1096-0031.1993.tb00216.x; BALLARD JWO, 1992, SCIENCE, V258, P1345, DOI 10.1126/science.1455227; CHRISTEN R, 1991, EMBO J, V10, P499, DOI 10.1002/j.1460-2075.1991.tb07975.x; DEQUEIROZ K, 1990, SYST ZOOL, V39, P307, DOI 10.2307/2992353; EERNISE DJ, 1993, SYST BIOL, V41, P305; EMIG C C, 1976, Zeitschrift fuer Zoologische Systematik und Evolutionsforschung, V14, P10; Emig C.C., 1982, P741; EMIG CC, 1982, ADV MAR BIOL, V19, P1, DOI 10.1016/S0065-2881(08)60086-3; FAITH DP, 1991, SYST ZOOL, V40, P366, DOI 10.2307/2992329; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Ghiselin M.T., 1988, Oxford Surveys in Evolutionary Biology, V5, P66; GUSTUS RM, 1972, ACTA ZOOL-STOCKHOLM, V53, P299; HALANYCH KM, 1993, BIOL BULL, V185, P417, DOI 10.2307/1542482; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; Hyman L. H., 1940, INVERTEBRATES PROTOZ, V1; Hyman L. H., 1959, INVERTEBRATES SMALLE, VV; HYMAN LH, 1958, BIOL BULL, V114, P106, DOI 10.2307/1538968; Jagersten G, 1972, EVOLUTION METAZOAN L; LAKE JA, 1989, INT CONGR SER, V824, P273; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; LAKE JA, UNPUB; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; MASLOV DA, 1994, NATURE, V368, P345, DOI 10.1038/368345a0; Nielsen C, 1977, BIOL BRYOZOANS, P519; OLSEN GJ, 1994, P NATL ACAD SCI USA, V91, P1455; PATTERSON C, 1989, INT CONGR SER, V824, P471; ROWELL AJ, 1982, LETHAIA, V15, P299, DOI 10.1111/j.1502-3931.1982.tb01695.x; Rudall K. M., 1973, BIOL REV, V40, P597; Schram F.R., 1991, P35; SWOFFORDS DL, 1993, PHYLOGENETIC ANAL US; TELFORD MJ, 1993, MOL BIOL EVOL, V10, P660; VALENTINE JW, 1973, SYST ZOOL, V22, P97, DOI 10.2307/2412093; VALENTINE JW, 1975, AM ZOOL, V15, P391; WADA H, 1994, P NATL ACAD SCI USA, V91, P1801, DOI 10.1073/pnas.91.5.1801; WILLIAMS A, 1977, PATTERNS EVOLUTION I, P79; Willmer P, 1990, INVERTEBRATE RELATIO; Zimmer R.L., 1973, P593; [No title captured]	41	465	482	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	1995	267	5204					1641	1643		10.1126/science.7886451	http://dx.doi.org/10.1126/science.7886451			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886451				2022-12-24	WOS:A1995QM39700035
J	PERRY, IJ; WANNAMETHEE, SG; WALKER, MK; THOMSON, AG; WHINCUP, PH; SHAPER, AG				PERRY, IJ; WANNAMETHEE, SG; WALKER, MK; THOMSON, AG; WHINCUP, PH; SHAPER, AG			PROSPECTIVE-STUDY OF RISK-FACTORS FOR DEVELOPMENT OF NON-INSULIN-DEPENDENT DIABETES IN MIDDLE-AGED BRITISH MEN	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; PHYSICAL-ACTIVITY; MELLITUS; RESISTANCE; POPULATION	Objective-To determine the risk factors for noninsulin dependent diabetes in a cohort representative of middle aged British men. Design-Prospective study. Subjects and setting-7735 men aged 40-59, drawn from one group practice in each of 24 towns in Britain. Known and probable cases of diabetes at screening (n=158) were excluded. Main outcome measures-Non-insulin dependent diabetes (doctor diagnosed) over a mean follow up period of 12 . 8 years. Results-There were 194 new cases of non-insulin dependent diabetes. Body mass index was the dominant risk factor for diabetes, with an age adjusted relative risk (upper fifth to lower fifth) of 11 . 6; 95% confidence interval 5 . 4 to 16 . 8. Men engaged in moderate levels of physical activity had a substantially reduced risk of diabetes, relative to the physically inactive men, after adjustment for age and body mass index (0 . 4; 0 . 2 to 0 . 7), an association which persisted in full multivariate analysis. A nonlinear relation between alcohol intake and diabetes was observed, with the lowest risk among moderate drinkers (16-42 units/week) relative to the baseline group of occasional drinkers (0 . 6; 0 . 4 to 1 . 0). Additional significant predictors of diabetes in multivariate analysis included serum triglyceride concentration, high density lipoprotein cholesterol concentration (inverse association), heart rate, uric acid concentration, and prevalent coronary heart disease. Conclusion-These finding emphasise the interrelations between risk factors for non-insulin dependent diabetes and coronary heart disease and the potential value of an integrated approach to the prevention of these conditions based on the prevention of obesity and the promotion of physical activity.			PERRY, IJ (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Perry, Ivan/0000-0002-4965-9792; Wannamethee, Sasiwarang/0000-0001-9484-9977; Whincup, Peter/0000-0002-5589-4107	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHATURVEDI N, 1994, DIABETOLOGIA, V37, P765, DOI 10.1007/s001250050177; COOK DG, 1986, POSTGRAD MED J, V62, P1001, DOI 10.1136/pgmj.62.733.1001; COX DR, 1972, J R STAT SOC B, V34, P187; EVERHART J, 1985, DIABETES AM DIABETES; FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; LAWS A, 1993, BAILLIERE CLIN ENDOC, V7, P1063, DOI 10.1016/S0950-351X(05)80245-9; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; OHLSON LO, 1988, DIABETOLOGIA, V31, P798; PHILLIPS AN, 1986, THESIS U LONDON LOND; POCOCK SJ, 1989, J CLIN PATHOL, V42, P172, DOI 10.1136/jcp.42.2.172; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAVAGE PJ, 1993, BRIT HEART J, V69, P473; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; SHAPER AG, 1988, LANCET, V2, P1268; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; WALKER M, 1984, J R COLL GEN PRACT, V34, P197; WILLIAMS R, 1994, HLTH CARE NEEDS ASSE, V1, P31; 1992, CM1986 SECR STAT HLT	28	407	458	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					560	564		10.1136/bmj.310.6979.560	http://dx.doi.org/10.1136/bmj.310.6979.560			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888929	Green Published			2022-12-24	WOS:A1995QK70000017
J	LAPINLEIMU, H; VIIKARI, J; JOKINEN, E; SALO, P; ROUTI, T; LEINO, A; RONNEMAA, T; SEPPANEN, R; VALIMAKI, I; SIMELL, O				LAPINLEIMU, H; VIIKARI, J; JOKINEN, E; SALO, P; ROUTI, T; LEINO, A; RONNEMAA, T; SEPPANEN, R; VALIMAKI, I; SIMELL, O			PROSPECTIVE RANDOMIZED TRIAL IN 1062 INFANTS OF DIET LOW IN SATURATED FAT AND CHOLESTEROL	LANCET			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; CHILDREN	Interventions to avoid atherosclerosis might be more successful if launched early in life when eating and lifestyle patterns are formed, but dietary interventions have been limited by fears of diet-induced growth failure. We investigated the effects of a diet low in saturated fat and cholesterol on serum lipid concentrations and growth in 1062 healthy 7-month-old infants in a randomised study. Every 1-3 months, families in the intervention group received dietary advice aimed at adequate energy supply, with low fat intake (30-35% energy, polyunsaturated/ monounsaturated/saturated fatty acid ratio 1/1/1, and cholesterol intake <200 mg daily). Infants in control families consumed an unrestricted diet. 3-day food records were collected at ages 8 and 13 months. Growth was carefully monitored. Between 7 and 13 months serum cholesterol and non-high-density-lipoprotein cholesterol concentrations did not change significantly in the intervention group (mean change -0.03 [SD 0.72] mmol/L and 0.01 [0.67] mmol/L) but increased substantially in the control group (0.24 [0.64] mmol/L and 0.23 [0.60] mmol/L; p for difference in mean changes between groups <0 001). Daily intakes of energy and saturated fat were lower in the intervention than in the control group at 13 months (4065 [796] vs 4370 [748] kJ, p=0.033, and 9.3 [3.5] vs 14.5 [4.8] g, p<0.001, respectively), and intake of polyunsaturated fat was higher (5.8 [2.2] vs 4.4 [1.4] g, p<0.001). Growth did not differ between the groups and was as expected for children at this age. Serum cholesterol concentrations fell significantly in parents of intervention-group infants. The increases in serum cholesterol and non-high-density-lipoprotein cholesterol concentration that occur in infants between the ages of 7 and 13 months can be avoided by individualised diets, with no effect on the children's growth.	UNIV TURKU, DEPT PAEDIAT, TURKU, FINLAND; UNIV TURKU, DEPT MED, TURKU, FINLAND; SOCIAL INSURANCE INST, RES & DEV UNIT, TURKU, FINLAND	University of Turku; University of Turku	LAPINLEIMU, H (corresponding author), UNIV TURKU, CARDIORESP RES UNIT, KIINAMYLLYNKATU 10, SF-20520 TURKU, FINLAND.		Lapinleimu, Helena/AAT-8415-2021					DOUGHERTY RM, 1988, AM J CLIN NUTR, V48, P970, DOI 10.1093/ajcn/48.4.970; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; ERKKOLA R, 1986, BIOL RES PREG PERIN, V7, P47; FRIEDMAN G, 1976, PEDIATRICS, V58, P655; GRUNDY SM, 1990, J LIPID RES, V31, P1149; KAPLAN RM, 1992, PREV MED, V21, P33, DOI 10.1016/0091-7435(92)90004-2; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KNUIMAN JT, 1987, ARTERIOSCLEROSIS, V7, P612, DOI 10.1161/01.ATV.7.6.612; LAPINLEIMU H, 1994, ACTA PAEDIATR, V83, P383, DOI 10.1111/j.1651-2227.1994.tb18124.x; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; NEWMAN TB, 1990, AM J DIS CHILD, V144, P851; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; PESONEN E, 1990, EUR HEART J, V11, P53, DOI 10.1093/eurheartj/11.suppl_E.53; PYORALA K, 1985, CARDIOLOGY, V72, P35, DOI 10.1159/000173839; RASANEN L, 1991, ANN MED, V23, P73, DOI 10.3109/07853899109147934; RASANEN L, 1992, ACTA PAEDIATR, V81, P7, DOI 10.1111/j.1651-2227.1992.tb12069.x; ROSENTHAL SL, 1993, CLIN PEDIATR, V32, P135, DOI 10.1177/000992289303200302; SORVA R, 1990, ACTA PAEDIATR SCAND, V79, P490, DOI 10.1111/j.1651-2227.1990.tb11502.x; VARTIAINEN E, 1987, CARDIOVASCULAR RISK, P183; VIIKARI J, 1985, ACTA PAEDIATR SCAND, P103; WALTER HJ, 1988, NEW ENGL J MED, V318, P1093, DOI 10.1056/NEJM198804283181704; 1989, RECOMMENDED DIETARY; 1991, PEDIATRICS, V89, P495	24	169	171	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	1995	345	8948					471	476		10.1016/S0140-6736(95)90580-4	http://dx.doi.org/10.1016/S0140-6736(95)90580-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861873				2022-12-24	WOS:A1995QH92900007
J	TRANSUE, ER				TRANSUE, ER			SHREDS OF A FLOWERED SHIRT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					623	623		10.1001/jama.273.8.623	http://dx.doi.org/10.1001/jama.273.8.623			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844871				2022-12-24	WOS:A1995QG74800026
J	ANTO, JM; SUNYER, J				ANTO, JM; SUNYER, J			NITROGEN-DIOXIDE AND ALLERGIC-ASTHMA - STARTING TO CLARIFY AN OBSCURE ASSOCIATION	LANCET			English	Editorial Material							EXPOSURE				ANTO, JM (corresponding author), UNIV AUTONOMA BARCELONA,INST MUNICIPAL INVEST MED,IMAS,BARCELONA,SPAIN.		Anto, J M/H-2676-2014; Sunyer, Jordi/G-6909-2014	Anto, J M/0000-0002-4736-8529; Sunyer, Jordi/0000-0002-2602-4110				ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; BROUGHT GFJ, 1993, LR941 WARR SPRING LA; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; FOLINSBEE LJ, 1992, TOXICOL IND HEALTH, V8, P273; HARLOS DP, 1988, THESIS HARVARD SCH P; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258, DOI 10.1164/ajrccm/148.5.1258; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X	9	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					402	403		10.1016/S0140-6736(95)90395-X	http://dx.doi.org/10.1016/S0140-6736(95)90395-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853945				2022-12-24	WOS:A1995QG90400003
J	SHARP, D				SHARP, D			WORMS, SPIRALS, FLUKES AS CARCINOGENS	LANCET			English	Editorial Material																		SHARP DW, 1993, SCI WATCH, V4, P5; 1994, IARC MONGRAPHS EVALU, V61; 1994, IARC MONOGRAPHS EVAL, V59	3	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					403	404		10.1016/S0140-6736(95)90396-8	http://dx.doi.org/10.1016/S0140-6736(95)90396-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853946				2022-12-24	WOS:A1995QG90400004
J	STEIN, A; STEIN, J; WALTERS, EA; FAIRBURN, CG				STEIN, A; STEIN, J; WALTERS, EA; FAIRBURN, CG			EATING HABITS AND ATTITUDES AMONG MOTHERS OF CHILDREN WITH FEEDING DISORDERS	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,PARK HOSP CHILDREN,CHILD & ADOLESCENT PSYCHIAT SECT,OXFORD OX3 7LQ,ENGLAND; UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND	University of Oxford; University of Oxford			Fairburn, Christopher/AAM-9792-2020; Fairburn, Christopher/AAG-6234-2019	Fairburn, Christopher/0000-0002-9673-9795; Stein, Alan/0000-0001-8207-2822; Stein, Jurgen/0000-0003-3558-3341	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1992, ICD 10 CLASSIFICATIO; FAIRBURN CG, 1990, AM J PSYCHIAT, V147, P401; FAIRBURN CG, IN PRESS INT J EAT D; SKUSE D, 1994, CHILD ADOL PSYCH CL, P467; STEIN A, 1994, J CHILD PSYCHOL PSYC, V35, P733, DOI 10.1111/j.1469-7610.1994.tb01218.x	5	29	29	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					228	228		10.1136/bmj.310.6974.228	http://dx.doi.org/10.1136/bmj.310.6974.228			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE496	7866126	Green Published			2022-12-24	WOS:A1995QE49600024
J	LIUZZO, G; BIASUCCI, LM; GALLIMORE, JR; GRILLO, RL; REBUZZI, AG; PEPYS, MB; MASERI, A				LIUZZO, G; BIASUCCI, LM; GALLIMORE, JR; GRILLO, RL; REBUZZI, AG; PEPYS, MB; MASERI, A			THE PROGNOSTIC VALUE OF C-REACTIVE PROTEIN AND SERUM AMYLOID-A PROTEIN IN SEVERE UNSTABLE ANGINA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR INHIBITOR-1; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; ACUTE-PHASE RESPONSE; A-PROTEIN; NATURAL-HISTORY; SILENT ISCHEMIA; INFLAMMATION; MACROPHAGES	Background. The pathogenesis of unstable angina is poorly understood, and predicting the prognosis is problematic. Evidence suggests that there may be active inflammation, possibly in the coronary arteries, in this syndrome. We therefore studied the prognostic value of measurements of the circulating acute-phase reactants C-reactive protein and serum amyloid A protein, which are sensitive indicators of inflammation. Methods. We measured C-reactive protein, serum amyloid A protein, creatine kinase, and cardiac troponin T in 32 patients with chronic stable angina, 31 with severe unstable angina, and 29 with acute myocardial infarction. Results. At the time of hospital admission, creatine kinase and cardiac troponin T levels were normal in all the patients, but the levels of C-reactive protein and serum amyloid A protein were greater than or equal to 0.3 mg per deciliter (exceeding the 90th percentile of the normal distribution) in 4 of the patients with stable angina (13 percent), 20 of the patients with unstable angina (65 percent), and 22 of the patients with acute myocardial infarction (76 percent). The 20 patients with unstable angina who had levels of acute-phase reactants greater than or equal to 0.3 mg per deciliter had more ischemic episodes in the hospital than those with levels <0.3 mg per deciliter (mean [+/-SD] number of episodes per patient, 4.8+/-2.5 vs. 1.8+/-2.4; P = 0.004); 5 patients subsequently had a myocardial infarction, 2 died, and 12 required immediate coronary revascularization. In contrast, no deaths or myocardial infarction occurred among the 11 patients with levels of acute-phase reactants <0.3 mg per deciliter, and only 2 of them required coronary revascularization. Among the patients admitted with a diagnosis of acute myocardial infarction, unstable angina preceded infarction in 14 of the 22 patients (64 percent) with levels of acute-phase reactants greater than or equal to 0.3 mg per deciliter but in none of the 7 patients with levels <0.3 mg per deciliter. Conclusions. Elevation of C-reactive protein and serum amyloid A protein at the time of hospital admission predicts a poor outcome in patients with unstable angina and may reflect an important inflammatory component in the pathogenesis of this condition.	UNIV CATTOLICA SACRO CUORE, IST MICROBIOL, ROME, ITALY; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT MED, LONDON, ENGLAND	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Imperial College London	LIUZZO, G (corresponding author), UNIV CATTOLICA SACRO CUORE, IST CARDIOL, LARGO AGOSTINO GEMELLI 8, I-00168 ROME, ITALY.		LIUZZO, GIOVANNA/J-8090-2018	LIUZZO, GIOVANNA/0000-0002-5714-0907; biasucci, luigi m/0000-0002-6921-6497				ANDREOTTI F, 1990, J AM COLL CARDIOL, V16, P1553, DOI 10.1016/0735-1097(90)90300-E; Baroldi G, 1988, Am J Cardiovasc Pathol, V2, P159; BAUSSERMAN LL, 1989, CLIN CHIM ACTA, V184, P297, DOI 10.1016/0009-8981(89)90063-6; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; BOGATY P, 1993, CIRCULATION, V87, P1938, DOI 10.1161/01.CIR.87.6.1938; CARRY M, 1992, CIRCULATION, V85, P230, DOI 10.1161/01.CIR.85.1.230; CIABATTONI G, 1993, J AM COLL CARDIOL, V21, P1377, DOI 10.1016/0735-1097(93)90312-O; DEBEER FC, 1982, BRIT HEART J, V47, P239; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P287; GOTTLIEB SO, 1987, J AM COLL CARDIOL, V10, P756, DOI 10.1016/S0735-1097(87)80267-X; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; JUHANVAGUE I, 1989, ARTERIOSCLEROSIS, V9, P362, DOI 10.1161/01.ATV.9.3.362; KOHCHI K, 1985, CIRCULATION, V71, P709, DOI 10.1161/01.CIR.71.4.709; KUSHNER I, 1978, J CLIN INVEST, V61, P235, DOI 10.1172/JCI108932; LANGER A, 1989, J AM COLL CARDIOL, V13, P1495, DOI 10.1016/0735-1097(89)90338-0; LINNANMAKI E, 1993, CIRCULATION, V87, P1130, DOI 10.1161/01.CIR.87.4.1130; MARHAUG G, 1986, ACTA MED SCAND, V220, P303; MAURY CPJ, 1988, J CLIN PATHOL, V41, P1263, DOI 10.1136/jcp.41.12.1263; MAZZONE A, 1993, CIRCULATION, V88, P358, DOI 10.1161/01.CIR.88.2.358; MULCAHY R, 1981, AM J CARDIOL, V48, P525, DOI 10.1016/0002-9149(81)90083-7; MULCAHY R, 1985, AM HEART J, V109, P753, DOI 10.1016/0002-8703(85)90634-9; NADEMANEE K, 1987, J AM COLL CARDIOL, V10, P1, DOI 10.1016/S0735-1097(87)80152-3; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; SATO T, 1987, ATHEROSCLEROSIS, V68, P191, DOI 10.1016/0021-9150(87)90198-5; SERNERI GGN, 1992, CIRCULATION, V86, P790, DOI 10.1161/01.CIR.86.3.790; SHAINKINKESTENBAUM R, 1986, J CLIN PATHOL, V39, P635, DOI 10.1136/jcp.39.6.635; SHINE B, 1981, CLIN CHIM ACTA, V117, P13, DOI 10.1016/0009-8981(81)90005-X; VEJAR M, 1990, THROMB HAEMOSTASIS, V63, P163; WALLSH E, 1986, TEX HEART I J, V13, P105; WILKINS J, 1994, CLIN CHEM, V40, P1284; YOSHIMOTO T, 1992, J IMMUNOL, V148, P3596; 1987, WHO TECH REP SER, V760, P21	35	1921	2045	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					417	424		10.1056/NEJM199408183310701	http://dx.doi.org/10.1056/NEJM199408183310701			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	7880233				2022-12-24	WOS:A1994PB50100001
J	THOMPSON, C				THOMPSON, C			IGE DECLARES WAR ON PARASITES	LANCET			English	Editorial Material							SCHISTOSOMIASIS; REINFECTION; RESISTANCE											BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; CAPRON A, 1992, MEM I OSWALDO CRUZ, V87, P19, DOI [10.1590/S0074-02761992000800003, 10.1016/S0171-2985(11)80480-8]; CAPRON M, 1986, Parasitology Today, V2, P69, DOI 10.1016/0169-4758(86)90158-4; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; GUONNI AS, 1994, NATURE, V67, P183; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; 1993, WHO TECH REP SER, V830, P86	7	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					309	310		10.1016/S0140-6736(94)91159-2	http://dx.doi.org/10.1016/S0140-6736(94)91159-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905141				2022-12-24	WOS:A1994MU98500005
J	EVAINBRION, D; PORQUET, D; THEROND, P; FJELLESTADPAULSEN, A; GRENECHE, MO; FRANCOIS, L; CZERNICHOW, P				EVAINBRION, D; PORQUET, D; THEROND, P; FJELLESTADPAULSEN, A; GRENECHE, MO; FRANCOIS, L; CZERNICHOW, P			VITAMIN-A-DEFICIENCY AND NOCTURNAL GROWTH-HORMONE SECRETION IN SHORT CHILDREN	LANCET			English	Note							ALPHA-TOCOPHEROL; RETINOL	In the growth hormone (GH) neurosecretory dysfunction syndrome affecting slowly growing children with delayed bone age, low nocturnal GH secretion is accompanied by normal responses to pharmacological stimuli. We compared plasma vitamin A with physiological nocturnal and stimulated GH secretion in 68 short prepubertal children. Fasting plasma vitamin A correlated with nocturnal GH secretion but not with stimulated GH secretion. Total dietary vitamin A intake was significantly lower in short children with abnormal nocturnal GH secretion than in normal children and in endocrinologically-normal short children. 9 of 12 children with low nocturnal GH secretion and normal stimulated GH peaks who were supplemented with vitamin A 3000 mug for 3 months had increased nocturnal GH secretion.	HOP ROBERT DEBRE,SERV BIOCHIM HORMONOL,F-75019 PARIS,FRANCE; HOP ROBERT DEBRE,DEPT DIETET,F-75019 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	EVAINBRION, D (corresponding author), HOP ROBERT DEBRE,SERV ENDOCRINOL & DIABETOL INFANTILE,48 BLVD SERURIER,F-75019 PARIS,FRANCE.							AMEDEEMANESME O, 1985, HEPATOLOGY, V5, P1143, DOI 10.1002/hep.1840050614; DELEENHEER AP, 1979, J CHROMATOGR, V162, P408, DOI 10.1016/S0378-4347(00)81528-5; MALVY JMD, 1989, INT J VITAM NUTR RES, V59, P29; MERRIAM GR, 1982, AM J PHYSIOL, V243, pE310, DOI 10.1152/ajpendo.1982.243.4.E310; PORQUET D, 1992, CLIN CHEM, V38, P1717; PORQUET D, 1993, HORM RES, V39, P19; SOUCI SW, 1989, COMPOSITION ALIMENTS; SPILIOTIS BE, 1984, JAMA-J AM MED ASSOC, V251, P2223, DOI 10.1001/jama.251.17.2223; ZADIK Z, 1985, PEDIATRICS, V76, P355	9	35	37	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					87	88		10.1016/S0140-6736(94)90819-2	http://dx.doi.org/10.1016/S0140-6736(94)90819-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903782				2022-12-24	WOS:A1994MQ09200014
J	TAYLOR, JA; WATSON, MA; DEVEREUX, TR; MICHELS, RY; SACCOMANNO, G; ANDERSON, M				TAYLOR, JA; WATSON, MA; DEVEREUX, TR; MICHELS, RY; SACCOMANNO, G; ANDERSON, M			P53 MUTATION HOTSPOT IN RADON-ASSOCIATED LUNG-CANCER	LANCET			English	Note							TUMOR SUPPRESSOR GENE; JAPAN	Mutations in gene p53 are the most common defects in lung cancer and may be a pathway through which environmental carcinogens initiate cancer. We investigated p53 mutations in lung cancers from uranium miners with high radon exposure. 16 (31%) of 52 large-cell and squamous-cell cancers from miners contained the same AGG to ATG transversion at codon 249, including cancers from 3 or 5 miners who had never smoked. This specific mutation has been reported in only 1 of 241 published p53 mutations from lung cancers. The codon 249 mutation may be a marker for radon-induced lung cancer.	NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; ST MARYS HOSP,GRAND JCT,CO	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	TAYLOR, JA (corresponding author), NIEHS,EPIDEMIOL BRANCH,POB 12233,RES TRIANGLE PK,NC 27709, USA.		taylor, jack a/C-7154-2019	taylor, jack a/0000-0001-5303-6398				DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; JABERABOANSARI A, 1991, RADIAT RES, V127, P202, DOI 10.2307/3577966; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KONDO K, 1992, BIOCHEM BIOPH RES CO, V183, P1139, DOI 10.1016/S0006-291X(05)80309-2; MITSUDOMI T, 1992, ONCOGENE, V7, P171; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SOZZI G, 1992, CANCER RES, V52, P6079; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2	10	139	149	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					86	87		10.1016/S0140-6736(94)90818-4	http://dx.doi.org/10.1016/S0140-6736(94)90818-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903781				2022-12-24	WOS:A1994MQ09200013
J	BROWN, MJ				BROWN, MJ			ANGIOTENSIN RECEPTOR BLOCKERS IN ESSENTIAL-HYPERTENSION	LANCET			English	Editorial Material											BROWN, MJ (corresponding author), ADDENBROOKES HOSP,CLIN PHARMACOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.							BURNIER M, 1991, AM J HYPERTENS, V4, P438, DOI 10.1093/ajh/4.5.438; CHRISTEN Y, 1991, CIRCULATION, V83, P133; DOIG JK, 1993, J CARDIOVASC PHARM, V21, P7323; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; MORICE AH, 1987, LANCET, V2, P1116; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; WEBER MA, 1992, AM J HYPERTENS, V5, pS247, DOI 10.1093/ajh/5.12.247S	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1374	1375		10.1016/0140-6736(93)92745-F	http://dx.doi.org/10.1016/0140-6736(93)92745-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901674				2022-12-24	WOS:A1993MK09500002
J	GRUBER, A; PAL, A; KISS, RG; SAS, G; GRIFFIN, JH				GRUBER, A; PAL, A; KISS, RG; SAS, G; GRIFFIN, JH			GENERATION OF ACTIVATED PROTEIN-C DURING THROMBOLYSIS	LANCET			English	Note								The observation that urokinase infusion increases circulating levels of the anticoagulant activated protein C (APC) in baboons implies that APC might be elevated during thrombolytic therapy. Patients undergoing coronary thrombolysis showed an 11-fold increase (means from 6 to 69 mug/L) in APC during infusion of streptokinase. Thrombolytic therapy thus generates at least two potent antithrombotic factors in the circulation-the fibrinolytic enzyme, plasmin, and the anticoagulant enzyme, APC. APC may help prevent reocclusion during or after thrombolysis.	Scripps Res Inst, RES INST, LA JOLLA, CA 92037 USA; POSTGRAD MED UNIV, H-1389 BUDAPEST, HUNGARY	Scripps Research Institute				Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANSON HE, 1983, LANCET, V2, P1165; COLLEN D, 1993, LANCET, V342, P34, DOI 10.1016/0140-6736(93)91888-S; EISENBERG PR, 1987, J AM COLL CARDIOL, V10, P527, DOI 10.1016/S0735-1097(87)80194-8; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESPANA F, 1991, BLOOD, V77, P1754; GEIGER M, 1989, THROMB HAEMOSTASIS, V61, P86; GRUBER A, 1991, CIRCULATION, V84, P2454, DOI 10.1161/01.CIR.84.6.2454; GRUBER A, 1992, BLOOD, V79, P2340; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; VARADI K, 1992, CIRCULATION, V86, pA736	10	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1275	1276		10.1016/0140-6736(93)92364-Y	http://dx.doi.org/10.1016/0140-6736(93)92364-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901587				2022-12-24	WOS:A1993MH56600014
J	BOYLE, P; MACFARLANE, GJ; SCULLY, C				BOYLE, P; MACFARLANE, GJ; SCULLY, C			ORAL-CANCER - NECESSITY FOR PREVENTION STRATEGIES	LANCET			English	Editorial Material									BRISTOL DENT HOSP & SCH, CTR STUDY ORAL DIS, BRISTOL, ENGLAND	University of Bristol	BOYLE, P (corresponding author), EUROPEAN INST ONCOL, DIV EPIDEMIOL & BIOSTAT, MILAN, ITALY.		Macfarlane, Gary J/I-9521-2014; Boyle, Peter/A-4380-2014	Macfarlane, Gary J/0000-0003-2322-3314; Boyle, Peter/0000-0001-6251-0610				BOYLE P, 1990, J ROY SOC MED, V83, P724, DOI 10.1177/014107689008301116; DAVIS S, 1987, LANCET, V2, P910; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; JENSEN OM, 1990, EUR J CANCER, V26, P1167; LAVECCHIA C, 1992, EUR J CANCER, V28A, P132; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; MACFARLANE GJ, 1992, BRIT MED J, V305, P1121, DOI 10.1136/bmj.305.6862.1121; MACFARLANE GJ, 1987, LANCET, V2, P912; MALAOWALLA AM, 1976, CANCER-AM CANCER SOC, V37, P1882, DOI 10.1002/1097-0142(197604)37:4<1882::AID-CNCR2820370437>3.0.CO;2-2; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; SCULLY C, 1992, ORAL ONCOL, V28B, P87, DOI 10.1016/0964-1955(92)90033-W	11	32	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1993	342	8880					1129	1129		10.1016/0140-6736(93)92119-E	http://dx.doi.org/10.1016/0140-6736(93)92119-E			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901471				2022-12-24	WOS:A1993MF19800005
J	TANG, WZ; LUO, HY; ENG, B; WAYE, JS; CHUI, DHK				TANG, WZ; LUO, HY; ENG, B; WAYE, JS; CHUI, DHK			IMMUNOCYTOLOGICAL TEST TO DETECT ADULT CARRIERS OF (--SEA/) DELETIONAL ALPHA-THALASSEMIA	LANCET			English	Note							GLOBIN; THALASSEMIA	The gene frequency for (--SEA/) deletional alpha-thalassaemia is high in Southeast Asian populations. We report a simple immunocytological test that is highly sensitive and specific for the detection of adult carriers of the (--SEA/) deletion. We prospectively studied 296 consecutive adult blood samples. All 41 with the (--SEA/) deletion had a positive test; all but 1 of the 165 non-carriers were negative. This test, whose major requirement is a fluorescence microscope, should be useful to identify couples at risk of conceiving fetuses with homozygous alpha-thalassaemia.	MCMASTER UNIV,SCH MED,DEPT PATHOL,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University				Chui, David/0000-0002-1475-7309				BOWDEN DK, 1992, BRIT J HAEMATOL, V81, P104, DOI 10.1111/j.1365-2141.1992.tb08180.x; CHUI DHK, 1986, NEW ENGL J MED, V314, P76, DOI 10.1056/NEJM198601093140203; FUCHAROEN S, 1991, BLOOD, V78, pA198; HIGGS DR, 1989, BLOOD, V73, P1081; TANG WZ, 1992, BLOOD, V80, P517; WAYE JS, 1993, CLIN INVEST MED, V16, P358; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, P2315; ZENG YT, 1985, LANCET, V1, P304	8	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1145	1147		10.1016/0140-6736(93)92125-D	http://dx.doi.org/10.1016/0140-6736(93)92125-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901477				2022-12-24	WOS:A1993MF19800011
J	HAMILTON, VH; RACICOT, FE; ZOWALL, H; COUPAL, L; GROVER, SA				HAMILTON, VH; RACICOT, FE; ZOWALL, H; COUPAL, L; GROVER, SA			THE COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITORS TO PREVENT CORONARY HEART-DISEASE - ESTIMATING THE BENEFITS OF INCREASING HDL-C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH BLOOD CHOLESTEROL; STAGE RENAL-DISEASE; HYPERCHOLESTEROLEMIA; MANAGEMENT; LEVEL; CARE; RISK	Objective.-To evaluate the lifetime cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors for treatment of high blood cholesterol levels. Design.-We added cost data to a validated coronary heart disease (CHD) prevention computer model that estimates the benefits of lifelong risk factor modification. The updated model takes into account the costs of cholesterol reduction, the savings in CHD health care costs attributable to intervention, the additional non-CHD costs resulting from patients' living longer, and the beneficial effects of reducing CHD risk by reducing total cholesterol and increasing high-density lipoprotein cholesterol (HDL-C). Patients.-Men and women aged 30 to 70 years who were free of CHD, had total cholesterol levels equal to the 90th percentile of the US distribution in their age and sex group, had HDL-C levels equal to the mean of the US distribution in their age and sex group, and were either with or without additional CHD risk factors. Intervention.-Use of 20 mg of lovastatin per day, which on average reduces total serum cholesterol by 17% and increases HDL-C by 7%. Main Outcome Measures.-Cost per year of life saved after discounting benefits and costs by 5% annually. Results.-The increase in HDL-C associated with lovastatin lowered cost-effectiveness ratios by approximately 40%, such that the treatment of hypercholesterolemia was relatively cost-effective for men (as low as $20 882 per year of life saved at age 50 years) and women ($36 627 per year of life saved at age 60 years) with additional risk factors. Non-CHD costs resulting from longer life expectancy after intervention added at most 23% to the cost-effectiveness ratios for patients who began treatment at age 70 years, and as little as 3% for patients at age 30 years. Conclusion.-The cost-effectiveness of HMG-CoA reductase inhibitors varied widely by age and sex and was sensitive to the presence of non-lipid CHD risk factors. The additional non-CHD costs due to increased life expectancy may be significant for the elderly, Accounting for the drug effects of raising HDL-C levels increased the proportion of the population for which medication treatment was relatively cost-effective.	MONTREAL GEN HOSP,CTR ANAL COST EFFECT CARE,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,CTR CARDIOVASC RICK ASSESSMENT,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT ECON,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University			Racicot, François-Éric/O-3079-2019	Coupal, Louis/0000-0003-0828-9665				BARER ML, 1987, SOC SCI MED, V24, P851, DOI 10.1016/0277-9536(87)90186-9; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Gorecki P. K., 1992, CONTROLLING DRUG EXP; GREGOR RD, 1990, NOVA SCOTIA MED J, V69, P146; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; GROVER SA, 1994, DRUG SAFETY, V10, P301, DOI 10.2165/00002018-199410040-00004; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; KANNEL WB, 1988, NIH882969 NAT HEART; KANNEL WB, 1987, US DHEW NIH872284 PU; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MIELE NF, 1992, JAMA-J AM MED ASSOC, V267, P507, DOI 10.1001/jama.1992.03480040055017; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; Russell LB., 1986, IS PREVENTION BETTER; SCHULMAN KA, 1990, JAMA-J AM MED ASSOC, V264, P3025, DOI 10.1001/jama.264.23.3025; 1992, HLTH REP, V4, P8; 1989, MANUEL MED OMNIPRACT; 1989, HLTH REP S, V1; 1989, SCHEDULE BENEFITS PH; 1991, STATISTIQUES ANN, P77; 1981, 82538 STAT CAN CAT; [No title captured]; 1991, HLTH REP S5, V3, P32; 1992, HLTH REP, V4, P339; 1993, VITAL HLTH STAT 242, V11; 1989, 84532 STAT CAN HLTH; 1991, HLTH REP, V3, P229	40	80	80	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1032	1038		10.1001/jama.273.13.1032	http://dx.doi.org/10.1001/jama.273.13.1032			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897787				2022-12-24	WOS:A1995QP89000034
J	CONSTANTZ, BR; ISON, IC; FULMER, MT; POSER, RD; SMITH, ST; VANWAGONER, M; ROSS, J; GOLDSTEIN, SA; JUPITER, JB; ROSENTHAL, DI				CONSTANTZ, BR; ISON, IC; FULMER, MT; POSER, RD; SMITH, ST; VANWAGONER, M; ROSS, J; GOLDSTEIN, SA; JUPITER, JB; ROSENTHAL, DI			SKELETAL REPAIR BY IN-SITU FORMATION OF THE MINERAL PHASE OF BONE	SCIENCE			English	Article								A process has been developed for the in situ formation of the mineral phase of bone. inorganic calcium and phosphate sources are combined to form a paste that is surgically implanted by injection. Under physiological conditions, the material hardens in minutes concurrent with the formation of dahllite. After 12 hours, dahllite formation was nearly complete, and an ultimate compressive strength of 55 megapascals was achieved. The composition and crystal morphology of the dahllite formed are similar to those of bone. Animal studies provide evidence that the material is remodeled in vivo. A novel approach to skeletal repair is being tested in human trials for various applications; in one of the trials the new biomaterial is being percutaneously placed into acute fractures. After hardening, it serves as internal fixation to maintain proper alignment while healing occurs.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; UNIV MICHIGAN,ORTHORPAED SURG SECT,ANN ARBOR,MI 48109; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Stanford University; University of Michigan System; University of Michigan; Harvard University; Massachusetts General Hospital	CONSTANTZ, BR (corresponding author), NORIAN CORP,CUPERTINO,CA 95014, USA.							ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; CONSTANTZ BR, 1992, MATER RES SOC SYMP P, V252, P79; Cullity B.D, 1978, ELEMENTS XRAY DIFFRA, V2nd ed., P99; DIAS JJ, 1987, INJURY, V18, P304, DOI 10.1016/0020-1383(87)90047-7; Fess EE., 1992, CLIN ASSESSMENT RECO, P41; FRANKENBURG EP, 1994, 40TH T ANN M ORTH RE, V19, P157; GLIMCHER MJ, 1981, J CRYST GROWTH, V53, P100, DOI 10.1016/0022-0248(81)90058-0; JUPITER JB, 1991, J BONE JOINT SURG AM, V73A, P461, DOI 10.2106/00004623-199173030-00019; MCCONNELL D, 1952, J DENT RES, V31, P53, DOI 10.1177/00220345520310012301; NELSON DGA, 1981, J DENT RES, V60, P1621, DOI 10.1177/002203458106000312011; Pool C, 1973, J Bone Joint Surg Br, V55, P540; Posner A. S., 1984, Phosphate Minerals, P330; POST JE, 1989, REV MINERAL, V20, P277; REY C, 1991, CALCIFIED TISSUE INT, V49, P251, DOI 10.1007/BF02556214; ROHL L, 1991, J BIOMECH, V24, P1143, DOI 10.1016/0021-9290(91)90006-9; SCHLESINGER PH, 1991, AM J PHYS, V260, pC1315; SCHMALHOLZ A, 1990, CLIN ORTHOP RELAT R, V254, P236; Vaes G., 1988, CLIN ORTHOP RELAT R, V231, P239; Weiner S., 1989, BIOMINERALIZATION, P144; Wolff J, 1892, GESETZ TRANSFORMATIO	20	608	668	1	93	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1796	1799		10.1126/science.7892603	http://dx.doi.org/10.1126/science.7892603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892603				2022-12-24	WOS:A1995QN70200031
J	SMITH, CD; AIN, KB				SMITH, CD; AIN, KB			BRAIN METABOLISM IN HYPOTHYROIDISM STUDIED WITH P-31 MAGNETIC-RESONANCE SPECTROSCOPY	LANCET			English	Note							SKELETAL-MUSCLE	Metabolic consequences of hypothyroidism in adult human brain, despite neuropsychological symptoms, have not been reported. We used P-31 nuclear magnetic-resonance spectroscopy of the frontal lobe to examine the effect of acute hypothyroidism on cerebral metabolism. Paired analysis showed that the phosphocreatine/inorganic-phosphate (PCr/Pi) ratio increased from a median of 2.04 (interquartile range 0.15) to 2.22 (0.25) after treatment with levothyroxine (p=0.01). These reversible alterations in adult cerebral phosphate metabolism during acute hypothyroidism parallel PCr/Pi ratio changes described in skeletal muscle. This is the first direct evidence of cerebral metabolic effects of hypothyroidism on adult brain.	UNIV KENTUCKY,MED CTR,DEPT MAGNET RESONANCE IMAGING,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,CTR SPECT,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,DEPT INTERNAL MED,DIV ENDOCRINOL DIABET & METAB,LEXINGTON,KY 40536; VET ADM MED CTR,MED SERV,LEXINGTON,KY 40511	University of Kentucky; University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	SMITH, CD (corresponding author), UNIV KENTUCKY,MED CTR,DEPT NEUROL,LEXINGTON,KY 40536, USA.		Ain, Kenneth/A-5179-2012	Ain, Kenneth/0000-0002-2668-934X	NCI NIH HHS [1-R29-CA58935-01A1] Funding Source: Medline; NINDS NIH HHS [NSO1421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARGOV Z, 1988, J CLIN INVEST, V81, P1695, DOI 10.1172/JCI113508; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; KAMINSKY P, 1992, J CLIN ENDOCR METAB, V74, P124, DOI 10.1210/jc.74.1.124; OBRIEN MD, 1968, LANCET, V1, P1170; RADDA G, 1984, BIOCHEM SOC T, V14, P517; SCHEINBERG P, 1950, J CLIN INVEST, V29, P1139, DOI 10.1172/JCI102351; SENSENBACH W, 1954, J CLIN INVEST, V33, P1434, DOI 10.1172/JCI103021; TAYLOR DJ, 1992, EUR J CLIN INVEST, V22, P358, DOI 10.1111/j.1365-2362.1992.tb01474.x	8	35	35	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					619	620		10.1016/S0140-6736(95)90522-7	http://dx.doi.org/10.1016/S0140-6736(95)90522-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898179				2022-12-24	WOS:A1995QM07500010
J	GREENBERG, AS; AVILA, D; HUGHES, M; HUGHES, A; MCKINNEY, EC; FLAJNIK, MF				GREENBERG, AS; AVILA, D; HUGHES, M; HUGHES, A; MCKINNEY, EC; FLAJNIK, MF			A NEW ANTIGEN RECEPTOR GENE FAMILY THAT UNDERGOES REARRANGEMENT AND EXTENSIVE SOMATIC DIVERSIFICATION IN SHARKS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; CELL; IMMUNOGLOBULINS; RECOGNITION; EVOLUTION; PROTEINS; XENOPUS; TREES	IMMUNOGLOBULIN and T-cell receptor (TCR) molecules are central to the adaptive immune system, Sequence conservation, similarities in domain structure, and usage of similar recombination signal sequences and recombination machinery indicate that there was probably a time during evolution when an ancestral receptor diverged to the modern-day immunoglobulin and TCR(1-3). Other molecules that undergo rearrangement have not been described in vertebrates, nor have intermediates been identified that have features of both these gene families, We report here the isolation of a new member of the immunoglobulin superfamily from the nurse shark, Ginglymostoma cirratum, which contains one variable and five constant domains and is found as a dimer in serum. Analyses of complementary DNA clones show extensive sequence diversity within variable domains, which is generated by both rearrangement and somatic diversification mechanisms, Our results suggest that rearranging loci distinct from immunoglobulin and TCR have arisen during evolution.	BASEL INST IMMUNOL,CH-4058 BASEL,SWITZERLAND; PENN STATE UNIV,DEPT BIOL,ERWIN W MUELLER LAB 208,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	GREENBERG, AS (corresponding author), UNIV MIAMI,SCH MED,DEPT MICROBIOL & IMMUNOL,POB 016960,R-138,MIAMI,FL 33101, USA.			Flajnik, Martin Francis/0000-0002-2792-5084				CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLEM LW, 1971, P NATL ACAD SCI USA, V68, P139, DOI 10.1073/pnas.68.1.139; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Du Pasquier Louis, 1993, P199; FLAJNIK MF, 1991, AM ZOOL, V31, P580; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P10603, DOI 10.1073/pnas.90.22.10603; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HSU E, 1984, MOL IMMUNOL, V21, P257, DOI 10.1016/0161-5890(84)90096-8; Kabat EA, 1991, SEQUENCES PROTEINS I; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKELA O, 1980, NATURE, V287, P639, DOI 10.1038/287639a0; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; RZHETSKY A, 1992, MOL BIOL EVOL, V9, P945; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SMITH LC, 1994, ANN NY ACAD SCI, V712, P213, DOI 10.1111/j.1749-6632.1994.tb33575.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	23	488	588	10	80	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					168	173		10.1038/374168a0	http://dx.doi.org/10.1038/374168a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877689				2022-12-24	WOS:A1995QL39700061
J	GIBBONS, A				GIBBONS, A			OUT OF AFRICA - AT LAST	SCIENCE			English	Editorial Material																		HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532	1	4	4	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1272	1273		10.1126/science.7871421	http://dx.doi.org/10.1126/science.7871421			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871421				2022-12-24	WOS:A1995QK06800024
J	KIRCHGESSNER, CU; PATIL, CK; EVANS, JW; CUOMO, CA; FRIED, LM; CARTER, T; OETTINGER, MA; BROWN, JM				KIRCHGESSNER, CU; PATIL, CK; EVANS, JW; CUOMO, CA; FRIED, LM; CARTER, T; OETTINGER, MA; BROWN, JM			DNA-DEPENDENT KINASE (P350) AS A CANDIDATE GENE FOR THE MURINE SCID DEFECT	SCIENCE			English	Article							STRAND BREAK-REPAIR; COMBINED IMMUNE-DEFICIENCY; PLASMINOGEN-ACTIVATOR GENE; PRE-B CELLS; V(D)J RECOMBINATION; PROTEIN-KINASE; HUMAN CHROMOSOME-8; INSITU HYBRIDIZATION; KU PROTEIN; POLYMERASE-BETA	Severe combined immunodeficient (SCID) mice are deficient in a recombination process utilized in both DNA double-strand break repair and in V(D)J recombination. The phenotype of these mice involves both cellular hypersensitivity to ionizing radiation and a lack of B and T cell immunity. The catalytic subunit of DNA-dependent protein kinase, p350, was identified as a strong candidate for the murine gene SCID. Both p350 and a gene complementing the SCID defect colocalize to human chromosome 8q11. Chromosomal fragments expressing p350 complement the SCID phenotype, and p350 protein levels are greatly reduced in cells derived from SCID mice compared to cells from wild-type mice.	STANFORD UNIV,SCH MED,DEPT RADIAT ONCOL,STANFORD,CA 94305; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; ST JOHNS UNIV,DEPT BIOL SCI,JAMAICA,NY 11439	Stanford University; Harvard University; Massachusetts General Hospital; Saint John's University			Cuomo, Christina/L-2222-2019	Cuomo, Christina/0000-0002-5778-960X	NATIONAL CANCER INSTITUTE [R01CA015201, R37CA015201, R01CA037761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048026] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37761, CA 15201] Funding Source: Medline; NIGMS NIH HHS [GM48026] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ATHWAL RS, 1994, MUTAT RES, V315, P239; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA GC, 1989, IMMUNOGENETICS, V29, P54, DOI 10.1007/BF02341614; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNIZZARO LA, 1988, CYTOGENET CELL GENET, V47, P121, DOI 10.1159/000132527; CARROLL AM, 1989, J IMMUNOL, V143, P1087; CARROLL AM, 1988, EUR J IMMUNOL, V18, P1965, DOI 10.1002/eji.1830181215; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHANG C, 1993, CANCER RES, V53, P1244; CHEN DJ, 1992, GENOMICS, V13, P1088, DOI 10.1016/0888-7543(92)90023-L; CLEUTJENS CBJM, 1993, GENOMICS, V16, P520, DOI 10.1006/geno.1993.1220; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COX DR, 1989, GENOMICS, V4, P397, DOI 10.1016/0888-7543(89)90347-9; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA AJ, 1990, GENE CHROMOSOME CANC, V2, P248, DOI 10.1002/gcc.2870020314; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; GLASER T, 1989, GENOMICS, V6, P48; GOSS SJ, 1975, NATURE, V255, P680, DOI 10.1038/255680a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HENDRICKSON EA, 1988, GENE DEV, V2, P817, DOI 10.1101/gad.2.7.817; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; ITOH M, 1993, RADIAT RES, V134, P362; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KIRCHGESSNER C, UNPUB; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KOMATSU K, 1993, HUM MOL GENET, V2, P1031, DOI 10.1093/hmg/2.7.1031; KURIMASA A, 1994, HUM GENET, V93, P21; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MCBRIDE OW, 1990, CYTOGENET CELL GENET, V53, P108, DOI 10.1159/000132906; MILLER RD, 1993, GENOMICS, V16, P740, DOI 10.1006/geno.1993.1256; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; MORRIS CM, 1989, HUM GENET, V81, P339, DOI 10.1007/BF00283687; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; PROPST F, 1989, GENOMICS, V5, P118, DOI 10.1016/0888-7543(89)90094-3; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROWE LW, COMMUNICATION; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SPARU M, 1994, GENOMICS, V21, P208; Spurr N. K., 1995, Cytogenetics and Cell Genetics, V68, P147, DOI 10.1159/000133908; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; TRIPPUTI P, 1986, CYTOGENET CELL GENET, V42, P24, DOI 10.1159/000132245; VERHEIJEN JH, 1986, HUM GENET, V72, P153; WEIER HUG, 1991, HUM GENET, V87, P489; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; Wood S, 1993, Cytogenet Cell Genet, V64, P134; WOOD S, IN PRESS CYTOGENET C	70	576	585	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1178	1183		10.1126/science.7855601	http://dx.doi.org/10.1126/science.7855601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855601				2022-12-24	WOS:A1995QJ23700041
J	UEHARA, Y; MINOWA, O; MORI, C; SHIOTA, K; KUNO, J; NODA, T; KITAMURA, N				UEHARA, Y; MINOWA, O; MORI, C; SHIOTA, K; KUNO, J; NODA, T; KITAMURA, N			PLACENTAL DEFECT AND EMBRYONIC LETHALITY IN MICE LACKING HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR	NATURE			English	Article							SCATTER FACTOR; MOUSE TROPHOBLAST; MOLECULAR-CLONING; MET PROTOONCOGENE; MESSENGER-RNA; EXPRESSION; RAT; DIFFERENTIATION; IDENTIFICATION; PURIFICATION	HEPATOCYTE growth factor/scatter factor (HGF/SF) functions as a mitogen, motogen and morphogen for a variety of cultured cells(1-7). The genes for HGF/SF and its receptor (the c-met protooncogene product(8)) are expressed in many tissues during the embryonic periods and in the adult(9-14). HGF/SF is thought to mediate a signal exchange between the mesenchyme and epithelia during mouse development(15). To examine the physiological role of HGF/SF, we generated mutant mice with a targeted disruption of the HGF/SF gene. Here we report that homozygous mutant embryos have severely impaired placentas with markedly reduced numbers of labyrinthine trophoblast cells, and die before birth. The growth of trophoblast cells was stimulated by HGF/SF in vitro, and the HCF/SF activity was released by allantois in primary culture of normal but not mutant embryos. These findings suggest that HGF/SF is an essential mediator of allantoic mesenchyme-trophoblastic epithelia interaction required for placental organogenesis.	KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN; CANC INST,DEPT CELL BIOL,TOKYO 170,JAPAN; KYOTO UNIV,SCH MED,DEPT ANAT,KYOTO 606,JAPAN	Kansai Medical University; Japanese Foundation for Cancer Research; Kyoto University			Noda, Tetsuo/B-1667-2016; Minowa, Osamu/AAM-1238-2020					BARLOW PW, 1972, J EMBRYOL EXP MORPH, V27, P447; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DERENZO MF, 1991, ONCOGENE, V6, P1997; GARBISBERKVENS JM, 1987, PHARMACOKINETICS TER, P13; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUNTENER M, 1977, ACTA ANAT, V98, P241; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P95555; PEEL S, 1977, J ANAT, V124, P675; ROSSANT J, 1981, J EMBRYOL EXP MORPH, V62, P217; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; ZARNEGAR R, 1989, CANCER RES, V49, P3314	30	906	938	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					702	705		10.1038/373702a0	http://dx.doi.org/10.1038/373702a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854453				2022-12-24	WOS:A1995QH92800055
J	TANG, TL; FREEMAN, RM; OREILLY, AM; NEEL, BG; SOKOL, SY				TANG, TL; FREEMAN, RM; OREILLY, AM; NEEL, BG; SOKOL, SY			THE SH2-CONTAINING PROTEIN-TYROSINE-PHOSPHATASE SH-PTP2 IS REQUIRED UPSTREAM OF MAP KINASE FOR EARLY XENOPUS DEVELOPMENT	CELL			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; CAENORHABDITIS-ELEGANS; MESODERM INDUCTION; SH3 DOMAINS; MOTH-EATEN; PHOSPHORYLATION; EMBRYOS; GENE; ENCODES	SH-PTP2, the vertebrate homolog of Drosophila cork screw, associates with several activated growth factor receptors, but its biological function is unknown. We assayed the effects of injection of wild-type and mutant SH-PTP2 RNAs on Xenopus embryogenesis. An internal phosphatase domain deletion (Delta P) acts as a dominant negative mutant, causing severe posterior truncations. This phenotype is rescued by SH-PTP2, but not by the closely related SH-PTP1. In ectodermal explants, Delta P blocks fibroblast growth factor (FGF)and activin-mediated induction of mesoderm and FGF-induced mitogen-activated protein (MAP) kinase activation. Our results indicate that SH-PTP2 is required for early vertebrate development, acting as a positive component in FGF signaling downstream of the FGF receptor and upstream of MAP kinase.	BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	TANG, TL (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.			Sokol, Sergei/0000-0002-3963-9202; Freeman, Robert/0000-0003-1463-9748	NATIONAL CANCER INSTITUTE [R01CA049152, R37CA049152] Funding Source: NIH RePORTER; NCI NIH HHS [CA49152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAWID IB, 1991, MESODERM INDUCTION; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GRAVES LM, 1994, P NATL ACAD SCI USA, V91, P1662, DOI 10.1073/pnas.91.5.1662; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAN M, 1990, GENETICS, V126, P899; HARTLEY RS, 1994, DEV BIOL, V163, P521, DOI 10.1006/dbio.1994.1168; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; INNIS MA, 1990, PCR PROTOCOLS; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; ITOH K, 1994, DEVELOPMENT, V120, P2703; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LABONNE C, 1994, DEVELOPMENT, V120, P463; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; XIAO S, 1994, J BIOL CHEM, V269, P21244; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	80	301	309	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					473	483		10.1016/0092-8674(95)90498-0	http://dx.doi.org/10.1016/0092-8674(95)90498-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859288	Bronze			2022-12-24	WOS:A1995QG47000014
J	TULJAPURKAR, S; LI, N; FELDMAN, MW				TULJAPURKAR, S; LI, N; FELDMAN, MW			HIGH SEX-RATIOS IN CHINA FUTURE	SCIENCE			English	Article							RECENT TRENDS; FERTILITY; POPULATION; BANGLADESH; PREFERENCE; MORTALITY; CHILDREN; BIRTH	In China in recent years, male live births have exceeded those of females by amounts far greater than those that occur naturally in human populations, a trend with significant demographic consequences. The resulting imbalance in the first-marriage market is estimated to be about 1 million males per year after 2010. These ''excess'' males were not easily accommodated in models with substantial changes in first-marriage patterns, The current sex ratio at birth has little effect on a couple's probability of having at least one son, so future increases in the sex ratio may well occur, especially given increasing access to sex-selective abortion.	XIAN JIAOTONG UNIV,INST POPULAT RES,XIAN 710049,PEOPLES R CHINA	Xi'an Jiaotong University	TULJAPURKAR, S (corresponding author), STANFORD UNIV,MORRISON INST POPULAT & RESOURCE STUDIES,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Tuljapurkar, Shripad/0000-0001-5549-4245	NICHD NIH HHS [HD-16640] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016640] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANISTER J, 1990, CHANGING FAMILY STRU, P263; BENNETT NG, 1983, SEX SELECTION CHILDR; BITTLES AH, 1993, URBAN ECOLOGY HLTH T, P244; CANGPING W, 1992, 1990 INT SEM CHIN PO; CHAHNAZARIAN A, SOC BIOL, V35, P214; CHOWDHURY MK, 1990, POPUL DEV REV, V16, P749, DOI 10.2307/1972966; COALE A, 1992, 1990 INT SEM CHIN PO; Coale A., 1984, RAPID POPULATION CHA; COALE AJ, 1991, POPUL DEV REV, V17, P517, DOI 10.2307/1971953; COALE AJ, 1991, SCIENCE, V251, P389, DOI 10.1126/science.251.4992.389; DASGUPTA M, 1987, POPUL DEV REV, V13, P77; DICKEMAN M, 1975, ANNU REV ECOL SYST, V6, P107, DOI 10.1146/annurev.es.06.110175.000543; FEENEY G, 1989, POPUL DEV REV, V15, P297, DOI 10.2307/1973706; GOLDMAN N, 1984, POPUL INDEX, V50, P5, DOI 10.2307/2736903; GREENHALGH S, 1994, POPUL DEV REV, V20, P365, DOI 10.2307/2137523; HULL TH, 1990, POPUL DEV REV, V16, P63, DOI 10.2307/1972529; JOHANSSON S, 1991, POPUL DEV REV, V17, P35, DOI 10.2307/1972351; JOHANSSON S, 1991, J OFFICIAL STAT, V7, P25; KEYFITZ N, 1990, WORLD POPULATION ANA; LAVELY W, 1990, DEMOGRAPHY, V27, P357, DOI 10.2307/2061373; LI J, 1994, MAY ANN M POP ASS AM; MUHURI PK, 1991, POPUL DEV REV, V17, P415, DOI 10.2307/1971948; PARK CB, 1983, DEMOGRAPHY, V20, P333, DOI 10.2307/2061246; PENG Y, 1994, 27TH SESS UN POP COM; SCHOEN R, 1981, DEMOGRAPHY, V18, P201, DOI 10.2307/2061093; SEN A, 1993, SCI AM, V268, P40, DOI 10.1038/scientificamerican0593-40; SWEET JA, 1987, AM FAMILIES HOUSEHOL, pCH2; ZENG Y, 1993, POPUL DEV REV, V19, P283; 1991, 10 PERCENT SAMPLING; 1983, MANUAL X INDIRECT TE	30	87	92	1	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					874	876		10.1126/science.7846529	http://dx.doi.org/10.1126/science.7846529			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG207	7846529				2022-12-24	WOS:A1995QG20700055
J	ZUCKERMAN, B; FORVEILLE, T; KASTNER, JH				ZUCKERMAN, B; FORVEILLE, T; KASTNER, JH			INHIBITION OF GIANT-PLANET FORMATION BY RAPID GAS DEPLETION AROUND YOUNG STARS	NATURE			English	Article							T-TAURI STARS; POINT-SOURCE CATALOG; SAO STARS; GG-TAURI; DISK; EVOLUTION; ROTATION; EMISSION; HD-98800; NEBULA	ALTHOUGH stars form from clouds of gas and dust, there are insignificant amounts of gas around ordinary (Sun-like) stars. This suggests that hydrogen and helium, the primary constituents of planets such as Jupiter and Saturn, are not easily retained in orbit as a star matures. The gas-giant planets in the Solar System must therefore have formed rapidly. Models of their formation generally suggest that a solid core formed in less than or equal to 10(6) yr, followed by the accretion of the massive gaseous envelope in similar to 10(7) yr (refs 1-5). But how and when the gas of the solar nebula dissipated, and how this compares with the predicted timescale of gas-giant formation, remains unclear(6,7), in part because direct observations of circumstellar gas have been made only for stars either younger or older than the critical range of 10(6)-10(7) yr (refs 8-15). Here we report observations of the molecular gas surrounding 20 stars whose ages are likely to be in this range. The gas dissipates rapidly; after a few million years the mass remaining is typically much less than the mass of Jupiter. Thus, if gas-giant planets are common in the Galaxy, they must form even more quickly than present models suggest.	OBSERV GRENOBLE,ASTROPHYS GRP,F-38041 GRENOBLE,FRANCE; MIT,CTR SPACE RES,CAMBRIDGE,MA 02139	Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Massachusetts Institute of Technology (MIT)	ZUCKERMAN, B (corresponding author), UNIV CALIF LOS ANGELES,DEPT PHYS & ASTRON,LOS ANGELES,CA 90024, USA.							Adams F.C., 1993, PROTOSTARS PLANETS, P721; Beckwith S. V. W., 1993, PROTOSTARS PLANETS, VIII, P521; BECKWITH SVW, 1993, ASTROPHYS J, V402, P280, DOI 10.1086/172131; CHIAR JE, 1994, ASTROPHYS J, V426, P240, DOI 10.1086/174058; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; DUTREY A, 1994, ASTRON ASTROPHYS, V286, P149; FEKEL FC, 1993, ASTROPHYS J, V419, pL89, DOI 10.1086/187144; FRANCHINI M, 1992, ASTRON ASTROPHYS, V256, P525; GREGORIOHETEM J, 1992, ASTRON J, V103, P549, DOI 10.1086/116082; HERBST W, 1988, ASTRON J, V96, P1949, DOI 10.1086/114941; HOBBS LM, 1985, ASTROPHYS J, V293, pL29, DOI 10.1086/184485; JENSEN ELN, 1994, ASTROPHYS J, V429, pL29, DOI 10.1086/187405; JURA M, 1993, ASTROPHYS J, V418, pL37, DOI 10.1086/187110; KAWABE R, 1993, ASTROPHYS J, V404, pL63, DOI 10.1086/186744; KOERNER DW, 1993, ASTROPHYS J, V408, pL93, DOI 10.1086/186839; KOERNER DW, 1993, ICARUS, V106, P2, DOI 10.1006/icar.1993.1154; Lin D.N.C., 1985, PROTOSTARS PLANETS, VII, P981; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; LISSAUER JJ, IN PRESS NEPTUNE; OMODAKA T, 1992, ASTROPHYS J, V396, pL87, DOI 10.1086/186523; OUDMAIJER RD, 1992, ASTRON ASTROPHYS SUP, V96, P625; Podolak M., 1993, PROTOSTARS PLANETS, P1109; PRINN RG, 1993, PROTOSTARS PLANETS, V3, P1005; RUDEN SP, 1991, ASTROPHYS J, V375, P740, DOI 10.1086/170239; SARGENT AI, 1991, ASTROPHYS J, V382, pL31, DOI 10.1086/186207; SARGENT AI, 1993, ANNU REV ASTRON ASTR, V31, P297; SAVOLDINI M, 1994, ASTRON ASTROPHYS, V285, P467; SKRUTSKIE MF, 1991, ASTRON J, V102, P1749, DOI 10.1086/115997; SODERBLOM DR, 1993, ASTROPHYS J SUPPL S, V85, P315, DOI 10.1086/191767; STENCEL RE, 1991, ASTROPHYS J SUPPL S, V75, P905, DOI 10.1086/191553; STEVENSON DJ, 1988, ICARUS, V75, P146, DOI 10.1016/0019-1035(88)90133-9; STROM SE, 1994, REV MEX ASTRON ASTR, V29, P23; TIELENS AGGM, 1991, ASTROPHYS J, V381, P181, DOI 10.1086/170640; WEINTRAUB DA, 1989, ASTROPHYS J, V344, P915, DOI 10.1086/167859; WETHERILL GW, 1991, SCIENCE, V253, P535, DOI 10.1126/science.253.5019.535; WETHERILL GW, IN PRESS PLANETARY S; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0; YAMASHITA T, 1993, ASTROPHYS J, V402, pL65, DOI 10.1086/186701; ZUCKERMAN B, 1993, ASTROPHYS J, V406, pL25, DOI 10.1086/186778; ZUCKERMAN B, 1994, ASTROPHYS J, V414, P793; ZUCKERMAN B, IN PRESS CIRCUMSTELL	42	318	318	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					494	496		10.1038/373494a0	http://dx.doi.org/10.1038/373494a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845460				2022-12-24	WOS:A1995QF72400049
J	SMITH, CP; PARLE, M; MORRIS, DJ				SMITH, CP; PARLE, M; MORRIS, DJ			IMPLEMENTATION OF GOVERNMENT RECOMMENDATIONS FOR IMMUNIZING INFANTS AT RISK OF HEPATITIS-B	BRITISH MEDICAL JOURNAL			English	Article									N MANCHESTER GRP HOSP,DEPT AUDIT,MANCHESTER M8 6RB,LANCS,ENGLAND; BOOTH HALL CHILDRENS HOSP,N MANCHESTER VIRUS LAB,MANCHESTER M9 7AA,LANCS,ENGLAND	Royal Manchester Children's Hospital	SMITH, CP (corresponding author), BOOTH HALL CHILDRENS HOSP,DEPT CHILD HLTH,MANCHESTER M9 7AA,LANCS,ENGLAND.							BIRNBAUM JM, 1992, AM J INFECT CONTROL, V20, P172, DOI 10.1016/S0196-6553(05)80142-7; BROOK MG, 1989, Q J MED, V264, P313; Waters J R, 1989, Can Dis Wkly Rep, V15, P29; 1992, IMMUNISATION INFECTI, P110	4	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1339	1339		10.1136/bmj.309.6965.1339	http://dx.doi.org/10.1136/bmj.309.6965.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866083	Green Published			2022-12-24	WOS:A1994PT62500024
J	WILLIAMSON, BD; MAN, KC; DAOUD, E; NIEBAUER, M; STRICKBERGER, SA; MORADY, F				WILLIAMSON, BD; MAN, KC; DAOUD, E; NIEBAUER, M; STRICKBERGER, SA; MORADY, F			RADIOFREQUENCY CATHETER MODIFICATION OF ATRIOVENTRICULAR-CONDUCTION TO CONTROL THE VENTRICULAR RATE DURING ATRIAL-FIBRILLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NODAL REENTRANT TACHYCARDIA; SLOW-PATHWAY; ABLATION REGISTRY; JUNCTION; ENERGY; ANTERIOR; DEATH	Background. In some patients with atrial fibrillation, the Ventricular rate may be difficult to control with medications. We evaluated a radiofrequency catheter technique to modify atrioventricular conduction in atrial fibrillation in order to control the ventricular rate without creating pathologic atrioventricular block. Methods. We studied 19 consecutive patients with atrial fibrillation and uncontrolled ventricular rates refractory to drug therapy. They had had atrial fibrillation for a mean (+/-SD) of 5.5+/-4.9 years, had had 4.9+/-0.9 unsuccessful drug trials, and were 62+/-5 years old. Before the procedure, the maximal ventricular rate during exercise was 180+/-39 beats per minute. A total of 11+/-5 radiofrequency-energy applications were delivered to the posterior septal or midseptal right atrium, near the ostium of the coronary sinus. Results. Successful control of the ventricular rate without pathologic atrioventricular block was achieved in 14 of the 19 patients (74 percent). Persistent third-degree atrioventricular block requiring a permanent pacemaker occurred inadvertently in four patients (21 percent). Atrioventricular conduction was intentionally ablated in one patient. The 14 patients who had successful modification of conduction had persistent reductions in maximal ventricular rate during exercise (rate at three months, 126+/-24 beats per minute; P<0.01). These patients had resolution of symptoms related to rapid rates during 8+/-2 months of follow-up. One patient had a recurrence of a rapid ventricular rate but was again asymptomatic after a second modification procedure. One patient with dilated cardiomyopathy died suddenly, five months after a successful procedure. Conclusions. A catheter technique to modify atrioventricular conduction without creating pathologic atrioventricular block is feasible in the majority of patients with symptomatic atrial fibrillation and a rapid ventricular rate refractory to drug therapy.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV CARDIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								AKHTAR M, 1991, ANN INTERN MED, V114, P499, DOI 10.7326/0003-4819-114-6-499; BHARATI S, 1985, CHEST, V88, P883, DOI 10.1378/chest.88.6.883; EVANS GT, 1987, PACE, V10, P1395; EVANS GT, 1991, CIRCULATION, V84, P1924, DOI 10.1161/01.CIR.84.5.1924; FLECK RP, 1993, PACE, V16, P377, DOI 10.1111/j.1540-8159.1993.tb01597.x; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; HAISSAGUERRE M, 1992, CIRCULATION, V85, P2162, DOI 10.1161/01.CIR.85.6.2162; HUANG SK, 1987, J AM COLL CARDIOL, V9, P349, DOI 10.1016/S0735-1097(87)80388-1; HUANG SKS, 1989, CIRCULATION, V80, P951, DOI 10.1161/01.CIR.80.4.951; JACKMAN WM, 1991, CIRCULATION, V83, P1562, DOI 10.1161/01.CIR.83.5.1562; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; JANSE MJ, 1993, J CARDIOVASC ELECTR, V4, P561, DOI 10.1111/j.1540-8167.1993.tb01244.x; JAZAYERI MR, 1992, CIRCULATION, V85, P1318, DOI 10.1161/01.CIR.85.4.1318; KALBFLEISCH SJ, 1994, J AM COLL CARDIOL, V23, P716, DOI 10.1016/0735-1097(94)90759-5; KAY GN, 1992, CIRCULATION, V85, P1675, DOI 10.1161/01.CIR.85.5.1675; KUNZE KP, 1988, AM J CARDIOL, V61, P657, DOI 10.1016/0002-9149(88)90788-6; LANGBERG JJ, 1993, CIRCULATION, V87, P1551, DOI 10.1161/01.CIR.87.5.1551; LANGBERG JJ, 1991, AM J CARDIOL, V67, P142, DOI 10.1016/0002-9149(91)90436-O; LANGBERG JJ, 1989, CIRCULATION, V80, P1527, DOI 10.1161/01.CIR.80.6.1527; MITRANI RD, 1993, J AM COLL CARDIOL, V21, P432, DOI 10.1016/0735-1097(93)90686-U; MORADY F, 1993, J AM COLL CARDIOL, V21, P102, DOI 10.1016/0735-1097(93)90723-E; SCHEINMAN MM, 1984, CIRCULATION, V70, P1024, DOI 10.1161/01.CIR.70.6.1024; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; SOUSA J, 1991, CIRCULATION, V84, P567, DOI 10.1161/01.CIR.84.2.567; THAKUR RK, 1993, J AM COLL CARDIOL, V22, P1706, DOI 10.1016/0735-1097(93)90600-6; WATHEN M, 1992, AM J CARDIOL, V70, P886, DOI 10.1016/0002-9149(92)90732-E; WU DL, 1993, J AM COLL CARDIOL, V21, P1612, DOI 10.1016/0735-1097(93)90376-C; YEUNGLAIWAH JA, 1991, J AM COLL CARDIOL, V18, P1753, DOI 10.1016/0735-1097(91)90516-C	29	209	211	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					910	917		10.1056/NEJM199410063311404	http://dx.doi.org/10.1056/NEJM199410063311404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	7848418				2022-12-24	WOS:A1994PJ41900004
J	WOOD, N; STANDEN, G; HOWS, J; BRADLEY, B; BIDWELL, J				WOOD, N; STANDEN, G; HOWS, J; BRADLEY, B; BIDWELL, J			DIAGNOSIS OF SICKLE-CELL DISEASE WITH A UNIVERSAL HETERODUPLEX GENERATOR	LANCET			English	Note							ENZYMATIC AMPLIFICATION; GENOMIC DNA; ANEMIA	A new diagnostic technique, universal heteroduplex generator screening, has been developed to detect homozygosity and heterozygosity for sickle-cell disease. Since it is a polymerase chain reaction-based technique, it may be used to detect haemoglobin S and haemoglobin C genotypes in adults, neonates, or from coelocentesis during the first 10 weeks of pregnancy. Beta-globin gene nucleotide sequences are amplified by the polymerase chain reaction, and are heteroduplexed with a beta-globulin universal heteroduplex generator. Haemoglobins S and C mutations are identified by characteristic polyacrylamide minigel banding patterns. The technique is simple and rapid to do, even by nonspecialist laboratories, and is applicable to large-scale screening for haemoglobin S and C mutations as well as prenatal diagnosis of sickle cell disease.	UNIV BRISTOL, HOMOEOPATH HOSP, DEPT TRANSPLANTAT SCI, BRISTOL BS6 6JU, ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP, DEPT HAEMATOL, BRISTOL BS2 8HW, AVON, ENGLAND; SOUTHMEAD HLTH SERV, DEPT HAEMATOL, BRISTOL, ENGLAND	University of Bristol; Bristol Royal Infirmary								BIDWELL JL, 1993, HDB HLA TYPING TECHN, P99; CHEHAB FF, 1990, LANCET, V335, P15, DOI 10.1016/0140-6736(90)90138-U; HUISMAN THJ, 1993, BAILLIERE CLIN HAEM, V6, P1, DOI 10.1016/S0950-3536(05)80064-2; JURKOVIC D, 1993, LANCET, V341, P1623, DOI 10.1016/0140-6736(93)90761-5; LOSEKOOT M, 1990, BRIT J HAEMATOL, V76, P269, DOI 10.1111/j.1365-2141.1990.tb07883.x; RIGHETTI PG, 1986, METHODS HEMATOLOGY S, V15, P47; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; STEINBERG MH, 1993, AM J HEMATOL, V43, P110, DOI 10.1002/ajh.2830430208; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	10	20	22	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1519	1520		10.1016/S0140-6736(05)80086-8	http://dx.doi.org/10.1016/S0140-6736(05)80086-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902902				2022-12-24	WOS:A1993MM40200013
J	ARTHUR, RR; ELSHARKAWY, MS; COPE, SE; BOTROS, BA; OUN, S; MORRILL, JC; SHOPE, RE; HIBBS, RG; DARWISH, MA; IMAM, IZE				ARTHUR, RR; ELSHARKAWY, MS; COPE, SE; BOTROS, BA; OUN, S; MORRILL, JC; SHOPE, RE; HIBBS, RG; DARWISH, MA; IMAM, IZE			RECURRENCE OF RIFT-VALLEY FEVER IN EGYPT	LANCET			English	Note								Rift Valley fever (RVF) has been recorded in man and in domestic animals in Egypt after a 12-year absence. Human infections were first noted in the Aswan Governorate in late May, 1993. Only cases of ocular disease, an infrequent and late manifestation, were reported. Of 41 cases, 35 were tested serologically and 27 (77%) had RVF virus-specific IgM antibodies. An estimated 600-1500 infections occurred in the region. Abortions in cattle and buffalo were seen concurrently and antibodies to RVFV were present in 39% of domestic livestock, presumably unvaccinated. RVFV was isolated from an aborted water buffalo fetus.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT IMMUNOL & INFECT DIS,BALTIMORE,MD 21218; MINIST HLTH CAIRO,CAIRO,EGYPT; USA,INFECT DIS RES INST,FT DETRICK,MD; YALE UNIV,YALE ARBOVIRUS RES UNIT,NEW HAVEN,CT 06520; AIN SHAMS UNIV,FAC MED,CAIRO,EGYPT	Johns Hopkins University; Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt; Yale University; Egyptian Knowledge Bank (EKB); Ain Shams University	ARTHUR, RR (corresponding author), USN,MED RES UNIT 3,CODE 307,PSC 452,BOX 5000,FPO AE 09835 000,CAIRO,EGYPT.				NIAID NIH HHS [AI 10984] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI010984, R37AI010984, R01AI010984] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		IMAM IZE, 1981, J EGYPT PUBL HLTH AS, V56, P435; NIKLASSON B, 1984, J CLIN MICROBIOL, V19, P225, DOI 10.1128/JCM.19.2.225-229.1984; SIAM AL, 1980, T ROY SOC TROP MED H, V74, P539, DOI 10.1016/0035-9203(80)90074-7; 1985, INT CATALOGUE ARBOVI, P857	4	78	81	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1149	1150		10.1016/0140-6736(93)92128-G	http://dx.doi.org/10.1016/0140-6736(93)92128-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901480				2022-12-24	WOS:A1993MF19800014
J	WANG, T; XIE, ZP; LU, B				WANG, T; XIE, ZP; LU, B			NITRIC-OXIDE MEDIATES ACTIVITY-DEPENDENT SYNAPTIC SUPPRESSION AT DEVELOPING NEUROMUSCULAR SYNAPSES	NATURE			English	Article							LONG-TERM POTENTIATION; GLYCERYL TRINITRATE; METHYLENE-BLUE; MESSENGER; MUSCLE; RELAXATION	TEMPORAL correlation between pre- and postsynaptic activities is an important mechanism that regulates synaptic connectivity during development and synaptic plasticity in the adult(1-3). In developing neuromuscular junctions, postsynaptic activity is critical in functional suppression and, ultimately, elimination of the synapses(4-6). Although repetitive postsynaptic firing asynchronous to the presynaptic activity results in a persistent synaptic suppression(7-10), the underlying molecular mechanism remains unknown. Here we provide evidence that nitric oxide (NO), a free radical implicated in several forms of synaptic plasticity(11-15), may serve as a retrograde signal for activity-dependent suppression in the neuromuscular synapse. NO donors and activators of the cyclic GMP pathway suppressed spontaneous and evoked synaptic currents. Moreover, the synaptic suppression induced by repetitive postsynaptic depolarization was prevented by the NO-binding protein haemoglobin and by inhibitors of NO synthase. Thus, synaptic suppression may be triggered by NO released from a postsynaptic myocyte that fires asynchronously to the presynaptic terminal.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110				Lu, Bai/A-4018-2012	Lu, Bai/0000-0001-5418-9759				BETZ WJ, 1987, VERTEBRATE NEUROMUSC; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CONSTAINTINEPAT.M, 1990, A REV NEUROSCI, V13, P129; Crepel F, 1990, Neuroreport, V1, P133, DOI 10.1097/00001756-199010000-00013; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; GHEZ C, 1991, PRINCIPLE NEURAL SCI; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KIDOKORO Y, 1984, Neuroscience Research, V1, P157, DOI 10.1016/S0168-0102(84)80013-9; LO YJ, 1994, J NEUROSCI, V14, P4684; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LO YJ, 1994, J NEUROSCI, V14, P4694; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; SRIHARI T, 1978, J NEUROCYTOL, V7, P529, DOI 10.1007/BF01260887; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WOLIN MS, 1982, J BIOL CHEM, V257, P13312	28	169	172	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					262	266		10.1038/374262a0	http://dx.doi.org/10.1038/374262a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885445				2022-12-24	WOS:A1995QM38700050
J	MASU, M; IWAKABE, H; TAGAWA, Y; MIYOSHI, T; YAMASHITA, M; FUKUDA, Y; SASAKI, H; HIROI, K; NAKAMURA, Y; SHIGEMOTO, R; TAKADA, M; NAKAMURA, K; NAKAO, K; KATSUKI, M; NAKANISHI, S				MASU, M; IWAKABE, H; TAGAWA, Y; MIYOSHI, T; YAMASHITA, M; FUKUDA, Y; SASAKI, H; HIROI, K; NAKAMURA, Y; SHIGEMOTO, R; TAKADA, M; NAKAMURA, K; NAKAO, K; KATSUKI, M; NAKANISHI, S			SPECIFIC DEFICIT OF THE ON RESPONSE IN VISUAL TRANSMISSION BY TARGETED DISRUPTION OF THE MGLUR6 GENE	CELL			English	Article							ROD BIPOLAR CELLS; METABOTROPIC GLUTAMATE-RECEPTOR; LATERAL GENICULATE-NUCLEUS; C-LIKE IMMUNOREACTIVITY; MAMMALIAN RETINA; FIELD PROPERTIES; OLFACTORY-BULB; CONDUCTANCE; PROTEIN; ELECTRORETINOGRAM	Taking advantage of the restricted expression of metabotropic glutamate receptor subtype 6 (mGluR6) in retinal ON bipolar cells, we generated knockout mice lacking mGluRG6expression. The homozygous mutant mice showed a loss of ON responses but unchanged OFF responses to light. The mutant mice displayed no obvious changes in retinal cell organization nor in the projection of optic fibers to the brain. Furthermore, the mGluR6-deficient mice showed visual behavioral responses to light stimulation as examined by shuttle box avoidance behavior experiments using light exposure as a conditioned stimulus. The results demonstrate that mGluR6 is essential in synaptic transmission to the ON bipolar cell and that the OFF response provides an important means for transmitting visual information.	KYOTO UNIV,FAC MED,DEPT OPHTHALMOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL,OSAKA 565,JAPAN; HYOGO MED UNIV,DEPT PHYSIOL,NISHINOMIYA,HYOGO 663,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT ANAT,TOKYO 113,JAPAN; KYUSHU UNIV,MED INST BIOREGULAT,FUKUOKA 812,JAPAN	Kyoto University; Kyoto University; Osaka University; Hyogo College of Medicine; University of Hyogo; Tokyo Medical & Dental University (TMDU); Kyushu University	MASU, M (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.		Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				AKAZAWA C, 1994, NEUROSCI LETT, V171, P52, DOI 10.1016/0304-3940(94)90602-5; ASHMORE JF, 1980, J PHYSIOL-LONDON, V300, P115, DOI 10.1113/jphysiol.1980.sp013155; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BURESOVA O, 1976, TECHNIQUES BASIC EXP, P91; DAW NW, 1990, TRENDS NEUROSCI, V13, P110, DOI 10.1016/0166-2236(90)90187-F; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; DEVRIES SH, 1993, NEURON S, V10, P139; DODT E, 1951, NATURE, V168, P738, DOI 10.1038/168738a0; FUKUDA Y, 1978, JPN J PHYSIOL, V28, P385; GREFERATH U, 1990, J COMP NEUROL, V301, P433, DOI 10.1002/cne.903010308; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; HAYHOW WR, 1962, J COMP NEUROL, V118, P295, DOI 10.1002/cne.901180303; HORTON JC, 1984, J NEUROSCI, V4, P374; INOUE A, 1992, J BIOL CHEM, V267, P10613; KNAPP AG, 1983, J NEUROPHYSIOL, V50, P1236, DOI 10.1152/jn.1983.50.5.1236; KNAPP AG, 1984, VISION RES, V24, P1841, DOI 10.1016/0042-6989(84)90016-6; KOLB H, 1994, OPHTHALMOL VIS SCI, V35, P2385; MESULAM MM, 1978, J HISTOCHEM CYTOCHEM, V26, P106, DOI 10.1177/26.2.24068; MILLER RF, 1986, TRENDS NEUROSCI, V9, P211, DOI 10.1016/0166-2236(86)90061-5; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NEGISHI K, 1988, NEUROSCI LETT, V94, P247, DOI 10.1016/0304-3940(88)90025-0; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SASAKI H, 1993, PROG BRAIN RES, V95, P103, DOI 10.1016/S0079-6123(08)60361-1; SCHILLER PH, 1982, NATURE, V297, P580, DOI 10.1038/297580a0; SCHILLER PH, 1986, NATURE, V322, P824, DOI 10.1038/322824a0; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; Schiller PH, 1984, HDB PHYSL, VIII, P457; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SHERK H, 1984, J NEUROSCI, V4, P381; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; Steinberg RH., 1991, PROGR RETINAL RES, V10, P121, DOI 10.1016/0278-4327(91)90011-P; STOCKTON RA, 1989, J GEN PHYSIOL, V93, P101, DOI 10.1085/jgp.93.1.101; TESSIERLAVIGNE M, 1991, PRINCIPLES NEURAL SC, P400; WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; Wurst W., 1993, Gene targeting: a practical approach., P33	43	391	401	1	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					757	765		10.1016/0092-8674(95)90354-2	http://dx.doi.org/10.1016/0092-8674(95)90354-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889569	Bronze			2022-12-24	WOS:A1995QM39900012
J	PRANGE, R; ENGLE, IM; CLARKE, JT; DUNLOP, M; BALLESTER, GE; IP, WH; MAURICE, S; TRAUGER, J				PRANGE, R; ENGLE, IM; CLARKE, JT; DUNLOP, M; BALLESTER, GE; IP, WH; MAURICE, S; TRAUGER, J			AURORAL SIGNATURE OF COMET SHOEMAKER-LEVY-9 IN THE JOVIAN MAGNETOSPHERE	SCIENCE			English	Article								The electrodynamic interaction of the dust and gas comae of comet Shoemaker-Levy 9 with the jovian magnetosphere was unique and different from the atmospheric effects. Early theoretical predictions of auroral-type processes on the comet magnetic field line and advanced modeling of the time-varying morphology of these lines allowed dedicated observations with the Hubble Space Telescope Wide Field Planetary Camera 2 and resulted in the detection of a bright auroral spot, In that respect, this observation of the surface signature of an externally triggered auroral process can be considered as a ''magnetospheric active experiment'' on Jupiter.	INST ASTROPHYS,PARIS,FRANCE; USN ACAD,DEPT PHYS,ANNAPOLIS,MD 21402; UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SPACE & ATMOSPHER PHYS GRP,LONDON SW7 2BZ,ENGLAND; MAX PLANCK INST AERON,D-37191 KATLENBURG DUHM,GERMANY; EUROPEAN SPACE AGCY,ESTEC,DEPT SPACE SCI,SO,2200 AG NOORDWIJK,NETHERLANDS; JET PROPULS LAB,PASADENA,CA 91109	UDICE-French Research Universities; Sorbonne Universite; United States Department of Defense; United States Navy; United States Naval Academy; University of Michigan System; University of Michigan; Imperial College London; Max Planck Society; European Space Agency; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	PRANGE, R (corresponding author), UNIV PARIS 11,CNRS,INST ASTROPHYS SPATIALE,F-91405 ORSAY,FRANCE.		Clarke, John/C-8644-2013; dunlop, malcolm w/F-1347-2010	dunlop, malcolm w/0000-0002-8195-5137				BOLIN O, 1994, GEOPHYS RES LETT, V21, P1063, DOI 10.1029/94GL00890; CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; CONNERNEY JEP, 1981, J GEOPHYS RES-SPACE, V86, P8370, DOI 10.1029/JA086iA10p08370; CONNERNEY JEP, 1992, PLANETARY RADIO EM 3, V13; DOUGHERTY MK, COMMUNICATION; ENGLE I, UNPUB; ENGLE IM, 1992, J GEOPHYS RES-SPACE, V97, P17169, DOI 10.1029/92JA02036; ENGLE IM, 1991, J GEOPHYS RES-SPACE, V96, P7793, DOI 10.1029/90JA02391; FARRELL WM, 1994, GEOPHYS RES LETT, V21, P1067, DOI 10.1029/94GL01066; FELDMAN PD, 1994, 6027 INT ASTR UN CIR; GERARD JC, 1993, J GEOPHYS RES-PLANET, V98, P18793, DOI 10.1029/93JE01334; GERARD JC, IN PRESS PLANET SPAC; HERBERT F, 1994, GEOPHYS RES LETT, V21, P1047, DOI 10.1029/94GL00884; IP WH, 1994, GEOPHYS RES LETT, V21, P1051, DOI 10.1029/94GL01063; KELLOGG PJ, 1994, GEOPHYS RES LETT, V21, P1055, DOI 10.1029/94GL01293; LIPATOV AS, 1994, GEOPHYS RES LETT, V21, P1059, DOI 10.1029/94GL01295; MOURENAS D, 1993, PLANET SPACE SCI, V41, P347, DOI 10.1016/0032-0633(93)90068-D; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424	18	14	14	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1317	1320		10.1126/science.7871430	http://dx.doi.org/10.1126/science.7871430			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871430				2022-12-24	WOS:A1995QK06800035
J	STAHL, N; FARRUGGELLA, TJ; BOULTON, TG; ZHONG, Z; DARNELL, JE; YANCOPOULOS, GD				STAHL, N; FARRUGGELLA, TJ; BOULTON, TG; ZHONG, Z; DARNELL, JE; YANCOPOULOS, GD			CHOICE OF STATS AND OTHER SUBSTRATES SPECIFIED BY MODULAR TYROSINE-BASED MOTIFS IN CYTOKINE RECEPTORS	SCIENCE			English	Article							GAMMA SIGNAL-TRANSDUCTION; INTERFERON-ALPHA/BETA; KINASE; PATHWAY; GP-130; FAMILY; JAK2	Many members of the cytokine receptor superfamily initiate intracellular signaling by activating members of the Jak family of tyrosine kinases. Activation of the same Jaks by multiple cytokines raises the question of how these cytokines activate distinct intracellular signaling pathways. Selection of particular substrates-the transcriptional activator Stat3 and protein tyrosine phosphatase PTP1D-that characterize responses to the ciliary neurotrophic factor-interleukin-6 cytokine family depended not on which Jak was activated, but was instead determined by specific tyrosine-based motifs in the receptor components-gp130 and LIFR-shared by these cytokines. Further, these tyrosine-based motifs were modular, because addition of a Stat3-specifying motif to another cytokine receptor, that for erythropoietin, caused it to activate Stat3 in a ligand-dependent fashion.	ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University	STAHL, N (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CASE RD, 1994, J BIOL CHEM, V269, P10467; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, UNPUB; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	876	890	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	1995	267	5202					1349	1353		10.1126/science.7871433	http://dx.doi.org/10.1126/science.7871433			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871433				2022-12-24	WOS:A1995QK06800046
J	WELL, D; BLANCHARD, S; KAPLAN, J; GUILFORD, P; GIBSON, F; WALSH, J; MBURU, P; VARELA, A; LEVILLERS, J; WESTON, MD; KELLEY, PM; KIMBERLING, WJ; WAGENAAR, M; LEVIACOBAS, F; LARGETPIET, D; MUNNICH, A; STEEL, KP; BROWN, SDM; PETIT, C				WELL, D; BLANCHARD, S; KAPLAN, J; GUILFORD, P; GIBSON, F; WALSH, J; MBURU, P; VARELA, A; LEVILLERS, J; WESTON, MD; KELLEY, PM; KIMBERLING, WJ; WAGENAAR, M; LEVIACOBAS, F; LARGETPIET, D; MUNNICH, A; STEEL, KP; BROWN, SDM; PETIT, C			DEFECTIVE MYOSIN VIIA GENE RESPONSIBLE FOR USHER SYNDROME TYPE 1B	NATURE			English	Article							SYNDROME TYPE-I; NASAL CILIA; HAIR-CELLS; CHROMOSOME-11; LINKAGE; MOTOR; MAPS	USHER syndrome represents the association of a hearing impairment with retinitis pigmentosa(1) and is the most frequent cause of deaf-blindness in humans. it is inherited as an autosomal recessive trait which is clinically and genetically heterogeneous(2,3). Some patients show abnormal organization of microtubules in the axoneme of their photoreceptors cells (connecting cilium)(4-6), nasal ciliar cells(7) and sperm cells(5), as well as widespread degeneration of the organ of Corti(8). Usher syndrome type 1 (USH1) is characterized by a profound congenital sensorineural hearing loss, constant vestibular dysfunction and prepubertal onset of retinitis pigmentosa. Of three different genes responsible for USH1(9-11) USH1B maps to 11q13.5 (ref. 10) and accounts for about 75% of USH1 patients(2,3). The mouse deafness shaker-1 (sh1) mutation has been localized to the homologous murine region(12,13). Taking into account the cytoskeletal abnormalities in USH patients, the identification of a gene encoding an unconventional myosin as a candidate for shaker-1 (ref. 14) led us to consider the human homologue as a good candidate for the gene that is defective in USH1B. Here we present evidence that a gene encoding myosin VIIA is responsible for USH1B. Two different premature stop codons, a six-base-pair deletion and two different missense mutations were detected in five unrelated families. In one of these families, the mutations were identified in both alleles. These mutations, which are located at the amino-terminal end of the motor domain of the protein, are likely to result in the absence of a functional protein. Thus USH1B appears as a primary cytoskeletal protein defect. These results implicate the genes encoding other unconventional myosins and their interacting proteins as candidates for other genetic forms of Usher syndrome.	INST PASTEUR, CNRS, UNITE GENET MOLEC HUMAINE 1968, F-75724 PARIS 15, FRANCE; HOP NECKER ENFANTS MALAD, INSERM, U393, UNITE RECH HANDICAPS GENET ENFANT, F-75743 PARIS 15, FRANCE; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT BIOCHEM & MOLEC GENET, LONDON W2 1PG, ENGLAND; BOYS TOWN NATL RES HOSP, DEPT PATHOL, OMAHA, NE 68131 USA; CATHOLIC UNIV NIJMEGEN, ST RADBOUD HOSP, 6500 HB NIJMEGEN, NETHERLANDS; MRC, INST HEARING RES, NOTTINGHAM NG7 2RD, ENGLAND	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Boys Town National Research Hospital; Radboud University Nijmegen				Guilford, Parry/0000-0002-7256-9576				ADAMS RJ, 1989, CELL MOTIL CYTOSKEL, V14, P178, DOI 10.1002/cm.970140203; ARDEN GB, 1979, NATURE, V279, P534, DOI 10.1038/279534a0; ASSAD JA, 1992, J NEUROSCI, V12, P3291; BARRONG SD, 1992, ARCH OPHTHALMOL-CHIC, V110, P706, DOI 10.1001/archopht.1992.01080170128040; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BONNEAU D, 1993, J MED GENET, V30, P253, DOI 10.1136/jmg.30.3.253; BROWN KA, 1992, GENOMICS, V13, P189, DOI 10.1016/0888-7543(92)90219-I; BROWN SDM, 1994, HUM MOL GENET, V3, P1453, DOI 10.1093/hmg/3.suppl_1.1453; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; COLLUCIO LM, 1989, J CELL BIOL, V108, P495; EVANS KL, 1993, HUM MOL GENET, V2, P115, DOI 10.1093/hmg/2.2.115; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; HUNTER DG, 1986, ARCH OPHTHALMOL-CHIC, V104, P385; JAEGER RG, 1994, HEARING RES, V77, P207, DOI 10.1016/0378-5955(94)90268-2; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; LARGETPIET D, 1994, GENOMICS, V21, P138, DOI 10.1006/geno.1994.1235; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; METCALF AB, 1994, P NATL ACAD SCI USA, V91, P11821, DOI 10.1073/pnas.91.25.11821; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SHINKAWA H, 1986, ANN OTO RHINOL LARYN, V95, P313, DOI 10.1177/000348948609500321; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SMITH RJH, 1994, AM J MED GENET, V50, P32, DOI 10.1002/ajmg.1320500107; STEELKP, 1994, TRENDS GENET SCI, V10, P428; TILNEY LG, 1992, ANNU REV CELL BIOL, V8, P257, DOI 10.1146/annurev.cb.08.110192.001353; USHER CR, 1913, LOND OPHTHAL HOSDP R, V19, P130; WILLIAMS DS, 1992, J CELL SCI, V103, P183	31	831	849	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	1995	374	6517					60	61		10.1038/374060a0	http://dx.doi.org/10.1038/374060a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870171				2022-12-24	WOS:A1995QK07900051
J	YANG, JH; SKLAR, P; AXEL, R; MANIATIS, T				YANG, JH; SKLAR, P; AXEL, R; MANIATIS, T			EDITING OF GLUTAMATE-RECEPTOR SUBUNIT-B PRE-MESSENGER-RNA IN-VITRO BY SITE-SPECIFIC DEAMINATION OF ADENOSINE	NATURE			English	Article							UNWINDING ACTIVITY; CA2+ PERMEABILITY; ION FLOW; CHANNELS; RNA; DETERMINANTS	EDITING Of the glutamate receptor subunit B (GluR-B) pre-mRNA at a single adenosine residue results in an amino-acid change that profoundly alters the electrophysiological properties of the (1-7). Here we show that the GluR-B pre-mRNA is efficiently and accurately edited in vitro, and that base-pair interactions between the editing site and a sequence in the downstream introns are required for substrate recognition. In addition, we directly demonstrate that editing results from the conversion of adenosine to inosine by enzymatic deamination. The biochemical properties of this GluR-B editing activity are similar to those of a double-stranded-RNA-dependent adenosine deaminase(9-15), but RNA competition and column fractionation experiments indicate that the GluR-B editing and deaminase activities are distinct. Thus, the GluR-B editing enzyme may contain the adenosine deaminase, or a similar activity, and an RNA recognition subunit that specifically targets the enzyme to the editing site.	COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT BIOCHEM,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute; Columbia University	YANG, JH (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,7 DIVIN AVE,CAMBRIDGE,MA 01238, USA.			Axel, Richard/0000-0002-3141-4076				BAS BL, 1993, RNA WORLD, P383; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass Brenda L., 1992, Seminars in Developmental Biology, V3, P425; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; MOORE MJ, 1993, SCIENCE, V256, P992; PASCHEN W, 1994, J NEUROCHEM, V63, P1596, DOI 10.1046/j.1471-4159.1994.63051596.x; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647	21	115	118	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					77	81		10.1038/374077a0	http://dx.doi.org/10.1038/374077a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870177				2022-12-24	WOS:A1995QK07900057
J	HUGHESJONES, NC				HUGHESJONES, NC			RISK ASSESSMENT AND FACTOR-VIII CONCENTRATES	LANCET			English	Editorial Material											HUGHESJONES, NC (corresponding author), MRC CTR,MOLEC IMMUNOPATHOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND.							ALLAN HP, 1993, SIDA HEMOPHILES MON; [Anonymous], 1992, RISK ANAL PERCEPTION; BLOOM AL, 1984, LANCET, V1, P1452; DESFORGES JF, 1983, NEW ENGL J MED, V308, P94, DOI 10.1056/NEJM198301133080209; FRASER L, 1984, GENERAL PRACTIT 1019, P3; HUGHESJONES NC, 1979, LECTURE NOTES HAEMAT; LAYFIELD F, 1987, SIZEWELL B PUBLIC EN; ROWE PM, 1994, LANCET, V344, P876, DOI 10.1016/S0140-6736(94)92838-X; 1984, LANCET, V2, P1433	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					502	503		10.1016/S0140-6736(95)90589-8	http://dx.doi.org/10.1016/S0140-6736(95)90589-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861880				2022-12-24	WOS:A1995QH92900016
J	JIANG, J; STRUHL, G				JIANG, J; STRUHL, G			PROTEIN KINASE-A AND HEDGEHOG SIGNALING IN DROSOPHILA LIMB DEVELOPMENT	CELL			English	Article							SEGMENT-POLARITY GENE; SITE-SPECIFIC RECOMBINATION; CELL-CELL COMMUNICATION; PATCHED GENE; EXPRESSION; WINGLESS; COMPARTMENT; MELANOGASTER; PRODUCT; ENCODES	The Drosophila hedgehog (hh) gene encodes a secreted protein involved in organizing growth and patterning in many developmental processes. Hh appears to act by inducing the localized expression of at least two other signaling molecules, decapentaplegic (dpp) and wingless (wg), which then govern cell proliferation and patterning in surrounding tissue. Here, we demonstrate that cyclic AMP (cAMP)-dependent protein kinase A (PKA) is essential during limb development to prevent inappropriate dpp and wg expression. We also show that a constitutively active form of PKA can prevent inappropriate dpp and wg expression, but does not interfere with their normal induction by hh. We propose that the basal activity of PKA imposes a block on the transcription of dpp and wg and that hh exerts its organizing influence by alleviating this block.			JIANG, J (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, HOWARD HUGHES MED INST, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL G, 1995, IN PRESS DEVELOPMENT; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHOU TB, 1992, GENETICS, V131, P643; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DUNINBORKOWSKI OM, 1995, IN PRESS DEV BIOL; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HIDALGO A, 1990, DEVELOPMENT, V110, P291; Hooper J.E., 1992, Results and Problems in Cell Differentiation, V18, P1; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; SEGAL D, 1985, GENETICS, V109, P119; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; XU T, 1993, DEVELOPMENT, V117, P1223	45	290	299	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	1995	80	4					563	572		10.1016/0092-8674(95)90510-3	http://dx.doi.org/10.1016/0092-8674(95)90510-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867064	Bronze			2022-12-24	WOS:A1995QJ60200008
J	SKAPEK, SX; RHEE, J; SPICER, DB; LASSAR, AB				SKAPEK, SX; RHEE, J; SPICER, DB; LASSAR, AB			INHIBITION OF MYOGENIC DIFFERENTIATION IN PROLIFERATING MYOBLASTS BY CYCLIN D1-DEPENDENT KINASE	SCIENCE			English	Article							RETINOBLASTOMA PROTEIN; EXPRESSION; MUSCLE; P21	Although the myogenic regulator MyoD is expressed in proliferating myoblasts, differentiation of these cells is limited to the G(0) phase of the cell cycle. Forced expression of cyclin D1, but not cyclins A, B, or E, inhibited the ability of MyoD to transactivate muscle-specific genes and correlated with phosphorylation of MyoD. Transfection of myoblasts with cyclin-dependent kinase (Cdk) inhibitors p21 and p16 augmented muscle-specific gene expression in cells maintained in high concentrations of serum, suggesting that an active cyclin-Cdk complex suppresses MyoD function in proliferating cells.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PEDIAT HEMATOL ONCOL,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute			Rhee, James/V-9973-2019		NIAMS NIH HHS [1F32AR08214-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008214] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; KATO J, 1993, GENE DEV, V7, P331; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NODA A, 1994, EXP CELL RES, V211, P98; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SKAPEK SX, UNPUB; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	33	470	471	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1022	1024		10.1126/science.7863328	http://dx.doi.org/10.1126/science.7863328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863328				2022-12-24	WOS:A1995QG99000038
J	VARNUM, BC; YOUNG, C; ELLIOTT, G; GARCIA, A; BARTLEY, TD; FRIDELL, YW; HUNT, RW; TRAIL, G; CLOGSTON, C; TOSO, RJ; YANAGIHARA, D; BENNETT, L; SYLBER, M; MEREWETHER, LA; TSENG, A; ESCOBAR, E; LIU, ET; YAMANE, HK				VARNUM, BC; YOUNG, C; ELLIOTT, G; GARCIA, A; BARTLEY, TD; FRIDELL, YW; HUNT, RW; TRAIL, G; CLOGSTON, C; TOSO, RJ; YANAGIHARA, D; BENNETT, L; SYLBER, M; MEREWETHER, LA; TSENG, A; ESCOBAR, E; LIU, ET; YAMANE, HK			AXL RECEPTOR TYROSINE KINASE STIMULATED BY THE VITAMIN-K-DEPENDENT PROTEIN ENCODED BY GROWTH-ARREST-SPECIFIC GENE-6	NATURE			English	Article							BLOOD-COAGULATION; SEQUENCE; CDNA	THE Axl receptor tyrosine kinase was identified as a protein encoded by a transforming gene from primary human myeloid leukaemia cells by DNA-mediated transformation of NIH 3T3 cells(1-3). Axl is the founding member of a family of related receptors that includes Eyk(4), encoded by a chicken proto-oncogene originally described as a retroviral transforming gene, and c-Mer(5), encoded by a human proto-oncogene expressed in neoplastic B- and T-cell lines. The transforming activity of Axl demonstrates that the receptor can drive cellular proliferation. The function of Axl in non-transformed cells and tissues is unknown, but may involve the stimulation of cell proliferation in response to an appropriate signal, namely a ligand that activates the receptor. We report here the purification of an Axl stimulatory factor, and its identification as the product of growth-arrest-specific gene 6 (ref. 6). This is, to our knowledge, the first description of a ligand for the Axl family of receptors.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	VARNUM, BC (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.		Liu, Edison/C-4141-2008					DECLERCK YA, 1991, J BIOL CHEM, V226, P3893; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FAUSSET PR, 1991, ELECTROPHORESIS, V12, P22, DOI 10.1002/elps.1150120106; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1990, MOL CELL BIOL, V11, P5016; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	15	402	430	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					623	626		10.1038/373623a0	http://dx.doi.org/10.1038/373623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854420				2022-12-24	WOS:A1995QG99700057
J	RASENACK, JWF; SCHLAYER, HJ; HETTLER, F; PETERS, T; PREISLERADAMS, S; GEROK, W				RASENACK, JWF; SCHLAYER, HJ; HETTLER, F; PETERS, T; PREISLERADAMS, S; GEROK, W			HEPATITIS-B VIRUS-INFECTION WITHOUT IMMUNOLOGICAL MARKERS AFTER OPEN-HEART-SURGERY	LANCET			English	Note							CHRONIC LIVER-DISEASE; SURFACE-ANTIGEN; DNA; IDENTIFICATION; SEQUENCE	Post-transfusion hepatitis is still an important problem, despite the screening of blood donors for hepatitis B (HBV) and C virus infections. We assessed whether HBV DNA might be detected by PCR in prospectively collected serum samples of patients with unexplained post-transfusion hepatitis but no immunological HBV markers. We found HBV DNA in 4 (20%) of 20 patients with unexplained post transfusion hepatitis and in 5 patients with mildly increased aminotransferases. The clinical course of these HBV infections was usually mild and self-limiting. Thus we found that low-titre, immunologically negative HBV infections do exist and might represent a significant cause of post-transfusion hepatitis.			RASENACK, JWF (corresponding author), UNIV FREIBURG,DEPT GASTROENTEROL & HEPATOL,D-79106 FREIBURG,GERMANY.							AZAR N, 1993, J HEPATOL, V18, P24, DOI 10.1016/S0168-8278(05)80006-6; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; CHAZOUILLERES O, 1994, LANCET, V343, P142, DOI 10.1016/S0140-6736(94)90934-2; LAI MY, 1990, HEPATOLOGY, V12, P575, DOI 10.1002/hep.1840120321; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; PETERS T, 1994, J MED VIROL, V42, P420, DOI 10.1002/jmv.1890420416; PREISLERADAMS S, 1993, NUCLEIC ACIDS RES, V21, P2258, DOI 10.1093/nar/21.9.2258; PREISLERADAMS S, 1993, ARCH VIROL, V133, P385, DOI 10.1007/BF01313777; THIERS V, 1988, LANCET, V2, P1273; WANG JT, 1991, J INFECT DIS, V163, P397, DOI 10.1093/infdis/163.2.397	10	18	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					355	357		10.1016/S0140-6736(95)90342-9	http://dx.doi.org/10.1016/S0140-6736(95)90342-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845117	Bronze			2022-12-24	WOS:A1995QF72200010
J	FERVEUR, JF; STORTKUHL, KF; STOCKER, RF; GREENSPAN, RJ				FERVEUR, JF; STORTKUHL, KF; STOCKER, RF; GREENSPAN, RJ			GENETIC FEMINIZATION OF BRAIN STRUCTURES AND CHANGED SEXUAL ORIENTATION IN MALE DROSOPHILA	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; MOTH MANDUCA-SEXTA; ANTENNAL LOBE; REPRODUCTIVE-BEHAVIOR; OLFACTORY GLOMERULI; COURTSHIP BEHAVIOR; MELANOGASTER; MOSAICS; RECOGNITION; INFORMATION	The neural basis of sexual orientation in Drosophila was studied by the production of males with regionally feminized brains. Such flies express the female form of the sex determination gene transformer in a limited number oi neurons under the control of GAL4 enhancer trap inserts. This method facilitated the creation of lines with a stable pattern of feminization. In tests of sexual preferences, flies that were feminized in a portion of the antennal lobes or in a subset of the corpora pedunculata (mushroom bodies) courted both males and females. These two brain structures, both of which are involved in olfactory processing, may function in the recognition of sex-specific pheromones, in the control of sex-specific behaviors, or both.	NYU,DEPT BIOL,NEW YORK,NY 10003; NYU,CTR NEURAL SCI,NEW YORK,NY 10003; UNIV FRIBOURG,INST ZOOL,CH-1700 FRIBOURG,SWITZERLAND	New York University; New York University; University of Fribourg								ANTONY C, 1982, J INSECT PHYSIOL, V28, P873, DOI 10.1016/0022-1910(82)90101-9; BAKER BS, 1980, GENETICS, V94, P383; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHRISTENSEN TA, 1993, J COMP PHYSIOL A, V173, P385, DOI 10.1007/BF00193512; COBB M, 1990, ANIM BEHAV, V39, P1058, DOI 10.1016/S0003-3472(05)80778-X; COBB M, 1985, BEHAVIOUR, V97, P182; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; EWING AW, 1983, BIOL REV, V58, P275, DOI 10.1111/j.1469-185X.1983.tb00390.x; FERVEUR JF, 1989, NEUROBIOLOGY OF SENSORY SYSTEMS, P397; FERVEUR JF, UNPUB; FISCHBACH KF, 1984, J EXP BIOL, V112, P65; FISHER JA, 1988, NATURE, V332, P853; FOELIX RF, 1989, CELL TISSUE RES, V258, P277, DOI 10.1007/BF00239448; GAILEY DA, 1989, GENETICS, V121, P773; HALL JC, 1977, BEHAV GENET, V7, P291, DOI 10.1007/BF01066800; HALL JC, 1979, GENETICS, V92, P437; HALL JC, 1982, Q REV BIOPHYS, V15, P223, DOI 10.1017/S0033583500004844; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; HALL JC, 1978, BEHAV GENET, V8, P125, DOI 10.1007/BF01066870; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HANSSON BS, 1992, SCIENCE, V256, P1313, DOI 10.1126/science.1598574; HANSSON BS, 1991, J COMP NEUROL, V312, P264, DOI 10.1002/cne.903120209; HOMBERG U, 1989, ANNU REV ENTOMOL, V34, P477, DOI 10.1146/annurev.en.34.010189.002401; HOTTA Y, 1972, NATURE, V240, P527, DOI 10.1038/240527a0; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; JALLON JM, 1984, BEHAV GENET, V14, P441, DOI 10.1007/BF01065444; JALLON JM, 1982, CR HEBD ACAD SCI, V292, P1147; JALLON JM, 1979, BEHAV GENET, V9, P487; KELLEY DB, 1988, ANNU REV NEUROSCI, V11, P225; LEVAY S, 1991, SCIENCE, V253, P1034, DOI 10.1126/science.1887219; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MCROBERT SP, 1983, BEHAV GENET, V13, P517, DOI 10.1007/BF01065927; PAILLETTE M, 1991, Bioacoustics, V3, P247; PECHINE JM, 1988, J CHEM ECOL, V14, P1071, DOI 10.1007/BF01019336; POSSIDENTE DR, 1989, DEV BIOL, V132, P448, DOI 10.1016/0012-1606(89)90241-8; ROBERTSON HM, 1988, GENETICS, V118, P461; RODRIGUES V, 1988, BRAIN RES, V453, P299, DOI 10.1016/0006-8993(88)90170-9; ROSPARS JP, 1983, J COMP NEUROL, V220, P80, DOI 10.1002/cne.902200108; SCOTT D, 1988, ANIM BEHAV, V36, P1164, DOI 10.1016/S0003-3472(88)80075-7; SIEGEL RW, 1979, P NATL ACAD SCI USA, V76, P3430, DOI 10.1073/pnas.76.7.3430; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SINGH RN, 1985, INT J INSECT MORPHOL, V14, P296; STOCKER RF, 1983, CELL TISSUE RES, V232, P237, DOI 10.1007/BF00213783; STOCKER RF, 1989, BEHAV GENET, V19, P371, DOI 10.1007/BF01066165; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; STOCKER RF, 1990, CELL TISSUE RES, V262, P9, DOI 10.1007/BF00327741; Strausfeld NJ., 1976, ATLAS INSECT BRAIN, DOI 10.1007/978-3-642-66179-2; TAYLOR BJ, 1994, DEV GENET, V15, P275, DOI 10.1002/dvg.1020150309; Technau GM, 1984, J NEUROGENET, V1, P113, DOI 10.3109/01677068409107077; TOMPKINS L, 1986, TRENDS GENET, V2, P14, DOI 10.1016/0168-9525(86)90162-9; TOMPKINS L, 1983, GENETICS, V103, P179; VENARD R, 1989, NEUROBIOLOGY OF SENSORY SYSTEMS, P377; WITHERS GS, 1993, NATURE, V364, P238, DOI 10.1038/364238a0	55	188	190	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					902	905		10.1126/science.7846534	http://dx.doi.org/10.1126/science.7846534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846534				2022-12-24	WOS:A1995QG20700064
J	VALONE, TJ; BROWN, JH				VALONE, TJ; BROWN, JH			EFFECTS OF COMPETITION, COLONIZATION, AND EXTINCTION ON RODENT SPECIES-DIVERSITY	SCIENCE			English	Article							CHIHUAHUAN DESERT; FOOD ADDITION; PRODUCTIVITY; COMMUNITY; REMOVAL	Analyses of long-term experimental data from the Chihuahuan desert. revealed that species diversity of other rodents was higher on plots from which kangaroo rats (Dipodomys spp.) had been removed. The difference was due to consistently higher colonization and lower extinction probabilities of small granivorous rodents in the absence of competitively dominant kangaroo rats. The results of this ecosystem experiment demonstrate the importance of both competitive exclusion and metapopulation dynamics for biological diversity in a natural community.	UNIV NEW MEXICO,DEPT BIOL,ALBUQUERQUE,NM 87131	University of New Mexico				Valone, Thomas/0000-0002-7657-3126				BOWERS MA, 1987, OECOLOGIA, V72, P77, DOI 10.1007/BF00385048; BOWERS MA, 1981, ECOLOGY, V63, P391; BOWERS MA, 1993, OECOLOGIA, V92, P242; BROWN JH, 1985, ECOLOGY, V66, P1545, DOI 10.2307/1938017; BROWN JH, 1989, ECOLOGY, V70, P1507, DOI 10.2307/1938209; BROWN JH, 1990, SCIENCE, V250, P1705, DOI 10.1126/science.250.4988.1705; BROWN JH, 1977, ECOLOGY, V58, P445, DOI 10.2307/1935620; CARPENTER S R, 1988, P119; CARPENTER SR, 1985, BIOSCIENCE, V35, P634, DOI 10.2307/1309989; CLARK CW, 1994, AM NAT, V143, P583, DOI 10.1086/285621; Cody M. L., 1975, ECOLOGY EVOLUTION CO; CONNELL JH, 1961, ECOLOGY, V42, P710, DOI 10.2307/1933500; Drake, 1986, ECOLOGY BIOL INVASIO; FRYE RJ, 1983, OECOLOGIA, V59, P74, DOI 10.1007/BF00388076; Gause GF, 1934, STRUGGLE EXISTENCE; Gilpin M.E., 1991, METAPOPULATION DYNAM; HAIRSTON NG, 1989, ECOLOGICAL EXPT; HANSKI I, 1982, OIKOS, V38, P210, DOI 10.2307/3544021; HESKE EJ, 1993, OECOLOGIA, V95, P520, DOI 10.1007/BF00317436; HESKE EJ, 1994, ECOLOGY, V75, P438, DOI 10.2307/1939547; Hoffmeister D. F., 1986, MAMMALS ARIZONA; HORN HS, 1972, ECOLOGY, V53, P749, DOI 10.2307/1934797; Keddy P.A., 1989, COMPETITION; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; Ludwig JA., 1988, STAT ECOLOGY; MAC ARTHUR ROBERT H., 1967; MacArthur R.H., 1972, pvii; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; PARK T, 1948, ECOL MONOGR, V18, P265, DOI 10.2307/1948641; Pimm S.L, 1982, FOOD WEBS; Pimm S. L., 1991, BALANCE NATURE ECOLO; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; Ricklefs R.E., 1993, J EVOLUTION BIOL, DOI DOI 10.1046/J.1420-9101.1993.6020171.X; Roughgarden J, 1986, COMMUNITY ECOL, P333; SIMBERLOFF D, 1979, ECOLOGICAL DIVERSITY, P159; SLATKIN M, 1974, ECOLOGY, V55, P128, DOI 10.2307/1934625; TILMAN D, 1993, ECOLOGY, V74, P2179, DOI 10.2307/1939572; VANDERMEER JH, 1969, ECOLOGY, V50, P362, DOI 10.2307/1933884; [No title captured]	40	68	70	1	24	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					880	883		10.1126/science.7846530	http://dx.doi.org/10.1126/science.7846530			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846530				2022-12-24	WOS:A1995QG20700057
J	BRAVEMAN, P; SCHAAF, VM; EGERTER, S; BENNETT, T; SCHECTER, W				BRAVEMAN, P; SCHAAF, VM; EGERTER, S; BENNETT, T; SCHECTER, W			INSURANCE-RELATED DIFFERENCES IN THE RISK OF RUPTURED APPENDIX	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEE-FOR-SERVICE; RANDOMIZED CONTROLLED TRIAL; HEALTH-INSURANCE; RESOURCE UTILIZATION; HOSPITAL PATIENTS; PRENATAL-CARE; MEDICAL-CARE; MASSACHUSETTS; COVERAGE; OUTCOMES	Background. We studied differences in the incidence of appendiceal perforation in patients with acute appendicitis according to their insurance coverage. Methods. In a retrospective analysis of hospital-discharge data, we examined the likelihood of ruptured appendix among adults 18 to 64 years old who were hospitalized for acute appendicitis in California from 1984 to 1989. Results. After controlling for age, sex, psychiatric diagnoses, substance abuse, diabetes, poverty, race or ethnic group, and hospital characteristics, we found that ruptured appendix was more likely among both Medicaid-covered and uninsured patients with appendicitis than among patients with private capitated coverage (odds ratios, 1.49 [95 percent confidence interval, 1.41 to 1.59] and 1.46 [95 percent confidence interval, 1.39 to 1.54], respectively). After adjustment for the above factors, the risk of appendiceal rupture associated with a lack of private in-surance was elevated at both county and other hospitals, but admission to a county hospital was an independent risk factor. In all income groups, appendiceal rupture was more likely with fee-for-service than capitated private coverage (overall odds ratio, 1.20 [95 percent confidence interval, 1.15 to 1.25]). Conclusions. Among patients with appendicitis an increased risk of ruptured appendix may be due to insurance-related delays in obtaining medical care. Both organizational and financial features of Medicaid and various types or levels of private third-party coverage may be involved. The significant association between ruptured appendix and insurance coverage after adjustment for socioeconomic differences suggests barriers to receiving medically necessary acute care that should be considered in current deliberations on health policy.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,MED CTR,DEPT MED,SAN FRANCISCO,CA 94110; SAN FRANCISCO GEN HOSP,MED CTR,DEPT SURG,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center	BRAVEMAN, P (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,BOX 0900,SAN FRANCISCO,CA 94143, USA.							ADAY LA, 1984, ACCESS MED CARE; ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BILLINGS J, 1990, CONSIDERATION USE SM; BLUMBERG MS, 1991, 169504 HOSP RES ED T; BRAVEMAN P, 1993, JAMA-J AM MED ASSOC, V269, P1285, DOI 10.1001/jama.269.10.1285; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BRAVEMAN PA, 1991, JAMA-J AM MED ASSOC, V266, P3300, DOI 10.1001/jama.266.23.3300; BRENDER JD, 1985, PEDIATRICS, V76, P301; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BUCHMAN TG, 1984, SURG GYNECOL OBSTET, V158, P260; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P845, DOI 10.1001/jama.270.7.845; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; FOSSETT JW, 1992, J HEALTH POLIT POLIC, V17, P273, DOI 10.1215/03616878-17-2-273; FOSSETT JW, 1990, MILBANK Q, V68, P111, DOI 10.2307/3350079; FRANKS P, 1993, AM J PUBLIC HEALTH, V83, P1295, DOI 10.2105/AJPH.83.9.1295; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; HUTTON N, 1985, EFFECTIVENESS MED CA, P120; KLEIN SR, 1988, POSTGRAD MED, V83, P247; LUCKMANN R, 1990, AM J EPIDEMIOL, V131, P1102; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; Pieper R, 1986, Acta Chir Scand Suppl, V530, P51; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; RICCI MA, 1988, AM SURGEON, V54, P273; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SCHER KS, 1980, SURG GYNECOL OBSTET, V150, P535; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SIU AL, 1988, JAMA-J AM MED ASSOC, V259, P1343, DOI 10.1001/jama.259.9.1343; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; STERN RS, 1989, ARCH INTERN MED, V149, P1185, DOI 10.1001/archinte.149.5.1185; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; WAY LW, 1988, CURRENT SURGICAL DIA, P556; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; 1991, INT CLASSIFICATION D; 1985, SAS USERS GUIDE STAT; 1989, 1989 1990 DIRECTORY	50	195	196	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					444	449		10.1056/NEJM199408183310706	http://dx.doi.org/10.1056/NEJM199408183310706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB501	7880234	Bronze			2022-12-24	WOS:A1994PB50100006
J	LEFRERE, JJ; MARIOTTI, M; THAUVIN, M				LEFRERE, JJ; MARIOTTI, M; THAUVIN, M			B19 PARVOVIRUS DNA IN SOLVENT DETERGENT-TREATED ANTI-HEMOPHILIA CONCENTRATES	LANCET			English	Note							INFECTION	A transfusional B19 parvovirus infection may have severe consequences in immunocompromised hosts. The presence of B19 DNA was investigated with a polymerase chain reaction (PCR) assay in 30 batches of solvent/detergent-treated clotting factor concentrates (12 batches of factor VIII, 16 batches of factor IX, 1 batch of factor VII, and 1 batch of PPSB). B19 DNA was detected in 6 (20%) batches, including 3 factor VIII and 3 factor IX concentrates. Because of the frequency of B19 DNA in batches of clotting factors, measures to prevent transfusional risk of B19 infection via these blood products are justified, especially in recipients immunocompromised by HIV infection.			LEFRERE, JJ (corresponding author), HOP ST ANTOINE,INST NATL TRANSFUS SANGUINE,53 BLVD DIDEROT,F-75571 PARIS 12,FRANCE.							AZZI A, 1992, AM J HEMATOL, V39, P228, DOI 10.1002/ajh.2830390315; CORSI OB, 1988, J MED VIROL, V25, P165, DOI 10.1002/jmv.1890250206; LEFRERE JJ, 1992, BRIT J HAEMATOL, V82, P467, DOI 10.1111/j.1365-2141.1992.tb06446.x; LEFRERE JJ, 1986, BRIT J HAEMATOL, V62, P653, DOI 10.1111/j.1365-2141.1986.tb04088.x; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MORFINI M, 1992, AM J HEMATOL, V39, P149, DOI 10.1002/ajh.2830390217; MORTIMER PP, 1983, LANCET, V2, P482; NAIDES SJ, 1993, J INFECT DIS, V168, P101, DOI 10.1093/infdis/168.1.101; SOL N, 1993, J GEN VIROL, V74, P2011, DOI 10.1099/0022-1317-74-9-2011; ZAKRZEWSKA K, 1992, BRIT J HAEMATOL, V81, P407, DOI 10.1111/j.1365-2141.1992.tb08248.x	10	81	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					211	212		10.1016/S0140-6736(94)90993-8	http://dx.doi.org/10.1016/S0140-6736(94)90993-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904670				2022-12-24	WOS:A1994MT33200012
J	THOMPSON, C				THOMPSON, C			A SLIPPERY DEFENSE AGAINST HIV	LANCET			English	Editorial Material																		LEHNER T, 1993, P NATL ACAD SCI USA, V90, P8638, DOI 10.1073/pnas.90.18.8638; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; LEHNER T, IN PRESS J VIROL	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1500	1500		10.1016/S0140-6736(05)80077-7	http://dx.doi.org/10.1016/S0140-6736(05)80077-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902894				2022-12-24	WOS:A1993MM40200004
J	BEDARIDA, GV; KIM, D; BLASCHKE, TF; HOFFMAN, BB				BEDARIDA, GV; KIM, D; BLASCHKE, TF; HOFFMAN, BB			VENODILATION IN RAYNAUDS-DISEASE	LANCET			English	Article							SUPERFICIAL HAND VEINS; NITRIC-OXIDE; L-ARGININE; SYSTEMIC-SCLEROSIS; ENDOTHELIUM; RESPONSIVENESS; PHENYLEPHRINE; RELAXATION; RESPONSES; THERAPY	The pathogenesis of Raynaud's disease is unclear; an enhanced reponse to catecholamines has been hypothesised to contribute to this vasospastic disorder. Impaired endothelium-dependent dilation occurs in other diseases associated with vasospasm, such as coronary atherosclerosis. We investigated both endothelium-dependent and endothelium-independent venodilatory function in Raynaud's disease using the hand-vein compliance technique. Full dose-response curves to noradrenaline were constructed in 10 subjects with primary Raynaud's disease and 10 age and sex matched control subjects. The two groups did not have a different response to noradrenaline. Mean (SD) log values of ED50s (the dose producing half maximum response) were 1.00 (0.59) (geometric mean 10 ng/min) in Raynaud's disease compared with 1.29 (0.66) (20 ng/min) in control subjects (p = 0.16). The efficacy of noradrenaline as a venoconstrictor was similar in the two groups: mean maximum dilation (E(max)) to noradrenaline was 81 (14)% in the Raynaud's group and 89 (8)% in the control group (p = 0.08). Full dose-response curves to the endothelium-dependent dilator bradykinin were constructed. E(max) to bradykinin was significantly lower in the Raynaud's group than in the control group (65 [21] vs 91 [29%], p = 0.02). ED50 values (doses producing half maximum response) for bradykinin were similar in the two groups. Maximum dilation with nitroprusside, a direct releaser of the vasodilator nitric oxide, was not diminished in the Raynaud's group (94 [23] vs 102 [15]% in controls, p = 0.26). These results suggest that endothelium-dependent venodilation is impaired in peripheral vessels in Raynaud's disease, possibly due to diminished release of nitric oxide, and may contribute to the pathogenesis of the disorder.	STANFORD UNIV, MED CTR, DIV CLIN PHARMACOL, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR GERIATR RES EDUC & CLIN, PALO ALTO, CA 94304 USA	Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Blaschke, Terrence/0000-0001-5307-2620	NIA NIH HHS [AG 05627] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AELLIG WH, 1981, BRIT J CLIN PHARMACO, V11, P237, DOI 10.1111/j.1365-2125.1981.tb00527.x; AGOSTONI A, 1991, INT J CLIN LAB RES, V21, P202; Allen EV, 1932, AM J MED SCI, V183, P187, DOI 10.1097/00000441-193202000-00004; ARNOLD JMO, 1993, ANN INTERN MED, V118, P619, DOI 10.7326/0003-4819-118-8-199304150-00008; COFFMAN JD, 1991, HYPERTENSION, V17, P593, DOI 10.1161/01.HYP.17.5.593; COLLIER JG, 1972, CLIN SCI, V43, P455, DOI 10.1042/cs0430455; DACHMAN WD, 1993, J CARDIOVASC PHARM, V21, P241, DOI 10.1097/00005344-199302000-00009; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; DREXLER H, 1991, HYPERTENSION, V18, P90, DOI 10.1161/01.HYP.18.4_Suppl.II90; EDWARDS JM, 1987, J VASC SURG, V5, P38, DOI 10.1067/mva.1987.avs0050038; EICHLER HG, 1989, CLIN SCI, V76, P283, DOI 10.1042/cs0760283; EICHLER HG, 1989, J CLIN INVEST, V83, P108, DOI 10.1172/JCI113845; FLEMING WW, 1972, J PHARMACOL-PARIS, V181, P339; FREEDMAN RR, 1989, ARTHRITIS RHEUM, V32, P61, DOI 10.1002/anr.1780320110; FREEMONT AJ, 1992, BRIT J DERMATOL, V126, P561; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; GRAAFSMA SJ, 1991, CLIN SCI, V80, P325, DOI 10.1042/cs0800325; LIU M-F, 1991, Taiwan yixuehui zazhi, V90, P221; MARASINI B, 1992, INT J MICROCIRC, V11, P375; MATUCCICERINIC M, 1990, CLIN EXP RHEUMATOL, V8, P561; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; OKEEFFE ST, 1992, ANN INTERN MED, V116, P985, DOI 10.7326/0003-4819-116-12-985; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PAN HYM, 1986, J PHARMACOL EXP THER, V239, P802; RAYNAUD M, 1888, LOCAL ASPHYXIA SYMME, P99; TERBORG EJ, 1990, SEMIN ARTHRITIS RHEU, V20, P164, DOI 10.1016/0049-0172(90)90057-M; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VINCENT J, 1992, CLIN PHARMACOL THER, V51, P68, DOI 10.1038/clpt.1992.9; WOLLERSHEIM H, 1989, EUR J CLIN INVEST, V19, P535, DOI 10.1111/j.1365-2362.1989.tb00271.x	31	50	50	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1451	1454		10.1016/0140-6736(93)92932-J	http://dx.doi.org/10.1016/0140-6736(93)92932-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902481				2022-12-24	WOS:A1993ML21700008
J	REES, M				REES, M			MENARCHE WHEN AND WHY	LANCET			English	Editorial Material											REES, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.							DANN TC, 1993, J BIOSOC SCI, V25, P531, DOI 10.1017/S0021932000021908; FRISCH RE, 1990, BAILLIERE CLIN OB GY, V4, P419, DOI 10.1016/S0950-3552(05)80302-5; KJAER K, 1992, J CLIN ENDOCR METAB, V75, P524, DOI 10.1210/jc.75.2.524; MOISAN J, 1990, AM J EPIDEMIOL, V132, P953, DOI 10.1093/oxfordjournals.aje.a115738; Rosetta L, 1993, Oxf Rev Reprod Biol, V15, P113	5	55	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1375	1376		10.1016/0140-6736(93)92746-G	http://dx.doi.org/10.1016/0140-6736(93)92746-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK095	7901675				2022-12-24	WOS:A1993MK09500003
J	SCOTT, RAP; WILSON, NM; ASHTON, HA; KAY, DN				SCOTT, RAP; WILSON, NM; ASHTON, HA; KAY, DN			IS SURGERY NECESSARY FOR ABDOMINAL AORTIC-ANEURYSM LESS-THAN 6 CM IN DIAMETER	LANCET			English	Note								During 8 years of an ultrasound screening programme for abdominal aortic aneurysm (AAA), 8944 people aged 65-80 years were scanned. 356 (4%) had AAA of diameter 3 cm or greater. Under our criteria repair was indicated if the aortic diameter reached 6 cm, if expansion reached 1 cm per year, or if the AAA caused symptoms; 124 patients met these criteria. Among the 8820 screened patients who did not meet the criteria, 1 death (0.4%) was attributed to ruptured aneurysm, although the retroperitoneal haematoma had developed within 5 days of surgery for a colon tumour. The risk of aortic rupture in patients with AAA less than 6 cm diameter with these criteria (0.4%) is lower than that for elective surgery (1-8%). Surgical repair is unnecessary and possibly detrimental in such patients, provided that ultrasound surveillance is undertaken.	ST RICHARDS HOSP,DEPT RADIOL,CHICHESTER PO19 4SE,W SUSSEX,ENGLAND		SCOTT, RAP (corresponding author), ST RICHARDS HOSP,SCOTT RES UNIT,SPITALFIELD LANE,CHICHESTER PO19 4SE,W SUSSEX,ENGLAND.							Campbell W B, 1991, Eur J Vasc Surg, V5, P111; COLLIN J, 1987, LANCET, V1, P909; COOLEY DA, 1984, CIRCULATION, V70, P1; DARLING RC, 1977, CIRCULATION, V56, P161; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; Johansson G, 1990, Eur J Vasc Surg, V4, P497, DOI 10.1016/S0950-821X(05)80791-1; SCOTT A, 1992, ANN ROY COLL SURG, V74, P205; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; TURK KAD, 1965, P ROY SOC MED, V58, P869, DOI 10.1177/003591576505811P109	10	64	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1395	1396		10.1016/0140-6736(93)92756-J	http://dx.doi.org/10.1016/0140-6736(93)92756-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901685				2022-12-24	WOS:A1993MK09500013
J	BOWLING, TE; RAIMUNDO, AH; GRIMBLE, GK; SILK, DBA				BOWLING, TE; RAIMUNDO, AH; GRIMBLE, GK; SILK, DBA			REVERSAL BY SHORT-CHAIN FATTY-ACIDS OF COLONIC FLUID SECRETION INDUCED BY ENTERAL FEEDING	LANCET			English	Article							ABSORPTION; DIET; NUTRITION; INTESTINE; DIARRHEA; RAT	Diarrhoea complicates enteral feeding in up to 25% of patients. In-vivo perfusion studies in healthy subjects have shown secretion of salt and water in the ascending colon in response to enteral feeding. This study investigated the effect of short-chain fatty acids (SCFA) on this secretory response. Six healthy volunteers underwent segmental in-vivo colonic perfusion. First, baseline fasting colonic water and electrolyte movement was established, then a standard polymeric enteral diet was infused into the stomach while the colon was perfused with either a control electrolyte solution or a test solution containing SCFA. The electrolyte concentrations and osmolality of the two perfusates were identical. In the fasting state water was absorbed throughout the colon. During the control infusion there was significant (p < 0.05) secretion of water in the ascending colon (median rate 1.0 mL per min [95% CI 2.8 mL per min secretion to 0.8 mL per min absorption]). During the SCFA infusion the secretion was significantly reversed (p < 0.05) and there was net absorption (1.6 [0.8-3.7] mL per min). In the distal colon water absorption was significantly greater during the control infusion than during fasting (3.7 [2.5-4.6] vs 1.3 [0.3-2.2] mL per min); during the test infusion this absorption persisted (2.8 [1.3-3.6] mL per min). Movement of sodium, chloride, and potassium ions was similar to that of water in all stages of the study. Bicarbonate movement did not significantly change at any stage. Infusion of SCFA directly into the caecum reverses the fluid secretion seen in the ascending colon during enteral feeding. This finding could have implications for the management of diarrhoea related to enteral feeding.			SILK, DBA (corresponding author), CENT MIDDLESEX HOSP TRUST,DEPT GASTROENTEROL & NUTR,LONDON NW10 7NS,ENGLAND.							BINDER HJ, 1989, GASTROENTEROLOGY, V96, P989, DOI 10.1016/0016-5085(89)91614-4; BOWLING TE, 1993, EUR J GASTROEN HEPAT, V5, P809; BOWLING TE, 1993, GUT               S1, V34, pA54; BOWLING TE, 1993, CLIN NUTR S2, V12, P23; CUMMINGS JH, 1984, SCAND J GASTROENTERO, V19, P89; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; DEVROEDE GJ, 1969, GASTROENTEROLOGY, V56, P92; DOBB GJ, 1986, INTENS CARE MED, V12, P113; FORD EG, 1987, J PEDIATR SURG, V22, P597, DOI 10.1016/S0022-3468(87)80106-9; JACOBS LR, 1983, AM J CLIN NUTR, V37, P954, DOI 10.1093/ajcn/37.6.954; JONES BJM, 1983, GUT, V24, P78, DOI 10.1136/gut.24.1.78; KEOHANE PP, 1984, BMJ-BRIT MED J, V288, P678, DOI 10.1136/bmj.288.6418.678; Kritchevsky D., 1986, DIETARY FIBER, P131, DOI DOI 10.1007/978-1-4613-2111-8_10; LEVITAN R, 1962, J CLIN INVEST, V41, P1754, DOI 10.1172/JCI104634; MACFARLANE GT, 1992, J APPL BACTERIOL, V72, P57, DOI 10.1111/j.1365-2672.1992.tb05187.x; OKEEFE SJD, 1984, GUT, V25, P942, DOI 10.1136/gut.25.9.942; PHILLIPS SF, 1973, J LAB CLIN MED, V81, P733; RAIMUNDO AH, 1988, GUT, V29, pA1469; RAIMUNDO AH, 1990, GUT, V31, pA1195; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; RUPPIN H, 1980, GASTROENTEROLOGY, V78, P1500; SILK DBA, 1987, CLIN NUTR, V6, P61, DOI 10.1016/0261-5614(87)90023-9; WAITZBERG D, 1988, CLIN NUTR S1, V7, P58; WHALEN GE, 1966, GASTROENTEROLOGY, V51, P975	24	97	99	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1266	1268		10.1016/0140-6736(93)92360-6	http://dx.doi.org/10.1016/0140-6736(93)92360-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901584				2022-12-24	WOS:A1993MH56600010
J	SACKS, SH; ZHOU, WD; ANDREWS, PA; HARTLEY, B				SACKS, SH; ZHOU, WD; ANDREWS, PA; HARTLEY, B			ENDOGENOUS COMPLEMENT C3 SYNTHESIS IN IMMUNE-COMPLEX NEPHRITIS	LANCET			English	Note							BIOSYNTHESIS; C-4	Human renal epithelial and mesangial cells have been shown to synthesise complement C3 in culture, but the relevance of this finding to the development of complement-mediated nephritis is uncertain. We investigated C3 gene expression in tissue biopsies that showed three main categories of renal injury. By semiquantitative polymerase chain reaction, biopsies from patients with immune-complex glomerulonephritis and those with cell-mediated interstitial nephritis showed increased C3 expression (p < 0.05), but biopsies from patients with non-immune glomerular injury did not. These findings suggest that local C3 production is enhanced in immune-mediated nephritis and are consistent with the hypothesis that locally synthesised complement components are involved in the pathogenesis of tissue injury.			SACKS, SH (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,RENAL LAB,3RD FLOOR GUYS TOWER,LONDON SE1 9RT,ENGLAND.			Sacks, Steven/0000-0001-6361-9095	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; Colten H R, 1979, Ann N Y Acad Sci, V332, P482, DOI 10.1111/j.1749-6632.1979.tb47142.x; COUSER WG, 1985, KIDNEY INT, V28, P879, DOI 10.1038/ki.1985.214; FEUCHT HE, 1989, NEPHRON, V53, P338, DOI 10.1159/000185778; FEY G, 1981, FED PROC, V40, P2099; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; SACKS SH, 1993, IMMUNOLOGY, V79, P348; SACKS SH, IN PRESS CLIN EXP IM; ZHOU W, IN PRESS EUR J IMMUN	10	68	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1273	1274		10.1016/0140-6736(93)92362-W	http://dx.doi.org/10.1016/0140-6736(93)92362-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901586				2022-12-24	WOS:A1993MH56600012
J	BLONDELGUINDI, S; CWIRLA, SE; DOWER, WJ; LIPSHUTZ, RJ; SPRANG, SR; SAMBROOK, JF; GETHING, MJH				BLONDELGUINDI, S; CWIRLA, SE; DOWER, WJ; LIPSHUTZ, RJ; SPRANG, SR; SAMBROOK, JF; GETHING, MJH			AFFINITY PANNING OF A LIBRARY OF PEPTIDES DISPLAYED ON BACTERIOPHAGES REVEALS THE BINDING-SPECIFICITY OF BIP	CELL			English	Article							MHC CLASS-I; SECRETORY PROTEINS; TRANSLOCATION; POLYPEPTIDE; LIGANDS; RESOLUTION; MOLECULES; PHAGE; GROEL; DNAK	We have used affinity panning of libraries of bacteriophages that display random octapeptide or dodecapeptide sequences at the N-terminus of the adsorption protein (pIII) to characterize peptides that bind to the endoplasmic reticulum chaperone BiP and to develop a scoring system that predicts potential BiP-binding sequences in naturally occurring polypeptides. BiP preferentially binds peptides containing a subset of aromatic and hydrophobic amino acids in alternating positions, suggesting that peptides bind in an extended conformation, with the side chains of alternating residues pointing into a cleft on the BiP molecule. Synthetic peptides with sequences corresponding to those displayed by BiP-binding bacteriophages bind to BiP and stimulate its ATPase activity, with a half-maximal concentration in the range 10-60 muM.	UNIV TEXAS,DALLAS,TX 75235; AFFYMAX RES INST,PALO ALTO,CA 94304	University of Texas System; University of Texas Dallas	BLONDELGUINDI, S (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED,DALLAS,TX 75235, USA.							BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOWER W J, 1992, Current Biology, V2, P251, DOI 10.1016/0960-9822(92)90368-K; Efron B., 1982, MONOGRAPH SOC IND AP; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; KOZUTSUMI Y, 1989, J CELL SCI S, V11, P115; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; OBLAS B, 1990, BIOCHEM BIOPH RES CO, V166, P978, DOI 10.1016/0006-291X(90)90907-5; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHONBERGER O, 1991, MOL MICROBIOL, V11, P2663; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Smith G P, 1991, Curr Opin Biotechnol, V2, P668, DOI 10.1016/0958-1669(91)90032-Z; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	34	561	595	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					717	728		10.1016/0092-8674(93)90492-9	http://dx.doi.org/10.1016/0092-8674(93)90492-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7902213	Bronze			2022-12-24	WOS:A1993MH74900017
J	KUEHN, MJ; OGG, DJ; KIHLBERG, J; SLONIM, LN; FLEMMER, K; BERGFORS, T; HULTGREN, SJ				KUEHN, MJ; OGG, DJ; KIHLBERG, J; SLONIM, LN; FLEMMER, K; BERGFORS, T; HULTGREN, SJ			STRUCTURAL BASIS OF PILUS SUBUNIT RECOGNITION BY THE PAPD CHAPERONE	SCIENCE			English	Article							TOXIGENIC ESCHERICHIA-COLI; AREA-DETECTOR DIFFRACTOMETER; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; PEPTIDE-BINDING; PROTEIN SUBUNIT; GENE; EXPRESSION; FIMBRIAE; CELL	The assembly of different types of virulence-associated surface fibers called pili in Gram-negative bacteria requires periplasmic chaperones. PapD is the prototype member of the periplasmic chaperone family, and the structural basis of its interactions with pilus subunits was investigated. Peptides corresponding to the carboxyl terminus of pilus subunits bound PapD and blocked the ability of PapD to bind to the pilus adhesin PapG in vitro. The crystal structure of PapD complexed to the PapG carboxyl-terminal peptide was determined to 3.0 angstrom resolution. The peptide bound in an extended conformation with its carboxyl terminus anchored in the interdomain cleft of the chaperone via hydrogen bonds to invariant chaperone residues Arg8 and Lys112. Main chain hydrogen bonds and contacts between hydrophobic residues in the peptide and the chaperone stabilized the complex and may play a role in determining binding specificity. Site-directed mutations in Arg8 and Lys112 abolished the ability of PapD to bind pilus subunits and mediate pilus assembly in vivo, an indication that the PapD-peptide crystal structure is a reflection of at least part of the PapD-subunit interaction.	WASHINGTON UNIV,DEPT MOLEC MICROBIOL,BOX 8230,ST LOUIS,MO 63110; SYMBICOM AB,PROT STRUCT LAB,S-75183 UPPSALA,SWEDEN; LUND UNIV,DEPT ORGAN CHEM,S-22100 LUND,SWEDEN; UNIV UPPSALA,DEPT MICROBIOL,S-75105 UPPSALA,SWEDEN	Washington University (WUSTL); Lund University; Uppsala University			Kuehn, Meta/AAL-2950-2021; Kihlberg, Jan/S-4739-2019	Kuehn, Meta/0000-0003-0519-3019; 	NIAID NIH HHS [AI07172, R01AI29549] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549, T32AI007172] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN BL, 1991, J BACTERIOL, V173, P916, DOI 10.1128/jb.173.2.916-920.1991; BAGA M, 1987, CELL, V49, P241, DOI 10.1016/0092-8674(87)90565-4; BRUNGER A, 1992, X PLOR MANUAL; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CLOUTHIER SC, 1993, J BACTERIOL, V175, P2523, DOI 10.1128/JB.175.9.2523-2533.1993; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DERRICK JP, 1992, NATURE, V359, P752, DOI 10.1038/359752a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAASTRA W, 1981, FEMS MICROBIOL LETT, V12, P41; GAASTRA W, 1984, FEMS MICROBIOL LETT, V22, P253; GALYOV EE, 1991, FEBS LETT, V286, P79, DOI 10.1016/0014-5793(91)80945-Y; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILSDORF JR, 1990, INFECT IMMUN, V58, P1065, DOI 10.1128/IAI.58.4.1065-1072.1990; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HOLMGREN A, UNPUB; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; Jacob-Dubuisson Francoise, 1993, Trends in Microbiology, V1, P50, DOI 10.1016/0966-842X(93)90032-M; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; JALAJAKUMARI MB, 1989, MOL MICROBIOL, V3, P1685, DOI 10.1111/j.1365-2958.1989.tb00154.x; JONES AT, 1992, VERSION 5 6; JONES CH, 1993, P NATL ACAD SCI USA, V90, P8397, DOI 10.1073/pnas.90.18.8397; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LINTERMANS P, 1988, INFECT IMMUN, V56, P1475, DOI 10.1128/IAI.56.6.1475-1484.1988; LINTERMANS P, 1990, THESIS RIJKSUNIVERSI; LIVEY I, 1987, MOL MICROBIOL, V1, P203, DOI 10.1111/j.1365-2958.1987.tb00513.x; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MOOI FR, 1990, FEMS MICROBIOL LETT, V54, P327; Normark S., 1986, Microbial lectins and agglutinins, P113; ORNDORFF PE, 1985, J BACTERIOL, V162, P454, DOI 10.1128/JB.162.1.454-457.1985; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; ROOSENDAAL B, 1989, J BACTERIOL, V171, P1262; SCHMOLL T, 1987, FEMS MICROBIOL LETT, V41, P229; SCHMOLL T, 1989, MOL MICROBIOL, V3, P1735, DOI 10.1111/j.1365-2958.1989.tb00159.x; SIMONS BL, 1990, FEMS MICROBIOL LETT, V67, P107, DOI 10.1111/j.1574-6968.1990.tb13845.x; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; 1979, WA44AD DAR LAB	51	195	199	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1234	1241		10.1126/science.7901913	http://dx.doi.org/10.1126/science.7901913			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	7901913				2022-12-24	WOS:A1993MH32400030
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR ADVANCED PANCREATIC-CANCER AUTHORIZED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-24	WOS:A1995QP89000009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR AIDS-RELATED WASTING AUTHORIZED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-24	WOS:A1995QP89000006
